Building-associated CAPITAL NNP O
pulmonary NN pneumonic D
disease NN disease D
from JJ stopwords O
exposure NN exposure O
to NN stopwords O
Stachybotrys CAPITAL NNP O
chartarum NNS O
and DT stopwords O
Aspergillus CAPITAL DT Aspergillus O
versicolor NN O

Electron CAPITAL NNP electron O
microscopic NN microscopic O
studies NN survey O
of NN stopwords O
Mycoplasma CAPITAL NNP mycoplasma O
( ( O
PPLO CAPITAL NNP pleuropneumonialike_organism O
strain NN strain O
880 DIGITS CD O
) ) O
in NN stopwords inch O
artificial DT artificial O
medium NN medium O
and DT stopwords O
in NN stopwords inch O
tissue NN tissue O
culture NNS culture O

Nevertheless CAPITAL NNP however O
this NN stopwords O
hypothesis NN hypothesis O
is NN stopwords be O
currently NNS presently O
unconfirmed JJ unconfirmed O
by NN stopwords by O
epidemiological NN epidemiologic O
studies NN survey O

Psychosexual CAPITAL NNP psychosexual O
care VB care O
in NN stopwords inch O
a DT stopwords angstrom O
multi-ethnic NN multiethnic O
society NN society O

Five CAPITAL NNP five O
themes NN subject O
emerged NN emerge O
from JJ stopwords O
the NN stopwords O
videotaped NN videotape O
interviews NN interview O
: : O
( ( O
1 DIGITS CD one O
) ) O
Heart-healthy CAPITAL NNP heart-healthy O
practices NN practice O
predominated NN predominate O
the NN stopwords O
responses NN response O

Thirty CAPITAL NNP thirty O
minutes NN minutes O
after DT stopwords after O
the NN stopwords O
injection NN injection O
of NN stopwords O
40 DIGITS CD forty O
microg NN O
of NN stopwords O
8-OH-DPAT/kg CD O
, , O
plasma NN plasma O
cortisol NNS hydrocortisone O
levels NN degree O
had VB stopwords have O
increased NN increase O
from JJ stopwords O
12 DIGITS CD twelve O
to NN stopwords O
149 DIGITS CD O
ng/ml JJ O
, , O
whereupon NN O
they NN stopwords O
fell JJ hide O
, , O
reaching NN reach O
baseline VB baseline O
levels NN degree O
after DT stopwords after O
4 DIGITS CD four O
h. NN O
The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
1-40 CD O
microg NN O
8-OH-DPAT/kg CD O
on NN stopwords on O
plasma NN plasma O
cortisol NNS hydrocortisone O
concentrations NNS concentration O
was VB stopwords Washington O
dose-dependent NN O

La CAPITAL VB lanthanum O
Serna CAPITAL NNP O
et NN O
al DT aluminum O
. . O
( ( O
Lancet CAPITAL VB lancet_arch O
1987 DIGITS CD O
; : O
26 DIGITS CD twenty-six O
: : O
1517 DIGITS CD O
) ) O
were NN stopwords be O
the NN stopwords O
first NN first O
to NN stopwords O
treat NN dainty O
adults DT adult O
with NN stopwords O
recurrent NN perennial D
pericarditis NN pericarditis D
with NN stopwords O
colchicine NNS colchicine T
, , O
and DT stopwords O
were NN stopwords be O
followed JJ follow O
by NN stopwords by O
other JJ stopwords other O
authors DT writer O

Glutathione CAPITAL NNP O
S-transferase CAPITAL NNP O
activity DT activity O
in NN stopwords inch O
epithelial NN epithelial D
ovarian NN ovarian D
cancer VB cancer D
: : O
association DT association O
with NN stopwords O
response NN response O
to NN stopwords O
chemotherapy NNS chemotherapy T
and DT stopwords O
disease NN disease O
outcome JJ result O

A CAPITAL DT angstrom O
modest NN modest O
excess NN excess O
of NN stopwords O
breast NN breast D
cancer VB cancer D
and DT stopwords O
colon NNS colon D
cancer VB cancer D
was VB stopwords Washington O
found JJ found O
in NN stopwords inch O
potentially NN potentially O
linked NN associate O
families VB family O
in NN stopwords inch O
comparison NNS comparison O
with NN stopwords O
potentially NN potentially O
unlinked JJ O
families VB family O
, , O
but NN stopwords merely O
this NN stopwords O
difference NN difference O
was VB stopwords Washington O
not JJ stopwords not O
statistically NN statistically O
significant NN significant O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
3rd CD third O
Congress CAPITAL NNP Congress O
of NN stopwords O
the NN stopwords O
International CAPITAL PRP International O
Society CAPITAL NNP society O
of NN stopwords O
NeuroImmunoModulation CAPITAL NNP O
( ( O
ISNIM CAPITAL PRP O
) ) O

Paclitaxel CAPITAL VB T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
lymphoma NN lymphoma D

Congenital CAPITAL NNP congenital D
aortic DT aortal D
stenosis NN stenosis D

Effect CAPITAL NNP consequence O
of NN stopwords O
cereal NNS cereal O
fibre NN fiber O
source NN beginning O
and DT stopwords O
processing NN processing O
on NN stopwords on O
rectal NN rectal O
epithelial NN epithelial O
cell NNS cell O
proliferation NN proliferation O

Blood CAPITAL NNP blood O
loss NN loss O
in NN stopwords inch O
artificial DT artificial O
interruption NN break O
of NN stopwords O
pregnancy NN pregnancy O

Survey CAPITAL NNP survey O
and DT stopwords O
assessment DT appraisal O
of NN stopwords O
the NN stopwords O
actual DT actual O
state NN state O
of NN stopwords O
routine NN routine O
measurement NN measurement O
of NN stopwords O
glycohaemoglobin/GHb NN O
by NN stopwords by O
commercial NNS commercial O
methods NN method O
: : O
warning NN warning O
to NN stopwords O
the NN stopwords O
users JJ user O
and DT stopwords O
the NN stopwords O
providers NN supplier O

Additionally CAPITAL DT additionally O
, , O
epidemiologic NN epidemiologic O
evidence NN evidence O
of NN stopwords O
a DT stopwords angstrom O
marked NN tag O
decline NN decline O
in NN stopwords inch O
new JJ new O
KS CAPITAL NNP Kansas D
since NN O
the NN stopwords O
widespread NN widespread O
use JJ use O
of NN stopwords O
highly NN highly T
active DT active_agent T
antiretroviral DT T
therapy NN therapy T
( ( T
HAART CAPITAL NNP drug_cocktail T
) ) T
advocates DT advocate O
its NN stopwords information_technology O
use JJ use O

Seventy-one CAPITAL NNP seventy-one O
percent NN percentage O
said VB state O
that NN stopwords O
they NN stopwords O
anticipate DT expect O
making NN devising O
a DT stopwords angstrom O
change NNS change O
in NN stopwords inch O
their NN stopwords O
lifestyle NN life_style O
in NN stopwords inch O
the NN stopwords O
future JJ future O
, , O
and DT stopwords O
70 DIGITS CD seventy O
% NN O
said VB state O
that NN stopwords O
they NN stopwords O
would NN O
recommend NN recommend O
their NN stopwords O
lifestyle NN life_style O
to NN stopwords O
their NN stopwords O
patients VB patient O

the NN stopwords O
patient VB patient O
was VB stopwords Washington O
a DT stopwords angstrom O
62-year-old CD O
man VB man O
with NN stopwords O
squamous NN D
cell NNS cell D
lung NN lung D
cancer VB cancer D
, , O
which NN stopwords O
was VB stopwords Washington O
first NN first O
successfully NN successfully O
treated NN treat O
by NN stopwords by O
a DT stopwords angstrom O
combination NNS combination T
of NN stopwords T
radiation VB radiation T
therapy NN therapy T
and DT stopwords T
chemotherapy NNS chemotherapy T
, , O
but NN stopwords merely O
showed NN show O
local NN local O
recurrence NN recurrence O
after DT stopwords after O
8 DIGITS CD eight O
months NN calendar_month O

Fever CAPITAL NNP fever D
in NN stopwords inch O
Africa CAPITAL DT Africa O
: : O
do NN stopwords bash O
patients VB patient O
know NN know O
when NN stopwords O
they NN stopwords O
are DT stopwords are O
hot NN hot O
? . O

Vascular CAPITAL VB vascular D
Parkinson CAPITAL VB Parkinson D
syndromes NN syndrome D
: : O
a DT stopwords angstrom O
controversial NNS controversial O
concept NNS concept O

CONCLUSION CAPITAL NNP decision O
: : O
These CAPITAL NNP O
data VB data O
are DT stopwords are O
consistent NNS consistent O
with NN stopwords O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
maternal VB maternal O
expression NN expression O
of NN stopwords O
PIBF CAPITAL NNP O
in NN stopwords inch O
T-lymphocytes CAPITAL NNP O
soon NN soon O
after DT stopwords after O
trophoblast NN trophoblast O
invasion NN invasion O
may VB May O
depend NN depend O
on NN stopwords on O
successful NN successful O
implantation JJ implantation O

The CAPITAL NNP O
inhibitory NN inhibitory O
effect NN consequence O
of NN stopwords O
n-3 SYM T
polyunsaturated NN polyunsaturated T
fatty VB fatso T
acids DT acid T
on NN stopwords on O
human NN homo D
colorectal NNS colorectal D
cancer VB cancer D
has VB stopwords hour_angle O
been NN stopwords be O
speculated NN speculate O
on NN stopwords on O
from JJ stopwords O
epidemiological NN epidemiologic O
data VB data O
and DT stopwords O
animal DT animal O
studies NN survey O

DESIGN CAPITAL NNP design O
: : O
Randomised CAPITAL VB randomize O
trial NN test O
of NN stopwords O
three NN three O
approaches DT approach O
to NN stopwords O
sore NN sore D
throat NN throat D
: : O
a DT stopwords angstrom O
10 DIGITS CD ten O
day VB day O
prescription NN prescription O
of NN stopwords O
antibiotics DT antibiotic T
, , O
no NNS stopwords no O
antibiotics DT antibiotic O
, , O
or NN stopwords Oregon O
a DT stopwords angstrom O
delayed NN delay O
prescription NN prescription O
if NN stopwords O
the NN stopwords O
sore NN sore D
throat NN throat D
had VB stopwords have O
not JJ stopwords not O
started NN get_down O
to NN stopwords O
settle NN settle O
after DT stopwords after O
three NN three O
days VB days O

Simultaneous CAPITAL NNP coincident O
microsurgical NN T
vasal NN T
reconstruction NN Reconstruction T
and DT stopwords O
varicocele NN varicocele T
ligation NN ligation T
: : O
safety VB safety O
profile NN profile O
and DT stopwords O
outcomes JJ result O

Olanzapine CAPITAL NNP T
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
atypical DT atypical O
antipsychotic DT major_tranquilizer O
effective NN effective O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
schizophrenic JJ schizophrenic D
patients VB patient D

The CAPITAL NNP O
difference NN difference O
between NN stopwords between O
the NN stopwords O
calcium-vitamin VB O
D CAPITAL NN vitamin_D O
and DT stopwords O
placebo NN placebo O
groups NN group O
was VB stopwords Washington O
significant NN significant O
at DT stopwords astatine O
all DT stopwords all O
skeletal NN skeletal O
sites NN site O
after DT stopwords after O
one JJ one O
year NN year O
, , O
but NN stopwords merely O
it NN stopwords information_technology O
was VB stopwords Washington O
significant NN significant O
only JJ stopwords lone O
for NN stopwords O
total-body NN O
bone NN bone O
mineral NN mineral O
density NN density O
in NN stopwords inch O
the NN stopwords O
second NN second O
and DT stopwords O
third NN one-third O
years NN old_age O

IX CAPITAL PRP nine O

An CAPITAL DT Associate_in_Nursing O
electrophysiology NN O
study NN survey O

New CAPITAL NNP new O
approaches DT approach O
to NN stopwords O
stroke NN stroke D
require NN necessitate O
immediate JJ immediate O
action DT action O

CyberCHEST CAPITAL NNP O

Doppler CAPITAL NNP Doppler O
echocardiography NN echocardiography O
reveals NN uncover O
a DT stopwords angstrom O
21-mm CD O
Hg CAPITAL NNP mercury O
gradient NN gradient O
across DT across O
the NN stopwords O
valve NN valve O
at DT stopwords astatine O
rest NN remainder O

The CAPITAL NNP O
follow-up JJ follow-up O
ranged VB range O
from JJ stopwords O
1 DIGITS CD one O
to NN stopwords O
4.5 CD O
years NN old_age O
( ( O
mean NN mean O
2 DIGITS CD two O
years NN old_age O
) ) O

A CAPITAL DT angstrom O
fine NN fine O
structural NN structural O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
epidermis NN epidermis O
of NN stopwords O
the NN stopwords O
earthworm VB earthworm O
, , O
Lumbricus CAPITAL NNP O
terrestris NN O
L. CAPITAL NNP O

CONCLUSION CAPITAL NNP decision O
: : O
In CAPITAL PRP inch O
this NN stopwords O
series NN series O
, , O
PCCC CAPITAL NNP T
with NN stopwords T
anterior DT front_tooth T
vitrectomy NN vitrectomy T
was VB stopwords Washington O
the NN stopwords O
only JJ stopwords lone O
effective NN effective O
method NN method O
of NN stopwords O
preventing NN prevent O
or NN stopwords Oregon O
delaying NN delay O
secondary NN secondary D
cataract VB cataract D
formation NN formation D
in NN stopwords inch O
infants NN baby O
and DT stopwords O
children JJ child O

The CAPITAL NNP O
prison NN prison O
patient VB patient O

Hepatocerebral CAPITAL NNP D
degeneration NN degeneration D
( ( D
portal NN portal D
systemic NN systemic D
encephalopathy NN brain_disorder D
) ) D

Child CAPITAL NNP child O
sexual NN sexual O
abuse DT maltreatment O
: : O
when NN stopwords O
a DT stopwords angstrom O
doctor NN doctor O
's POS O
duty NN duty O
to NN stopwords O
report NN report O
abuse DT maltreatment O
conflicts NNS conflict O
with NN stopwords O
a DT stopwords angstrom O
duty NN duty O
of NN stopwords O
confidentiality NNS confidentiality O
to NN stopwords O
the NN stopwords O
victim NN victim O

Even CAPITAL NNP evening O
after DT stopwords after O
correction NNS correction O
, , O
8 DIGITS CD eight O
out JJ stopwords out O
of NN stopwords O
11 DIGITS CD eleven O
methods NN method O
still JJ still O
remained NN stay O
of NN stopwords O
little NN little O
practical NN practical O
use JJ use O
because NN stopwords O
of NN stopwords O
their NN stopwords O
large NN large O
relative NN relative O
errors NN mistake O

Surgical CAPITAL NNP surgical O
aspects DT aspect O
in NN stopwords inch O
the NN stopwords O
multidisciplinary NN O
treatment NN treatment O
of NN stopwords O
soft NN soft D
tissue NN tissue D
sarcomas VB sarcoma D

These CAPITAL NNP O
three NN three O
NICUs CAPITAL NNP neonatal_intensive_care_unit O
moved NN travel O
infants NN baby O
from JJ stopwords O
radiant VB beaming O
warmers NN heater O
into NN stopwords O
incubators NN incubator O
at DT stopwords astatine O
significantly NN significantly O
different NN different O
mean NN mean O
ages DT age O

for NN stopwords O
patients VB patient O
with NN stopwords O
stage NN phase D
i NN stopwords iodine D
or NN stopwords Oregon D
ii NN two D
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
, , O
surgical NN surgical T
resection NN resection T
is NN stopwords be O
considered NNS see O
the NN stopwords O
standard NN standard O
of NN stopwords O
care VB care O

stages NN phase O
of NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
that NN stopwords O
are DT stopwords are O
potential NN potential O
candidates VB campaigner O
for NN stopwords O
surgical NN surgical T
resection NN resection T
have VB stopwords rich_person O
been NN stopwords be O
treated NN treat O
in NN stopwords inch O
several NN several O
ways VB ways O
: : O
surgery NN surgery T
alone DT alone O
is NN stopwords be O
curative NNS remedy O
in NN stopwords inch O
only JJ stopwords lone O
two-thirds NN two-thirds O
of NN stopwords O
cases VB case O
and DT stopwords O
post-operative NN T
radiotherapy VB radiotherapy T
( ( T
rt NN T
) ) T
provides NN supply O
only JJ stopwords lone O
weak NN weak O
control NNS control O
of NN stopwords O
advanced-stage DT O
disease NN disease O

We CAPITAL NNP O
treated NN treat O
two NN two O
children JJ child O
with NN stopwords O
influenza-associated NN D
acute DT acute_accent D
encephalopathy NN brain_disorder D
by NN stopwords by O
a DT stopwords angstrom O
combination NNS combination T
of NN stopwords T
mild NN mild T
hypothermia NN hypothermia T
and DT stopwords T
steroid NN steroid T
pulse NN pulsation T
therapy NN therapy T

Preparing CAPITAL NNP fix O
for NN stopwords O
thalidomide NN thalidomide T
's POS T
comeback NNS rejoinder O

METHODS CAPITAL NNP method O
: : O
In CAPITAL PRP inch O
398 DIGITS CD O
hospitals NN hospital O
, , O
7169 DIGITS CD O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
were NN stopwords be O
randomly VB randomly O
assigned DT delegate O
to NN stopwords O
weight-adjusted NN O
, , O
accelerated DT accelerate O
infusion NN infusion O
of NN stopwords O
100 DIGITS CD hundred O
mg NN milligram O
of NN stopwords O
alteplase DT T
or NN stopwords Oregon O
to NN stopwords O
a DT stopwords angstrom O
bolus NN bolus O
of NN stopwords O
50 DIGITS CD fifty O
mg NN milligram O
of NN stopwords O
alteplase DT T
over JJ stopwords over O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
1 DIGITS CD one O
to NN stopwords O
3 DIGITS CD three O
minutes NN minutes O
followed JJ follow O
30 DIGITS CD thirty O
minutes NN minutes O
later NN later O
by NN stopwords by O
a DT stopwords angstrom O
second NN second O
bolus NN bolus O
of NN stopwords O
50 DIGITS CD fifty O
mg NN milligram O
( ( O
or NN stopwords Oregon O
40 DIGITS CD forty O
mg NN milligram O
for NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
weighed NN weigh O
less NN lupus_erythematosus O
than NN stopwords O
60 DIGITS CD sixty O
kg NN kilogram O
) ) O

Time-domain CAPITAL NNP O
quanification NN O
of NN stopwords O
amplitude DT amplitude O
, , O
chemical NNS chemical O
shift NN shift O
, , O
apparent DT apparent O
relaxation NN relaxation O
time NN time O
T2 CAPITAL CD O
, , O
and DT stopwords O
phase NN phase O
by NN stopwords by O
wavelet-transform VB O
analysis DT analysis O

A CAPITAL DT angstrom O
reluctant NN loath O
doctor NN doctor O
shopper NN shopper O

Our CAPITAL NNP O
purpose NN purpose O
was VB stopwords Washington O
to NN stopwords O
systematically NN systematically O
review NN reappraisal O
data VB data O
on NN stopwords on O
brain NN brain O
serotonin NN serotonin O
neurotoxicity JJ O
in NN stopwords inch O
animals DT animal O
treated NN treat O
with NN stopwords O
fenfluramines JJ T
and DT stopwords O
the NN stopwords O
evidence NN evidence O
linking NN associate O
fenfluramines JJ T
to NN stopwords O
primary NN primary D
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D
( ( D
PPH CAPITAL NNP D
) ) D

Is CAPITAL PRP be O
the NN stopwords O
task VB undertaking O
hopeless NN hopeless O
? . O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
the NN stopwords O
early VB early O
outcome JJ result O
of NN stopwords O
acute DT acute_accent O
myocardial NN myocardial D
infarction NN infarct D
in NN stopwords inch O
women NN woman O
and DT stopwords O
men NN work_force O

Then CAPITAL NNP then O
we NN stopwords O
approach DT approach O
among DT O
other JJ stopwords other O
things NN things O
the NN stopwords O
way VB manner O
to NN stopwords O
consider NNS see O
the NN stopwords O
maxillary VB upper_jaw O
process NN procedure O
with NN stopwords O
regard NN respect O
to NN stopwords O
the NN stopwords O
other JJ stopwords other O
facial VB facial O
processes NN procedure O

Adjuvant CAPITAL DT adjuvant T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
early VB early O
soft NN soft D
tissue NN tissue D
sarcoma VB sarcoma D
and DT stopwords O
palliative VB palliative T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
advanced DT advance O
soft NN soft D
tissue NN tissue D
sarcoma VB sarcoma D
in NN stopwords inch O
adults DT adult O

The CAPITAL NNP O
stable NN stable O
carbon VB carbon O
isotope NN isotope O
compositions NNS composition O
of NN stopwords O
individual NN person O
amino DT amino O
acids DT acid O
in NN stopwords inch O
Murchison CAPITAL NNP O
support NN support O
an DT stopwords Associate_in_Nursing O
extraterrestrial NN extraterrestrial_being O
origin IN beginning O
-- : O
rather VB rather O
than NN stopwords O
a DT stopwords angstrom O
terrestrial NN tellurian O
overprint JJ overprint O
of NN stopwords O
biological NN biological O
amino DT amino O
acids-although DT O
reservations NN reservation O
have VB stopwords rich_person O
persisted NN prevail O

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

Spontaneous CAPITAL NNP spontaneous O
rectus NN rectus D
sheath NN sheath D
hematoma NN hematoma D
during NN stopwords O
pregnancy NN pregnancy O
mimicking NN mimic O
abruptio DT D
placenta NN placenta D

Clinical CAPITAL NNP clinical O
familial VB familial O
case VB case O
study NN survey O

Municipal CAPITAL NNP municipal O
animal DT animal O
control NNS control O
ordinances JJ regulation O
-- : O
some NN stopwords some O
legal NN legal O
issues NN issue O

CONCLUSIONS CAPITAL NNP decision O
: : O
In CAPITAL PRP inch O
men NN work_force O
and DT stopwords O
women NN woman O
65 DIGITS CD sixty-five O
years NN old_age O
of NN stopwords O
age DT age O
or NN stopwords Oregon O
older JJ aged O
who NN stopwords World_Health_Organization O
are DT stopwords are O
living NN life O
in NN stopwords inch O
the NN stopwords O
community NNS community O
, , O
dietary NN dietary T
supplementation NN supplement T
with NN stopwords T
calcium VB calcium T
and DT stopwords T
vitamin NN vitamin T
D CAPITAL NN vitamin_D T
moderately NN reasonably O
reduced NN reduce O
bone NN bone D
loss NN loss D
measured NN measure O
in NN stopwords inch O
the NN stopwords O
femoral JJ femoral O
neck JJ neck O
, , O
spine JJ spinal_column O
, , O
and DT stopwords O
total NN sum O
body NN body O
over JJ stopwords over O
the NN stopwords O
three-year NN O
study NN survey O
period NN time_period O
and DT stopwords O
reduced NN reduce O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
nonvertebral JJ D
fractures NN fracture D

The CAPITAL NNP O
association DT association O
of NN stopwords O
parvovirus NN parvovirus D
B19 CAPITAL NNP D
infection NN infection D
and DT stopwords O
hydrops NN edema D
fetalis JJ D
is NN stopwords be O
well NN well O
known NN know O

Arrest CAPITAL DT apprehension O
of NN stopwords O
dilation NN dilation O
was VB stopwords Washington O
the NN stopwords O
most NN stopwords most O
common NNS park O
indication NN indication O
in NN stopwords inch O
both NN stopwords both O
`` `` O
corrected NNS correct O
'' POS O
subgroups NN subgroup O
( ( O
23.4 CD O
and DT stopwords O
24.6 CD O
% NN O
, , O
respectively NN respectively O
) ) O

Blacks CAPITAL NNP black O
were NN stopwords be O
less NN lupus_erythematosus O
likely NN likely O
to NN stopwords O
have VB stopwords rich_person O
poorly NN ailing O
differentiated NN distinguish O
( ( O
grade NN class O
3 DIGITS CD three O
) ) O
tumors NN tumor D
( ( O
odds JJ odds O
ratio VB ratio O
( ( O
OR CAPITAL NNP Oregon O
) ) O
, , O
0.44 LS O
; : O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
, , O
0.22-0.88 LS O
) ) O
and DT stopwords O
lymphoid NN lymphoid O
reaction NN chemical_reaction O
( ( O
OR CAPITAL NNP Oregon O
, , O
0.49 LS O
; : O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
, , O
0.26-0.90 LS O
) ) O
when NN stopwords O
compared NNS compare O
with NN stopwords O
whites NN White O

RESULTS CAPITAL NNP consequence O
: : O
Parasites CAPITAL VB parasite O
were NN stopwords be O
identified NN identify O
in NN stopwords inch O
26.2 CD O
% NN O
of NN stopwords O
population NN population O

Index CAPITAL PRP index O
to NN stopwords O
current NNS current O
literature NN literature O

Cure CAPITAL NNP remedy O
of NN stopwords O
Helicobacter CAPITAL NNP D
pylori NN pylorus D
infection NN infection D
improves JJ better O
gastric VB gastric O
acid DT acid O
secretion NN secretion O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
corpus NNS principal D
gastritis VB gastritis D

The CAPITAL NNP O
Federated CAPITAL NNP federate O
Council CAPITAL NNP council O
of NN stopwords O
Internal CAPITAL PRP internal O
Medicine CAPITAL NNP medicine O
's POS O
resource NN resource O
guide NN usher O
for NN stopwords O
residency NN residency O
education NN education O
: : O
an DT stopwords Associate_in_Nursing O
instrument NN instrument O
for NN stopwords O
curricular NNS curricular O
change NNS change O

One CAPITAL NNP one O
hundred NN hundred O
and DT stopwords O
twenty-seven NN twenty-seven O
departments NN department O
responded NN react O
to NN stopwords O
a DT stopwords angstrom O
questionnaire NN questionnaire O
sent NN sent O
in NN stopwords inch O
March CAPITAL NNP March O
1996 DIGITS CD O

Comparative CAPITAL NNP comparative O
fates VB destiny O
of NN stopwords O
intravenously NN intravenously O
and DT stopwords O
orally NN orally O
administered DT administer O
aldosterone DT aldosterone O
: : O
evidence NN evidence O
for NN stopwords O
extrahepatic NN O
formation NN formation O
of NN stopwords O
acid-hydrolyzable DT O
conjugate NNS conjugate_solution O
in NN stopwords inch O
man VB man O

METHODS CAPITAL NNP method O
AND CAPITAL DT O
RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
present NN present O
multicenter NN O
registry NN register O
included NN include O
719 DIGITS CD O
consecutive NNS back-to-back O
patients VB patient O
with NN stopwords O
major VB major D
pulmonary NN pneumonic D
embolism NN embolism D
according DT harmonize O
to NN stopwords O
clinical JJ clinical O
, , O
echocardiographic NN O
, , O
scintigraphic JJ O
, , O
and DT stopwords O
cardiac VB cardiac O
catheterization VB catheterization O
criteria JJ standard O

STUDY CAPITAL NNP survey O
SELECTION CAPITAL NNP choice O
: : O
Reports CAPITAL NNP report O
dealing NN dealing O
with NN stopwords O
long-term NN long-run O
effects NN effects O
of NN stopwords O
fenfluramines JJ T
on NN stopwords on O
brain NN brain O
serotonin NN serotonin O
neurons JJ nerve_cell O
, , O
body NN body O
weight NN weight O
, , O
and DT stopwords O
pulmonary NN pneumonic O
function JJ function O
in NN stopwords inch O
animals DT animal O
and DT stopwords O
humans NN world O

In CAPITAL PRP inch O
vitro NN O
and DT stopwords O
in NN stopwords inch O
vivo NN O
comparison NNS comparison O
between NN stopwords between O
the NN stopwords O
effects NN effects O
of NN stopwords O
treatment NN treatment O
with NN stopwords O
adenosine DT adenosine T
triphosphate NN T
and DT stopwords O
treatment NN treatment O
with NN stopwords O
buthionine NN T
sulfoximine NN T
on NN stopwords on O
chemosensitization NNS O
and DT stopwords O
tumour NN tumor O
growth NN growth O
of NN stopwords O
B16 CAPITAL NNP D
melanoma NN melanoma D

based VB establish O
on NN stopwords on O
the NN stopwords O
results NN consequence O
of NN stopwords O
three NN three O
well-designed NN O
studies NN survey O
demonstrating NN show O
the NN stopwords O
vaccine NN vaccine O
's POS O
safety VB safety O
, , O
immunogenicity JJ immunogenicity O
, , O
and DT stopwords O
efficacy NN efficacy O
, , O
the NN stopwords O
vaccine NN vaccine T
is NN stopwords be O
safe VB safe O
and DT stopwords O
effective NN effective O
for NN stopwords O
active DT active_agent O
immunization JJ immunization O
of NN stopwords O
children JJ child O
< NN O
2 DIGITS CD two O
years NN old_age O
of NN stopwords O
age DT age O
against DT stopwords O
invasive NN invasive D
disease NN disease D
caused VB cause D
by NN stopwords by D
seven NN seven D
streptococcus NN streptococcus D
pneumoniae NN D
serotypes NN D
included NN include O
in NN stopwords inch O
the NN stopwords O
vaccine NN vaccine O

The CAPITAL NNP O
administration DT administration O
of NN stopwords O
dioxins NN dioxin O
during NN stopwords O
pregnancy NN pregnancy O
and DT stopwords O
nursing RB nursing O
causes VB cause O
altered DT change O
development NN development O
of NN stopwords O
the NN stopwords O
reproductive NN generative O
system NN system O
, , O
decreased NN decrease O
spermatogenesis NN spermatogenesis O
, , O
hypothyroidism NN hypothyroidism D
and DT stopwords O
disturbed NN disturb O
psychomotor NN psychomotor O
development NN development O
in NN stopwords inch O
the NN stopwords O
offspring JJ offspring O

CONTEXT CAPITAL NNP context O
: : O
Susceptibility CAPITAL NNP susceptibility O
to NN stopwords O
multiple NN multiple D
sclerosis JJ sclerosis D
( ( D
MS CAPITAL NNP multiple_sclerosis D
) ) D
involves NN involve O
a DT stopwords angstrom O
genetically NN genetically O
complex NNS complex O
autoimmune DT autoimmune O
component NNS component O

New CAPITAL NNP new O
asthma DT asthma D
guidelines NN guideline O
emphasize NN stress O
better NN better O
diagnosis NN diagnosis O
, , O
stricter NN rigorous O
control NNS control O

Synthesis CAPITAL NNP synthesis O
and DT stopwords O
fragmentation NN atomization O
behavior NN behavior O
of NN stopwords O
deuterium-labeled NN O
12-keto CD O
steroids NN steroid O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
VIIIth CAPITAL NNP O
International CAPITAL PRP International O
Conference CAPITAL NNP conference O
on NN stopwords on O
the NN stopwords O
Na/K-ATPase CAPITAL NNP O
and DT stopwords O
Related CAPITAL NNP associate O
Transport CAPITAL NNP conveyance O
ATPases CAPITAL DT O

Fluoride CAPITAL NNP fluoride T
treatment NN treatment T
increased NN increase O
serum NN serum O
IGF-1 CAPITAL PRP O
, , O
bone NN bone O
turnover NN employee_turnover O
, , O
and DT stopwords O
bone NN bone O
mass VB mass O
, , O
but NN stopwords merely O
not JJ stopwords not O
bone NN bone O
strength NN strength O
, , O
in NN stopwords inch O
rabbits NN rabbit O

A CAPITAL DT angstrom O
note JJ note O
on NN stopwords on O
the NN stopwords O
assay DT assay O
of NN stopwords O
corticoid NNS corticosteroid O
preparations NN preparation O
by NN stopwords by O
tetrazolium NN O
salt VB salt O

The CAPITAL NNP O
frequency JJ frequency O
of NN stopwords O
parasitation NN D
was VB stopwords Washington O
superior NN superior O
in NN stopwords inch O
adults DT adult O
( ( O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.0001 LS O
) ) O
, , O
with NN stopwords O
a DT stopwords angstrom O
slight JJ rebuff O
predominance NN predominance O
in NN stopwords inch O
the NN stopwords O
female JJ female O
sex NN sexual_activity O

< NN O
TO_SEE CAPITAL NNP O
> NN O
We CAPITAL NNP O
report NN report O
a DT stopwords angstrom O
case VB case O
of NN stopwords O
a DT stopwords angstrom O
29-year-old CD O
male VB male O
chronic NN chronic O
HBV CAPITAL NNP O
carrier VB carrier O
who NN stopwords World_Health_Organization O
developed NN develop O
fulminant JJ fulminant D
reactivated NN reactivate D
HBV CAPITAL NNP D
infection NN infection D
following JJ following O
intensive NN intensifier O
chemotherapy NNS chemotherapy T
for NN stopwords O
stage NN phase D
IVB CAPITAL PRP D
large NN large D
cell NNS cell D
B-cell CAPITAL NNP D
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D
associated DT associate O
with NN stopwords O
extensive NN extensive O
central NNS central O
nervous RB nervous O
system NN system O
and DT stopwords O
bone NN bone O
marrow NN marrow O
involvement NN engagement O

conclusions NNS decision O
: : O
both NN stopwords both O
the NN stopwords O
response NN response O
rate VB rate O
and DT stopwords O
survival NN survival O
data VB data O
in NN stopwords inch O
this NN stopwords O
retrospective NN retrospective O
study NN survey O
suggest NN propose O
a DT stopwords angstrom O
high NN high O
degree NN degree O
of NN stopwords O
activity DT activity O
of NN stopwords O
this NN stopwords O
combination NNS combination T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
malignant VB malignant D
pleural NN pleural D
effusions NN effusion D
from JJ stopwords D
nsclc JJ D

Sudden CAPITAL NNP sudden O
death NN death O
in NN stopwords inch O
young NN young O
athletes DT athlete O
: : O
screening NN screening O
for NN stopwords O
the NN stopwords O
needle JJ acerate_leaf O
in NN stopwords inch O
a DT stopwords angstrom O
haystack VB haystack O

Chronic CAPITAL NNP chronic T
vagus NN vagus T
nerve RB nerve T
stimulation JJ stimulation T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
seizures JJ seizure D

Immunoglobulin CAPITAL PRP immunoglobulin O
superfamily NN superfamily O
molecules NN molecule O
in NN stopwords inch O
the NN stopwords O
brain NN brain O
are DT stopwords are O
involved NN involve O
in NN stopwords inch O
distinct NN distinct O
aspects DT aspect O
of NN stopwords O
nervous RB nervous O
system NN system O
histogenesis NN O
, , O
for NN stopwords O
example NN example O
neuronal JJ neural O
migration NN migration O
and DT stopwords O
axonal DT axonal O
growth NN growth O

Inverse CAPITAL PRP inverse O
correlation NNS correlation O
between NN stopwords between O
loss NN loss O
of NN stopwords O
heterozygosity NN heterozygosity O
of NN stopwords O
the NN stopwords O
short NN short O
arm DT arm O
of NN stopwords O
chromosome NN chromosome O
12 DIGITS CD twelve O
and DT stopwords O
p15ink4B/p16ink4 NN O
gene NN gene O
inactivation NN inactivation O
in NN stopwords inch O
childhood JJ childhood D
acute DT acute_accent D
lymphoblastic NN D
leukaemia NN leukemia D

An CAPITAL DT Associate_in_Nursing O
easy-to-use VB O
technique NN technique O
for NN stopwords O
detection NN detection O
of NN stopwords O
antibodies DT antibody O
specific NN particular O
for NN stopwords O
the NN stopwords O
parasite NN parasite O
L. CAPITAL NNP O
donovani NN O
in NN stopwords inch O
human NN homo O
serum NN serum O
sample VB sample O
has VB stopwords hour_angle O
been NN stopwords be O
developed NN develop O

Both CAPITAL NNP both O
right-sided NN O
and DT stopwords O
left-sided NN O
heart NN heart O
valves NN valve O
were NN stopwords be O
involved NN involve O

RESULTS CAPITAL NNP consequence O
: : O
Familial CAPITAL NNP familial O
and DT stopwords O
AL CAPITAL DT aluminum O
echocardiograms NN echocardiogram O
were NN stopwords be O
morphologically NN morphologically O
indistinguishable NN identical O
, , O
with NN stopwords O
similar NN similar O
left NN left O
ventricular NN ventricular O
wall VB wall O
thickness NN thickness O
, , O
mean NN mean O
( ( O
SD CAPITAL NNP South_Dakota O
) ) O
15.4 CD O
( ( O
2.3 CD O
) ) O
nu NNS nu O
15.8 CD O
( ( O
2.5 CD O
) ) O
mm NNS millimeter O
, , O
respectively NN respectively O
; : O
right NN right O
ventricular NN ventricular O
wall VB wall O
thickness NN thickness O
was VB stopwords Washington O
also DT besides O
similar NN similar O
between NN stopwords between O
amyloid DT amyloid O
types NN type O
: : O
9.6 CD O
( ( O
2.8 CD O
) ) O
nu NNS nu O
9.7 CD O
( ( O
6.5 CD O
) ) O
mm NNS millimeter O
, , O
respectively NN respectively O

Hyperbaric CAPITAL NNP T
oxygen JJ oxygen T
, , T
whole-body NN T
X CAPITAL NN ten T
irradiation NN irradiation T
, , T
and DT stopwords T
cyclophosphamide NNS T
combination NNS combination T
therapy NN therapy T
in NN stopwords inch O
mouse NN mouse D
leukemia NN leukemia D
L1210 CAPITAL NNP D

conclusion NNS decision O
: : O
oxaliplatin NN T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
fluorouracil/folinic JJ T
acid DT acid T
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
effective NN effective O
treatment NN treatment O
option JJ option O
for NN stopwords O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
colorectal NNS colorectal D
cancer VB cancer D
, , O
both NN stopwords both O
as DT stopwords arsenic O
a DT stopwords angstrom O
first-line NN O
therapy NN therapy O
and DT stopwords O
in NN stopwords inch O
patients VB patient O
refractory NN furnace_lining O
to NN stopwords O
previous NN previous O
chemotherapy NNS chemotherapy O

conclusions NNS decision O
: : O
lymph NN lymph O
node JJ node O
immunoreactivity JJ O
and DT stopwords O
li NN lithium O
significantly NN significantly O
influence NN influence O
long NN hanker O
term NN term O
survival NN survival O
after DT stopwords after O
curative NNS remedy T
surgery NN surgery T
for NN stopwords O
patients VB patient O
with NN stopwords O
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
lung NN lung D
and DT stopwords O
may VB May O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
stratifying NN stratify O
patients VB patient O
for NN stopwords O
prospective NN prospective O
trials NN test O
of NN stopwords O
adjuvant DT adjuvant O
treatment NN treatment O
, , O
including NN include O
immunotherapy JJ immunotherapy O

The CAPITAL NNP O
enzyme NN enzyme O
activity DT activity O
of NN stopwords O
mitogen-activated NN O
protein NN protein O
kinase NN kinase O
( ( O
MAP CAPITAL NNP map O
kinase NN kinase O
) ) O
increases NN addition O
in NN stopwords inch O
response NN response O
to NN stopwords O
agents DT agent O
acting DT acting O
on NN stopwords on O
a DT stopwords angstrom O
variety NN assortment O
of NN stopwords O
cell NNS cell O
surface NN surface O
receptors NN receptor O
, , O
including NN include O
receptors NN receptor O
linked NN associate O
to NN stopwords O
heterotrimeric NN O
G CAPITAL NN gram O
proteins NN protein O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Coronary CAPITAL NNP coronary_thrombosis O
artery DT artery O
problems NN problem O
during NN stopwords O
homograft NN homograft O
aortic DT aortal O
valve NN valve O
replacement NN replacement O
: : O
role NN function O
of NN stopwords O
transesophageal NN O
echocardiography NN echocardiography O

It CAPITAL PRP information_technology O
was VB stopwords Washington O
found JJ found O
that NN stopwords O
with NN stopwords O
appropriate DT allow O
enzymes NN enzyme O
, , O
peak NN extremum O
outputs JJ end_product O
occurred JJ happen O
within NN inside O
approximately DT approximately O
5 DIGITS CD five O
min NN minute O
( ( O
4-20 CD O
times NN times O
faster VB fast O
than NN stopwords O
without NN O
enzymes NN enzyme O
) ) O
and DT stopwords O
peak NN extremum O
response NN response O
magnitudes VB magnitude O
were NN stopwords be O
up JJ stopwords up O
to NN stopwords O
nine-fold NN nonuple O
greater NN greater O
than NN stopwords O
without NN O
enzymes NN enzyme O

Special CAPITAL NNP special O
report NN report O
: : O
pressure-reducing NN T
support NN support T
surfaces NN surface T
in NN stopwords inch O
the NN stopwords O
prevention NN prevention O
and DT stopwords O
treatment NN treatment O
of NN stopwords O
pressure NN pressure D
ulcers JJ ulcer D
: : O
group NN group O
1 DIGITS CD one O
technologies NN technology O

OBSERVATIONS CAPITAL NNP observation O
: : O
Localized CAPITAL NNP place O
Darier CAPITAL NNP D
disease NN disease D
occurred JJ happen O
with NN stopwords O
equal NN peer O
frequency JJ frequency O
in NN stopwords inch O
males VB male O
and DT stopwords O
females JJ female O

Direct CAPITAL NNP direct O
readings NN reading O
can VB stopwords can O
be NN stopwords beryllium O
obtained NN obtain O
after DT stopwords after O
signal NN signal O
enhancement NN enhancement O
through NN stopwords done O
a DT stopwords angstrom O
photomultiplier NN O
tube NN tube O
within NN inside O
5 DIGITS CD five O
min NN minute O

Keeping CAPITAL NNP keeping O
us JJ United_States O
on NN stopwords on O
our NN stopwords O
toes NN toe O
! . O

Shark CAPITAL NNP shark T
cartilage VB cartilage T
for NN stopwords O
cancer VB cancer D
? . O

An CAPITAL DT Associate_in_Nursing O
open JJ open O
future JJ future O

Studies CAPITAL NNP survey O
on NN stopwords on O
nitrogen NN nitrogen O
metabolism NN metamorphosis O
of NN stopwords O
Penicillium CAPITAL NNP Penicillium O
chrysogenum NN O
Thom CAPITAL NNP O
. . O
I CAPITAL PRP iodine O
. . O
Effects CAPITAL NNP effects O
of NN stopwords O
lactose NN lactose O
and DT stopwords O
sucrose NN sucrose O
additions DT addition O
on NN stopwords on O
nitrogen NN nitrogen O
metabolism NN metamorphosis O

High CAPITAL NNP high O
affinity DT affinity O
binding NN binding O
of NN stopwords O
biotin NN biotin O
to NN stopwords O
immobilized JJ immobilize O
streptavidin NN O
was VB stopwords Washington O
clearly NNS clearly O
detectable NN detectable O
at DT stopwords astatine O
receptor NN receptor O
surface NN surface O
concentrations NNS concentration O
as DT stopwords arsenic O
low NN low O
as DT stopwords arsenic O
1-2 CD O
x NN ten O
10 DIGITS CD ten O
( ( O
10 DIGITS CD ten O
) ) O
binding NN binding O
sites/mm2 NN O

Schizophrenic CAPITAL NNP schizophrenic D
illnesses NN illness D
occur JJ happen O
with NN stopwords O
approximately DT approximately O
the NN stopwords O
same VB stopwords Lapp O
incidence NN incidence O
in NN stopwords inch O
all DT stopwords all O
human NN homo O
populations NN population O
with NN stopwords O
a DT stopwords angstrom O
characteristic NNS feature O
distribution NN distribution O
( ( O
slightly JJ slightly O
earlier VB earlier O
in NN stopwords inch O
males VB male O
) ) O
of NN stopwords O
ages DT age O
of NN stopwords O
onset JJ onset O

Social CAPITAL NNP sociable O
ties NN necktie O
and DT stopwords O
susceptibility NN susceptibility O
to NN stopwords O
the NN stopwords O
common NNS park D
cold NNS cold D

Common CAPITAL NNP park O
nutritional JJ nutritional O
issues NN issue O
in NN stopwords inch O
pediatric NN pediatric O
and DT stopwords O
adult DT adult O
critical JJ critical O
care VB care O
medicine NN medicine O

despite NN contempt O
the NN stopwords O
poor NN poor_people O
overall JJ overall O
prognosis NN prognosis O
in NN stopwords inch O
high-grade NN high-grade O
neuroendocrine JJ neuroendocrine D
tumors NN tumor D
of NN stopwords D
the NN stopwords D
lung NN lung D
, , O
surgery NN surgery T
remains NN remains O
a DT stopwords angstrom O
viable NN feasible O
adjunct DT adjunct O
in NN stopwords inch O
the NN stopwords O
early VB early O
stages NN phase O
of NN stopwords O
this NN stopwords O
disease NN disease O

Tuberculosis CAPITAL NNP tuberculosis D
of NN stopwords O
the NN stopwords O
parotid NN parotid O
gland NN gland O
: : O
a DT stopwords angstrom O
rare NN rare O
differential NN derived_function O
diagnosis NN diagnosis O
of NN stopwords O
parotid NN parotid D
tumor NN tumor D

Colorimetric CAPITAL NNP colorimetric O
assay DT assay O
of NN stopwords O
thiomesterone NN O

In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
neutropenia JJ neutropenia D
, , O
splenomegaly NN splenomegaly D
has VB stopwords hour_angle O
been NN stopwords be O
described NN describe O
with NN stopwords O
long-term NN long-run O
use JJ use O
, , O
and DT stopwords O
extramedullary NN D
hematopoiesis NN hematopoiesis D
has VB stopwords hour_angle O
also DT besides O
been NN stopwords be O
reported NN report O

Drug CAPITAL NNP drug T
therapy NN therapy T
for NN stopwords O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D
: : O
the NN stopwords O
Sheffield CAPITAL NNP Sheffield O
table VB table O

The CAPITAL NNP O
genetically NN genetically O
significant NN significant O
dose NN dose O
from JJ stopwords O
roentgen NN roentgen O
examinations NN examination O
in NN stopwords inch O
Finland CAPITAL NNP Finland O
in NN stopwords inch O
1963 DIGITS CD O

A CAPITAL DT angstrom O
randomized VB randomize O
controlled NNS control O
trial NN test O

Center CAPITAL NNP center O
for NN stopwords O
genetic NN familial O
research NN research O
on NN stopwords on O
scleroderma JJ scleroderma D

Skilled CAPITAL NNP skilled O
workers NN worker O
are DT stopwords are O
vital NN critical O
to NN stopwords O
maintenance VB care O
cost NNS cost O
cuts NNS cut O

Are CAPITAL DT are O
ABVD CAPITAL DT T
and DT stopwords O
MOPP/ABV CAPITAL NNP T
truly NN truly O
equivalent NN equivalent O
for NN stopwords O
treating NN treat O
Hodgkin CAPITAL NNP Hodgkin D
's POS D
disease NN disease D
at DT stopwords astatine O
advanced DT advance O
stages NN phase O
? . O

The CAPITAL NNP O
coding NNS cryptography O
audit DT audited_account O

Targeted CAPITAL VB target O
development NN development O
of NN stopwords O
microsatellite NN O
markers NN marker O
from JJ stopwords O
the NN stopwords O
defined NN specify O
region NN region O
of NN stopwords O
bovine NN bovine O
chromosome NN chromosome O
6q21-31 CD O

Its CAPITAL PRP information_technology O
predictive NN predictive O
accuracy DT accuracy O
is NN stopwords be O
superior NN superior O
for NN stopwords O
predicting NN predict O
revascularization NN D

Detection CAPITAL NNP detection O
of NN stopwords O
four JJ four O
novel JJ novel O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
iduronate-2-sulfatase NN O
gene NN gene O

126 DIGITS CD O

Implications CAPITAL PRP deduction O
for NN stopwords O
genetic NN familial O
studies NN survey O

Further CAPITAL NNP foster O
data VB data O
on NN stopwords on O
mediastinal NN D
and DT stopwords D
pulmonary NN pneumonic D
tumors NN tumor D
of NN stopwords O
the NN stopwords O
child JJ child O

We CAPITAL NNP O
propose NN propose O
that NN stopwords O
switch JJ switch O
recombinase NN O
activity DT activity O
becomes NN become O
activated DT trip O
during NN stopwords O
B CAPITAL NN bacillus O
cell NNS cell O
ontogeny JJ growth O
independent NN mugwump O
of NN stopwords O
or NN stopwords Oregon O
prior NN prior O
to NN stopwords O
the NN stopwords O
acquisition DT acquisition O
of NN stopwords O
CH CAPITAL NNP O
locus NN venue O
accessibility DT handiness O
and DT stopwords O
that NN stopwords O
endogenous NN endogenous O
S CAPITAL NN second O
segment NN section O
targeting VB target O
to NN stopwords O
pre-existing NN preexistent O
recombinase NN O
requires NN necessitate O
a DT stopwords angstrom O
level NN degree O
of NN stopwords O
accessibility DT handiness O
beyond NN beyond O
transcriptional NN O
activation DT activation O

The CAPITAL NNP O
involvement NN engagement O
of NN stopwords O
structures NN structure O
in NN stopwords inch O
the NN stopwords O
medial NN medial O
temporal NN temporal_role O
lobe NN lobe O
during NN stopwords O
the NN stopwords O
encoding NN encoding O
of NN stopwords O
visual NN ocular O
associations DT association O
was VB stopwords Washington O
studied NN analyze O
with NN stopwords O
functional JJ functional O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O

Thalidomide CAPITAL NNP thalidomide T
, , O
laser NN laser O
cavity VB pit O
preparation NN preparation O
and DT stopwords O
oral NN oral O
hydrogen NN hydrogen O
peroxide NN hydrogen_peroxide O

Other CAPITAL NNP other O
chose NNS choose O
to NN stopwords O
undergo JJ undergo O
them NN stopwords O
to NN stopwords O
escape NN escape O
discrimination NN discrimination O
and DT stopwords O
social NN sociable O
disapprobation NN disapprobation O

Effect CAPITAL NNP consequence O
of NN stopwords O
HAART CAPITAL NNP drug_cocktail O
on NN stopwords on O
natural RB natural O
history NN history O
of NN stopwords O
AIDS-related CAPITAL DT D
opportunistic JJ opportunist D
disorders NN disorder D

Relationship CAPITAL NNP relationship O
between NN stopwords between O
topotecan NN T
systemic NN systemic O
exposure NN exposure O
and DT stopwords O
tumor NN tumor O
response NN response O
in NN stopwords inch O
human NN homo O
neuroblastoma JJ neuroblastoma D
xenografts JJ heterograft D

Interaction CAPITAL PRP interaction O
of NN stopwords O
aggressive DT aggressive O
and DT stopwords O
sexual NN sexual O
behavior NN behavior O
in NN stopwords inch O
male VB male O
mice NN mouse O

Demotion CAPITAL NNP demotion O
in NN stopwords inch O
industrial NN industrial O
management VB management O

International CAPITAL PRP International O
forensic NN forensic O
science JJ science O
and DT stopwords O
justice NN justice O

As CAPITAL DT arsenic O
single NN single O
agent DT agent O
therapy NN therapy O
in NN stopwords inch O
malignant VB malignant D
melanoma NN melanoma D
, , O
interferon NN interferon T
alfa-2a DT T
was VB stopwords Washington O
only JJ stopwords lone O
marginally NN marginally O
useful JJ useful O
in NN stopwords inch O
most NN stopwords most O
patients VB patient O

An CAPITAL DT Associate_in_Nursing O
ecologic NN ecological O
analysis DT analysis O
of NN stopwords O
psychosocial NN D
stress NN stress D
and DT stopwords O
heart NN heart D
disease NN disease D
in NN stopwords inch O
British CAPITAL NNP British O
Columbia CAPITAL NNP Columbia O

A CAPITAL DT angstrom O
72-year CD O
old JJ old O
man VB man O
who NN stopwords World_Health_Organization O
had VB stopwords have O
been NN stopwords be O
prescribed NN order O
amiodarone DT amiodarone T
for NN stopwords O
more NN stopwords More O
than NN stopwords O
one JJ one O
year NN year O
before NN stopwords earlier O
for NN stopwords O
arrhythmogenic DT D
right NN right D
ventricular NN ventricular D
dystrophy NN muscular_dystrophy D
, , O
repeatedly NN repeatedly O
took NN take O
PL CAPITAL NNP O
granules NN granule O
at DT stopwords astatine O
one-week JJ O
intervals NN time_interval O
because NN stopwords O
of NN stopwords O
sneezing NN sneeze O
and DT stopwords O
fever JJ fever O

FINDINGS CAPITAL NNP findings O
: : O
The CAPITAL NNP O
primary NN primary O
event NN event O
was VB stopwords Washington O
first NN first O
occurrence JJ happening O
of NN stopwords O
reinfarction NN O
, , O
non-fatal JJ O
ischaemic NN ischemic D
stroke NN stroke D
, , O
or NN stopwords Oregon O
cardiovascular VB cardiovascular O
death NN death O

Malnutrition CAPITAL NNP malnutrition D
and DT stopwords O
microcephaly NN microcephaly D
in NN stopwords inch O
Australian CAPITAL DT Australian O
aboriginal DT Aborigine O
children JJ child O

Clinical CAPITAL NNP clinical O
trials NN test O
show NN show O
levofloxacin NN T
to NN stopwords O
be NN stopwords beryllium O
as DT stopwords arsenic O
effective NN effective O
as DT stopwords arsenic O
cephalosporins NNS cephalosporin O
in NN stopwords inch O
acute DT acute_accent O
exacerbation NN aggravation O
of NN stopwords O
chronic NN chronic D
bronchitis NN bronchitis D
and DT stopwords O
as DT stopwords arsenic O
effective NN effective O
as DT stopwords arsenic O
co-amoxiclav NNS O
, , O
cephalosporins NNS cephalosporin O
or NN stopwords Oregon O
amoxycillin DT O
in NN stopwords inch O
community-acquired NNS D
pneumonia NN pneumonia D

Prevention CAPITAL NNP prevention O
in NN stopwords inch O
the NN stopwords O
home NN home O
health NN health O
setting NN setting O

The CAPITAL NNP O
method NN method O
is NN stopwords be O
based VB establish O
on NN stopwords on O
an DT stopwords Associate_in_Nursing O
evanescent NN evanescent O
wave VB wave O
generated NN generate O
from JJ stopwords O
a DT stopwords angstrom O
tapered VB taper O
configuration NNS configuration O
of NN stopwords O
decladded NN O
optical JJ optical O
fibre NN fiber O
and DT stopwords O
does NN stopwords Department_of_Energy O
not JJ stopwords not O
require NN necessitate O
any DT stopwords any O
volumetric NN volumetric O
measurement NN measurement O

BACKGROUND CAPITAL IN background O
: : O
Diabetic CAPITAL NNP diabetic O
foot JJ foot D
infections NN infection D
cause VB cause O
substantial NN significant O
morbidity NN morbidity O
and DT stopwords O
mortality NN mortality O

February CAPITAL NNP February O
3-6 LS O
, , O
1996 DIGITS CD O

Antimicrobial CAPITAL DT disinfectant T
therapy NN therapy T
in NN stopwords inch O
neutropenia JJ neutropenia D

Brimonidine CAPITAL NNP T
tartrate VB tartrate T
0.2 LS O
% NN O
twice NN twice O
daily IN daily O
vs NN volt O
timolol NN timolol T
0.5 LS O
% NN O
twice NN twice O
daily IN daily O
: : O
1-year CD O
results NN consequence O
in NN stopwords inch O
glaucoma NN glaucoma D
patients VB patient O

IV CAPITAL PRP four O

The CAPITAL NNP O
realpolitik NN realpolitik O
of NN stopwords O
a DT stopwords angstrom O
new JJ new O
National CAPITAL NNP national O
Health CAPITAL NNP health O
Service CAPITAL NNP service O
for NN stopwords O
the NN stopwords O
UK CAPITAL NNP United_Kingdom O

However CAPITAL NNP however O
, , O
the NN stopwords O
results NN consequence O
of NN stopwords O
this NN stopwords O
study NN survey O
indicate NN bespeak O
that NN stopwords O
procainamide NN T
may VB May O
be NN stopwords beryllium O
effective NN effective O
in NN stopwords inch O
suppressing NN suppress O
the NN stopwords O
induction NN initiation O
of NN stopwords O
sustained NN prolong O
ventricular NN ventricular D
tachycardia VB tachycardia D
at DT stopwords astatine O
a DT stopwords angstrom O
relatively NN relatively O
low NN low O
plasma NN plasma O
concentration NNS concentration O
, , O
but NN stopwords merely O
not JJ stopwords not O
at DT stopwords astatine O
a DT stopwords angstrom O
higher NN higher O
plasma NN plasma O
concentration NNS concentration O

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
macrosomic VB O
and DT stopwords O
large-for-gestational-age NN O
infants NN baby O
were NN stopwords be O
5 DIGITS CD five O
and DT stopwords O
11 DIGITS CD eleven O
% NN O
, , O
respectively NN respectively O
, , O
in NN stopwords inch O
the NN stopwords O
early VB early O
group NN group O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
25 DIGITS CD twenty-five O
and DT stopwords O
29 DIGITS CD twenty-nine O
% NN O
in NN stopwords inch O
the NN stopwords O
`` `` O
late NN late O
'' POS O
group NN group O
( ( O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O

Update CAPITAL NNP update O
on NN stopwords on O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
research NN research O

These CAPITAL NNP O
results NN consequence O
provide NN supply O
electrophysiological NN O
evidence NN evidence O
for NN stopwords O
early VB early O
semantic NN semantic O
activation DT activation O
and DT stopwords O
later NN later O
phonological NN phonological O
encoding NN encoding O

Antenatally CAPITAL DT O
detectable NN detectable O
markers NN marker O
for NN stopwords O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
autosomally DT D
trisomic NN D
fetuses JJ fetus D
in NN stopwords inch O
at-risk DT O
pregnancies NN pregnancy O

BACKGROUND CAPITAL IN background O
: : O
Cochlear CAPITAL NNP cochlear T
implantation JJ implantation T
is NN stopwords be O
nowadays JJ present O
a DT stopwords angstrom O
reliable NN reliable O
and DT stopwords O
well-accepted NN O
method NN method O
of NN stopwords O
auditory DT auditory O
rehabilitation NN rehabilitation O
in NN stopwords inch O
selected NN choose O
adults DT adult O
and DT stopwords O
children JJ child O

Reattendance CAPITAL NNP O
and DT stopwords O
complications NNS complication O
in NN stopwords inch O
a DT stopwords angstrom O
randomised VB randomize O
trial NN test O
of NN stopwords O
prescribing NN order O
strategies NN scheme O
for NN stopwords O
sore NN sore O
throat NN throat O
: : O
the NN stopwords O
medicalising NN O
effect NN consequence O
of NN stopwords O
prescribing NN order O
antibiotics DT antibiotic O

Peak CAPITAL NNP extremum O
2-point CD O
affecteds-only DT O
lod NN O
scores JJ tons O
( ( O
n=54 JJ O
) ) O
were NN stopwords be O
1.3 CD O
, , O
1.6 CD O
, , O
2.7 CD O
, , O
and DT stopwords O
2.2 CD O
and DT stopwords O
affected DT affect O
relative NN relative O
pairs IN pair O
P CAPITAL NN phosphorus O
values NN values O
( ( O
n=54 JJ O
) ) O
were NN stopwords be O
.04 . O
, , O
.03 . O
, , O
.14 . O
, , O
and DT stopwords O
.04 . O
for NN stopwords O
D12S373 CAPITAL NNP O
, , O
D12S1057 CAPITAL NNP O
, , O
D12S1042 CAPITAL NNP O
, , O
and DT stopwords O
D12S390 CAPITAL NNP O
, , O
respectively NN respectively O

Screening CAPITAL NNP screening O
all DT stopwords all O
women NN woman O
aged DT aged O
& CC O
# # O
60 DIGITS CD sixty O
; : O
or NN stopwords Oregon O
= NN O
25 DIGITS CD twenty-five O
and DT stopwords O
all DT stopwords all O
women NN woman O
who NN stopwords World_Health_Organization O
had VB stopwords have O
had VB stopwords have O
two NN two O
or NN stopwords Oregon O
more NN stopwords More O
partners NN spouse O
in NN stopwords inch O
the NN stopwords O
past VB past O
year NN year O
would NN O
have VB stopwords rich_person O
detected NN detect O
87 DIGITS CD eighty-seven O
% NN O
( ( O
20/23 CD O
) ) O
of NN stopwords O
infections NN infection O

An CAPITAL DT Associate_in_Nursing O
approach DT approach O
to NN stopwords O
quantitative NN quantitative O
analysis DT analysis O
of NN stopwords O
intrauterine NN intrauterine O
pressure NN pressure O
data VB data O

Commentary CAPITAL NNP comment O
: : O
discharge NN discharge O
packs VB battalion O
: : O
how NN stopwords O
much NN much O
do NN stopwords bash O
they NN stopwords O
matter VB matter O
? . O

only JJ stopwords lone O
22 DIGITS CD twenty-two O
patients VB patient O
( ( O
10 DIGITS CD ten O
% NN O
) ) O
were NN stopwords be O
alive DT alive O
at DT stopwords astatine O
five NN five O
years NN old_age O
: : O
19 DIGITS CD nineteen O
patients VB patient O
with NN stopwords O
nsclc JJ D
who NN stopwords World_Health_Organization O
had VB stopwords have O
got NN get O
surgical NN surgical T
treatment NN treatment T
, , O
one JJ one O
patient VB patient O
with NN stopwords O
nsclc JJ D
( ( D
stage NN phase D
iiib NN D
) ) D
who NN stopwords World_Health_Organization O
had VB stopwords have O
recieved NN O
radiotherapy VB radiotherapy T
, , O
and DT stopwords O
two NN two O
patients VB patient O
with NN stopwords O
sclc JJ D
, , D
limited NN express D
disease NN disease D
, , O
treated NN treat O
with NN stopwords O
chemo- NNS T
and DT stopwords T
radiotherapy VB radiotherapy T

Intensive CAPITAL PRP intensifier O
insulin NN insulin O
regimens NN regimen O
in NN stopwords inch O
primary NN primary O
prevention NN prevention O
should NN stopwords O
be NN stopwords beryllium O
assessed DT measure O

A CAPITAL DT angstrom O
postal NN postal O
survey NN survey O
was VB stopwords Washington O
performed NN perform O
to NN stopwords O
determine NN determine O
the NN stopwords O
current NNS current O
practices NN practice O
and DT stopwords O
attitudes DT attitude O
of NN stopwords O
radiologists VB radiologist O
towards NN O
the NN stopwords O
imaging NN imagination O
of NN stopwords O
suspected NN suspect O
lower NN lower_berth O
limb NN limb O
deep NN deep D
vein NN vein D
thrombosis NN thrombosis D
( ( D
DVT CAPITAL NNP D
) ) D

Hormone CAPITAL NNP hormone T
replacement NN replacement T
therapy NN therapy T

The CAPITAL NNP O
24 DIGITS CD twenty-four O
women NN woman O
( ( O
29 DIGITS CD twenty-nine O
% NN O
) ) O
, , O
who NN stopwords World_Health_Organization O
initiated JJ originate O
treatment NN treatment O
after DT stopwords after O
the NN stopwords O
34th CD thirty-fourth O
week NN week O
, , O
composed NNS compose O
the NN stopwords O
`` `` O
late NN late O
'' POS O
group NN group O

The CAPITAL NNP O
current NNS current O
report NN report O
considers NNS see O
the NN stopwords O
additional DT extra O
benefit NN benefit O
of NN stopwords O
combination NNS combination T
therapy NN therapy T
( ( T
interferon NN interferon T
alfa DT T
and DT stopwords T
ribavirin NN ribavirin T
) ) T
compared NNS compare O
with NN stopwords O
monotherapy NN O
( ( O
interferon NN interferon O
alfa DT O
alone DT alone O
) ) O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D

This CAPITAL NNP O
article DT article O
reviews NN reappraisal O
current NNS current O
trends NN tendency O
in NN stopwords inch O
management VB management O
of NN stopwords O
esophageal NN esophageal D
achalasia DT D
, , O
highlighting NN highlight O
short-term NN short-run O
outcome JJ result O
and DT stopwords O
cost NNS cost O
comparisons NNS comparison O
of NN stopwords O
three NN three O
treatments NN treatment O
: : O
botulinum NN botulinus T
toxin NN toxin T
injection NN injection T
, , O
pneumatic NN pneumatic T
dilation NN dilation T
, , O
and DT stopwords O
laparoscopic NN T
myotomy NN myotomy T

< NN O
TO_SEE CAPITAL NNP O
> NN O
Postoperative CAPITAL NNP postoperative O
alkaline DT alkaline D
reflux NN reflux D
after DT stopwords after O
total NN sum T
gastrectomy VB gastrectomy T
for NN stopwords O
stomach NN stomach D
cancer VB cancer D

Safe CAPITAL VB safe O
motherhood NN motherhood O
: : O
can VB stopwords can O
we NN stopwords O
make NN brand O
a DT stopwords angstrom O
difference NN difference O
? . O

Predisposition CAPITAL NNP sensitivity O
genetic NN familial O
testing NN testing O
for NN stopwords O
late-onset NN D
disorders NN disorder D
in NN stopwords inch O
adults DT adult O

Chronic CAPITAL NNP chronic O
exposure NN exposure O
of NN stopwords O
female JJ female O
Rhesus CAPITAL NNP rhesus O
monkeys NN monkey O
increases NN addition O
the NN stopwords O
incidence NN incidence O
and DT stopwords O
severity NN badness O
of NN stopwords O
endometriosis NN endometriosis D

The CAPITAL NNP O
addition DT addition O
of NN stopwords O
peroxynitrite NN O
to NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
produces NN produce O
of NN stopwords O
the NN stopwords O
adduct DT adduct O
ONOO-CO2- CAPITAL NNP O
( ( O
1 DIGITS CD one O
) ) O

The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
intraocular NN T
pressure NN pressure T
reduction NN decrease T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
normal-tension RB D
glaucoma NN glaucoma D

Losing CAPITAL NNP lose O
weight NN weight O
-- : O
an DT stopwords Associate_in_Nursing O
ill-fated NN doomed O
New CAPITAL NNP new O
Year CAPITAL NNP year O
's POS O
resolution NN resolution O

Big CAPITAL NNP large O
city NN city O
health NN health O

Interleukin-8 CAPITAL PRP O
participates NN participate O
in NN stopwords inch O
angiogenesis DT angiogenesis O
in NN stopwords inch O
non-small JJ O
cell NNS cell O
, , O
but NN stopwords merely O
not JJ stopwords not O
small JJ small O
cell NNS cell O
carcinoma VB carcinoma D
of NN stopwords O
the NN stopwords O
lung NN lung O

Unlike CAPITAL NNP unlike O
earlier VB earlier O
quinolones NN O
, , O
levofloxacin NN T
has VB stopwords hour_angle O
excellent NN excellent O
activity DT activity O
against DT stopwords O
Streptococcus CAPITAL NNP streptococcus D
pneumoniae NN D
, , O
including NN include O
strains NN strain O
resistant NN immune O
to NN stopwords O
penicillin NN penicillin O

Biologic CAPITAL NNP biological O
markers NN marker O
as DT stopwords arsenic O
predictors NN forecaster O
of NN stopwords O
clinical JJ clinical O
outcome JJ result O
from JJ stopwords O
systemic NN systemic T
therapy NN therapy T
for NN stopwords O
primary NN primary O
operable JJ operable O
breast NN breast D
cancer VB cancer D

V CAPITAL NN volt O

< NN O
TO_SEE CAPITAL NNP O
> NN O
i NN stopwords iodine O
concluded NNS reason O
that NN stopwords O
6-month CD O
regimen NN regimen O
containing NNS incorporate O
pyrazinamide NN T
was VB stopwords Washington O
effective NN effective O
for NN stopwords O
the NN stopwords O
patients VB patient O
with NN stopwords O
isoniazid-rifampicin NN D
susceptible NN susceptible D
tuberculosis NN tuberculosis D
patients VB patient O
except NN demur O
the NN stopwords O
patients VB patient O
complicated NNS complicate O
with NN stopwords O
diabetes NN diabetes D
mellitus NN D

Studies CAPITAL NNP survey O
on NN stopwords on O
the NN stopwords O
anti-microbial DT O
activity DT activity O
of NN stopwords O
nonionic JJ nonionized O
and DT stopwords O
anionic DT anionic_detergent O
surfactants NN wetting_agent O

Risk CAPITAL NN hazard O
factor VB factor O
analysis DT analysis O
and DT stopwords O
implications JJ deduction O
for NN stopwords O
genetic NN familial O
testing NN testing O

Although CAPITAL DT O
improved JJ better O
glycemic NN T
control NNS control T
, , O
maintenance VB care O
of NN stopwords O
normal RB convention O
blood NN blood O
pressure NN pressure O
, , O
and DT stopwords O
use JJ use O
of NN stopwords O
angiotensin-converting DT T
enzyme NN enzyme T
inhibitors NN inhibitor T
are DT stopwords are O
important JJ important O
strategies NN scheme O
to NN stopwords O
avoid DT avoid O
developing NN development O
microalbuminuria NN D
, , O
dietary NN dietary O
macronutrient VB O
intake NN consumption O
may VB May O
also DT besides O
play NN play O
a DT stopwords angstrom O
role NN function O

Exercise CAPITAL NNP exercise O
might NN might O
indeed NN indeed O
induce NN induce O
changes NNS change O
in NN stopwords inch O
several NN several O
salivary VB salivary O
components NNS component O
such NN stopwords such O
as DT stopwords arsenic O
immunoglobulins JJ immunoglobulin O
, , O
hormones NN hormone O
, , O
lactate NN lactate O
, , O
proteins NN protein O
and DT stopwords O
electrolytes NN electrolyte O

PURPOSE CAPITAL NNP purpose O
: : O
We CAPITAL NNP O
review NN reappraisal O
our NN stopwords O
initial JJ initial O
experience NN experience O
with NN stopwords O
direct NN direct T
percutaneous NN transdermal T
transluminal NN T
angioplasty DT angioplasty T
( ( T
PTA CAPITAL NNP T
) ) T
as DT stopwords arsenic O
a DT stopwords angstrom O
reperfusion NN T
treatment NN treatment T
for NN stopwords O
acute DT acute_accent D
occlusion JJ occlusion D
of NN stopwords D
the NN stopwords D
middle NN center D
cerebral NNS cerebral D
artery DT artery D

External CAPITAL NNP external T
counterpulsation NNS T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
chronic NN chronic D
stable NN stable D
angina DT angina D
pectoris NN D

The CAPITAL NNP O
antigenic DT antigenic O
factor VB factor O
would NN O
appear DT look O
to NN stopwords O
be NN stopwords beryllium O
located NN locate O
on NN stopwords on O
the NN stopwords O
sperm NN sperm O
as DT stopwords arsenic O
opposed JJ oppose O
to NN stopwords O
the NN stopwords O
seminal NN seminal O
fluid JJ fluid O
itself NN stopwords O

An CAPITAL DT Associate_in_Nursing O
omission IN omission O

Isotopic CAPITAL PRP isotopic O
evidence NN evidence O
for NN stopwords O
extraterrestrial NN extraterrestrial_being O
non-racemic JJ O
amino DT amino O
acids DT acid O
in NN stopwords inch O
the NN stopwords O
Murchison CAPITAL NNP O
meteorite NN meteorite O

The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
treatment NN treatment O
was VB stopwords Washington O
assessed DT measure O
by NN stopwords by O
conducting NNS conducting O
three NN three O
measurements NN measurement O
on NN stopwords on O
each VB stopwords each O
muscle NN muscle O
before NN stopwords earlier O
and DT stopwords O
immediately JJ immediately O
after DT stopwords after O
treatment NN treatment O
: : O
subjective NN subjective O
pain IN pain O
intensity NN intensity O
( ( O
( ( O
PI CAPITAL NN pi O
) ) O
with NN stopwords O
a DT stopwords angstrom O
visual NN ocular O
analog DT analogue O
scale JJ scale O
) ) O
, , O
pressure NN pressure O
pain IN pain O
threshold NN threshold O
( ( O
( ( O
PT CAPITAL NNP platinum O
) ) O
with NN stopwords O
algometry DT algometry O
) ) O
, , O
and DT stopwords O
range VB scope O
of NN stopwords O
motion NN gesture O
( ( O
( ( O
ROM CAPITAL NNP read-only_memory O
) ) O
with NN stopwords O
a DT stopwords angstrom O
goniometer NN goniometer O
) ) O
of NN stopwords O
upper JJ upper_berth O
trapezius NN trapezius O
muscle NN muscle O
( ( O
lateral NN lateral_pass O
bending NN bending O
of NN stopwords O
cervical NNS cervical O
spine JJ spinal_column O
to NN stopwords O
the NN stopwords O
opposite JJ antonym O
side NN side O
) ) O

( ( O
5 DIGITS CD five O
) ) O
Future CAPITAL NNP future O
plans NN plan O
were NN stopwords be O
either NN either O
singular NN singular O
in NN stopwords inch O
focus JJ focus O
or NN stopwords Oregon O
limited NN express O
to NN stopwords O
maintenance VB care O
of NN stopwords O
current NNS current O
health NN health O
habits NN habit O

The CAPITAL NNP O
torsion-angle NN O
molecular NN molecular O
dynamics NN dynamics O
algorithm DT algorithm O
starts NN start O
from JJ stopwords O
an DT stopwords Associate_in_Nursing O
extended NN widen O
strand NN strand O
conformation NNS conformation O
and DT stopwords O
proceeds NN return O
in NN stopwords inch O
four JJ four O
stages NN phase O
: : O
high-temperature NN O
torsion-angle NN O
molecular NN molecular O
dynamics NN dynamics O
, , O
slow-cooling NN O
torsion-angle NN O
molecular NN molecular O
dynamics NN dynamics O
, , O
Cartesian CAPITAL VB Cartesian O
molecular NN molecular O
dynamics NN dynamics O
, , O
and DT stopwords O
minimization NN minimization O

Mass CAPITAL NNP mass O
population NN population O
skin JJ skin D
cancer VB cancer D
screening NN screening O
is NN stopwords be O
not JJ stopwords not O
worthwhile NN worthwhile O

Factors CAPITAL NNP factor O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
rate VB rate O
of NN stopwords O
fall VB fall O
of NN stopwords O
thyroid NN thyroid_gland O
stimulating JJ stimulate O
hormone NN hormone O
in NN stopwords inch O
treated NN treat O
hypothyroidism NN hypothyroidism D

Transbronchial CAPITAL NNP O
biopsy NN biopsy O
revealed NN uncover O
inflammatory NN inflammatory D
nonspecific JJ nonspecific D
alveolar DT alveolar_consonant D
lesions NN lesion D
suggestive NN implicative D
of NN stopwords D
bronchiolitis NN bronchiolitis D
obliterans NN D
organizing JJ form D
pneumonia NN pneumonia D
, , O
which NN stopwords O
responded NN react O
well NN well O
clinically JJ clinically O
and DT stopwords O
radiologically VB O
to NN stopwords O
oral NN oral T
corticosteroids NNS corticosteroid T

Analysis CAPITAL DT analysis O
of NN stopwords O
steroids NN steroid O

The CAPITAL NNP O
American CAPITAL DT American O
Medical CAPITAL NNP checkup O
Association CAPITAL DT association O
Guidelines CAPITAL NNP guideline O
for NN stopwords O
Adolescent CAPITAL DT adolescent O
Preventive CAPITAL NNP preventive O
Services CAPITAL NNP services O

The CAPITAL NNP O
survey NN survey O
indicated NN bespeak O
a DT stopwords angstrom O
variety NN assortment O
of NN stopwords O
thermal NN thermal O
care VB care O
styles NN manner O

Multicentre CAPITAL NNP O
clinical JJ clinical O
evaluation NN evaluation O
of NN stopwords O
vigabatrin NN T
( ( T
Sabril CAPITAL NNP T
) ) T
in NN stopwords inch O
mild NN mild D
to NN stopwords D
moderate NN centrist D
partial NN partial_derivative D
epilepsies NN epilepsy D

Online CAPITAL NNP on-line O

Sliding CAPITAL NNP skid T
door NN door T
technique NN technique T
for NN stopwords O
the NN stopwords O
repair NN repair O
of NN stopwords O
midline NN midplane D
incisional NN D
hernias NN hernia D

Autonomy CAPITAL DT autonomy O
in NN stopwords inch O
the NN stopwords O
face VB face O
of NN stopwords O
a DT stopwords angstrom O
devastating NN lay_waste_to O
diagnosis NN diagnosis O

Troponin-T CAPITAL NNP O
concentrations NNS concentration O
should NN stopwords O
be NN stopwords beryllium O
measured NN measure O

Its CAPITAL PRP information_technology O
role NN function O
in NN stopwords inch O
hepatic NN liverwort O
BSP CAPITAL NNP O
extraction NN extraction O

Pelvic CAPITAL NNP pelvic T
floor JJ floor T
stimulation JJ stimulation T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
adult DT adult D
urinary JJ urinary D
incontinence NN incontinence D

Development CAPITAL NNP development O
of NN stopwords O
neurosurgery JJ neurosurgery T
in NN stopwords inch O
Greece CAPITAL NNP Greece O
: : O
past VB past O
, , O
present NN present O
, , O
and DT stopwords O
future JJ future O

Two CAPITAL NNP two O
cases VB case O

Three CAPITAL NNP three O
patients VB patient O
in NN stopwords inch O
whom NN stopwords O
splenomegaly NN splenomegaly D
was VB stopwords Washington O
detected NN detect O
during NN stopwords O
their NN stopwords O
staging NN theatrical_production O
evaluation NN evaluation O
underwent JJ undergo O
splenectomy NN splenectomy T

Poverty CAPITAL NNP poverty O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
isolated NN isolate O
factor VB factor O
in NN stopwords inch O
relation NN relation O
to NN stopwords O
perinatal NN perinatal D
asphyxia DT asphyxia D

The CAPITAL NNP O
implantation JJ implantation O
and DT stopwords O
pregnancy NN pregnancy O
rates VB rates O
per NN O
embryo NN embryo O
transfer NN transportation O
were NN stopwords be O
13 DIGITS CD thirteen O
and DT stopwords O
29 DIGITS CD twenty-nine O
% NN O
respectively NN respectively O

Attitudes CAPITAL DT attitude O
toward NN O
health-care NN O
, , O
HIV CAPITAL NNP HIV D
infection NN infection D
, , O
and DT stopwords O
perinatal NN perinatal O
transmission NN transmission O
interventions NN intervention O
in NN stopwords inch O
a DT stopwords angstrom O
cohort NNS cohort O
of NN stopwords O
inner-city NN O
, , O
pregnant NN pregnant O
women NN woman O

The CAPITAL NNP O
fluoroquinolones JJ T
for NN stopwords O
urinary JJ urinary D
tract NN tract D
infections NN infection D
: : O
a DT stopwords angstrom O
review NN reappraisal O

Characterization CAPITAL NNP word_picture O
of NN stopwords O
the NN stopwords O
orf31-petG JJ O
gene NN gene O
cluster NNS bunch O
from JJ stopwords O
the NN stopwords O
plastid NN plastid O
genome NN genome O
of NN stopwords O
Populus CAPITAL NNP Populus O
deltoides NN O

Cytoplasmic CAPITAL NNP cytoplasmic O
transport NN conveyance O
in NN stopwords inch O
Drosophila CAPITAL NNP drosophila O
ovarian NN ovarian O
follicles JJ follicle O
: : O
the NN stopwords O
migration NN migration O
of NN stopwords O
microinjected NN O
fluorescent JJ fluorescent O
probes NN probe O
through NN stopwords done O
intercellular NN intercellular O
bridges NN Bridges O
depends NN depend O
neither JJ neither O
on NN stopwords on O
electrical NN electrical O
charge NNS charge O
nor RB stopwords O
on NN stopwords on O
external NN external O
osmolarity JJ O

These CAPITAL NNP O
dual-analyte NN O
arrays DT array O
allow DT let O
for NN stopwords O
the NN stopwords O
simultaneous NN coincident O
, , O
independent NN mugwump O
measurement NN measurement O
of NN stopwords O
the NN stopwords O
analyte DT O
of NN stopwords O
interest NN interest O
and DT stopwords O
the NN stopwords O
transducing NN transduce O
analyte DT O

We CAPITAL NNP O
examined NN analyze O
the NN stopwords O
remnant NN leftover O
stomach NN stomach O
for NN stopwords O
H. CAPITAL NNP O
pylori NN pylorus O
infection NN infection O
after DT stopwords after O
gastrectomy VB gastrectomy T
for NN stopwords O
gastric VB gastric D
cancer VB cancer D
or NN stopwords Oregon D
peptic NN peptic D
ulcer JJ ulcer D
between NN stopwords between O
October CAPITAL NNP October O
1992 DIGITS CD O
and DT stopwords O
July CAPITAL NNP July O
1997 DIGITS CD O

A CAPITAL DT angstrom O
classification NNS categorization O
of NN stopwords O
nucleotide-diphospho-sugar JJ O
glycosyltransferases NN O
based VB establish O
on NN stopwords on O
amino DT amino O
acid DT acid O
sequence NN sequence O
similarities NN similarity O

Deletion CAPITAL NNP omission O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
p16/CDKN2 NN O
gene NN gene O
in NN stopwords inch O
head NN head O
and DT stopwords O
neck JJ neck O
squamous NN O
cell NNS cell O
carcinoma VB carcinoma D
using JJ exploitation O
quantitative NN quantitative O
polymerase NN polymerase O
chain NNS chain O
reaction NN chemical_reaction O
method NN method O

Identification CAPITAL PRP designation O
, , O
localization NN localization O
, , O
and DT stopwords O
expression NN expression O
of NN stopwords O
two NN two O
novel JJ novel O
human NN homo O
genes NN gene O
similar NN similar O
to NN stopwords O
deoxyribonuclease NN O
I CAPITAL PRP iodine O
. . O

Abstracts CAPITAL DT abstraction O

It CAPITAL PRP information_technology O
is NN stopwords be O
suggested NN propose O
that NN stopwords O
damaged VB damage D
mucosal NN mucosal D
tissues NN tissue D
with NN stopwords O
AHF CAPITAL DT T
can VB stopwords can O
be NN stopwords beryllium O
effectively NN efficaciously O
compensated NNS compensate O
by NN stopwords by O
enhanced NN enhance O
regeneration NN regeneration O
response NN response O
due NN due O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
adequately DT adequately O
high NN high O
dose NN dose O
intensity NN intensity O
, , O
suggesting NN propose O
a DT stopwords angstrom O
possible NN possible O
tolerability NN O
advantage DT advantage O
for NN stopwords O
AHF CAPITAL DT O

On CAPITAL NNP on O
experimental NN experimental O
design NN design O

Alternative CAPITAL DT option O
medicine NN medicine O

Rate CAPITAL VB rate O
of NN stopwords O
RhD CAPITAL NNP Red_Hand_Defenders O
sensitisation NN sensitization O
before NN stopwords earlier O
and DT stopwords O
after DT stopwords after O
implementation JJ execution O
of NN stopwords O
a DT stopwords angstrom O
community NNS community O
based VB establish O
antenatal DT prenatal O
prophylaxis NN prophylaxis O
programme NN program O

RESULTS CAPITAL NNP consequence O
: : O
Incidence CAPITAL PRP incidence O
of NN stopwords O
subsequent NN subsequent O
cancers VB cancer D
was VB stopwords Washington O
statistically NN statistically O
significantly NN significantly O
elevated NN elevated_railway O
only JJ stopwords lone O
in NN stopwords inch O
the NN stopwords O
961 DIGITS CD O
patients VB patient O
with NN stopwords O
hereditary NN familial O
retinoblastoma NN retinoblastoma D
, , O
in NN stopwords inch O
whom NN stopwords O
190 DIGITS CD one_hundred_ninety O
cancers VB cancer D
were NN stopwords be O
diagnosed NN diagnose O
, , O
vs NN volt O
6.3 CD O
expected NN expect O
in NN stopwords inch O
the NN stopwords O
general NN general O
population NN population O
( ( O
relative NN relative O
risk NN hazard O
( ( O
RR CAPITAL NNP O
) ) O
, , O
30 DIGITS CD thirty O
( ( O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
, , O
26-47 CD O
) ) O
) ) O

Human CAPITAL NNP homo O
papillomavirus VB O
in NN stopwords inch O
the NN stopwords O
woman NN woman O
with NN stopwords O
HIV CAPITAL NNP HIV O

Antibiotics CAPITAL DT antibiotic T
after DT stopwords after O
dog NN dog D
bite NN bite D

CONTEXT CAPITAL NNP context O
: : O
Approximately CAPITAL DT approximately O
9 DIGITS CD nine O
% NN O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
cases VB case O
have VB stopwords rich_person O
been NN stopwords be O
estimated NN estimate O
to NN stopwords O
result NN consequence O
from JJ stopwords O
inheritance NN inheritance O
of NN stopwords O
mutated NN mutate O
prostate NN prostate_gland O
cancer VB cancer O
susceptibility NN susceptibility O
genes NN gene O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Physician CAPITAL NNP doctor O
heal NN mend O
thyself NN O
: : O
are DT stopwords are O
antibiotics DT antibiotic T
the NN stopwords O
cure NNS remedy O
or NN stopwords Oregon O
the NN stopwords O
disease NN disease O
? . O

In CAPITAL PRP inch O
case VB case O
2 DIGITS CD two O
, , O
cidofovir NN T
was VB stopwords Washington O
compounded NNS intensify O
as DT stopwords arsenic O
a DT stopwords angstrom O
3 DIGITS CD three O
% NN O
cream NNS cream O
in NN stopwords inch O
a DT stopwords angstrom O
combination NNS combination O
vehicle NN vehicle O
( ( O
Dermovan CAPITAL NNP O
) ) O
for NN stopwords O
extensive NN extensive O
facial VB facial O
involvement NN engagement O
, , O
and DT stopwords O
complete NNS complete O
resolution NN resolution O
of NN stopwords O
MCV CAPITAL NNP D
was VB stopwords Washington O
seen NN see O
after DT stopwords after O
1 DIGITS CD one O
month NN calendar_month O
of NN stopwords O
therapy NN therapy O

WHO CAPITAL NNP World_Health_Organization O
decides NN decide O
: : O
food JJ food O
irradiation NN irradiation O
safe VB safe O
at DT stopwords astatine O
any DT stopwords any O
level NN degree O

a DT stopwords angstrom O
phase NN phase O
ii NN two O
study NN survey O
of NN stopwords O
irinotecan JJ T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
cisplatin NN T
( ( T
platinol NN T
) ) T
resulted NN result O
in NN stopwords inch O
a DT stopwords angstrom O
response NN response O
rate VB rate O
of NN stopwords O
86 DIGITS CD eighty-six O
% NN O
and DT stopwords O
a DT stopwords angstrom O
median NN median O
survival NN survival O
of NN stopwords O
13.0 CD O
months NN calendar_month O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
extensive-disease NN D
small-cell JJ D
lung NN lung D
cancer VB cancer D

A CAPITAL DT angstrom O
national RB national O
survey NN survey O
of NN stopwords O
physician-assisted NN O
suicide JJ suicide O
and DT stopwords O
euthanasia NN euthanasia O
in NN stopwords inch O
the NN stopwords O
United CAPITAL NNP unite O
States CAPITAL NNP state O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

The CAPITAL NNP O
PR CAPITAL NNP praseodymium O
was VB stopwords Washington O
observed NN detect O
in NN stopwords inch O
one JJ one O
patient VB patient O
with NN stopwords O
non-functioning JJ D
endocrine NN hormone D
pancreatic VB pancreatic D
tumor NN tumor D
with NN stopwords D
progressive NN progressive D
liver NN liver D
and DT stopwords D
lymph NN lymph D
node JJ node D
metastases NN metastasis D
after DT stopwords after O
16 DIGITS CD sixteen O
months NN calendar_month O
of NN stopwords O
i.m NN T
. . T
lanreotide NN T
therapy NN therapy T

Low-dose CAPITAL NNP T
steroids NN steroid T
reduce NN reduce O
flu-like JJ D
symptoms NN symptom D
at DT stopwords astatine O
the NN stopwords O
initiation JJ initiation O
of NN stopwords O
IFNbeta-1b CAPITAL PRP O
in NN stopwords inch O
relapsing-remitting NN O
MS CAPITAL NNP multiple_sclerosis O

The CAPITAL NNP O
use JJ use O
of NN stopwords O
quinidine NN quinidine T
sulphate NN sulfate T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
atrial DT atrial D
fibrillation NN fibrillation D
in NN stopwords inch O
twelve NN twelve O
horses NN horse O

Disseminated CAPITAL NNP circulate D
lupus NN lupus D
erythematosus NN D
in NN stopwords inch O
pregnancy NN pregnancy O

Here CAPITAL NNP here O
we NN stopwords O
show NN show O
that NN stopwords O
the NN stopwords O
medial NN medial O
temporal NN temporal_role O
region NN region O
is NN stopwords be O
active DT active_agent O
during NN stopwords O
encoding NN encoding O
and DT stopwords O
that NN stopwords O
the NN stopwords O
hemisphere NN hemisphere O
activated DT trip O
and DT stopwords O
the NN stopwords O
amount DT sum O
of NN stopwords O
activation DT activation O
depend NN depend O
on NN stopwords on O
the NN stopwords O
type NN type O
of NN stopwords O
stimulus JJ stimulation O
presented NN show O
( ( O
objects NN object O
or NN stopwords Oregon O
words NN words O
) ) O
, , O
whether NN O
the NN stopwords O
stimulus JJ stimulation O
can VB stopwords can O
be NN stopwords beryllium O
encoded NN encode O
for NN stopwords O
meaning NN meaning O
( ( O
real NN real_number O
objects NN object O
and DT stopwords O
words NN words O
versus NN O
nonsense JJ nonsense O
objects NN object O
and DT stopwords O
words NN words O
) ) O
, , O
and DT stopwords O
task VB undertaking O
experience NN experience O
( ( O
first NN first O
versus NN O
the NN stopwords O
second NN second O
time NN time O
a DT stopwords angstrom O
task VB undertaking O
is NN stopwords be O
performed NN perform O
) ) O

We CAPITAL NNP O
describe NN describe O
a DT stopwords angstrom O
technique NN technique O
that NN stopwords O
enables NN enable O
the NN stopwords O
autologous DT autologous T
repair NN repair T
of NN stopwords O
large NN large D
midline NN midplane D
incisional NN D
hernias NN hernia D
by NN stopwords by O
restoring NN restore O
the NN stopwords O
functional JJ functional O
musculoaponeurotic NN O
support NN support O
of NN stopwords O
the NN stopwords O
abdominal DT abdominal O
wall VB wall O

The CAPITAL NNP O
evidence NN evidence O
supports NN support O
surgery NN surgery T
as DT stopwords arsenic O
initial JJ initial O
therapy NN therapy O
and DT stopwords O
as DT stopwords arsenic O
a DT stopwords angstrom O
secondary NN secondary O
form NN form O
of NN stopwords O
therapy NN therapy O
after DT stopwords after O
failure VB failure O
of NN stopwords O
other JJ stopwords other O
treatments NN treatment O
for NN stopwords O
stress NN stress D
urinary JJ urinary D
incontinence NN incontinence D

Multivalent CAPITAL NNP multivalent O
cations VB cation O
depress NN depress O
ligand NN ligand O
affinity DT affinity O
of NN stopwords O
insulin-like NN O
growth NN growth O
factor-binding VB O
proteins-3 NN O
and DT stopwords O
-5 : O
on NN stopwords on O
human NN homo O
GM-10 CAPITAL NNP O
fibroblast NN fibroblast O
cell NNS cell O
surfaces NN surface O

Rhabdomyolysis CAPITAL NNP D
and DT stopwords O
carbon VB carbon D
monoxide NN monoxide D
poisoning NN poisoning D

SETTING CAPITAL NNP setting O
: : O
Perinatal CAPITAL NNP perinatal O
research NN research O
unit JJ unit_of_measurement O
, , O
World CAPITAL NNP universe O
Health CAPITAL NNP health O
Organisation CAPITAL NNP administration O
's POS O
collaborative NNS collaborative O
research NN research O
centre NNS Centre O

conclusions NNS decision O
: : O
this NN stopwords O
constitutes NNS constitute O
one JJ one O
of NN stopwords O
the NN stopwords O
largest NN large O
single-institution NN O
reports NN report O
on NN stopwords on O
carinal VB carinal T
resection NN resection T
for NN stopwords O
bronchogenic NN D
carcinoma VB carcinoma D
involving NN involve D
the NN stopwords D
carina VB Carina D

Estimation CAPITAL NNP appraisal O
of NN stopwords O
loads NN tons O
and DT stopwords O
stresses NN stress O
in NN stopwords inch O
abdominal DT abdominal O
muscles NN muscle O
during NN stopwords O
slow NN decelerate O
lifts NN lift O

Neurone CAPITAL NNP O
development NN development O
and DT stopwords O
death NN death O
, , O
from JJ stopwords O
a DT stopwords angstrom O
cell NNS cell O
biologist NN biologist O
's POS O
perspective NN position O

Users CAPITAL NNP user O
' '' O
guides NN usher O
to NN stopwords O
the NN stopwords O
medical NN checkup O
literature NN literature O
: : O
XIV CAPITAL NN fourteen O

Mental CAPITAL NNP mental O
health NN health O
and DT stopwords O
the NN stopwords O
law NN law O

Relation CAPITAL NNP relation O
between NN stopwords between O
intellectual NN intellectual D
dysfunctioning NN D
and DT stopwords O
mortality NN mortality O
in NN stopwords inch O
community-residing NNS O
older JJ aged O
people NN people O

Nonneoplastic CAPITAL NNP D
disorders NN disorder D
of NN stopwords D
the NN stopwords D
eccrine NN eccrine D
glands NN gland D

we NN stopwords O
thereby NN thereby O
recommend NN recommend O
that NN stopwords O
surgery NN surgery T
should NN stopwords O
only JJ stopwords lone O
be NN stopwords beryllium O
performed NN perform O
for NN stopwords O
those NN stopwords O
n NN nitrogen D
2 DIGITS CD two D
nsclc JJ D
patients VB patient O
diagnosed NN diagnose O
as DT stopwords arsenic O
t NN stopwords thymine O
1 DIGITS CD one O
or NN stopwords Oregon O
t NN stopwords thymine O
2 DIGITS CD two O
with NN stopwords O
a DT stopwords angstrom O
classification NNS categorization O
of NN stopwords O
p1 NN O
or NN stopwords Oregon O
less NN lupus_erythematosus O

Severe CAPITAL NNP severe O
preeclampsia NN preeclampsia D
was VB stopwords Washington O
defined NN specify O
by NN stopwords by O
standard NN standard O
criteria JJ standard O

Spontaneous CAPITAL NNP spontaneous O
splenic NN splenic D
rupture NN rupture D
following JJ following O
administration DT administration O
of NN stopwords O
granulocyte NN granulocyte T
colony-stimulating NNS T
factor VB factor T
( ( T
G-CSF CAPITAL NNP T
) ) T
: : O
occurrence JJ happening O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
allogeneic DT allogeneic O
donor NN donor O
of NN stopwords O
peripheral NN peripheral O
blood NN blood O
stem NN root O
cells NNS cell O

The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
glucocorticoids NN glucocorticoid T
in NN stopwords inch O
treating NN treat O
croup NNS croup D
: : O
meta-analysis NN O
( ( O
see NN see O
comments NNS remark O
) ) O

in NN stopwords inch O
three NN three O
patients VB patient O
with NN stopwords O
bos NN Bos D
and DT stopwords D
concurrent NNS coincident D
acute DT acute_accent D
rejection NN rejection D
, , O
therapy NN therapy T
with NN stopwords T
extracorporeal NN T
photopheresis NN T
led NN light-emitting_diode O
to NN stopwords O
the NN stopwords O
resolution NN resolution O
of NN stopwords O
the NN stopwords O
acute DT acute_accent O
rejection NN rejection O
episode NN episode O

Women CAPITAL NNP woman O
randomised VB randomize O
to NN stopwords O
screen-and-treat NN O
received NN receive O
appropriate DT allow O
antibiotics DT antibiotic T
only JJ stopwords lone O
if NN stopwords O
screening NN screening O
proved NN prove O
positive NN positive O
for NN stopwords O
one JJ one O
or NN stopwords Oregon O
more NN stopwords More O
infection NN infection D

Subjectively CAPITAL NNP subjectively O
, , O
these NN stopwords O
patients VB patient O
stated NN state O
that NN stopwords O
their NN stopwords O
level NN degree O
of NN stopwords O
pain IN pain O
, , O
walking VB walk O
tolerance NN tolerance O
, , O
and DT stopwords O
overall JJ overall O
satisfaction VB satisfaction O
improved JJ better O
significantly NN significantly O
after DT stopwords after O
the NN stopwords O
arthrodesis DT arthrodesis T

A CAPITAL DT angstrom O
new JJ new O
modified NN modify O
technique NN technique O
for NN stopwords O
harvest NN crop O
of NN stopwords O
calcaneal VB calcaneal O
bone NN bone O
grafts NN graft O
in NN stopwords inch O
surgery NN surgery T
on NN stopwords on O
the NN stopwords O
foot JJ foot O
and DT stopwords O
ankle DT ankle O

With CAPITAL NNP O
the NN stopwords O
Gly-11 CAPITAL NNP O
, , O
Gly-13 CAPITAL NNP O
, , O
and DT stopwords O
Gly-15 CAPITAL NNP O
analogs DT analogue O
, , O
the NN stopwords O
increase NN addition O
in NN stopwords inch O
SDS CAPITAL NNP South_Dakota O
concentration NNS concentration O
results NN consequence O
in NN stopwords inch O
the NN stopwords O
formation NN formation O
of NN stopwords O
a DT stopwords angstrom O
single NN single O
species NN species O
; : O
however NN however O
, , O
for NN stopwords O
the NN stopwords O
Gly-9 CAPITAL NNP O
, , O
Ala-9 CAPITAL DT O
, , O
and DT stopwords O
Ala-15 CAPITAL DT O
analogs DT analogue O
, , O
heterogeneity NN heterogeneity O
remains NN remains O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Granulocyte CAPITAL NNP granulocyte O
colony-stimulating NNS O
factor VB factor O
( ( O
G-CSF CAPITAL NNP O
) ) O
has VB stopwords hour_angle O
been NN stopwords be O
used JJ use O
to NN stopwords O
improve JJ better O
granulocyte NN granulocyte O
count NNS count O
in NN stopwords inch O
chronic NN chronic O
neutropenia JJ neutropenia O
and DT stopwords O
myelodysplasia NN O
, , O
to NN stopwords O
minimize NN minimize O
the NN stopwords O
incidence NN incidence O
and DT stopwords O
duration NN duration O
of NN stopwords O
neutropenia JJ neutropenia O
during NN stopwords O
conventional NNS conventional O
chemotherapy NNS chemotherapy O
, , O
and DT stopwords O
to NN stopwords O
mobilize NN mobilize O
peripheral NN peripheral O
blood NN blood O
stem NN root O
cells NNS cell O
prior NN prior O
to NN stopwords O
leukapheresis NN O
for NN stopwords O
use JJ use O
in NN stopwords inch O
autologous DT autologous O
and DT stopwords O
allogeneic DT allogeneic O
marrow NN marrow O
transplantation NN transplant O

This CAPITAL NNP O
did NN stopwords make O
not JJ stopwords not O
increase NN addition O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
infusion NN infusion O
of NN stopwords O
30 DIGITS CD thirty O
mcg/kg NN O
per NN O
min NN minute O
of NN stopwords O
dobutamine NN O
, , O
which NN stopwords O
resulted NN result O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
the NN stopwords O
cardiac VB cardiac O
output JJ end_product O
from JJ stopwords O
1.96 CD O
to NN stopwords O
5.46 CD O
l/min NN O

Ex CAPITAL NN ex-husband O
vivo NN O
whole NN whole O
blood NN blood O
measurements NN measurement O
using JJ exploitation O
the NN stopwords O
lactate NN lactate O
catheter VB catheter O
( ( O
y NN stopwords yttrium O
) ) O
give NN give O
a DT stopwords angstrom O
correlation NNS correlation O
with NN stopwords O
the NN stopwords O
BIOSEN CAPITAL NNP O
Med CAPITAL NNP Master_of_Education O
L CAPITAL NN liter O
( ( O
x NN ten O
) ) O
of NN stopwords O
y NN stopwords yttrium O
= NN O
( ( O
1.010x CD O
+ NN O
0.513 LS O
) ) O
mmol/l NN O
( ( O
r NN roentgen O
= NN O
0.9748 LS O
) ) O

However CAPITAL NNP however O
, , O
in NN stopwords inch O
the NN stopwords O
first NN first O
case VB case O
, , O
activation DT activation O
of NN stopwords O
apoptosis DT apoptosis O
is NN stopwords be O
blocked NN barricade O
by NN stopwords by O
the NN stopwords O
basal VB radical O
activity DT activity O
of NN stopwords O
p210 NN O
( ( O
BCR-ABL CAPITAL NNP O
) ) O
, , O
whereas NN O
in NN stopwords inch O
the NN stopwords O
second NN second O
, , O
the NN stopwords O
presence NN presence O
of NN stopwords O
p210 NN O
( ( O
BCR-ABL CAPITAL NNP O
) ) O
appears DT look O
to NN stopwords O
accelerate DT accelerate O
the NN stopwords O
onset JJ onset O
of NN stopwords O
apoptosis DT apoptosis O
by NN stopwords by O
a DT stopwords angstrom O
mechanism NN mechanism O
that NN stopwords O
may VB May O
involve NN involve O
an DT stopwords Associate_in_Nursing O
activation DT activation O
of NN stopwords O
its NN stopwords information_technology O
kinase NN kinase O
function JJ function O

An CAPITAL DT Associate_in_Nursing O
electron NN electron O
microscope NN microscope O
study NN survey O
of NN stopwords O
plant NN plant D
neoplasia JJ neoplasia D
induced NN induce O
by NN stopwords by O
wound NN wound D
tumor NN tumor D
virus NN virus D

Matrix CAPITAL NNP matrix T
metalloproteinase NN T
inhibitors NN inhibitor T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
cancer VB cancer D

These CAPITAL NNP O
drugs NN drug O
are DT stopwords are O
very NN stopwords very O
efficacious NN efficacious O
and DT stopwords O
generally NN by_and_large O
devoided NN O
of NN stopwords O
important JJ important O
side NN side O
effects NN effects O
, , O
but NN stopwords merely O
they NN stopwords O
are DT stopwords are O
expensive NN expensive O
and DT stopwords O
therefore NN therefore O
have VB stopwords rich_person O
to NN stopwords O
be NN stopwords beryllium O
compared NNS compare O
with NN stopwords O
other JJ stopwords other O
, , O
more NN stopwords More O
conventional NNS conventional O
drugs NN drug O
with NN stopwords O
established NN establish O
or NN stopwords Oregon O
assumed DT assume O
efficacy NN efficacy O

It CAPITAL PRP information_technology O
identifies NN identify O
the NN stopwords O
learning NN learning O
experiences NN experience O
that NN stopwords O
should NN stopwords O
be NN stopwords beryllium O
part NN part O
of NN stopwords O
general NN general O
internal NN internal O
medicine NN medicine O
residency NN residency O
training NN training O
, , O
lists NN list O
the NN stopwords O
clinical JJ clinical O
competencies NNS competence O
that NN stopwords O
are DT stopwords are O
important JJ important O
for NN stopwords O
primary NN primary O
care VB care O
practice NN practice O
, , O
and DT stopwords O
describes NN describe O
the NN stopwords O
role NN function O
of NN stopwords O
the NN stopwords O
integrative NN integrative O
disciplines NN discipline O
that NN stopwords O
should NN stopwords O
inform NN inform O
the NN stopwords O
care VB care O
of NN stopwords O
every NN every O
patient VB patient O

Activation CAPITAL DT activation O
at DT stopwords astatine O
the NN stopwords O
germinal NN Germinal O
vesicle NN vesicle O
stage NN phase O
of NN stopwords O
starfish NN starfish O
oocytes JJ oocyte O
produces NN produce O
parthenogenetic NN agamic O
development NN development O
through NN stopwords done O
the NN stopwords O
failure VB failure O
of NN stopwords O
polar NN polar O
body NN body O
extrusion NN bulge O

Ovarian CAPITAL NNP ovarian D
cancer VB cancer D
: : O
diagnostic NN diagnostic O
limitations NN restriction O
, , O
treatment NN treatment O
obstacles NN obstacle O

The CAPITAL NNP O
safety-net VB O
role NN function O
of NN stopwords O
international NN International O
medical NN checkup O
graduates NN alumnus O

Retinopathy CAPITAL NNP retinopathy D
was VB stopwords Washington O
assessed DT measure O
by NN stopwords by O
ophthalmoscopy JJ ophthalmoscopy O
after DT stopwords after O
pupillary NN pupillary O
dilation NN dilation O
and DT stopwords O
classified NNS classified_ad O
as DT stopwords arsenic O
any DT stopwords any O
retinopathy NN retinopathy D
or NN stopwords Oregon O
as DT stopwords arsenic O
nonproliferative JJ O
and DT stopwords O
proliferative NN O

covered NNS cover O
or NN stopwords Oregon O
noncovered JJ O
metallic NN metallic T
stents NN stent T
were NN stopwords be O
used JJ use O
for NN stopwords O
the NN stopwords O
esophageal NN esophageal D
stenoses NN stenosis D
, , O
except NN demur O
in NN stopwords inch O
1 DIGITS CD one O
patient VB patient O
treated NN treat O
with NN stopwords O
a DT stopwords angstrom O
silicone NN silicone O
stent NN stent O

Fever CAPITAL NNP fever O
of NN stopwords O
unknown JJ unknown O
origin IN beginning O

Molecular CAPITAL NNP molecular O
systematics NN systematics O
of NN stopwords O
tanagers VB tanager O
( ( O
Thraupinae CAPITAL NNP O
) ) O
: : O
evolution NN development O
and DT stopwords O
biogeography NN biogeography O
of NN stopwords O
a DT stopwords angstrom O
diverse NN divers O
radiation VB radiation O
of NN stopwords O
neotropical JJ O
birds NN bird O

Diagnosis CAPITAL NNP diagnosis O
and DT stopwords O
therapy NN therapy O
of NN stopwords O
primary NN primary O
stomach NN stomach D
lymphoma NN lymphoma D

Transient CAPITAL NNP transient O
side NN side O
effects NN effects O
occurred JJ happen O
in NN stopwords inch O
five NN five O
patients VB patient O
( ( O
14 DIGITS CD fourteen O
% NN O
) ) O
, , O
but NN stopwords merely O
there NN stopwords there O
were NN stopwords be O
no NNS stopwords no O
persistent NN persistent O
complications NNS complication O

objective NN aim O
: : O
careful VB careful O
patient VB patient O
selection NN choice O
is NN stopwords be O
vital NN critical O
when NN stopwords O
video-assisted NN T
thoracoscopic NN T
surgical NN surgical T
( ( T
vats NN VAT T
) ) T
therapeutic NN remedy T
pulmonary NN pneumonic T
metastasectomy NN T
of NN stopwords O
colorectal NNS colorectal D
carcinoma VB carcinoma D
is NN stopwords be O
considered NNS see O

Cross-reactivity CAPITAL NNP O
of NN stopwords O
specific NN particular O
antibodies DT antibody O
directed NN direct O
to NN stopwords O
heat NN heat O
shock NN daze O
proteins NN protein O
from JJ stopwords O
periodontopathogenic NN O
bacteria VB bacteria O
and DT stopwords O
of NN stopwords O
human NN homo O
origin IN beginning O
( ( O
corrected NNS correct O
) ) O

Outcomes CAPITAL NNP result O
data VB data O
were NN stopwords be O
extracted NN extract O
from JJ stopwords O
articles DT article O
accepted DT accept O
after DT stopwords after O
panel VB panel O
review NN reappraisal O

Controlled CAPITAL NNP control O
trials NN test O
of NN stopwords O
cidofovir NN T
therapy NN therapy T
for NN stopwords O
MCV CAPITAL NNP D
in NN stopwords inch O
persons NN person O
infected NN infect O
with NN stopwords O
human NN homo O
immunodeficiency JJ immunodeficiency O
virus NN virus O
are DT stopwords are O
warranted NN justify O

the NN stopwords O
notable JJ luminary O
exception NN exception O
has VB stopwords hour_angle O
been NN stopwords be O
docetaxel NN T
, , O
which NN stopwords O
has VB stopwords hour_angle O
been NN stopwords be O
extensively NN extensively O
studied NN analyze O
as DT stopwords arsenic O
a DT stopwords angstrom O
second-line NN O
therapy NN therapy O
for NN stopwords O
nsclc JJ D

Montelukast CAPITAL NNP T
, , T
a DT stopwords angstrom T
leukotriene-receptor NN T
antagonist DT adversary T
, , T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
mild NN mild D
asthma DT asthma D
and DT stopwords D
exercise-induced NN D
bronchoconstriction NN D

Technoogy CAPITAL NNP O
, , O
automation DT automation O
and DT stopwords O
human NN homo O
welfare NN social_welfare O

Our CAPITAL NNP O
study NN survey O
shows NN show O
that NN stopwords O
a DT stopwords angstrom O
significant NN significant O
fraction NN fraction O
of NN stopwords O
hereditary NN familial O
prostate NN prostate_gland D
cancers VB cancer D
are DT stopwords are O
diagnosed NN diagnose O
in NN stopwords inch O
advanced DT advance O
stages NN phase O
, , O
emphasizing NN emphasizing O
the NN stopwords O
clinical JJ clinical O
importance JJ importance O
of NN stopwords O
early VB early O
detection NN detection O
in NN stopwords inch O
men NN work_force O
potentially NN potentially O
carrying VB transport O
prostate NN prostate_gland O
cancer VB cancer O
susceptibility NN susceptibility O
genes NN gene O

Azithromycin CAPITAL DT azithromycin T
therapy NN therapy T
for NN stopwords O
scrub NN scrub D
typhus NN typhus D
during NN stopwords O
pregnancy NN pregnancy O

124 DIGITS CD O

Dose-dependent CAPITAL NNP O
effects NN effects O
of NN stopwords O
recombinant NN recombinant O
human NN homo O
interleukin-6 NN O
on NN stopwords on O
glucose NN glucose O
regulation NN regulation O

Nephrotic CAPITAL NNP D
syndrome NN syndrome D
associated DT associate O
with NN stopwords O
hypocomplementemia NN D
in NN stopwords inch O
a DT stopwords angstrom O
4-year-old CD O
boy NN male_child O
with NN stopwords O
hemophilia NN hemophilia D
B CAPITAL NN bacillus D

Mutational CAPITAL NNP mutational O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
cystathionine NNS O
beta-synthase NN O
gene NN gene O
: : O
a DT stopwords angstrom O
splicing NN splice O
mutation NN mutant O
, , O
two NN two O
missense NN O
mutations NN mutant O
and DT stopwords O
an DT stopwords Associate_in_Nursing O
insertion NN interpolation O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
homocystinuria NN D

Treatment CAPITAL NNP treatment O
of NN stopwords O
hypertension NN high_blood_pressure D
in NN stopwords inch O
elderly NN aged O
patients VB patient O

Cataract CAPITAL VB cataract D
surgery NN surgery T
and DT stopwords O
its NN stopwords information_technology O
effect NN consequence O
on NN stopwords on O
intraocular NN O
pressure NN pressure O

Randomised CAPITAL VB randomize O
trial NN test O
of NN stopwords O
roxithromycin NN T
in NN stopwords inch O
non-Q-wave JJ D
coronary NNS coronary_thrombosis D
syndromes NN syndrome D
: : O
ROXIS CAPITAL NNP O
Pilot CAPITAL NNP pilot O
Study CAPITAL NNP survey O

II CAPITAL PRP two O

METHODS CAPITAL NNP method O
AND CAPITAL DT O
RESULTS CAPITAL NNP consequence O
: : O
From CAPITAL NNP O
1959 DIGITS CD O
to NN stopwords O
1998 DIGITS CD O
, , O
84 DIGITS CD eighty-four O
patients VB patient O
underwent JJ undergo O
a DT stopwords angstrom O
total NN sum O
of NN stopwords O
90 DIGITS CD ninety O
operations JJ operations T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
pulmonary NN pneumonic D
aspergilloma DT D
in NN stopwords inch O
the NN stopwords O
Marie-Lannelongue CAPITAL NNP O
Hospital CAPITAL NNP hospital O

Surgical CAPITAL NNP surgical T
treatment NN treatment T
of NN stopwords O
uterine JJ uterine D
cervix NNS neck D
insufficiency NN insufficiency D
during NN stopwords O
the NN stopwords O
2d CD second O
trimester NN trimester O
of NN stopwords O
pregnancy NN pregnancy O

Proposals CAPITAL NNP proposal O
for NN stopwords O
action DT action O
by NN stopwords by O
individuals NN person O
and DT stopwords O
the NN stopwords O
Catholic CAPITAL VB Catholic O
Church CAPITAL NNP church O

The CAPITAL NNP O
relative NN relative O
risk NN hazard O
and DT stopwords O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
were NN stopwords be O
calculated VB calculate O
for NN stopwords O
the NN stopwords O
risk NN hazard O
of NN stopwords O
preeclampsia NN preeclampsia D

In CAPITAL PRP inch O
the NN stopwords O
present NN present O
study NN survey O
, , O
we NN stopwords O
report NN report O
the NN stopwords O
molecular NN molecular O
cloning NNS cloning O
of NN stopwords O
three NN three O
isoforms NN O
, , O
the NN stopwords O
biochemical NN biochemical O
analysis DT analysis O
and DT stopwords O
the NN stopwords O
immunohistochemical JJ O
characterization NNS word_picture O
of NN stopwords O
one JJ one O
of NN stopwords O
the NN stopwords O
proteins NN protein O
identified NN identify O
in NN stopwords inch O
this NN stopwords O
screen NN screen O

Care CAPITAL VB care O
in NN stopwords inch O
normal RB convention O
birth NN birth O
: : O
a DT stopwords angstrom O
practical NN practical O
guide NN usher O

Do CAPITAL NNP bash O
it NN stopwords information_technology O
or NN stopwords Oregon O
lose NN lose O
it NN stopwords information_technology O

The CAPITAL NNP O
LPL CAPITAL NNP O
model NN model O
defines NN specify O
the NN stopwords O
time NN time O
available DT available O
for NN stopwords O
repair NN repair O
of NN stopwords O
PLD CAPITAL NNP O
( ( O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
) ) O
as DT stopwords arsenic O
the NN stopwords O
time NN time O
taken VB take O
to NN stopwords O
reach NN range O
maximal VB maximal O
survival NN survival O
in NN stopwords inch O
a DT stopwords angstrom O
delayed-plating NN O
recovery NN recovery O
experiment NN experiment O

The CAPITAL NNP O
advances DT progress O
in NN stopwords inch O
the NN stopwords O
understanding JJ understanding O
of NN stopwords O
the NN stopwords O
neuro-hormonal JJ O
mechanisms NN mechanism O
of NN stopwords O
heart NN heart O
failure VB failure O
have VB stopwords rich_person O
modified NN modify O
the NN stopwords O
therapeutic NN remedy O
strategy NN scheme O
: : O
the NN stopwords O
deleterious NN deleterious O
effect NN consequence O
of NN stopwords O
the NN stopwords O
activation DT activation O
of NN stopwords O
the NN stopwords O
sympathetic NN sympathetic O
nervous RB nervous O
system NN system O
on NN stopwords on O
the NN stopwords O
myocardium NN myocardium O
has VB stopwords hour_angle O
served NN serve O
as DT stopwords arsenic O
the NN stopwords O
rationale VB rationale O
for NN stopwords O
randomized VB randomize O
clinical JJ clinical O
trials NN test O
comparing NNS comparison O
beta-blockade NN O
to NN stopwords O
placebo NN placebo O
: : O
the NN stopwords O
current NNS current O
data VB data O
are DT stopwords are O
promising NN promise O
, , O
suggesting NN propose O
a DT stopwords angstrom O
beneficial NN beneficial O
effect NN consequence O
on NN stopwords on O
survival NN survival O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
on NN stopwords on O
quality NN quality O
of NN stopwords O
life NN life O

Potential CAPITAL NNP potential O
ethological NN O
isolating NN isolate O
mechanisms NN mechanism O
and DT stopwords O
assortative DT O
mating VB coupling O
in NN stopwords inch O
the NN stopwords O
domestic NN domestic O
fowl JJ domestic_fowl O

Fiercer CAPITAL NNP ferocious O
competition NNS competition O
between NN stopwords between O
athletes DT athlete O
and DT stopwords O
a DT stopwords angstrom O
wider NN wide O
knowledge NN cognition O
of NN stopwords O
optimal JJ optimum O
training NN training O
regimens NN regimen O
dramatically NN dramatically O
influence NN influence O
current NNS current O
training NN training O
methods NN method O

Pharmacological CAPITAL NNP pharmacological O
and DT stopwords O
clinical JJ clinical O
effectiveness NN effectiveness O
of NN stopwords O
a DT stopwords angstrom O
fixed NN repair T
phytogenic NN T
combination NNS combination T
trembling NN shaking T
poplar NN poplar T
( ( T
Populus CAPITAL NNP Populus T
tremula NN T
) ) T
, , T
true NN true T
goldenrod NN goldenrod T
( ( T
Solidago CAPITAL NNP Solidago T
virgaurea NN T
) ) T
and DT stopwords T
ash DT ash T
( ( T
Fraxinus CAPITAL NNP Fraxinus T
excelsior NN excelsior T
) ) T
in NN stopwords inch O
mild NN mild D
to NN stopwords D
moderate NN centrist D
rheumatic NN rheumatic D
complaints NNS ailment D

CONCLUSIONS CAPITAL NNP decision O
: : O
Complications CAPITAL NNP complication O
and DT stopwords O
early VB early O
return NN tax_return O
resulting NN result O
from JJ stopwords O
no NNS stopwords no O
or NN stopwords Oregon O
delayed NN delay O
prescribing NN order O
of NN stopwords O
antibiotics DT antibiotic T
for NN stopwords O
sore NN sore D
throat NN throat D
are DT stopwords are O
rare NN rare O

Adolescent CAPITAL DT adolescent O
Gynecology CAPITAL NNP gynecology O
and DT stopwords O
Endocrinology CAPITAL NNP endocrinology O
: : O
Basic CAPITAL IN BASIC O
and DT stopwords O
Clinical CAPITAL NNP clinical O
Aspects CAPITAL DT aspect O

Transurethral CAPITAL NNP T
microwave NN microwave T
thermotherapy NN thermotherapy T

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

The CAPITAL NNP O
rabbits NN rabbit O
were NN stopwords be O
divided NN divide O
into NN stopwords O
two NN two O
study NN survey O
groups NN group O
, , O
one JJ one O
control NNS control O
and DT stopwords O
the NN stopwords O
other JJ stopwords other O
receiving NN receive O
about DT stopwords about O
16 DIGITS CD sixteen O
mg NN milligram O
fluoride/rabbit/day JJ O
in NN stopwords inch O
their NN stopwords O
drinking NN drinking O
water VB water O

DESIGN CAPITAL NNP design O
: : O
Case CAPITAL VB case O
report NN report O

Aarhus CAPITAL DT Arhus O
, , O
Denmark CAPITAL NNP Denmark O
, , O
21-24 CD O
May CAPITAL NNP May O
1997 DIGITS CD O

Urine CAPITAL NNP urine O
toxicology NN toxicology O
screens NN screen O
were NN stopwords be O
prospectively NN O
obtained NN obtain O
on NN stopwords on O
147 DIGITS CD O
women NN woman O
with NN stopwords O
preterm NN D
PROM CAPITAL NNP promenade D

American CAPITAL DT American O
College CAPITAL NNP college O
of NN stopwords O
Physicians CAPITAL NNP doctor O

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
positive NN positive O
urine JJ urine O
drug NN drug O
screens NN screen O
for NN stopwords O
cocaine NNS cocaine O
was VB stopwords Washington O
8.2 CD O
% NN O

As CAPITAL DT arsenic O
increasing NN increase O
numbers JJ Numbers O
of NN stopwords O
these NN stopwords O
patients VB patient O
with NN stopwords O
similar NN similar O
clinical JJ clinical O
features NN feature O
were NN stopwords be O
identified NN identify O
, , O
there NN stopwords there O
appeared DT look O
to NN stopwords O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
association DT association O
between NN stopwords between O
these NN stopwords O
features NN feature O
and DT stopwords O
fenfluramine-phentermine JJ T
therapy NN therapy T

In CAPITAL PRP inch O
two NN two O
patients VB patient O
small JJ small O
ischemic NN ischemic D
infarctions NN infarct D
involving NN involve O
the NN stopwords O
corona NNS aureole O
radiata VB O
were NN stopwords be O
found JJ found O
, , O
and DT stopwords O
in NN stopwords inch O
one JJ one O
a DT stopwords angstrom O
venous NN venous D
infarction NN infarct D
was VB stopwords Washington O
detected NN detect O

purpose NN purpose O
: : O
given NN given O
the NN stopwords O
cisplatin-related NN O
myelotoxicity NN O
and DT stopwords O
nonhematologic JJ O
toxicities NN toxicity O
, , O
we NN stopwords O
were NN stopwords be O
prompted NN motivate O
to NN stopwords O
undertake JJ undertake O
a DT stopwords angstrom O
study NN survey O
of NN stopwords O
the NN stopwords O
noncisplatin JJ T
combination NNS combination T
of NN stopwords T
paclitaxel VB T
plus NN asset T
gemcitabine NN T
to NN stopwords O
evaluate NN measure O
the NN stopwords O
efficacy NN efficacy O
, , O
tolerance NN tolerance O
, , O
and DT stopwords O
survival NN survival O
of NN stopwords O
this NN stopwords O
combination NNS combination O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
locally NN locally D
advanced DT advance D
and DT stopwords D
metastatic NN metastatic D
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D

SUBJECTS CAPITAL NNP subject O
AND CAPITAL DT O
METHODS CAPITAL NNP method O
: : O
The CAPITAL NNP O
study NN survey O
included NN include O
2 DIGITS CD two O
, , O
039 DIGITS CD O
patients VB patient O
, , O
which NN stopwords O
were NN stopwords be O
classified NNS classified_ad O
in NN stopwords inch O
three NN three O
groups NN group O
( ( O
asymptomatic DT asymptomatic O
( ( O
group NN group O
A CAPITAL DT angstrom O
) ) O
, , O
with NN stopwords O
suspicion NN intuition O
of NN stopwords O
parasitosis NN D
( ( O
group NN group O
B CAPITAL NN bacillus O
) ) O
, , O
with NN stopwords O
diarrhoea NN diarrhea D
( ( O
group NN group O
C CAPITAL SYM degree_centigrade O
) ) O
) ) O

Joint CAPITAL NNP joint O
annual DT annual O
session NN session O
of NN stopwords O
the NN stopwords O
North CAPITAL NNP North O
German CAPITAL NNP German O
Society CAPITAL NNP society O
of NN stopwords O
Radiology CAPITAL VB radiology O
and DT stopwords O
the NN stopwords O
Radiology CAPITAL VB radiology O
Society CAPITAL NNP society O
of NN stopwords O
Lower CAPITAL NNP lower_berth O
Saxony CAPITAL VB Saxony O
and DT stopwords O
Sachsen CAPITAL VB Saxony O
Anhalt CAPITAL DT O

Chelation CAPITAL NNP chelation T
therapy NN therapy T
for NN stopwords O
peripheral NN peripheral D
arterial DT arterial D
occlusive JJ stop_consonant D
disease NN disease D
: : O
a DT stopwords angstrom O
systematic NN systematic O
review NN reappraisal O

Overall CAPITAL NNP overall O
1 DIGITS CD one O
year NN year O
survival NN survival O
( ( O
operative JJ secret_agent O
deaths NN death O
excluded NN exclude O
) ) O
was VB stopwords Washington O
68 DIGITS CD sixty-eight O
% NN O
after DT stopwords after O
tumor NN tumor D
resection NN resection T
compared NNS compare O
to NN stopwords O
31 DIGITS CD thirty-one O
% NN O
after DT stopwords after O
palliative VB palliative O
surgery NN surgery O
( ( O
P CAPITAL NN phosphorus O
< NN O
0.001 LS O
) ) O

Successful CAPITAL NNP successful O
replantation NN O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
amputated DT amputate O
tongue NN tongue O

In CAPITAL PRP inch O
all DT stopwords all O
simple NN simple O
salines VB saline_solution O
, , O
irrespective NN regardless O
of NN stopwords O
their NN stopwords O
osmolarity JJ O
, , O
Lucifer CAPITAL NNP Satan O
Yellow CAPITAL NNP yellow O
CH CAPITAL NNP O
was VB stopwords Washington O
found JJ found O
to NN stopwords O
preferentially NN preferentially O
migrate NN migrate O
in NN stopwords inch O
the NN stopwords O
posterior NN buttocks O
direction NN direction O
and DT stopwords O
to NN stopwords O
accumulate DT roll_up O
in NN stopwords inch O
the NN stopwords O
oocyte JJ oocyte O
due NN due O
to NN stopwords O
progressive NN progressive O
binding NN binding O
to NN stopwords O
yolk NN egg_yolk O
spheres NN sphere O

two NN two T
triazole NN T
antifungal DT antifungal T
agents DT agent T
, , T
fluconazole JJ T
and DT stopwords T
itraconazole NN itraconazole T
, , O
were NN stopwords be O
introduced NN introduce O
over JJ stopwords over O
a DT stopwords angstrom O
decade NN decade O
ago DT ago O
and DT stopwords O
since NN O
then NN stopwords then O
have VB stopwords rich_person O
been NN stopwords be O
used JJ use O
extensively NN extensively O
for NN stopwords O
the NN stopwords O
prophylaxis NN prophylaxis O
and DT stopwords O
treatment NN treatment O
of NN stopwords O
a DT stopwords angstrom O
variety NN assortment O
of NN stopwords O
fungal JJ fungal D
infections NN infection D

Epilepsy CAPITAL NNP epilepsy O
and DT stopwords O
attention DT attention O
deficit NN deficit O
hyperactivity NN hyperactivity O
disorder NN disorder O
: : O
is NN stopwords be O
methylphenidate NN methylphenidate O
safe VB safe O
and DT stopwords O
effective NN effective O
? . O

Comparison CAPITAL NNP comparison O
of NN stopwords O
the NN stopwords O
effects NN effects O
of NN stopwords O
salmeterol VB T
and DT stopwords O
ipratropium NN T
bromide NN bromide T
on NN stopwords on O
exercise NN exercise O
performance NN performance O
and DT stopwords O
breathlessness NN shortness_of_breath O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
stable NN stable D
chronic NN chronic D
obstructive NN clogging D
pulmonary NN pneumonic D
disease NN disease D
. . O

Use CAPITAL NNP use O
of NN stopwords O
cisapride NN T
in NN stopwords inch O
treatment NN treatment O
of NN stopwords O
constipation NNS constipation D
in NN stopwords inch O
children JJ child O

Adjuvant CAPITAL DT adjuvant O
radiotherapy VB radiotherapy O
was VB stopwords Washington O
delivered NN deliver O
after DT stopwords after O
surgery NN surgery O
for NN stopwords O
women NN woman O
with NN stopwords O
surgical NN surgical O
stage NN phase O
pT2b NN O
or NN stopwords Oregon O
greater NN greater O
, , O
less NN lupus_erythematosus O
than NN stopwords O
3 DIGITS CD three O
mm NNS millimeter O
of NN stopwords O
safe VB safe O
cervical NNS cervical O
stroma NN stroma O
, , O
cut-through NNS O
, , O
or NN stopwords Oregon O
positive NN positive O
nodes JJ node O

the NN stopwords O
matrix VB matrix T
metalloproteinase NN T
inhibitors NN inhibitor T
marimastat NN T
and DT stopwords T
bms-275291 NN T
are DT stopwords are O
under JJ stopwords nether O
evaluation NN evaluation O
in NN stopwords inch O
sclc JJ D

117 DIGITS CD O

Distinguishing CAPITAL NNP distinguish O
silent NN silent D
lacunar NN D
infarction NN infarct D
from JJ stopwords O
enlarged NN enlarge D
Virchow-Robin CAPITAL NNP D
spaces NN space D
: : O
a DT stopwords angstrom O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O
and DT stopwords O
pathological VB pathological O
study NN survey O

standard NN standard O
operations JJ operations O
for NN stopwords O
lung NN lung D
cancer VB cancer D
patients VB patient O
are DT stopwords are O
generally NN by_and_large O
accepted DT accept O
as DT stopwords arsenic O
performing NN acting O
lobectomy NN lobectomy T
or NN stopwords Oregon T
pneumonectomy NN pneumonectomy T
on NN stopwords on O
the NN stopwords O
tumor NN tumor O
baring NN denudation O
lung NN lung O
and DT stopwords O
ipsilateral NN ipsilateral O
hilar NN hilar O
and DT stopwords O
mediastinal NN O
lymphadenectomy NN O
including NN include O
subcarinal NN O
lymph NN lymph O
nodes JJ node O

Psychosexual CAPITAL NNP psychosexual D
problems NN problem D

Recommendations CAPITAL NNP recommendation O
on NN stopwords on O
antiretroviral DT T
treatment NN treatment T

Cancer CAPITAL VB cancer D
risk NN hazard O
in NN stopwords inch O
the NN stopwords O
rubber NN rubber O
industry NN industry O
: : O
a DT stopwords angstrom O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
recent NN Holocene O
epidemiological NN epidemiologic O
evidence NN evidence O

The CAPITAL NNP O
metabolism NN metamorphosis O
of NN stopwords O
intravenously NN intravenously O
injected NN inject O
isotopic NN isotopic O
cholic NNS O
acid DT acid O
in NN stopwords inch O
Laennec CAPITAL VB D
's POS D
cirrhosis NN cirrhosis D

As CAPITAL DT arsenic O
the NN stopwords O
ambient DT ambient O
temperature NN temperature O
increases NN addition O
, , O
there NN stopwords there O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
insensible NN insensible O
fluid JJ fluid O
loss NN loss O
and DT stopwords O
the NN stopwords O
potential NN potential O
for NN stopwords O
dehydration NN dehydration O

In CAPITAL PRP inch O
addition DT addition O
, , O
we NN stopwords O
demonstrate NN show O
using JJ exploitation O
a DT stopwords angstrom O
fusion JJ fusion O
protein NN protein O
expressed NN express O
in NN stopwords inch O
eukaryotic NN eukaryotic O
cells NNS cell O
that NN stopwords O
chLAMP NNS O
has VB stopwords hour_angle O
homophilic NN O
binding NN binding O
activity DT activity O

We CAPITAL NNP O
present NN present O
the NN stopwords O
case VB case O
of NN stopwords O
a DT stopwords angstrom O
15-month-old CD O
girl NN girl O
with NN stopwords O
TSS CAPITAL NNP toxic_shock D
, , O
but NN stopwords merely O
without NN O
erythroderma NN erythroderma D
or NN stopwords Oregon O
desquamation NN desquamation D

Drug CAPITAL NNP drug O
information NN information O
questions NN question O
and DT stopwords O
answers DT answer O
: : O
new JJ new O
for NN stopwords O
psoriasis NN psoriasis D
: : O
colchicine NNS colchicine T

purpose NN purpose O
: : O
this NN stopwords O
randomized VB randomize O
trial NN test O
was VB stopwords Washington O
designed NN plan O
to NN stopwords O
determine NN determine O
whether NN O
paclitaxel VB T
plus NN asset T
carboplatin VB T
( ( T
pc NN personal_computer T
) ) T
offered JJ offer O
a DT stopwords angstrom O
survival NN survival O
advantage DT advantage O
over JJ stopwords over O
vinorelbine NN T
plus NN asset T
cisplatin NN T
( ( T
vc NN T
) ) T
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
non JJ not D
-- : D
small-cell JJ D
lung NN lung D
cancer VB cancer D

In CAPITAL PRP inch O
this NN stopwords O
retrospective NN retrospective O
, , O
case-controlled VB O
study NN survey O
, , O
the NN stopwords O
rate VB rate O
of NN stopwords O
severe NN severe O
pre-eclampsia NN preeclampsia D
was VB stopwords Washington O
significantly NN significantly O
increased NN increase O
in NN stopwords inch O
triplet NN three O
gestations NN gestation O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
twins NN twins O
although DT O
the NN stopwords O
overall JJ overall O
rate VB rate O
of NN stopwords O
preeclampsia NN preeclampsia D
was VB stopwords Washington O
not JJ stopwords not O

The CAPITAL NNP O
AIDS CAPITAL DT AIDS O
Study CAPITAL NNP survey O
Group CAPITAL NNP group O
of NN stopwords O
the NN stopwords O
Spanish CAPITAL NNP Spanish O
Society CAPITAL NNP society O
of NN stopwords O
Infectious CAPITAL PRP infectious O
Diseases CAPITAL NNP disease O
and DT stopwords O
Clinical CAPITAL NNP clinical O
Microbiology CAPITAL NNP microbiology O

BRCA1 CAPITAL NNP O
sequence NN sequence O
analysis DT analysis O
in NN stopwords inch O
women NN woman O
at DT stopwords astatine O
high NN high O
risk NN hazard O
for NN stopwords O
susceptibility NN susceptibility O
mutations NN mutant O

an DT stopwords Associate_in_Nursing T
aggressive DT aggressive T
surgical NN surgical T
approach DT approach T
is NN stopwords be O
justified NN justify O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
mplc NN D
and DT stopwords O
offers JJ offer O
the NN stopwords O
greatest NN greatest O
chance NNS opportunity O
for NN stopwords O
long-term NN long-run O
survival NN survival O
even NN evening O
in NN stopwords inch O
the NN stopwords O
case VB case O
of NN stopwords O
limited NN express O
resection NN resection O

It CAPITAL PRP information_technology O
has VB stopwords hour_angle O
been NN stopwords be O
determined NN determine O
that NN stopwords O
the NN stopwords O
plasma NN plasma O
FFA CAPITAL NNP O
turnover NN employee_turnover O
rate VB rate O
is NN stopwords be O
sufficiently NN sufficiently O
rapid VB rapid O
to NN stopwords O
account DT history O
for NN stopwords O
most NN stopwords most O
of NN stopwords O
the NN stopwords O
fat VB fat O
metabolised NN metabolize O
during NN stopwords O
low NN low O
intensity NN intensity O
exercise NN exercise O
( ( O
25 DIGITS CD twenty-five O
to NN stopwords O
40 DIGITS CD forty O
% NN O
VO2max CAPITAL NNP O
) ) O

IV CAPITAL PRP four O

When CAPITAL NNP O
each VB stopwords each O
group NN group O
was VB stopwords Washington O
divided NN divide O
into NN stopwords O
two NN two O
additional DT extra O
subgroups NN subgroup O
based VB establish O
on NN stopwords on O
the NN stopwords O
initial JJ initial O
PI CAPITAL NN pi O
, , O
it NN stopwords information_technology O
was VB stopwords Washington O
found JJ found O
that NN stopwords O
ENS CAPITAL NNP en O
could NNS O
reduce NN reduce O
PI CAPITAL NN pi O
and DT stopwords O
increase NN addition O
PT CAPITAL NNP platinum O
significantly NN significantly O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
, , O
but NN stopwords merely O
did NN stopwords make O
not JJ stopwords not O
significantly NN significantly O
( ( O
P CAPITAL NN phosphorus O
> NN O
0.05 LS O
) ) O
improve JJ better O
ROM CAPITAL NNP read-only_memory O
, , O
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
the NN stopwords O
placebo NN placebo O
group NN group O
for NN stopwords O
both NN stopwords both O
subgroups NN subgroup O

This CAPITAL NNP O
phenomenon NN phenomenon O
raises VB raise O
different NN different O
questions NN question O
, , O
in NN stopwords inch O
particular NN particular O
about DT stopwords about O
the NN stopwords O
relation NN relation O
of NN stopwords O
this NN stopwords O
disposition NN disposition O
with NN stopwords O
the NN stopwords O
nasoseptal RB O
center NNS center O
, , O
the NN stopwords O
medial NN medial O
part NN part O
of NN stopwords O
the NN stopwords O
nasodorsal RB O
center NNS center O

The CAPITAL NNP O
induction NN initiation O
of NN stopwords O
HMGI-C CAPITAL NNP O
mRNA NN messenger_RNA O
level NN degree O
is NN stopwords be O
sensitive NN medium O
to NN stopwords O
both NN stopwords both O
the NN stopwords O
protein NN protein O
synthesis NN synthesis O
inhibitor NN inhibitor O
cycloheximide NNS O
and DT stopwords O
transcription NN transcription O
inhibitor NN inhibitor O
actinomycin DT actinomycin O
D CAPITAL NN vitamin_D O

Asbestos CAPITAL DT asbestos O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
urban JJ urban O
air DT air O
contaminant NNS contaminant O

Clinical CAPITAL NNP clinical O
experience NN experience O
with NN stopwords O
the NN stopwords O
surface NN surface T
anesthetic DT anesthetic T
xylocaine JJ Lidocaine T
in NN stopwords inch O
obstetrics NN obstetrics O

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

Anticytokine CAPITAL DT T
therapy NN therapy T
-- : O
a DT stopwords angstrom O
new JJ new O
era NN era O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
rheumatoid NN arthritic D
arthritis DT arthritis D
? . O

When CAPITAL NNP O
bleeding NN bleeding D
is NN stopwords be O
stopped NN stop O
via NN O
surgical NN surgical T
or NN stopwords Oregon T
radiological VB radiological T
methods NN method T
, , O
the NN stopwords O
clinical JJ clinical O
course NNS course O
of NN stopwords O
hemobilia-associated NN O
pancreatitis VB pancreatitis O
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
benign NN benign O

Fulminant CAPITAL NNP fulminant O
hepatic NN liverwort D
failure VB failure D
in NN stopwords inch O
murine NN murine D
hepatitis NN hepatitis D
virus NN virus D
strain NN strain D
3 DIGITS CD three D
infection NN infection D
: : O
tissue-specific NN O
expression NN expression O
of NN stopwords O
a DT stopwords angstrom O
novel JJ novel O
fgl2 JJ O
prothrombinase NN prothrombinase O

In CAPITAL PRP inch O
particular NN particular O
they NN stopwords O
stress NN stress O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
senescence NN aging O
can VB stopwords can O
be NN stopwords beryllium O
due NN due O
to NN stopwords O
a DT stopwords angstrom O
sum NN sum O
of NN stopwords O
molecular NN molecular O
damages VB damages O
caused VB cause O
by NN stopwords by O
free JJ free O
radicals VB group O
, , O
and DT stopwords O
to NN stopwords O
the NN stopwords O
loss NN loss O
of NN stopwords O
telomeric NN O
DNA CAPITAL NNP deoxyribonucleic_acid O

Hydrogen CAPITAL NNP hydrogen O
ion NN ion O
equilibrium NN equilibrium O
in NN stopwords inch O
heart NN heart D
failure VB failure D

Some CAPITAL NNP some O
inflammatory NN inflammatory D
disorders NN disorder D
of NN stopwords O
the NN stopwords O
large NN large O
intestine NN intestine O

Lumbar CAPITAL NNP lumbar D
spine JJ spinal_column D
stenosis NN stenosis D
: : O
a DT stopwords angstrom O
common NNS park O
cause VB cause O
of NN stopwords O
back VB back O
and DT stopwords O
leg NN leg O
pain IN pain D

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONCLUSION CAPITAL NNP decision O
: : O
Direct CAPITAL NNP direct O
PTA CAPITAL NNP O
may VB May O
be NN stopwords beryllium O
performed NN perform O
safely VB safely O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
alternative DT option O
to NN stopwords O
thrombolytic NN thrombolytic O
therapy NN therapy O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
acute DT acute_accent O
occlusion JJ occlusion O
of NN stopwords O
the NN stopwords O
middle NN center O
cerebral NNS cerebral O
artery DT artery O
when NN stopwords O
early VB early O
CT CAPITAL NNP Connecticut O
findings NN findings O
and/or DT O
lenticulostriate NN O
artery DT artery O
involvement NN engagement O
are DT stopwords are O
present NN present O
or NN stopwords Oregon O
when NN stopwords O
superselective NN O
local NN local O
angiography DT angiography O
shows NN show O
the NN stopwords O
presence NN presence O
of NN stopwords O
a DT stopwords angstrom O
large NN large O
embolus NN embolus O
or NN stopwords Oregon O
high-grade NN high-grade O
stenosis NN stenosis O

Prognostic CAPITAL NNP omen O
factors VB factor O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
locally NN locally O
advanced DT advance O
rectal NN rectal D
adenocarcinoma DT adenocarcinoma D
treated NN treat O
with NN stopwords O
preoperative NN preoperative T
radiotherapy VB radiotherapy T
and DT stopwords O
surgery NN surgery T

Therapy CAPITAL NNP therapy O
of NN stopwords O
degenerative NN degenerative D
diseases NN disease D
of NN stopwords D
the NN stopwords D
musculoskeletal NN musculoskeletal D
system NN system D
with NN stopwords O
South CAPITAL NNP South T
African CAPITAL DT African T
devil NN Satan T
's POS T
claw NNS claw T
( ( T
Harpagophytum CAPITAL NNP T
procumbens NN T
DC CAPITAL NNP District_of_Columbia T
) ) T

Antibiotics CAPITAL DT antibiotic T
prescribed NN order O
for NN stopwords O
sore NN sore D
throat NN throat D
during NN stopwords O
the NN stopwords O
previous NN previous O
year NN year O
had VB stopwords have O
an DT stopwords Associate_in_Nursing O
additional DT extra O
effect NN consequence O
( ( O
hazard NN hazard O
ratio VB ratio O
1.69 CD O
, , O
1.20 CD O
to NN stopwords O
2.37 CD O
) ) O

a DT stopwords angstrom O
retrospective NN retrospective O
immunohistochemical JJ O
study NN survey O
was VB stopwords Washington O
performed NN perform O
on NN stopwords on O
material VB material O
from JJ stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
were NN stopwords be O
newly JJ newly O
diagnosed NN diagnose O
with NN stopwords O
osteogenic JJ D
sarcoma VB sarcoma D
who NN stopwords World_Health_Organization O
were NN stopwords be O
treated NN treat O
according DT harmonize O
to NN stopwords O
the NN stopwords O
t12 RB T
protocol NN protocol T
from JJ stopwords O
the NN stopwords O
authors DT writer O
' '' O
institution NN institution O
between NN stopwords between O
1986 DIGITS CD O
to NN stopwords O
1993 DIGITS CD O

Urogynaecology CAPITAL NNP O
proceedings NN proceeding O
of NN stopwords O
the NN stopwords O
joint NN joint O
RCOG/BAUS CAPITAL NNP O
urogynaecology JJ O
meeting NN meeting O

In CAPITAL PRP inch O
one JJ one O
, , O
suppression NN suppression O
of NN stopwords O
virus NN virus O
replication NN reproduction O
occurred JJ happen O
and DT stopwords O
has VB stopwords hour_angle O
persisted NN prevail O
for NN stopwords O
90 DIGITS CD ninety O
weeks NN week O
( ( O
bDNA NN O
, , O
& CC O
# # O
60 DIGITS CD sixty O
; : O
500 DIGITS CD five_hundred O
human NN homo O
immunodeficiency JJ immunodeficiency O
virus NN virus O
type NN type O
1 DIGITS CD one O
( ( O
HIV-1 CAPITAL NNP O
) ) O
RNA CAPITAL NNP ribonucleic_acid O
copies/ml NNS O
) ) O

The CAPITAL NNP O
authors DT writer O
report NN report O
the NN stopwords O
postoperative NN postoperative O
magnetic VB magnetic O
resonance NN resonance O
( ( O
MR CAPITAL NNP Mister O
) ) O
imaging NN imagination O
findings NN findings O
in NN stopwords inch O
36 DIGITS CD thirty-six O
patients VB patient O
with NN stopwords O
advanced DT advance D
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
who NN stopwords World_Health_Organization O
underwent JJ undergo O
unilateral JJ unilateral T
microelectrode-guided NN T
posteroventral NN T
pallidotomy VB T

Kiel CAPITAL NNP O
, , O
20-21 CD O
February CAPITAL NNP February O
1998 DIGITS CD O

Fascioloidiasis CAPITAL NNP D
in NN stopwords inch O
game-ranched VB O
elk NN elk O
from JJ stopwords O
Montana CAPITAL NNP Montana O

Is CAPITAL PRP be O
moxonidine NN T
a DT stopwords angstrom O
useful JJ useful O
addition DT addition O
to NN stopwords O
the NN stopwords O
growing NN growth O
number JJ number O
of NN stopwords O
antihypertensives DT antihypertensive O
on NN stopwords on O
the NN stopwords O
market NN market O
? . O

The CAPITAL NNP O
CYP1A1 CAPITAL NNP O
MspI CAPITAL NNP O
heterozygous NN heterozygous O
genotype NN genotype O
was VB stopwords Washington O
present NN present O
in NN stopwords inch O
18 DIGITS CD eighteen O
percent NN percentage O
of NN stopwords O
cases VB case O
and DT stopwords O
16 DIGITS CD sixteen O
percent NN percentage O
of NN stopwords O
controls NNS control O
, , O
and DT stopwords O
one JJ one O
percent NN percentage O
of NN stopwords O
cases VB case O
and DT stopwords O
controls NNS control O
were NN stopwords be O
CYP1A1 CAPITAL NNP O
MspI CAPITAL NNP O
homozygous NN homozygous O
variant NN discrepancy O

Study CAPITAL NNP survey O
of NN stopwords O
cortical NNS cortical D
atrophy DT atrophy D
with NN stopwords O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O
in NN stopwords inch O
corticobasal NNS D
degeneration NN degeneration D

Use CAPITAL NNP use O
of NN stopwords O
a DT stopwords angstrom O
modified NN modify O
version NN version O
of NN stopwords O
the NN stopwords O
Overt CAPITAL NNP overt O
Aggression CAPITAL DT aggression O
Scale CAPITAL NNP scale O
in NN stopwords inch O
the NN stopwords O
measurement NN measurement O
and DT stopwords O
assessment DT appraisal O
of NN stopwords O
aggressive DT aggressive O
behaviours NN behavior O
following JJ following O
brain NN brain D
injury NN injury D

However CAPITAL NNP however O
, , O
the NN stopwords O
increases NN addition O
in NN stopwords inch O
bone NN bone O
mass VB mass O
and DT stopwords O
bone NN bone O
formation NN formation O
were NN stopwords be O
not JJ stopwords not O
reflected NN reflect O
in NN stopwords inch O
improved JJ better O
bone NN bone O
strength NN strength O

Surgical CAPITAL NNP surgical T
management VB management T
of NN stopwords O
soft NN soft D
tissue NN tissue D
sarcomas VB sarcoma D
: : O
principles NN principle O
of NN stopwords O
resection NN resection T
and DT stopwords O
reconstructive NN reconstructive O
plastic NN plastic O
procedures NN procedure O

HIV CAPITAL NNP HIV T
vaccines NN vaccine T
: : O
prospects NN prospect O
and DT stopwords O
challenges NNS challenge O

The CAPITAL NNP O
molecule NN molecule O
is NN stopwords be O
a DT stopwords angstrom O
glycosylphosphatidyl-inositol-anchored NN O
60 DIGITS CD sixty O
kDa NN O
protein NN protein O
with NN stopwords O
three NN three O
immunoglobulin-like JJ O
domains NN sphere O
and DT stopwords O
contains NNS incorporate O
40 DIGITS CD forty O
% NN O
N-linked CAPITAL NNP O
carbohydrate VB carbohydrate O

Preservation CAPITAL NNP preservation O
of NN stopwords O
electrocardiographic NN electrocardiographic O
voltage NN voltage O
in NN stopwords inch O
familial VB familial O
amyloidosis DT amyloidosis D
suggests NN propose O
that NN stopwords O
the NN stopwords O
particular NN particular O
biochemical NN biochemical O
characteristics NNS feature O
of NN stopwords O
distinct NN distinct O
types NN type O
of NN stopwords O
amyloid DT amyloid O
fibril NN fibril O
have VB stopwords rich_person O
different NN different O
pathological VB pathological O
effects NN effects O
on NN stopwords on O
the NN stopwords O
myocardium NN myocardium O

these NN stopwords O
aggressive DT aggressive T
chemotherapeutic NNS chemotherapeutic T
combinations NNS combination T
will NN stopwords volition O
hopefully NN hopefully O
improve JJ better O
survival NN survival O
and DT stopwords O
quality NN quality O
of NN stopwords O
life NN life O
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
nsclc JJ D

Glutamate CAPITAL NNP glutamate O
receptors NN receptor O
and DT stopwords O
gene NN gene O
induction NN initiation O
: : O
signalling NN sign O
from JJ stopwords O
receptor NN receptor O
to NN stopwords O
nucleus JJ nucleus O

Nevertheless CAPITAL NNP however O
, , O
both NN stopwords both O
primary NN primary O
CML CAPITAL NNP O
cells NNS cell O
and DT stopwords O
BCR-ABL+ CAPITAL NNP O
BAF3 CAPITAL IN O
cells NNS cell O
show NN show O
the NN stopwords O
same VB stopwords Lapp O
dose-dependent NN O
sensitivity NN sensitivity O
to NN stopwords O
TNF-alpha CAPITAL NNP O
or NN stopwords Oregon O
ceramide-induced NNS O
apoptosis DT apoptosis O
as DT stopwords arsenic O
their NN stopwords O
respective NN respective O
normal RB convention O
counterparts NNS counterpart O

A CAPITAL DT angstrom O
knowledge NN cognition O
of NN stopwords O
the NN stopwords O
neural JJ nervous O
control NNS control O
of NN stopwords O
salivary VB salivary O
secretion NN secretion O
is NN stopwords be O
especially NN particularly O
important JJ important O
for NN stopwords O
the NN stopwords O
understanding JJ understanding O
of NN stopwords O
the NN stopwords O
effects NN effects O
of NN stopwords O
exertion NN effort O
on NN stopwords on O
salivary VB salivary O
secretion NN secretion O

The CAPITAL NNP O
widespread NN widespread O
use JJ use O
of NN stopwords O
ultrasound JJ ultrasound O
is NN stopwords be O
encouraging NN promote O
, , O
however NN however O
, , O
there NN stopwords there O
are DT stopwords are O
clearly NNS clearly O
diverse NN divers O
views NN position O

Mainz CAPITAL NNP O
, , O
Germany CAPITAL NNP Germany O
, , O
October CAPITAL NNP October O
23-25 CD O
, , O
1997 DIGITS CD O

The CAPITAL NNP O
present NN present O
study NN survey O
set NN set O
out JJ stopwords out O
to NN stopwords O
establish NN establish O
in NN stopwords inch O
a DT stopwords angstrom O
large NN large O
sample VB sample O
if NN stopwords O
any DT stopwords any O
ears VB ear O
could NNS O
be NN stopwords beryllium O
found JJ found O
that NN stopwords O
lacked NN miss O
TEOAEs CAPITAL NNP O
despite NN contempt O
normal RB convention O
hearing NN hearing O
threshold NN threshold O
levels NN degree O
( ( O
HTL CAPITAL NNP O
) ) O

The CAPITAL NNP O
use JJ use O
and DT stopwords O
effects NN effects O
of NN stopwords O
postcoital NN O
contraception NNS contraception O

Chemotherapy CAPITAL NNP chemotherapy T
with NN stopwords T
praziquantel NN T
has VB stopwords hour_angle O
the NN stopwords O
potential NN potential O
to NN stopwords O
reduce NN reduce O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
Echinococcus CAPITAL NNP echinococcus D
multilocularis NN D
in NN stopwords inch O
wild NN wild O
foxes JJ fox O
( ( O
Vulpes CAPITAL NNP Vulpes O
vulpes NN Vulpes O
) ) O

whether NN O
the NN stopwords O
era NN era O
of NN stopwords O
platinum-based NN T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
nsclc JJ D
should NN stopwords O
continue NNS continue O
or NN stopwords Oregon O
not JJ stopwords not O
must NN must O
be NN stopwords beryllium O
determined NN determine O
by NN stopwords by O
phase NN phase O
iii NN three O
trials NN test O
, , O
evaluating NN measure O
the NN stopwords O
use JJ use O
of NN stopwords O
a DT stopwords angstrom O
platinum NN platinum O
agent DT agent O
with NN stopwords O
one JJ one O
of NN stopwords O
the NN stopwords O
new JJ new O
agent DT agent O
combinations NNS combination O

Use CAPITAL NNP use O
of NN stopwords O
public NN populace O
performance NN performance O
reports NN report O
: : O
a DT stopwords angstrom O
survey NN survey O
of NN stopwords O
patients VB patient O
undergoing JJ undergo O
cardiac VB cardiac T
surgery NN surgery T

These CAPITAL NNP O
relationships NN relationship O
were NN stopwords be O
preserved NN continue O
in NN stopwords inch O
the NN stopwords O
subjects NN subject O
without NN O
prior NN prior O
events NN event O
at DT stopwords astatine O
the NN stopwords O
time NN time O
of NN stopwords O
scanning JJ scanning O

CONCLUSIONS CAPITAL NNP decision O
: : O
Biliary CAPITAL NNP bilious D
dyskinesia NN dyskinesia D
patients VB patient O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
cholecystectomy NNS cholecystectomy T
had VB stopwords have O
significantly NN significantly O
greater NN greater O
symptom NN symptom O
improvement JJ improvement O
compared NNS compare O
with NN stopwords O
nonsurgical JJ nonsurgical O
patients VB patient O

Most CAPITAL NNP most O
evidence NN evidence O
available DT available O
to NN stopwords O
general NN general O
practitioners NN practitioner O
( ( O
GPs CAPITAL NNP Global_Positioning_System O
) ) O
addresses DT address O
only JJ stopwords lone O
the NN stopwords O
bio-medical NN O
perspective NN position O
and DT stopwords O
is NN stopwords be O
often JJ frequently O
not JJ stopwords not O
directly NN directly O
applicable DT applicable O
to NN stopwords O
primary NN primary O
care VB care O
, , O
as DT stopwords arsenic O
it NN stopwords information_technology O
derives NN deduce O
from JJ stopwords O
secondary NN secondary O
or NN stopwords Oregon O
tertiary NN Tertiary O
care VB care O

Medical CAPITAL NNP checkup O
Injury CAPITAL PRP injury O
Compensation CAPITAL NNP compensation O
Reform CAPITAL NNP reform O
Act CAPITAL DT act O
: : O
good NN good O
or NN stopwords Oregon O
bad VB bad O
? . O

Genetic CAPITAL NNP familial O
testing NN testing O
opens JJ open O
brave NN brave O
new JJ new O
world NN universe O

Protocols CAPITAL NNP protocol O
for NN stopwords O
wound NN wound O
management VB management O

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
clomipramine NNS clomipramine T
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
adjunct DT adjunct O
to NN stopwords O
behavioural NN behavioral T
therapy NN therapy T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
separation-related NN D
problems NN problem D
in NN stopwords inch O
dogs NN dog O

< NN O
TO_SEE CAPITAL NNP O
> NN O
While CAPITAL NNP while O
diastolic NN diastolic D
left NN left D
ventricular NN ventricular D
( ( D
LV CAPITAL NNP fifty-five D
) ) D
dysfunction NN dysfunction D
is NN stopwords be O
frequent JJ patronize O
and DT stopwords O
associated DT associate O
with NN stopwords O
cardiovascular VB cardiovascular D
complications NNS complication D
in NN stopwords inch O
end-stage NN D
renal NN nephritic D
disease NN disease D
treated NN treat O
with NN stopwords O
dialysis NN dialysis T
, , O
controversial NNS controversial O
information NN information O
exists NN exist O
on NN stopwords on O
diastolic NN diastolic O
LV CAPITAL NNP fifty-five O
function JJ function O
after DT stopwords after O
renal NN nephritic O
transplantation NN transplant O

According CAPITAL DT harmonize O
to NN stopwords O
the NN stopwords O
present NN present O
study NN survey O
it NN stopwords information_technology O
seems NN look O
that NN stopwords O
inhaled NN inhale T
corticosteroid NNS corticosteroid T
treatment NN treatment T
during NN stopwords O
and DT stopwords O
after DT stopwords after O
the NN stopwords O
acute DT acute_accent O
phase NN phase O
of NN stopwords O
infant NN baby D
RSV CAPITAL NNP D
bronchiolitis NN bronchiolitis D
may VB May O
have VB stopwords rich_person O
a DT stopwords angstrom O
beneficial NN beneficial O
effect NN consequence O
on NN stopwords on O
subsequent NN subsequent O
bronchial NN bronchial O
wheezing NN wheeze O
tendency NN inclination O

Finally CAPITAL NNP finally O
, , O
the NN stopwords O
modelling NN modeling O
of NN stopwords O
the NN stopwords O
face VB face O
is NN stopwords be O
evocated NN O
, , O
in NN stopwords inch O
which NN stopwords O
the NN stopwords O
dissociation NN dissociation O
between NN stopwords between O
the NN stopwords O
olfactive JJ olfactory O
and DT stopwords O
buccal NN buccal O
spheres NN sphere O
is NN stopwords be O
pointed NN indicate O
out JJ stopwords out O
, , O
with NN stopwords O
the NN stopwords O
disparition NN O
of NN stopwords O
the NN stopwords O
muzzle NN gun_muzzle O
, , O
as DT stopwords arsenic O
it NN stopwords information_technology O
is NN stopwords be O
established NN establish O
in NN stopwords inch O
the NN stopwords O
haplorhinae VB O
, , O
a DT stopwords angstrom O
class NNS class O
of NN stopwords O
primates NN Primates O
in NN stopwords inch O
which NN stopwords O
the NN stopwords O
human NN homo O
being NN stopwords being O
is NN stopwords be O
involved NN involve O

Authorship CAPITAL DT writing O

Retraction CAPITAL NNP retraction O

Nonanesthetic CAPITAL NNP O
volatile NN volatile O
drugs NN drug O
obey NN obey O
the NN stopwords O
Meyer-Overton CAPITAL NNP O
correlation NNS correlation O
in NN stopwords inch O
two NN two O
molecular NN molecular O
protein NN protein O
site NN site O
models NN model O

Anterior CAPITAL DT front_tooth D
glenohumeral NN D
dislocations NN dislocation D
: : O
what NN stopwords O
to NN stopwords O
do NN stopwords bash O
and DT stopwords O
how NN stopwords O
to NN stopwords O
do NN stopwords bash O
it NN stopwords information_technology O

Human CAPITAL NNP homo O
fetal JJ fetal O
pituitary NN pituitary O
expresses NN express O
functional JJ functional O
growth NN growth O
hormone-releasing NN O
peptide NN peptide O
receptors NN receptor O

Sarcoidosis CAPITAL VB sarcoidosis T
involving NN involve O
the NN stopwords O
veriform NN O
appendix DT appendix O

According CAPITAL DT harmonize O
to NN stopwords O
the NN stopwords O
RMR CAPITAL NNP O
model NN model O
, , O
all DT stopwords all O
potentially NN potentially O
lethal NN deadly O
lesions NN lesion O
should NN stopwords O
also DT besides O
be NN stopwords beryllium O
committed NNS perpetrate O
by NN stopwords by O
that NN stopwords O
time NN time O
and DT stopwords O
be NN stopwords beryllium O
unavailable JJ unavailable O
for NN stopwords O
repair NN repair O
in NN stopwords inch O
the NN stopwords O
new JJ new O
medium NN medium O

Hormone CAPITAL NNP hormone T
replacement NN replacement T
therapy NN therapy T
and DT stopwords O
breast NN breast D
cancer VB cancer D
. . O

in NN stopwords inch O
the NN stopwords O
present NN present O
report NN report O
, , O
we NN stopwords O
reviewed NN review O
articles DT article O
on NN stopwords on O
pulmonary NN pneumonic T
angiography DT angiography T
for NN stopwords O
patients VB patient O
with NN stopwords O
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D

Early CAPITAL NN early O
death NN death O
amongst DT O
anaesthetists DT anesthesiologist O

The CAPITAL NNP O
margin NN margin O
of NN stopwords O
safety VB safety O
between NN stopwords between O
the NN stopwords O
usual JJ usual O
dietary NN dietary O
intake NN consumption O
and DT stopwords O
the NN stopwords O
intake NN consumption O
that NN stopwords O
would NN O
produce NN produce O
adverse DT adverse O
effects NN effects O
varies NN change O
greatly NN greatly O
among DT O
the NN stopwords O
different NN different O
nutrients JJ food O

An CAPITAL DT Associate_in_Nursing O
analysis DT analysis O
of NN stopwords O
molecular NN molecular O
variance NN discrepancy O
( ( O
AMOVA CAPITAL DT O
) ) O
revealed NN uncover O
no NNS stopwords no O
correspondence NNS correspondence O
between NN stopwords between O
mtDNA NN O
phylogeography NN O
and DT stopwords O
subspecies NN subspecies O
delimitation NN boundary_line O
, , O
nor RB stopwords O
between NN stopwords between O
matrilines VB O
and DT stopwords O
areas DT area O
characterized NNS qualify O
by NN stopwords by O
a DT stopwords angstrom O
high NN high O
incidence NN incidence O
of NN stopwords O
the NN stopwords O
viverrid-type NN D
rabies NN rabies D
, , O
of NN stopwords O
which NN stopwords O
the NN stopwords O
yellow NN yellow O
mongoose NN mongoose O
is NN stopwords be O
the NN stopwords O
principal NN principal O
vector NN vector O

Treatment CAPITAL NNP treatment O
of NN stopwords O
verruca NN wart D
vulgaris NN D
with NN stopwords O
topical NN topical T
cidofovir NN T

Low-molecular-weight CAPITAL NNP T
heparins NN heparin T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
venous NN venous D
thromboembolism NN thromboembolism D

Although CAPITAL DT O
the NN stopwords O
combination NNS combination O
has VB stopwords hour_angle O
not JJ stopwords not O
been NN stopwords be O
approved DT approve O
by NN stopwords by O
the NN stopwords O
FDA CAPITAL NNP Food_and_Drug_Administration O
, , O
in NN stopwords inch O
1996 DIGITS CD O
the NN stopwords O
total NN sum O
number JJ number O
of NN stopwords O
prescriptions NN prescription O
in NN stopwords inch O
the NN stopwords O
United CAPITAL NNP unite O
States CAPITAL NNP state O
for NN stopwords O
fenfluramine JJ T
and DT stopwords O
phentermine NN T
exceeded NN exceed O
18 DIGITS CD eighteen O
million NN million O

< NN O
TO_SEE CAPITAL NNP O
> NN O
PURPOSE CAPITAL NNP purpose O
: : O
The CAPITAL NNP O
purposes NN purpose O
of NN stopwords O
this NN stopwords O
descriptive NN descriptive O
, , O
longitudinal NN longitudinal O
study NN survey O
were NN stopwords be O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
MacDibbs CAPITAL NNP O
Mouth CAPITAL NNP mouth O
Assessment CAPITAL DT appraisal O
instrument NN instrument O
for NN stopwords O
the NN stopwords O
assessment DT appraisal O
of NN stopwords O
mucositis NN O
in NN stopwords inch O
the NN stopwords O
radiation VB radiation T
therapy NN therapy T
patient VB patient O
being NN stopwords being O
treated NN treat O
for NN stopwords O
head NN head D
and DT stopwords D
neck JJ neck D
cancer VB cancer D
and DT stopwords O
to NN stopwords O
describe NN describe O
the NN stopwords O
course NNS course O
of NN stopwords O
radiation-induced VB D
mucositis NN D
in NN stopwords inch O
these NN stopwords O
patients VB patient O

Several CAPITAL NNP several O
recent NN Holocene O
retrospective NN retrospective O
studies NN survey O
have VB stopwords rich_person O
suggested NN propose O
that NN stopwords O
chronic NN chronic O
treatment NN treatment O
with NN stopwords O
short-acting NN T
dihydropyridines NN T
increased NN increase O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
cardiac VB cardiac D
events NN event D
, , O
cancer VB cancer D
and DT stopwords O
gastrointestinal VB gastrointestinal D
bleedings NN bleeding D

Dual CAPITAL NNP double O
leadership NN leadership O
in NN stopwords inch O
complex NNS complex O
organizations JJ organization O

Comparison CAPITAL NNP comparison O
by NN stopwords by O
anatomical DT anatomical_reference O
subsite NN O
showed NN show O
that NN stopwords O
blacks NN black O
had VB stopwords have O
statistically NN statistically O
significantly NN significantly O
better NN better O
differentiated NN distinguish O
tumors NN tumor D
for NN stopwords O
cancers VB cancer D
of NN stopwords O
the NN stopwords O
proximal NN proximal O
and DT stopwords O
transverse NN cross O
colon NNS colon O
but NN stopwords merely O
not JJ stopwords not O
for NN stopwords O
the NN stopwords O
distal NN distal O

CONCLUSION CAPITAL NNP decision O
: : O
Adrenal-sparing CAPITAL DT T
surgery NN surgery T
is NN stopwords be O
safe VB safe O
and DT stopwords O
effective NN effective O
, , O
and DT stopwords O
may VB May O
become NN become O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
choice NNS choice O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
hereditary NN familial D
phaeochromocytoma NN pheochromocytoma D

Neonatal CAPITAL NNP neonatal O
BAEP CAPITAL IN O
specificity NN specificity O
for NN stopwords O
excluding NN exclude O
subsequent NN subsequent O
hearing NN hearing D
loss NN loss D
was VB stopwords Washington O
76 DIGITS CD seventy-six O
% NN O

The CAPITAL NNP O
ameboid DT ameboid O
form NN form O
was VB stopwords Washington O
observed NN detect O
only JJ stopwords lone O
in NN stopwords inch O
diarrhoeal NN diarrheal O
stools NN stool O

RESULTS CAPITAL NNP consequence O
: : O
Retinopathy CAPITAL NNP retinopathy D
was VB stopwords Washington O
present NN present O
in NN stopwords inch O
70 DIGITS CD seventy O
( ( O
41 DIGITS CD forty-one O
% NN O
) ) O
subjects NN subject O
, , O
and DT stopwords O
4 DIGITS CD four O
( ( O
2.3 CD O
% NN O
) ) O
subjects NN subject O
had VB stopwords have O
proliferative NN O
retinopathy NN retinopathy D

The CAPITAL NNP O
CaMI CAPITAL VB O
gene NN gene O
contains NNS incorporate O
six NN six O
exons NN exon O

Correct CAPITAL NNP correct O
use JJ use O
of NN stopwords O
serotonin NN serotonin T
agonists DT protagonist T
in NN stopwords inch O
migraine NN migraine D
: : O
oral NN oral O
or NN stopwords Oregon O
injectable NN injectable O
form NN form O
? . O

There CAPITAL NNP there O
was VB stopwords Washington O
no NNS stopwords no O
significant NN significant O
difference NN difference O
in NN stopwords inch O
the NN stopwords O
frequency JJ frequency O
of NN stopwords O
hearing NN hearing D
loss NN loss D
between NN stopwords between O
subjects NN subject O
with NN stopwords O
abnormal DT abnormal O
( ( O
5/21 CD O
, , O
or NN stopwords Oregon O
24 DIGITS CD twenty-four O
% NN O
) ) O
and DT stopwords O
those NN stopwords O
with NN stopwords O
normal RB convention O
BAEP CAPITAL IN O
thresholds NN threshold O
( ( O
7/59 CD O
, , O
or NN stopwords Oregon O
12 DIGITS CD twelve O
% NN O
; : O
Fisher CAPITAL NNP fisherman O
Exact CAPITAL NNP demand O
Test CAPITAL NNP trial O
, , O
p NN phosphorus O
= NN O
0.28 LS O
) ) O

Variation CAPITAL VB variation O
in NN stopwords inch O
proficiency NN proficiency O
testing NN testing O
performance NN performance O
by NN stopwords by O
testing NN testing O
site NN site O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
a DT stopwords angstrom O
five-day NN O
regimen NN regimen O
of NN stopwords O
cefdinir NNS T
with NN stopwords O
a DT stopwords angstrom O
seven-day NN weeklong O
regimen NN regimen O
of NN stopwords O
loracarbef NN T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
acute DT acute_accent O
exacerbations NN aggravation O
of NN stopwords O
chronic NN chronic D
bronchitis NN bronchitis D

Carcinogenesis CAPITAL VB O
in NN stopwords inch O
transgenic NN O
mouse NN mouse O
models NN model O

Extracorporeal CAPITAL NNP O
photopheresis NN O
in NN stopwords inch O
S CAPITAL NNP O
( ( O
c NNS degree_centigrade O
) ) O
zary NN O
syndrome NN syndrome O

Diagnostic CAPITAL NNP diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
is NN stopwords be O
highly NN highly O
predictive NN predictive O
of NN stopwords O
the NN stopwords O
presence NN presence O
of NN stopwords O
intra-abdominal NN D
injury NN injury D

The CAPITAL NNP O
search NN search O

< NN O
TO_SEE CAPITAL NNP O
> NN O
BACKGROUND CAPITAL IN background O
: : O
The CAPITAL NNP O
growing NN growth O
teratoma NN teratoma O
syndrome NN syndrome O
refers NN mention O
to NN stopwords O
the NN stopwords O
phenomenon NN phenomenon O
whereby NN O
germ NN source O
cell NNS cell O
tumors NN tumor O
enlarge NN enlarge O
after DT stopwords after O
chemotherapy NNS chemotherapy O
despite NN contempt O
complete NNS complete O
eradication NN eradication O
of NN stopwords O
malignant VB malignant O
cells NNS cell O
and DT stopwords O
normalization RB standardization O
of NN stopwords O
serum NN serum O
tumor NN tumor O
markers NN marker O

< NN O
TO_SEE CAPITAL NNP O
> NN O
No CAPITAL NNP no O
skeletal NN skeletal D
fluorosis JJ fluorosis D
or NN stopwords Oregon O
osteomalacia JJ osteomalacia D
was VB stopwords Washington O
observed NN detect O
histologically NN histologically O
, , O
nor RB stopwords O
did NN stopwords make O
fluoride JJ fluoride T
affect DT affect O
serum NN serum O
PTH CAPITAL NNP O
or NN stopwords Oregon O
Vitamin CAPITAL NNP vitamin O
D CAPITAL NN vitamin_D O
metabolites NN metabolite O
( ( O
P CAPITAL NN phosphorus O
> NN O
0.4 LS O
) ) O

Filter CAPITAL NNP filter O
paper VB paper O
blood NN blood O
spot NN topographic_point O
assay DT assay O
of NN stopwords O
human NN homo O
insulin-like NN O
growth NN growth O
factor VB factor O
I CAPITAL PRP iodine O
( ( O
IGF-I CAPITAL PRP O
) ) O
and DT stopwords O
IGF-binding CAPITAL PRP O
protein-3 NN O
and DT stopwords O
preliminary NN preliminary O
application DT application O
in NN stopwords inch O
the NN stopwords O
evaluation NN evaluation O
of NN stopwords O
growth NN growth O
hormone NN hormone O
status NN status O

Pediatric CAPITAL NNP pediatric D
cervical NNS cervical D
spine JJ spinal_column D
injury NN injury D
sustained NN prolong O
in NN stopwords inch O
falls VB falls O
from JJ stopwords O
low NN low O
heights NN high O

Golf CAPITAL NNP golf D
injuries NN injury D

methods NN method O
: : O
the NN stopwords O
cost NNS cost O
of NN stopwords O
surgical NN surgical T
treatment NN treatment T
in NN stopwords inch O
1997 DIGITS CD O
and DT stopwords O
1998 DIGITS CD O
for NN stopwords O
patients VB patient O
with NN stopwords O
resectable NN D
primary NN primary D
or NN stopwords Oregon D
metastatic NN metastatic D
lung NN lung D
carcinoma VB carcinoma D
was VB stopwords Washington O
analyzed DT analyze O
from JJ stopwords O
itemized NN enumerate O
statements NN statement O
of NN stopwords O
hospital NN hospital O
charges NNS charge O

RESULTS CAPITAL NNP consequence O
: : O
None CAPITAL NNP none O
of NN stopwords O
the NN stopwords O
25 DIGITS CD twenty-five O
children JJ child O
of NN stopwords O
this NN stopwords O
sample VB sample O
who NN stopwords World_Health_Organization O
were NN stopwords be O
seizure JJ seizure O
free JJ free O
had VB stopwords have O
attacks DT attack O
while NN stopwords while O
taking VB pickings O
methylphenidate NN methylphenidate O

amifostine DT T
( ( O
340 DIGITS CD O
mg/m2 NN O
) ) O
also DT besides O
provided NN supply O
significant NN significant O
protection NN protection O
against DT stopwords O
pneumonitis NN pneumonitis D
and DT stopwords D
oesophagitis JJ esophagitis D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
lung NN lung D
cancer VB cancer D
receiving NN receive O
thoracic NN pectoral T
irradiation NN irradiation T
in NN stopwords inch O
a DT stopwords angstrom O
preliminary NN preliminary O
report NN report O
from JJ stopwords O
a DT stopwords angstrom O
phase NN phase O
iii NN three O
trial NN test O
( ( O
n NN nitrogen O
= NN O
144 DIGITS CD gross O
) ) O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
dietary NN dietary O
protein NN protein O
source NN beginning O
on NN stopwords on O
serum NN serum O
proteins NN protein O

A CAPITAL DT angstrom O
two-dose NN O
combined NNS unite O
hepatitis NN hepatitis D
A CAPITAL DT angstrom D
and DT stopwords D
B CAPITAL NN bacillus D
vaccine NN vaccine T
would NN O
facilitate VB facilitate O
immunisation JJ immunization O
programs NN plan O

IGF-1 CAPITAL PRP O
was VB stopwords Washington O
increased NN increase O
by NN stopwords by O
fluoride JJ fluoride O
and DT stopwords O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
increased NN increase O
bone NN bone O
turnover NN employee_turnover O
, , O
but NN stopwords merely O
was VB stopwords Washington O
not JJ stopwords not O
correlated NNS correlate O
with NN stopwords O
bone NN bone O
formation NN formation O
markers NN marker O

Anesthesiology CAPITAL DT anesthesiology O
and DT stopwords O
computers NNS computer O

Long CAPITAL NNP hanker O
term NN term O
results NN consequence O
in NN stopwords inch O
the NN stopwords O
300 DIGITS CD three_hundred O
most NN stopwords most O
grave NN grave O
cases VB case O
out JJ stopwords out O
of NN stopwords O
4000 DIGITS CD O
hyperthyroid NN D
patients VB patient D
treated NN treat O
with NN stopwords O
iodine NN iodine T
I-131 CAPITAL PRP T
at DT stopwords astatine O
the NN stopwords O
center NNS center O
of NN stopwords O
Ancona CAPITAL DT O

Most CAPITAL NNP most O
( ( O
85 DIGITS CD eighty-five O
% NN O
) ) O
viewed NN see O
pregnancy NN pregnancy O
as DT stopwords arsenic O
inappropriate NN inappropriate O
for NN stopwords O
HIV CAPITAL NNP HIV D
infected NN infect O
women NN woman O
and DT stopwords O
primarily NN chiefly O
drug NN drug O
users JJ user O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.06 LS O
) ) O
would NN O
abort DT abort O
if NN stopwords O
HIV CAPITAL NNP HIV D
infected NN infect O

Automation CAPITAL DT automation O
in NN stopwords inch O
cervical NNS cervical O
cytology NNS cytology O
: : O
whose NN O
cost NNS cost O
and DT stopwords O
whose NN O
benefit NN benefit O
? . O

< NN O
TO_SEE CAPITAL NNP O
> NN O
BACKGROUND CAPITAL IN background O
: : O
In CAPITAL PRP inch O
the NN stopwords O
present NN present O
study NN survey O
we NN stopwords O
investigated NN investigate O
the NN stopwords O
efficacy NN efficacy O
and DT stopwords O
tolerability NN O
of NN stopwords O
i.m NN T
. . T
octreotide JJ T
acetate DT acetate T
( ( T
octreotide JJ T
LAR CAPITAL VB T
) ) T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
neuroendocrine JJ neuroendocrine D
tumors NN tumor D
( ( D
NETs CAPITAL NNP internet D
) ) D
previously NN previously O
treated NN treat O
and DT stopwords O
failed VB fail O
on NN stopwords on O
i.m NN T
. . T
lanreotide NN T

Sequelae CAPITAL NNP sequela O
include NN include O
severe NN severe O
developmental NN developmental O
delay NN delay O
and DT stopwords O
asymmetric DT asymmetrical O
double NN double O
hemiplegia NN hemiplegia D

Proposed CAPITAL NNP propose O
genetic NN familial O
nomenclature JJ terminology O
rules NN rule O
for NN stopwords O
Tetrahymena CAPITAL NNP tetrahymena O
thermophila NN O
, , O
Paramecium CAPITAL VB paramecium O
primaurelia NN O
and DT stopwords O
Paramecium CAPITAL VB paramecium O
tetraurelia NN O

Intranasal CAPITAL PRP T
immunization JJ immunization T
with NN stopwords O
Chlamydia CAPITAL NNP chlamydia D
trachomatis NN D
, , D
serovar NN D
E CAPITAL NN vitamin_E D
, , O
protects NN protect O
from JJ stopwords O
a DT stopwords angstrom O
subsequent NN subsequent O
vaginal NN vaginal O
challenge NNS challenge O
with NN stopwords O
the NN stopwords O
homologous NN homologous O
serovar NN O

A CAPITAL DT angstrom O
series NN series O
of NN stopwords O
comparative NNS comparative O
analyses DT analysis O
show NN show O
that NN stopwords O
inhaled NN inhale T
fluticasone JJ T
propionate NN T
is NN stopwords be O
more NN stopwords More O
cost NNS cost O
effective NN effective O
than NN stopwords O
oral NN oral O
zafirlukast NN O
and DT stopwords O
triamcinolone NN triamcinolone O
acetonide DT O
and DT stopwords O
slightly JJ slightly O
more NN stopwords More O
cost NNS cost O
effective NN effective O
than NN stopwords O
flunisolide JJ O
in NN stopwords inch O
adult DT adult O
patients VB patient O
with NN stopwords O
asthma DT asthma D

exploratory NN exploratory T
interventions NN intervention T
, , T
partial NN partial_derivative T
tumor NN tumor T
resections NN resection T
and DT stopwords T
lung NN lung T
resections NN resection T
for NN stopwords O
metastasis NN metastasis D
were NN stopwords be O
more NN stopwords More O
frequently JJ frequently O
performed NN perform O
in NN stopwords inch O
young NN young O
patients VB patient O
than NN stopwords O
in NN stopwords inch O
older JJ aged O
patients VB patient O

Switch CAPITAL NNP switch O
substrate NN substrate O
retrovectors NN O
( ( O
SSR CAPITAL NNP O
) ) O
contain NNS incorporate O
a DT stopwords angstrom O
long-terminal NN O
repeat-driven NN O
neomycin JJ neomycin O
( ( O
Neo CAPITAL NNP neo O
) ) O
gene NN gene O
for NN stopwords O
proviral NN O
chromosomal NN chromosomal O
maintenance VB care O
( ( O
pre- NN O
and DT stopwords O
post-S NN O
recombination NN recombination O
) ) O
and DT stopwords O
a DT stopwords angstrom O
CMV CAPITAL NNP cytomegalovirus O
promoter-driven NN O
, , O
chimeric JJ chimeric O
hygromycin-thymidine NN O
kinase NN kinase O
( ( O
Hytk CAPITAL NNP O
) ) O
gene NN gene O
( ( O
flanked NN flank O
by NN stopwords by O
S CAPITAL NN second O
mu NN mu O
and DT stopwords O
S CAPITAL NN second O
gamma VB gamma O
2b CD O
recombination NN recombination O
targets VB target O
) ) O
to NN stopwords O
select NN choose O
for NN stopwords O
( ( O
ganciclovir VB O
) ) O
and DT stopwords O
against DT stopwords O
( ( O
hygromycin NN O
B CAPITAL NN bacillus O
) ) O
S CAPITAL NN second O
region NN region O
recombination NN recombination O

A CAPITAL DT angstrom O
call VB call O
for NN stopwords O
stepped-up NN O
melanoma NN melanoma D
screening NN screening O

Certain CAPITAL NNP certain O
dioxins NN dioxin O
, , O
particularly NN particularly O
2 DIGITS CD two O
, , O
3 DIGITS CD three O
, , O
7 DIGITS CD seven O
, , O
8-tetrachlorodibenzo-p-dioxin CD O
, , O
are DT stopwords are O
very NN stopwords very O
toxic NN toxic O
and DT stopwords O
able DT able O
to NN stopwords O
induce NN induce O
numerous JJ numerous O
clinical JJ clinical O
conditions NNS conditions O

Poppy CAPITAL NNP poppy O
tea NN tea O
and DT stopwords O
the NN stopwords O
baker NN baker O
's POS O
first NN first O
seizure JJ seizure D

Germinal CAPITAL NNP Germinal D
tumor NN tumor D
metastases NN metastasis D

Homeopathy CAPITAL NNP homeopathy T
for NN stopwords O
postoperative NN postoperative D
ileus NN intestinal_obstruction D
? . O
A CAPITAL DT angstrom O
meta-analysis NN O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Probucol CAPITAL NNP T
and DT stopwords T
multivitamins NN multivitamin T
in NN stopwords inch O
the NN stopwords O
prevention NN prevention O
of NN stopwords O
restenosis NN D
after DT stopwords after O
coronary NNS coronary_thrombosis O
angioplasty DT angioplasty O

Mesh CAPITAL NNP mesh O
plug NN plug O
repair NN repair O
and DT stopwords O
groin NN groin D
hernia NN hernia D
surgery NN surgery T

Magnetic CAPITAL NNP magnetic O
resonance NN resonance O
imaging NN imagination O
in NN stopwords inch O
focal JJ focal D
myositis NN myositis D

Immunomodulatory CAPITAL PRP O
effects NN effects O
of NN stopwords O
acupuncture DT acupuncture T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
allergic DT allergic D
asthma DT asthma D
: : O
a DT stopwords angstrom O
randomized VB randomize O
controlled NNS control O
study NN survey O

Gas CAPITAL VB gas O
permeability NN permeability O
of NN stopwords O
plastic NN plastic O
membranes NN membrane O
for NN stopwords O
artificial DT artificial T
lungs NN lung T

These CAPITAL NNP O
inner-city NN O
, , O
pregnant NN pregnant O
women NN woman O
disapproved NN disapprove O
of NN stopwords O
pregnancy NN pregnancy O
if NN stopwords O
HIV CAPITAL NNP HIV D
infected NN infect O
and DT stopwords O
thought NN idea O
the NN stopwords O
risk NN hazard O
of NN stopwords O
transmission NN transmission O
was VB stopwords Washington O
high NN high O

< NN O
TO_SEE CAPITAL NNP O
> NN O
The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
bisoprolol NN T
on NN stopwords on O
perioperative NN D
mortality NN mortality D
and DT stopwords O
myocardial NN myocardial D
infarction NN infarct D
in NN stopwords inch O
high-risk NN bad O
patients VB patient O
undergoing JJ undergo O
vascular NN vascular T
surgery NN surgery T

Pneumococcal CAPITAL NNP pneumococcal D
vaccine NN vaccine T
: : O
a DT stopwords angstrom O
second NN second O
look NN expression O

1981 DIGITS CD O

BACKGROUND CAPITAL IN background O
: : O
Antiplatelet CAPITAL DT T
therapy NN therapy T
with NN stopwords T
aspirin DT aspirin T
and DT stopwords T
systematic NN systematic T
anticoagulation DT anticoagulation T
with NN stopwords T
warfarin NN warfarin T
reduce NN reduce O
cardiovascular VB cardiovascular D
morbidity NN morbidity D
and DT stopwords D
mortality NN mortality D
after DT stopwords after D
myocardial NN myocardial D
infarction NN infarct D
when NN stopwords O
given NN given O
alone DT alone O

Significant CAPITAL NNP significant O
inhibition NN inhibition O
of NN stopwords O
monocyte NN monocyte O
SA CAPITAL VB SA O
output JJ end_product O
stimulated JJ stimulate O
with NN stopwords O
IgG-treated CAPITAL PRP O
zymosan NN O
( ( O
ITZ CAPITAL PRP O
) ) O
and DT stopwords O
fluoride JJ fluoride O
ion NN ion O
( ( O
F CAPITAL NN degree_Fahrenheit O
) ) O
, , O
but NN stopwords merely O
not JJ stopwords not O
serum-treated NN O
zymosan NN O
( ( O
STZ CAPITAL NNP O
) ) O
was VB stopwords Washington O
demonstrated NN show O
following JJ following O
steroid NN steroid T
therapy NN therapy T
in NN stopwords inch O
RA CAPITAL VB radium D

Few CAPITAL NNP few O
data VB data O
exist NN exist O
as DT stopwords arsenic O
to NN stopwords O
whether NN O
there NN stopwords there O
are DT stopwords are O
clinical JJ clinical O
differences NN difference O
between NN stopwords between O
prostate NN prostate_gland D
cancers VB cancer D
that NN stopwords O
are DT stopwords are O
inherited NN inherit O
and DT stopwords O
those NN stopwords O
that NN stopwords O
occur JJ happen O
in NN stopwords inch O
the NN stopwords O
general NN general O
population NN population O

3 DIGITS CD three O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
continuous NNS continuous T
infusion NN infusion T
of NN stopwords T
alteplase DT T
with NN stopwords T
double-bolus NN T
administration DT administration T
for NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

The CAPITAL NNP O
use JJ use O
of NN stopwords O
nurses RB nurse O
in NN stopwords inch O
alternative DT option O
dispute NN dispute O
resolution NN resolution O

Systematic CAPITAL NNP systematic O
review NN reappraisal O
of NN stopwords O
prophylactic NN preventive O
vs NN volt O
rescue NN rescue O
surfactant NN wetting_agent O

Treatment CAPITAL NNP treatment O
of NN stopwords O
hypertensive NN hypertensive O
patients VB patient O
with NN stopwords O
diabetes NN diabetes D

Thus CAPITAL NNP frankincense O
, , O
s-ECP SYM O
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
a DT stopwords angstrom O
useful JJ useful O
marker NN marker O
for NN stopwords O
determining NN determine O
when NN stopwords O
a DT stopwords angstrom O
step-down NN decrease O
in NN stopwords inch O
iBDP NN T
therapy NN therapy T
is NN stopwords be O
indicated NN bespeak O
, , O
and DT stopwords O
thus NN frankincense O
may VB May O
contribute NNS lend O
to NN stopwords O
successful NN successful O
long-term NN long-run O
management VB management O
of NN stopwords O
chronic NN chronic D
asthma DT asthma D

Atomic CAPITAL DT atomic O
legacy NN bequest O
in NN stopwords inch O
the NN stopwords O
Marshall CAPITAL NNP Marshall O
Islands CAPITAL PRP island O

patients VB patient O
: : O
during NN stopwords O
this NN stopwords O
period NN time_period O
, , O
a DT stopwords angstrom O
total NN sum O
of NN stopwords O
77 DIGITS CD seventy-seven O
patients VB patient O
underwent JJ undergo O
lung NN lung T
resection NN resection T
for NN stopwords O
the NN stopwords O
following JJ following O
neuroendocrine JJ neuroendocrine D
neoplasms JJ tumor D
: : O
typical NN typical D
carcinoid VB carcinoid D
( ( D
tc NN technetium D
) ) D
, , O
50 DIGITS CD fifty O
patients VB patient O
; : O
atypical DT atypical D
carcinoid VB carcinoid D
( ( D
ac DT actinium D
) ) D
, , O
5 DIGITS CD five O
patients VB patient O
; : O
large NN large D
cell NNS cell D
neuroendocrine JJ neuroendocrine D
carcinoma VB carcinoma D
( ( D
lcnec NN D
) ) D
, , O
9 DIGITS CD nine O
patients VB patient O
; : O
mixed NN blend D
large-small NN D
cell NNS cell D
neuroendocrine JJ neuroendocrine D
carcinoma VB carcinoma D
( ( D
lsnec NN D
) ) D
, , O
4 DIGITS CD four O
patients VB patient O
; : O
or NN stopwords Oregon O
small JJ small D
cell NNS cell D
neuroendocrine JJ neuroendocrine D
carcinoma VB carcinoma D
( ( D
scc JJ D
) ) D
, , O
9 DIGITS CD nine O
patients VB patient O

Effects CAPITAL NNP effects O
of NN stopwords O
the NN stopwords O
Japanese CAPITAL NNP Japanese T
herbal NN herb_tea T
medicine NN medicine T
'Inchinko-to POS T
' '' T
( ( T
TJ-135 CAPITAL NNP T
) ) T
on NN stopwords on O
concanavalin NNS D
A-induced CAPITAL DT D
hepatitis NN hepatitis D
in NN stopwords inch O
mice NN mouse O

Career CAPITAL VB career O
anchorage DT anchorage O
: : O
managerial VB managerial O
mobility NN mobility O
motivations NN motivation O

thus NN frankincense O
, , O
we NN stopwords O
should NN stopwords O
recognize NN acknowledge O
this NN stopwords O
immanent JJ immanent O
risk NN hazard O
and DT stopwords O
perform NN perform O
peri- NN T
and DT stopwords T
postoperative NN postoperative T
management VB management T
for NN stopwords O
patients VB patient O
with NN stopwords O
gh-producing NN D
tumors NN tumor D

Cataract CAPITAL VB cataract D
surgical NN surgical O
problem NN problem O

Serial CAPITAL NNP serial O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O
findings NN findings O
for NN stopwords O
a DT stopwords angstrom O
spontaneously NN spontaneously O
resolving NN resolution O
spinal JJ spinal_anesthesia D
subdural NN subdural D
hematoma NN hematoma D
: : O
case VB case O
report NN report O

Fever CAPITAL NNP fever D
in NN stopwords inch O
Africa CAPITAL DT Africa O
and DT stopwords O
WHO CAPITAL NNP World_Health_Organization O
recommendation NN recommendation O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
3rd CD third O
International CAPITAL PRP International O
Congress CAPITAL NNP Congress O

Interview CAPITAL PRP interview O
by NN stopwords by O
Tom CAPITAL NNP Tom O
Heinemann CAPITAL NNP O

Neuroimmunomodulation CAPITAL NNP O
: : O
Molecular CAPITAL NNP molecular O
Aspects CAPITAL DT aspect O
, , O
Integrative CAPITAL PRP integrative O
Systems CAPITAL NNP system O
, , O
and DT stopwords O
Clinical CAPITAL NNP clinical O
Advances CAPITAL DT progress O

Renal CAPITAL NNP nephritic D
trauma NN injury D
and DT stopwords O
the NN stopwords O
risk NN hazard O
of NN stopwords O
long-term NN long-run O
complications NNS complication O
in NN stopwords inch O
shock NN daze T
wave VB wave T
lithotripsy NN T

Aromatization CAPITAL DT O
of NN stopwords O
7-alpha-hydroxydehydroepiandrosterone CD O
and DT stopwords O
of NN stopwords O
its NN stopwords information_technology O
3-sulphate LS O
by NN stopwords by O
ovarian NN ovarian O
and DT stopwords O
placental NN placental O
tissue NN tissue O
cultures NNS culture O

OBJECTIVE CAPITAL NNP aim O
: : O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
possible NN possible O
existence NN being O
of NN stopwords O
the NN stopwords O
so-called NN alleged O
< NN O
Roux-en-Y CAPITAL NNP O
syndrome NN syndrome O
> NN O
in NN stopwords inch O
a DT stopwords angstrom O
group NN group O
of NN stopwords O
21 DIGITS CD twenty-one O
patients VB patient O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
surgery NN surgery T
to NN stopwords O
correct NNS correct O
postoperative NN postoperative D
alkaline DT alkaline D
reflux NN reflux D
gastritis VB gastritis D

These CAPITAL NNP O
data VB data O
suggest NN propose O
that NN stopwords O
psoriasis NN psoriasis D
may VB May O
respond NN react O
to NN stopwords O
active DT active_agent T
metabolites NN metabolite T
of NN stopwords T
vitamin NN vitamin T
D3 CAPITAL NNP T
and DT stopwords O
that NN stopwords O
abnormalities DT abnormality O
in NN stopwords inch O
vitamin NN vitamin O
D CAPITAL NN vitamin_D O
metabolism NN metamorphosis O
or NN stopwords Oregon O
in NN stopwords inch O
responsiveness NN responsiveness O
of NN stopwords O
the NN stopwords O
skin JJ skin O
cells NNS cell O
to NN stopwords O
active DT active_agent O
metabolites NN metabolite O
of NN stopwords O
vitamin NN vitamin O
D CAPITAL NN vitamin_D O
may VB May O
be NN stopwords beryllium O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
pathogenesis VB pathogenesis O
of NN stopwords O
this NN stopwords O
skin JJ skin O
disease NN disease O

The CAPITAL NNP O
patient VB patient O
's POS O
ability DT ability O
to NN stopwords O
wear NN wear O
shoes NN place O
improved JJ better O
from JJ stopwords O
0.87 LS O
to NN stopwords O
3.1 LS O

Fifty-one CAPITAL NNP fifty-one O
per NN O
cent NNS cent O
of NN stopwords O
stroke NN stroke D
victims NN victim O
were NN stopwords be O
below NN stopwords below O
the NN stopwords O
age DT age O
of NN stopwords O
54 DIGITS CD fifty-four O
years NN old_age O

Studies CAPITAL NNP survey O
on NN stopwords on O
the NN stopwords O
natural RB natural O
posterior NN buttocks O
pituitary NN pituitary O
hormones NN hormone O

d-penicillamine LS T
( ( T
2-amino-3-mercapto-3-methylbutanoic CD T
acid DT acid T
) ) T
, , T
a DT stopwords angstrom T
well-known NN well-known T
heavy NN heavy T
metal NN metallic_element T
chelator NNS T
, , O
is NN stopwords be O
the NN stopwords O
drug NN drug O
of NN stopwords O
choice NNS choice O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
wilson NN Wilson D
's POS D
disease NN disease D
and DT stopwords O
is NN stopwords be O
also DT besides O
effective NN effective O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
several NN several D
disorders NN disorder D
including NN include D
rheumatoid NN arthritic D
arthritis DT arthritis D
, , D
primary NN primary D
biliary NN bilious D
cirrhosis NN cirrhosis D
, , D
scleroderma JJ scleroderma D
, , D
fibrotic NN D
lung NN lung D
diseases NN disease D
and DT stopwords D
progressive NN progressive D
systemic NN systemic D
sclerosis JJ sclerosis D

What CAPITAL NNP O
is NN stopwords be O
the NN stopwords O
real NN real_number O
role NN function O
of NN stopwords O
CD40 CAPITAL NNP O
in NN stopwords inch O
cancer VB cancer D
immunotherapy JJ immunotherapy T
? . O

Undergraduate CAPITAL NNP undergraduate O
research NN research O
assistants DT assistant O
in NN stopwords inch O
the NN stopwords O
Faculty CAPITAL NNP faculty O
of NN stopwords O
Medicine CAPITAL NNP medicine O

BCR-ABL+ CAPITAL NNP O
cells NNS cell O
treated NN treat O
with NN stopwords O
ceramide NNS O
also DT besides O
showed NN show O
a DT stopwords angstrom O
rapid VB rapid O
and DT stopwords O
sequential NN consecutive O
increase NN addition O
in NN stopwords inch O
the NN stopwords O
tyrosine NN tyrosine O
phosphorylation NN O
of NN stopwords O
p210 NN O
( ( O
BCR-ABL CAPITAL NNP O
) ) O
, , O
p46-56SHC NN O
and DT stopwords O
p120Cbl NN O

The CAPITAL NNP O
complexing NNS O
of NN stopwords O
calcium VB calcium O
by NN stopwords by O
citrate NN citrate O
, , O
ortho- JJ O
and DT stopwords O
polyphosphates NN polyphosphate O

Cerebral CAPITAL NNP cerebral D
abscesses DT abscess D
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
AIDS CAPITAL DT AIDS D
caused VB cause O
by NN stopwords by O
methicillin-resistant NN O
Staphylococcus CAPITAL NNP staphylococcus O
aureus DT O
( ( O
MRSA CAPITAL NNP O
) ) O

Aortocoronary CAPITAL DT T
bypass NN beltway T
grafting NN graft T
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
accepted DT accept O
procedure NN procedure O
for NN stopwords O
ischemic NN ischemic D
heart NN heart D
disease NN disease D

Fathers CAPITAL NNP father O
in NN stopwords inch O
the NN stopwords O
delivery NN delivery O
room NN room O
-- : O
an DT stopwords Associate_in_Nursing O
opposition JJ resistance O
standpoint NN point_of_view O

Effect CAPITAL NNP consequence O
of NN stopwords O
epinephrine NN epinephrine O
on NN stopwords on O
myocardial NN myocardial O
triglyceride NN triglyceride O
and DT stopwords O
free JJ free O
fatty VB fatso O
acid DT acid O
utilization JJ use O

Efficacy CAPITAL NNP efficacy O
of NN stopwords O
open-bite JJ D
treatment NN treatment O
with NN stopwords O
the NN stopwords O
Thera-spoon CAPITAL NNP T

Identification CAPITAL PRP designation O
of NN stopwords O
five NN five O
new JJ new O
mutations NN mutant O
and DT stopwords O
three NN three O
novel JJ novel O
polymorphisms NN polymorphism O
in NN stopwords inch O
the NN stopwords O
muscle NN muscle O
chloride NNS chloride O
channel NNS channel O
gene NN gene O
( ( O
CLCN1 CAPITAL NNP O
) ) O
in NN stopwords inch O
20 DIGITS CD twenty O
Italian CAPITAL PRP Italian O
patients VB patient O
with NN stopwords O
dominant NN dominant O
and DT stopwords O
recessive NN recessive_allele O
myotonia NN myotonia D
congenita NNS D

We CAPITAL NNP O
feel JJ feel O
that NN stopwords O
pleuroperitoneal NN T
shunting NN shunt T
is NN stopwords be O
a DT stopwords angstrom O
valid NN valid O
new JJ new O
method NN method O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
malignant VB malignant D
pleural NN pleural D
effusions NN effusion D
which NN stopwords O
can VB stopwords can O
effectively NN efficaciously O
palliate VB extenuate O
respiratory NN respiratory O
symptoms NN symptom O
with NN stopwords O
low NN low O
morbidity NN morbidity O

The CAPITAL NNP O
Stresst'er CAPITAL NNP O
ergometer NN dynamometer O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
alternative DT option O
to NN stopwords O
treadmill NN treadmill O
testing NN testing O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
claudication NNS lameness D

Ten CAPITAL NNP ten O
patients VB patient O
with NN stopwords O
advanced DT advance D
stage NN phase D
( ( D
TNM CAPITAL NNP D
IIB-IVB CAPITAL PRP D
) ) D
mycosis NN fungal_infection D
fungoides JJ D
were NN stopwords be O
treated NN treat O
with NN stopwords O
a DT stopwords angstrom O
combination NNS combination T
chemotherapy NNS chemotherapy T
program NN plan T
consisting NNS dwell T
of NN stopwords T
bleomycin NN T
and DT stopwords T
methotrexate NN methotrexate T
weekly NN weekly T
, , T
doxorubicin NN doxorubicin T
every NN every T
3 DIGITS CD three T
weeks NN week T
, , T
and DT stopwords T
topical NN topical T
nitrogen NN nitrogen T
mustard NN mustard T
daily IN daily T
( ( T
BAM-M CAPITAL IN T
) ) T

Drug CAPITAL NNP drug O
histories NN history O
were NN stopwords be O
taken VB take O
and DT stopwords O
samples VB sample O
were NN stopwords be O
tested NN test O
for NN stopwords O
alcohol DT alcohol O
and DT stopwords O
six NN six O
of NN stopwords O
the NN stopwords O
most NN stopwords most O
commonly NNS normally O
abused DT mistreat O
drugs NN drug O

Medical CAPITAL NNP checkup T
treatment NN treatment T
of NN stopwords O
stone NN rock D
disease NN disease D

Two CAPITAL NNP two O
iterative NN iterative O
procedures NN procedure O
have VB stopwords rich_person O
been NN stopwords be O
developed NN develop O

BACKGROUND CAPITAL IN background O
: : O
The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
LTG CAPITAL NNP T
as DT stopwords arsenic O
add-on DT addition O
therapy NN therapy O
for NN stopwords O
partial NN partial_derivative D
seizures JJ seizure D
in NN stopwords inch O
adults DT adult O
has VB stopwords hour_angle O
previously NN previously O
been NN stopwords be O
established NN establish O

RESEARCH CAPITAL NNP research O
DESIGN CAPITAL NNP design O
AND CAPITAL DT O
METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
studied NN analyze O
171 DIGITS CD O
Pima CAPITAL NNP Pima O
Indians CAPITAL PRP Indian O
with NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D
between NN stopwords between O
the NN stopwords O
ages DT age O
of NN stopwords O
30-70 CD O
years NN old_age O
in NN stopwords inch O
a DT stopwords angstrom O
population-based NN O
epidemiological NN epidemiologic O
survey NN survey O

After CAPITAL DT after O
is NN stopwords be O
considered NNS see O
constitution NNS fundamental_law O
and DT stopwords O
natured RB O
of NN stopwords O
the NN stopwords O
prechordal NN O
plate NN home_plate O
which NN stopwords O
has VB stopwords hour_angle O
been NN stopwords be O
diversely NN variously O
explained NN explain O

Anesthesia CAPITAL DT anesthesia T
accidents DT accident O

Physiologic CAPITAL NNP physiologic T
treatment NN treatment T
of NN stopwords O
depressive NN depressive D
reactions NN chemical_reaction D
: : O
a DT stopwords angstrom O
pilot NN pilot O
study NN survey O

expandable NN expandable T
metal NN metallic_element T
stents NN stent T
were NN stopwords be O
inserted NN insert O
in NN stopwords inch O
two NN two O
patients VB patient O
with NN stopwords O
severe NN severe D
dyspnea NN dyspnea D
due NN due D
to NN stopwords D
tracheal NN tracheal D
stenosis NN stenosis D
caused VB cause D
by NN stopwords by D
lung NN lung D
cancer VB cancer D
and DT stopwords D
esophageal NN esophageal D
cancer VB cancer D

Therapeutic CAPITAL NNP remedy T
pneumothorax NN pneumothorax T
( ( T
TP CAPITAL NNP T
) ) T
proved NN prove O
its NN stopwords information_technology O
efficacy NN efficacy O
in NN stopwords inch O
pre-antibiotic NN O
era NN era O
, , O
so NN stopwords sol O
one JJ one O
can VB stopwords can O
assume DT assume O
that NN stopwords O
it NN stopwords information_technology O
can VB stopwords can O
be NN stopwords beryllium O
applied DT use O
with NN stopwords O
the NN stopwords O
same VB stopwords Lapp O
success NN success O
in NN stopwords inch O
multidrug NN D
resistant NN immune D
TB CAPITAL NN terbium D

purpose NN purpose O
: : O
many VB many O
patients VB patient O
with NN stopwords O
locally NN locally D
advanced DT advance D
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
la-nsclc NN D
) ) D
are DT stopwords are O
eligible NN eligible O
for NN stopwords O
combined-modality NNS T
therapy NN therapy T
( ( T
cmt NNS T
; : T
chemotherapy NNS chemotherapy T
and DT stopwords T
radiotherapy VB radiotherapy T
) ) T

Effect CAPITAL NNP consequence O
of NN stopwords O
zanamivir NN T
on NN stopwords on O
duration NN duration O
and DT stopwords O
resolution NN resolution O
of NN stopwords O
influenza NN influenza D
symptoms NN symptom O

Abstracts CAPITAL DT abstraction O

Verona CAPITAL NNP Verona O
, , O
Italy CAPITAL PRP Italy O
, , O
September CAPITAL NNP September O
21-22 CD O
, , O
1995 DIGITS CD O

Successful CAPITAL NNP successful O
treatment NN treatment O
with NN stopwords O
lamivudine NN lamivudine T
for NN stopwords O
fulminant JJ fulminant D
reactivated NN reactivate D
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
infectioN NN infection D
following JJ following O
intensive NN intensifier T
therapy NN therapy T
for NN stopwords O
high-grade NN high-grade D
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D

Nursing CAPITAL NNP nursing O
across DT across O
state NN state O
lines NN line O
poses NN airs O
complications NNS complication O
: : O
state-bound NN O
regulatory NN regulative O
and DT stopwords O
licensure NN O
issues NN issue O

On CAPITAL NNP on O
the NN stopwords O
National CAPITAL NNP national O
Institute CAPITAL PRP institute O
of NN stopwords O
Hygienic CAPITAL NNP hygienic O
Sciences CAPITAL NNP science O
Standard CAPITAL NNP standard O
`` `` O
lysozyme NN lysozyme O
standard NN standard O
'' POS O

For CAPITAL NNP O
spontaneous NN spontaneous O
major VB major O
haemorrhage VB bleeding O
( ( O
not JJ stopwords not O
procedure NN procedure O
related NN associate O
) ) O
, , O
1-year CD O
life-table NN O
estimates NN estimate O
were NN stopwords be O
0.74 LS O
% NN O
( ( O
0.43-1.1 LS O
) ) O
in NN stopwords inch O
the NN stopwords O
160 DIGITS CD one_hundred_sixty O
mg NN milligram O
aspirin DT aspirin O
group NN group O
and DT stopwords O
1.4 CD O
% NN O
( ( O
0.94-1.8 LS O
) ) O
in NN stopwords inch O
the NN stopwords O
3 DIGITS CD three O
mg NN milligram O
warfarin NN warfarin O
with NN stopwords O
80 DIGITS CD eighty O
mg NN milligram O
aspirin DT aspirin O
group NN group O
( ( O
p NN phosphorus O
= NN O
0.014 LS O
log NN log O
rank VB rank O
on NN stopwords on O
follow-up JJ follow-up O
) ) O

Dose-volume CAPITAL NNP O
histograms NN histogram O
can VB stopwords can O
be NN stopwords beryllium O
interpreted NN interpret O
in NN stopwords inch O
different NN different O
ways VB ways O

Abdominal CAPITAL DT abdominal D
tuberculosis NN tuberculosis D
involving NN involve O
hepatic NN liverwort O
hilar NN hilar O
lymph NN lymph O
nodes JJ node O

Use CAPITAL NNP use O
of NN stopwords O
a DT stopwords angstrom O
Foley CAPITAL NNP O
catheter VB catheter O
in NN stopwords inch O
the NN stopwords O
removal NN removal O
of NN stopwords O
a DT stopwords angstrom O
substernal NN D
goiter NN goiter D

Successful CAPITAL NNP successful O
patterning VB model O
was VB stopwords Washington O
demonstrated NN show O
by NN stopwords by O
challenging NNS challenge O
surfaces NN surface O
with NN stopwords O
goat NN goat O
anti-mouse DT O
antibody DT antibody O
conjugated NNS conjugate O
to NN stopwords O
tetramethylrhodamine NN O
isothiocyanate NN isothiocyanate O

Electron CAPITAL NNP electron O
beam NN radio_beam O
computed NNS calculate O
tomographic NN O
coronary NNS coronary_thrombosis O
calcium VB calcium O
as DT stopwords arsenic O
a DT stopwords angstrom O
predictor NN forecaster O
of NN stopwords O
coronary NNS coronary_thrombosis O
events NN event O
: : O
comparison NNS comparison O
of NN stopwords O
two NN two O
protocols NN protocol O

Coronary CAPITAL NNP coronary_thrombosis O
arterioluminal DT O
communications NNS communications O
in NN stopwords inch O
routine NN routine O
angiography DT angiography O

A CAPITAL DT angstrom O
preterm NN O
newborn JJ neonate O
female JJ female O
triplet NN three O
with NN stopwords O
diffuse NN diffuse O
cystic NNS cystic O
changes NNS change O
in NN stopwords inch O
the NN stopwords O
left NN left O
lung NN lung O

Invited CAPITAL PRP invite O
commentary NNS comment O
: : O
le NN lupus_erythematosus O
mystre NN O
de NN Delaware O
Montr CAPITAL NNP O
( ( O
c NNS degree_centigrade O
) ) O
al DT aluminum O
. . O

The CAPITAL NNP O
treatment NN treatment O
was VB stopwords Washington O
for NN stopwords O
30 DIGITS CD thirty O
days VB days O

Caution CAPITAL VB caution O
is NN stopwords be O
warranted NN justify O
for NN stopwords O
those NN stopwords O
still JJ still O
having VB stopwords have O
seizures JJ seizure O
while NN stopwords while O
receiving NN receive O
AED CAPITAL DT O
therapy NN therapy O

conclusions NNS decision O
: : O
for NN stopwords O
patients VB patient O
with NN stopwords O
both NN stopwords both O
esophageal NN esophageal D
and DT stopwords D
tracheobronchial NN D
stenoses NN stenosis D
, , O
a DT stopwords angstrom O
stent NN stent T
should NN stopwords O
be NN stopwords beryllium O
introduced NN introduce O
into NN stopwords O
the NN stopwords O
tracheobronchus NN O
first NN first O

Adequacy CAPITAL DT adequacy O
of NN stopwords O
SMAC CAPITAL NNP O
's POS O
statement NN statement O
should NN stopwords O
be NN stopwords beryllium O
judged NN judge O
by NN stopwords by O
clinicians JJ clinician O
, , O
not JJ stopwords not O
health NN health O
economists NN economist O

Pharmacological CAPITAL NNP pharmacological T
management VB management T
of NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

A CAPITAL DT angstrom O
case-control VB O
study NN survey O
of NN stopwords O
cytochrome NNS cytochrome O
P450 CAPITAL NNP O
1A1 CD O
, , O
glutathione NN O
S-transferase CAPITAL NNP O
M1 CAPITAL NNP M1 O
, , O
cigarette NN cigarette O
smoking JJ smoke O
and DT stopwords O
lung NN lung O
cancer VB cancer O
susceptibility NN susceptibility O
( ( O
Massachusetts CAPITAL NNP Massachusetts O
, , O
United CAPITAL NNP unite O
States CAPITAL NNP state O
) ) O

The CAPITAL NNP O
deduced NN deduce O
amino DT amino O
acid DT acid O
( ( O
aa DT aa O
) ) O
sequence NN sequence O
is NN stopwords be O
identical NN identical O
to NN stopwords O
the NN stopwords O
one JJ one O
of NN stopwords O
chicken JJ chicken O
CaMII CAPITAL VB O
which NN stopwords O
consists NNS dwell O
of NN stopwords O
148 DIGITS CD O
aa DT aa O

Adolescent CAPITAL DT adolescent O
pregnancy NN pregnancy O
and DT stopwords O
sexual NN sexual O
abuse DT maltreatment O

While CAPITAL NNP while O
these NN stopwords O
findings NN findings O
are DT stopwords are O
observed NN detect O
for NN stopwords O
all DT stopwords all O
classes NNS class O
of NN stopwords O
oral NN oral O
drugs NN drug O
, , O
the NN stopwords O
issue NN issue O
is NN stopwords be O
especially NN particularly O
critical JJ critical O
for NN stopwords O
cancer VB cancer D
chemotherapy NNS chemotherapy T
, , O
in NN stopwords inch O
which NN stopwords O
a DT stopwords angstrom O
narrow RB narrow O
therapeutic NN remedy O
index NN index O
is NN stopwords be O
frequently JJ frequently O
observed NN detect O

DESIGN CAPITAL NNP design O
: : O
Cross CAPITAL NNP cross O
sectional NN sectional O
survey NN survey O

Doing CAPITAL NNP make O
everything NN O

Positive CAPITAL NNP positive O
overtraining JJ O
can VB stopwords can O
be NN stopwords beryllium O
regarded NN see O
as DT stopwords arsenic O
a DT stopwords angstrom O
natural RB natural O
process NN procedure O
when NN stopwords O
the NN stopwords O
end NN end O
result NN consequence O
is NN stopwords be O
adaptation DT adaptation O
and DT stopwords O
improved JJ better O
performance NN performance O
: : O
the NN stopwords O
supercompensation NN O
principle NN principle O
-- : O
which NN stopwords O
includes NN include O
the NN stopwords O
breakdown NN dislocation O
process NN procedure O
( ( O
training NN training O
) ) O
followed JJ follow O
by NN stopwords by O
the NN stopwords O
recovery NN recovery O
process NN procedure O
( ( O
rest NN remainder O
) ) O
-- : O
is NN stopwords be O
well NN well O
known NN know O
in NN stopwords inch O
sports NN sport O

Comparative CAPITAL NNP comparative O
effects NN effects O
of NN stopwords O
two NN two O
benzodiazepine NN benzodiazepine O
compounds NNS compound O
on NN stopwords on O
isolated NN isolate O
human NN homo O
myometrium NN myometrium O

However CAPITAL NNP however O
, , O
several NN several O
studies NN survey O
have VB stopwords rich_person O
questioned NN question O
routine NN routine O
exploration NN exploration O
and DT stopwords O
have VB stopwords rich_person O
drawn NN pull O
attention DT attention O
to NN stopwords O
the NN stopwords O
associated DT associate O
morbidity NN morbidity O
of NN stopwords O
negative JJ negative O
celiotomy NNS O

Its CAPITAL PRP information_technology O
intron/exon NN O
organization JJ organization O
is NN stopwords be O
identical NN identical O
to NN stopwords O
that NN stopwords O
of NN stopwords O
the NN stopwords O
chicken JJ chicken O
CaMII CAPITAL VB O
and DT stopwords O
the NN stopwords O
CaMI CAPITAL VB O
and DT stopwords O
CaMIII CAPITAL VB O
genes NN gene O
of NN stopwords O
rat VB rat O
and DT stopwords O
human NN homo O

Side CAPITAL NNP side O
effects NN effects O
were NN stopwords be O
recorded NN record O

A CAPITAL DT angstrom O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
cleavage NNS cleavage O
site NN site O
that NN stopwords O
enhanced NN enhance O
the NN stopwords O
availability DT handiness O
of NN stopwords O
a DT stopwords angstrom O
protein NN protein O
that NN stopwords O
was VB stopwords Washington O
rate VB rate O
limiting NN modification O
for NN stopwords O
virus NN virus O
maturation VB maturation O
would NN O
confer NNS confer O
on NN stopwords on O
that NN stopwords O
virus NN virus O
a DT stopwords angstrom O
significant NN significant O
growth NN growth O
advantage DT advantage O
and DT stopwords O
may VB May O
explain NN explain O
the NN stopwords O
uniform JJ uniform O
emergence NN emergence O
of NN stopwords O
viruses NN virus O
with NN stopwords O
alterations DT change O
at DT stopwords astatine O
the NN stopwords O
p7/p1 NN O
cleavage NNS cleavage O
site NN site O

A CAPITAL DT angstrom O
survey NN survey O
of NN stopwords O
the NN stopwords O
attitudes DT attitude O
of NN stopwords O
chronic NN chronic O
psychiatric NN psychiatric O
patients VB patient O
living NN life O
in NN stopwords inch O
the NN stopwords O
community NNS community O
toward NN O
their NN stopwords O
medication NN medicine O

After CAPITAL DT after O
adjusting DT adjust O
for NN stopwords O
age DT age O
, , O
gender NN gender O
, , O
pack-years VB O
of NN stopwords O
smoking JJ smoke O
, , O
and DT stopwords O
years NN old_age O
since NN O
quitting NN discontinue O
smoking JJ smoke O
, , O
while NN stopwords while O
neither JJ neither O
the NN stopwords O
CYP1A1 CAPITAL NNP O
MspI CAPITAL NNP O
heterozygous NN heterozygous O
genotype NN genotype O
alone DT alone O
nor RB stopwords O
the NN stopwords O
GSTM1 CAPITAL NNP O
null JJ nothing O
genotype NN genotype O
alone DT alone O
were NN stopwords be O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
significant NN significant O
increase NN addition O
in NN stopwords inch O
lung NN lung D
cancer VB cancer D
risk NN hazard O
, , O
having VB stopwords have O
both NN stopwords both O
genetic NN familial O
traits NN trait O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
twofold NN double O
increase NN addition O
in NN stopwords inch O
risk NN hazard O
( ( O
95 DIGITS CD ninety-five O
percent NN percentage O
confidence NNS assurance O
interval NN time_interval O
( ( O
CI CAPITAL NNP curie O
) ) O
= NN O
1.0-3.4 CD O
) ) O

Bullous CAPITAL NNP O
eruption NN volcanic_eruption O
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
systemic NN systemic D
lupus NN lupus D
erythematosus NN D
: : O
mite NN touch D
dermatitis NN dermatitis D
caused VB cause O
by NN stopwords by O
Cheyletiella CAPITAL NNP O
blakei NN O

in NN stopwords inch O
addition DT addition O
, , O
oxaliplatin NN T
has VB stopwords hour_angle O
shown NN show O
efficacy NN efficacy O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
platinum-pretreated NN D
ovarian NN ovarian D
cancer VB cancer D
and DT stopwords O
achieved DT achieve O
objective NN aim O
response NN response O
rates VB rates O
similar NN similar O
to NN stopwords O
paclitaxel VB O
in NN stopwords inch O
this NN stopwords O
setting NN setting O
( ( O
16 DIGITS CD sixteen O
vs NN volt O
17 DIGITS CD seventeen O
% NN O
) ) O

The CAPITAL NNP O
replacement NN replacement O
of NN stopwords O
tryptophan NN tryptophan O
at DT stopwords astatine O
positions NN position O
15 DIGITS CD fifteen O
and DT stopwords O
9 DIGITS CD nine O
with NN stopwords O
alanine DT alanine O
was VB stopwords Washington O
found JJ found O
to NN stopwords O
produce NN produce O
more NN stopwords More O
species NN species O
heterogeneity NN heterogeneity O
than NN stopwords O
found JJ found O
with NN stopwords O
glycine NN glycine O
substitution NN substitution O
at DT stopwords astatine O
the NN stopwords O
same VB stopwords Lapp O
positions NN position O

Patterning CAPITAL VB model O
of NN stopwords O
immobilized JJ immobilize O
antibody DT antibody O
layers NN layer O
via NN O
photolithography NN photolithography O
and DT stopwords O
oxygen JJ oxygen O
plasma NN plasma O
exposure NN exposure O

Internal CAPITAL PRP internal O
fixation NN arrested_development O
was VB stopwords Washington O
achieved DT achieve O
with NN stopwords O
either NN either O
dual NN double O
intrameduilary NN O
threaded NN weave O
Steinmann CAPITAL NNP O
pins NN pin O
or NN stopwords Oregon O
an DT stopwords Associate_in_Nursing O
obliquely NN sidelong O
placed NN put O
AO CAPITAL DT O
compression NNS compaction O
screw NN prison_guard O
and DT stopwords O
a DT stopwords angstrom O
three- NN O
or NN stopwords Oregon O
four-hole JJ O
one-third JJ one-third O
tubular NN tubular O
dorsal NN dorsal O
neutralization JJ neutralization O
plate NN home_plate O

Repository CAPITAL NNP depository O
vitamin NN vitamin O
B CAPITAL NN bacillus O
12 DIGITS CD twelve O
preparations NN preparation O

CONCLUSIONS CAPITAL NNP decision O
: : O
Although CAPITAL DT O
diabetic NN diabetic D
retinopathy NN retinopathy D
in NN stopwords inch O
Pima CAPITAL NNP Pima O
Indians CAPITAL PRP Indian O
with NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D
is NN stopwords be O
not JJ stopwords not O
associated DT associate O
with NN stopwords O
PAI-1 CAPITAL VB O
activity DT activity O
, , O
subjects NN subject O
with NN stopwords O
the NN stopwords O
4G/4G CD O
and DT stopwords O
4G/5G CD O
genotype NN genotype O
had VB stopwords have O
a DT stopwords angstrom O
higher NN higher O
prevalence NN prevalence O
of NN stopwords O
retinopathy NN retinopathy D
compared NNS compare O
with NN stopwords O
5G/5G CD O
PAI-1genotype CAPITAL VB O

Residual CAPITAL NNP remainder O
resist NN defy O
was VB stopwords Washington O
stripped NN deprive O
with NN stopwords O
acetone DT acetone O

Vitamin CAPITAL NNP vitamin O
K2 CAPITAL NNP K2 O
and DT stopwords O
serum NN serum O
cholesterol NNS cholesterol O
in NN stopwords inch O
patients VB patient O
on NN stopwords on O
continuous NNS continuous O
ambulatory DT ambulatory O
peritoneal NN peritoneal T
dialysis NN dialysis T

The CAPITAL NNP O
production NN production O
of NN stopwords O
1 DIGITS CD one O
greatly NN greatly O
accelerates DT accelerate O
the NN stopwords O
decomposition NN decomposition O
of NN stopwords O
peroxynitrite NN O
to NN stopwords O
give NN give O
nitrate NN nitrate O

BACKGROUND CAPITAL IN background O
: : O
For CAPITAL NNP O
more NN stopwords More O
than NN stopwords O
30 DIGITS CD thirty O
years NN old_age O
it NN stopwords information_technology O
has VB stopwords hour_angle O
been NN stopwords be O
known NN know O
that NN stopwords O
gastric VB gastric O
acid DT acid O
secretion NN secretion O
is NN stopwords be O
inversely NN inversely O
related NN associate O
to NN stopwords O
the NN stopwords O
extent NN extent O
and DT stopwords O
severity NN badness O
of NN stopwords O
corpal NNS D
gastritis VB gastritis D

A CAPITAL DT angstrom O
conceptual NNS conceptual O
model NN model O

Disability CAPITAL NNP disability O
models NN model O
in NN stopwords inch O
geriatrics NN geriatrics O
: : O
comprehensive NNS comprehensive_examination O
rather VB rather O
than NN stopwords O
competing NNS compete O
models NN model O
should NN stopwords O
be NN stopwords beryllium O
promoted NN promote O

Symptom CAPITAL NNP symptom O
onset JJ onset O
was VB stopwords Washington O
acute DT acute_accent O
( ( O
& CC O
# # O
60 DIGITS CD sixty O
; : O
48 DIGITS CD forty-eight O
hours NN hours O
) ) O
in NN stopwords inch O
63 DIGITS CD sixty-three O
% NN O
of NN stopwords O
patients VB patient O

A CAPITAL DT angstrom O
double-blind NN O
, , O
crossover NNS crossing_over O
design NN design O
was VB stopwords Washington O
used JJ use O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
effects NN effects O
of NN stopwords O
methylphenidate NN methylphenidate T
versus NN O
placebo NN placebo O
on NN stopwords on O
an DT stopwords Associate_in_Nursing O
electroencephalogram NN electroencephalogram O
, , O
AED CAPITAL DT O
levels NN degree O
, , O
and DT stopwords O
the NN stopwords O
CPT CAPITAL NNP O

The CAPITAL NNP O
angiogram DT angiogram O
in NN stopwords inch O
the NN stopwords O
study NN survey O
of NN stopwords O
hypertension NN high_blood_pressure D

Epidemiology CAPITAL NNP epidemiology O
and DT stopwords O
association DT association O
with NN stopwords O
extra-gastrointestinal NN D
diseases NN disease D

Ventilatory CAPITAL NNP ventilatory O
responses NN response O
to NN stopwords O
acute DT acute_accent O
and DT stopwords O
sustained NN prolong O
hypoxia NN hypoxia O
during NN stopwords O
isoflurane NN isoflurane O
anesthesia DT anesthesia O

INTERPRETATION CAPITAL PRP interpretation O
: : O
There CAPITAL NNP there O
is NN stopwords be O
no NNS stopwords no O
treatment NN treatment O
of NN stopwords O
choice NNS choice O
for NN stopwords O
early-stage VB O
cervical NNS cervical D
carcinoma VB carcinoma D
in NN stopwords inch O
terms NN footing O
of NN stopwords O
overall JJ overall O
or NN stopwords Oregon O
disease-free NN O
survival NN survival O

Practice CAPITAL NNP practice O
parameters NN parameter O
for NN stopwords O
the NN stopwords O
forensic NN forensic O
evaluation NN evaluation O
of NN stopwords O
children JJ child O
and DT stopwords O
adolescents DT adolescent O
who NN stopwords World_Health_Organization O
may VB May O
have VB stopwords rich_person O
been NN stopwords be O
physically NN physically O
or NN stopwords Oregon O
sexually NN sexually O
abused DT mistreat O

It CAPITAL PRP information_technology O
is NN stopwords be O
of NN stopwords O
interest NN interest O
to NN stopwords O
note JJ note O
that NN stopwords O
the NN stopwords O
state NN state O
of NN stopwords O
disorder NN disorder O
( ( O
or NN stopwords Oregon O
the NN stopwords O
fractal NN fractal O
dimension NN dimension O
) ) O
and DT stopwords O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficient NNS coefficient O
both NN stopwords both O
increase NN addition O
as DT stopwords arsenic O
the NN stopwords O
reaction NN chemical_reaction O
progresses NN advancement O
on NN stopwords on O
the NN stopwords O
biosensor NN O
surface NN surface O

The CAPITAL NNP O
diffusion-limited NN O
binding NN binding O
kinetics NN dynamics O
of NN stopwords O
antigen DT antigen O
( ( O
or NN stopwords Oregon O
antibody DT antibody O
) ) O
in NN stopwords inch O
solution NN solution O
to NN stopwords O
antibody DT antibody O
( ( O
or NN stopwords Oregon O
antigen DT antigen O
) ) O
immobilized JJ immobilize O
on NN stopwords on O
a DT stopwords angstrom O
biosensor NN O
and DT stopwords O
other JJ stopwords other O
surfaces NN surface O
is NN stopwords be O
analyzed DT analyze O
within NN inside O
a DT stopwords angstrom O
fractal NN fractal O
framework NN model O

Cesarean CAPITAL NNP cesarean_delivery O
sections NN section O
: : O
women NN woman O
's POS O
choice NNS choice O
for NN stopwords O
giving NN giving O
birth NN birth O
? . O

Conference CAPITAL NNP conference O
proceedings NN proceeding O

CONCLUSION CAPITAL NNP decision O
: : O
With CAPITAL NNP O
a DT stopwords angstrom O
standardised NN standardize O
rate VB rate O
of NN stopwords O
68 DIGITS CD sixty-eight O
per NN O
100000 DIGITS CD hundred_thousand O
and DT stopwords O
a DT stopwords angstrom O
first-week NN O
mortality NN mortality O
rate VB rate O
of NN stopwords O
35 DIGITS CD thirty-five O
% NN O
, , O
stroke NN stroke D
must NN must O
now JJ stopwords now O
be NN stopwords beryllium O
considered NNS see O
an DT stopwords Associate_in_Nursing O
important JJ important O
cause VB cause O
of NN stopwords O
morbidity NN morbidity O
and DT stopwords O
mortality NN mortality O
in NN stopwords inch O
the NN stopwords O
population NN population O

Bilateral CAPITAL NNP bilateral T
lung NN lung T
transplantation NN transplant T
should NN stopwords O
be NN stopwords beryllium O
considered NNS see O
in NN stopwords inch O
younger NN younger O
patients VB patient O
with NN stopwords O
severe NN severe O
, , O
generalized NN generalize O
bronchiectasis NN D
and DT stopwords D
respiratory NN respiratory D
failure VB failure D

Microalbuminuria CAPITAL NNP D
is NN stopwords be O
positively NN positively O
associated DT associate O
with NN stopwords O
usual JJ usual O
dietary NN dietary O
saturated VB saturate O
fat VB fat O
intake NN consumption O
and DT stopwords O
negatively JJ negatively O
associated DT associate O
with NN stopwords O
usual JJ usual O
dietary NN dietary O
protein NN protein O
intake NN consumption O
in NN stopwords inch O
people NN people O
with NN stopwords O
insulin-dependent NN D
diabetes NN diabetes D
mellitus NN D

Acid CAPITAL DT acid T
suppression NN suppression T
therapy NN therapy T
in NN stopwords inch O
Barrett CAPITAL IN D
's POS D
esophagus NN esophagus D
: : O
the NN stopwords O
importance JJ importance O
of NN stopwords O
pH NN pH O
monitoring NN monitoring O

Control CAPITAL NNP control O
of NN stopwords O
post-haemorrhoidectomy NN D
bleeding NN bleeding D
with NN stopwords O
a DT stopwords angstrom T
Foley CAPITAL NNP T
catheter VB catheter T
and DT stopwords T
a DT stopwords angstrom T
pack VB battalion T

Recombinant CAPITAL NNP recombinant T
glycoprotein NN glycoprotein T
vaccine NN vaccine T
for NN stopwords O
the NN stopwords O
prevention NN prevention O
of NN stopwords O
genital NN genital D
HSV-2 CAPITAL NNP herpes_simplex_2 D
infection NN infection D
: : O
two NN two O
randomized VB randomize O
controlled NNS control O
trials NN test O

patients VB patient O
with NN stopwords O
a DT stopwords angstrom O
single NN single D
non-sclc JJ D
, , D
breast NN breast D
, , D
melanoma NN melanoma D
, , D
renal NN nephritic D
cell NNS cell D
, , D
and DT stopwords D
ovarian NN ovarian D
carcinoma VB carcinoma D
brain NN brain D
metastasis NN metastasis D
have VB stopwords rich_person O
the NN stopwords O
best NN best O
chance NNS opportunity O
for NN stopwords O
long-term NN long-run O
survival NN survival O
if NN stopwords O
treated NN treat O
with NN stopwords O
surgical NN surgical T
resection NN resection T
and DT stopwords T
wbrt NN T

The CAPITAL NNP O
authors DT writer O
found JJ found O
no NNS stopwords no O
consistent NNS consistent O
correlations NNS correlation O
between NN stopwords between O
lesion NN lesion O
size NN size O
and DT stopwords O
location NN location O
and DT stopwords O
clinical JJ clinical O
outcome JJ result O
as DT stopwords arsenic O
measured NN measure O
by NN stopwords by O
a DT stopwords angstrom O
global NN global O
outcome JJ result O
score JJ mark O
, , O
the NN stopwords O
Unified CAPITAL NNP unify O
Parkinson CAPITAL VB Parkinson O
's POS O
Disease CAPITAL NNP disease O
Rating CAPITAL VB evaluation O
Scale CAPITAL NNP scale O
motor NN motor O
, , O
activities DT activity O
of NN stopwords O
daily IN daily O
living NN life O
, , O
and DT stopwords O
bradykinesia NN O
`` `` O
off JJ stopwords murder O
'' POS O
scores JJ tons O
or NN stopwords Oregon O
rating VB evaluation O
of NN stopwords O
dyskinesias NN dyskinesia O

X-ray CAPITAL LS X_ray O
diffraction NN diffraction O
showed NN show O
altered DT change O
mineral NN mineral O
crystal NNS crystal O
thickness NN thickness O
in NN stopwords inch O
fluoride-treated JJ O
bones NN bones O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O
, , O
and DT stopwords O
there NN stopwords there O
was VB stopwords Washington O
a DT stopwords angstrom O
negative JJ negative O
association DT association O
between NN stopwords between O
crystal NNS crystal O
width NN width O
and DT stopwords O
fracture NN fracture O
stress NN stress O
of NN stopwords O
the NN stopwords O
femur JJ femur O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.02 LS O
) ) O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Adolescents CAPITAL DT adolescent O
' '' O
willingness NN willingness O
to NN stopwords O
disclose NN unwrap O
general NN general O
information NN information O
, , O
willingness NN willingness O
to NN stopwords O
disclose NN unwrap O
information NN information O
about DT stopwords about O
sensitive NN medium O
topics NN subject O
, , O
intended NN intend O
honesty NN honesty O
, , O
and DT stopwords O
likelihood NN likelihood O
of NN stopwords O
return NN tax_return O
visits NN visit O
to NN stopwords O
the NN stopwords O
physician NN doctor O
depicted NN picture O
in NN stopwords inch O
the NN stopwords O
scenario JJ scenario O
were NN stopwords be O
assessed DT measure O
by NN stopwords by O
anonymous DT anonymous O
written NN write O
questionnaire NN questionnaire O

RESULTS CAPITAL NNP consequence O
: : O
PIBF CAPITAL NNP O
was VB stopwords Washington O
detected NN detect O
in NN stopwords inch O
29.5 CD O
% NN O
of NN stopwords O
non-pregnant JJ O
women NN woman O
and DT stopwords O
52.5 CD O
% NN O
of NN stopwords O
pregnant NN pregnant O
women NN woman O

Interviews CAPITAL PRP interview O
were NN stopwords be O
transcribed NN transcribe O
verbatim NN direct O
and DT stopwords O
analyzed DT analyze O
for NN stopwords O
themes NN subject O
with NN stopwords O
a DT stopwords angstrom O
constant NNS constant O
comparative NNS comparative O
method NN method O

D19S574 CAPITAL NNP O
showed NN show O
a DT stopwords angstrom O
significant NN significant O
effect NN consequence O
( ( O
P=.015 CAPITAL NNP O
) ) O
in NN stopwords inch O
Caucasian CAPITAL VB White O
patients VB patient O
with NN stopwords O
MS CAPITAL NNP multiple_sclerosis O
due NN due O
to NN stopwords O
the NN stopwords O
increased NN increase O
frequency JJ frequency O
of NN stopwords O
a DT stopwords angstrom O
single NN single O
allele DT allele O
( ( O
P=.002 CAPITAL NNP O
) ) O

background VB background O
and DT stopwords O
objectives NN aim O
: : O
thoracic NN pectoral T
paravertebral NN T
block NN block T
( ( T
tpvb NN T
) ) T
is NN stopwords be O
a DT stopwords angstrom O
unilateral JJ unilateral O
analgesic DT analgesic O
technique NN technique O
that NN stopwords O
has VB stopwords hour_angle O
been NN stopwords be O
advocated DT recommend O
in NN stopwords inch O
both NN stopwords both O
acute DT acute_accent D
and DT stopwords D
chronic NN chronic D
thoracic NN pectoral D
and DT stopwords D
abdominal DT abdominal D
pain IN pain D

In CAPITAL PRP inch O
contrast NNS contrast O
, , O
on NN stopwords on O
language NN language O
development NN development O
testing NN testing O
, , O
19 DIGITS CD nineteen O
children JJ child O
demonstrated NN show O
receptive NN receptive O
language NN language O
delay NN delay O

Authorship CAPITAL DT writing O

Hemodynamic CAPITAL NNP hemodynamic O
effects NN effects O
of NN stopwords O
acute DT acute_accent O
tetrandrine NN O
and DT stopwords O
terlipressin NN O
administration DT administration O
on NN stopwords on O
portal NN portal O
hypertensive NN hypertensive O
rats VB rat O

There CAPITAL NNP there O
was VB stopwords Washington O
no NNS stopwords no O
difference NN difference O
between NN stopwords between O
groups NN group O
in NN stopwords inch O
early VB early O
return NN tax_return O
( ( O
13/238 CD O
( ( O
5.5 CD O
% NN O
) ) O
v NN volt O
27/437 CD O
( ( O
6 DIGITS CD six O
% NN O
) ) O
) ) O
, , O
or NN stopwords Oregon O
complications NNS complication O
( ( O
2/236 CD O
( ( O
0.8 LS O
% NN O
) ) O
v NN volt O
3/434 CD O
( ( O
0.7 LS O
% NN O
) ) O
) ) O

Redundant CAPITAL NNP excess O
myelin NN myelin O
sheaths NN sheath O
and DT stopwords O
other JJ stopwords other O
ultrastructural JJ O
features NN feature O
of NN stopwords O
the NN stopwords O
toad NN frog O
cerebellum NNS cerebellum O

Also CAPITAL DT besides O
, , O
its NN stopwords information_technology O
was VB stopwords Washington O
determined NN determine O
the NN stopwords O
morphology NN morphology O
and DT stopwords O
quantification NN quantification O
of NN stopwords O
parasites NN parasite O

Violence CAPITAL NNP violence O

the NN stopwords O
current NNS current O
study NN survey O
was VB stopwords Washington O
designed NN plan O
to NN stopwords O
assess DT buttocks O
the NN stopwords O
prognostic NN omen O
value NN value O
of NN stopwords O
immunomorphologic JJ O
changes NNS change O
in NN stopwords inch O
locoregional NN O
lymph NN lymph O
nodes JJ node O
and DT stopwords O
lymphocytic NN lymphocytic O
infiltration NN infiltration O
of NN stopwords O
primary NN primary O
tumor NN tumor O
( ( O
li NN lithium O
) ) O
in NN stopwords inch O
patients VB patient O
who NN stopwords World_Health_Organization O
undergo JJ undergo O
resection NN resection T
for NN stopwords O
bronchogenic NN D
carcinoma VB carcinoma D

A CAPITAL DT angstrom O
review NN reappraisal O
of NN stopwords O
interferon NN interferon O
immunogenicity JJ immunogenicity O

Something CAPITAL NNP O
from JJ stopwords O
nothing JJ nothing O
: : O
the NN stopwords O
evolution NN development O
and DT stopwords O
utility JJ utility O
of NN stopwords O
satellite VB satellite O
repeats NN repeat O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

A CAPITAL DT angstrom O
preliminary NN preliminary O
report NN report O

Policies CAPITAL NNP policy O
for NN stopwords O
posting NN poster O
biomedical NN biomedical O
journal NN diary O
information NN information O
on NN stopwords on O
the NN stopwords O
Internet CAPITAL PRP internet O

An CAPITAL DT Associate_in_Nursing O
LRP CAPITAL NNP O
was VB stopwords Washington O
only JJ stopwords lone O
observed NN detect O
on NN stopwords on O
no-go RB no-go O
trials NN test O
when NN stopwords O
the NN stopwords O
semantic NN semantic O
( ( O
not JJ stopwords not O
the NN stopwords O
phonological NN phonological O
) ) O
decision NN decision O
determined NN determine O
the NN stopwords O
response NN response O
hand VB hand O

Clinical CAPITAL NNP clinical O
significance NN significance O
of NN stopwords O
Blastocystis CAPITAL NNP D
hominis NN D
infection NN infection D
: : O
epidemiologic NN epidemiologic O
study NN survey O

Effects CAPITAL NNP effects O
of NN stopwords O
alanine DT alanine O
and DT stopwords O
glycine NN glycine O
substitution NN substitution O
for NN stopwords O
tryptophan NN tryptophan O
on NN stopwords on O
the NN stopwords O
heterogeneity NN heterogeneity O
of NN stopwords O
gramicidin NN gramicidin O
A CAPITAL DT angstrom O
analogs DT analogue O
in NN stopwords inch O
micelles NN micelle O

Should CAPITAL NNP O
we NN stopwords O
accept DT accept O
mediocrity NN averageness O
? . O

The CAPITAL NNP O
very NN stopwords very O
motivation NN motivation O
for NN stopwords O
seeking NN quest O
an DT stopwords Associate_in_Nursing O
`` `` O
origin IN beginning O
'' POS O
of NN stopwords O
homosexuality NN homosexuality O
reveals NN uncover O
homophobia NN homophobia O

In CAPITAL PRP inch O
vitro NN O
interactions NN interaction O
of NN stopwords O
oxidatively IN O
modified NN modify O
LDL CAPITAL NNP low-density_lipoprotein O
with NN stopwords O
type NN type O
I CAPITAL PRP iodine O
, , O
II CAPITAL PRP two O
, , O
III CAPITAL PRP three O
, , O
IV CAPITAL PRP four O
, , O
and DT stopwords O
V CAPITAL NN volt O
collagen NNS collagen O
, , O
laminin NN O
, , O
fibronectin NN O
, , O
and DT stopwords O
poly-D-lysine NN O

CONCLUSIONS CAPITAL NNP decision O
: : O
Fenfluramine CAPITAL NNP T
and DT stopwords O
dexfenfluramine NN T
have VB stopwords rich_person O
been NN stopwords be O
demonstrated NN show O
to NN stopwords O
damage VB damage O
brain NN brain O
serotonin NN serotonin O
neurons JJ nerve_cell O
in NN stopwords inch O
animal DT animal O
studies NN survey O

Purification CAPITAL NNP purification O
and DT stopwords O
characterization NNS word_picture O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
acetyl DT acetyl O
xylan JJ O
esterase NN O
from JJ stopwords O
Bacillus CAPITAL IN bacillus O
pumilus NN O

The CAPITAL NNP O
first NN first O
year NN year O
of NN stopwords O
consultation NNS consultation O

Wegener CAPITAL NNP Wegener D
's POS D
granulomatosis NN D
of NN stopwords O
the NN stopwords O
head NN head O
and DT stopwords O
neck JJ neck O

Prevention CAPITAL NNP prevention O
of NN stopwords O
stone NN rock D
formation NN formation D

Audit CAPITAL DT audited_account O
commission NNS committee O
tackles VB tackle O
anaesthetic DT anesthetic O
services NN services O

We CAPITAL NNP O
assessed DT measure O
the NN stopwords O
effects NN effects O
of NN stopwords O
early VB early T
replacement NN replacement T
therapy NN therapy T
with NN stopwords T
protein-C NN T
concentrate NNS dressed_ore T
together NN together T
with NN stopwords T
continuous NNS continuous T
veno-venous NN T
haemodiafiltration VB T
and DT stopwords O
conventional NNS conventional O
treatment NN treatment O
in NN stopwords inch O
meningococcaemia NN D

Effect CAPITAL NNP consequence O
of NN stopwords O
thoracic NN pectoral O
cava VB O
obstruction NN obstruction O
on NN stopwords on O
response NN response O
of NN stopwords O
proximal NN proximal O
tubule NN tubule O
sodium NN sodium O
reabsorption NN resorption O
to NN stopwords O
saline VB saline_solution O
infusion NN infusion O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Ulceration CAPITAL NNP ulcer D
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
ileocolic NN D
anastomosis DT anastomosis D
treated NN treat O
with NN stopwords O
ranitidin VB T

American CAPITAL DT American O
Academy CAPITAL DT academy O
of NN stopwords O
Child CAPITAL NNP child O
and DT stopwords O
Adolescent CAPITAL DT adolescent O
Psychiatry CAPITAL NNP psychiatry O

By CAPITAL NNP by O
using JJ exploitation O
a DT stopwords angstrom O
TQR CAPITAL NNP O
scale JJ scale O
, , O
structured NN structure O
around DT about O
the NN stopwords O
scale JJ scale O
developed NN develop O
for NN stopwords O
ratings VB evaluation O
of NN stopwords O
perceived NN perceive O
exertion NN effort O
( ( O
RPE CAPITAL NNP O
) ) O
, , O
the NN stopwords O
recovery NN recovery O
process NN procedure O
can VB stopwords can O
be NN stopwords beryllium O
monitored NN monitor O
and DT stopwords O
matched VB match O
against DT stopwords O
the NN stopwords O
breakdown NN dislocation O
( ( O
training NN training O
) ) O
process NN procedure O
( ( O
TQR CAPITAL NNP O
versus NN O
RPE CAPITAL NNP O
) ) O

FINDINGS CAPITAL NNP findings O
: : O
A CAPITAL DT angstrom O
statistically NN statistically O
significant NN significant O
reduction NN decrease O
in NN stopwords inch O
the NN stopwords O
primary NN primary O
composite NNS complex O
triple NN triple O
endpoint NN end_point O
rates VB rates O
was VB stopwords Washington O
observed NN detect O
in NN stopwords inch O
the NN stopwords O
roxithromycin NN O
group NN group O
: : O
p NN phosphorus O
= NN O
0.032 LS O

Coronary CAPITAL NNP coronary_thrombosis T
artery DT artery T
bypass NN beltway T
grafting NN graft T
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
both NN stopwords both O
cases VB case O
, , O
and DT stopwords O
the NN stopwords O
outcome JJ result O
was VB stopwords Washington O
successful NN successful O

Endoscopic CAPITAL NNP endoscopic T
excision NN deletion T
of NN stopwords O
a DT stopwords angstrom D
forehead NN brow D
mass VB mass D

in NN stopwords inch O
the NN stopwords O
past VB past O
several NN several O
years NN old_age O
, , O
new JJ new T
chemotherapeutic NNS chemotherapeutic T
agents DT agent T
, , T
including NN include T
the NN stopwords T
taxanes VB T
and DT stopwords T
the NN stopwords T
topoisomerase NN T
i NN stopwords iodine T
inhibitors NN inhibitor T
, , O
have VB stopwords rich_person O
demonstrated NN show O
substantial NN significant O
activity DT activity O
against DT stopwords O
small-cell JJ D
carcinoma VB carcinoma D

48 DIGITS CD forty-eight O
( ( O
28 DIGITS CD twenty-eight O
% NN O
) ) O
surgery-group NN O
patients VB patient O
had VB stopwords have O
severe NN severe O
morbidity NN morbidity O
compared NNS compare O
with NN stopwords O
19 DIGITS CD nineteen O
( ( O
12 DIGITS CD twelve O
% NN O
) ) O
radiotherapy-group VB O
patients VB patient O
( ( O
p NN phosphorus O
= NN O
0.0004 LS O
) ) O

Differential CAPITAL NNP derived_function O
expression NN expression O
of NN stopwords O
fibroblast NN fibroblast O
growth NN growth O
factor-2 VB O
and DT stopwords O
receptor NN receptor O
by NN stopwords by O
glial NN glial O
cells NNS cell O
in NN stopwords inch O
experimental NN experimental O
autoimmune DT autoimmune D
encephalomelitis NN D
( ( D
EAE CAPITAL VB D
) ) D

cyclophosphamide NNS T
therapy NN therapy T
is NN stopwords be O
effective NN effective O
for NN stopwords O
bronchiolitis NN bronchiolitis D
obliterans NN D
occurring JJ happen D
as DT stopwords arsenic D
a DT stopwords angstrom D
late NN late D
manifestation VB manifestation D
of NN stopwords D
lupus NN lupus D
erythematosus NN D
( ( O
letter NN letter O
) ) O

SETTING CAPITAL NNP setting O
: : O
International CAPITAL PRP International O
referral NN referral O
centre NNS Centre O
for NN stopwords O
amyloid DT amyloid O
research NN research O
and DT stopwords O
treatment NN treatment O

Guidelines CAPITAL NNP guideline O
and DT stopwords O
cardiac VB cardiac O
anaesthetists DT anesthesiologist O

conclusion NNS decision O
: : O
our NN stopwords O
results NN consequence O
suggest NN propose O
that NN stopwords O
pseudoephedrine NN pseudoephedrine T
plus NN asset T
acetaminophen DT acetaminophen T
is NN stopwords be O
effective NN effective O
for NN stopwords O
relief NN relief O
of NN stopwords O
symptoms NN symptom D
attributable DT attributable D
to NN stopwords D
the NN stopwords D
paranasal NN paranasal D
sinuses NN fistula D
that NN stopwords O
may VB May O
develop NN develop O
early VB early O
in NN stopwords inch O
the NN stopwords O
course NNS course O
of NN stopwords O
a DT stopwords angstrom O
cold NNS cold O

Clinical CAPITAL NNP clinical O
diagnosis NN diagnosis O
of NN stopwords O
frontotemporal JJ D
dementia NN dementia D

Examples CAPITAL NNP example O
of NN stopwords O
other JJ stopwords other O
sources NN beginning O
of NN stopwords O
signals NN signal O
are DT stopwords are O
prescription NN prescription O
event NN event O
monitoring NN monitoring O
, , O
large NN large O
automated DT automatize O
data VB data O
resources NN resource O
on NN stopwords on O
morbidity NN morbidity O
and DT stopwords O
drug NN drug O
use JJ use O
( ( O
including NN include O
record NN record O
linkage NN linkage O
) ) O
, , O
case-control VB O
surveillance NN surveillance O
and DT stopwords O
follow-up JJ follow-up O
studies NN survey O

Getting CAPITAL NNP acquiring O
a DT stopwords angstrom O
handle VB handle O
on NN stopwords on O
the NN stopwords O
molecules NN molecule O
that NN stopwords O
guide NN usher O
axons DT axon O

Evidence-based CAPITAL NNP O
medicine NN medicine O
( ( O
EBM CAPITAL NN O
) ) O
aids DT AIDS O
clinical JJ clinical O
decision NN decision O
making NN devising O
in NN stopwords inch O
all DT stopwords all O
fields NN Fields O
of NN stopwords O
medicine NN medicine O
, , O
including NN include O
primary NN primary O
care VB care O

Replicated CAPITAL NNP retroflex O
declines NN decline O
in NN stopwords inch O
assault DT assault O
rates VB rates O
after DT stopwords after O
implementation JJ execution O
of NN stopwords O
the NN stopwords O
Assaulted CAPITAL DT assail O
Staff CAPITAL NNP staff O
Action CAPITAL DT action O
Program CAPITAL NNP plan O

Protective CAPITAL NNP protective O
effect NN consequence O
of NN stopwords O
pralidoxime NN T
on NN stopwords on O
muscle NN muscle D
fiber NN fiber D
necrosis JJ necrosis D
induced NN induce O
by NN stopwords by O
organophosphate JJ organophosphate O
compounds NNS compound O

Influence CAPITAL PRP influence O
of NN stopwords O
physician NN doctor O
confidentiality NNS confidentiality O
assurances DT assurance O
on NN stopwords on O
adolescents DT adolescent O
' '' O
willingness NN willingness O
to NN stopwords O
disclose NN unwrap O
information NN information O
and DT stopwords O
seek NN seek O
future JJ future O
health NN health O
care VB care O

Re CAPITAL NNP rhenium O
: : O
Friday CAPITAL NNP Friday O
afternoon DT afternoon O
pulmonary NN pneumonic T
arteriography DT arteriography T
( ( T
FAPA CAPITAL NNP T
) ) T
: : O
are DT stopwords are O
Fridays CAPITAL NNP Friday O
good NN good O
for NN stopwords O
your NN stopwords O
health NN health O
? . O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Prevalence CAPITAL NNP prevalence O
of NN stopwords O
C CAPITAL SYM degree_centigrade D
trachomatis NN D
infection NN infection D
in NN stopwords inch O
women NN woman O
aged DT aged O
18-35 CD O
on NN stopwords on O
the NN stopwords O
basis VB footing O
of NN stopwords O
each VB stopwords each O
test NN trial O
; : O
sensitivity NN sensitivity O
and DT stopwords O
specificity NN specificity O
of NN stopwords O
both NN stopwords both O
tests NN trial O
in NN stopwords inch O
this NN stopwords O
population NN population O

Very CAPITAL NNP very O
few JJ stopwords few O
autonomic DT autonomic O
tests NN trial O
have VB stopwords rich_person O
been NN stopwords be O
done NN make O
on NN stopwords on O
pediatric NN pediatric O
patients VB patient O
thus NN frankincense O
far VB Army_for_the_Liberation_of_Rwanda O

Evidence CAPITAL NNP evidence O
of NN stopwords O
a DT stopwords angstrom O
new JJ new O
susceptibility NN susceptibility O
locus NN venue O
in NN stopwords inch O
Caucasian CAPITAL VB White O
and DT stopwords O
Chinese CAPITAL NNP Chinese O
patients VB patient O

Relatives CAPITAL NNP relative O
in NN stopwords inch O
the NN stopwords O
resuscitation NN resuscitation O
room NN room O
: : O
their NN stopwords O
point NN point O
of NN stopwords O
view NN position O

Similarly CAPITAL NNP similarly O
, , O
within NN inside O
1 DIGITS CD one O
h NN hydrogen O
after DT stopwords after O
the NN stopwords O
administration DT administration O
of NN stopwords O
kainic VB O
acid DT acid O
in NN stopwords inch O
vivo NN O
, , O
SHARP-2 CAPITAL NNP O
is NN stopwords be O
induced NN induce O
in NN stopwords inch O
neurons JJ nerve_cell O
throughout NN throughout O
the NN stopwords O
rat VB rat O
cerebral NNS cerebral O
cortex NNS cerebral_cortex O

background VB background O
: : O
the NN stopwords O
role NN function O
of NN stopwords O
surgical NN surgical T
staging NN theatrical_production T
of NN stopwords O
patients VB patient O
with NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
continues NNS continue O
to NN stopwords O
evolve NN evolve O

Contemporary CAPITAL NNP contemporary O
asthma DT asthma O
management VB management O
guidelines NN guideline O
list NN list O
inhaled NN inhale T
corticosteroids NNS corticosteroid T
as DT stopwords arsenic O
the NN stopwords O
preferred NN prefer O
controller NNS accountant O
medication NN medicine O
for NN stopwords O
patients VB patient O
with NN stopwords O
persistent NN persistent D
asthma DT asthma D

The CAPITAL NNP O
value NN value O
based VB establish O
on NN stopwords on O
PFGE CAPITAL NNP O
is NN stopwords be O
used JJ use O
to NN stopwords O
calculate VB calculate O
the NN stopwords O
value NN value O
of NN stopwords O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
predicted NN predict O
by NN stopwords by O
the NN stopwords O
DSB CAPITAL NNP O
model NN model O
( ( O
2.6 CD O
+/- NN O
0.1 LS O
h NN hydrogen O
) ) O
, , O
which NN stopwords O
agrees DT agree O
with NN stopwords O
the NN stopwords O
value NN value O
determined NN determine O
experimentally NN experimentally O
as DT stopwords arsenic O
the NN stopwords O
time NN time O
when NN stopwords O
changing NNS change O
the NN stopwords O
delayed-plating NN O
medium NN medium O
from JJ stopwords O
growth NN growth O
medium NN medium O
to NN stopwords O
conditioned NNS condition O
medium NN medium O
no NNS stopwords no O
longer NN longer O
gives NN give O
the NN stopwords O
full JJ full_moon O
recovery NN recovery O
seen NN see O
with NN stopwords O
delayed NN delay O
plating NN plating O
in NN stopwords inch O
conditioned NNS condition O
medium NN medium O
( ( O
2.5 CD O
h NN hydrogen O
) ) O

Optimal CAPITAL NNP optimum O
detection NN detection O
of NN stopwords O
weak NN weak O
nJ NNS New_Jersey O
( ( O
1H- CD O
119Sn CD O
) ) O
couplings NNS yoke O
by NN stopwords by O
gradient-enhanced NN O
1D CD O
and DT stopwords O
2D CD second O
heteronuclear NN O
multiple-quantum NN O
correlation NNS correlation O
spectroscopy NN spectroscopy O

Twenty-four CAPITAL NNP twenty-four O
patients VB patient O
with NN stopwords O
cerebral NNS cerebral D
palsy VB paralysis D
and DT stopwords O
24 DIGITS CD twenty-four O
control NNS control O
subjects NN subject O
between NN stopwords between O
the NN stopwords O
ages DT age O
of NN stopwords O
4 DIGITS CD four O
and DT stopwords O
12 DIGITS CD twelve O
yr NN year O
were NN stopwords be O
enrolled NN enroll O
in NN stopwords inch O
this NN stopwords O
study NN survey O

SHARPs CAPITAL NNP sharp O
: : O
mammalian VB mammal O
enhancer-of-split- NN O
and DT stopwords O
hairy-related NN O
proteins NN protein O
coupled NNS match O
to NN stopwords O
neuronal JJ neural O
stimulation JJ stimulation O

Chromosome CAPITAL NNP chromosome O
22qII CD O
deletions NN omission O

Ribavirin CAPITAL NN ribavirin T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
IFN CAPITAL PRP T
alpha DT alpha T
exerts NN exert O
an DT stopwords Associate_in_Nursing O
additional DT extra O
anti-viral/immunmodulatory DT O
effect NN consequence O
which NN stopwords O
manifests VB manifest O
itself NN stopwords O
in NN stopwords inch O
phase NN phase O
2 DIGITS CD two O
of NN stopwords O
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D
viremia NN viremia D
decline NN decline O

In CAPITAL PRP inch O
the NN stopwords O
presence NN presence O
of NN stopwords O
antigen DT antigen O
, , O
these NN stopwords O
cells NNS cell O
undergo JJ undergo O
excitable NN excitable O
activation DT activation O
responses NN response O
which NN stopwords O
result NN consequence O
in NN stopwords inch O
increased NN increase O
metabolism NN metamorphosis O
and DT stopwords O
the NN stopwords O
exocytosis NN O
of NN stopwords O
stored NN store O
intracellular NN intracellular O
mediators NN mediator O

MEASUREMENTS CAPITAL NNP measurement O
: : O
Liver CAPITAL NNP liver O
tissue NN tissue O
was VB stopwords Washington O
analyzed DT analyze O
to NN stopwords O
determine NN determine O
the NN stopwords O
activities DT activity O
of NN stopwords O
two NN two O
urea JJ urea O
cycle NNS cycle O
enzymes NN enzyme O
and DT stopwords O
glutamine NN glutamine O
synthetase NN O

In CAPITAL PRP inch O
conclusion NNS decision O
, , O
in NN stopwords inch O
some NN stopwords some O
cases VB case O
of NN stopwords O
MDR CAPITAL NNP D
TB CAPITAL NN terbium D
, , O
the NN stopwords O
TP CAPITAL NNP T
( ( O
if NN stopwords O
there NN stopwords there O
are DT stopwords are O
no NNS stopwords no O
pleural NN pleural O
adherences DT attachment O
) ) O
may VB May O
lead NN lead O
to NN stopwords O
good NN good O
results NN consequence O

It CAPITAL PRP information_technology O
has VB stopwords hour_angle O
been NN stopwords be O
reported NN report O
previously NN previously O
that NN stopwords O
amino DT amino O
acids DT acid O
in NN stopwords inch O
the NN stopwords O
Murchison CAPITAL NNP O
meteorite NN meteorite O
exhibit NN exhibit O
an DT stopwords Associate_in_Nursing O
excess NN excess O
of NN stopwords O
L-enantiomers CAPITAL NNP O
, , O
raising VB elevation O
the NN stopwords O
possibility NN possibility O
that NN stopwords O
a DT stopwords angstrom O
similar NN similar O
excess NN excess O
was VB stopwords Washington O
present NN present O
in NN stopwords inch O
the NN stopwords O
initial JJ initial O
inventory NN inventory O
of NN stopwords O
organic JJ organic O
compounds NNS compound O
on NN stopwords on O
the NN stopwords O
Earth CAPITAL NN Earth O

Clinico-statistical CAPITAL NNP O
considerations NNS consideration O
on NN stopwords on O
vescicular NN D
mole NN gram_molecule D

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
describe NN describe O
the NN stopwords O
effect NN consequence O
of NN stopwords O
influenza NN influenza D
vaccination NN inoculation T
on NN stopwords on O
long-term NN long-run O
change NNS change O
in NN stopwords inch O
CD4 CAPITAL NNP cluster_of_differentiation_4 O
count NNS count O
and DT stopwords O
HIV CAPITAL NNP HIV O
RNA CAPITAL NNP ribonucleic_acid O
level NN degree O
, , O
and DT stopwords O
on NN stopwords on O
progression NN progression O
to NN stopwords O
AIDS CAPITAL DT AIDS O
or NN stopwords Oregon O
death NN death O

Treatment CAPITAL NNP treatment O
of NN stopwords O
spontaneous NN spontaneous D
carotid-cavernous VB D
fistula NN fistulous_withers D
in NN stopwords inch D
Ehlers-Danlos CAPITAL NN D
syndrome NN syndrome D
by NN stopwords by O
transvenous NN T
occlusion JJ occlusion T
with NN stopwords T
Guglielmi CAPITAL NNP T
detachable NN detachable T
coils JJ coil T

Continuous CAPITAL NNP continuous T
arteriovenous DT arteriovenous T
hemofiltration NN T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
anasarca DT anasarca D
and DT stopwords D
acute DT acute_accent D
renal NN nephritic D
failure VB failure D
in NN stopwords inch O
severely NN badly O
burned NN burn O
patients VB patient O

Polymorphisms CAPITAL NNP polymorphism O
in NN stopwords inch O
the NN stopwords O
coding NNS cryptography O
exons NN exon O
of NN stopwords O
the NN stopwords O
human NN homo O
luteinizing NN O
hormone NN hormone O
receptor NN receptor O
gene NN gene O

Low-fat CAPITAL NNP O
diets NN diet O

Large-scale CAPITAL VB large-scale O
trials NN test O
are DT stopwords are O
needed JJ necessitate O
to NN stopwords O
confirm NNS confirm O
these NN stopwords O
preliminary NN preliminary O
observations NN observation O

Auditory CAPITAL DT auditory D
perception NN percept D
disorders NN disorder D
due NN due O
to NN stopwords O
bilateral NN bilateral D
cortical NNS cortical D
lesions NN lesion D

Preoperative CAPITAL NNP preoperative O
thromboxane NN O
A2/prostaglandin CAPITAL DT O
H2 CAPITAL $ O
receptor NN receptor O
activity DT activity O
predicts NN predict O
early VB early O
graft NN graft D
thrombosis NN thrombosis D

Patients CAPITAL VB patient O
were NN stopwords be O
followed JJ follow O
up JJ stopwords up O
for NN stopwords O
a DT stopwords angstrom O
maximum VB maximum O
of NN stopwords O
33 DIGITS CD thirty-three O
months NN calendar_month O
( ( O
median NN median O
14 DIGITS CD fourteen O
months NN calendar_month O
) ) O

We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
antimicrobial/ DT T
antituberculous DT T
agents DT agent T
have VB stopwords rich_person O
only JJ stopwords lone O
a DT stopwords angstrom O
minor NN child O
short-term NN short-run O
effect NN consequence O
in NN stopwords inch O
long-lasting NN durable O
CGM CAPITAL NNP D
of NN stopwords O
undetermined JJ undetermined O
cause VB cause O

On CAPITAL NNP on O
the NN stopwords O
2 DIGITS CD two O
days VB days O
of NN stopwords O
testing NN testing O
, , O
the NN stopwords O
child JJ child O
received NN receive O
AEDs CAPITAL DT T
and DT stopwords O
a DT stopwords angstrom O
capsule VB capsule O
containing NNS incorporate O
either NN either O
placebo NN placebo O
or NN stopwords Oregon O
methylphenidate NN methylphenidate T

Effect CAPITAL NNP consequence O
of NN stopwords O
interferon NN interferon T
on NN stopwords on O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
. . O

Hematopoietic CAPITAL NNP hematopoietic T
stem-cell NN T
transplantation NN transplant T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
severe NN severe D
combined NNS unite D
immunodeficiency JJ immunodeficiency D

Further CAPITAL NNP foster O
studies NN survey O
of NN stopwords O
localized NN place O
Darier CAPITAL NNP D
disease NN disease D
may VB May O
therefore NN therefore O
prove NN prove O
to NN stopwords O
be NN stopwords beryllium O
instrumental NN instrumental O
in NN stopwords inch O
the NN stopwords O
search NN search O
for NN stopwords O
the NN stopwords O
Darier CAPITAL NNP D
disease NN disease D
gene NN gene O

Linear CAPITAL NNP linear O
regression NN arrested_development O
analysis DT analysis O
showed NN show O
that NN stopwords O
the NN stopwords O
lower NN lower_berth O
the NN stopwords O
qCT JJ O
at DT stopwords astatine O
the NN stopwords O
beginning NN beginning O
of NN stopwords O
the NN stopwords O
observation NN observation O
period NN time_period O
, , O
the NN stopwords O
higher NN higher O
was VB stopwords Washington O
the NN stopwords O
percentage NN percentage O
increase NN addition O
of NN stopwords O
spinal JJ spinal_anesthesia O
qCT JJ O
in NN stopwords inch O
the NN stopwords O
entire NN stallion O
group NN group O
during NN stopwords O
12 DIGITS CD twelve O
mo NN moment O
of NN stopwords O
dancing VB dancing O
( ( O
r NN roentgen O
= NN O
0.52 LS O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.0001 LS O
) ) O

Clinical CAPITAL NNP clinical O
physiopathology NN O
of NN stopwords O
the NN stopwords O
patency VB patency O
of NN stopwords O
Botallo CAPITAL NNP D
's POS D
ductus NN D
arteriosus DT D

Mutation CAPITAL NNP mutant O
frequencies JJ frequency O
detected NN detect O
following JJ following O
irradiation NN irradiation T
of NN stopwords O
virgin NN virgin O
and DT stopwords O
inseminated NN inseminate O
Drosophila CAPITAL NNP drosophila O
melanogaster NN O
females JJ female O

Antenatal CAPITAL DT prenatal T
indomethacin NN indomethacin T
-- : O
adverse DT adverse O
fetal JJ fetal O
effects NN effects O
confirmed NNS confirm O

Reanalysis CAPITAL NNP O
of NN stopwords O
the NN stopwords O
original IN master O
data VB data O
on NN stopwords on O
DSB CAPITAL NNP O
repair NN repair O
shows NN show O
that NN stopwords O
they NN stopwords O
are DT stopwords are O
consistent NNS consistent O
with NN stopwords O
two NN two O
first-order NN O
repair NN repair O
rates VB rates O
( ( O
18 DIGITS CD eighteen O
+/- NN O
7 DIGITS CD seven O
min NN minute O
and DT stopwords O
about DT stopwords about O
52 DIGITS CD fifty-two O
min NN minute O
) ) O

Update CAPITAL NNP update O
on NN stopwords on O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
research NN research O

k1 NN O
and DT stopwords O
Df1 CAPITAL NNP O
exhibit NN exhibit O
a DT stopwords angstrom O
linear NN linear O
increase NN addition O
with NN stopwords O
the NN stopwords O
reciprocal NN reciprocal O
of NN stopwords O
the NN stopwords O
IGF-1 CAPITAL PRP O
concentration NNS concentration O
in NN stopwords inch O
solution NN solution O

Interview CAPITAL PRP interview O
by NN stopwords by O
Grethe CAPITAL NNP O
Kjaergaard CAPITAL NNP O

The CAPITAL NNP O
carcinogenicity VB O
of NN stopwords O
dioxins NN dioxin O
is NN stopwords be O
well NN well O
documented NN document O
in NN stopwords inch O
animal DT animal O
models NN model O
and DT stopwords O
has VB stopwords hour_angle O
been NN stopwords be O
described NN describe O
in NN stopwords inch O
humans NN world O
after DT stopwords after O
professional NN professional O
and DT stopwords O
accidental DT accidental O
exposures NN exposure O

Research CAPITAL NNP research O
into NN stopwords O
sexual NN sexual O
orientation-simplistically IN O
referred NN mention O
to NN stopwords O
as DT stopwords arsenic O
`` `` O
gay VB homosexual O
gene NN gene O
'' POS O
research-is NN O
an DT stopwords Associate_in_Nursing O
example NN example O
of NN stopwords O
research NN research O
that NN stopwords O
provokes NN arouse O
intense NN intense O
controversy NNS controversy O

Epithelial CAPITAL NNP epithelial O
metaplasia NN D
of NN stopwords O
the NN stopwords O
endometrium NN endometrium O

The CAPITAL NNP O
possible NN possible O
role NN function O
of NN stopwords O
this NN stopwords O
protein NN protein O
and DT stopwords O
that NN stopwords O
of NN stopwords O
the NN stopwords O
calcareous VB calcareous O
corpuscles NNS atom O
in NN stopwords inch O
the NN stopwords O
protoscolex NN O
are DT stopwords are O
discussed NN discourse O

Several CAPITAL NNP several O
large-scale NN large-scale O
trials NN test O
have VB stopwords rich_person O
firmly NN firm O
established NN establish O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
thrombolytic NN thrombolytic T
therapy NN therapy T
, , O
beta NN beta T
blockers NN blocker T
, , O
and DT stopwords O
aspirin DT aspirin T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
AMI CAPITAL DT D

Intrathecal CAPITAL PRP T
sufentanil NN T
provides NN supply O
approximately DT approximately O
2 DIGITS CD two O
h NN hydrogen O
of NN stopwords O
excellent NN excellent O
labor NN labor D
analgesia DT analgesia O
with NN stopwords O
minimal NN minimal O
motor NN motor O
blockade NN blockade O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
a DT stopwords angstrom O
social NN sociable O
support NN support O
boosting NN hike O
intervention NN intervention O
on NN stopwords on O
stress NN stress O
, , O
coping NNS header O
, , O
and DT stopwords O
social NN sociable O
support NN support O
in NN stopwords inch O
caregivers VB health_professional O
of NN stopwords O
children JJ child O
with NN stopwords O
HIV/AIDS CAPITAL NNP D

This CAPITAL NNP O
value NN value O
is NN stopwords be O
nearly RB about O
identical NN identical O
to NN stopwords O
the NN stopwords O
value NN value O
of NN stopwords O
27 DIGITS CD twenty-seven O
+/- NN O
1 DIGITS CD one O
min NN minute O
determined NN determine O
from JJ stopwords O
the NN stopwords O
data VB data O
obtained NN obtain O
by NN stopwords by O
Cheong CAPITAL NNP O
et NN O
al DT aluminum O
. . O
using JJ exploitation O
pulsed-field NN O
gel NN gel O
electrophoresis NN electrophoresis O
( ( O
PFGE CAPITAL NNP O
) ) O
( ( O
Mutat CAPITAL NNP O

A CAPITAL DT angstrom O
radioautographic VB O
study NN survey O
with NN stopwords O
H3-thymidine CAPITAL $ O
on NN stopwords on O
adrenal DT adrenal_gland O
medulla NN myelin O
nuclei JJ nucleus O
of NN stopwords O
rats VB rat O
intermittently NN intermittently O
exposed NN expose O
to NN stopwords O
cold NNS cold O

The CAPITAL NNP O
academic DT academician O
medicine NN medicine O
-- : O
alternative DT option O
medicine NN medicine O
tension NN tension O
field NN field O

considering NNS see O
that NN stopwords O
hamsters VB hamster O
had VB stopwords have O
a DT stopwords angstrom O
lung NN lung O
metastasis NN metastasis O
rate VB rate O
of NN stopwords O
50 DIGITS CD fifty O
% NN O
before NN stopwords earlier O
mdp-lys NN O
treatment NN treatment O
, , O
liposomal NN T
mdp-lys NN T
given NN given O
at DT stopwords astatine O
a DT stopwords angstrom O
dose NN dose O
of NN stopwords O
20 DIGITS CD twenty O
microg NN O
twice/week NN O
was VB stopwords Washington O
effective NN effective O
for NN stopwords O
inhibiting NN suppress O
lung NN lung D
metastasis NN metastasis D
at DT stopwords astatine O
a DT stopwords angstrom O
far VB Army_for_the_Liberation_of_Rwanda O
lower NN lower_berth O
dose NN dose O
of NN stopwords O
mdp-lys NN O
than NN stopwords O
that NN stopwords O
given NN given O
as DT stopwords arsenic O
a DT stopwords angstrom O
solution NN solution O
( ( O
40 DIGITS CD forty O
microg NN O
vs. NN O
350 DIGITS CD O
microg NN O
per NN O
week NN week O
) ) O

conclusion NNS decision O
: : O
mr-guided NN T
rfa NN T
using JJ exploitation T
single NN single T
cooled NNS cool T
tip NN tip T
electrodes NN electrode T
is NN stopwords be O
safe VB safe O
and DT stopwords O
technically NN technically O
effective NN effective O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
hepatic NN liverwort D
neoplasms JJ tumor D
up JJ stopwords up O
to NN stopwords O
3 DIGITS CD three O
cm NNS centimeter O
in NN stopwords inch O
size NN size O
, , O
however NN however O
further NN stopwords foster O
improvements JJ improvement O
are DT stopwords are O
necessary JJ necessity O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Patients CAPITAL VB patient O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
early VB early O
thrombolytic NN thrombolytic O
treatment NN treatment O
had VB stopwords have O
a DT stopwords angstrom O
reduced NN reduce O
rate VB rate O
of NN stopwords O
recurrent NN perennial O
pulmonary NN pneumonic O
embolism NN embolism O
( ( O
7.7 CD O
versus NN O
18.7 CD O
% NN O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.001 . O
) ) O
but NN stopwords merely O
also DT besides O
a DT stopwords angstrom O
higher NN higher O
frequency JJ frequency O
of NN stopwords O
major VB major O
bleeding NN bleeding O
episodes NN episode O
( ( O
21.9 CD O
% NN O
versus NN O
7.8 CD O
% NN O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.001 . O
) ) O

M1/4llerian CAPITAL NNP O
agenesis DT agenesis O
: : O
an DT stopwords Associate_in_Nursing O
update JJ update O

CONCLUSIONS CAPITAL NNP decision O
: : O
Amoxicillin CAPITAL DT amoxicillin T
remains NN remains O
the NN stopwords O
antibiotic DT antibiotic O
of NN stopwords O
choice NNS choice O
for NN stopwords O
initial JJ initial O
empiric NN empiric O
treatment NN treatment O
of NN stopwords O
AOM CAPITAL DT D
, , O
although DT O
the NN stopwords O
traditional NN traditional O
dosage NN dose O
should NN stopwords O
be NN stopwords beryllium O
increased NN increase O
in NN stopwords inch O
patients VB patient O
at DT stopwords astatine O
risk NN hazard O
for NN stopwords O
drug-resistant NN O
S. CAPITAL NNP O
pneumoniae NN O

Joint CAPITAL NNP joint O
Commission CAPITAL NNP committee O
on NN stopwords on O
Accreditation CAPITAL DT accreditation O
of NN stopwords O
Healthcare CAPITAL NNP healthcare O
Organizations CAPITAL NNP organization O
' '' O
infection NN infection O
control NNS control O
requirements NN requirement O
: : O
fact VB fact O
or NN stopwords Oregon O
fiction NN fiction O
? . O

Low-molecular-weight CAPITAL NNP O
heparins NN heparin O

Clinical CAPITAL NNP clinical O
evaluation NN evaluation O
of NN stopwords O
adjuvant DT adjuvant T
chemoradiotherapy NNS T
with NN stopwords T
CDDP CAPITAL NNP T
, , T
5-FU CD T
, , T
and DT stopwords T
VP-16 CAPITAL NNP T
for NN stopwords O
advanced DT advance D
esophageal NN esophageal D
cancer VB cancer D

Only CAPITAL NNP lone O
the NN stopwords O
DSB CAPITAL NNP O
model NN model O
correctly NNS correctly O
predicted NN predict O
that NN stopwords O
PLD CAPITAL NNP O
( ( O
= NN O
DSBs CAPITAL NNP O
) ) O
would NN O
still JJ still O
be NN stopwords beryllium O
available DT available O
for NN stopwords O
repair NN repair O
after DT stopwords after O
that NN stopwords O
time NN time O

Joint CAPITAL NNP joint O
International CAPITAL PRP International O
Symposium CAPITAL NNP symposium O
of NN stopwords O
the NN stopwords O
Danish CAPITAL NNP Danish O
Cancer CAPITAL VB cancer O
Society CAPITAL NNP society O
, , O
European CAPITAL NNP European O
Cancer CAPITAL VB cancer O
Prevention CAPITAL NNP prevention O
Organization CAPITAL NNP organization O
and DT stopwords O
National CAPITAL NNP national O
Food CAPITAL NNP food O
Agency CAPITAL DT agency O
of NN stopwords O
Denmark CAPITAL NNP Denmark O

Simple CAPITAL NNP simple O
antiseptic DT antiseptic T
mouthwashes NN gargle T
are DT stopwords are O
best NN best O
for NN stopwords O
infection NN infection D

Haematoma CAPITAL NNP hematoma T
block NN block T
versus NN O
intravenous NN intravenous T
regional NN regional T
anaesthesia DT anesthesia T
in NN stopwords inch O
Colles CAPITAL NNP D
' '' D
fractures NN fracture D

SETTING CAPITAL NNP setting O
: : O
11 DIGITS CD eleven O
general NN general O
practices NN practice O
in NN stopwords inch O
England CAPITAL NNP England O

Academic CAPITAL DT academician O
medicine NN medicine O
-- : O
alternative DT option O
medicine NN medicine O
from JJ stopwords O
the NN stopwords O
viewpoint NN point_of_view O
of NN stopwords O
public NN populace O
health NN health O
public NN populace O
health NN health O
directors NN director O

Purposeful CAPITAL NNP purposeful O
`` `` O
heroic NN heroic_verse O
'' POS O
heart NN heart O
treatment NN treatment O

Researchers CAPITAL NNP research_worker O
make NN brand O
slow NN decelerate O
headway NN headroom O
in NN stopwords inch O
managing VB pull_off O
dry NN dry D
mouth NN mouth D

Evidence-based CAPITAL NNP O
medicine NN medicine O
and DT stopwords O
general NN general O
practice NN practice O

Interaction CAPITAL PRP interaction O
effects NN effects O
between NN stopwords between O
DR2 CAPITAL NNP O
and DT stopwords O
chromosome NN chromosome O
19q13.2 CD O
or NN stopwords Oregon O
MBP CAPITAL NNP O
in NN stopwords inch O
MS CAPITAL NNP multiple_sclerosis O
susceptibility NN susceptibility O
were NN stopwords be O
not JJ stopwords not O
apparent DT apparent O

Even CAPITAL NNP evening O
low NN low O
concentrations NNS concentration O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
that NN stopwords O
result NN consequence O
from JJ stopwords O
the NN stopwords O
dissolution NN dissolution O
of NN stopwords O
ambient DT ambient O
CO2 CAPITAL NNP carbon_dioxide O
can VB stopwords can O
have VB stopwords rich_person O
pronounced NN pronounce O
catalytic VB catalytic O
effects NN effects O

Randomized CAPITAL VB randomize O
prospective NN prospective O
studies NN survey O
have VB stopwords rich_person O
, , O
however NN however O
, , O
never JJ never O
been NN stopwords be O
able DT able O
to NN stopwords O
confirm NNS confirm O
these NN stopwords O
observations NN observation O

METHODS CAPITAL NNP method O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Toxicological CAPITAL NNP toxicological O
screening NN screening O
using JJ exploitation O
enzyme-linked NN O
immunoassay JJ immunoassay O
techniques NN technique O
, , O
with NN stopwords O
all DT stopwords all O
positive NN positive O
samples VB sample O
being NN stopwords being O
reanalysed NN O

SETTING CAPITAL NNP setting O
: : O
A CAPITAL DT angstrom O
collaborative NNS collaborative O
study NN survey O
between NN stopwords between O
the NN stopwords O
Rotunda CAPITAL NNP rotunda O
Hospital CAPITAL NNP hospital O
, , O
Dublin CAPITAL NNP Dublin O
and DT stopwords O
the NN stopwords O
Irish CAPITAL PRP Irish O
National CAPITAL NNP national O
Drug CAPITAL NNP drug O
Advisory CAPITAL DT advisory O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
Treatment CAPITAL NNP treatment O
Centre CAPITAL NNP Centre O

The CAPITAL NNP O
author DT writer O
presents NN present O
background VB background O
information NN information O
, , O
including NN include O
incidence NN incidence O
and DT stopwords O
etiology NN etiology O

Other CAPITAL NNP other O
claims NNS claim O
suggest NN propose O
that NN stopwords O
it NN stopwords information_technology O
causes VB cause O
fewer JJ fewer O
unwanted JJ unwanted O
effects NN effects O
than NN stopwords O
older JJ aged O
centrally-acting NNS O
antihypertensive DT antihypertensive T
drugs NN drug T
such NN stopwords such O
as DT stopwords arsenic O
clonidine NNS clonidine T
and DT stopwords O
methyldopa NN methyldopa T

Hypertrophic CAPITAL NNP O
obstructive NN clogging O
cardiomyopathy VB cardiomyopathy D

CONCLUSIONS CAPITAL NNP decision O
: : O
There CAPITAL NNP there O
is NN stopwords be O
a DT stopwords angstrom O
higher NN higher O
incidence NN incidence O
of NN stopwords O
preeclampsia NN preeclampsia D
in NN stopwords inch O
women NN woman O
conceiving NNS gestate O
by NN stopwords by O
intrauterine NN intrauterine T
insemination NN insemination T
with NN stopwords O
washed VB wash O
donor NN donor O
sperm NN sperm O
compared NNS compare O
with NN stopwords O
intrauterine NN intrauterine T
insemination NN insemination T
with NN stopwords O
washed VB wash O
partner NN spouse O
sperm NN sperm O
. . O

Genetic CAPITAL NNP familial O
study NN survey O
of NN stopwords O
the NN stopwords O
memorization NN memorization O
of NN stopwords O
words NN words O
and DT stopwords O
pictures NN picture O

A CAPITAL DT angstrom O
significant NN significant O
minority NN minority O
of NN stopwords O
departments NN department O
depend NN depend O
principally NN chiefly O
upon JJ O
venography NN venography O
in NN stopwords inch O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
DVT CAPITAL NNP D

Issues CAPITAL PRP issue O
regarding NN see O
antiretroviral DT T
treatment NN treatment T
for NN stopwords O
patients VB patient O
with NN stopwords O
HIV-1 CAPITAL NNP D
infection NN infection D

Management CAPITAL NNP management O
of NN stopwords O
life-threatening NN dangerous O
acid-base DT D
disorders NN disorder D

Another CAPITAL DT another O
potential NN potential O
use JJ use O
of NN stopwords O
troglitazone NN T
in NN stopwords inch O
noninsulin-dependent JJ D
diabetes NN diabetes D
mellitus NN D

Congenital CAPITAL NNP congenital D
heart NN heart D
disease NN disease D
, , O
deaf-mutism NN deaf-mutism D
and DT stopwords O
associated DT associate D
somatic NN bodily D
malformations VB deformity D
occurring JJ happen O
in NN stopwords inch O
several NN several O
members NN member O
of NN stopwords O
one JJ one O
family VB family O

Treatment CAPITAL NNP treatment O
of NN stopwords O
men NN work_force O
with NN stopwords O
paraphilia NN paraphilia D
with NN stopwords O
a DT stopwords angstrom O
long-acting NN long-acting O
analogue DT analogue T
of NN stopwords T
gonadotropin-releasing NN T
hormone NN hormone T

The CAPITAL NNP O
authors DT writer O
describe NN describe O
the NN stopwords O
case VB case O
of NN stopwords O
a DT stopwords angstrom O
child JJ child O
with NN stopwords O
status NN status D
epilepticus NN D
in NN stopwords inch O
whom NN stopwords O
phenytoin NN diphenylhydantoin T
was VB stopwords Washington O
administered DT administer O
via NN O
the NN stopwords O
intraosseous NN O
route NN path O
, , O
and DT stopwords O
seizure JJ seizure O
resolution NN resolution O
and DT stopwords O
therapeutic NN remedy O
serum NN serum O
levels NN degree O
were NN stopwords be O
achieved DT achieve O

A CAPITAL DT angstrom O
piece NN piece O
of NN stopwords O
my NN stopwords O
mind NN mind O

The CAPITAL NNP O
temporal NN temporal_role O
properties NN property O
of NN stopwords O
semantic NN semantic O
and DT stopwords O
phonological NN phonological O
processes NN procedure O
in NN stopwords inch O
speech NN address O
production NN production O
were NN stopwords be O
investigated NN investigate O
in NN stopwords inch O
a DT stopwords angstrom O
new JJ new O
experimental NN experimental O
paradigm NN paradigm O
using JJ exploitation O
movement-related NN O
brain NN brain O
potentials NN potential O

Magnesium CAPITAL NNP magnesium T
sulphate NN sulfate T
for NN stopwords O
the NN stopwords O
control NNS control O
of NN stopwords O
spasms NN spasm D
in NN stopwords inch D
severe NN severe D
tetanus NN tetanus D

Budapest CAPITAL NNP Budapest O
, , O
Hungary CAPITAL NNP Hungary O
, , O
August CAPITAL DT August O
24-27 CD O
, , O
1997 DIGITS CD O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
heliox NN T
in NN stopwords inch O
acute DT acute_accent D
severe NN severe D
asthma DT asthma D
: : O
a DT stopwords angstrom O
randomized VB randomize O
controlled NNS control O
trial NN test O
. . O

Follow CAPITAL NNP follow O
up JJ stopwords up O
after DT stopwords after O
potential NN potential O
curative NNS remedy O
surgery NN surgery T
of NN stopwords O
colorectal NNS colorectal D
cancer VB cancer D

These CAPITAL NNP O
findings NN findings O
suggest NN propose O
growth NN growth O
factor VB factor O
deprivation NN privation O
and DT stopwords O
treatment NN treatment O
with NN stopwords O
TNF-alpha CAPITAL NNP O
or NN stopwords Oregon O
ceramide NNS O
trigger NN gun_trigger O
different NN different O
initial JJ initial O
events NN event O
both NN stopwords both O
of NN stopwords O
which NN stopwords O
can VB stopwords can O
lead NN lead O
to NN stopwords O
apoptosis DT apoptosis O
in NN stopwords inch O
factor-dependent VB O
hematopoietic NN hematopoietic O
cells NNS cell O

Report CAPITAL NNP report O
from JJ stopwords O
the NN stopwords O
collaborative NNS collaborative O
study NN survey O
of NN stopwords O
cerebral NNS cerebral O
palsy VB paralysis O

Minimal CAPITAL NNP minimal O
or NN stopwords Oregon O
no NNS stopwords no O
cutaneous NNS cutaneous O
signs NN sign O
were NN stopwords be O
present NN present O

Morphology CAPITAL NNP morphology O
and DT stopwords O
molecular NN molecular O
biology NN biology O
of NN stopwords O
malignant VB malignant O
soft NN soft D
tissue NN tissue D
sarcomas VB sarcoma D

background VB background O
: : O
we NN stopwords O
examined NN analyze O
the NN stopwords O
complications NNS complication O
and DT stopwords O
outcomes JJ result O
of NN stopwords O
placing NN put O
stents NN stent T
for NN stopwords O
both NN stopwords both O
esophageal NN esophageal D
and DT stopwords D
tracheobronchial NN D
stenoses NN stenosis D

Chemotherapy CAPITAL NNP chemotherapy T
may VB May O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
alternative DT option O
to NN stopwords O
radiotherapy VB radiotherapy O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
metastatic NN metastatic D
dysgerminoma NN D
and DT stopwords O
should NN stopwords O
also DT besides O
be NN stopwords beryllium O
considered NNS see O
for NN stopwords O
selected NN choose O
patients VB patient O
with NN stopwords O
Stage CAPITAL NNP phase O
I CAPITAL PRP iodine O
disease NN disease O

Subcutaneous CAPITAL NNP hypodermic O
autologous DT autologous O
ovarian NN ovarian O
transplantation NN transplant O
in NN stopwords inch O
Wistar CAPITAL NNP O
rats VB rat O
maintains VB keep O
hormone NN hormone O
secretion NN secretion O

conclusions NNS decision O
: : O
the NN stopwords O
maximum VB maximum O
tolerated NN digest O
dose NN dose O
of NN stopwords O
this NN stopwords O
combination NNS combination O
for NN stopwords O
patients VB patient O
with NN stopwords O
resistant NN immune D
sclc JJ D
is NN stopwords be O
ifosfamide NN T
2000 DIGITS CD O
mg/m2 NN O
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
paclitaxel VB T
175 DIGITS CD one_hundred_seventy-five O
mg/m2 NN O
and DT stopwords O
carboplatin VB T
auc DT United_Self-Defense_Force_of_Colombia O
6 DIGITS CD six O
mg/ml NN O
min NN minute O
administered DT administer O
on NN stopwords on O
the NN stopwords O
first NN first O
day VB day O
of NN stopwords O
a DT stopwords angstrom O
21-day CD O
cycle NNS cycle O

We CAPITAL NNP O
recommend NN recommend O
this NN stopwords O
procedure NN procedure O
instead NN alternatively O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
excisional NN T
arthroplasty DT arthroplasty T
to NN stopwords O
maintain VB keep O
high NN high O
level NN degree O
of NN stopwords O
function JJ function O
and DT stopwords O
overall JJ overall O
patient VB patient O
satisfaction VB satisfaction O

Lyme CAPITAL NNP D
disease NN disease D
presenting NN show O
as DT stopwords arsenic O
Tourette CAPITAL NNP Tourette D
's POS D
syndrome NN syndrome D

3 DIGITS CD three O

Omphalocele-Exstrophy-Imperforate CAPITAL NNP D
anus-Spinal DT D
defects NN defect D
( ( D
OEIS CAPITAL NNP D
complex NNS complex D
) ) D
, , O
a DT stopwords angstrom O
combination NNS combination O
of NN stopwords O
omphalocele JJ umbilical_hernia D
, , O
exstrophy NN D
of NN stopwords D
the NN stopwords D
bladder NN bladder D
, , O
an DT stopwords Associate_in_Nursing O
imperforate JJ imperforate O
anus DT anus O
and DT stopwords O
spinal JJ spinal_anesthesia D
defects NN defect D
, , O
arises DT originate O
from JJ stopwords O
a DT stopwords angstrom O
single NN single O
localized NN place O
defect NN defect O
in NN stopwords inch O
the NN stopwords O
early VB early O
development NN development O
of NN stopwords O
the NN stopwords O
mesoderm NN mesoderm O
that NN stopwords O
will NN stopwords volition O
later NN later O
contribute NNS lend O
to NN stopwords O
infraumbilical NN O
mesenchyme NN mesenchyme O
, , O
cloacal NNS O
septum NN septum O
, , O
and DT stopwords O
caudal VB caudal O
vertebrae NN vertebra O

SGA CAPITAL NNP O
infants NN baby O
may VB May O
be NN stopwords beryllium O
programmed NN program O
for NN stopwords O
a DT stopwords angstrom O
number JJ number O
of NN stopwords O
adverse DT adverse O
outcomes JJ result O
; : O
the NN stopwords O
possibility NN possibility O
that NN stopwords O
such NN stopwords such O
events NN event O
are DT stopwords are O
altered DT change O
by NN stopwords by O
choice NNS choice O
of NN stopwords O
postnatal NN postnatal O
diet NN diet O
is NN stopwords be O
a DT stopwords angstrom O
key NN key O
issue NN issue O
for NN stopwords O
future JJ future O
research NN research O

The CAPITAL NNP O
Overactive CAPITAL NNP hyperactive T
Bladder CAPITAL NNP bladder T
: : O
From CAPITAL NNP O
Basic CAPITAL IN BASIC O
Science CAPITAL NNP science O
to NN stopwords O
Clinical CAPITAL NNP clinical O
Management CAPITAL NNP management O
Consensus CAPITAL NNP consensus O
Conference CAPITAL NNP conference O

We CAPITAL NNP O
would NN O
like NN like O
to NN stopwords O
emphasize NN stress O
that NN stopwords O
an DT stopwords Associate_in_Nursing O
accurate DT accurate O
prenatal NN prenatal O
diagnosis NN diagnosis O
of NN stopwords O
OEIS CAPITAL NNP D
complex NNS complex D
and DT stopwords O
associated DT associate O
malformations VB deformity O
is NN stopwords be O
important JJ important O
for NN stopwords O
the NN stopwords O
detailed NN detail O
counseling NNS guidance O
of NN stopwords O
the NN stopwords O
family VB family O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
appropriate DT allow O
perinatal NN perinatal O
management VB management O
by NN stopwords by O
the NN stopwords O
obstetricians NN obstetrician O
, , O
pediatric NN pediatric O
surgeons NN surgeon O
, , O
urologists JJ urologist O
, , O
neurosurgeons JJ neurosurgeon O
, , O
and DT stopwords O
neonatologists JJ O

Neutralization CAPITAL NNP neutralization O
of NN stopwords O
hepatitis NN hepatitis D
A CAPITAL DT angstrom D
virus NN virus D
( ( D
HAV CAPITAL NNP D
) ) D
by NN stopwords by O
an DT stopwords Associate_in_Nursing O
immunoadhesin JJ T
containing NNS incorporate T
the NN stopwords T
cysteine-rich NNS T
region NN region T
of NN stopwords T
HAV CAPITAL NNP T
cellular NNS cellular T
receptor-1 NN T

Impact CAPITAL PRP impact O
of NN stopwords O
postmenopausal NN postmenopausal O
hormone NN hormone T
therapy NN therapy T
on NN stopwords on O
cardiovascular VB cardiovascular O
events NN event O
and DT stopwords O
cancer VB cancer D
. . O

, , O
hemidesmosomes NN O
, , O
and DT stopwords O
an DT stopwords Associate_in_Nursing O
adepidermal DT O
globular NN ball-shaped O
layer NN layer O
in NN stopwords inch O
developing NN development O
newt JJ newt O
epidermis NN epidermis O

The CAPITAL NNP O
AF-4 CAPITAL DT O
gene NN gene O
on NN stopwords on O
human NN homo O
chromosome NN chromosome O
4q21 CD O
is NN stopwords be O
involved NN involve O
in NN stopwords inch O
reciprocal NN reciprocal O
translocations NN translocation O
to NN stopwords O
the NN stopwords O
ALL-1 CAPITAL DT O
gene NN gene O
on NN stopwords on O
chromosome NN chromosome O
11q23 CD O
, , O
which NN stopwords O
are DT stopwords are O
associated DT associate O
with NN stopwords O
acute DT acute_accent D
lymphoblastic NN D
leukaemias NN leukemia D

Current CAPITAL NNP current O
and DT stopwords O
future JJ future O
uses JJ use O
of NN stopwords O
recombinant NN recombinant T
interferon NN interferon T
alpha DT alpha T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
low-grade NN low-grade D
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D

patients VB patient O
: : O
patients VB patient O
with NN stopwords O
a DT stopwords angstrom O
single NN single O
( ( O
n NN nitrogen O
= NN O
2 DIGITS CD two O
, , O
764 DIGITS CD O
) ) O
and DT stopwords O
synchronous NN synchronous O
nsclc JJ D
( ( O
n NN nitrogen O
= NN O
85 DIGITS CD eighty-five O
) ) O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
pulmonary NN pneumonic T
resection NN resection T

Small CAPITAL NNP small O
amounts DT sum O
of NN stopwords O
two NN two O
anionic DT anionic_detergent O
dyes NN dye O
( ( O
Lucifer CAPITAL NNP Satan O
Yellow CAPITAL NNP yellow O
CH CAPITAL NNP O
and DT stopwords O
Lucifer CAPITAL NNP Satan O
Yellow CAPITAL NNP yellow O
dextran NN O
) ) O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
of NN stopwords O
two NN two O
cationic VB cationic O
dyes NN dye O
( ( O
rhodamine NN O
6G CD O
and DT stopwords O
tetramethylrhodamine NN O
dextran-lysine NN O
) ) O
were NN stopwords be O
iontophoretically NN O
microinjected NN O
either NN either O
into NN stopwords O
a DT stopwords angstrom O
nurse RB nurse O
cell NNS cell O
or NN stopwords Oregon O
into NN stopwords O
the NN stopwords O
oocyte JJ oocyte O
of NN stopwords O
stage-10 NN O
follicles JJ follicle O

Cyclin CAPITAL NNP O
D1 CAPITAL NNP O
overexpression JJ O
in NN stopwords inch O
malignant VB malignant D
lymphomas NN lymphoma D

Res CAPITAL NNP reticuloendothelial_system O

RESULTS CAPITAL NNP consequence O
: : O
Assurances CAPITAL DT assurance O
of NN stopwords O
confidentiality NNS confidentiality O
increased NN increase O
the NN stopwords O
number JJ number O
of NN stopwords O
adolescents DT adolescent O
willing NN volition O
to NN stopwords O
disclose NN unwrap O
sensitive NN medium O
information NN information O
about DT stopwords about O
sexuality NN sex O
, , O
substance NN substance O
use JJ use O
, , O
and DT stopwords O
mental NN mental O
health NN health O
from JJ stopwords O
39 DIGITS CD thirty-nine O
% NN O
( ( O
68/175 CD O
) ) O
to NN stopwords O
46.5 CD O
% NN O
( ( O
178/383 CD O
) ) O
( ( O
beta=.10 NN O
, , O
P=.02 CAPITAL NNP O
) ) O
and DT stopwords O
increased NN increase O
the NN stopwords O
number JJ number O
willing NN volition O
to NN stopwords O
seek NN seek O
future JJ future O
health NN health O
care VB care O
from JJ stopwords O
53 DIGITS CD fifty-three O
% NN O
( ( O
93/175 CD O
) ) O
to NN stopwords O
67 DIGITS CD sixty-seven O
% NN O
( ( O
259/386 CD O
) ) O
( ( O
beta=.17 NN O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.001 . O
) ) O

A CAPITAL DT angstrom O
bolus NN bolus O
infusion NN infusion O
of NN stopwords O
tissue NN tissue T
plasminogen NN plasminogen T
activator DT activator T
was VB stopwords Washington O
administered DT administer O
during NN stopwords O
CPR CAPITAL NNP cardiopulmonary_resuscitation T
in NN stopwords inch O
refractory NN furnace_lining D
ventricular NN ventricular D
fibrillation NN fibrillation D
( ( O
two NN two O
cases VB case O
) ) O
and DT stopwords O
pulseless NN breathless D
ventricular NN ventricular D
tachycardia VB tachycardia D
( ( O
one JJ one O
case VB case O
) ) O

Randomized CAPITAL VB randomize O
trial NN test O
of NN stopwords O
intensive NN intensifier T
cyclophosphamide NNS T
, , T
epirubicin NN T
, , T
and DT stopwords T
fluorouracil JJ fluorouracil T
chemotherapy NNS chemotherapy T
compared NNS compare O
with NN stopwords O
cyclophosphamide NNS T
, , T
methotrexate NN methotrexate T
, , T
and DT stopwords T
fluorouracil JJ fluorouracil T
in NN stopwords inch O
premenopausal NN premenopausal O
women NN woman O
with NN stopwords O
node-positive JJ D
breast NN breast D
cancer VB cancer D

Diagnosis CAPITAL NNP diagnosis O

Micronutrients CAPITAL NNP micronutrient T
and DT stopwords O
human NN homo O
cancer VB cancer D
risks NN hazard D
-- : O
prospects NN prospect O
for NN stopwords O
prevention NN prevention O

Implications CAPITAL PRP deduction O
for NN stopwords O
research NN research O
and DT stopwords O
policy NN policy O

Observations CAPITAL NNP observation O
on NN stopwords on O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
following JJ following O
of NN stopwords O
visual NN ocular O
and DT stopwords O
auditory DT auditory O
stimuli JJ stimulation O
in NN stopwords inch O
naive IN naive O
mallard VB mallard O
ducklings NN duckling O
( ( O
Anas CAPITAL DT Anas O
platyrhynchos NN O
) ) O

Determination CAPITAL NNP determination O
of NN stopwords O
silicone NN silicone O
oil NN oil O
in NN stopwords inch O
disposable NN disposable O
plastic NN plastic O
syringes NN panpipe O

An CAPITAL DT Associate_in_Nursing O
overview JJ overview O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

The CAPITAL NNP O
daily IN daily O
high NN high O
ambient DT ambient O
temperature NN temperature O
in NN stopwords inch O
our NN stopwords O
urban JJ urban O
area DT area O
was VB stopwords Washington O
subsequently NN subsequently O
obtained NN obtain O

Gorlin CAPITAL NNP D
syndrome NN syndrome D
: : O
identification NN designation O
of NN stopwords O
4 DIGITS CD four O
novel JJ novel O
germ-line NN O
mutations NN mutant O
of NN stopwords O
the NN stopwords O
human NN homo O
patched VB patch O
( ( O
PTCH CAPITAL NNP O
) ) O
gene NN gene O

This CAPITAL NNP O
study NN survey O
is NN stopwords be O
designed NN plan O
to NN stopwords O
investigate NN investigate O
the NN stopwords O
immediate JJ immediate O
effectiveness NN effectiveness O
of NN stopwords O
electrotherapy NN electrotherapy T
on NN stopwords on O
myofascial NN D
trigger NN gun_trigger D
points NN point D
of NN stopwords D
upper JJ upper_berth D
trapezius NN trapezius D
muscle NN muscle D

A CAPITAL DT angstrom O
dose-response NN O
was VB stopwords Washington O
demonstrated NN show O
for NN stopwords O
both NN stopwords both O
opioids IN O

Intolerance CAPITAL PRP intolerance O
to NN stopwords O
milk NN milk O
in NN stopwords inch O
ulcerative JJ ulcerative D
colitis NNS colitis D

1981 DIGITS CD O

as DT stopwords arsenic O
a DT stopwords angstrom O
best-case NN O
scenario JJ scenario O
, , O
postoperative NN postoperative T
irradiation NN irradiation T
may VB May O
improve JJ better O
the NN stopwords O
chance NNS opportunity O
for NN stopwords O
long-term NN long-run O
survival NN survival O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
n2 RB D
tumors NN tumor D

Doses CAPITAL NNP dose O
of NN stopwords O
fenfluramines JJ O
that NN stopwords O
produce NN produce O
signs NN sign O
of NN stopwords O
brain NN brain O
serotonin NN serotonin O
neurotoxicity JJ O
in NN stopwords inch O
animals DT animal O
are DT stopwords are O
on NN stopwords on O
the NN stopwords O
same VB stopwords Lapp O
order JJ order O
as DT stopwords arsenic O
those NN stopwords O
used JJ use O
to NN stopwords O
treat NN dainty O
humans NN world O
for NN stopwords O
weight NN weight O
loss NN loss O
when NN stopwords O
one JJ one O
takes VB return O
into NN stopwords O
account DT history O
known NN know O
relations NN relations O
between NN stopwords between O
body NN body O
mass VB mass O
and DT stopwords O
drug NN drug O
clearance NNS clearance O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Intrapleural CAPITAL PRP T
injection NN injection T
of NN stopwords T
irradiated NN enlighten T
LLC-IL2 CAPITAL NNP T
cured NNS bring_around O
pre-existing NN preexistent D
lung NN lung D
LLC CAPITAL NNP D
tumors NN tumor D
and DT stopwords O
extended NN widen O
the NN stopwords O
survival NN survival O
of NN stopwords O
the NN stopwords O
mice NN mouse O
but NN stopwords merely O
did NN stopwords make O
not JJ stopwords not O
affect DT affect O
survival NN survival O
of NN stopwords O
mice NN mouse O
with NN stopwords O
pre-existing NN preexistent O
peritoneal NN peritoneal D
tumors NN tumor D
nor RB stopwords O
did NN stopwords make O
it NN stopwords information_technology O
affect DT affect O
the NN stopwords O
growth NN growth O
of NN stopwords O
s.c. NN D
tumors NN tumor D

Surgical CAPITAL NNP surgical T
management VB management T
of NN stopwords O
syringomyelia NN D
associated DT associate D
with NN stopwords D
spinal JJ spinal_anesthesia D
adhesive DT adhesive_material D
arachnoiditis DT D

The CAPITAL NNP O
sterilization NN sterilization O
and DT stopwords O
contaminated NNS pollute O
waste VB waste O
disposal NN disposal O
practices NN practice O
in NN stopwords inch O
all DT stopwords all O
14 DIGITS CD fourteen O
dental NN alveolar_consonant O
clinics JJ clinic O
operated JJ operate O
by NN stopwords by O
the NN stopwords O
Southern CAPITAL NNP southern O
Sydney CAPITAL NNP Sydney O
Area CAPITAL DT area O
Health CAPITAL NNP health O
Service CAPITAL NNP service O
were NN stopwords be O
surveyed NN survey O

Neither CAPITAL NNP neither O
serum NN serum O
FSH CAPITAL NNP follicle-stimulating_hormone O
values NN values O
nor RB stopwords O
testicular NN testicular O
size NN size O
were NN stopwords be O
predictive NN predictive O
of NN stopwords O
the NN stopwords O
chances NNS opportunity O
to NN stopwords O
find NN discovery O
spermatozoa NN sperm O
for NN stopwords O
ICSI CAPITAL PRP O

Recent CAPITAL NNP Holocene O
intervention NN intervention O
studies NN survey O
have VB stopwords rich_person O
demonstrated NN show O
the NN stopwords O
necessity JJ necessity O
to NN stopwords O
treat NN dainty O
vigorously NN vigorously O
dysipidemias NN D

We CAPITAL NNP O
observed NN detect O
the NN stopwords O
effects NN effects O
of NN stopwords O
cisapride NN T
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
idiopathic JJ idiopathic D
constipation NNS constipation D
in NN stopwords inch O
children JJ child O

Y CAPITAL NN yttrium O

Electroencephalography CAPITAL NNP O
, , O
AED CAPITAL DT O
determinations NN determination O
, , O
and DT stopwords O
the NN stopwords O
continuous-performance NNS O
task VB undertaking O
( ( O
CPT CAPITAL NNP O
) ) O
test NN trial O
were NN stopwords be O
done NN make O
at DT stopwords astatine O
baseline VB baseline O
and DT stopwords O
after DT stopwords after O
2 DIGITS CD two O
months NN calendar_month O
of NN stopwords O
methylphenidate NN methylphenidate O
therapy NN therapy O

New CAPITAL NNP new O
names RB name_calling O

Online CAPITAL NNP on-line O

< NN O
TO_SEE CAPITAL NNP O
> NN O
mediastinoscopy NN O
facilitates VB facilitate O
identification NN designation O
of NN stopwords O
patients VB patient O
with NN stopwords O
regionally NN regionally D
advanced DT advance D
disease NN disease D
prior NN prior D
to NN stopwords D
resection NN resection D
, , O
allowing DT let O
neoadjuvant JJ T
therapy NN therapy T
and DT stopwords O
avoiding DT avoid O
unnecessary JJ unnecessary O
resections NN resection O

No CAPITAL NNP no O
major VB major O
drug-related NN O
adverse DT adverse O
effects NN effects O
were NN stopwords be O
observed NN detect O

In CAPITAL PRP inch O
addition DT addition O
, , O
well-conducted NN well-conducted O
studies NN survey O
using JJ exploitation O
verapamil NN verapamil T
and DT stopwords O
diltiazem NN diltiazem T
have VB stopwords rich_person O
suggested NN propose O
that NN stopwords O
these NN stopwords O
calcium VB calcium T
antagonists DT adversary T
may VB May O
even NN evening O
improve JJ better O
cardiovascular VB cardiovascular D
mortality NN mortality D
and DT stopwords D
morbidity NN morbidity D
of NN stopwords O
the NN stopwords O
hypertensive NN hypertensive O
patient VB patient O

The CAPITAL NNP O
telomerase NN telomerase O
prevents NN prevent O
the NN stopwords O
shortening NN shortening O
of NN stopwords O
telomeres NN telomere O
in NN stopwords inch O
neoplastic JJ neoplastic O
cells NNS cell O
and DT stopwords O
therefore NN therefore O
renders NN render O
them NN stopwords O
immortal JJ immortal O

VIII CAPITAL NNP eight O

Mass CAPITAL NNP mass O
spectrometry NN spectroscopy O
in NN stopwords inch O
structural NN structural O
and DT stopwords O
stereochemical NN O
problems NN problem O

The CAPITAL NNP O
ethics NN ethical_motive O
industry NN industry O

conclusion NNS decision O
: : O
pc NN personal_computer T
is NN stopwords be O
equally NN equally O
efficacious NN efficacious O
as DT stopwords arsenic O
vc NN T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
advanced DT advance D
non JJ not D
-- : D
small-cell JJ D
lung NN lung D
cancer VB cancer D

CONCLUSIONS CAPITAL NNP decision O
: : O
Neonatal CAPITAL NNP neonatal O
BAEP CAPITAL IN O
threshold NN threshold O
recordings NN recording O
were NN stopwords be O
of NN stopwords O
limited NN express O
value NN value O
for NN stopwords O
predicting NN predict O
subsequent NN subsequent O
hearing NN hearing D
loss NN loss D
common NNS park O
in NN stopwords inch O
ECMO CAPITAL NNP T
-treated : O
survivors NN survivor O

Flutamide CAPITAL NNP T
plus NN asset T
castration VB castration T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
previously NN previously O
untreated JJ untreated O
prostate NN prostate_gland D
cancer VB cancer D

All CAPITAL DT all O
of NN stopwords O
the NN stopwords O
clinics JJ clinic O
used JJ use O
autoclaves DT autoclave O
for NN stopwords O
sterilization NN sterilization O

Consequently CAPITAL NNP consequently O
, , O
parenteral NN parenteral T
nutrition JJ nutrition T
( ( T
PN CAPITAL NNP T
) ) T
solutions NN solution T
used JJ use O
to NN stopwords O
treat NN dainty O
malnourished VB undernourish O
patients VB patient O
with NN stopwords O
chronic NN chronic D
renal NN nephritic D
failure VB failure D
usually JJ normally O
are DT stopwords are O
prepared NN fix O
with NN stopwords O
little NN little O
supplementation NN supplement O
of NN stopwords O
these NN stopwords O
cations VB cation O

However CAPITAL NNP however O
, , O
knowledge NN cognition O
regarding NN see O
all DT stopwords all O
possible NN possible O
mutations NN mutant O
and DT stopwords O
the NN stopwords O
relationship NN relationship O
between NN stopwords between O
risk NN hazard O
factors VB factor O
and DT stopwords O
mutations NN mutant O
is NN stopwords be O
incomplete NN incomplete O

tc-tf NN O
chest NNS thorax O
scintigraphy JJ O
correlated NNS correlate O
well NN well O
with NN stopwords O
pgp NN O
or NN stopwords Oregon O
mrp1 NN O
expression NN expression O
and DT stopwords O
accurately DT accurately O
predicted NN predict O
the NN stopwords O
response NN response O
to NN stopwords O
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
sclc JJ D

Social CAPITAL NNP sociable O
class NNS class O
and DT stopwords O
premarital NN prenuptial O
sexual NN sexual O
permissiveness NN permissiveness O
: : O
a DT stopwords angstrom O
re-examination NN O

Persons CAPITAL NNP person O
successful NN successful O
at DT stopwords astatine O
long-term NN long-run O
weight NN weight O
loss NN loss O
and DT stopwords O
maintenance VB care O
continue NNS continue O
to NN stopwords O
consume NNS devour O
a DT stopwords angstrom O
low-energy NN O
, , O
low-fat NN O
diet NN diet O

Fruit CAPITAL NNP fruit O
juice NN juice O
consumption NNS consumption O

Clinical CAPITAL NNP clinical O
factors VB factor O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
higher NN higher O
death NN death O
rate VB rate O
were NN stopwords be O
syncope NN faint D
( ( O
P=.012 CAPITAL NNP O
) ) O
, , O
arterial DT arterial D
hypotension NN hypotension D
( ( O
P=.021 CAPITAL NNP O
) ) O
, , O
history NN history O
of NN stopwords O
congestive NNS congestive D
heart NN heart D
failure VB failure D
( ( O
P=.013 CAPITAL NNP O
) ) O
, , O
and DT stopwords O
chronic NN chronic D
pulmonary NN pneumonic D
disease NN disease D
( ( O
P=.032 CAPITAL NNP O
) ) O

More CAPITAL NNP More O
than NN stopwords O
1600 DIGITS CD O
patients VB patient O
with NN stopwords O
neoplastic JJ neoplastic D
disorders NN disorder D
have VB stopwords rich_person O
received NN receive O
recombinant NN recombinant T
human NN homo T
interferon NN interferon T
alfa-2a DT T
( ( T
Roferon-A CAPITAL NNP T
, , T
Hoffmann-La CAPITAL NNP T
Roche CAPITAL NNP T
, , T
Nutley CAPITAL NNP T
, , T
NJ CAPITAL NNP New_Jersey T
) ) T
as DT stopwords arsenic O
part NN part O
of NN stopwords O
ongoing JJ ongoing O
or NN stopwords Oregon O
completed NNS complete O
clinical JJ clinical O
trials NN test O

II CAPITAL PRP two O

Steroids CAPITAL NNP steroid T
in NN stopwords inch O
lateral NN lateral_pass D
epicondylitis NN epicondylitis D

Lung CAPITAL NNP lung T
volume NN volume T
reduction NN decrease T
surgery NN surgery T
for NN stopwords O
emphysema NN emphysema D

These CAPITAL NNP O
findings NN findings O
support NN support O
the NN stopwords O
current NNS current O
recommendations NN recommendation O
to NN stopwords O
screen NN screen O
men NN work_force O
with NN stopwords O
a DT stopwords angstrom O
positive NN positive O
family VB family O
history NN history O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
beginning NN beginning O
at DT stopwords astatine O
age DT age O
40 DIGITS CD forty O
years NN old_age O

When CAPITAL NNP O
the NN stopwords O
concentration NNS concentration O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
is NN stopwords be O
lower NN lower_berth O
than NN stopwords O
that NN stopwords O
of NN stopwords O
peroxynitrite NN O
, , O
the NN stopwords O
reformation NN reformation O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
amplifies DT magnify O
the NN stopwords O
fraction NN fraction O
of NN stopwords O
peroxynitrite NN O
that NN stopwords O
reacts NN react O
with NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O

Prolonged CAPITAL NNP prolong T
cortisone NNS cortisone T
therapy NN therapy T
in NN stopwords inch O
treatment NN treatment O
of NN stopwords O
allergic DT allergic D
diseases NN disease D

We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
to NN stopwords O
reduce NN reduce O
the NN stopwords O
rate VB rate O
of NN stopwords O
macrosomic VB D
infants NN baby D
in NN stopwords inch D
gestational NN gestational D
diabetes NN diabetes D
cases VB case D
, , O
good NN good T
glycemic NN T
control NNS control T
should NN stopwords O
be NN stopwords beryllium O
initiated JJ originate O
before NN stopwords earlier O
34 DIGITS CD thirty-four O
completed NNS complete O
gestational NN gestational O
weeks NN week O

Producing CAPITAL NNP produce O
consistent NNS consistent O
estimates NN estimate O
of NN stopwords O
the NN stopwords O
power NN power O
spectral NN spectral O
density NN density O
of NN stopwords O
NN CAPITAL NNP O
sequences NN sequence O

For CAPITAL NNP O
an DT stopwords Associate_in_Nursing O
elite NN elite O
athlete DT athlete O
to NN stopwords O
refrain NN refrain O
from JJ stopwords O
training NN training O
for NN stopwords O
> NN O
72 DIGITS CD seventy-two O
hours NN hours O
is NN stopwords be O
extremely NN highly O
undesirable JJ undesirable O
, , O
highlighting NN highlight O
the NN stopwords O
importance JJ importance O
of NN stopwords O
a DT stopwords angstrom O
carefully VB carefully O
monitored NN monitor O
recovery NN recovery O
process NN procedure O

Effect CAPITAL NNP consequence O
of NN stopwords O
cholecystectomy NNS cholecystectomy T
on NN stopwords on O
gastroesophageal VB gastroesophageal D
and DT stopwords D
duodenogastric NN D
reflux NN reflux D

Occupational CAPITAL NNP occupational O
asthma DT asthma D
due NN due O
to NN stopwords O
porcine NN porcine O
pancreatic VB pancreatic O
amylase DT amylase O

The CAPITAL NNP O
curriculum NNS course_of_study O
emphasizes NN stress O
student NN student O
understanding JJ understanding O
of NN stopwords O
the NN stopwords O
roles NN function O
of NN stopwords O
rehabilitation NN rehabilitation O
team NN team O
members NN member O

Satellite CAPITAL VB satellite O
DNA CAPITAL NNP deoxyribonucleic_acid O
repeat NN repeat O
sequence NN sequence O
variation NN variation O
is NN stopwords be O
low NN low O
in NN stopwords inch O
three NN three O
species NN species O
of NN stopwords O
burying NN burying O
beetles NN beetle O
in NN stopwords inch O
the NN stopwords O
genus NN genus O
Nicrophorus CAPITAL NNP O
( ( O
Coleoptera CAPITAL NNP Coleoptera O
: : O
Silphidae CAPITAL NNP O
) ) O

In CAPITAL PRP inch O
the NN stopwords O
Coumadin CAPITAL NNP warfarin O
Aspirin CAPITAL DT aspirin O
Reinfarction CAPITAL NNP O
Study CAPITAL NNP survey O
( ( O
CARS CAPITAL VB car O
) ) O
, , O
we NN stopwords O
aimed DT aim O
to NN stopwords O
find NN discovery O
out JJ stopwords out O
whether NN O
a DT stopwords angstrom O
combination NNS combination O
of NN stopwords O
low-dose NN O
warfarin NN warfarin T
and DT stopwords O
low-dose NN T
aspirin DT aspirin T
would NN O
give NN give O
superior NN superior O
results NN consequence O
to NN stopwords O
standard NN standard O
aspirin DT aspirin T
monotherapy NN T
without NN O
excessive NN excessive O
bleeding NN bleeding O
risk NN hazard O

to NN stopwords O
perform NN perform O
a DT stopwords angstrom O
curative NNS remedy O
operation JJ operation O
for NN stopwords O
the NN stopwords O
lung NN lung D
cancer VB cancer D
without NN O
myocardial NN myocardial O
infarction NN infarct O
, , O
minimally NN minimally T
invasive NN invasive T
direct NN direct T
coronary NNS coronary_thrombosis T
artery DT artery T
bypass NN beltway T
and DT stopwords T
left NN left T
lower NN lower_berth T
lobectomy NN lobectomy T
with NN stopwords T
video-endoscopic NN T
assistance DT aid T
were NN stopwords be O
performed NN perform O
simultaneously NN simultaneously O

for NN stopwords O
symptomatic NN diagnostic D
metastases NN metastasis D
in NN stopwords inch D
bone NN bone D
or NN stopwords Oregon D
brain NN brain D
, , O
radiotherapy VB radiotherapy T
usually JJ normally O
gives NN give O
temporary NN temp O
palliation VB palliation O

( ( O
When CAPITAL NNP O
CO2 CAPITAL NNP carbon_dioxide O
is NN stopwords be O
present NN present O
in NN stopwords inch O
excess NN excess O
, , O
its NN stopwords information_technology O
concentration NNS concentration O
remains NN remains O
nearly RB about O
constant NNS constant O
during NN stopwords O
the NN stopwords O
decomposition NN decomposition O
of NN stopwords O
peroxynitrite NN O
, , O
and DT stopwords O
the NN stopwords O
recycling NN recycling O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
, , O
although DT O
it NN stopwords information_technology O
occurs JJ happen O
, , O
can VB stopwords can O
not JJ stopwords not O
be NN stopwords beryllium O
detected NN detect O
kinetically NN O
) ) O

Interaction CAPITAL PRP interaction O
between NN stopwords between O
electronic NN electronic O
article DT article O
surveillance NN surveillance O
systems NN system O
and DT stopwords O
implantable JJ O
defibrillators NN defibrillator O
: : O
insights NN penetration O
from JJ stopwords O
a DT stopwords angstrom O
fourth JJ fourth O
generation NN coevals O
ICD CAPITAL PRP O

INTERVENTIONS CAPITAL PRP intervention O
: : O
Clinical CAPITAL NNP clinical O
predication NN postulation O
of NN stopwords O
intra-abdominal NN D
injury NN injury D
in NN stopwords inch O
the NN stopwords O
emergency NN emergency O
department NN department O
and DT stopwords O
DPL CAPITAL NNP O
performed NN perform O
in NN stopwords inch O
the NN stopwords O
operating JJ operate O
room NN room O
before NN stopwords earlier O
the NN stopwords O
initiation JJ initiation O
of NN stopwords O
celiotomy NNS O

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONCLUSION CAPITAL NNP decision O
: : O
Hyperammonemia CAPITAL NNP O
after DT stopwords after O
transplantation NN transplant O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
hepatic NN liverwort O
glutamine NN glutamine O
synthetase NN O
deficiency NN lack O
in NN stopwords inch O
two NN two O
patients VB patient O
, , O
but NN stopwords merely O
the NN stopwords O
causal VB causal O
relation NN relation O
between NN stopwords between O
these NN stopwords O
two NN two O
conditions NNS conditions O
must NN must O
be NN stopwords beryllium O
further NN stopwords foster O
studied NN analyze O

Why CAPITAL NNP why O
Oedipus CAPITAL NNP Oedipus O
and DT stopwords O
not JJ stopwords not O
Christ CAPITAL NNP Jesus O
? . O
: : O
a DT stopwords angstrom O
psychoanalytic NN psychoanalytical O
inquiry NN inquiry O
into NN stopwords O
innocence NN artlessness O
, , O
human NN homo O
sacrifice VB forfeit O
, , O
and DT stopwords O
the NN stopwords O
sacred VB sacred O
-- : O
Part CAPITAL VB part O
I CAPITAL PRP iodine O
: : O
Innocence CAPITAL PRP artlessness O
, , O
spirituality JJ spiritualty O
, , O
and DT stopwords O
human NN homo O
sacrifice VB forfeit O

Also CAPITAL DT besides O
, , O
there NN stopwords there O
was VB stopwords Washington O
no NNS stopwords no O
statistical NN statistical O
difference NN difference O
of NN stopwords O
mean NN mean O
RRIV CAPITAL NNP O
between NN stopwords between O
the NN stopwords O
two NN two O
groups NN group O

Supramaximal CAPITAL NNP T
medial NN medial T
and DT stopwords T
lateral NN lateral_pass T
rectus NN rectus T
surgery NN surgery T
was VB stopwords Washington O
performed NN perform O
to NN stopwords O
correct NNS correct O
horizontal NN horizontal D
deviations NN deviation D
in NN stopwords inch D
seven NN seven D
cases VB case D
of NN stopwords D
sixth NN sixth D
nerve RB nerve D
palsy VB paralysis D
and DT stopwords D
three NN three D
cases VB case D
of NN stopwords D
third NN one-third D
nerve RB nerve D
palsy VB paralysis D
, , O
with NN stopwords O
satisfactory VB satisfactory O
results NN consequence O
in NN stopwords inch O
most NN stopwords most O
cases VB case O

Reconstruction CAPITAL NNP Reconstruction O
of NN stopwords O
thoracic NN pectoral O
wall VB wall O
defects NN defect O
after DT stopwords after O
tumor NN tumor D
resection NN resection T
using JJ exploitation O
a DT stopwords angstrom O
polytetrafluoroethylene NN Teflon O
soft NN soft O
tissue NN tissue O
( ( O
Gore-Tex CAPITAL NNP O
) ) O
patch VB spot O

A CAPITAL DT angstrom O
randomized VB randomize O
trial NN test O
of NN stopwords O
one-to-one JJ one-to-one O
nurse RB nurse O
support NN support O
of NN stopwords O
women NN woman O
in NN stopwords inch O
labor NN labor O

Subcutaneous CAPITAL NNP hypodermic T
injection NN injection T
of NN stopwords T
irradiated NN enlighten T
LLC-IL2 CAPITAL NNP T
did NN stopwords make O
not JJ stopwords not O
affect DT affect O
the NN stopwords O
growth NN growth O
of NN stopwords O
preexisting NN preexist O
s.c. NN D
tumors NN tumor D
and DT stopwords O
also DT besides O
did NN stopwords make O
not JJ stopwords not O
improve JJ better O
survival NN survival O
of NN stopwords O
mice NN mouse O
bearing NN bearing O
the NN stopwords O
lung NN lung D
or NN stopwords Oregon D
peritoneal NN peritoneal D
tumors NN tumor D

the NN stopwords O
combination NNS combination T
of NN stopwords T
txt NN T
, , T
gem NN gem T
and DT stopwords T
cddp SYM T
may VB May O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
recurrent NN perennial D
non-small-cell JJ D
lung NN lung D
carcinoma VB carcinoma D
, , O
even NN evening O
in NN stopwords inch O
patients VB patient O
that NN stopwords O
have VB stopwords rich_person O
failed VB fail O
to NN stopwords O
respond NN react O
to NN stopwords O
more NN stopwords More O
than NN stopwords O
one JJ one O
chemotherapy NNS chemotherapy O
regimen NN regimen O

of NN stopwords O
1 DIGITS CD one O
, , O
042 DIGITS CD O
patients VB patient O
with NN stopwords O
primary NN primary D
lung NN lung D
cancer VB cancer D
who NN stopwords World_Health_Organization O
underwent JJ undergo O
resection NN resection T
from JJ stopwords O
1982 DIGITS CD O
to NN stopwords O
1995 DIGITS CD O
, , O
549 DIGITS CD O
patients VB patient O
with NN stopwords O
adenocarcinoma DT adenocarcinoma O
( ( O
ad DT ad O
) ) O
and DT stopwords O
363 DIGITS CD O
with NN stopwords O
squamous NN O
cell NNS cell O
carcinoma VB carcinoma O
( ( O
sq NN O
) ) O
were NN stopwords be O
included NN include O
in NN stopwords inch O
this NN stopwords O
study NN survey O

Copenhagen CAPITAL NNP Copenhagen O
, , O
23-26 CD O
October CAPITAL NNP October O
1997 DIGITS CD O

Home CAPITAL NNP home O
care VB care O
workers NN worker O
face VB face O
an DT stopwords Associate_in_Nursing O
increasing NN increase O
risk NN hazard O
for NN stopwords O
workplace NN workplace O
violence NN violence O

We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
1 DIGITS CD one T
% NN T
permethrin NN T
treatment NN treatment T
was VB stopwords Washington O
effective NN effective O
in NN stopwords inch O
louse NN louse D
control NNS control O
in NN stopwords inch O
this NN stopwords O
refugee NN refugee O
population NN population O

We CAPITAL NNP O
advise DT rede O
that NN stopwords O
lamivudine NN lamivudine T
should NN stopwords O
be NN stopwords beryllium O
considered NNS see O
during NN stopwords O
intensive NN intensifier O
chemotherapy NNS chemotherapy T
treatment NN treatment T
of NN stopwords O
chronic NN chronic O
carriers VB carrier O
of NN stopwords O
HBV CAPITAL NNP D

College CAPITAL NNP college O
students NN student O
spend NN spend O
4 DIGITS CD four O
hr NN hour O
weekly NN weekly O
on NN stopwords on O
the NN stopwords O
PM CAPITAL NNP autopsy O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
R CAPITAL NN roentgen O
consultation NNS consultation O
service NN service O
as DT stopwords arsenic O
team NN team O
members NN member O
under JJ stopwords nether O
resident NN resident O
supervision NN supervision O

Refugees CAPITAL NNP refugee O
with NN stopwords O
crawling NNS crawl D
lice NN louse D
were NN stopwords be O
treated NN treat O
with NN stopwords O
a DT stopwords angstrom O
pediculicide NN pediculicide T
containing NNS incorporate T
1 DIGITS CD one T
% NN T
permethrin NN T

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONCLUSIONS CAPITAL NNP decision O
: : O
Malnourished CAPITAL NNP undernourish O
patients VB patient O
with NN stopwords O
chronic NN chronic D
renal NN nephritic D
failure VB failure D
receiving NN receive O
PN CAPITAL NNP T
are DT stopwords are O
at DT stopwords astatine O
risk NN hazard O
of NN stopwords O
developing NN development O
electrolyte NN electrolyte D
abnormalities DT abnormality D
, , O
particularly NN particularly O
hypophosphatemia NN D

Does CAPITAL NNP Department_of_Energy O
hyperglycemia NN hyperglycemia D
really NN truly O
cause VB cause O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D
? . O

Therapy CAPITAL NNP therapy O
designed NN plan O
to NN stopwords O
control NNS control O
the NN stopwords O
efferent NN motor_nerve D
phase NN phase D
of NN stopwords D
established NN establish D
asthma DT asthma D
by NN stopwords by O
augmenting DT augment T
down-regulatory NN T
Th1 CAPITAL NNP T
counterbalancing NNS compensate T
mechanisms NN mechanism T
should NN stopwords O
be NN stopwords beryllium O
effective NN effective O

urpose JJ O
: : O
to NN stopwords O
assess DT buttocks O
results NN consequence O
with NN stopwords O
twice-daily NN O
high-dose NN O
radiotherapy VB radiotherapy T
( ( T
rt NN T
) ) T
for NN stopwords O
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D

Interview CAPITAL PRP interview O
by NN stopwords by O
Mike CAPITAL NNP microphone O
Grace CAPITAL NNP grace O

Oligohydramnios CAPITAL NNP O
and DT stopwords O
the NN stopwords O
appropriately DT appropriately O
grown NN turn O
fetus JJ fetus O

Implementation CAPITAL PRP execution O
of NN stopwords O
pharmaceutical NN pharmaceutical O
practice NN practice O
guidelines NN guideline O

Alterations CAPITAL DT change O
in NN stopwords inch O
the NN stopwords O
developing NN development O
immune JJ immune O
system NN system O
of NN stopwords O
the NN stopwords O
F344 CAPITAL NNP O
rat VB rat O
after DT stopwords after O
perinatal NN perinatal O
exposure NN exposure O
to NN stopwords O
2 DIGITS CD two O
, , O
3 DIGITS CD three O
, , O
7 DIGITS CD seven O
, , O
8-tetrachlorodibenzo-p-dioxin CD O
: : O
II CAPITAL PRP two O

Structure CAPITAL NNP structure O
and DT stopwords O
function JJ function O
of NN stopwords O
the NN stopwords O
long NN hanker O
terminal NN terminal O
repeats NN repeat O
of NN stopwords O
feline JJ feline O
leukemia NN leukemia O
viruses NN virus O
derived NN deduce O
from JJ stopwords O
naturally RB naturally O
occurring JJ happen O
acute DT acute_accent D
myeloid NN myeloid D
leukemias NN leukemia D
in NN stopwords inch O
cats VB cat O

Is CAPITAL PRP be O
conservative NNS conservative T
surgery NN surgery T
for NN stopwords O
tubal NN tubal D
pregnancy NN pregnancy D
preferable NN preferable O
to NN stopwords O
salpingectomy VB salpingectomy T
? . O
An CAPITAL DT Associate_in_Nursing O
economic NN economic O
analysis DT analysis O

Lesioning CAPITAL NNP O
of NN stopwords O
pallidal VB O
and DT stopwords O
subpallidal NN O
pathways VB nerve_pathway O
may VB May O
contribute NNS lend O
to NN stopwords O
the NN stopwords O
sustained NN prolong O
clinical JJ clinical O
benefit NN benefit O
in NN stopwords inch O
this NN stopwords O
series NN series O

Familial CAPITAL NNP familial O
and DT stopwords O
primary NN primary O
( ( O
AL CAPITAL DT aluminum O
) ) O
cardiac VB cardiac D
amyloidosis DT amyloidosis D
: : O
echocardiographically NN O
similar NN similar O
diseases NN disease O
with NN stopwords O
distinctly NN distinctly O
different NN different O
clinical JJ clinical O
outcomes JJ result O

A CAPITAL DT angstrom O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
fetal-maternal JJ O
carboxyhemoglobin VB O
relationships NN relationship O
and DT stopwords O
the NN stopwords O
differences NN difference O
in NN stopwords inch O
fetal JJ fetal O
oxyhemoglobin JJ oxyhemoglobin O
physiology NN physiology O
are DT stopwords are O
used JJ use O
to NN stopwords O
explain NN explain O
the NN stopwords O
recommendation NN recommendation O
that NN stopwords O
pregnant NN pregnant O
women NN woman O
with NN stopwords O
carbon VB carbon D
monoxide NN monoxide D
poisoning NN poisoning D
should NN stopwords O
receive NN receive O
100 DIGITS CD hundred O
% NN O
oxygen JJ oxygen T
therapy NN therapy T
for NN stopwords O
up JJ stopwords up O
to NN stopwords O
five NN five O
times NN times O
longer NN longer O
than NN stopwords O
is NN stopwords be O
otherwise JJ otherwise O
necessary JJ necessity O

only JJ stopwords lone O
the NN stopwords O
combination NNS combination T
of NN stopwords T
a DT stopwords angstrom T
cell NNS cell T
wall-active VB T
antibiotic DT antibiotic T
to NN stopwords T
which NN stopwords T
the NN stopwords T
enterococcus NN T
is NN stopwords be T
susceptible NN susceptible T
( ( T
ie NN Internet_Explorer T
, , T
certain NNS certain T
beta-lactams NN T
or NN stopwords Oregon T
vancomycin NN vancomycin T
) ) T
plus NN asset T
an DT stopwords Associate_in_Nursing T
aminoglycoside DT T
( ( T
ie NN Internet_Explorer T
, , T
gentamicin NN gentamicin T
or NN stopwords Oregon T
streptomycin NN streptomycin T
) ) T
is NN stopwords be O
bactericidal VB bactericidal O
, , O
and DT stopwords O
is NN stopwords be O
required NN necessitate O
for NN stopwords O
cure NNS remedy O
of NN stopwords O
endocarditis NN endocarditis D
, , D
meningitis NN meningitis D
and DT stopwords D
probably NN probably D
infection NN infection D
in NN stopwords inch D
neutropenic JJ D
patients VB patient D
; : O
bacteriostatic VB bacteriostatic O
activity DT activity O
is NN stopwords be O
sufficient NN sufficient O
to NN stopwords O
treat NN dainty O
most NN stopwords most O
other JJ stopwords other O
infections NN infection O

CDA CAPITAL NNP O
opposes JJ oppose O
proposed NN propose O
HBV CAPITAL NNP O
recommendations NN recommendation O

OBJECTIVES CAPITAL NNP aim O
: : O
To CAPITAL NNP O
estimate NN estimate O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
Chlamydia CAPITAL NNP chlamydia D
trachomatis NN D
in NN stopwords inch O
asymptomatic DT asymptomatic O
women NN woman O
attending DT attention O
general NN general O
practice NN practice O
: : O
to NN stopwords O
assess DT buttocks O
the NN stopwords O
potential NN potential O
of NN stopwords O
the NN stopwords O
ligase NN O
chain NNS chain O
reaction NN chemical_reaction O
as DT stopwords arsenic O
a DT stopwords angstrom O
screening NN screening O
tool NN tool O
; : O
and DT stopwords O
to NN stopwords O
evaluate NN measure O
selective NN selective O
screening NN screening O
criteria JJ standard O

A CAPITAL DT angstrom O
novel JJ novel O
point NN point O
mutation NN mutant O
in NN stopwords inch O
a DT stopwords angstrom O
splice NN splice O
acceptor DT acceptor O
site NN site O
of NN stopwords O
intron NN intron O
1 DIGITS CD one O
of NN stopwords O
the NN stopwords O
human NN homo O
low NN low O
density NN density O
lipoprotein NN lipoprotein O
receptor NN receptor O
gene NN gene O
which NN stopwords O
causes VB cause O
severe NN severe O
hypercholesterolemia NN hypercholesterolemia D
: : O
an DT stopwords Associate_in_Nursing O
unexpected JJ unexpected O
absence DT absence O
of NN stopwords O
exon NN exon O
skipping JJ jump O

CONCLUSIONS CAPITAL NNP decision O
: : O
Octreotide CAPITAL NNP T
LAR CAPITAL VB T
20 DIGITS CD twenty O
mg NN milligram O
shows NN show O
significant NN significant O
efficacy NN efficacy O
in NN stopwords inch O
terms NN footing O
of NN stopwords O
objective NN aim O
response NN response O
rate VB rate O
( ( O
PR CAPITAL NNP praseodymium O
+ NN O
SD CAPITAL NNP South_Dakota O
) ) O
, , O
biochemical NN biochemical O
and DT stopwords O
symptomatic NN diagnostic O
control NNS control O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
NETs CAPITAL NNP internet D
of NN stopwords O
the NN stopwords O
GEP CAPITAL NNP O
system NN system O
pretreated NN O
and DT stopwords O
progressing NN progress O
on NN stopwords on O
slow NN decelerate O
release NN release O
lanreotide NN O

Structure CAPITAL NNP structure O
and DT stopwords O
in NN stopwords inch O
vitro NN O
substrate NN substrate O
specificity NN specificity O
of NN stopwords O
the NN stopwords O
murine NN murine O
multidrug NN O
resistance-associated NN O
protein NN protein O

Fat CAPITAL NNP fat O
absorption DT absorption O
: : O
a DT stopwords angstrom O
transport NN conveyance O
problem NN problem O

Q CAPITAL NN Q D
fever JJ fever D
at DT stopwords astatine O
a DT stopwords angstrom O
combined NNS unite O
meat NN meat O
and DT stopwords O
poultry NN domestic_fowl O
abattoir DT abattoir O

8th CD eighth O
European CAPITAL NNP European O
Meeting CAPITAL NNP meeting O
on NN stopwords on O
Dysmorphology CAPITAL NNP O

A CAPITAL DT angstrom O
discriminant NN O
function JJ function O
for NN stopwords O
preeclampsia NN preeclampsia D
: : O
case-control VB O
study NN survey O
of NN stopwords O
minor NN child O
hemoglobins NN hemoglobin O
, , O
red NN red O
cell NNS cell O
enzymes NN enzyme O
, , O
and DT stopwords O
clinical JJ clinical O
laboratory NN lab O
values NN values O

Online CAPITAL NNP on-line O

Similarly CAPITAL NNP similarly O
, , O
rates VB rates O
of NN stopwords O
replication NN reproduction O
of NN stopwords O
viruses NN virus O
with NN stopwords O
mutations NN mutant O
M46L/I CAPITAL NNP O
, , O
I54V CAPITAL PRP O
, , O
and DT stopwords O
V82A CAPITAL NNP O
in NN stopwords inch O
protease NN protease O
were NN stopwords be O
enhanced NN enhance O
both NN stopwords both O
in NN stopwords inch O
the NN stopwords O
presence NN presence O
and DT stopwords O
in NN stopwords inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
Indinavir CAPITAL PRP indinavir O
when NN stopwords O
combined NNS unite O
with NN stopwords O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
gag VB joke O
p7/p1 NN O
and DT stopwords O
the NN stopwords O
gag VB joke O
p1/p6 NN O
cleavage NNS cleavage O
sites NN site O

Case CAPITAL VB case O
of NN stopwords O
the NN stopwords O
month NN calendar_month O

an DT stopwords Associate_in_Nursing O
anti-idiotypic DT T
monoclonal NN monoclonal_antibody T
antibody DT antibody T
against DT stopwords O
the NN stopwords O
gd3 NN O
ganglioside VB O
, , O
bec-2 NN O
, , O
is NN stopwords be O
being NN stopwords being O
evaluated NN measure O
after DT stopwords after O
chemotherapy NNS chemotherapy O
in NN stopwords inch O
sclc JJ D
patients VB patient O
in NN stopwords inch O
a DT stopwords angstrom O
european NN European O
study NN survey O

In CAPITAL PRP inch O
PC12 CAPITAL NNP O
cells NNS cell O
, , O
a DT stopwords angstrom O
model NN model O
system NN system O
to NN stopwords O
study NN survey O
neurite JJ O
outgrowth JJ outgrowth O
, , O
SHARP CAPITAL NNP sharp O
genes NN gene O
can VB stopwords can O
be NN stopwords beryllium O
induced NN induce O
by NN stopwords by O
NGF CAPITAL NNP nerve_growth_factor O
with NN stopwords O
the NN stopwords O
kinetics NN dynamics O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
immediate-early JJ O
gene NN gene O

The CAPITAL NNP O
posterior NN buttocks O
capsule VB capsule O
and DT stopwords O
anterior DT front_tooth O
vitreous NN vitreous O
were NN stopwords be O
managed VB pull_off O
in NN stopwords inch O
a DT stopwords angstrom O
variety NN assortment O
of NN stopwords O
ways VB ways O
: : O
In CAPITAL PRP inch O
5 DIGITS CD five O
eyes NN eyes O
, , O
the NN stopwords O
posterior NN buttocks O
capsule VB capsule O
was VB stopwords Washington O
left NN left O
intact NN integral O
; : O
in NN stopwords inch O
15 DIGITS CD fifteen O
eyes NN eyes O
, , O
a DT stopwords angstrom O
posterior NN buttocks T
continuous NNS continuous T
curvilinear NNS curvilineal T
capsulorhexis VB T
( ( T
PCCC CAPITAL NNP T
) ) T
was VB stopwords Washington O
performed NN perform O
- : O
6 DIGITS CD six O
with NN stopwords O
and DT stopwords O
9 DIGITS CD nine O
without NN O
anterior DT front_tooth T
vitrectomy NN vitrectomy T
; : O
in NN stopwords inch O
8 DIGITS CD eight O
eyes NN eyes O
, , O
posterior NN buttocks T
optic JJ eye T
capture VB capture T
was VB stopwords Washington O
performed NN perform O
- : O
3 DIGITS CD three O
with NN stopwords O
and DT stopwords O
5 DIGITS CD five O
without NN O
vitrectomy NN vitrectomy T

A CAPITAL DT angstrom O
patient VB patient O
suffering NN agony O
baclofen VB D
overdose JJ overdose D
successfully NN successfully O
treated NN treat O
with NN stopwords O
atropine DT atropine T
is NN stopwords be O
reported NN report O

For CAPITAL NNP O
homosexual NN homosexual O
people NN people O
who NN stopwords World_Health_Organization O
live NN populate O
in NN stopwords inch O
countries NNS state O
with NN stopwords O
no NNS stopwords no O
legal NN legal O
protections NN protection O
these NN stopwords O
dangers VB danger O
are DT stopwords are O
particularly NN particularly O
serious NN serious O

A CAPITAL DT angstrom O
population-based NN O
registry NN register O
on NN stopwords on O
paraproteinaemia NN D
in NN stopwords inch O
The CAPITAL NNP O
Netherlands CAPITAL NNP Netherlands O

On CAPITAL NNP on O
the NN stopwords O
influence NN influence O
of NN stopwords O
cytostatic NNS O
agents DT agent O
and DT stopwords O
immune JJ immune O
bodies NN body O
on NN stopwords on O
choriocarcinoma NNS O
cells NNS cell O
in NN stopwords inch O
tissue NN tissue O
culture NNS culture O

Renal CAPITAL NNP nephritic D
vascular NN vascular D
hypertension NN high_blood_pressure D
; : O
diagnosis NN diagnosis O
and DT stopwords O
treatment NN treatment O

SETTING CAPITAL NNP setting O
: : O
Four CAPITAL NNP four O
general NN general O
practices NN practice O
in NN stopwords inch O
northeast RB northeast O
London CAPITAL NNP London O

The CAPITAL NNP O
present NN present O
study NN survey O
was VB stopwords Washington O
performed NN perform O
to NN stopwords O
examine NN analyze O
whether NN O
omega3 JJ T
fatty VB fatso T
acids DT acid T
also DT besides O
exhibit NN exhibit O
mood-stabilizing NN O
properties NN property O
in NN stopwords inch O
bipolar NN bipolar D
disorder NN disorder D

Dioxins CAPITAL NNP dioxin O
: : O
current NNS current O
knowledge NN cognition O
about DT stopwords about O
health NN health O
effects NN effects O

All CAPITAL DT all O
patients VB patient O
underwent JJ undergo O
TEFNA CAPITAL NNP T
and DT stopwords O
TESE CAPITAL NNP T
consecutively NNS consecutively O

Many CAPITAL NNP many O
widely NN widely O
discussed NN discourse O
putative NN putative O
adverse DT adverse O
effects NN effects O
of NN stopwords O
vitamin NN vitamin O
C CAPITAL SYM degree_centigrade O
, , O
vitamin NN vitamin O
E CAPITAL NN vitamin_E O
, , O
and DT stopwords O
trivalent NN trivalent O
chromium NN chromium O
have VB stopwords rich_person O
little NN little O
factual VB actual O
basis VB footing O

The CAPITAL NNP O
current NNS current O
study NN survey O
reviews NN reappraisal O
evidence NN evidence O
for NN stopwords O
Ca2+ CAPITAL VB O
dysregulation NN O
during NN stopwords O
aging DT ripening O
which NN stopwords O
could NNS O
interact NN interact O
with NN stopwords O
Ca CAPITAL VB calcium O
( ( O
2+ CD O
) ) O
-dependent : O
synaptic NN synaptic O
plasticity NN malleability O

Use CAPITAL NNP use O
of NN stopwords O
ES CAPITAL NN einsteinium T
to NN stopwords O
treat NN dainty O
CBD CAPITAL NNP D
stones NN rock D
on NN stopwords on O
a DT stopwords angstrom O
routine NN routine O
basis VB footing O
was VB stopwords Washington O
therefore NN therefore O
not JJ stopwords not O
found JJ found O
to NN stopwords O
be NN stopwords beryllium O
any DT stopwords any O
better NN better O
than NN stopwords O
one-time JJ erstwhile O
surgical NN surgical O
exploration NN exploration O

To CAPITAL NNP O
address DT address O
this NN stopwords O
, , O
our NN stopwords O
article DT article O
first NN first O
refers NN mention O
to NN stopwords O
the NN stopwords O
main VB main O
aspects DT aspect O
of NN stopwords O
salivary VB salivary O
gland NN gland O
physiology NN physiology O

Behavior CAPITAL NNP behavior O
of NN stopwords O
the NN stopwords O
tetanus NN tetanus D
patient VB patient O
subjected NN subject O
to NN stopwords O
resuscitation NN resuscitation T
treatment NN treatment T

Although CAPITAL DT O
Escherichia CAPITAL NNP escherichia O
coli NNS O
and DT stopwords O
Saccharomyes CAPITAL VB O
cerevisiae NNS O
produce NN produce O
a DT stopwords angstrom O
CPD-specific CAPITAL NNP O
photolyase NN O
that NN stopwords O
eliminates NN extinguish O
only JJ stopwords lone O
this NN stopwords O
class NNS class O
of NN stopwords O
dimer NN dimer O
, , O
Arabidopsis CAPITAL DT Arabidopsis O
thaliana NN O
, , O
Drosphila CAPITAL NNP O
melanogaster NN O
, , O
Crotalus CAPITAL NNP Crotalus O
atrox DT O
, , O
and DT stopwords O
Xenopus CAPITAL NN Xenopus O
laevis NN O
have VB stopwords rich_person O
recently NN recently O
been NN stopwords be O
shown NN show O
to NN stopwords O
photoreactivate NN O
both NN stopwords both O
CPDs CAPITAL NNP O
and DT stopwords O
6-4 CD O
products NN merchandise O

Community CAPITAL NNP community O
clinic JJ clinic O
treatment NN treatment O
for NN stopwords O
back-ward VB O
patients VB patient O

The CAPITAL NNP O
lipophilic NN lipophilic O
character NNS fictional_character O
of NN stopwords O
dioxins NN dioxin O
prevents NN prevent O
their NN stopwords O
excretion NN elimination O
in NN stopwords inch O
the NN stopwords O
urine JJ urine O
and DT stopwords O
causes VB cause O
their NN stopwords O
accumulation DT accretion O
in NN stopwords inch O
body NN body O
fat VB fat O

With CAPITAL NNP O
two NN two O
bolus NN bolus O
doses NN dose O
of NN stopwords O
alteplase DT T
, , O
further NN stopwords foster O
shortening NN shortening O
the NN stopwords O
duration NN duration O
of NN stopwords O
administration DT administration O
, , O
complete NNS complete O
reperfusion NN O
was VB stopwords Washington O
achieved DT achieve O
in NN stopwords inch O
more NN stopwords More O
than NN stopwords O
85 DIGITS CD eighty-five O
percent NN percentage O
of NN stopwords O
the NN stopwords O
patients VB patient O
in NN stopwords inch O
initial JJ initial O
angiographic DT O
studies NN survey O

Human CAPITAL NNP homo O
bodily NN bodily O
health NN health O
and DT stopwords O
the NN stopwords O
common NNS park O
good NN good O

Oral CAPITAL NNP oral T
contraceptives NNS contraceptive T
, , O
thrombosis NN thrombosis D
, , O
and DT stopwords O
cyclical NNS cyclic O
factors VB factor O
affecting DT affect O
veins NN vein O
. . O

To CAPITAL NNP O
investigate NN investigate O
the NN stopwords O
molecular NN molecular O
nature RB nature O
underlying JJ underlie O
cellular NNS cellular O
responses NN response O
to NN stopwords O
Raf-1 CAPITAL VB O
activation DT activation O
, , O
we NN stopwords O
have VB stopwords rich_person O
stably NN stably O
transfected NN O
rat VB rat O
salivary VB salivary O
epithelial NN epithelial O
Pa-4 CAPITAL VB O
cells NNS cell O
with NN stopwords O
human NN homo O
Raf-1-estrogen CAPITAL VB O
receptor NN receptor O
fusion JJ fusion O
gene NN gene O
( ( O
DeltaRaf-1 CAPITAL NNP O
: : O
ER CAPITAL NN erbium O
) ) O
and DT stopwords O
used JJ use O
mRNA NN messenger_RNA O
differential NN derived_function O
display NN display O
in NN stopwords inch O
search NN search O
of NN stopwords O
messages NN message O
induced NN induce O
by NN stopwords by O
DeltaRaf-1 CAPITAL NNP O
: : O
ER CAPITAL NN erbium O
activation DT activation O

conclusion NNS decision O
: : O
vip NN very_important_person T
combination NNS combination T
chemotherapy NNS chemotherapy T
and DT stopwords T
early VB early T
concurrent NNS coincident T
thoracic NN pectoral T
irradiation NN irradiation T
for NN stopwords O
patients VB patient O
with NN stopwords O
limited NN express D
stage NN phase D
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
revealed NN uncover O
excellent NN excellent O
antitumor DT anticancer O
response NN response O
with NN stopwords O
tolerable NN tolerable O
toxicity NN toxicity O

HIV CAPITAL NNP HIV O
treatment NN treatment O
strategies NN scheme O
: : O
planning NN planning O
for NN stopwords O
the NN stopwords O
long NN hanker O
term NN term O

Use CAPITAL NNP use O
of NN stopwords O
statins NN lipid-lowering_medicine T

I CAPITAL PRP iodine O
. . O
Effects CAPITAL NNP effects O
of NN stopwords O
radiation VB radiation O
on NN stopwords on O
physical NN physical O
and DT stopwords O
chemical NNS chemical O
properties NN property O
of NN stopwords O
injection NN injection O
needles JJ acerate_leaf O

for NN stopwords O
patients VB patient O
with NN stopwords O
solitary NN solitary_confinement D
pulmonary NN pneumonic D
metastasis NN metastasis D
, , O
the NN stopwords O
authors DT writer O
routinely NN routinely O
performed NN perform O
thoracoscopic NN T
partial NN partial_derivative T
resection NN resection T
of NN stopwords T
the NN stopwords T
lung NN lung T

PURPOSE CAPITAL NNP purpose O
: : O
A CAPITAL DT angstrom O
phase NN phase O
I/II CAPITAL PRP O
trial NN test O
of NN stopwords O
docetaxel NN T
, , O
cisplatin NN T
, , O
fluorouracil JJ fluorouracil T
( ( T
5-FU CD T
) ) T
, , O
and DT stopwords O
leucovorin NN T
( ( T
TPFL5 CAPITAL NNP T
) ) T
induction NN initiation T
chemotherapy NNS chemotherapy T
for NN stopwords O
patients VB patient O
with NN stopwords O
locally NN locally D
advanced DT advance D
squamous NN D
cell NNS cell D
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
head NN head D
and DT stopwords D
neck JJ neck D
( ( D
SCCHN CAPITAL NNP D
) ) D

Inhaled CAPITAL PRP inhale T
sodium NN sodium T
cromoglycate NNS T
in NN stopwords inch O
young NN young O
children JJ child O
with NN stopwords O
moderate NN centrist O
asthma DT asthma D

Three CAPITAL NNP three O
cases VB case O
of NN stopwords O
mild NN mild O
preeclampsia NN preeclampsia D
were NN stopwords be O
found JJ found O
in NN stopwords inch O
the NN stopwords O
partner NN spouse T
insemination NN insemination T
program NN plan O
and DT stopwords O
nine NN nine O
cases VB case O
of NN stopwords O
preeclampsia NN preeclampsia D
( ( O
five NN five O
severe NN severe O
, , O
four JJ four O
mild NN mild O
) ) O
in NN stopwords inch O
the NN stopwords O
donor NN donor T
insemination NN insemination T
program NN plan O
( ( O
relative NN relative O
risk NN hazard O
1.85 CD O
, , O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
1.20 CD O
to NN stopwords O
2.85 CD O
) ) O
. . O

Although CAPITAL DT O
hepatic NN liverwort O
rupture NN rupture O
due NN due O
to NN stopwords O
metastatic NN metastatic O
cancer VB cancer O
is NN stopwords be O
extremely NN highly O
rare NN rare O
, , O
transcatheter NN T
arterial DT arterial T
embolization NN T
( ( T
TAE CAPITAL VB T
) ) T
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
appropriate DT allow O
and DT stopwords O
useful JJ useful O
treatment NN treatment O
for NN stopwords O
massive VB massive D
hemorrhage NN bleeding D
caused VB cause D
by NN stopwords by D
spontaneous NN spontaneous D
rupture NN rupture D
of NN stopwords D
liver NN liver D
metastasis NN metastasis D

Firearm CAPITAL NNP firearm O
injury NN injury O
prevention NN prevention O

Given CAPITAL NNP given O
the NN stopwords O
potential NN potential O
for NN stopwords O
treatment NN treatment O
to NN stopwords O
produce NN produce O
side NN side O
effects NN effects O
, , O
the NN stopwords O
use JJ use O
of NN stopwords O
zinc NN zinc T
lozenges NN lozenge T
to NN stopwords O
treat NN dainty O
cold NNS cold D
symptoms NN symptom D
deserves NN deserve O
further NN stopwords foster O
study NN survey O

Are CAPITAL DT are O
academic DT academician O
medicine-alternative NN O
medicine NN medicine O
incompatible NN incompatible O
, , O
compatible NNS compatible O
, , O
complementary NNS complementary_color O
? . O

Determination CAPITAL NNP determination O
of NN stopwords O
serum NN serum O
oxytocinase JJ O
( ( O
1-cystine-aminopeptidase CD O
) ) O
activity DT activity O

Nervous CAPITAL NNP nervous D
system NN system D
borreliosis NN D
with NN stopwords O
pseudo-lymphoma NN O
cells NNS cell O
in NN stopwords inch O
cerebrospinal NNS cerebrospinal O
fluid JJ fluid O

For CAPITAL NNP O
the NN stopwords O
3382 DIGITS CD O
patients VB patient O
assigned DT delegate O
3 DIGITS CD three O
mg NN milligram O
warfarin NN warfarin T
with NN stopwords O
80 DIGITS CD eighty O
mg NN milligram O
aspirin DT aspirin T
, , O
the NN stopwords O
INR CAPITAL PRP Bureau_of_Intelligence_and_Research O
results NN consequence O
were NN stopwords be O
: : O
at DT stopwords astatine O
week NN week O
1 DIGITS CD one O
( ( O
n NN nitrogen O
= NN O
2985 DIGITS CD O
) ) O
median NN median O
1.51 CD O
( ( O
IQR CAPITAL PRP O
1.23-2.13 CD O
) ) O
; : O
at DT stopwords astatine O
week NN week O
4 DIGITS CD four O
( ( O
n NN nitrogen O
= NN O
2701 DIGITS CD O
) ) O
1.27 CD O
( ( O
1.13-1.64 CD O
) ) O
; : O
at DT stopwords astatine O
month NN calendar_month O
6 DIGITS CD six O
( ( O
n NN nitrogen O
= NN O
2145 DIGITS CD O
) ) O
1.19 CD O
( ( O
1.08-1.44 CD O
) ) O

( ( O
3 DIGITS CD three O
) ) O
Critical CAPITAL NNP critical O
care VB care O
nurses RB nurse O
readily NN readily O
listed NN list O
barriers NN barrier O
to NN stopwords O
healthy NN healthy O
living NN life O

Prophylaxis CAPITAL NNP prophylaxis O
after DT stopwords after O
occupational JJ occupational O
exposure NN exposure O
to NN stopwords O
HIV CAPITAL NNP HIV O

We CAPITAL NNP O
investigated NN investigate O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
an DT stopwords Associate_in_Nursing T
antichlamydial DT T
macrolide VB T
antibiotic DT antibiotic T
, , T
roxithromycin NN T
, , O
can VB stopwords can O
prevent NN prevent O
or NN stopwords Oregon O
reduce NN reduce O
recurrent NN perennial O
major VB major O
ischaemic NN ischemic O
events NN event O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
unstable JJ unstable D
angina DT angina D

< NN O
TO_SEE CAPITAL NNP O
> NN O
the NN stopwords O
availability DT handiness O
of NN stopwords O
four JJ four O
antiviral DT antiviral T
agents DT agent T
that NN stopwords O
effectively NN efficaciously O
prevent NN prevent O
and DT stopwords O
treat NN dainty O
influenza NN influenza D
provides NN supply O
the NN stopwords O
physician NN doctor O
with NN stopwords O
considerable NNS considerable O
flexibility JJ flexibility O
for NN stopwords O
their NN stopwords O
use JJ use O
in NN stopwords inch O
influenza NN influenza O
control NNS control O

G-CSF CAPITAL NNP T
therapy NN therapy T
was VB stopwords Washington O
generally NN by_and_large O
well NN well O
tolerated NN digest O

Other CAPITAL NNP other O
possible NN possible O
causes VB cause O
for NN stopwords O
the NN stopwords O
patient VB patient O
's POS O
illness NN illness O
were NN stopwords be O
excluded NN exclude O

The CAPITAL NNP O
results NN consequence O
of NN stopwords O
several NN several O
clinical JJ clinical O
investigations NN probe O
showed NN show O
the NN stopwords O
efficacy NN efficacy O
and DT stopwords O
safety VB safety O
of NN stopwords O
artichoke DT artichoke T
extracts NN infusion T
( ( T
Cynara CAPITAL NNP Cynara T
scolymus JJ Scolymus T
L. CAPITAL NNP T
) ) T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
hepato-biliary NN D
dysfunction NN dysfunction D
and DT stopwords D
digestive NN digestive D
complaints NNS ailment D
, , O
such NN stopwords such O
as DT stopwords arsenic O
sensation NN sensation O
of NN stopwords O
fullness JJ comprehensiveness O
, , O
loss NN loss D
of NN stopwords D
appetite DT appetite D
, , O
nausea RB nausea D
and DT stopwords O
abdominal DT abdominal D
pain IN pain D

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
asymptomatic DT asymptomatic O
carriers VB carrier O
was VB stopwords Washington O
3.3 LS O
% NN O

Extended CAPITAL NNP widen O
use JJ use O
of NN stopwords O
glatiramer NN T
acetate DT acetate T
( ( T
Copaxone CAPITAL NNP T
) ) T
is NN stopwords be O
well NN well O
tolerated NN digest O
and DT stopwords O
maintains VB keep O
its NN stopwords information_technology O
clinical JJ clinical O
effect NN consequence O
on NN stopwords on O
multiple NN multiple D
sclerosis JJ sclerosis D
relapse NN backsliding O
rate VB rate O
and DT stopwords O
degree NN degree O
of NN stopwords O
disability NN disability O

The CAPITAL NNP O
effects NN effects O
of NN stopwords O
oral NN oral T
fluoride JJ fluoride T
on NN stopwords on O
24 DIGITS CD twenty-four O
female JJ female O
, , O
Dutch-Belted CAPITAL NNP O
, , O
young NN young O
adult DT adult O
rabbits NN rabbit O
were NN stopwords be O
studied NN analyze O

American CAPITAL DT American O
Academy CAPITAL DT academy O
of NN stopwords O
Child CAPITAL NNP child O
and DT stopwords O
Adolescent CAPITAL DT adolescent O
Psychiatry CAPITAL NNP psychiatry O

The CAPITAL NNP O
Preterm CAPITAL NNP O
Prediction CAPITAL NNP prediction O
Study CAPITAL NNP survey O
: : O
association DT association O
of NN stopwords O
cesarean NNS cesarean_delivery T
delivery NN delivery T
with NN stopwords O
increases NN addition O
in NN stopwords inch O
maternal VB maternal O
weight NN weight O
and DT stopwords O
body NN body O
mass VB mass O
index NN index O

In CAPITAL PRP inch O
a DT stopwords angstrom O
subset NN subset O
of NN stopwords O
71 DIGITS CD seventy-one O
Ashkenazi CAPITAL DT Ashkenazi O
Jewish CAPITAL NNP Jewish O
women NN woman O
, , O
only JJ stopwords lone O
2 DIGITS CD two O
distinct NN distinct O
deleterious NN deleterious O
mutations NN mutant O
were NN stopwords be O
found JJ found O
: : O
185delAG CD O
in NN stopwords inch O
17 DIGITS CD seventeen O
cases VB case O
and DT stopwords O
5382insC CD O
in NN stopwords inch O
7 DIGITS CD seven O
cases VB case O

VI CAPITAL NNP six O

Of CAPITAL NNP O
37 DIGITS CD thirty-seven O
subjects NN subject O
who NN stopwords World_Health_Organization O
had VB stopwords have O
nonvertebral JJ O
fractures NN fracture O
, , O
26 DIGITS CD twenty-six O
were NN stopwords be O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O
and DT stopwords O
11 DIGITS CD eleven O
were NN stopwords be O
in NN stopwords inch O
the NN stopwords O
calcium-vitamin VB O
D CAPITAL NN vitamin_D O
group NN group O
( ( O
P=0.02 CAPITAL NNP O
) ) O

PURPOSE CAPITAL NNP purpose O
: : O
To CAPITAL NNP O
determine NN determine O
the NN stopwords O
effect NN consequence O
of NN stopwords O
various NN assorted O
methods NN method O
of NN stopwords O
managing VB pull_off O
the NN stopwords O
posterior NN buttocks O
capsule VB capsule O
and DT stopwords O
anterior DT front_tooth O
vitreous NN vitreous O
on NN stopwords on O
the NN stopwords O
rate VB rate O
of NN stopwords O
posterior NN buttocks D
capsule VB capsule D
opacification NN opacification D
in NN stopwords inch O
pediatric NN pediatric O
eyes NN eyes O
implanted JJ implant O
with NN stopwords O
posterior NN buttocks T
chamber NNS chamber T
intraocular NN T
lenses NN lens T
( ( T
PC CAPITAL NNP personal_computer T
IOLs CAPITAL PRP lens_implant T
) ) T

CONCLUSIONS CAPITAL NNP decision O
: : O
Although CAPITAL DT O
cardiac VB cardiac O
involvement NN engagement O
is NN stopwords be O
echocardiographically NN O
indistinguishable NN identical O
, , O
cardiac VB cardiac O
mortality NN mortality O
is NN stopwords be O
very NN stopwords very O
different NN different O
between NN stopwords between O
the NN stopwords O
two NN two O
forms NN form O
of NN stopwords O
amyloidosis DT amyloidosis D

The CAPITAL NNP O
GSTM1 CAPITAL NNP O
null JJ nothing O
genotype NN genotype O
was VB stopwords Washington O
detected NN detect O
in NN stopwords inch O
54 DIGITS CD fifty-four O
percent NN percentage O
of NN stopwords O
cases VB case O
and DT stopwords O
52 DIGITS CD fifty-two O
percent NN percentage O
of NN stopwords O
controls NNS control O

Paradoxically CAPITAL VB paradoxically O
the NN stopwords O
protection NN protection O
of NN stopwords O
the NN stopwords O
telomere NN telomere O
is NN stopwords be O
exactly NN precisely O
what NN stopwords O
must NN must O
be NN stopwords beryllium O
avoided DT avoid O
in NN stopwords inch O
the NN stopwords O
case VB case O
of NN stopwords O
tumor NN tumor O
cells NNS cell O

Gene CAPITAL NNP gene T
therapy NN therapy T
for NN stopwords O
cancer VB cancer D

Evidence-based CAPITAL NNP O
guidelines NN guideline O
for NN stopwords O
universal JJ universal O
counselling NNS guidance O
and DT stopwords O
offering JJ offer O
of NN stopwords O
HIV CAPITAL NNP HIV O
testing NN testing O
in NN stopwords inch O
pregnancy NN pregnancy O
in NN stopwords inch O
Canada CAPITAL VB Canada O

Amperometric CAPITAL DT O
lactate NN lactate O
oxidase IN oxidase O
catheter VB catheter O
for NN stopwords O
real-time NN real-time O
lactate NN lactate O
monitoring NN monitoring O
based VB establish O
on NN stopwords on O
thin NN thin O
film NN movie O
technology NN technology O

However CAPITAL NNP however O
, , O
limitations NN restriction O
of NN stopwords O
our NN stopwords O
study NN survey O
preclude NN prevent O
a DT stopwords angstrom O
conclusion NNS decision O
about DT stopwords about O
this NN stopwords O
potential NN potential O
interaction NN interaction O

Early CAPITAL NN early O
treatment NN treatment O
of NN stopwords O
gestational NN gestational D
diabetes NN diabetes D
reduces NN reduce O
the NN stopwords O
rate VB rate O
of NN stopwords O
fetal JJ fetal D
macrosomia VB D

RESULTS CAPITAL NNP consequence O
: : O
More CAPITAL NNP More O
than NN stopwords O
70 DIGITS CD seventy O
% NN O
of NN stopwords O
the NN stopwords O
critical JJ critical O
care VB care O
nurses RB nurse O
who NN stopwords World_Health_Organization O
responded NN react O
engage NN prosecute O
in NN stopwords inch O
exercise NN exercise O
and DT stopwords O
follow JJ follow O
a DT stopwords angstrom O
healthy NN healthy O
, , O
low-fat NN O
diet NN diet O

other JJ stopwords other T
blocks NN block T
such NN stopwords such T
as DT stopwords arsenic T
interpleural NN T
and DT stopwords T
epidural NN epidural_anesthesia T
can VB stopwords can O
be NN stopwords beryllium O
effectively NN efficaciously O
used JJ use O
in NN stopwords inch O
pleuritic NN D
pain IN pain D

We CAPITAL NNP O
now JJ stopwords now O
describe NN describe O
a DT stopwords angstrom O
case VB case O
of NN stopwords O
spontaneous NN spontaneous O
splenic NN splenic D
rupture NN rupture D
four JJ four O
days VB days O
following JJ following O
a DT stopwords angstrom O
six-day NN O
course NNS course O
of NN stopwords O
G-CSF CAPITAL NNP T
therapy NN therapy T
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
allogeneic DT allogeneic O
donor NN donor O
of NN stopwords O
peripheral NN peripheral O
blood NN blood O
stem NN root O
cells NNS cell O

Hazards CAPITAL NNP hazard O
of NN stopwords O
running NN run O
a DT stopwords angstrom O
marathon NN marathon O

Obstructive CAPITAL NNP clogging O
sleep NN sleep D
apnoea DT D

Diagnostic CAPITAL NNP diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
easily VB easily O
performed NN perform O
and DT stopwords O
inexpensive NN cheap O
test NN trial O
that NN stopwords O
may VB May O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
this NN stopwords O
situation NN situation O

Reflectometric CAPITAL NNP O
interference NN intervention O
spectroscopy NN spectroscopy O
, , O
an DT stopwords Associate_in_Nursing O
optical JJ optical O
transducer NN transducer O
which NN stopwords O
allows DT let O
the NN stopwords O
monitoring NN monitoring O
of NN stopwords O
a DT stopwords angstrom O
few JJ stopwords few O
picograms NN O
per NN O
square NN square O
millimetre NN millimeter O
changes NNS change O
in NN stopwords inch O
surface NN surface O
coverage NNS coverage O
, , O
was VB stopwords Washington O
used JJ use O
to NN stopwords O
study NN survey O
two NN two O
model NN model O
systems NN system O

Hepatic CAPITAL NNP liverwort O
arterial DT arterial O
infusion NN infusion O
of NN stopwords O
chemotherapy NNS chemotherapy T
after DT stopwords after O
resection NN resection T
of NN stopwords O
hepatic NN liverwort D
metastases NN metastasis D
from JJ stopwords O
colorectal NNS colorectal D
cancer VB cancer D

BACKGROUND CAPITAL IN background O
: : O
Inadequate CAPITAL PRP inadequate O
dietary NN dietary O
intake NN consumption O
of NN stopwords O
calcium VB calcium O
and DT stopwords O
vitamin NN vitamin O
D CAPITAL NN vitamin_D O
may VB May O
contribute NNS lend O
to NN stopwords O
the NN stopwords O
high NN high O
prevalence NN prevalence O
of NN stopwords O
osteoporosis JJ osteoporosis D
among DT O
older JJ aged O
persons NN person O

We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
bolus NN bolus T
thrombolytic NN thrombolytic T
infusions NN infusion T
during NN stopwords O
CPR CAPITAL NNP cardiopulmonary_resuscitation D
may VB May O
facilitate VB facilitate O
spontaneous NN spontaneous O
return NN tax_return O
of NN stopwords O
circulation NN circulation O
in NN stopwords inch O
select NN choose O
patients VB patient O
with NN stopwords O
confirmed NNS confirm D
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
, , O
witnessed NN witness O
cardiac VB cardiac D
arrest DT apprehension D
in NN stopwords inch O
the NN stopwords O
ED CAPITAL NNP erectile_dysfunction O
, , O
and DT stopwords O
refractory NN furnace_lining D
ventricular NN ventricular D
fibrillation NN fibrillation D
or NN stopwords Oregon O
tachycardia VB tachycardia D

in NN stopwords inch O
2 DIGITS CD two O
studies NN survey O
, , O
surgery NN surgery T
with NN stopwords O
curative NNS remedy O
intent NN purpose O
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
16 DIGITS CD sixteen O
and DT stopwords O
51 DIGITS CD fifty-one O
% NN O
of NN stopwords O
patients VB patient O
with NN stopwords O
initially JJ initially O
unresectable JJ D
liver NN liver D
metastases NN metastasis D
following JJ following O
oxaliplatin/fluorouracil/folinic NN T
acid DT acid T
therapy NN therapy T
; : O
the NN stopwords O
5-year CD O
survival NN survival O
rates VB rates O
were NN stopwords be O
40 DIGITS CD forty O
and DT stopwords O
50 DIGITS CD fifty O
% NN O
, , O
respectively NN respectively O

The CAPITAL NNP O
positive NN positive O
predictive NN predictive O
value NN value O
( ( O
predicting NN predict O
the NN stopwords O
chance NNS opportunity O
to NN stopwords O
find NN discovery O
spermatozoa NN sperm O
for NN stopwords O
ICSI CAPITAL PRP O
) ) O
of NN stopwords O
normal-sized RB O
testicle NN testis O
was VB stopwords Washington O
not JJ stopwords not O
different NN different O
from JJ stopwords O
that NN stopwords O
of NN stopwords O
small-sized JJ O
( ( O
& CC O
# # O
60 DIGITS CD sixty O
; : O
15 DIGITS CD fifteen O
ml NN milliliter O
) ) O
testicle NN testis O
( ( O
50 DIGITS CD fifty O
% NN O
) ) O

These CAPITAL NNP O
findings NN findings O
demonstrate NN show O
that NN stopwords O
the NN stopwords O
medial NN medial O
temporal NN temporal_role O
lobe NN lobe O
memory NN memory O
system NN system O
is NN stopwords be O
engaged NN prosecute O
automatically DT automatically O
when NN stopwords O
we NN stopwords O
attend DT attend O
to NN stopwords O
a DT stopwords angstrom O
perceptual NN perceptual O
event NN event O
and DT stopwords O
that NN stopwords O
the NN stopwords O
location NN location O
and DT stopwords O
amount DT sum O
of NN stopwords O
activation DT activation O
depend NN depend O
on NN stopwords on O
stimulus JJ stimulation O
characteristics NNS feature O
( ( O
physical NN physical O
form NN form O
, , O
meaning NN meaning O
) ) O
and DT stopwords O
experience NN experience O

Depression CAPITAL NNP depression D
after DT stopwords after O
childbirth JJ childbirth O
: : O
the NN stopwords O
views NN position O
of NN stopwords O
medical NN checkup O
students NN student O
and DT stopwords O
women NN woman O
compared NNS compare O

RESULTS CAPITAL NNP consequence O
: : O
Visually CAPITAL NNP visually O
significant NN significant O
secondary NN secondary O
cataract VB cataract D
developed NN develop O
in NN stopwords inch O
the NN stopwords O
five NN five O
eyes NN eyes O
with NN stopwords O
intact NN integral O
posterior NN buttocks O
capsules VB capsule O
and DT stopwords O
in NN stopwords inch O
the NN stopwords O
four JJ four O
eyes NN eyes O
that NN stopwords O
had VB stopwords have O
PCCC CAPITAL NNP T
without NN O
vitrectomy NN vitrectomy T
and DT stopwords O
without NN O
posterior NN buttocks T
optic JJ eye T
capture VB capture T
( ( O
i.e NN O
. . O
, , O
the NN stopwords O
optic JJ eye O
was VB stopwords Washington O
left NN left O
in NN stopwords inch O
the NN stopwords O
capsular VB capsular O
bag VB bag O
) ) O

Topical CAPITAL NNP topical O
dictionary NN dictionary O

The CAPITAL NNP O
Continuous CAPITAL NNP continuous O
Infusion CAPITAL PRP infusion O
versus NN O
Double-Bolus CAPITAL NNP O
Administration CAPITAL DT administration O
of NN stopwords O
Alteplase CAPITAL DT O
( ( O
COBALT CAPITAL NNP cobalt O
) ) O
Investigators CAPITAL PRP research_worker O

OBJECTIVE CAPITAL NNP aim O
AND CAPITAL DT O
IMPORTANCE CAPITAL PRP importance O
: : O
The CAPITAL NNP O
use JJ use O
of NN stopwords O
chronic NN chronic T
intrathecal NN T
morphine NN morphine T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
intractable NN intractable D
, , D
nonmalignant JJ D
pain IN pain D
is NN stopwords be O
becoming NN become O
more NN stopwords More O
prevalent NN prevailing O

< NN O
TO_SEE CAPITAL NNP O
> NN O
As CAPITAL DT arsenic O
concomitant NNS accompaniment D
thrombocytosis NN thrombocytosis D
persisted NN prevail O
despite NN contempt O
treatment NN treatment O
with NN stopwords O
hydroxyurea NN T
, , O
the NN stopwords O
new JJ new O
megakaryocyte NN megakaryocyte T
inhibitor NN inhibitor T
anagrelide DT T
( ( T
Agrelin CAPITAL DT T
) ) T
was VB stopwords Washington O
administered DT administer O
and DT stopwords O
led NN light-emitting_diode O
to NN stopwords O
normalization RB standardization O
of NN stopwords O
the NN stopwords O
platelet NN platelet O
count NNS count O
within NN inside O
11 DIGITS CD eleven O
days VB days O

However CAPITAL NNP however O
, , O
except NN demur O
for NN stopwords O
genes NN gene O
in NN stopwords inch O
the NN stopwords O
HLA CAPITAL NNP O
system NN system O
, , O
specific NN particular O
susceptibility NN susceptibility O
loci NN venue O
are DT stopwords are O
unknown JJ unknown O
or NN stopwords Oregon O
unconfirmed JJ unconfirmed O

We CAPITAL NNP O
speculate NN speculate O
that NN stopwords O
regional NN regional O
hot NN hot O
spots NN musca_volitans O
of NN stopwords O
the NN stopwords O
viverrid NN D
rabies NN rabies D
biotype NN biotype O
reflect NN reflect O
population NN population O
density NN density O
differences NN difference O
in NN stopwords inch O
the NN stopwords O
yellow NN yellow O
mongoose NN mongoose O
that NN stopwords O
are DT stopwords are O
not JJ stopwords not O
underscored JJ underscore O
by NN stopwords by O
genetic NN familial O
partitioning NN breakdown O
, , O
at DT stopwords astatine O
least NN least O
at DT stopwords astatine O
the NN stopwords O
level NN degree O
of NN stopwords O
resolution NN resolution O
provided NN supply O
by NN stopwords by O
our NN stopwords O
analyses DT analysis O

Controversies CAPITAL NNP controversy O
in NN stopwords inch O
hydrating NN hydrate O
the NN stopwords O
terminally NN terminally O
ill NN ailment O
patient VB patient O

The CAPITAL NNP O
case VB case O
of NN stopwords O
the NN stopwords O
missing NN miss O
methylphenidate NN methylphenidate T

93 DIGITS CD ninety-three O

Twin CAPITAL NNP twin O
pregnancy NN pregnancy O
and DT stopwords O
fetal JJ fetal O
and DT stopwords O
infantile NN childish O
perinatal NN perinatal D
mortality NN mortality D

When CAPITAL NNP O
indomethacin NN indomethacin T
was VB stopwords Washington O
applied DT use O
immediately JJ immediately O
after DT stopwords after O
irradiation NN irradiation O
, , O
UVR CAPITAL NNP O
( ( O
ultraviolet JJ ultraviolet O
radiation VB radiation O
) ) O
dose-dependent NN O
suppression NN suppression O
of NN stopwords O
erythema NN erythema D
was VB stopwords Washington O
demonstrated NN show O
for NN stopwords O
both NN stopwords both O
wavelengths VB wavelength O
until JJ stopwords O
36 DIGITS CD thirty-six O
h NN hydrogen O
after DT stopwords after O
irradiation NN irradiation O
when NN stopwords O
both NN stopwords both O
indomethacin NN indomethacin O
and DT stopwords O
control NNS control O
gel NN gel O
base-treated VB O
sites NN site O
were NN stopwords be O
equally NN equally O
erythematous NN erythematous O

Mucous CAPITAL NNP mucous D
membrane NN membrane D
melanomas NN melanoma D
of NN stopwords O
the NN stopwords O
upper JJ upper_berth O
aerodigestive DT O
tract NN tract O

Laying CAPITAL VB laying O
the NN stopwords O
foundation JJ foundation O
for NN stopwords O
Healthy CAPITAL NNP healthy O
People CAPITAL NNP people O
2010 DIGITS CD O

Effects CAPITAL NNP effects O
of NN stopwords O
dobutamine NN T
at DT stopwords astatine O
maximally VB maximally O
tolerated NN digest O
dose NN dose O
on NN stopwords on O
myocardial NN myocardial O
blood NN blood O
flow JJ flow O
in NN stopwords inch O
humans NN world O
with NN stopwords O
ischemic NN ischemic D
heart NN heart D
disease NN disease D
. . O

Neuropeptides CAPITAL NNP O
in NN stopwords inch O
Development CAPITAL NNP development O
and DT stopwords O
Aging CAPITAL DT ripening O

IPPB CAPITAL PRP T
in NN stopwords inch O
severe NN severe D
pulmonary NN pneumonic D
emphysema NN emphysema D
: : O
limited NN express O
applications DT application O

Transesophageal CAPITAL NNP O
echocardiography NN echocardiography O
probe NN probe O
holder NN holder O

State CAPITAL NNP state O
regulation NN regulation O
in NN stopwords inch O
a DT stopwords angstrom O
world NN universe O
of NN stopwords O
`` `` O
boundary-less NN O
'' POS O
technology NN technology O

Dyspepsia CAPITAL NNP indigestion D

Calcium CAPITAL VB calcium T
antagonists DT adversary T
have VB stopwords rich_person O
been NN stopwords be O
used JJ use O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
cardiovascular VB cardiovascular D
diseases NN disease D
for NN stopwords O
more NN stopwords More O
than NN stopwords O
25 DIGITS CD twenty-five O
years NN old_age O

Breastfeeding CAPITAL NNP breastfeed O
and DT stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
pacifiers VB conciliator O

There CAPITAL NNP there O
was VB stopwords Washington O
no NNS stopwords no O
significant NN significant O
difference NN difference O
in NN stopwords inch O
the NN stopwords O
reason NN reason O
for NN stopwords O
delivery NN delivery O
between NN stopwords between O
the NN stopwords O
two NN two O
groups NN group O
of NN stopwords O
patients VB patient O

Septic CAPITAL NNP septic D
arthritis DT arthritis D

USAN CAPITAL NNP O
Council CAPITAL NNP council O

The CAPITAL NNP O
results NN consequence O
lends NN lend O
further NN stopwords foster O
support NN support O
to NN stopwords O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
the NN stopwords O
brain NN brain O
serotonergic NN O
system NN system O
plays NN play O
a DT stopwords angstrom O
key NN key O
role NN function O
in NN stopwords inch O
integrating NN integration O
autonomic DT autonomic O
, , O
behavioral NN behavioral O
and DT stopwords O
neuroendocrine JJ neuroendocrine O
stress-responses NN O
in NN stopwords inch O
fish NN fish O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
mammals VB mammal O
, , O
suggesting NN propose O
that NN stopwords O
not JJ stopwords not O
only JJ stopwords lone O
the NN stopwords O
structural NN structural O
and DT stopwords O
biochemical NN biochemical O
organization JJ organization O
, , O
but NN stopwords merely O
also DT besides O
the NN stopwords O
function JJ function O
of NN stopwords O
the NN stopwords O
serotonergic NN O
system NN system O
has VB stopwords hour_angle O
been NN stopwords be O
conserved NNS conserve O
during NN stopwords O
vertebrate NN vertebrate O
evolution NN development O

Long-term CAPITAL NNP long-run O
benefit NN benefit O
of NN stopwords O
one JJ one O
thrombolytic NN thrombolytic T
over JJ stopwords over O
another DT another O

Proceedings CAPITAL NNP proceeding O

The CAPITAL NNP O
50 DIGITS CD fifty O
% NN O
and DT stopwords O
95 DIGITS CD ninety-five O
% NN O
effective NN effective O
dose NN dose O
values NN values O
for NN stopwords O
each VB stopwords each O
opioid IN O
to NN stopwords O
achieve DT achieve O
a DT stopwords angstrom O
VAS CAPITAL VB vessel O
score JJ mark O
& CC O
# # O
60 DIGITS CD sixty O
; : O
10 DIGITS CD ten O
mm NNS millimeter O
were NN stopwords be O
F CAPITAL NN degree_Fahrenheit O
33 DIGITS CD thirty-three O
microg NN O
and DT stopwords O
92 DIGITS CD ninety-two O
microg NN O
and DT stopwords O
S CAPITAL NN second O
6.7 CD O
microg NN O
and DT stopwords O
17.5 CD O
microg NN O

Cyclic CAPITAL NNP cyclic O
AMP CAPITAL DT ampere O
inhibitors NN inhibitor O
inhibits NN suppress O
PDGF-stimulated CAPITAL NNP O
mitogen-activated NN O
protein NN protein O
kinase NN kinase O
activity DT activity O
in NN stopwords inch O
rat VB rat O
aortic DT aortal O
smooth JJ smooth O
muscle NN muscle O
cells NNS cell O
via NN O
inactivation NN inactivation O
of NN stopwords O
c-Raf-1 SYM O
kinase NN kinase O
and DT stopwords O
induction NN initiation O
of NN stopwords O
MAP CAPITAL NNP map O
kinase NN kinase O
phosphatase-1 NN O

Several CAPITAL NNP several O
dioxins NN dioxin O
are DT stopwords are O
extremely NN highly O
stable NN stable O
compounds NNS compound O
and DT stopwords O
persist NN prevail O
for NN stopwords O
years NN old_age O
in NN stopwords inch O
the NN stopwords O
environment NN environment O

Chronic CAPITAL NNP chronic O
telogen NN D
effluvium NN effluvium D
: : O
potential NN potential O
complication NNS complication O
for NN stopwords O
clinical JJ clinical O
trials NN test O
in NN stopwords inch O
female JJ female O
androgenetic DT androgenetic D
alopecia DT alopecia D
? . O

1981 DIGITS CD O

A CAPITAL DT angstrom O
simple NN simple O
technique NN technique O
for NN stopwords O
correction NNS correction O
of NN stopwords O
mucosal NN mucosal D
irregularities NN abnormality D
of NN stopwords D
the NN stopwords D
lip NN lip D

BACKGROUND CAPITAL IN background O
: : O
Drainage CAPITAL NNP drain O
methods NN method O
for NN stopwords O
the NN stopwords O
gastric VB gastric O
conduit NNS conduit O
after DT stopwords after O
esophagectomy NN T
for NN stopwords O
carcinoma VB carcinoma D
have VB stopwords rich_person O
been NN stopwords be O
controversial NNS controversial O

The CAPITAL NNP O
role NN function O
of NN stopwords O
the NN stopwords O
extracellular NN extracellular O
signal-related NN O
kinase NN kinase O
( ( O
ERK CAPITAL NNP O
) ) O
signaling NN signal O
pathway VB nerve_pathway O
in NN stopwords inch O
the NN stopwords O
HMGI-C CAPITAL NNP O
induction NN initiation O
was VB stopwords Washington O
highlighted NN foreground O
by NN stopwords by O
the NN stopwords O
result NN consequence O
that NN stopwords O
the NN stopwords O
MAP CAPITAL NNP map O
kinase NN kinase O
kinase NN kinase O
( ( O
MEK CAPITAL NNP Mujahidin-e_Khalq_Organization O
) ) O
inhibitor NN inhibitor O
, , O
PD CAPITAL NNP palladium O
98059 DIGITS CD O
, , O
blocked NN barricade O
DeltaRaf-1 CAPITAL NNP O
: : O
ER- CAPITAL NNP O
and DT stopwords O
12-O-tetradecanoylphorbol-13-acetate-stimulated CD O
HMGI-C CAPITAL NNP O
induction NN initiation O

The CAPITAL NNP O
role NN function O
of NN stopwords O
the NN stopwords O
school JJ school O
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
attention DT attention D
deficit NN deficit D
hyperactivity NN hyperactivity D
disorder NN disorder D

Because CAPITAL NNP O
exploratory NN exploratory T
celiotomy NNS T
is NN stopwords be O
routinely NN routinely O
performed NN perform O
on NN stopwords on O
patients VB patient O
with NN stopwords O
gunshot NN gunfire D
wounds NN wound D
to NN stopwords D
the NN stopwords D
abdomen DT abdomen D
, , O
DPL CAPITAL NNP O
is NN stopwords be O
rarely NN rarely O
employed NN use O

Therefore CAPITAL NNP therefore O
, , O
it NN stopwords information_technology O
can VB stopwords can O
be NN stopwords beryllium O
concluded NNS reason O
that NN stopwords O
with NN stopwords O
two NN two O
injections NN injection O
of NN stopwords O
the NN stopwords O
high-dose NN O
hepatitis NN hepatitis D
A CAPITAL DT angstrom D
and DT stopwords D
B CAPITAL NN bacillus D
vaccine NN vaccine T
, , O
6 DIGITS CD six O
months NN calendar_month O
apart DT apart O
, , O
a DT stopwords angstrom O
similar NN similar O
immune JJ immune O
response NN response O
can VB stopwords can O
be NN stopwords beryllium O
obtained NN obtain O
as DT stopwords arsenic O
induced NN induce O
with NN stopwords O
three NN three O
doses NN dose O
of NN stopwords O
Twinrix CAPITAL NNP T
at DT stopwords astatine O
months NN calendar_month O
0 DIGITS CD zero O
, , O
1 DIGITS CD one O
and DT stopwords O
6 DIGITS CD six O

The CAPITAL NNP O
mean NN mean O
training NN training O
time NN time O
per NN O
week NN week O
was VB stopwords Washington O
3.2 LS O
+/- NN O
0.8 LS O
h. NN O
In CAPITAL PRP inch O
the NN stopwords O
entire NN stallion O
group NN group O
of NN stopwords O
female JJ female O
dancers VB dancer O
, , O
no NNS stopwords no O
significant NN significant O
effects NN effects O
of NN stopwords O
dancing VB dancing O
on NN stopwords on O
radial VB radial O
or NN stopwords Oregon O
lumbar NN lumbar O
bone NN bone O
density NN density O
could NNS O
be NN stopwords beryllium O
observed NN detect O

Auto-uro CAPITAL DT T
therapy NN therapy T
: : O
status NN status O
and DT stopwords O
future JJ future O
prospects NN prospect O

Surgery CAPITAL NNP surgery T
for NN stopwords O
chronic NN chronic D
thromboembolic NN D
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D

I CAPITAL PRP iodine O
. . O
The CAPITAL NNP O
production NN production O
and DT stopwords O
detection NN detection O
of NN stopwords O
anti-insulin DT O
serum NN serum O
and DT stopwords O
anti-guinea-pig DT O
globulin NN globulin O
rabbit NN rabbit O
serum NN serum O

Review CAPITAL NNP reappraisal O
and DT stopwords O
personal NN personal O
cases VB case O

Perforated CAPITAL NNP punch D
peptic NN peptic D
ulcer JJ ulcer D
in NN stopwords inch O
pregnancy NN pregnancy O

Histochemistry CAPITAL NNP O
of NN stopwords O
hydrolytic NN O
and DT stopwords O
oxidative IN oxidative O
enzymes NN enzyme O
in NN stopwords inch O
the NN stopwords O
human NN homo O
and DT stopwords O
experimentally NN experimentally O
induced NN induce O
adenocarcinoma DT adenocarcinoma D
of NN stopwords O
the NN stopwords O
endometrium NN endometrium O

Evaluating CAPITAL NNP measure O
prostate NN prostate_gland T
needle JJ acerate_leaf T
biopsy NN biopsy T
: : O
therapeutic NN remedy O
and DT stopwords O
prognostic NN omen O
importance JJ importance O

In CAPITAL PRP inch O
three NN three O
patients VB patient O
no NNS stopwords no O
lesion NN lesion O
was VB stopwords Washington O
identified NN identify O
despite NN contempt O
sustained NN prolong O
clinical JJ clinical O
improvement JJ improvement O

Homology CAPITAL NNP homology O
modeling NN mold O
of NN stopwords O
adenylosuccinate DT O
synthetase NN O
from JJ stopwords O
Saccharomyces CAPITAL VB Saccharomyces O
cerevisiae NNS O
reveals NN uncover O
a DT stopwords angstrom O
possible NN possible O
binding NN binding O
region NN region O
for NN stopwords O
single-stranded NN single-stranded O
ARS CAPITAL DT argon O
sequences NN sequence O

The CAPITAL NNP O
function JJ function O
of NN stopwords O
the NN stopwords O
short NN short O
form NN form O
was VB stopwords Washington O
examined NN analyze O
after DT stopwords after O
cotransfection NNS O
of NN stopwords O
both NN stopwords both O
the NN stopwords O
long NN hanker O
and DT stopwords O
short NN short O
forms NN form O

Mutations CAPITAL NNP mutant O
of NN stopwords O
the NN stopwords O
Drosophila CAPITAL NNP drosophila O
dDP NN O
, , O
dE2F NN O
, , O
and DT stopwords O
cyclin NNS O
E CAPITAL NN vitamin_E O
genes NN gene O
reveal NN uncover O
distinct NN distinct O
roles NN function O
for NN stopwords O
the NN stopwords O
E2F-DP CAPITAL RB O
transcription NN transcription O
factor VB factor O
and DT stopwords O
cyclin NNS O
E CAPITAL NN vitamin_E O
during NN stopwords O
the NN stopwords O
G1-S CAPITAL NNP O
transition NN passage O

CONCLUSIONS CAPITAL NNP decision O
: : O
Families CAPITAL NNP family O
that NN stopwords O
provide NN supply O
evidence NN evidence O
for NN stopwords O
segregation NN segregation O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
altered DT change O
HPC1 CAPITAL NNP O
gene NN gene O
are DT stopwords are O
characterized NNS qualify O
by NN stopwords by O
multiple NN multiple O
cases VB case O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
that NN stopwords O
, , O
in NN stopwords inch O
most NN stopwords most O
respects NN respects O
, , O
are DT stopwords are O
indistinguishable NN identical O
from JJ stopwords O
nonhereditary JJ nonhereditary O
cases VB case O

Endoscopic CAPITAL NNP endoscopic T
ultrasound JJ ultrasound T
miniprobe-guided NN T
steroid NN steroid T
injection NN injection T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
refractory NN furnace_lining D
esophageal NN esophageal D
strictures NN stenosis D

The CAPITAL NNP O
family VB family O
physician NN doctor O
and DT stopwords O
cervical NNS cervical D
carcinoma VB carcinoma D
-- : O
challenge NNS challenge O
and DT stopwords O
opportunity JJ opportunity O

Magnetic CAPITAL NNP magnetic O
resonance NN resonance O
imaging NN imagination O
analysis DT analysis O
showed NN show O
that NN stopwords O
intraoperative NN O
microelectrode NN O
recording NN recording O
facilitated VB facilitate O
accurate DT accurate O
placement NN placement O
of NN stopwords O
the NN stopwords O
lesion NN lesion O
in NN stopwords inch O
this NN stopwords O
critical JJ critical O
area DT area O

The CAPITAL NNP O
market NN market O
for NN stopwords O
health NN health O
care VB care O
: : O
where NN stopwords O
is NN stopwords be O
the NN stopwords O
patient VB patient O
? . O

RESULTS CAPITAL NNP consequence O
: : O
Twenty-four CAPITAL NNP twenty-four O
women NN woman O
( ( O
mean NN mean O
( ( O
+/-SD NN O
) ) O
age DT age O
, , O
44+/-8 CD O
years NN old_age O
) ) O
were NN stopwords be O
evaluated NN measure O
12.3+/-7.1 CD O
months NN calendar_month O
after DT stopwords after O
the NN stopwords O
initiation JJ initiation O
of NN stopwords O
fenfluramine-phentermine JJ T
therapy NN therapy T

1 DIGITS CD one O
mM NNS millimeter O
) ) O
suggest NN propose O
that NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
modulates NN modulate O
most NN stopwords most O
of NN stopwords O
the NN stopwords O
reactions NN chemical_reaction O
of NN stopwords O
peroxynitrite NN O
in NN stopwords inch O
biological NN biological O
systems NN system O

This CAPITAL NNP O
approach DT approach O
is NN stopwords be O
being NN stopwords being O
extended NN widen O
to NN stopwords O
the NN stopwords O
clinic JJ clinic O
, , O
and DT stopwords O
trials NN test O
are DT stopwords are O
now JJ stopwords now O
underway JJ afoot O
evaluating NN measure O
combinations NNS combination O
of NN stopwords O
interferon NN interferon T
and DT stopwords O
various NN assorted O
cytotoxic NNS cytotoxic T
drugs NN drug T
known NN know O
from JJ stopwords O
previous NN previous O
studies NN survey O
to NN stopwords O
be NN stopwords beryllium O
active DT active_agent O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
low-grade NN low-grade D
non-Hodgkin JJ D
's POS D
lymphomas NN lymphoma D

Those CAPITAL NNP O
data VB data O
show NN show O
that NN stopwords O
after DT stopwords after O
this NN stopwords O
time NN time O
has VB stopwords hour_angle O
elapsed NN elapse O
, , O
contrary NNS reverse O
to NN stopwords O
the NN stopwords O
expectation NN expectation O
of NN stopwords O
the NN stopwords O
LPL CAPITAL NNP O
model NN model O
, , O
survival NN survival O
can VB stopwords can O
be NN stopwords beryllium O
increased NN increase O
by NN stopwords by O
changing NNS change O
the NN stopwords O
medium NN medium O
used JJ use O
for NN stopwords O
delayed NN delay O
plating NN plating O
from JJ stopwords O
fresh JJ fresh O
growth NN growth O
medium NN medium O
to NN stopwords O
conditioned NNS condition O
medium NN medium O

Exon/intron CAPITAL NNP O
structure NN structure O
of NN stopwords O
the NN stopwords O
human NN homo O
AF-4 CAPITAL DT O
gene NN gene O
, , O
a DT stopwords angstrom O
member NN member O
of NN stopwords O
the NN stopwords O
AF-4/LAF-4/FMR-2 CAPITAL DT O
gene NN gene O
family VB family O
coding NNS cryptography O
for NN stopwords O
a DT stopwords angstrom O
nuclear JJ nuclear O
protein NN protein O
with NN stopwords O
structural NN structural O
alterations DT change O
in NN stopwords inch O
acute DT acute_accent O
leukaemia NN leukemia D

< NN O
TO_SEE CAPITAL NNP O
> NN O
New-onset CAPITAL NNP O
angina DT angina O
preceding NN predate O
acute DT acute_accent O
myocardial NN myocardial O
infarction NN infarct O
is NN stopwords be O
associated DT associate O
with NN stopwords O
improved JJ better O
contractile NNS contractile O
recovery NN recovery O
after DT stopwords after O
thrombolysis NN thrombolysis O

Remifentanil CAPITAL NNP T
in NN stopwords inch O
the NN stopwords O
critically JJ critically O
ill NN ailment O

'' POS O
Combined CAPITAL NNP unite O
pediatric NN pediatric O
and DT stopwords O
radiation VB radiation O
oncology JJ oncology O
grand NN thousand O
rounds NN round O
addresses DT address O
severe NN severe O
illness NN illness O
and DT stopwords O
death NN death O

Intra-abdominal CAPITAL PRP D
injury NN injury D
was VB stopwords Washington O
present NN present O
in NN stopwords inch O
32 DIGITS CD thirty-two O
( ( O
73 DIGITS CD seventy-three O
% NN O
) ) O
of NN stopwords O
these NN stopwords O
patients VB patient O

Coexistence CAPITAL NNP coexistence O
of NN stopwords O
subdural NN subdural O
and DT stopwords O
archnoidal DT O
collections NNS collection O
of NN stopwords O
fluid JJ fluid O
: : O
an DT stopwords Associate_in_Nursing O
unusual JJ unusual O
case VB case O

In CAPITAL PRP inch O
vitro NN O
radiation-induced VB O
apoptosis DT apoptosis O
and DT stopwords O
tumour NN tumor O
response NN response O
to NN stopwords O
radiotherapy VB radiotherapy T
: : O
a DT stopwords angstrom O
prospective NN prospective O
study NN survey O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
non-Hodgkin JJ D
lymphomas NN lymphoma D
treated NN treat O
by NN stopwords by O
low-dose NN T
irradiation NN irradiation T

The CAPITAL NNP O
problems NN problem O
of NN stopwords O
staging NN theatrical_production O
and DT stopwords O
grading NN scaling O

Treatment CAPITAL NNP treatment O
of NN stopwords O
irritable NN cranky D
bowel NN intestine D
syndrome NN syndrome D
with NN stopwords O
Chinese CAPITAL NNP Chinese T
herbal NN herb_tea T
medicine NN medicine T
: : O
a DT stopwords angstrom O
randomized VB randomize O
controlled NNS control O
trial NN test O

We CAPITAL NNP O
hypothesize NN speculate O
that NN stopwords O
there NN stopwords there O
is NN stopwords be O
a DT stopwords angstrom O
higher NN higher O
incidence NN incidence O
of NN stopwords O
preeclampsia NN preeclampsia D
( ( D
proteinuric NN D
hypertension NN high_blood_pressure D
) ) D
in NN stopwords inch O
women NN woman O
conceiving NNS gestate O
by NN stopwords by O
intrauterine NN intrauterine O
insemination NN insemination O
with NN stopwords O
donor NN donor O
sperm NN sperm O
versus NN O
intrauterine NN intrauterine O
insemination NN insemination O
with NN stopwords O
partner NN spouse O
sperm NN sperm O

Histologic CAPITAL NNP histological O
diagnosis NN diagnosis O
of NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
, , O
grading NN scaling O
and DT stopwords O
staging NN theatrical_production O

The CAPITAL NNP O
risk NN hazard O
of NN stopwords O
high NN high O
systolic NN systolic O
blood NN blood O
pressure NN pressure O
was VB stopwords Washington O
also DT besides O
lower NN lower_berth O
in NN stopwords inch O
the NN stopwords O
calcium VB calcium O
group NN group O
than NN stopwords O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O
( ( O
relative NN relative O
risk NN hazard O
0.59 LS O
; : O
0.39 LS O
to NN stopwords O
0.90 LS O
) ) O
and DT stopwords O
particularly NN particularly O
among DT O
children JJ child O
in NN stopwords inch O
the NN stopwords O
highest NN high O
fourth JJ fourth O
of NN stopwords O
body NN body O
mass VB mass O
index NN index O
( ( O
0.43 LS O
; : O
0.26 LS O
to NN stopwords O
0.71 LS O
) ) O

This CAPITAL NNP O
study NN survey O
tested NN test O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
to NN stopwords O
reduce NN reduce O
the NN stopwords O
rate VB rate O
of NN stopwords O
macrosomic VB O
infants NN baby O
in NN stopwords inch O
gestational NN gestational O
diabetes NN diabetes O
cases VB case O
, , O
good NN good O
glycemic NN O
control NNS control O
should NN stopwords O
be NN stopwords beryllium O
initiated JJ originate O
before NN stopwords earlier O
34 DIGITS CD thirty-four O
completed NNS complete O
gestational NN gestational O
weeks NN week O

The CAPITAL NNP O
TQR CAPITAL NNP O
method NN method O
to NN stopwords O
facilitate VB facilitate O
monitoring NN monitoring O
of NN stopwords O
the NN stopwords O
recovery NN recovery O
process NN procedure O
is NN stopwords be O
then NN stopwords then O
suggested NN propose O
and DT stopwords O
a DT stopwords angstrom O
conceptual NNS conceptual O
model NN model O
that NN stopwords O
incorporates NN integrate O
all DT stopwords all O
of NN stopwords O
the NN stopwords O
important JJ important O
parameters NN parameter O
for NN stopwords O
performance NN performance O
gain NN addition O
( ( O
adaptation DT adaptation O
) ) O
and DT stopwords O
loss NN loss O
( ( O
maladaptation VB O
) ) O

A CAPITAL DT angstrom O
priori NN O
stratification NN stratification O
by NN stopwords by O
APOE CAPITAL DT O
genotype NN genotype O
identified NN identify O
27 DIGITS CD twenty-seven O
families VB family O
that NN stopwords O
had VB stopwords have O
at DT stopwords astatine O
least NN least O
1 DIGITS CD one O
member NN member O
with NN stopwords O
AD CAPITAL DT ad O
whose NN O
genotype NN genotype O
did NN stopwords make O
not JJ stopwords not O
contain NNS incorporate O
an DT stopwords Associate_in_Nursing O
APOE*4 CAPITAL DT O
allele DT allele O

Finally CAPITAL NNP finally O
, , O
in NN stopwords inch O
vivo NN O
administration DT administration O
of NN stopwords O
recombinant NN recombinant O
TRAIL CAPITAL NNP trail T
substantially NN well O
inhibited NN suppress O
subcutaneous NN hypodermic O
tumor NN tumor O
growth NN growth O
of NN stopwords O
human NN homo O
cholangiocarcinoma NNS D
cells NNS cell O

Reflex CAPITAL NNP reflex D
sympathetic NN sympathetic D
dystrophy NN muscular_dystrophy D
: : O
fact VB fact O
and DT stopwords O
fiction NN fiction O

The CAPITAL NNP O
study NN survey O
was VB stopwords Washington O
controlled NNS control O
for NN stopwords O
other JJ stopwords other O
factors VB factor O
that NN stopwords O
could NNS O
influence NN influence O
the NN stopwords O
parasite NN parasite O
's POS O
prevalence NN prevalence O
, , O
such NN stopwords such O
as DT stopwords arsenic O
the NN stopwords O
availability DT handiness O
of NN stopwords O
intermediate NN intermediate O
hosts NN host O

results NN consequence O
: : O
all DT stopwords all O
patients VB patient O
experienced NN experience O
improvement JJ improvement O
of NN stopwords O
grades NN class O
of NN stopwords O
both NN stopwords both O
dysphagia NN dysphagia D
and DT stopwords D
respiratory NN respiratory D
symptoms NN symptom D
after DT stopwords after O
stent NN stent T
therapy NN therapy T

Using CAPITAL NNP exploitation O
a DT stopwords angstrom O
positional NN positional O
cloning NNS cloning O
strategy NN scheme O
, , O
we NN stopwords O
have VB stopwords rich_person O
identified NN identify O
the NN stopwords O
gene NN gene O
( ( O
PDS CAPITAL NNP palladium O
) ) O
mutated NN mutate O
in NN stopwords inch O
Pendred CAPITAL NNP D
syndrome NN syndrome D
and DT stopwords O
found JJ found O
three NN three O
apparently DT apparently O
deleterious NN deleterious O
mutations NN mutant O
, , O
each VB stopwords each O
segregating NN segregate O
with NN stopwords O
the NN stopwords O
disease NN disease O
in NN stopwords inch O
the NN stopwords O
respective NN respective O
families VB family O
in NN stopwords inch O
which NN stopwords O
they NN stopwords O
occur JJ happen O

Trisomy CAPITAL NNP trisomy D
21 DIGITS CD twenty-one D
presented NN show O
with NN stopwords O
the NN stopwords O
following JJ following O
features NN feature O
: : O
hydramnios NN hydramnios O
, , O
complex NNS complex O
malformations VB deformity O
, , O
pyelectasis NN D
, , O
and DT stopwords O
duodenal NN duodenal D
atresia DT atresia D

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

A CAPITAL DT angstrom O
proposal NN proposal O
is NN stopwords be O
made VB make O
for NN stopwords O
a DT stopwords angstrom O
standard NN standard O
signal NN signal O
management VB management O
procedure NN procedure O
at DT stopwords astatine O
pharmacovigilance NN O
centres NNS Centre O
, , O
including NN include O
the NN stopwords O
following JJ following O
steps NN stairs O
: : O
signal NN signal O
delineation NN word_picture O
, , O
literature NN literature O
search NN search O
, , O
preliminary NN preliminary O
inventory NN inventory O
of NN stopwords O
data VB data O
, , O
collection NNS collection O
of NN stopwords O
additional DT extra O
information NN information O
, , O
consultation NNS consultation O
with NN stopwords O
the NN stopwords O
World CAPITAL NNP universe O
Health CAPITAL NNP health O
Organization CAPITAL NNP organization O
Centre CAPITAL NNP Centre O
for NN stopwords O
International CAPITAL PRP International O
Drug CAPITAL NNP drug O
Monitoring CAPITAL NNP monitoring O
and DT stopwords O
the NN stopwords O
relevant NN relevant O
drug NN drug O
companies NNS company O
, , O
aggregated DT aggregate O
data VB data O
assessment DT appraisal O
and DT stopwords O
a DT stopwords angstrom O
report NN report O
in NN stopwords inch O
writing NN writing O

Consequently CAPITAL NNP consequently O
, , O
the NN stopwords O
number JJ number O
of NN stopwords O
athletes DT athlete O
who NN stopwords World_Health_Organization O
are DT stopwords are O
overtraining JJ O
and DT stopwords O
have VB stopwords rich_person O
insufficient NN insufficient O
rest NN remainder O
is NN stopwords be O
increasing NN increase O

Two CAPITAL NNP two O
NICUs CAPITAL NNP neonatal_intensive_care_unit O
preferred NN prefer O
to NN stopwords O
admit DT admit O
infants NN baby O
to NN stopwords O
incubators NN incubator O
, , O
the NN stopwords O
other JJ stopwords other O
three NN three O
favoring VB prefer O
radiant VB beaming O
warmers NN heater O

However CAPITAL NNP however O
, , O
negative JJ negative O
overtraining JJ O
, , O
causing VB causing O
maladaptation VB O
and DT stopwords O
other JJ stopwords other O
negative JJ negative O
consequences NNS consequence O
such NN stopwords such O
as DT stopwords arsenic O
staleness NN triteness O
, , O
can VB stopwords can O
occur JJ happen O

conclusion NNS decision O
: : O
extracorporeal NN T
photopheresis NN T
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
a DT stopwords angstrom O
promising NN promise O
therapy NN therapy O
for NN stopwords O
patients VB patient O
with NN stopwords O
early VB early D
bos NN Bos D

No CAPITAL NNP no O
racial VB racial O
differences NN difference O
were NN stopwords be O
found JJ found O
for NN stopwords O
blood NN blood O
vessel NN vessel O
and DT stopwords O
lymphatic NN lymphatic D
invasion NN invasion D
, , O
necrosis JJ necrosis D
, , O
fibrosis NN fibrosis D
, , O
and DT stopwords O
mucinous NN mucinous O
type NN type O
of NN stopwords O
histology NN histology O

The CAPITAL NNP O
metabolism NN metamorphosis O
of NN stopwords O
cortisol NNS hydrocortisone O
by NN stopwords by O
human NN homo O
extra-hepatic NN O
tissues NN tissue O

Psoas CAPITAL NNP psoas D
abscess DT abscess D

Sarasota CAPITAL VB Sarasota O
, , O
Florida CAPITAL NNP Florida O
, , O
USA CAPITAL NNP United_States O

gemcitabine NN T
and DT stopwords T
carboplatin VB T
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D

A CAPITAL DT angstrom O
field NN field O
study NN survey O
was VB stopwords Washington O
carried VB transport O
out JJ stopwords out O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
effect NN consequence O
of NN stopwords O
vaccination NN inoculation T
against DT stopwords O
swine JJ swine D
enzootic NN enzootic D
pneumonia NN pneumonia D
in NN stopwords inch O
different NN different O
production NN production O
systems NN system O
( ( O
closed NNS close O
or NN stopwords Oregon O
one-site JJ O
, , O
and DT stopwords O
open JJ open O
, , O
two- NN O
or NN stopwords Oregon O
three-site NN O
, , O
systems NN system O
) ) O

The CAPITAL NNP O
optical JJ optical O
axis DT axis O
remained NN stay O
clear NNS clear O
in NN stopwords inch O
the NN stopwords O
six NN six O
eyes NN eyes O
that NN stopwords O
had VB stopwords have O
PC CAPITAL NNP personal_computer T
IOL CAPITAL PRP lens_implant T
implantation JJ implantation T
with NN stopwords O
vitrectomy NN vitrectomy T
( ( O
with NN stopwords O
or NN stopwords Oregon O
without NN O
posterior NN buttocks T
optic JJ eye T
capture VB capture T
) ) O

Comparing CAPITAL NNP comparison O
the NN stopwords O
efficacy NN efficacy O
and DT stopwords O
safety VB safety O
of NN stopwords O
fluoxetine JJ fluoxetine T
and DT stopwords O
venlafaxine NN T
in NN stopwords inch O
outpatient JJ outpatient D
depression NN depression D

Reduced CAPITAL NNP reduce O
ratio VB ratio O
of NN stopwords O
male VB male O
to NN stopwords O
female JJ female O
births NN birth O
in NN stopwords inch O
several NN several O
industrial NN industrial O
countries NNS state O
: : O
a DT stopwords angstrom O
sentinel NN lookout O
health NN health O
indicator NN index O
? . O

In CAPITAL PRP inch O
three NN three O
consecutive NNS back-to-back O
Phase CAPITAL NNP phase O
II CAPITAL PRP two O
trials NN test O
of NN stopwords O
recombinant NN recombinant T
interferon NN interferon T
alfa-2a DT T
( ( O
rIFN NN O
alfa-2a DT O
; : O
Roferon-A CAPITAL NNP O
Hoffmann-La CAPITAL NNP O
Roche CAPITAL NNP O
, , O
Nutley CAPITAL NNP O
, , O
NJ CAPITAL NNP New_Jersey O
) ) O
involving NN involve O
96 DIGITS CD ninety-six O
patients VB patient O
with NN stopwords O
advanced DT advance D
malignant VB malignant D
melanoma NN melanoma D
, , O
an DT stopwords Associate_in_Nursing O
overall JJ overall O
response NN response O
rate VB rate O
of NN stopwords O
22 DIGITS CD twenty-two O
% NN O
was VB stopwords Washington O
observed NN detect O

Extracts CAPITAL NNP infusion O
of NN stopwords O
the NN stopwords O
secondary NN secondary O
tubers NN tuber O
of NN stopwords O
Devil CAPITAL NNP Satan T
's POS T
Claw CAPITAL NNP claw T
( ( T
Harpagophytum CAPITAL NNP T
procumbens NN T
) ) T
are DT stopwords are O
recommended NN recommend O
for NN stopwords O
the NN stopwords O
supportive NN supportive O
treatment NN treatment O
of NN stopwords O
degenerative NN degenerative D
painful IN painful D
rheumatism NN rheumatism D

Update CAPITAL NNP update O
on NN stopwords on O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
research NN research O

The CAPITAL NNP O
embryonic NN embryonic O
development NN development O
of NN stopwords O
the NN stopwords O
face VB face O
has VB stopwords hour_angle O
been NN stopwords be O
studied NN analyze O
in NN stopwords inch O
many VB many O
reviews NN reappraisal O
, , O
this NN stopwords O
work NN work O
purposes NN purpose O
only JJ stopwords lone O
to NN stopwords O
clear NNS clear O
up JJ stopwords up O
some NN stopwords some O
points NN point O
which NN stopwords O
remain NN stay O
obscure NN obscure O
concerning NNS refer O
cervico-facial NNS O
morphogenesis NN morphogenesis O

Some CAPITAL NNP some O
complications NNS complication O
may VB May O
occur JJ happen O
even NN evening O
following JJ following O
TEFNA CAPITAL NNP T

Somatic CAPITAL NNP bodily O
mesoderm NN mesoderm O
differentiation NN differentiation O
and DT stopwords O
the NN stopwords O
development NN development O
of NN stopwords O
a DT stopwords angstrom O
subset NN subset O
of NN stopwords O
pericardial NN pericardial O
cells NNS cell O
depend NN depend O
on NN stopwords on O
the NN stopwords O
not JJ stopwords not O
enough NN enough O
muscles NN muscle O
( ( O
nem JJ O
) ) O
locus NN venue O
, , O
which NN stopwords O
contains NNS incorporate O
the NN stopwords O
inscuteable NN O
gene NN gene O
and DT stopwords O
the NN stopwords O
intron NN intron O
located NN locate O
gene NN gene O
, , O
skittles JJ ninepins O

The CAPITAL NNP O
2D CD second O
NMR CAPITAL NNP nuclear_magnetic_resonance O
experiments NN experiment O
H CAPITAL NN hydrogen O
( ( O
C CAPITAL SYM degree_centigrade O
) ) O
CO2 CAPITAL NNP carbon_dioxide O
and DT stopwords O
HCCO2 CAPITAL NNP O
for NN stopwords O
assignment DT assignment O
and DT stopwords O
pH NN pH O
titration NN titration O
of NN stopwords O
carboxylate VB carboxylate O
groups NN group O
in NN stopwords inch O
uniformly JJ uniformly O
15N/13C-labeled CD O
proteins NN protein O

Background CAPITAL IN background O
: : O
Troglitazone CAPITAL NNP T
is NN stopwords be O
a DT stopwords angstrom O
new JJ new O
drug NN drug O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
type NN type D
2 DIGITS CD two D
diabetes NN diabetes D

The CAPITAL NNP O
histopathological NN O
features NN feature O
were NN stopwords be O
identical NN identical O
to NN stopwords O
those NN stopwords O
seen NN see O
in NN stopwords inch O
carcinoid VB carcinoid O
or NN stopwords Oregon O
ergotamine-induced NN O
valve NN valve D
disease NN disease D

Direct CAPITAL NNP direct T
percutaneous NN transdermal T
transluminal NN T
angioplasty DT angioplasty T
for NN stopwords O
acute DT acute_accent D
middle NN center D
cerebral NNS cerebral D
artery DT artery D
occlusion JJ occlusion D

Meeting CAPITAL NNP meeting O
of NN stopwords O
the NN stopwords O
European CAPITAL NNP European O
forum NN forum O
of NN stopwords O
nurses RB nurse O

Coronary CAPITAL NNP coronary_thrombosis T
angioplasty DT angioplasty T
for NN stopwords O
early VB early D
postinfarction NN D
unstable JJ unstable D
angina DT angina D

Health CAPITAL NNP health O
practices NN practice O
of NN stopwords O
critical JJ critical O
care VB care O
nurses RB nurse O
: : O
are DT stopwords are O
these NN stopwords O
nurses RB nurse O
good NN good O
role NN function O
models NN model O
for NN stopwords O
patients VB patient O
? . O

Studies CAPITAL NNP survey O
with NN stopwords O
various NN assorted O
interferon NN interferon T
alpha DT alpha T
preparations NN preparation T
, , O
including NN include O
interferons NN interferon T
induced NN induce O
in NN stopwords inch O
human NN homo O
leukocytes NN leukocyte O
, , O
interferon NN interferon T
alfa-N1 DT T
, , O
interferon NN interferon T
alfa-2a DT T
, , O
and DT stopwords O
interferon NN interferon T
alfa-2b DT T
, , O
have VB stopwords rich_person O
all DT stopwords all O
provided NN supply O
evidence NN evidence O
for NN stopwords O
modest NN modest O
but NN stopwords merely O
reproducible NN reproducible O
antitumor DT anticancer O
activity DT activity O
in NN stopwords inch O
advanced DT advance D
renal NN nephritic D
cell NNS cell D
carcinoma VB carcinoma D

But CAPITAL NNP merely O
there NN stopwords there O
are DT stopwords are O
other JJ stopwords other O
reasons NN reason O
to NN stopwords O
worry NN concern O
about DT stopwords about O
such NN stopwords such O
research NN research O

ATP-dependent CAPITAL DT O
transport NN conveyance O
of NN stopwords O
lipophilic NN lipophilic O
cytotoxic NNS cytotoxic O
drugs NN drug O
by NN stopwords by O
membrane NN membrane O
vesicles NN vesicle O
prepared NN fix O
from JJ stopwords O
MRP-overexpressing CAPITAL NNP O
HL60/ADR CAPITAL NNP O
cells NNS cell O

Pure CAPITAL NNP pure D
alexia DT visual_aphasia D
could NNS O
not JJ stopwords not O
be NN stopwords beryllium O
a DT stopwords angstrom O
disconnection NN disjunction O
syndrome NN syndrome O

This CAPITAL NNP O
may VB May O
be NN stopwords beryllium O
one JJ one O
method NN method O
to NN stopwords O
help NN aid O
manipulate VB manipulate O
or NN stopwords Oregon O
control NNS control O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficients NNS coefficient O
on NN stopwords on O
the NN stopwords O
reaction NN chemical_reaction O
surface NN surface O

Adrenal-sparing CAPITAL DT T
surgery NN surgery T
for NN stopwords O
phaeochromocytoma NN pheochromocytoma D

Interferon-antibodies CAPITAL PRP T
and DT stopwords O
the NN stopwords O
breakthrough NN discovery O
phenomenon NN phenomenon O
during NN stopwords O
ribavirin/interferon-alpha NN T
combination NNS combination T
therapy NN therapy T
and DT stopwords O
interferon-alpha NN T
monotherapy NN T
of NN stopwords O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D

Independent CAPITAL PRP mugwump O
measurement NN measurement O
of NN stopwords O
the NN stopwords O
transducing NN transduce O
analyte DT O
allows DT let O
penicillin NN penicillin T
or NN stopwords Oregon O
glucose NN glucose O
to NN stopwords O
be NN stopwords beryllium O
quantitated NN O
in NN stopwords inch O
the NN stopwords O
presence NN presence O
of NN stopwords O
a DT stopwords angstrom O
concurrent NNS coincident O
pH NN pH O
or NN stopwords Oregon O
O2 CAPITAL $ O
change NNS change O
, , O
respectively NN respectively O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
TRK-530 CAPITAL NNP T
on NN stopwords on O
experimental NN experimental O
arthritis DT arthritis D
in NN stopwords inch O
mice NN mouse O

We CAPITAL NNP O
find NN discovery O
that NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
is NN stopwords be O
a DT stopwords angstrom O
true NN true O
catalyst VB catalyst O
of NN stopwords O
the NN stopwords O
decomposition NN decomposition O
of NN stopwords O
peroxynitrite NN O
, , O
and DT stopwords O
this NN stopwords O
fundamental JJ fundamental O
insight NN penetration O
into NN stopwords O
its NN stopwords information_technology O
action DT action O
must NN must O
be NN stopwords beryllium O
rationalized VB apologize O
by NN stopwords by O
any DT stopwords any O
in NN stopwords inch O
vivo NN O
or NN stopwords Oregon O
in NN stopwords inch O
vitro NN O
reaction NN chemical_reaction O
mechanism NN mechanism O
that NN stopwords O
is NN stopwords be O
proposed NN propose O

A CAPITAL DT angstrom O
comment NNS remark O
on NN stopwords on O
`` `` O
anomy DT anomie O
'' POS O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Alopecia CAPITAL DT alopecia O
as DT stopwords arsenic O
a DT stopwords angstrom O
consequence NNS consequence O
of NN stopwords O
tacrolimus VB O
therapy NN therapy O
in NN stopwords inch O
renal NN nephritic O
transplantation NN transplant O
? . O

Cesarean CAPITAL NNP cesarean_delivery O
deliveries NN delivery O
at DT stopwords astatine O
a DT stopwords angstrom O
university JJ university O
hospital NN hospital O
: : O
analysis DT analysis O
of NN stopwords O
rates VB rates O
and DT stopwords O
indications NN indication O

the NN stopwords O
most NN stopwords most O
recent NN Holocene O
study NN survey O
, , O
involving NN involve O
over JJ stopwords over O
37 DIGITS CD thirty-seven O
, , O
000 DIGITS CD O
young NN young O
children JJ child O
, , O
also DT besides O
evaluated NN measure O
the NN stopwords O
vaccine NN vaccine O
's POS O
efficacy NN efficacy O
, , O
and DT stopwords O
reported NN report O
that NN stopwords O
the NN stopwords O
vaccine NN vaccine T
is NN stopwords be O
highly NN highly O
effective NN effective O
in NN stopwords inch O
preventing NN prevent O
invasive NN invasive D
disease NN disease D
and DT stopwords O
has VB stopwords hour_angle O
had VB stopwords have O
an DT stopwords Associate_in_Nursing O
impact JJ impact O
on NN stopwords on O
otitis IN otitis D
media NN medium D

Female CAPITAL NNP female O
Stress CAPITAL NNP stress O
Urinary CAPITAL NNP urinary O
Incontinence CAPITAL PRP incontinence O
Clinical CAPITAL NNP clinical O
Guidelines CAPITAL NNP guideline O
Panel CAPITAL VB panel O
summary NN summary O
report NN report O
on NN stopwords on O
surgical NN surgical T
management VB management T
of NN stopwords O
female JJ female D
stress NN stress D
urinary JJ urinary D
incontinence NN incontinence D

This CAPITAL NNP O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
the NN stopwords O
emergence NN emergence O
of NN stopwords O
drug-resistant NN O
variants NN discrepancy O

Physico-chemical CAPITAL NNP O
studies NN survey O
on NN stopwords on O
the NN stopwords O
stability NN stability O
of NN stopwords O
penicillin NN penicillin T
salts VB salt T

Radiation CAPITAL VB radiation O
dosimetry NN dosimetry O
by NN stopwords by O
localized NN place O
magnetic VB magnetic O
resonance NN resonance O
spectroscopy NN spectroscopy O

inhaled NN inhale T
corticosteroid NNS corticosteroid T
therapy NN therapy T
is NN stopwords be O
recommended NN recommend O
for NN stopwords O
patients VB patient O
with NN stopwords O
persistent NN persistent D
disease NN disease D
, , O
and DT stopwords O
careful VB careful O
instruction NN direction O
in NN stopwords inch O
the NN stopwords O
use JJ use O
of NN stopwords O
metered-dose NN O
inhalers NN inhaler O
is NN stopwords be O
particularly NN particularly O
important JJ important O
for NN stopwords O
the NN stopwords O
elderly NN aged O

Absorbable CAPITAL DT absorbable T
suture NN suture T
technique NN technique T
: : O
solution NN solution O
to NN stopwords O
the NN stopwords O
growth NN growth O
problem NN problem O
in NN stopwords inch O
pediatric NN pediatric O
pacing VB tempo O
with NN stopwords O
endocardial NN O
leads NN lead O

However CAPITAL NNP however O
, , O
in NN stopwords inch O
the NN stopwords O
panel VB panel O
's POS O
opinion IN opinion O
retropubic NN T
suspensions NN suspension T
and DT stopwords O
sling JJ sling T
procedures NN procedure T
are DT stopwords are O
associated DT associate O
with NN stopwords O
slightly JJ slightly O
higher NN higher O
complication NNS complication O
rates VB rates O
, , O
including NN include O
longer NN longer O
convalescence NNS convalescence O
and DT stopwords O
postoperative NN postoperative D
voiding NN elimination D
dysfunction NN dysfunction D

I CAPITAL PRP iodine O
. . O
Introduction CAPITAL PRP introduction O

CONCLUSIONS CAPITAL NNP decision O
: : O
In CAPITAL PRP inch O
adults DT adult O
, , O
open JJ open O
set NN set O
speech NN address O
understanding JJ understanding O
can VB stopwords can O
be NN stopwords beryllium O
achieved DT achieve O
even NN evening O
at DT stopwords astatine O
the NN stopwords O
first NN first O
tune-up NN warm-up O

Examination CAPITAL NNP examination O
and DT stopwords O
treatment NN treatment O
planning NN planning O
are DT stopwords are O
considered NNS see O
in NN stopwords inch O
relation NN relation O
to NN stopwords O
this NN stopwords O
patient VB patient O
's POS O
special NN special O
needs JJ need O

Diagnosis CAPITAL NNP diagnosis O
and DT stopwords O
therapy NN therapy O
of NN stopwords O
chronic NN chronic D
aspecific DT D
pancreatitis VB pancreatitis D

Breastfeeding CAPITAL NNP breastfeed O
after DT stopwords after O
early VB early O
discharge NN discharge O

Hyponatremia CAPITAL NNP hyponatremia D
with NN stopwords O
venlafaxine NN T
. . O

Diseases CAPITAL NNP disease O
transmitted NN convey O
by NN stopwords by O
non-conventional JJ O
agents DT agent O
( ( O
`` `` O
prions NN prion O
'' POS O
) ) O
: : O
nosology JJ nosology O
and DT stopwords O
diagnosis NN diagnosis O

The CAPITAL NNP O
wavelet-transform VB O
method NN method O
is NN stopwords be O
used JJ use O
to NN stopwords O
quantify NN quantify O
the NN stopwords O
magnetic VB magnetic O
resonance NN resonance O
spectroscopy NN spectroscopy O
( ( O
MRS CAPITAL NNP Mrs O
) ) O
parameters NN parameter O
: : O
chemical NNS chemical O
shift NN shift O
, , O
apparent DT apparent O
relaxation NN relaxation O
time NN time O
T2 CAPITAL CD O
, , O
resonance NN resonance O
amplitude DT amplitude O
, , O
and DT stopwords O
phase NN phase O

Occupational CAPITAL NNP occupational T
therapy NN therapy T
and DT stopwords O
outcomes JJ result O
for NN stopwords O
older JJ aged O
adults DT adult O

Acute CAPITAL DT acute_accent D
diverticulitis NN diverticulitis D

Therapeutic CAPITAL NNP remedy O
effect NN consequence O
of NN stopwords O
a DT stopwords angstrom O
left NN left T
ventricular NN ventricular T
assist DT aid T
device NN device T
on NN stopwords on O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
evaluated NN measure O
by NN stopwords by O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O

IDA-FLAG CAPITAL PRP T
( ( T
idarubicin NN T
, , T
fludarabine JJ T
, , T
cytarabine NNS T
, , T
G-CSF CAPITAL NNP T
) ) T
, , O
an DT stopwords Associate_in_Nursing O
effective NN effective O
remission-induction NN T
therapy NN therapy T
for NN stopwords O
poor-prognosis NN D
AML CAPITAL DT D
of NN stopwords D
childhood JJ childhood D
prior NN prior O
to NN stopwords O
allogeneic DT allogeneic O
or NN stopwords Oregon O
autologous DT autologous O
bone NN bone O
marrow NN marrow O
transplantation NN transplant O
: : O
experiences NN experience O
of NN stopwords O
a DT stopwords angstrom O
phase NN phase O
II CAPITAL PRP two O
trial NN test O

London CAPITAL NNP London O
, , O
England CAPITAL NNP England O
, , O
June CAPITAL NNP June O
29 DIGITS CD twenty-nine O
, , O
1997 DIGITS CD O

In CAPITAL PRP inch O
the NN stopwords O
present NN present O
study NN survey O
, , O
parthenogenotes NN O
were NN stopwords be O
obtained NN obtain O
by NN stopwords by O
the NN stopwords O
activation DT activation O
of NN stopwords O
immature JJ immature O
oocytes JJ oocyte O
with NN stopwords O
caffeine VB caffeine O
before NN stopwords earlier O
treatment NN treatment O
with NN stopwords O
1-methyladenine CD T
( ( T
1-MeAde CD T
) ) T
to NN stopwords O
induce NN induce O
oocyte JJ oocyte O
maturation VB maturation O

Antisense CAPITAL DT O
suppression NN suppression O
of NN stopwords O
4-coumarate CD O
: : O
coenzyme NNS coenzyme O
A CAPITAL DT angstrom O
ligase NN O
activity DT activity O
in NN stopwords inch O
Arabidopsis CAPITAL DT Arabidopsis O
leads NN lead O
to NN stopwords O
altered DT change O
lignin NN lignin O
subunit NN fractional_monetary_unit O
composition NNS composition O

For CAPITAL NNP O
villin NN O
14T CD O
, , O
a DT stopwords angstrom O
monomer NN monomer O
consisting NNS dwell O
of NN stopwords O
126 DIGITS CD O
residues NN residue O
, , O
structure NN structure O
determination NN determination O
by NN stopwords by O
torsion-angle NN O
molecular NN molecular O
dynamics NN dynamics O
has VB stopwords hour_angle O
a DT stopwords angstrom O
success NN success O
rate VB rate O
of NN stopwords O
85 DIGITS CD eighty-five O
% NN O
, , O
a DT stopwords angstrom O
more NN stopwords More O
than NN stopwords O
twofold NN double O
improvement JJ improvement O
over JJ stopwords over O
other JJ stopwords other O
methods NN method O

In CAPITAL PRP inch O
adult DT adult O
mice NN mouse O
, , O
Meis2 CAPITAL NNP O
is NN stopwords be O
mainly VB chiefly O
expressed NN express O
in NN stopwords inch O
the NN stopwords O
brain NN brain O
and DT stopwords O
female JJ female O
genital NN genital O
tract NN tract O
, , O
with NN stopwords O
a DT stopwords angstrom O
different NN different O
distribution NN distribution O
of NN stopwords O
the NN stopwords O
alternative DT option O
splice NN splice O
forms NN form O
in NN stopwords inch O
these NN stopwords O
organs JJ variety_meat O

Overdrugging CAPITAL NNP O
and DT stopwords O
undertreatment JJ O
in NN stopwords inch O
primary NN primary O
health NN health O
care VB care O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Hepatic CAPITAL NNP liverwort O
glutamine NN glutamine O
synthetase NN O
deficiency NN lack O
in NN stopwords inch O
fatal VB fatal O
hyperammonemia NN O
after DT stopwords after O
lung NN lung O
transplantation NN transplant O

As CAPITAL DT arsenic O
there NN stopwords there O
have VB stopwords rich_person O
been NN stopwords be O
few JJ stopwords few O
reports NN report O
of NN stopwords O
the NN stopwords O
obstetrical NN obstetric O
care VB care O
of NN stopwords O
affected DT affect O
patients VB patient O
, , O
we NN stopwords O
wish NN wish O
to NN stopwords O
document NN document O
two NN two O
pregnancies NN pregnancy O
in NN stopwords inch O
a DT stopwords angstrom O
woman NN woman O
with NN stopwords O
a DT stopwords angstrom O
Chronic CAPITAL NNP chronic D
Progressive CAPITAL NNP progressive D
External CAPITAL NNP external D
Ophthalmoplegia CAPITAL NNP ophthalmoplegia D
( ( D
Kearns-Sayre-like CAPITAL NNP D
syndrome NN syndrome D
) ) D

Phase CAPITAL NNP phase O
III CAPITAL PRP three O
randomized VB randomize O
study NN survey O
of NN stopwords O
cisplatin NN T
versus NN O
paclitaxel VB T
versus NN O
cisplatin NN T
and DT stopwords T
paclitaxel VB T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
suboptimal NN O
stage NN phase O
III CAPITAL PRP three O
or NN stopwords Oregon O
IV CAPITAL PRP four O
ovarian NN ovarian D
cancer VB cancer D
: : O
a DT stopwords angstrom O
gynecologic NN gynecological O
oncology JJ oncology O
group NN group O
study NN survey O

Here CAPITAL NNP here O
we NN stopwords O
present NN present O
two NN two O
cases VB case O
diagnosed NN diagnose O
in NN stopwords inch O
the NN stopwords O
late NN late O
third NN one-third O
trimester NN trimester O
and DT stopwords O
review NN reappraisal O
the NN stopwords O
literature NN literature O
regarding NN see O
prenatal NN prenatal O
diagnosis NN diagnosis O
of NN stopwords O
cloacal NNS D
anomalies DT anomaly D

< NN O
TO_SEE CAPITAL NNP O
> NN O
A CAPITAL DT angstrom O
71-year-old CD O
woman NN woman O
with NN stopwords O
autoimmune DT autoimmune O
hemolytic NN hemolytic O
anemia DT anemia O
underwent JJ undergo O
an DT stopwords Associate_in_Nursing O
emergency NN emergency O
endocardial NN T
patch VB spot T
repair NN repair T
for NN stopwords O
ventricular NN ventricular D
septal NN septal D
perforation NN perforation D
after DT stopwords after O
acute DT acute_accent O
myocardial NN myocardial O
infarction NN infarct O

During CAPITAL NNP O
the NN stopwords O
initial JJ initial O
2 DIGITS CD two O
months NN calendar_month O
of NN stopwords O
the NN stopwords O
study NN survey O
, , O
the NN stopwords O
children JJ child O
were NN stopwords be O
treated NN treat O
with NN stopwords O
antiepileptic DT anticonvulsant T
drugs NN drug T
( ( T
AEDs CAPITAL DT T
) ) T
only JJ stopwords lone O
, , O
and DT stopwords O
for NN stopwords O
the NN stopwords O
remaining NN stay O
2 DIGITS CD two O
months NN calendar_month O
, , O
methylphenidate NN methylphenidate T
was VB stopwords Washington O
added DT add O
at DT stopwords astatine O
a DT stopwords angstrom O
morning NN morning O
dose NN dose O
of NN stopwords O
0.3 LS O
mg/kg NN O

DATA CAPITAL NNP data O
SOURCES CAPITAL NNP beginning O
: : O
Archival CAPITAL DT archival O
articles DT article O
and DT stopwords O
reviews NN reappraisal O
identified NN identify O
through NN stopwords done O
a DT stopwords angstrom O
computerized NNS computerize O
search NN search O
of NN stopwords O
MEDLINE CAPITAL NNP MEDLINE O
from JJ stopwords O
1966 DIGITS CD O
to NN stopwords O
April CAPITAL DT April O
1997 DIGITS CD O
using JJ exploitation O
`` `` O
fenfluramine JJ O
( ( O
s NN stopwords second O
) ) O
, , O
'' POS O
`` `` O
serotonin NN serotonin O
, , O
'' POS O
`` `` O
neurotoxicity JJ O
, , O
'' POS O
`` `` O
behavior NN behavior O
, , O
'' POS O
`` `` O
anorexigens DT O
, , O
'' POS O
`` `` O
weight NN weight O
loss NN loss O
, , O
'' POS O
and DT stopwords O
`` `` O
primary NN primary O
pulmonary NN pneumonic O
hypertension NN high_blood_pressure O
'' POS O
as DT stopwords arsenic O
index NN index O
terms NN footing O

Imaging CAPITAL PRP imagination O
pulmonary NN pneumonic D
embolism NN embolism D

Infectious CAPITAL PRP infectious D
diseases NN disease D
: : O
their NN stopwords O
impact JJ impact O
on NN stopwords on O
dentistry NN dentistry O

After CAPITAL DT after O
7 DIGITS CD seven O
days VB days O
, , O
a DT stopwords angstrom O
TSS CAPITAL NNP toxic_shock D
toxin NN toxin O
1-producing CD O
strain NN strain O
of NN stopwords O
Staphylococcus CAPITAL NNP staphylococcus O
aureus DT O
was VB stopwords Washington O
cultured NNS culture O
from JJ stopwords O
an DT stopwords Associate_in_Nursing O
inguinal NN inguinal O
lymph NN lymph O
node JJ node O
, , O
where NN stopwords O
inflammation NN inflammation D
had VB stopwords have O
already DT already O
been NN stopwords be O
noticed JJ detect O
on NN stopwords on O
admission DT admission O

Receptive CAPITAL NNP receptive O
properties NN property O
of NN stopwords O
primary NN primary O
afferent DT sensory_nerve O
fibres NN fiber O
from JJ stopwords O
rabbit NN rabbit O
pleura NN pleura O
, , O
in NN stopwords inch O
vitro NN O

Dimension CAPITAL NNP dimension O
in NN stopwords inch O
defining NN shaping O
tumor NN tumor D
response NN response O

Using CAPITAL NNP exploitation O
immobilized JJ immobilize O
DNA CAPITAL NNP deoxyribonucleic_acid O
, , O
we NN stopwords O
investigated NN investigate O
the NN stopwords O
binding NN binding O
of NN stopwords O
common NNS park O
intercalators NN O
with NN stopwords O
respect NN respect O
to NN stopwords O
kinetics NN dynamics O
and DT stopwords O
thermodynamics NN thermodynamics O
by NN stopwords by O
evaluation NN evaluation O
of NN stopwords O
the NN stopwords O
association DT association O
and DT stopwords O
the NN stopwords O
dissociation NN dissociation O
part NN part O
of NN stopwords O
the NN stopwords O
binding NN binding O
curve NNS curve O

All CAPITAL DT all O
patients VB patient O
with NN stopwords O
MS CAPITAL NNP multiple_sclerosis O
were NN stopwords be O
diagnosed NN diagnose O
as DT stopwords arsenic O
having VB stopwords have O
clinically JJ clinically O
definite NN definite O
disease NN disease O
according DT harmonize O
to NN stopwords O
published NN print O
criteria JJ standard O

CONCLUSIONS CAPITAL NNP decision O
: : O
In CAPITAL PRP inch O
addition DT addition O
to NN stopwords O
the NN stopwords O
considerable NNS considerable O
body NN body O
of NN stopwords O
clinical JJ clinical O
evidence NN evidence O
supporting NN support O
the NN stopwords O
use JJ use O
of NN stopwords O
inhaled NN inhale T
fluticasone JJ T
propionate NN T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
asthma DT asthma D
, , O
accumulating DT roll_up O
short NN short O
term NN term O
cost-effectiveness NNS O
data VB data O
also DT besides O
suggest NN propose O
that NN stopwords O
this NN stopwords O
agent DT agent O
can VB stopwords can O
be NN stopwords beryllium O
administered DT administer O
for NN stopwords O
a DT stopwords angstrom O
similar NN similar O
or NN stopwords Oregon O
lower NN lower_berth O
cost NNS cost O
per NN O
outcome JJ result O
than NN stopwords O
other JJ stopwords other O
inhaled NN inhale O
corticosteroids NNS corticosteroid O
or NN stopwords Oregon O
oral NN oral O
zafirlukast NN O

The CAPITAL NNP O
single-place NN T
caisson VB coffer T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
decompression NN decompression D
accidents DT accident D

Metabolic CAPITAL NNP metabolic O
and DT stopwords O
endocrine NN hormone O
effects NN effects O
of NN stopwords O
lysergic NN O
acid DT acid O
diethylamide NN O
( ( O
LSD-25 CAPITAL NNP O
) ) O
on NN stopwords on O
male VB male O
rats VB rat O

hordei NN O
glyceraldehyde-3-phosphate NN O
dehydrogenase NN O
gene NN gene O

A CAPITAL DT angstrom O
multidimensional NN multidimensional O
study NN survey O
of NN stopwords O
preference NN preference O
judgements NN opinion O
for NN stopwords O
excerpts NN excerpt O
of NN stopwords O
music NN music O

Solvent CAPITAL NNP solvent O
solution NN solution O

International CAPITAL PRP International O
Workshop CAPITAL NNP workshop O
on NN stopwords on O
Bone CAPITAL NNP bone O
Research CAPITAL NNP research O
in NN stopwords inch O
Space CAPITAL NNP space O

Shadows CAPITAL NNP shadow O
and DT stopwords O
images NN image O

The CAPITAL NNP O
data VB data O
resulting NN result O
from JJ stopwords O
these NN stopwords O
clinical JJ clinical O
trials NN test O
indicate NN bespeak O
that NN stopwords O
interferon NN interferon T
alfa-2a DT T
is NN stopwords be O
effective NN effective O
in NN stopwords inch O
inducing NN inducement O
hematologic NN hematologic O
remissions NN remission O
in NN stopwords inch O
the NN stopwords O
majority VB majority O
of NN stopwords O
minimally NN minimally O
treated NN treat O
, , O
benign-phase NN D
CML CAPITAL NNP D
, , O
Ph1-positive CAPITAL NNP O
patients VB patient O

VII CAPITAL NNP seven O

For CAPITAL NNP O
how NN stopwords O
long NN hanker O
should NN stopwords O
antipsychotic DT major_tranquilizer T
medication NN medicine T
be NN stopwords beryllium O
continued NNS continue O
after DT stopwords after O
the NN stopwords O
first NN first O
psychotic NN psychotic D
episode NN episode D
in NN stopwords inch D
schizophrenics JJ schizophrenic D
? . O

05 DIGITS CD O
) ) O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
determine NN determine O
whether NN O
patients VB patient O
with NN stopwords O
myocardial NN myocardial D
amyloidosis DT amyloidosis D
due NN due O
either NN either O
to NN stopwords O
AL CAPITAL DT aluminum O
( ( O
primary NN primary O
) ) O
amyloid DT amyloid O
or NN stopwords Oregon O
familial VB familial O
amyloid DT amyloid O
have VB stopwords rich_person O
distinguishing NN distinguish O
echocardiographic NN O
or NN stopwords Oregon O
electrocardiographic NN electrocardiographic O
features NN feature O
; : O
and DT stopwords O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
heart NN heart D
failure VB failure D
and DT stopwords O
survival NN survival O
in NN stopwords inch O
the NN stopwords O
two NN two O
types NN type O
of NN stopwords O
amyloidosis DT amyloidosis D
in NN stopwords inch O
relation NN relation O
to NN stopwords O
echocardiographic NN O
findings NN findings O

Lansoprazole CAPITAL VB lansoprazole T
, , O
H. CAPITAL NNP O
pylori NN pylorus O
, , O
and DT stopwords O
atrophic DT atrophic D
gastritis VB gastritis D
. . O

Because CAPITAL NNP O
neonatal JJ neonatal O
ECMO CAPITAL NNP T
is NN stopwords be O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
high NN high O
risk NN hazard O
of NN stopwords O
hearing NN hearing D
and DT stopwords D
receptive NN receptive D
language NN language D
disorders NN disorder D
, , O
parents NN parent O
should NN stopwords O
be NN stopwords beryllium O
counseled NNS rede O
that NN stopwords O
audiologic DT O
and DT stopwords O
developmental NN developmental O
follow-up JJ follow-up O
evaluations NN evaluation O
in NN stopwords inch O
surviving NN survive O
children JJ child O
are DT stopwords are O
essential NN necessity O
regardless NN careless O
of NN stopwords O
the NN stopwords O
results NN consequence O
of NN stopwords O
neonatal JJ neonatal O
BAEP CAPITAL IN O
testing NN testing O

DNAS1L2 CAPITAL NNP O
is NN stopwords be O
located NN locate O
on NN stopwords on O
a DT stopwords angstrom O
16p13.3 CD O
cosmid NNS cosmid O
, , O
while NN stopwords while O
DNAS1L3 CAPITAL NNP O
maps VB map O
to NN stopwords O
3p14.3-p21.1 CD O
by NN stopwords by O
fluorescence JJ fluorescence O
in NN stopwords inch O
situ NN O
hybridization NN hybridization O
and DT stopwords O
by NN stopwords by O
PCR CAPITAL NNP O
analysis DT analysis O
of NN stopwords O
a DT stopwords angstrom O
radiation VB radiation O
hybrid NN loanblend O
panel VB panel O

A CAPITAL DT angstrom O
pediatrician NN baby_doctor O
's POS O
checklist NNS checklist O
for NN stopwords O
adolescents DT adolescent O

In CAPITAL PRP inch O
certain NNS certain O
clinical JJ clinical O
settings NN setting O
, , O
interventional NN T
radiologic VB T
procedures NN procedure T
have VB stopwords rich_person O
become NN become O
an DT stopwords Associate_in_Nursing O
important JJ important O
alternative DT option O
to NN stopwords O
surgery NN surgery O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
gallstones VB gallstone D
and DT stopwords O
their NN stopwords O
complications NNS complication O
; : O
techniques NN technique O
include NN include O
percutaneous NN transdermal T
cholecystostomy NNS T
and DT stopwords T
gallstone VB gallstone T
removal NN removal T

PATIENTS CAPITAL VB patient O
: : O
716 DIGITS CD O
patients VB patient O
aged DT aged O
4 DIGITS CD four O
and DT stopwords O
over JJ stopwords over O
with NN stopwords O
sore NN sore D
throat NN throat D
and DT stopwords O
an DT stopwords Associate_in_Nursing O
abnormal DT abnormal O
physical NN physical O
sign NN sign O
: : O
84 DIGITS CD eighty-four O
% NN O
had VB stopwords have O
tonsillitis NN tonsillitis D
or NN stopwords Oregon O
pharyngitis NN sore_throat D

2 DIGITS CD two O

A CAPITAL DT angstrom O
position NN position O
paper VB paper O
of NN stopwords O
the NN stopwords O
National CAPITAL NNP national O
Society CAPITAL NNP society O
of NN stopwords O
Genetic CAPITAL NNP familial O
Counselors CAPITAL NNP counselor O

Pharmacoeconomic CAPITAL NNP O
analysis DT analysis O
of NN stopwords O
ampicillin-sulbactam DT T
versus NN O
cefoxitin NNS T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
intraabdominal NN D
infections NN infection D

Further CAPITAL NNP foster O
investigation NN probe O
is NN stopwords be O
needed JJ necessitate O
to NN stopwords O
identify NN identify O
a DT stopwords angstrom O
confidentiality NNS confidentiality O
assurance DT assurance O
statement NN statement O
that NN stopwords O
explains NN explain O
the NN stopwords O
legal NN legal O
and DT stopwords O
ethical NN ethical O
limitations NN restriction O
of NN stopwords O
confidentiality NNS confidentiality O
without NN O
decreasing NN decrease O
adolescents DT adolescent O
' '' O
likelihood NN likelihood O
of NN stopwords O
seeking NN quest O
future JJ future O
health NN health O
care VB care O
for NN stopwords O
routine NN routine O
and DT stopwords O
nonreportable JJ O
sensitive NN medium O
health NN health O
concerns NNS concern O

Anal CAPITAL DT anal O
continence NNS continence O
after DT stopwords after O
surgery NN surgery T
for NN stopwords O
rectal NN rectal D
prolapse NN prolapse D

methods NN method O
: : O
we NN stopwords O
retrospectively NN retrospectively O
reviewed NN review O
14 DIGITS CD fourteen O
patients VB patient O
diagnosed NN diagnose O
with NN stopwords O
bos NN Bos D
who NN stopwords World_Health_Organization O
underwent JJ undergo O
therapy NN therapy T
with NN stopwords T
extracorporeal NN T
photopheresis NN T

Eleven CAPITAL NNP eleven O
unique JJ alone O
microsatellite-containing NN O
sequences NN sequence O
were NN stopwords be O
isolated NN isolate O
, , O
converted NNS convert O
into NN stopwords O
sequence-tagged NN O
microsatellite NN O
sites NN site O
, , O
and DT stopwords O
characterized NNS qualify O
concerning NNS refer O
their NN stopwords O
species-specific NN O
origin IN beginning O

The CAPITAL NNP O
influence NN influence O
of NN stopwords O
allergy DT allergy D
and DT stopwords O
smoking JJ smoke O
on NN stopwords on O
the NN stopwords O
sulphation NN O
of NN stopwords O
nasal RB nasal_consonant O
mucins NN mucin O

Some CAPITAL NNP some O
knowledges NN cognition O
on NN stopwords on O
the NN stopwords O
potency NN authority O
of NN stopwords O
heparin NN heparin O
fractions NN fraction O
obtained NN obtain O
by NN stopwords by O
gel NN gel O
filtration NN filtration O

this NN stopwords O
london NN London O
lung NN lung O
cancer VB cancer O
group NN group O
trial NN test O
of NN stopwords O
gemcitabine/carboplatin NN T
may VB May O
define NN specify O
an DT stopwords Associate_in_Nursing O
active DT active_agent O
, , O
safe VB safe O
, , O
and DT stopwords O
acceptable DT acceptable O
treatment NN treatment O
for NN stopwords O
patients VB patient O
with NN stopwords O
extensive-stage NN O
and DT stopwords O
poor-prognosis NN O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D

Cholecystectomy CAPITAL NNP cholecystectomy T
should NN stopwords O
be NN stopwords beryllium O
a DT stopwords angstrom O
first-line NN O
therapy NN therapy O
for NN stopwords O
biliary NN bilious D
dyskinesia NN dyskinesia D
patients VB patient O

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONCLUSIONS CAPITAL NNP decision O
: : O
Genetic CAPITAL NNP familial O
predisposition NN sensitivity O
has VB stopwords hour_angle O
a DT stopwords angstrom O
substantial NN significant O
impact JJ impact O
on NN stopwords on O
risk NN hazard O
of NN stopwords O
subsequent NN subsequent D
cancers VB cancer D
in NN stopwords inch O
retinoblastoma NN retinoblastoma D
patients VB patient O
, , O
which NN stopwords O
is NN stopwords be O
further NN stopwords foster O
increased NN increase O
by NN stopwords by O
radiation VB radiation T
treatment NN treatment T

Chlamydia CAPITAL NNP chlamydia D
screening NN screening O
practices NN practice O
of NN stopwords O
primary-care NN O
providers NN supplier O
-- : O
Wake CAPITAL WRB aftermath O
County CAPITAL NNP county O
, , O
North CAPITAL NNP North O
Carolina CAPITAL VB Carolina O
, , O
1996 DIGITS CD O

extent NN extent O
of NN stopwords O
pulmonary NN pneumonic O
involvement NN engagement O
at DT stopwords astatine O
diagnosis NN diagnosis O
, , O
response NN response O
of NN stopwords O
pm NN autopsy D
after DT stopwords after O
induction NN initiation T
chemotherapy NNS chemotherapy T
, , O
local NN local O
treatment NN treatment O
of NN stopwords O
pm NN autopsy O
thereafter NN thereafter O
, , O
and DT stopwords O
clinical JJ clinical O
outcome JJ result O
were NN stopwords be O
recorded NN record O

Malignant CAPITAL NNP malignant D
melanoma NN melanoma D
in NN stopwords inch O
situ NN O
: : O
an DT stopwords Associate_in_Nursing O
oxymoron JJ oxymoron O
whose NN O
time NN time O
has VB stopwords hour_angle O
come NNS semen O

Technical CAPITAL NNP technical O
note JJ note O
on NN stopwords on O
two NN two O
rates VB rates O
of NN stopwords O
mixed NN blend O
marriage NN marriage O

The CAPITAL NNP O
indoor NN indoor O
pollution NN pollution O
, , O
where NN stopwords O
the NN stopwords O
patients VB patient O
pass VB base_on_balls O
in NN stopwords inch O
general NN general O
close NNS stopping_point O
to NN stopwords O
90 DIGITS CD ninety O
% NN O
of NN stopwords O
their NN stopwords O
time NN time O
, , O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
important JJ important O
factor VB factor O
to NN stopwords O
take VB return O
in NN stopwords inch O
consideration NNS consideration O
if NN stopwords O
one JJ one O
wants VB privation O
to NN stopwords O
evaluate NN measure O
suitably JJ appropriately O
the NN stopwords O
effects NN effects O
of NN stopwords O
the NN stopwords O
air DT air O
pollution NN pollution O
on NN stopwords on O
the NN stopwords O
health NN health O

The CAPITAL NNP O
Bizarro CAPITAL NNP O
world NN universe O
of NN stopwords O
osteodistraction JJ T

Online CAPITAL NNP on-line O

Cyclosporiasis CAPITAL NNP D
and DT stopwords O
raspberries VB raspberry O

The CAPITAL NNP O
functional JJ functional O
neuroanatomy JJ neuroanatomy O
of NN stopwords O
episodic NN episodic O
memory NN memory O
retrieval NN retrieval O

Cervical CAPITAL NNP cervical D
cancer VB cancer D
screening NN screening O

Mar CAPITAL NNP March O
del NN O
Plata CAPITAL NNP O
, , O
Argentina CAPITAL DT Argentina O
, , O
August CAPITAL DT August O
26-30 CD O
, , O
1996 DIGITS CD O

Recently CAPITAL NNP recently O
, , O
the NN stopwords O
putative NN putative O
BCL-1 CAPITAL NNP O
proto-oncogene NN proto-oncogene O
turned NN turn O
out JJ stopwords out O
to NN stopwords O
be NN stopwords beryllium O
none JJ none O
other JJ stopwords other O
than NN stopwords O
the NN stopwords O
cyclin NNS O
D1 CAPITAL NNP O
gene NN gene O

The CAPITAL NNP O
cDNA SYM complementary_DNA O
was VB stopwords Washington O
expressed NN express O
in NN stopwords inch O
Escherichia CAPITAL NNP escherichia O
coli NNS O
using JJ exploitation O
the NN stopwords O
pGEX NN O
vector NN vector O
, , O
and DT stopwords O
a DT stopwords angstrom O
recombinant NN recombinant O
fusion JJ fusion O
protein NN protein O
( ( O
EgCaBP1-GST CAPITAL NNP O
) ) O
was VB stopwords Washington O
obtained NN obtain O

Additionally CAPITAL DT additionally O
, , O
radial VB radial O
bone NN bone O
density NN density O
did NN stopwords make O
not JJ stopwords not O
show NN show O
any DT stopwords any O
changes NNS change O
in NN stopwords inch O
either NN either O
group NN group O

Courtship CAPITAL NNP courtship O
behaviour NN behavior O
in NN stopwords inch O
the NN stopwords O
Drosophila CAPITAL NNP drosophila O
obscura NN O
group NN group O

A CAPITAL DT angstrom O
55-year-old CD O
lady NN lady O
underwent JJ undergo O
repeat NN repeat O
aortic DT aortal T
valve NN valve T
replacement NN replacement T
using JJ exploitation O
a DT stopwords angstrom O
16-mm CD O
Carbomedics CAPITAL VB O
prosthesis NN prosthesis O

CONCLUSIONS CAPITAL NNP decision O
: : O
Cidofovir CAPITAL NNP T
, , O
a DT stopwords angstrom O
nucleotide JJ nucleotide O
analog DT analogue O
of NN stopwords O
deoxycytidine NN deoxycytidine O
monophosphate NN O
, , O
appears DT look O
to NN stopwords O
have VB stopwords rich_person O
contributed NNS lend O
to NN stopwords O
clearing NNS clearing O
of NN stopwords O
advanced DT advance D
MCV CAPITAL NNP D
lesions NN lesion D
in NN stopwords inch O
these NN stopwords O
3 DIGITS CD three O
patients VB patient O
, , O
thus NN frankincense O
providing NN supply O
suggestive NN implicative O
evidence NN evidence O
of NN stopwords O
clinical JJ clinical O
activity DT activity O
against DT stopwords O
MCV CAPITAL NNP D

< NN O
TO_SEE CAPITAL NNP O
> NN O
Measles CAPITAL NNP measles D
vaccination NN inoculation T
and DT stopwords O
inflammatory NN inflammatory O
bowel NN intestine O
disease NN disease O

RESULTS CAPITAL NNP consequence O
: : O
Activities CAPITAL DT activity O
of NN stopwords O
carbamoyl VB O
phosphate NN phosphate O
synthetase NN O
I CAPITAL PRP iodine O
and DT stopwords O
ornithine JJ ornithine O
carbamoyltransferase VB O
in NN stopwords inch O
the NN stopwords O
liver NN liver O
were NN stopwords be O
normal RB convention O

Is CAPITAL PRP be O
zero NN nothing O
dose NN dose O
oral NN oral O
polio NN poliomyelitis D
vaccine NN vaccine T
effective NN effective O
in NN stopwords inch O
preterm NN O
babies NN baby O
? . O

methods NN method O
: : O
we NN stopwords O
analyzed DT analyze O
30 DIGITS CD thirty O
patients VB patient O
who NN stopwords World_Health_Organization O
were NN stopwords be O
discovered NN detect O
to NN stopwords O
have VB stopwords rich_person O
brain NN brain O
metastases NN metastasis O
during NN stopwords O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
121 DIGITS CD O
patients VB patient O
enrolled NN enroll O
in NN stopwords inch O
three NN three O
consecutive NNS back-to-back O
clinical JJ clinical O
trials NN test O
on NN stopwords on O
advanced DT advance D
nsclc JJ D
assessing DT measure O
combination NNS combination T
chemotherapy NNS chemotherapy T
of NN stopwords T
cisplatin NN T
, , T
ifosfamide NN T
and DT stopwords T
irinotecan JJ T
with NN stopwords T
rhg-csf NN T
support NN support T

The CAPITAL NNP O
daily IN daily O
high NN high O
temperature NN temperature O
ranged VB range O
from JJ stopwords O
71 DIGITS CD seventy-one O
to NN stopwords O
104 DIGITS CD O
degrees NN degree O
F CAPITAL NN degree_Fahrenheit O
and DT stopwords O
AFI CAPITAL DT O
values NN values O
ranged VB range O
from JJ stopwords O
1.7 CD O
to NN stopwords O
24.7 CD O
cm NNS centimeter O
during NN stopwords O
the NN stopwords O
study NN survey O
period NN time_period O

The CAPITAL NNP O
results NN consequence O
are DT stopwords are O
consistent NNS consistent O
with NN stopwords O
perturbations NN disturbance O
in NN stopwords inch O
red NN red O
cell NNS cell O
glycolysis NN glycolysis O
in NN stopwords inch O
preeclampsia NN preeclampsia D

The CAPITAL NNP O
mobilisation NN mobilization O
of NN stopwords O
FFA CAPITAL NNP O
is NN stopwords be O
primarily NN chiefly O
a DT stopwords angstrom O
function JJ function O
of NN stopwords O
sympathetic NN sympathetic O
nervous RB nervous O
activity DT activity O
directed NN direct O
towards NN O
the NN stopwords O
adipocytes DT O
, , O
or NN stopwords Oregon O
the NN stopwords O
'fat '' O
pad VB pad O
' '' O
. . O
This CAPITAL NNP O
nervous RB nervous O
activity DT activity O
can VB stopwords can O
be NN stopwords beryllium O
direct NN direct O
or NN stopwords Oregon O
may VB May O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
effect NN consequence O
of NN stopwords O
circulating NN go_around O
catecholamines VB catecholamine O
such NN stopwords such O
as DT stopwords arsenic O
adrenaline DT epinephrine O
( ( O
epinephrine NN epinephrine O
) ) O

Federal CAPITAL NNP Federal O
programs NN plan O
and DT stopwords O
Indian CAPITAL PRP Indian O
country NNS state O
: : O
a DT stopwords angstrom O
time NN time O
for NN stopwords O
reinvention NN O

Clinical CAPITAL NNP clinical T
management VB management T
and DT stopwords O
treatment NN treatment O
outcomes JJ result O
of NN stopwords O
Merkel CAPITAL NNP D
cell NNS cell D
carcinoma VB carcinoma D

Guidelines CAPITAL NNP guideline O
from JJ stopwords O
the NN stopwords O
Norwegian CAPITAL NNP Norwegian O
Gastrointestinal CAPITAL VB gastrointestinal O
Cancer CAPITAL VB cancer O
Group CAPITAL NNP group O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
investigate NN investigate O
the NN stopwords O
influence NN influence O
of NN stopwords O
physicians NN doctor O
' '' O
assurances DT assurance O
of NN stopwords O
confidentiality NNS confidentiality O
on NN stopwords on O
adolescents DT adolescent O
' '' O
willingness NN willingness O
to NN stopwords O
disclose NN unwrap O
information NN information O
and DT stopwords O
seek NN seek O
future JJ future O
health NN health O
care VB care O

High CAPITAL NNP high O
dose NN dose O
cyclophosphamide NNS T
with NN stopwords O
carboplatin VB T
: : O
a DT stopwords angstrom O
tolerable NN tolerable O
regimen NN regimen O
suitable JJ suitable O
for NN stopwords O
dose NN dose O
intensification NN intensification O
in NN stopwords inch O
children JJ child O
with NN stopwords O
solid NN solid D
tumors NN tumor D

All CAPITAL DT all O
hand VB hand O
instruments NN instrument O
, , O
handpieces VB O
and DT stopwords O
triplex NN ternary O
syringes NN panpipe O
were NN stopwords be O
autoclaved DT autoclave O
between NN stopwords between O
patients VB patient O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
examine NN analyze O
the NN stopwords O
relationship NN relationship O
between NN stopwords between O
plasma NN plasma O
plasminogen NN plasminogen O
activator DT activator O
inhibitor NN inhibitor O
1 DIGITS CD one O
( ( O
PAI-1 CAPITAL VB O
) ) O
activity DT activity O
and DT stopwords O
PAI-1 CAPITAL VB O
gene NN gene O
( ( O
4G/5G CD O
) ) O
polymorphism NN polymorphism O
and DT stopwords O
diabetic NN diabetic D
retinopathy NN retinopathy D
in NN stopwords inch O
Pima CAPITAL NNP Pima O
Indians CAPITAL PRP Indian O
with NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D

Slater CAPITAL NNP woodlouse O
revisited NN revisit O
: : O
6 DIGITS CD six O
year NN year O
follow JJ follow O
up JJ stopwords up O
study NN survey O
of NN stopwords O
patients VB patient O
with NN stopwords O
medically NN medically O
unexplained JJ unexplained O
motor NN motor D
symptoms NN symptom D

The CAPITAL NNP O
manufacturer VB manufacturer O
claims NNS claim O
that NN stopwords O
moxonidine NN T
`` `` O
accurately DT accurately O
targets VB target O
imidazoline JJ O
receptors NN receptor O
at DT stopwords astatine O
the NN stopwords O
cardiovascular VB cardiovascular O
control NNS control O
centre NNS Centre O
in NN stopwords inch O
the NN stopwords O
brainstem NN brainstem O
'' POS O
and DT stopwords O
is NN stopwords be O
`` `` O
as DT stopwords arsenic O
effective NN effective O
as DT stopwords arsenic O
current NNS current O
first-line NN O
therapies NN therapy O
for NN stopwords O
essential NN necessity D
hypertension NN high_blood_pressure D
`` `` O

Surgical CAPITAL NNP surgical T
management VB management T
of NN stopwords O
severe NN severe D
secondary NN secondary D
peritonitis NN peritonitis D

setting NN setting O
: : O
the NN stopwords O
nursing RB nursing O
center NNS center O
himawari NN O
design NN design O
, , O
patient VB patient O
, , O
and DT stopwords O
preparation NN preparation O
: : O
the NN stopwords O
regular NN regular O
dosage NN dose O
of NN stopwords O
nyt JJ T
( ( O
15 DIGITS CD fifteen O
g/d NN O
) ) O
was VB stopwords Washington O
prescribed NN order O
for NN stopwords O
7 DIGITS CD seven O
weeks NN week O
to NN stopwords O
one JJ one O
elderly NN aged O
patient VB patient O
with NN stopwords O
lung NN lung D
carcinoma VB carcinoma D

Treatment CAPITAL NNP treatment O
of NN stopwords O
hypertension NN high_blood_pressure D
with NN stopwords O
ascorbic DT T
acid DT acid T

Studies CAPITAL NNP survey O
on NN stopwords on O
contractile NNS contractile O
properties NN property O
of NN stopwords O
the NN stopwords O
blood NN blood O
serum NN serum O

Although CAPITAL DT O
technically NN technically O
demanding NN demand O
, , O
it NN stopwords information_technology O
provides NN supply O
long-term NN long-run O
stability NN stability O
to NN stopwords O
the NN stopwords O
hallux VB big_toe O
, , O
restores NN restore O
weightbearing NN O
, , O
and DT stopwords O
allows DT let O
for NN stopwords O
maintenance VB care O
of NN stopwords O
a DT stopwords angstrom O
propulsive NN propulsive O
gait NN pace O

Immune CAPITAL PRP immune O
cells NNS cell O
in NN stopwords inch O
vivo NN O
routinely NN routinely O
perform NN perform O
highly NN highly O
selective NN selective O
immunosensing JJ O
in NN stopwords inch O
blood NN blood O
and DT stopwords O
tissues NN tissue O
as DT stopwords arsenic O
part NN part O
of NN stopwords O
their NN stopwords O
normal RB convention O
immune JJ immune O
surveillance NN surveillance O
functions JJ function O

Down CAPITAL NNP down D
syndrome NN syndrome D
( ( O
12 DIGITS CD twelve O
cases VB case O
) ) O
and DT stopwords O
Edward CAPITAL NNP Edward D
syndrome NN syndrome D
( ( O
11 DIGITS CD eleven O
cases VB case O
) ) O
were NN stopwords be O
the NN stopwords O
most NN stopwords most O
common NNS park O
trisomies NN trisomy D
, , O
while NN stopwords while O
4 DIGITS CD four O
cases VB case O
of NN stopwords O
Patau CAPITAL VB D
syndrome NN syndrome D
were NN stopwords be O
also DT besides O
diagnosed NN diagnose O

Spontaneous CAPITAL NNP spontaneous O
exfoliation NN exfoliation O
of NN stopwords O
teeth NN dentition O
following JJ following O
severe NN severe O
elemental NN elemental O
mercury NN mercury D
poisoning NN poisoning D
: : O
case VB case O
report NN report O
and DT stopwords O
histological NN histological O
investigation NN probe O
for NN stopwords O
mechanism NN mechanism O

Microsurgical CAPITAL NNP T
treatment NN treatment T
of NN stopwords O
infratentorial NN D
malformations VB deformity D

138 DIGITS CD O

one JJ one O
course NNS course O
of NN stopwords O
chronochemotherapy NN T
was VB stopwords Washington O
effective NN effective O
for NN stopwords O
lymph NN lymph D
node JJ node D
and DT stopwords D
peritoneum NN peritoneum D
metastases NN metastasis D

Leukoplakia CAPITAL NNP D
of NN stopwords O
the NN stopwords O
vaginal NN vaginal O
portion NN part O
of NN stopwords O
the NN stopwords O
uterus JJ uterus O
and DT stopwords O
its NN stopwords information_technology O
clinical JJ clinical O
evaluation NN evaluation O

A CAPITAL DT angstrom O
qualitative NN qualitative O
, , O
direct NN direct O
PCR CAPITAL NNP O
assay DT assay O
reveals NN uncover O
that NN stopwords O
SSR CAPITAL NNP O
recombinations NN recombination O
are DT stopwords are O
stochastic NN stochastic O
in NN stopwords inch O
B CAPITAL NN bacillus O
cell NNS cell O
lines NN line O
generating NN generate O
a DT stopwords angstrom O
product NN merchandise O
array DT array O
akin DT akin O
to NN stopwords O
natural RB natural O
GH CAPITAL NNP O
class NNS class O
switching JJ switch O

College-age CAPITAL NNP O
drinking NN drinking O
problems NN problem O

Early CAPITAL NN early O
discharge NN discharge O
of NN stopwords O
newborns JJ neonate O

It CAPITAL PRP information_technology O
could NNS O
reduce NN reduce O
PI CAPITAL NN pi O
significantly NN significantly O
more NN stopwords More O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
than NN stopwords O
placebo NN placebo O
controls NNS control O
only JJ stopwords lone O
for NN stopwords O
the NN stopwords O
subgroup NN subgroup O
with NN stopwords O
mild NN mild O
to NN stopwords O
moderate NN centrist O
pain IN pain O
, , O
but NN stopwords merely O
not JJ stopwords not O
with NN stopwords O
severe NN severe O
pain IN pain O

CONCLUSION CAPITAL NNP decision O
: : O
In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
asthma DT asthma D
receiving NN receive O
repeated NN repeat T
inhaled NN inhale T
doses NN dose T
of NN stopwords T
FP CAPITAL NNP T
, , O
the NN stopwords O
systemic NN systemic O
exposure NN exposure O
( ( O
AUC CAPITAL DT United_Self-Defense_Force_of_Colombia O
) ) O
after DT stopwords after O
inhalation NN inhalation O
from JJ stopwords O
the NN stopwords O
Diskus CAPITAL NNP O
was VB stopwords Washington O
similar NN similar O
to NN stopwords O
that NN stopwords O
from JJ stopwords O
the NN stopwords O
Diskhaler CAPITAL NNP O
, , O
with NN stopwords O
no NNS stopwords no O
difference NN difference O
between NN stopwords between O
the NN stopwords O
DPIs CAPITAL NNP O
in NN stopwords inch O
the NN stopwords O
effects NN effects O
on NN stopwords on O
cortisol NNS hydrocortisone O
suppression NN suppression O

We CAPITAL NNP O
conducted NNS conduct O
a DT stopwords angstrom O
survey NN survey O
and DT stopwords O
audit DT audited_account O
of NN stopwords O
thermal NN thermal O
equipment NN equipment O
use JJ use O
in NN stopwords inch O
very NN stopwords very O
low-birth-weight NN O
infants NN baby O
in NN stopwords inch O
five NN five O
Ohio CAPITAL NNP Ohio O
neonatal JJ neonatal O
intensive NN intensifier O
care VB care O
units JJ unit_of_measurement O
( ( O
NICUs CAPITAL NNP neonatal_intensive_care_unit O
) ) O
to NN stopwords O
document NN document O
regional NN regional O
practice NN practice O

However CAPITAL NNP however O
, , O
careful VB careful O
visual NN ocular O
assessment DT appraisal O
of NN stopwords O
the NN stopwords O
recorded NN record O
waveforms VB wave_form O
for NN stopwords O
the NN stopwords O
remaining NN stay O
ears VB ear O
did NN stopwords make O
not JJ stopwords not O
unequivocally JJ unambiguously O
show NN show O
absence DT absence O
of NN stopwords O
TEOAE CAPITAL NNP O
characteristics NNS feature O
in NN stopwords inch O
any DT stopwords any O
ear VB ear O
with NN stopwords O
normal RB convention O
HTLs CAPITAL NNP O

Polymorphism CAPITAL NNP polymorphism O
in NN stopwords inch O
promoter NN promoter O
region NN region O
of NN stopwords O
inducible NN O
nitric NN azotic O
oxide IN oxide O
synthase NN O
gene NN gene O
and DT stopwords O
protection NN protection O
against DT stopwords O
malaria VB malaria D

Abdominal CAPITAL DT abdominal D
tuberculosis NN tuberculosis D
is NN stopwords be O
not JJ stopwords not O
uncommon JJ uncommon O
in NN stopwords inch O
the NN stopwords O
UK CAPITAL NNP United_Kingdom O
, , O
especially NN particularly O
in NN stopwords inch O
Asian CAPITAL DT Asian O
immigrants JJ immigrant O

Vancomycin-resistant CAPITAL VB O
Staphylococcus CAPITAL NNP staphylococcus O
aureus DT O
: : O
apocalypse DT apocalypse O
now JJ stopwords now O
? . O

hominis NN O
must NN must O
be NN stopwords beryllium O
considered NNS see O
as DT stopwords arsenic O
a DT stopwords angstrom O
pathogen VB pathogen O

Diabetic CAPITAL NNP diabetic O
retinopathy NN retinopathy O
, , O
promoter NN promoter O
( ( O
4G/5G CD O
) ) O
polymorphism NN polymorphism O
of NN stopwords O
PAI-1 CAPITAL VB O
gene NN gene O
, , O
and DT stopwords O
PAI-1 CAPITAL VB O
activity DT activity O
in NN stopwords inch O
Pima CAPITAL NNP Pima O
Indians CAPITAL PRP Indian O
with NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D

Molecular CAPITAL NNP molecular O
analysis DT analysis O
of NN stopwords O
cellulose NNS cellulose O
biosynthesis NN biosynthesis O
in NN stopwords inch O
Arabidopsis CAPITAL DT Arabidopsis O

This CAPITAL NNP O
approach DT approach O
has VB stopwords hour_angle O
allowed DT let O
us JJ United_States O
to NN stopwords O
show NN show O
that NN stopwords O
delta-19 NN O
, , O
lacking NN miss O
expression NN expression O
at DT stopwords astatine O
the NN stopwords O
plasma NN plasma O
membrane NN membrane O
, , O
can VB stopwords can O
transduce NN transduce O
the NN stopwords O
hormonal NN hormonal O
message NN message O
, , O
at DT stopwords astatine O
least NN least O
to NN stopwords O
a DT stopwords angstrom O
limited NN express O
extent NN extent O
( ( O
up JJ stopwords up O
to NN stopwords O
30 DIGITS CD thirty O
% NN O
of NN stopwords O
wild NN wild O
type NN type O
efficiency NN efficiency O
) ) O
, , O
providing NN supply O
that NN stopwords O
association/activation DT O
occurs JJ happen O
with NN stopwords O
a DT stopwords angstrom O
PRL-PRLR CAPITAL NNP O
complex NNS complex O
initiated JJ originate O
at DT stopwords astatine O
the NN stopwords O
cell NNS cell O
surface NN surface O
level NN degree O
; : O
box NN box O
1 DIGITS CD one O
of NN stopwords O
the NN stopwords O
cytoplasmic NNS cytoplasmic O
form NN form O
is NN stopwords be O
necessary JJ necessity O
to NN stopwords O
rescue NN rescue O
this NN stopwords O
partial NN partial_derivative O
transcriptional NN O
activity DT activity O
of NN stopwords O
the NN stopwords O
inactive NN inactive O
mutant NN mutant O

Steps CAPITAL NNP stairs O
still JJ still O
being NN stopwords being O
taken VB take O
to NN stopwords O
undo JJ undo O
damage VB damage O
of NN stopwords O
`` `` O
America CAPITAL DT United_States O
's POS O
Nuremberg CAPITAL NNP Nuremberg O
'' POS O

In CAPITAL PRP inch O
mitogen-stimulated NN O
human NN homo O
peripheral NN peripheral O
blood NN blood O
mononuclear NN mononuclear O
cells NNS cell O
the NN stopwords O
AF-4 CAPITAL DT O
antigen DT antigen O
was VB stopwords Washington O
predominantly NN predominantly O
located NN locate O
in NN stopwords inch O
the NN stopwords O
nucleus JJ nucleus O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Health CAPITAL NNP health O
insurance NN insurance O
for NN stopwords O
children JJ child O
-- : O
a DT stopwords angstrom O
model NN model O
for NN stopwords O
incremental NN incremental O
health NN health O
reform NN reform O
? . O

< NN O
TO_SEE CAPITAL NNP O
> NN O
There CAPITAL NNP there O
is NN stopwords be O
therefore NN therefore O
no NNS stopwords no O
reason NN reason O
to NN stopwords O
believe NN believe O
that NN stopwords O
the NN stopwords O
questionable NN questionable O
results NN consequence O
derived NN deduce O
from JJ stopwords O
retrospective NN retrospective O
studies NN survey O
of NN stopwords O
the NN stopwords O
effects NN effects O
of NN stopwords O
short-acting NN O
calcium VB calcium O
antagonists DT adversary O
on NN stopwords on O
cardiac VB cardiac O
and DT stopwords O
noncardiac JJ O
events NN event O
may VB May O
apply DT use O
to NN stopwords O
the NN stopwords O
newer JJ new O
generation NN coevals O
of NN stopwords O
long-acting NN long-acting O
calcium VB calcium O
antagonists DT adversary O

Further CAPITAL NNP foster O
observations NN observation O
on NN stopwords on O
the NN stopwords O
importance JJ importance O
of NN stopwords O
interatomic NN O
distance NN distance O
in NN stopwords inch O
the NN stopwords O
McLafferty CAPITAL NNP O
rearrangement NN rearrangement O

The CAPITAL NNP O
system NN system O
, , O
when NN stopwords O
tested NN test O
on NN stopwords on O
12 DIGITS CD twelve O
positive NN positive O
sera NN serum O
, , O
did NN stopwords make O
not JJ stopwords not O
show NN show O
any DT stopwords any O
false VB false O
negative JJ negative O
result NN consequence O

Misconceptions CAPITAL NNP misconception O
about DT stopwords about O
mosaicism NN mosaicism D

Profileplasty CAPITAL NNP T

Hyperbaric CAPITAL NNP T
oxygen JJ oxygen T
therapy NN therapy T
for NN stopwords O
children JJ child O
with NN stopwords O
cerebral NNS cerebral D
palsy VB paralysis D

Low CAPITAL NNP low O
voltage NN voltage O
electrocardiograms NN electrocardiogram O
( ( O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.5 LS O
mV NN millivolt O
) ) O
were NN stopwords be O
more NN stopwords More O
common NNS park O
in NN stopwords inch O
the NN stopwords O
AL CAPITAL DT aluminum O
( ( O
16/24 CD O
, , O
67 DIGITS CD sixty-seven O
% NN O
) ) O
than NN stopwords O
in NN stopwords inch O
the NN stopwords O
familial VB familial O
group NN group O
( ( O
4/12 CD O
, , O
25 DIGITS CD twenty-five O
% NN O
) ) O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O

The CAPITAL NNP O
Seventh CAPITAL NNP seventh O
International CAPITAL PRP International O
Meeting CAPITAL NNP meeting O
on NN stopwords on O
Ciliate CAPITAL NNP ciliate O
Molecular CAPITAL NNP molecular O
Biology CAPITAL NNP biology O
Genetics CAPITAL NNP genetics O
Nomenclature CAPITAL NNP terminology O

The CAPITAL NNP O
problem NN problem O
of NN stopwords O
medicinal NN medicative O
management VB management O
of NN stopwords O
labor NN labor O

Epidural CAPITAL NNP epidural_anesthesia O
and DT stopwords O
intramedullary NN O
abscess DT abscess O
of NN stopwords O
acute DT acute_accent O
onset JJ onset O

Missense CAPITAL NNP O
mutation NN mutant O
in NN stopwords inch O
exon NN exon O
11 DIGITS CD eleven O
( ( O
Codon CAPITAL NNP codon O
378 DIGITS CD O
) ) O
of NN stopwords O
the NN stopwords O
presenilin-1 NN O
gene NN gene O
in NN stopwords inch O
a DT stopwords angstrom O
French CAPITAL NNP French O
family VB family O
with NN stopwords O
early-onset VB O
Alzheimer CAPITAL DT D
's POS D
disease NN disease D
and DT stopwords O
transmission NN transmission O
study NN survey O
by NN stopwords by O
mismatch NN mismatch O
enhanced NN enhance O
allele DT allele O
specific NN particular O
amplification DT amplification O

Treatment CAPITAL NNP treatment O
of NN stopwords O
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
should NN stopwords O
begin NN Begin O
with NN stopwords O
a DT stopwords angstrom O
dopamine NN dopamine T
agonist DT protagonist T

Doppler CAPITAL NNP Doppler O
indices NN index O
of NN stopwords O
left NN left O
and DT stopwords O
right NN right O
ventricular NN ventricular O
function JJ function O
, , O
left NN left O
ventricular NN ventricular O
volume NN volume O
, , O
and DT stopwords O
ejection NN expulsion O
fraction NN fraction O
were NN stopwords be O
also DT besides O
similar NN similar O

Further CAPITAL NNP foster O
evidence NN evidence O
for NN stopwords O
the NN stopwords O
importance JJ importance O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
androgen DT androgen O
response NN response O
element NN component O
in NN stopwords inch O
the NN stopwords O
factor VB factor O
IX CAPITAL PRP nine O
promoter NN promoter O

The CAPITAL NNP O
obstetric NN obstetric O
experience NN experience O
of NN stopwords O
carriers VB carrier O
of NN stopwords O
haemophilia VB hemophilia D

Transesophageal CAPITAL NNP O
echocardiography NN echocardiography O
demonstrated NN show O
aliasing DT O
on NN stopwords on O
color NNS color O
flow JJ flow O
mapping VB function O
in NN stopwords inch O
the NN stopwords O
left NN left O
main VB main O
coronary NNS coronary_thrombosis O
artery DT artery O
in NN stopwords inch O
1 DIGITS CD one O
case VB case O
and DT stopwords O
proximal NN proximal O
right NN right O
coronary NNS coronary_thrombosis O
artery DT artery O
in NN stopwords inch O
the NN stopwords O
other JJ stopwords other O
, , O
along DT along O
with NN stopwords O
severely NN badly O
depressed NN depress O
left NN left O
ventricular NN ventricular O
anterior DT front_tooth O
wall VB wall O
and DT stopwords O
right NN right O
ventricular NN ventricular O
function JJ function O
, , O
respectively NN respectively O

The CAPITAL NNP O
relative NN relative O
risk NN hazard O
of NN stopwords O
the NN stopwords O
primary NN primary O
event NN event O
for NN stopwords O
the NN stopwords O
160 DIGITS CD one_hundred_sixty O
mg NN milligram O
aspirin DT aspirin O
group NN group O
compared NNS compare O
with NN stopwords O
the NN stopwords O
3 DIGITS CD three O
mg NN milligram O
warfarin NN warfarin O
with NN stopwords O
80 DIGITS CD eighty O
mg NN milligram O
aspirin DT aspirin O
group NN group O
was VB stopwords Washington O
0.95 LS O
( ( O
0.81-1.12 LS O
, , O
p NN phosphorus O
= NN O
0.57 LS O
) ) O

A CAPITAL DT angstrom O
major VB major O
non-LTR JJ O
retrotransposon NN O
of NN stopwords O
Bombyx CAPITAL NNP Bombyx O
mori NN O
, , O
L1Bm CAPITAL NNP O

BACKGROUND CAPITAL IN background O
: : O
Accelerated CAPITAL DT accelerate T
infusion NN infusion T
of NN stopwords T
alteplase DT T
( ( T
tissue NN tissue T
plasminogen NN plasminogen T
activator DT activator T
) ) T
over JJ stopwords over O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
90 DIGITS CD ninety O
minutes NN minutes O
induces NN induce O
more NN stopwords More O
rapid VB rapid O
lysis NN lysis O
of NN stopwords O
coronary-artery NNS D
thrombi NN thrombus D
than NN stopwords O
a DT stopwords angstrom O
3-hour LS O
infusion NN infusion O

A CAPITAL DT angstrom O
drop NN drop O
in NN stopwords inch O
pediatric NN pediatric O
subject NN subject O
examination NN examination O
scores JJ tons O
after DT stopwords after O
curriculum NNS course_of_study O
changes NNS change O
that NN stopwords O
emphasize NN stress O
general NN general O
pediatric NN pediatric O
topics NN subject O

Radiosterilization CAPITAL VB O
of NN stopwords O
medical NN checkup O
products NN merchandise O

High-affinity CAPITAL NNP O
binding NN binding O
of NN stopwords O
the NN stopwords O
neonatal JJ neonatal O
Fc CAPITAL NNP O
receptor NN receptor O
to NN stopwords O
its NN stopwords information_technology O
IgG CAPITAL PRP immunoglobulin_G O
ligand NN ligand O
requires NN necessitate O
receptor NN receptor O
immobilization JJ immobilization O

We CAPITAL NNP O
report NN report O
the NN stopwords O
primary NN primary O
clinical JJ clinical O
endpoints NN end_point O
( ( O
cardiac VB cardiac D
ischaemic NN ischemic D
death NN death D
, , O
myocardial NN myocardial D
infarction NN infarct D
, , O
and DT stopwords O
severe NN severe O
recurrent NN perennial O
ischaemia NN ischemia D
) ) O
, , O
assessed DT measure O
at DT stopwords astatine O
day VB day O
31 DIGITS CD thirty-one O
, , O
in NN stopwords inch O
202 DIGITS CD O
patients VB patient O
on NN stopwords on O
an DT stopwords Associate_in_Nursing O
intention-to-treat NN O
basis VB footing O

Comprehensive CAPITAL NNP comprehensive_examination O
Cancer CAPITAL VB cancer O
Centre CAPITAL NNP Centre O
West CAPITAL NNP West O
, , O
Leiden CAPITAL NNP Leiden O
, , O
The CAPITAL NNP O
Netherlands CAPITAL NNP Netherlands O

Helicobacter CAPITAL NNP O
pylori NN pylorus O
-- : O
more NN stopwords More O
light NN light O
, , O
less NN lupus_erythematosus O
heat NN heat O

Stroke CAPITAL NNP stroke D
incidence NN incidence O
rates VB rates O
among DT O
black NN black O
residents NN resident O
of NN stopwords O
Harare CAPITAL NNP Harare O
-- : O
a DT stopwords angstrom O
prospective NN prospective O
community-based NNS O
study NN survey O

Patients CAPITAL VB patient O
( ( O
mean NN mean O
age DT age O
, , O
62.8 CD O
years NN old_age O
) ) O
, , O
stratified NN stratify O
by NN stopwords by O
concomitant NNS accompaniment O
use JJ use O
of NN stopwords O
selegiline NN T
, , O
were NN stopwords be O
randomized VB randomize O
to NN stopwords O
ropinirole NN T
( ( O
n NN nitrogen O
= NN O
116 DIGITS CD O
) ) O
or NN stopwords Oregon O
placebo NN placebo O
( ( O
n NN nitrogen O
= NN O
125 DIGITS CD one_hundred_twenty-five O
) ) O

The CAPITAL NNP O
RFLP CAPITAL NNP O
analysis DT analysis O
revealed NN uncover O
13 DIGITS CD thirteen O
haplotypes VB haplotype O
which NN stopwords O
showed NN show O
weak NN weak O
geographical NN geographic O
patterning VB model O
consistent NNS consistent O
with NN stopwords O
a DT stopwords angstrom O
recent NN Holocene O
range VB scope O
expansion NN expansion O
from JJ stopwords O
a DT stopwords angstrom O
refugial NN O
population NN population O
( ( O
s NN stopwords second O
) ) O

A CAPITAL DT angstrom O
key NN key O
feature NN feature O
is NN stopwords be O
that NN stopwords O
these NN stopwords O
immune JJ immune O
cells NNS cell O
can VB stopwords can O
be NN stopwords beryllium O
selectively NN selectively O
engineered NN engineer O
to NN stopwords O
recognize NN acknowledge O
specific NN particular O
antigens DT antigen O
in NN stopwords inch O
vitro NN O

In CAPITAL PRP inch O
this NN stopwords O
problem NN problem O
of NN stopwords O
public NN populace O
health NN health O
we NN stopwords O
may VB May O
not JJ stopwords not O
underestimated JJ undervalue O
sensitive NN medium O
persons NN person O
and DT stopwords O
risky NN hazardous O
group NN group O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
long NN hanker O
terme NN O
effects NN effects O
, , O
and DT stopwords O
chronic NN chronic O
exposition NN exposition O
effects NN effects O

Thus CAPITAL NNP frankincense O
, , O
each VB stopwords each O
patient VB patient O
served NN serve O
as DT stopwords arsenic O
his NN stopwords O
own JJ stopwords own O
control NNS control O

Fluticasone CAPITAL NNP T
propionate NN T
is NN stopwords be O
one JJ one O
of NN stopwords O
several NN several O
inhaled NN inhale O
corticosteroids NNS corticosteroid O
used JJ use O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
asthma DT asthma D

the NN stopwords O
degree NN degree O
of NN stopwords O
healing NN healing O
and DT stopwords O
damage VB damage O
of NN stopwords O
the NN stopwords O
bronchial NN bronchial O
wall VB wall O
after DT stopwords after O
photodynamic NN T
therapy NN therapy T
, , T
nd-yag RB T
laser NN laser T
and DT stopwords T
electrocautery NN electrocautery T
for NN stopwords O
intraluminal NN D
early-stage VB D
cancer VB cancer D
have VB stopwords rich_person O
been NN stopwords be O
analysed DT analyze O

These CAPITAL NNP O
two NN two O
procedures NN procedure O
are DT stopwords are O
equally NN equally O
effective NN effective O
, , O
but NN stopwords merely O
differ NN differ O
in NN stopwords inch O
associated DT associate O
morbidity NN morbidity O
and DT stopwords O
type NN type O
of NN stopwords O
complications NNS complication O

Over CAPITAL NNP over O
half VB one-half O
thought NN idea O
HIV CAPITAL NNP HIV D
transmission NN transmission O
occurred JJ happen O
most NN stopwords most O
times NN times O
or NN stopwords Oregon O
always DT always O

A CAPITAL DT angstrom O
method NN method O
of NN stopwords O
determining NN determine O
the NN stopwords O
patency VB patency O
of NN stopwords O
the NN stopwords O
nasolacrimal RB O
apparatus DT apparatus O

An CAPITAL DT Associate_in_Nursing O
amperometric DT O
lactate NN lactate O
oxidase IN oxidase O
catheter VB catheter O
has VB stopwords hour_angle O
been NN stopwords be O
developed NN develop O
for NN stopwords O
in NN stopwords inch O
vivo NN O
application DT application O
to NN stopwords O
real-time NN real-time O
lactate NN lactate O
monitoring NN monitoring O

Anatomic CAPITAL DT anatomic O
and DT stopwords O
distributional NN distributional O
problems NN problem O

Lateralized CAPITAL VB lateralize O
readiness NN readiness O
potentials NN potential O
( ( O
LRPs CAPITAL NNP O
) ) O
were NN stopwords be O
derived NN deduce O
to NN stopwords O
test NN trial O
whether NN O
semantic NN semantic O
and DT stopwords O
phonological NN phonological O
information NN information O
activated DT trip O
motor NN motor O
processes NN procedure O
at DT stopwords astatine O
separate NN offprint O
moments NN moment O
in NN stopwords inch O
time NN time O

The CAPITAL NNP O
gene NN gene O
is NN stopwords be O
transcribed NN transcribe O
into NN stopwords O
four JJ four O
mRNAs NN messenger_RNA O
of NN stopwords O
0.8 LS O
, , O
1.4 CD O
, , O
1.7 CD O
and DT stopwords O
4.4 CD O
kb NN kilobit O
as DT stopwords arsenic O
determined NN determine O
by NN stopwords by O
Northern CAPITAL NNP Northern O
blot NN smudge O
analysis DT analysis O

There CAPITAL NNP there O
was VB stopwords Washington O
no NNS stopwords no O
significant NN significant O
difference NN difference O
of NN stopwords O
mean NN mean O
latency NN rotational_latency O
, , O
amplitude DT amplitude O
, , O
or NN stopwords Oregon O
amplitude DT amplitude O
ratio VB ratio O
of NN stopwords O
SSR CAPITAL NNP O
between NN stopwords between O
the NN stopwords O
two NN two O
groups NN group O
under JJ stopwords nether O
electric NN electric O
stimulus JJ stimulation O
, , O
startling NN startle O
stimulus JJ stimulation O
, , O
and DT stopwords O
deep NN deep O
breathing NN breathing O
conditions NNS conditions O

The CAPITAL NNP O
baseline VB baseline O
data VB data O
were NN stopwords be O
compared NNS compare O
with NN stopwords O
t NN stopwords thymine O
tests NN trial O
, , O
chi JJ qi O
2 DIGITS CD two O
analysis DT analysis O
and DT stopwords O
Fisher CAPITAL NNP fisherman O
's POS O
exact NN demand O
test NN trial O
where NN stopwords O
appropriate DT allow O

Inchinko-to CAPITAL PRP T
( ( T
TJ-135 CAPITAL NNP T
) ) T
is NN stopwords be O
a DT stopwords angstrom O
herbal NN herb_tea O
medicine NN medicine O
consisting NNS dwell O
of NN stopwords O
three NN three O
kinds NN kind O
of NN stopwords O
crude NNS petroleum O
drugs NN drug O
, , O
and DT stopwords O
in NN stopwords inch O
Japan CAPITAL NNP Japan O
it NN stopwords information_technology O
is NN stopwords be O
administered DT administer O
mainly VB chiefly O
to NN stopwords O
patients VB patient O
with NN stopwords O
cholestasis NNS acholia D

The CAPITAL NNP O
chromosomal NN chromosomal O
translocation NN translocation O
t NN stopwords thymine O
( ( O
11 DIGITS CD eleven O
; : O
14 DIGITS CD fourteen O
) ) O
( ( O
q13 RB O
: : O
q32 RB O
) ) O
, , O
involving NN involve O
rearrangement NN rearrangement O
of NN stopwords O
the NN stopwords O
BCL-1 CAPITAL NNP O
locus NN venue O
, , O
is NN stopwords be O
closely NNS closely O
associated DT associate O
with NN stopwords O
human NN homo D
lymphoid NN lymphoid D
neoplasia JJ neoplasia D
affecting DT affect O
mantle VB mantle D
cell NNS cell D
lymphomas NN lymphoma D
( ( D
MCL CAPITAL NNP D
) ) D

Saliva CAPITAL VB saliva O
composition NNS composition O
might NN might O
therefore NN therefore O
be NN stopwords beryllium O
used JJ use O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
alternative DT option O
noninvasive JJ noninvasive O
indicator NN index O
of NN stopwords O
the NN stopwords O
response NN response O
of NN stopwords O
the NN stopwords O
different NN different O
body NN body O
tissues NN tissue O
and DT stopwords O
systems NN system O
to NN stopwords O
physical NN physical O
exertion NN effort O

Marseille CAPITAL NNP Marseille O
, , O
France CAPITAL NNP France O
, , O
28-30 CD O
April CAPITAL DT April O
1998 DIGITS CD O

Myoepithelial CAPITAL NNP D
carcinoma VB carcinoma D
with NN stopwords O
predominance NN predominance O
of NN stopwords O
plasmacytoid NN O
cells NNS cell O
arising DT originate O
in NN stopwords inch O
a DT stopwords angstrom O
pleomorphic NN pleomorphic D
adenoma DT adenoma D
of NN stopwords O
the NN stopwords O
parotid NN parotid O
gland NN gland O

Treatment CAPITAL NNP treatment O
with NN stopwords O
omeprazole JJ omeprazole T
, , T
amoxicillin DT amoxicillin T
, , T
and DT stopwords T
clarithromycin NNS T
resulted NN result O
in NN stopwords inch O
eradication NN eradication O
of NN stopwords O
the NN stopwords O
infection NN infection D
in NN stopwords inch O
all DT stopwords all O
and DT stopwords O
in NN stopwords inch O
resolution NN resolution O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
symptoms NN symptom O
in NN stopwords inch O
15 DIGITS CD fifteen O
( ( O
80 DIGITS CD eighty O
% NN O
) ) O
of NN stopwords O
19 DIGITS CD nineteen O
patients VB patient O
who NN stopwords World_Health_Organization O
had VB stopwords have O
a DT stopwords angstrom O
follow-up JJ follow-up O
examination NN examination O

Pressure- CAPITAL NNP O
and DT stopwords O
Volume-Limited CAPITAL NNP O
Ventilation CAPITAL NNP ventilation O
Strategy CAPITAL NNP scheme O
Group CAPITAL NNP group O

Preliminary CAPITAL NNP preliminary O
evidence NN evidence O
suggests NN propose O
that NN stopwords O
interferons NN interferon T
beta NN beta T
and DT stopwords T
gamma VB gamma T
may VB May O
also DT besides O
induce NN induce O
regression NN arrested_development O
of NN stopwords O
metastatic NN metastatic D
renal NN nephritic D
cell NNS cell D
carcinoma VB carcinoma D

The CAPITAL NNP O
results NN consequence O
of NN stopwords O
this NN stopwords O
study NN survey O
show NN show O
that NN stopwords O
resection NN resection T
of NN stopwords O
extrahepatic NN D
bile NN bile D
duct NN duct D
carcinomas VB carcinoma D
, , O
particularly NN particularly O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
upper-third JJ O
localization NN localization O
, , O
is NN stopwords be O
often JJ frequently O
associated DT associate O
with NN stopwords O
worthwhile NN worthwhile O
long-term NN long-run O
survival NN survival O

DOTS CAPITAL NNP point O
-- : O
are DT stopwords are O
we NN stopwords O
over-optimistic JJ O
? . O

Chronic CAPITAL NNP chronic O
leg NN leg D
ulcers JJ ulcer D
: : O
beware NN beware O
the NN stopwords O
'wolf POS O
in NN stopwords inch O
sheep NN sheep O
's POS O
clothing NNS clothing O
! . O
' '' O
. . O

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
a DT stopwords angstrom O
ventilation NN ventilation T
strategy NN scheme T
to NN stopwords O
prevent NN prevent O
barotrauma NN D
in NN stopwords inch O
patients VB patient O
at DT stopwords astatine O
high NN high O
risk NN hazard O
for NN stopwords O
acute DT acute_accent D
respiratory NN respiratory D
distress NN distress D
syndrome NN syndrome D

pylori NN pylorus O
therapy NN therapy O

Blood CAPITAL NNP blood O
was VB stopwords Washington O
sampled VB sample O
and DT stopwords O
8-OH-DPAT CD O
administered DT administer O
through NN stopwords done O
a DT stopwords angstrom O
catheter VB catheter O
in NN stopwords inch O
the NN stopwords O
dorsal NN dorsal O
aorta DT aorta O

Primary CAPITAL NNP primary O
comparisons NNS comparison O
were NN stopwords be O
done NN make O
with NN stopwords O
all DT stopwords all O
follow-up JJ follow-up O
data VB data O

While CAPITAL NNP while O
the NN stopwords O
potential NN potential O
of NN stopwords O
this NN stopwords O
baiting IN baiting O
method NN method O
to NN stopwords O
remove NN remove O
E CAPITAL NN vitamin_E O

Evidence-Based CAPITAL NNP O
Medicine CAPITAL NNP medicine O
Working CAPITAL NNP working O
Group CAPITAL NNP group O

Preparing CAPITAL NNP fix O
health NN health O
professionals NN professional O
for NN stopwords O
the NN stopwords O
genetic NN familial O
revolution NN revolution O

Use CAPITAL NNP use O
of NN stopwords O
rotational NN rotational O
movements NN motion O
to NN stopwords O
remove NN remove O
mandibular VB mandibular O
molars NN molar O

Detection CAPITAL NNP detection O
of NN stopwords O
differentially NN differentially O
expressed NN express O
genes NN gene O
in NN stopwords inch O
head-neck NN D
carcinomas VB carcinoma D

Our CAPITAL NNP O
findings NN findings O
suggest NN propose O
that NN stopwords O
breastfeeding NN breastfeed O
may VB May O
promote NN promote O
faster VB fast O
growth NN growth O
in NN stopwords inch O
infants NN baby O
compromised NNS compromise O
by NN stopwords by O
poor NN poor_people O
growth NN growth O
in NN stopwords inch O
utero JJ O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Expression CAPITAL NNP expression O
of NN stopwords O
the NN stopwords O
CaMI CAPITAL VB O
gene NN gene O
was VB stopwords Washington O
detected NN detect O
in NN stopwords inch O
all DT stopwords all O
chicken JJ chicken O
tissues NN tissue O
examined NN analyze O
, , O
although DT O
at DT stopwords astatine O
varying NN change O
levels NN degree O

Modified CAPITAL NNP modify T
bra NN brassiere T
in NN stopwords inch O
the NN stopwords O
prevention NN prevention O
of NN stopwords O
mastitis VB mastitis D
in NN stopwords inch O
nursing RB nursing O
mothers NN mother O

Chromosomally CAPITAL NNP O
integrated NN integrate O
retroviral NN O
switch JJ switch O
( ( O
S CAPITAL NN second O
) ) O
substrates NN substrate O
have VB stopwords rich_person O
been NN stopwords be O
developed NN develop O
to NN stopwords O
reveal NN uncover O
switch JJ switch O
recombinase-like NN O
activities DT activity O
( ( O
SRLA CAPITAL NNP O
) ) O
in NN stopwords inch O
pre-B NN O
and DT stopwords O
mature VB mature O
B CAPITAL NN bacillus O
cell NNS cell O
lines NN line O

A CAPITAL DT angstrom O
66-year-old CD O
male VB male O
engineer NN engineer O
diagnosed NN diagnose O
with NN stopwords O
malignant VB malignant D
pleural NN pleural D
mesothelioma NN mesothelioma D
4 DIGITS CD four O
years NN old_age O
previously NN previously O
had VB stopwords have O
thoracotomy NN thoracotomy T
, , T
radiotherapy VB radiotherapy T
, , T
and DT stopwords T
chemotherapy NNS chemotherapy T

CONTEXT CAPITAL NNP context O
: : O
Four CAPITAL NNP four O
genetic NN familial O
loci NN venue O
have VB stopwords rich_person O
been NN stopwords be O
identified NN identify O
as DT stopwords arsenic O
contributing NNS lend O
to NN stopwords O
Alzheimer CAPITAL DT D
disease NN disease D
( ( D
AD CAPITAL DT ad D
) ) D
, , O
including NN include O
the NN stopwords O
amyloid DT amyloid O
precursor NN precursor O
protein NN protein O
gene NN gene O
, , O
the NN stopwords O
presenilin NN O
1 DIGITS CD one O
gene NN gene O
, , O
the NN stopwords O
presenilin NN O
2 DIGITS CD two O
gene NN gene O
, , O
and DT stopwords O
the NN stopwords O
apolipoprotein DT O
E CAPITAL NN vitamin_E O
gene NN gene O
, , O
but NN stopwords merely O
do NN stopwords bash O
not JJ stopwords not O
account DT history O
for NN stopwords O
all DT stopwords all O
the NN stopwords O
genetic NN familial O
risk NN hazard O
for NN stopwords O
AD CAPITAL DT ad O

The CAPITAL NNP O
first NN first O
integrated NN integrate O
optical-biosensors JJ O
using JJ exploitation O
this NN stopwords O
design NN design O
have VB stopwords rich_person O
been NN stopwords be O
prepared NN fix O
that NN stopwords O
allow DT let O
both NN stopwords both O
the NN stopwords O
dependent NN dependant O
and DT stopwords O
independent NN mugwump O
analytes DT O
to NN stopwords O
be NN stopwords beryllium O
measured NN measure O
simultaneously NN simultaneously O
, , O
for NN stopwords O
example NN example O
penicillin NN penicillin O
and DT stopwords O
pH NN pH O
( ( O
Healey CAPITAL NNP O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
Walt CAPITAL WRB O
, , O
1995 DIGITS CD O
) ) O
or NN stopwords Oregon O
glucose NN glucose O
and DT stopwords O
O2 CAPITAL $ O
( ( O
Li CAPITAL NN lithium O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
Walt CAPITAL WRB O
, , O
1995 DIGITS CD O
) ) O

Attacks CAPITAL DT attack O
on NN stopwords on O
tobacco NN tobacco O
industry NN industry O

Laparoscopic CAPITAL VB T
cornuostomy NNS T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
interstitial NN interstitial D
pregnancy NN pregnancy D
with NN stopwords O
subsequent NN subsequent O
hysterosalpingography NN O

Treatment CAPITAL NNP treatment O
of NN stopwords O
cavernous VB cavernous D
hemangiomas NN hemangioma D
with NN stopwords O
the NN stopwords O
neodymium JJ neodymium T
: : T
YAG CAPITAL VB T
laser NN laser T

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
one JJ one O
of NN stopwords O
these NN stopwords O
MMR CAPITAL NNP O
genes NN gene O
, , O
hMSH2 NN O
, , O
account DT history O
for NN stopwords O
about DT stopwords about O
half VB one-half O
of NN stopwords O
all DT stopwords all O
cases VB case O
of NN stopwords O
genetically NN genetically O
linked NN associate O
hereditary NN familial O
non-polyposis JJ O
colorectal NNS colorectal O
cancer VB cancer O

Reducing CAPITAL NNP reduction O
risk NN hazard O
is NN stopwords be O
best NN best O
strategy NN scheme O

In CAPITAL PRP inch O
this NN stopwords O
report NN report O
, , O
we NN stopwords O
demonstrated NN show O
that NN stopwords O
Raf-1 CAPITAL VB O
protein NN protein O
kinase NN kinase O
activity DT activity O
in NN stopwords inch O
the NN stopwords O
mouse NN mouse O
parotid NN parotid O
glands NN gland O
was VB stopwords Washington O
induced NN induce O
by NN stopwords by O
chronic NN chronic O
isoproterenol NN isoproterenol O
administration DT administration O
in NN stopwords inch O
whole NN whole O
animals DT animal O

conclusions NNS decision O
: : O
this NN stopwords O
case VB case O
report NN report O
supports NN support O
the NN stopwords O
notion JJ impression O
that NN stopwords O
, , O
in NN stopwords inch O
practice NN practice O
, , O
the NN stopwords T
paravertebral NN T
block NN block T
could NNS O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
effective NN effective O
and DT stopwords O
safe VB safe O
alternative DT option O
to NN stopwords O
relief NN relief O
of NN stopwords O
pleuritic NN D
pain IN pain D

Novel CAPITAL NNP novel O
treatment NN treatment O
strategies NN scheme O
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
NSCLC CAPITAL NNP D
may VB May O
involve NN involve O
chemotherapy NNS chemotherapy T
combined NNS unite O
with NN stopwords O
inhibition NN inhibition O
of NN stopwords O
NF-kappaB-dependent CAPITAL NNP O
cell-survival NNS O
pathways VB nerve_pathway O

Prenatal CAPITAL NNP prenatal O
diagnosis NN diagnosis O
can VB stopwords can O
be NN stopwords beryllium O
difficult NN difficult O
especially NN particularly O
if NN stopwords O
they NN stopwords O
present NN present O
in NN stopwords inch O
late NN late O
gestation NN gestation O

Predicting CAPITAL NNP predict O
changes NNS change O
in NN stopwords inch O
the NN stopwords O
distribution NN distribution O
of NN stopwords O
sweating NN perspiration D
following JJ following O
thoracoscopic NN T
sympathectomy NN sympathectomy T
. . O

The CAPITAL NNP O
data VB data O
were NN stopwords be O
then NN stopwords then O
meta-analyzed NN O
to NN stopwords O
produce NN produce O
outcome JJ result O
estimates NN estimate O
for NN stopwords O
alternative DT option O
surgical NN surgical T
procedures NN procedure T

Future CAPITAL NNP future O
studies NN survey O
should NN stopwords O
explore NN research O
the NN stopwords O
B/W CAPITAL NNP O
differences NN difference O
in NN stopwords inch O
tumor NN tumor O
biology NN biology O
using JJ exploitation O
molecular NN molecular O
markers NN marker O
that NN stopwords O
precede NN predate O
the NN stopwords O
conventional NNS conventional O
histological NN histological O
parameters NN parameter O
evaluated NN measure O
here NN stopwords here O

Expression CAPITAL NNP expression O
of NN stopwords O
cytokeratin NNS O
20 DIGITS CD twenty O
in NN stopwords inch O
urinary JJ urinary O
cytology NNS cytology O
of NN stopwords O
patients VB patient O
with NN stopwords O
bladder NN bladder D
carcinoma VB carcinoma D

A CAPITAL DT angstrom O
cell-based NNS O
immunobiosensor JJ O
with NN stopwords O
engineered NN engineer O
molecular NN molecular O
recognition NN recognition O
-- : O
Part CAPITAL VB part O
II CAPITAL PRP two O
: : O
Enzyme CAPITAL NNP enzyme O
amplification DT amplification O
systems NN system O

T-helper CAPITAL NNP T
type NN type T
2 DIGITS CD two T
cell-directed NNS T
therapy NN therapy T
for NN stopwords O
asthma DT asthma D

120 DIGITS CD long_hundred O

We CAPITAL NNP O
hypothesized NN speculate O
that NN stopwords O
fluoride JJ fluoride T
partly NN partially O
acts DT Acts_of_the_Apostles O
by NN stopwords by O
changing NNS change O
the NN stopwords O
levels NN degree O
of NN stopwords O
circulating NN go_around O
calcium-regulating VB O
hormones NN hormone O
and DT stopwords O
skeletal NN skeletal O
growth NN growth O
factors VB factor O

High-dose CAPITAL NNP T
chemotherapy NNS chemotherapy T
with NN stopwords T
autologous DT autologous T
hematopoietic NN hematopoietic T
stem-cell NN T
support NN support T
for NN stopwords O
breast NN breast D
cancer VB cancer D
in NN stopwords inch O
North CAPITAL NNP North O
America CAPITAL DT United_States O

Is CAPITAL PRP be O
dietary NN dietary O
fat VB fat O
a DT stopwords angstrom O
major VB major O
determinant NN determinant O
of NN stopwords O
body NN body O
fat VB fat O
? . O

DARTS/MEMO CAPITAL NNP O
Collaboration CAPITAL NNP collaboration O

animal DT animal O
studies NN survey O
suggest NN propose O
that NN stopwords O
the NN stopwords O
kidney NN kidney O
is NN stopwords be O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
elimination NN elimination O
of NN stopwords O
recombinant NN recombinant T
human NN homo T
granulocyte NN granulocyte T
colony-stimulating NNS T
factor VB factor T
( ( T
rhg-csf NN T
) ) T
, , O
which NN stopwords O
is NN stopwords be O
used JJ use O
for NN stopwords O
patients VB patient O
with NN stopwords O
neutropenia JJ neutropenia D
during NN stopwords O
cancer VB cancer D
chemotherapy NNS chemotherapy T

Tests CAPITAL NNP trial O
of NN stopwords O
the NN stopwords O
double-strand NN O
break NN interruption O
, , O
lethal-potentially NN O
lethal NN deadly O
and DT stopwords O
repair-misrepair NN O
models NN model O
for NN stopwords O
mammalian VB mammal O
cell NNS cell O
survival NN survival O
using JJ exploitation O
data VB data O
for NN stopwords O
survival NN survival O
as DT stopwords arsenic O
a DT stopwords angstrom O
function JJ function O
of NN stopwords O
delayed-plating NN O
interval NN time_interval O
for NN stopwords O
log-phase NN O
Chinese CAPITAL NNP Chinese O
hamster VB hamster O
V79 CAPITAL NNP O
cells NNS cell O

Effects CAPITAL NNP effects O
of NN stopwords O
clomipramine NNS clomipramine T
on NN stopwords on O
plasma NN plasma O
amino DT amino O
acids DT acid O
and DT stopwords O
serotonergic NN O
parameters NN parameter O
in NN stopwords inch O
panic VB panic D
disorder NN disorder D
and DT stopwords D
depression NN depression D
. . O

Confidentiality CAPITAL NNP confidentiality O
as DT stopwords arsenic O
a DT stopwords angstrom O
barrier NN barrier O
to NN stopwords O
treatment NN treatment O

this NN stopwords O
report NN report O
illustrates NN exemplify O
that NN stopwords O
tpvb NN T
could NNS O
also DT besides O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
this NN stopwords O
kind NN kind O
of NN stopwords O
pain IN pain D

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
noninvasive JJ noninvasive T
positive-pressure NN T
ventilation NN ventilation T
and DT stopwords O
conventional NNS conventional T
mechanical NN mechanical T
ventilation NN ventilation T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
respiratory NN respiratory D
failure VB failure D

In CAPITAL PRP inch O
a DT stopwords angstrom O
man-on-the-street VB O
approach DT approach O
, , O
23 DIGITS CD twenty-three O
nurses RB nurse O
participated NN participate O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
interview NN interview O
via NN O
video NN video O
camera VB camera O

What CAPITAL NNP O
about DT stopwords about O
our NN stopwords O
distinctiveness NN peculiarity O
? . O
1981 DIGITS CD O

Fifty-three CAPITAL NNP fifty-three O
triplet NN three O
pregnancies NN pregnancy O
between NN stopwords between O
1986 DIGITS CD O
and DT stopwords O
1993 DIGITS CD O
at DT stopwords astatine O
The CAPITAL NNP O
New CAPITAL NNP new O
York CAPITAL NNP York O
Hospital-Cornell CAPITAL NNP O
Medical CAPITAL NNP checkup O
Center CAPITAL NNP center O
were NN stopwords be O
reviewed NN review O

Treatment CAPITAL NNP treatment O
of NN stopwords O
a DT stopwords angstrom D
disorder NN disorder D
of NN stopwords D
perception NN percept D
and DT stopwords D
concept NNS concept D
formation NN formation D
in NN stopwords inch O
a DT stopwords angstrom O
case VB case O
of NN stopwords O
school JJ school O
failure VB failure O

Side CAPITAL NNP side O
effects NN effects O
from JJ stopwords O
influenza NN influenza D
vaccination NN inoculation T
: : O
differences NN difference O
between NN stopwords between O
returned NN return O
and DT stopwords O
random VB random O
surveys NN survey O

Thus CAPITAL NNP frankincense O
, , O
28 DIGITS CD twenty-eight O
subjects NN subject O
( ( O
9 DIGITS CD nine O
% NN O
) ) O
suffered NN suffer O
35 DIGITS CD thirty-five O
events NN event O

Altered CAPITAL DT change O
calcium VB calcium O
( ( O
Ca2+ CAPITAL VB O
) ) O
homeostasis NN homeostasis O
is NN stopwords be O
thought NN idea O
to NN stopwords O
play NN play O
a DT stopwords angstrom O
key NN key O
role NN function O
in NN stopwords inch O
aging DT ripening O
and DT stopwords O
neuropathology JJ O
resulting NN result O
in NN stopwords inch O
memory NN memory O
deficits NN deficit O

Effects CAPITAL NNP effects O
on NN stopwords on O
the NN stopwords O
pup NN pup O
and DT stopwords O
the NN stopwords O
adult DT adult O

Psychobiology CAPITAL NNP O
of NN stopwords O
Postraumatic CAPITAL NNP D
Stress CAPITAL NNP stress D
Disorder CAPITAL NNP disorder D

The CAPITAL NNP O
prevalence NN prevalence O
of NN stopwords O
chemical NNS chemical O
substance NN substance O
and DT stopwords O
alcohol DT alcohol O
abuse DT maltreatment O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
obstetric NN obstetric O
population NN population O
in NN stopwords inch O
Dublin CAPITAL NNP Dublin O

Over CAPITAL NNP over O
a DT stopwords angstrom O
1-year CD O
period NN time_period O
, , O
rigid NN rigid T
ureteroscopy JJ T
has VB stopwords hour_angle O
been NN stopwords be O
used JJ use O
to NN stopwords O
retrieve NN recover O
ureteric JJ D
calculi VB calculus D
in NN stopwords inch O
120 DIGITS CD long_hundred O
patients VB patient O

High CAPITAL NNP high O
energy NN energy O
roentgen NN roentgen O
ray VB beam O
contamination NNS contamination O
of NN stopwords O
the NN stopwords O
electron NN electron O
beam NN radio_beam O
from JJ stopwords O
a DT stopwords angstrom O
medical NN checkup O
betatron NN betatron O

Search CAPITAL NNP search O
for NN stopwords O
studies NN survey O
was VB stopwords Washington O
limited NN express O

External CAPITAL NNP external T
beam NN radio_beam T
radiation VB radiation T
therapy NN therapy T
for NN stopwords O
choroidal NNS D
neovascularization JJ D

Predicting CAPITAL NNP predict O
functional JJ functional O
appliance DT appliance O
treatment NN treatment O
outcome JJ result O
in NN stopwords inch O
Class CAPITAL NNP class O
II CAPITAL PRP two O
malocclusions VB malocclusion D
-- : O
a DT stopwords angstrom O
review NN reappraisal O

hominis NN O
was VB stopwords Washington O
identified NN identify O
in NN stopwords inch O
336 DIGITS CD O
patients VB patient O
( ( O
16.5 CD O
% NN O
) ) O

A CAPITAL DT angstrom O
kinder NN kind O
, , O
gentler NN gentle O
approach DT approach O

The CAPITAL NNP O
ability DT ability O
of NN stopwords O
PRL CAPITAL NNP O
to NN stopwords O
activate DT trip O
the NN stopwords O
promoter NN promoter O
of NN stopwords O
the NN stopwords O
beta-casein NN O
gene NN gene O
or NN stopwords Oregon O
the NN stopwords O
lactogenic NN lactogenic O
hormone NN hormone O
responsive NN responsive O
element NN component O
fused JJ blend O
to NN stopwords O
the NN stopwords O
luciferase NN O
reporter NN reporter O
was VB stopwords Washington O
assessed DT measure O
in NN stopwords inch O
Chinese CAPITAL NNP Chinese O
hamster VB hamster O
ovary NN ovary O
cells NNS cell O
or NN stopwords Oregon O
293 DIGITS CD O
fibroblasts NN fibroblast O
transiently NN transiently O
transfected NN O
with NN stopwords O
PRLR CAPITAL NNP O
cDNAs SYM complementary_DNA O

Acquired CAPITAL DT get O
haemophilia VB hemophilia D
, , O
an DT stopwords Associate_in_Nursing O
unusual JJ unusual O
cause VB cause O
of NN stopwords O
severe NN severe O
postpartum NN postnatal D
haemorrhage VB bleeding D

A CAPITAL DT angstrom O
semi-quantitative NN O
DC-PCR CAPITAL NNP O
assay DT assay O
detects NN detect O
a DT stopwords angstrom O
significant NN significant O
recombinase NN O
activity DT activity O
only JJ stopwords lone O
in NN stopwords inch O
a DT stopwords angstrom O
restricted NN restrict O
set NN set O
of NN stopwords O
late NN late O
stage NN phase O
pre-B NN O
and DT stopwords O
mature VB mature O
B CAPITAL NN bacillus O
cell NNS cell O
lines NN line O

In CAPITAL PRP inch O
absence DT absence O
of NN stopwords O
other JJ stopwords other O
causes VB cause O
, , O
B CAPITAL NN bacillus O

Mitochondrial CAPITAL NNP O
cytopathies NNS O
and DT stopwords O
renal NN nephritic D
tubular NN tubular D
acidosis DT acidosis D

It CAPITAL PRP information_technology O
resembles NN resemble O
Crohn CAPITAL NNP Crohn D
's POS D
disease NN disease D
clinically JJ clinically O
and DT stopwords O
radiologically VB O
, , O
and DT stopwords O
it NN stopwords information_technology O
may VB May O
be NN stopwords beryllium O
difficult NN difficult O
to NN stopwords O
differentiate NN distinguish O
between NN stopwords between O
them NN stopwords O
, , O
even NN evening O
at DT stopwords astatine O
laparotomy NN laparotomy O
or NN stopwords Oregon O
histology NN histology O

We CAPITAL NNP O
describe NN describe O
a DT stopwords angstrom O
rare NN rare O
case VB case O
of NN stopwords O
spontaneous NN spontaneous D
rupture NN rupture D
of NN stopwords D
a DT stopwords angstrom D
hepatic NN liverwort D
metastasis NN metastasis D
from JJ stopwords D
renal NN nephritic D
cell NNS cell D
carcinoma VB carcinoma D
that NN stopwords O
was VB stopwords Washington O
treated NN treat O
successfully NN successfully O
by NN stopwords by O
hepatic NN liverwort T
arterial DT arterial T
embolization NN T

Online CAPITAL NNP on-line O

Cor CAPITAL NNP O
pulmonale NN O

conclusion NNS decision O
: : O
as DT stopwords arsenic O
expected NN expect O
, , O
the NN stopwords O
type NN type O
of NN stopwords O
chemotherapy NNS chemotherapy T
we NN stopwords O
used JJ use O
, , O
to NN stopwords O
treat NN dainty O
non-seminomatous JJ D
germ-cell NN D
tumors NN tumor D
proved NN prove O
to NN stopwords O
be NN stopwords beryllium O
highly NN highly O
effective NN effective O
for NN stopwords O
seminomatous NN D
types NN type D
, , O
as DT stopwords arsenic O
well NN well O

Oviposition CAPITAL NNP O
and DT stopwords O
its NN stopwords information_technology O
regulation NN regulation O
in NN stopwords inch O
the NN stopwords O
polygynous NN polygynous O
society NN society O
of NN stopwords O
Polistes CAPITAL NNP Polistes O
gallicus VB O
L. CAPITAL NNP O

`` `` D
Whiplash CAPITAL NNP whiplash D
'' POS D
injury NN injury D
of NN stopwords O
the NN stopwords O
cervical NNS cervical O
spine JJ spinal_column O
: : O
value NN value O
of NN stopwords O
modern NN modern O
diagnostic NN diagnostic O
imaging NN imagination O

This CAPITAL NNP O
improvement JJ improvement O
may VB May O
be NN stopwords beryllium O
related NN associate O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
neutrophil JJ neutrophil O
superoxide NN superoxide O
production NN production O

We CAPITAL NNP O
hypothesize NN speculate O
that NN stopwords O
as DT stopwords arsenic O
temperature NN temperature O
increases NN addition O
there NN stopwords there O
would NN O
be NN stopwords beryllium O
a DT stopwords angstrom O
concomitant NNS accompaniment O
decrease NN decrease O
in NN stopwords inch O
AFI CAPITAL DT O

Genetics CAPITAL NNP genetics O

`` `` T
Tandem CAPITAL VB tandem T
'' POS T
high-dose NN T
chemoradiotherapy NNS T
with NN stopwords T
autologous DT autologous T
stem-cell NN T
support NN support T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
newly JJ newly O
diagnosed NN diagnose O
or NN stopwords Oregon O
responsive NN responsive O
multiple NN multiple D
myeloma NN myeloma D

Ilych CAPITAL PRP O
: : O
a DT stopwords angstrom O
critical JJ critical O
look NN expression O
at DT stopwords astatine O
the NN stopwords O
`` `` O
philosophy NN doctrine O
of NN stopwords O
hospice NN hospice O
'' POS O

a DT stopwords angstrom O
68-year-old CD O
man VB man O
underwent JJ undergo O
curative NNS remedy T
pancreaticoduodenectomy VB T
for NN stopwords O
bile NN bile D
duct NN duct D
cancer VB cancer D

Applying CAPITAL DT use O
excitation NN excitement O
sculpting JJ sculpt O
to NN stopwords O
construct NNS concept O
singly NN singly O
and DT stopwords O
doubly NN doubly O
selective NN selective O
1D CD O
NMR CAPITAL NNP nuclear_magnetic_resonance O
experiments NN experiment O

II CAPITAL PRP two O

Researchers CAPITAL NNP research_worker O
' '' O
objective NN aim O
is NN stopwords be O
to NN stopwords O
get NN get O
the NN stopwords O
job NN occupation O
done NN make O

carboplatin VB T
and DT stopwords T
ifosfamide NN T
performed NN perform O
well NN well O
and DT stopwords O
safe VB safe O
, , O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
non-bulky JJ D
metastatic NN metastatic D
seminoma NN seminoma D

Less CAPITAL NNP lupus_erythematosus O
than NN stopwords O
2 DIGITS CD two O
% NN O
of NN stopwords O
samples VB sample O
tested NN test O
positive NN positive O
for NN stopwords O
alcohol DT alcohol O

Online CAPITAL NNP on-line O

The CAPITAL NNP T
`` `` T
H CAPITAL NN hydrogen T
'' POS T
graft NN graft T
: : O
an DT stopwords Associate_in_Nursing O
alternative DT option O
approach DT approach O
for NN stopwords O
performing NN acting O
minimally NN minimally O
invasive NN invasive O
direct NN direct T
coronary NNS coronary_thrombosis T
artery DT artery T
bypass NN beltway T

Inhalation CAPITAL PRP inhalation O
of NN stopwords O
ammonium DT ammonium O
nitrate NN nitrate O
fuel JJ fuel O
oil NN oil O
explosive NN explosive O
( ( O
ANFO CAPITAL DT O
) ) O

RESULTS CAPITAL NNP consequence O
: : O
Overall CAPITAL NNP overall O
, , O
systolic NN systolic O
blood NN blood O
pressure NN pressure O
was VB stopwords Washington O
lower NN lower_berth O
in NN stopwords inch O
the NN stopwords O
calcium VB calcium O
group NN group O
( ( O
mean NN mean O
difference NN difference O
-1.4 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
; : O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
-3.2 : O
to NN stopwords O
0.5 LS O
) ) O
than NN stopwords O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O

The CAPITAL NNP O
different NN different O
examples NN example O
analyzed DT analyze O
and DT stopwords O
presented NN show O
together NN together O
provide NN supply O
a DT stopwords angstrom O
means NN means O
by NN stopwords by O
which NN stopwords O
the NN stopwords O
antigen-antibody DT O
reactions NN chemical_reaction O
may VB May O
be NN stopwords beryllium O
better NN better O
controlled NNS control O
by NN stopwords by O
noting JJ note O
the NN stopwords O
magnitude VB magnitude O
of NN stopwords O
the NN stopwords O
changes NNS change O
in NN stopwords inch O
the NN stopwords O
fractal NN fractal O
dimension NN dimension O
and DT stopwords O
in NN stopwords inch O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficient NNS coefficient O
as DT stopwords arsenic O
the NN stopwords O
reaction NN chemical_reaction O
progresses NN advancement O
on NN stopwords on O
the NN stopwords O
biosensor NN O
surface NN surface O

Performance CAPITAL NNP performance O
of NN stopwords O
ICSI CAPITAL PRP O
with NN stopwords O
testicular NN testicular O
sperm NN sperm O
in NN stopwords inch O
these NN stopwords O
cases VB case O
resulted NN result O
in NN stopwords inch O
satisfactory VB satisfactory O
fertilization NN fertilization O
and DT stopwords O
high NN high O
embryo NN embryo O
transfer NN transportation O
rates VB rates O

These CAPITAL NNP O
biosensors NN O
are DT stopwords are O
fabricated VB manufacture O
by NN stopwords by O
site-selective NN O
photodeposition NN O
of NN stopwords O
analyte-sensitive DT O
polymer NN polymer O
matrices VB matrix O
on NN stopwords on O
optical JJ optical O
imaging NN imagination O
fibres NN fiber O

In CAPITAL PRP inch O
the NN stopwords O
`` `` O
early VB early O
'' POS O
and DT stopwords O
`` `` O
late NN late O
'' POS O
groups NN group O
, , O
mean NN mean O
gestational NN gestational O
age DT age O
at DT stopwords astatine O
the NN stopwords O
beginning NN beginning O
of NN stopwords O
treatment NN treatment O
was VB stopwords Washington O
30.0 CD O
+/- NN O
3.8 LS O
and DT stopwords O
36.2 CD O
+/- NN O
1.2 CD O
weeks NN week O
, , O
and DT stopwords O
duration NN duration O
of NN stopwords O
treatment NN treatment O
was VB stopwords Washington O
9.6 CD O
+/- NN O
4.1 CD O
and DT stopwords O
3.7 LS O
+/- NN O
1.8 CD O
weeks NN week O
, , O
respectively NN respectively O

DESIGN CAPITAL NNP design O
: : O
Follow CAPITAL NNP follow O
up JJ stopwords up O
of NN stopwords O
a DT stopwords angstrom O
population NN population O
enrolled NN enroll O
in NN stopwords inch O
a DT stopwords angstrom O
double NN double O
blind NN blind O
, , O
randomised VB randomize O
, , O
placebo NN placebo O
controlled NNS control O
trial NN test O

Immunohistochemistry CAPITAL PRP immunohistochemistry O
using JJ exploitation O
a DT stopwords angstrom O
pool NN pool O
of NN stopwords O
anti-EgCaBP1-GST DT O
mouse NN mouse O
sera NN serum O
demonstrated NN show O
a DT stopwords angstrom O
strong NN strong O
association DT association O
of NN stopwords O
the NN stopwords O
protein NN protein O
with NN stopwords O
calcareous VB calcareous O
corpuscles NNS atom O

A CAPITAL DT angstrom O
de NN Delaware O
novo JJ O
missense NN O
mutation NN mutant O
( ( O
R1623Q CAPITAL NNP O
) ) O
of NN stopwords O
the NN stopwords O
SCN5A CAPITAL NNP O
gene NN gene O
in NN stopwords inch O
a DT stopwords angstrom O
Japanese CAPITAL NNP Japanese O
girl NN girl O
with NN stopwords O
sporadic NN sporadic D
long NN hanker D
QT CAPITAL NNP D
sydrome NN D

SUBJECTS CAPITAL NNP subject O
: : O
A CAPITAL DT angstrom O
total NN sum O
of NN stopwords O
120 DIGITS CD long_hundred O
Caucasian CAPITAL VB White O
patients VB patient O
with NN stopwords O
MS CAPITAL NNP multiple_sclerosis O
and DT stopwords O
107 DIGITS CD O
unrelated JJ unrelated O
control NNS control O
individuals NN person O
from JJ stopwords O
California CAPITAL VB California O
, , O
and DT stopwords O
32 DIGITS CD thirty-two O
patients VB patient O
and DT stopwords O
32 DIGITS CD thirty-two O
unrelated JJ unrelated O
control NNS control O
individuals NN person O
from JJ stopwords O
Beijing CAPITAL NNP Beijing O
, , O
China CAPITAL NNP China O

Nurses CAPITAL NNP nurse O
are DT stopwords are O
selling NN selling O
a DT stopwords angstrom O
product NN merchandise O
, , O
and DT stopwords O
that NN stopwords O
product NN merchandise O
is NN stopwords be O
health NN health O

we NN stopwords O
recently NN recently O
performed NN perform O
completion NNS completion T
pneumonectomy NN pneumonectomy T
of NN stopwords T
the NN stopwords T
left NN left T
lung NN lung T
in NN stopwords inch O
a DT stopwords angstrom O
70-year-old CD O
man VB man O
with NN stopwords O
hemophilia NN hemophilia O
a DT stopwords angstrom O
, , O
for NN stopwords O
squamous NN D
cell NNS cell D
carcinoma VB carcinoma D
in NN stopwords inch O
the NN stopwords O
residual NN remainder O
left NN left O
lung NN lung O

Between CAPITAL NNP between O
July CAPITAL NNP July O
1973 DIGITS CD O
and DT stopwords O
December CAPITAL NNP December O
1979 DIGITS CD O
, , O
1171 DIGITS CD O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
breast NN breast D
cancer VB cancer D
were NN stopwords be O
treated NN treat O
with NN stopwords O
doxorubicin-containing NN T
chemotherapy NNS chemotherapy T

She CAPITAL NNP O
made VB make O
an DT stopwords Associate_in_Nursing O
uneventful JJ uneventful O
postoperative NN postoperative O
recovery NN recovery O
and DT stopwords O
now JJ stopwords now O
leads NN lead O
an DT stopwords Associate_in_Nursing O
unrestricted JJ unrestricted O
life NN life O

In CAPITAL PRP inch O
contrast NNS contrast O
, , O
purified NN purify O
primary NN primary O
normal RB convention O
progenitors NN progenitor O
maintained VB keep O
under JJ stopwords nether O
the NN stopwords O
same VB stopwords Lapp O
conditions NNS conditions O
die NN die O
rapidly VB quickly O

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONTEXT CAPITAL NNP context O
: : O
There CAPITAL NNP there O
is NN stopwords be O
a DT stopwords angstrom O
substantial NN significant O
risk NN hazard O
of NN stopwords O
a DT stopwords angstrom O
second NN second O
cancer VB cancer O
for NN stopwords O
persons NN person O
with NN stopwords O
hereditary NN familial O
retinoblastoma NN retinoblastoma O
, , O
which NN stopwords O
is NN stopwords be O
enhanced NN enhance O
by NN stopwords by O
radiotherapy VB radiotherapy O

Association CAPITAL DT association O
between NN stopwords between O
thrombolytic NN thrombolytic T
treatment NN treatment T
and DT stopwords O
the NN stopwords O
prognosis NN prognosis O
of NN stopwords O
hemodynamically NN O
stable NN stable O
patients VB patient O
with NN stopwords O
major VB major D
pulmonary NN pneumonic D
embolism NN embolism D
: : O
results NN consequence O
of NN stopwords O
a DT stopwords angstrom O
multicenter NN O
registry NN register O
. . O

Use CAPITAL NNP use O
of NN stopwords O
a DT stopwords angstrom O
nerve RB nerve T
stimulator JJ T
for NN stopwords O
phrenic NN phrenic D
nerve RB nerve D
block NN block D
in NN stopwords inch O
treatment NN treatment O
of NN stopwords O
hiccups NN hiccup D

These CAPITAL NNP O
results NN consequence O
are DT stopwords are O
consistent NNS consistent O
with NN stopwords O
two NN two O
pools NN pool O
of NN stopwords O
DSBs CAPITAL NNP O
( ( O
or NN stopwords Oregon O
cells NNS cell O
) ) O
, , O
each VB stopwords each O
with NN stopwords O
their NN stopwords O
own JJ stopwords own O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O

Variation CAPITAL VB variation O
within NN inside O
the NN stopwords O
MBP CAPITAL NNP O
locus NN venue O
on NN stopwords on O
chromosome NN chromosome O
18q23 CD O
showed NN show O
no NNS stopwords no O
effect NN consequence O
in NN stopwords inch O
MS CAPITAL NNP multiple_sclerosis O

Nonimmune CAPITAL NNP liable D
hydrops NN edema D
fetails JJ D
diagnosed NN diagnose O
at DT stopwords astatine O
21 DIGITS CD twenty-one O
weeks NN week O
' '' O
gestation NN gestation O
with NN stopwords O
profound NN profound O
ascites DT ascites D
, , O
hydrothorax NN hydrothorax D
, , O
and DT stopwords O
pericardial NN pericardial D
effusion NN effusion D
receded NN withdraw O
gradually NN gradually O
with NN stopwords O
regression NN arrested_development O
of NN stopwords O
a DT stopwords angstrom O
subchorial NN O
placental NN placental O
lucencies NN O
immediately JJ immediately O
below NN stopwords below O
the NN stopwords O
umbilical JJ umbilical_cord O
cord NNS cord O
insertion NN interpolation O

A CAPITAL DT angstrom O
multifactorial NN multifactorial O
analysis DT analysis O
of NN stopwords O
facial VB facial O
nerve RB nerve O
results NN consequence O
in NN stopwords inch O
surgery NN surgery O
for NN stopwords O
cerebellopontine NNS O
angle DT angle O
tumors NN tumor O

Our CAPITAL NNP O
results NN consequence O
demonstrate NN show O
that NN stopwords O
the NN stopwords O
`` `` O
multigene-one-protein NN O
'' POS O
principle NN principle O
of NN stopwords O
CaM CAPITAL VB Cam O
synthesis NN synthesis O
is NN stopwords be O
not JJ stopwords not O
only JJ stopwords lone O
applicable DT applicable O
to NN stopwords O
mammals VB mammal O
whose NN O
CaM CAPITAL VB Cam O
is NN stopwords be O
encoded NN encode O
by NN stopwords by O
three NN three O
different NN different O
genes NN gene O
, , O
but NN stopwords merely O
also DT besides O
to NN stopwords O
chickens JJ chicken O

Results CAPITAL NNP consequence O
of NN stopwords O
early VB early O
rehabilitation NN rehabilitation O
seem NN look O
to NN stopwords O
be NN stopwords beryllium O
influenced NN influence O
by NN stopwords by O
duration NN duration O
and DT stopwords O
etiology NN etiology O
of NN stopwords O
deafness NN deafness D
, , O
experience NN experience O
with NN stopwords O
hearing NN hearing O
aids DT AIDS O
, , O
and DT stopwords O
other JJ stopwords other O
factors VB factor O

How CAPITAL NNP O
do NN stopwords bash O
you NN stopwords O
treat NN dainty O
refractory NN furnace_lining D
pouchitis NN D
and DT stopwords O
when NN stopwords O
do NN stopwords bash O
you NN stopwords O
decide NN decide O
to NN stopwords O
remove NN remove O
the NN stopwords O
pouch NN pouch O
? . O

A CAPITAL DT angstrom O
radium VB radium O
accident DT accident O
in NN stopwords inch O
a DT stopwords angstrom O
hospital NN hospital O

Factors CAPITAL NNP factor O
influencing NN influence O
blood NN blood O
flow JJ flow O
in NN stopwords inch O
the NN stopwords O
optic JJ eye O
nerve RB nerve O
head NN head O

The CAPITAL NNP O
place NN topographic_point O
of NN stopwords O
surgery NN surgery T
in NN stopwords inch O
hypertrophic NN D
obstructive NN clogging D
cardiomyopathy VB cardiomyopathy D
( ( D
idiopathic JJ idiopathic D
hypertrophic NN D
subaortic NN D
stenosis NN stenosis D
) ) D

Sixty CAPITAL NNP sixty O
patients VB patient O
( ( O
25 DIGITS CD twenty-five O
males VB male O
and DT stopwords O
35 DIGITS CD thirty-five O
females JJ female O
) ) O
who NN stopwords World_Health_Organization O
had VB stopwords have O
myofascial NN D
trigger NN gun_trigger D
points NN point D
in NN stopwords inch O
one JJ one O
side NN side O
of NN stopwords O
the NN stopwords O
upper JJ upper_berth O
trapezius NN trapezius O
muscles NN muscle O
were NN stopwords be O
studied NN analyze O

Despite CAPITAL NNP contempt O
this NN stopwords O
, , O
patient VB patient O
satisfaction VB satisfaction O
was VB stopwords Washington O
high NN high O

Radiation CAPITAL VB radiation O
dose NN dose O
and DT stopwords O
sarcoma VB sarcoma O
risk NN hazard O

Future CAPITAL NNP future O
studies NN survey O
should NN stopwords O
address DT address O
the NN stopwords O
long-term NN long-run O
consequences NNS consequence O
of NN stopwords O
prolonged NN prolong O
use JJ use O
of NN stopwords O
fenfluramines JJ T

the NN stopwords O
aim DT purpose O
of NN stopwords O
the NN stopwords O
current NNS current O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
objective NN aim O
response NN response O
and DT stopwords O
survival NN survival O
rates VB rates O
of NN stopwords O
patients VB patient O
with NN stopwords O
mrcc NN D
treated NN treat O
with NN stopwords O
il-2 NN T
administered DT administer O
either NN either O
systemically NN O
( ( O
syst NN O
, , O
subcutaneously NN subcutaneously O
) ) O
or NN stopwords Oregon O
via NN O
inhalation NN inhalation O
( ( O
inh NN isoniazid O
) ) O
, , O
using JJ exploitation O
relatively NN relatively O
large NN large O
sample VB sample O
sizes NN size O
to NN stopwords O
afford DT afford O
a DT stopwords angstrom O
more NN stopwords More O
meaningful NN meaningful O
comparison NNS comparison O

The CAPITAL NNP O
parthengenotes NN O
were NN stopwords be O
derived NN deduce O
only JJ stopwords lone O
from JJ stopwords O
eggs NN egg O
that NN stopwords O
failed VB fail O
to NN stopwords O
extrude NN extrude O
polar NN polar O
bodies NN body O
, , O
mostly NN largely O
from JJ stopwords O
eggs NN egg O
failing VB failing O
to NN stopwords O
extrude NN extrude O
a DT stopwords angstrom O
second NN second O
polar NN polar O
body NN body O

Furthermore CAPITAL NNP furthermore O
, , O
it NN stopwords information_technology O
is NN stopwords be O
widely NN widely O
documented NN document O
that NN stopwords O
endurance NN endurance O
activities DT activity O
increase NN addition O
the NN stopwords O
energy NN energy O
utilisation JJ use O
from JJ stopwords O
fat VB fat O
while NN stopwords while O
sparing NN spare O
carbohydrate VB carbohydrate O
sources NN beginning O

Mouth CAPITAL NNP mouth O
care VB care O
and DT stopwords O
skin JJ skin O
care VB care O
in NN stopwords inch O
palliative VB palliative O
medicine NN medicine O

Factors CAPITAL NNP factor O
affecting DT affect O
uptake JJ consumption O
of NN stopwords O
antenatal DT prenatal O
HIV CAPITAL NNP HIV O
testing NN testing O
in NN stopwords inch O
London CAPITAL NNP London O
: : O
results NN consequence O
of NN stopwords O
a DT stopwords angstrom O
multicentre NN O
study NN survey O

Ultrastructure CAPITAL NNP O
of NN stopwords O
human NN homo O
colostral NNS O
cells NNS cell O

INTERVENTION CAPITAL PRP intervention O
: : O
After CAPITAL DT after O
random VB random O
assignment DT assignment O
to NN stopwords O
1 DIGITS CD one O
of NN stopwords O
3 DIGITS CD three O
groups NN group O
, , O
the NN stopwords O
adolescents DT adolescent O
listened NN listen O
to NN stopwords O
a DT stopwords angstrom O
standardized NN standardize O
audiotape DT audiotape O
depiction NN word_picture O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
office JJ office O
visit NN visit O
during NN stopwords O
which NN stopwords O
they NN stopwords O
heard NN hear O
a DT stopwords angstrom O
physician NN doctor O
who NN stopwords World_Health_Organization O
assured DT guarantee O
unconditional JJ unconditional O
confidentiality NNS confidentiality O
, , O
a DT stopwords angstrom O
physician NN doctor O
who NN stopwords World_Health_Organization O
assured DT guarantee O
conditional NNS conditional O
confidentiality NNS confidentiality O
, , O
or NN stopwords Oregon O
a DT stopwords angstrom O
physician NN doctor O
who NN stopwords World_Health_Organization O
did NN stopwords make O
not JJ stopwords not O
mention NN mention O
confidentiality NNS confidentiality O

Providing CAPITAL NNP supply O
primary NN primary O
care VB care O
in NN stopwords inch O
the NN stopwords O
accident DT accident O
and DT stopwords O
emergency NN emergency O
department NN department O

< NN O
TO_SEE CAPITAL NNP O
> NN O
OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
examine NN analyze O
long-term NN long-run O
risk NN hazard O
of NN stopwords O
new JJ new O
primary NN primary O
cancers VB cancer O
in NN stopwords inch O
survivors NN survivor O
of NN stopwords O
childhood JJ childhood O
retinoblastoma NN retinoblastoma O
and DT stopwords O
quantify NN quantify O
the NN stopwords O
role NN function O
of NN stopwords O
radiotherapy VB radiotherapy O
in NN stopwords inch O
sarcoma VB sarcoma O
development NN development O

The CAPITAL NNP O
distribution NN distribution O
of NN stopwords O
haplotypes VB haplotype O
from JJ stopwords O
5 DIGITS CD five O
loci NN venue O
within NN inside O
the NN stopwords O
chromosome NN chromosome O
19q13.2 CD O
region NN region O
, , O
including NN include O
D19S178 CAPITAL NNP O
, , O
D19S574 CAPITAL NNP O
, , O
APOE CAPITAL DT O
, , O
APOC2 CAPITAL DT O
, , O
and DT stopwords O
D19S219 CAPITAL NNP O
, , O
differed NN differ O
between NN stopwords between O
patient VB patient O
and DT stopwords O
control NNS control O
samples VB sample O

PURPOSE CAPITAL NNP purpose O
: : O
Inhaled CAPITAL PRP inhale O
corticosteroids NNS corticosteroid T
have VB stopwords rich_person O
beneficial NN beneficial O
effects NN effects O
on NN stopwords on O
pulmonary NN pneumonic O
function JJ function O
and DT stopwords O
inflammation NN inflammation O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
asthma DT asthma D
, , O
but NN stopwords merely O
they NN stopwords O
also DT besides O
cause VB cause O
systemic NN systemic O
adverse DT adverse O
effects NN effects O
, , O
such NN stopwords such O
as DT stopwords arsenic O
adrenal DT adrenal_gland O
suppression NN suppression O

Dextran CAPITAL NNP O
of NN stopwords O
low NN low O
molecular NN molecular O
weight NN weight O
in NN stopwords inch O
peripheral NN peripheral D
arterial DT arterial D
insufficiency NN insufficiency D

Events CAPITAL NNP event O
were NN stopwords be O
defined NN specify O
as DT stopwords arsenic O
either NN either O
coronary NNS coronary_thrombosis O
death NN death O
, , O
myocardial NN myocardial D
infarction NN infarct D
, , O
or NN stopwords Oregon O
revascularization NN D

American CAPITAL DT American O
Diabetes CAPITAL NNP diabetes O
Association CAPITAL DT association O

Control CAPITAL NNP control O
of NN stopwords O
the NN stopwords O
malignant VB malignant D
hyperpyrexic NN D
syndrome NN syndrome D
in NN stopwords inch O
MHS CAPITAL NNP O
swine JJ swine O
by NN stopwords by O
dantrolene VB T
sodium NN sodium T

Successful CAPITAL NNP successful O
arthrodesis DT arthrodesis T
was VB stopwords Washington O
achieved DT achieve O
in NN stopwords inch O
all DT stopwords all O
five NN five O
feet JJ foot O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
rheumatoid NN arthritic D
arthritis DT arthritis D

Sibpair CAPITAL NNP O
analysis DT analysis O
( ( O
n=54 JJ O
) ) O
resulted NN result O
in NN stopwords inch O
maximum VB maximum O
lod NN O
scores JJ tons O
( ( O
MLSs CAPITAL NNP Master_of_Library_Science O
) ) O
of NN stopwords O
1.5 CD O
, , O
2.6 CD O
, , O
3.2 LS O
, , O
and DT stopwords O
2.3 CD O
for NN stopwords O
these NN stopwords O
markers NN marker O
, , O
with NN stopwords O
a DT stopwords angstrom O
peak NN extremum O
multipoint NN O
MLS CAPITAL NNP Master_of_Library_Science O
of NN stopwords O
3.5 LS O

The CAPITAL NNP O
accuracy DT accuracy O
is NN stopwords be O
demonstrated NN show O
by NN stopwords by O
the NN stopwords O
measurement NN measurement O
of NN stopwords O
control NNS control O
sera NN serum O

The CAPITAL NNP O
predicted NN predict O
protein NN protein O
, , O
pendrin NN O
, , O
is NN stopwords be O
closely NNS closely O
related NN associate O
to NN stopwords O
a DT stopwords angstrom O
number JJ number O
of NN stopwords O
known NN know O
sulphate NN sulfate O
transporters NN transporter O

METHODS CAPITAL NNP method O
: : O
During CAPITAL NNP O
a DT stopwords angstrom O
19-month CD O
period NN time_period O
, , O
seven NN seven O
children JJ child O
with NN stopwords O
empyema NN empyema D
underwent JJ undergo O
thoracoscopy NN T

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
melatonin NN melatonin O
administration DT administration O
on NN stopwords on O
ethanol-induced NN O
lipid NN lipid O
peroxidation NN O
in NN stopwords inch O
rats VB rat O

Ion CAPITAL PRP ion O
channels NNS channels O

All CAPITAL DT all O
114 DIGITS CD O
sarcomas VB sarcoma D
of NN stopwords O
diverse NN divers O
histologic NN histological O
types NN type O
occurred JJ happen O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
hereditary NN familial O
retinoblastoma NN retinoblastoma D

Hepatectomy CAPITAL NNP T
for NN stopwords O
cholangiocarcinoma NNS D
complicated NNS complicate O
with NN stopwords O
right NN right O
umbilical JJ umbilical_cord O
portion NN part O
: : O
anomalous DT anomalous O
configuration NNS configuration O
of NN stopwords O
the NN stopwords O
intrahepatic NN O
biliary NN bilious O
tree NN tree O

Cranial CAPITAL NNP cranial D
nerve RB nerve D
injuries NN injury D
during NN stopwords O
multifocal NN O
neuropathies JJ neuropathy O
with NN stopwords O
persistent NN persistent O
conduction NNS conduction O
blocks NN block O

Investigation CAPITAL PRP probe O
of NN stopwords O
antibiotic DT antibiotic T
prophylaxis NN prophylaxis T
usage JJ use O
for NN stopwords O
vascular NN vascular O
and DT stopwords O
nonvascular JJ O
interventional NN O
procedures NN procedure O

A CAPITAL DT angstrom O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
syndrome NN syndrome O
with NN stopwords O
a DT stopwords angstrom O
report NN report O
of NN stopwords O
4 DIGITS CD four O
cases VB case O

Epilepsy CAPITAL NNP epilepsy D
and DT stopwords O
psychiatric NN psychiatric D
disorders NN disorder D
: : O
epidemiological NN epidemiologic O
data VB data O

The CAPITAL NNP O
final NN final O
lactate NN lactate O
catheter VB catheter O
is NN stopwords be O
characterized NNS qualify O
by NN stopwords by O
a DT stopwords angstrom O
linear NN linear O
concentration NNS concentration O
range VB scope O
between NN stopwords between O
0.5 LS O
and DT stopwords O
20 DIGITS CD twenty O
mmol/l NN O
lactate NN lactate O
with NN stopwords O
a DT stopwords angstrom O
sensitivity NN sensitivity O
around DT about O
2 DIGITS CD two O
nA IN sodium O
mmol-1 NN O
l-1 SYM O
lactate NN lactate O

List CAPITAL NNP list O
No CAPITAL NNP no O

This CAPITAL NNP O
article DT article O
reviews NN reappraisal O
and DT stopwords O
conceptualises NNS gestate O
the NN stopwords O
whole NN whole O
overtraining JJ O
process NN procedure O

17th CD seventeenth O
European CAPITAL NNP European O
Workshop CAPITAL NNP workshop O
on NN stopwords on O
the NN stopwords O
Cell CAPITAL NNP cell O
Biology CAPITAL NNP biology O
of NN stopwords O
Phagocytes CAPITAL NNP phagocyte O

Hypodermic CAPITAL NNP hypodermic_syringe O
needles JJ acerate_leaf O
in NN stopwords inch O
the NN stopwords O
neuropathic JJ O
foot JJ foot O
of NN stopwords O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
diabetes NN diabetes D

Onset CAPITAL NNP onset O
of NN stopwords O
the NN stopwords O
preovulatory NN O
luteinizing NN O
hormone NN hormone O
surge NN rush O
: : O
diurnal NN diurnal O
timing NN timing O
and DT stopwords O
critical JJ critical O
follicular JJ follicular O
prerequisites NN prerequisite O

Abstracts CAPITAL DT abstraction O

At CAPITAL DT astatine O
6 DIGITS CD six O
months NN calendar_month O
follow-up JJ follow-up O
26 DIGITS CD twenty-six O
% NN O
( ( O
14/53 CD O
) ) O
of NN stopwords O
all DT stopwords all O
the NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
angioplasty DT angioplasty T
had VB stopwords have O
recurrence NN recurrence O
of NN stopwords O
angina DT angina D
, , O
which NN stopwords O
was VB stopwords Washington O
successfully NN successfully O
treated NN treat O
with NN stopwords O
repeat NN repeat T
angioplasty DT angioplasty T
, , T
bypass NN beltway T
surgery NN surgery T
, , T
or NN stopwords Oregon T
medical NN checkup T
therapy NN therapy T

High-dose CAPITAL NNP T
chemotherapy NNS chemotherapy T
with NN stopwords T
autologous DT autologous T
stem-cell NN T
support NN support T
for NN stopwords O
epithelial NN epithelial D
ovarian NN ovarian D
cancer VB cancer D

Anxiety CAPITAL DT anxiety O
and DT stopwords O
autonomic DT autonomic O
flexibility JJ flexibility O
: : O
a DT stopwords angstrom O
cardiovascular VB cardiovascular O
approach DT approach O

Glucose CAPITAL NNP glucose O
can VB stopwords can O
be NN stopwords beryllium O
measured NN measure O
in NN stopwords inch O
the NN stopwords O
range VB scope O
0.6-20.0 LS O
mM NNS millimeter O
in NN stopwords inch O
the NN stopwords O
O2 CAPITAL $ O
range VB scope O
20-100 CD O
% NN O

Should CAPITAL NNP O
patients VB patient O
with NN stopwords O
advanced DT advance D
sarcomas VB sarcoma D
be NN stopwords beryllium O
treated NN treat O
with NN stopwords O
chemotherapy NNS chemotherapy T
? . O

The CAPITAL NNP O
results NN consequence O
indicate NN bespeak O
that NN stopwords O
the NN stopwords O
wavelet-transform VB O
method NN method O
can VB stopwords can O
provide NN supply O
efficient NN efficient O
and DT stopwords O
accurate DT accurate O
quantification NN quantification O
of NN stopwords O
MRS CAPITAL NNP Mrs O
data VB data O

During CAPITAL NNP O
the NN stopwords O
postscanning NN O
period NN time_period O
, , O
18 DIGITS CD eighteen O
subjects NN subject O
( ( O
6 DIGITS CD six O
% NN O
) ) O
suffered NN suffer O
23 DIGITS CD twenty-three O
events NN event O
( ( O
5 DIGITS CD five O
coronary NNS coronary_thrombosis O
deaths NN death O
, , O
6 DIGITS CD six O
infarctions NN infarct D
, , O
and DT stopwords O
12 DIGITS CD twelve O
revascularizations NN D
) ) O

Sports-related CAPITAL NNP O
ocular JJ eyepiece D
injuries NN injury D

CONCLUSION CAPITAL NNP decision O
: : O
Calcium CAPITAL VB calcium T
supplementation NN supplement T
during NN stopwords O
pregnancy NN pregnancy O
is NN stopwords be O
associated DT associate O
with NN stopwords O
lower NN lower_berth O
systolic NN systolic O
blood NN blood O
pressure NN pressure O
in NN stopwords inch O
the NN stopwords O
offspring JJ offspring O
, , O
particularly NN particularly O
among DT O
overweight JJ corpulence O
children JJ child O

Perceived CAPITAL NNP perceive O
contraindications NNS contraindication O
to NN stopwords O
thrombolytic NN thrombolytic T
treatment NN treatment T
in NN stopwords inch O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

For CAPITAL NNP O
pain IN pain O
relief NN relief O
, , O
ENS CAPITAL NNP en O
was VB stopwords Washington O
significantly NN significantly O
better NN better O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
than NN stopwords O
EMS CAPITAL NNP em O
; : O
but NN stopwords merely O
for NN stopwords O
the NN stopwords O
improvement JJ improvement O
of NN stopwords O
ROM CAPITAL NNP read-only_memory O
, , O
EMS CAPITAL NNP em O
was VB stopwords Washington O
significantly NN significantly O
better NN better O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
than NN stopwords O
ENS CAPITAL NNP en O

the NN stopwords O
aim DT purpose O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
investigate NN investigate O
the NN stopwords O
relationships NN relationship O
among DT O
technetium-99m NN O
tetrofosmin NN O
( ( O
tc-tf NN O
) ) O
accumulation DT accretion O
in NN stopwords inch O
untreated JJ untreated O
small JJ small O
cell NNS cell O
lung NN lung O
cancer VB cancer O
( ( O
sclc JJ O
) ) O
, , O
the NN stopwords O
expression NN expression O
of NN stopwords O
p-glycoprotein SYM O
( ( O
pgp NN O
) ) O
and DT stopwords O
multidrug NN O
resistance NN resistance O
related NN associate O
protein-1 NN O
( ( O
mrp1 NN O
) ) O
, , O
and DT stopwords O
the NN stopwords O
response NN response O
to NN stopwords O
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
untreated JJ untreated D
sclc JJ D

Four CAPITAL NNP four O
murine NN murine O
cDNA SYM complementary_DNA O
isoforms NN O
have VB stopwords rich_person O
been NN stopwords be O
isolated NN isolate O
, , O
which NN stopwords O
are DT stopwords are O
likely NN likely O
to NN stopwords O
result NN consequence O
from JJ stopwords O
alternative DT option O
splicing NN splice O

besancon NN O
@ NN O
rockefeller1.univ.lyon1.fr NN O

Current CAPITAL NNP current O
pharmacovigilance NN O
is NN stopwords be O
predominantly NN predominantly O
based VB establish O
on NN stopwords on O
spontaneous NN spontaneous O
reporting NN coverage O
and DT stopwords O
is NN stopwords be O
mainly VB chiefly O
helpful NN helpful O
in NN stopwords inch O
detecting NN detection O
type NN type O
B CAPITAL NN bacillus O
effects NN effects O
( ( O
those NN stopwords O
effects NN effects O
that NN stopwords O
are DT stopwords are O
often JJ frequently O
allergic DT allergic O
or NN stopwords Oregon O
idiosyncratic JJ idiosyncratic O
reactions NN chemical_reaction O
, , O
characteristically NNS characteristically O
occurring JJ happen O
in NN stopwords inch O
only JJ stopwords lone O
a DT stopwords angstrom O
minority NN minority O
of NN stopwords O
patients VB patient O
and DT stopwords O
usually JJ normally O
unrelated JJ unrelated O
to NN stopwords O
dosage NN dose O
and DT stopwords O
that NN stopwords O
are DT stopwords are O
serious NN serious O
, , O
unexpected JJ unexpected O
and DT stopwords O
unpredictable JJ unpredictable O
) ) O
and DT stopwords O
unusual JJ unusual O
type NN type O
A CAPITAL DT angstrom O
effects NN effects O
( ( O
those NN stopwords O
effects NN effects O
that NN stopwords O
are DT stopwords are O
related NN associate O
to NN stopwords O
the NN stopwords O
pharmacological NN pharmacological O
effects NN effects O
of NN stopwords O
the NN stopwords O
drug NN drug O
and DT stopwords O
are DT stopwords are O
dosage-related NN O
) ) O

METHODS CAPITAL NNP method O
: : O
40 DIGITS CD forty O
diabetic NN diabetic O
patients VB patient O
with NN stopwords O
foot JJ foot D
infections NN infection D
were NN stopwords be O
enrolled NN enroll O
in NN stopwords inch O
a DT stopwords angstrom O
double-blind NN O
placebo-controlled NN O
study NN survey O

This CAPITAL NNP O
study NN survey O
was VB stopwords Washington O
designed NN plan O
to NN stopwords O
determine NN determine O
and DT stopwords O
compare NNS comparison O
the NN stopwords O
dose-response NN O
characteristics NNS feature O
, , O
speed NN speed O
of NN stopwords O
onset JJ onset O
, , O
and DT stopwords O
relative NN relative O
potency NN authority O
of NN stopwords O
single-dose NN O
epidural NN epidural_anesthesia T
fentanyl JJ Fentanyl T
( ( T
F CAPITAL NN degree_Fahrenheit T
) ) T
and DT stopwords O
sufentanil NN T
( ( T
S CAPITAL NN second T
) ) T
for NN stopwords O
postoperative NN postoperative D
pain IN pain D
relief NN relief D

Trends CAPITAL NNP tendency O
in NN stopwords inch O
HIV CAPITAL NNP HIV O
counseling NNS guidance O
and DT stopwords O
testing NN testing O
of NN stopwords O
clients JJ client O
attending DT attention O
a DT stopwords angstrom O
public NN populace O
sexually NN sexually O
transmitted NN convey O
disease NN disease O
clinic JJ clinic O
in NN stopwords inch O
Portland CAPITAL NNP Portland O
, , O
Oregon CAPITAL NNP Oregon O
, , O
1989-1995 CD O

background VB background O
: : O
both NN stopwords both O
gemcitabine NN T
and DT stopwords T
etoposide NN T
are DT stopwords are O
active DT active_agent O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
sclc JJ D
) ) D
, , O
and DT stopwords O
are DT stopwords are O
characterised NNS characterize O
by NN stopwords by O
mild NN mild O
toxicity NN toxicity O
profiles NN profile O

Atropine CAPITAL DT atropine T
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
treating NN treat O
cases VB case O
of NN stopwords O
baclofen VB D
overdose JJ overdose D
complicated NNS complicate O
by NN stopwords by O
bradycardia NN bradycardia O
and DT stopwords O
hypotension NN hypotension O

PARTICIPANTS CAPITAL VB participant O
: : O
Institutions CAPITAL PRP institution O
selected NN choose O
798 DIGITS CD O
persons NN person O
representing NN represent O
families VB family O
( ( O
1 DIGITS CD one O
person NN person O
for NN stopwords O
each VB stopwords each O
family VB family O
) ) O
thought NN idea O
to NN stopwords O
be NN stopwords beryllium O
at DT stopwords astatine O
elevated NN elevated_railway O
a DT stopwords angstrom O
priori NN O
risk NN hazard O
of NN stopwords O
BRCA1 CAPITAL NNP O
mutation NN mutant O
due NN due O
to NN stopwords O
potential NN potential O
risk NN hazard O
factors VB factor O
, , O
such NN stopwords such O
as DT stopwords arsenic O
multiple NN multiple O
cases VB case O
of NN stopwords O
breast NN breast D
cancer VB cancer D
, , O
early VB early O
age DT age O
of NN stopwords O
breast NN breast D
cancer VB cancer D
diagnosis NN diagnosis O
, , O
and DT stopwords O
cases VB case O
of NN stopwords O
ovarian NN ovarian D
cancer VB cancer D

The CAPITAL NNP O
recent NN Holocene O
introduction NN introduction O
of NN stopwords O
ribavirin NN ribavirin T
, , O
given NN given O
in NN stopwords inch O
combination NNS combination O
, , O
has VB stopwords hour_angle O
led NN light-emitting_diode O
to NN stopwords O
a DT stopwords angstrom O
re-appraisal NN O
of NN stopwords O
the NN stopwords O
management VB management O
of NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D

Practice CAPITAL NNP practice O
parameters NN parameter O
for NN stopwords O
the NN stopwords O
psychiatric NN psychiatric O
assessment DT appraisal O
of NN stopwords O
children JJ child O
and DT stopwords O
adolescents DT adolescent O

Vive CAPITAL NNP O
le NN lupus_erythematosus O
Malade CAPITAL NNP O
! . O

Current CAPITAL NNP current O
management VB management O
of NN stopwords O
corneal NNS corneal D
abrasions DT abrasion D
: : O
evidence NN evidence O
based VB establish O
practice NN practice O
? . O

This CAPITAL NNP O
suggests NN propose O
that NN stopwords O
neuronal JJ neural O
bHLH NN O
proteins NN protein O
are DT stopwords are O
also DT besides O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
`` `` O
adaptive DT adaptive O
'' POS O
changes NNS change O
of NN stopwords O
mature VB mature O
CNS CAPITAL NNP central_nervous_system O
neurons JJ nerve_cell O
which NN stopwords O
are DT stopwords are O
coupled NNS match O
to NN stopwords O
glutamatergic NN O
stimulation JJ stimulation O

Extending CAPITAL NNP widen O
the NN stopwords O
benefits NN benefit O
of NN stopwords O
breast NN breast D
cancer VB cancer D
screening NN screening O

An CAPITAL DT Associate_in_Nursing O
efficient NN efficient O
HN CAPITAL NNP hydrazoic_acid O
( ( O
CA CAPITAL VB calcium O
) ) O
NH CAPITAL NNP New_Hampshire O
pluse NN O
scheme JJ scheme O
for NN stopwords O
triple-resonance NN O
4D CD O
correlation NNS correlation O
of NN stopwords O
sequential NN consecutive O
amide DT amide O
protons NN proton O
and DT stopwords O
nitrogens-15 NN O
in NN stopwords inch O
deuterated NN O
proteins NN protein O

Early CAPITAL NN early O
inpatient NN inpatient O
rehabilitation NN rehabilitation O
after DT stopwords after O
elective NN elective_course O
hip NN hip O
and DT stopwords O
knee NN knee O
arthroplasty DT arthroplasty T

Objectives CAPITAL NNP aim O
include NN include O
demonstration NN presentation O
of NN stopwords O
working NN working O
knowledge NN cognition O
of NN stopwords O
the NN stopwords O
Biopsychosocial CAPITAL NNP O
Model CAPITAL NNP model O
, , O
the NN stopwords O
World CAPITAL NNP universe O
Health CAPITAL NNP health O
Organization CAPITAL NNP organization O
Model CAPITAL NNP model O
of NN stopwords O
disablement NN disability O
and DT stopwords O
interdisciplinary NN interdisciplinary O
rehabilitation NN rehabilitation O
intervention NN intervention O

Although CAPITAL DT O
the NN stopwords O
observed NN detect O
break NN interruption O
points NN point O
in NN stopwords inch O
the NN stopwords O
BCL-1 CAPITAL NNP O
locus NN venue O
are DT stopwords are O
not JJ stopwords not O
tightly NN tightly O
clustered NNS cluster O
, , O
its NN stopwords information_technology O
rearrangement NN rearrangement O
has VB stopwords hour_angle O
been NN stopwords be O
documented NN document O
in NN stopwords inch O
40-70 CD O
% NN O
of NN stopwords O
cases VB case O
of NN stopwords O
mantle VB mantle D
cell NNS cell D
lymphoma NN lymphoma D
, , O
whereas NN O
it NN stopwords information_technology O
only JJ stopwords lone O
rarely NN rarely O
occurs JJ happen O
in NN stopwords inch O
other JJ stopwords other O
B CAPITAL NN bacillus D
cell NNS cell D
lymphomas NN lymphoma D

Fat CAPITAL NNP fat O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
extremely NN highly O
important JJ important O
substrate NN substrate O
for NN stopwords O
muscle NN muscle O
contraction NNS contraction O
, , O
both NN stopwords both O
at DT stopwords astatine O
rest NN remainder O
and DT stopwords O
during NN stopwords O
exercise NN exercise O

MAJOR CAPITAL NNP major O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Sequence CAPITAL NNP sequence O
variants NN discrepancy O
detected NN detect O
in NN stopwords inch O
this NN stopwords O
sample VB sample O
are DT stopwords are O
presented NN show O
along DT along O
with NN stopwords O
analyses DT analysis O
designed NN plan O
to NN stopwords O
determine NN determine O
predictive NN predictive O
characteristics NNS feature O
of NN stopwords O
those NN stopwords O
testing NN testing O
positive NN positive O
for NN stopwords O
BRCA1 CAPITAL NNP O
mutations NN mutant O

122 DIGITS CD O

Therefore CAPITAL NNP therefore O
, , O
critical JJ critical O
care VB care O
nurses RB nurse O
' '' O
healthful NN healthful O
practices NN practice O
can VB stopwords can O
have VB stopwords rich_person O
a DT stopwords angstrom O
profound NN profound O
effect NN consequence O
on NN stopwords on O
their NN stopwords O
patients VB patient O

Critical CAPITAL NNP critical O
values NN values O
for NN stopwords O
chromosomal NN chromosomal O
regional NN regional O
follow-up JJ follow-up O
were NN stopwords be O
a DT stopwords angstrom O
P CAPITAL NN phosphorus O
value NN value O
of NN stopwords O
.05 . O
or NN stopwords Oregon O
less NN lupus_erythematosus O
for NN stopwords O
affected DT affect O
relative NN relative O
pair IN pair O
analysis DT analysis O
or NN stopwords Oregon O
sibpair NN O
analysis DT analysis O
, , O
a DT stopwords angstrom O
parametric NN parametric O
lod NN O
score JJ mark O
of NN stopwords O
1.0 CD O
or NN stopwords Oregon O
greater NN greater O
, , O
or NN stopwords Oregon O
both NN stopwords both O

The CAPITAL NNP O
various NN assorted O
available DT available O
data VB data O
strongly NN strongly O
suggesting NN propose O
an DT stopwords Associate_in_Nursing O
environmental NN environmental O
toxic NN toxic O
origin IN beginning O
for NN stopwords O
the NN stopwords O
`` `` O
sperm NN sperm O
fall VB fall O
'' POS O
will NN stopwords volition O
be NN stopwords beryllium O
presented NN show O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
the NN stopwords O
most NN stopwords most O
frequently JJ frequently O
suspected NN suspect O
class NNS class O
of NN stopwords O
substances NN substance O
, , O
the NN stopwords O
xenoestrogens JJ O

Immunogenicity CAPITAL PRP immunogenicity O
of NN stopwords O
three NN three O
Haemophilus CAPITAL NNP D
influenzae NN D
type NN type D
b NN bacillus D
protein NN protein O
conjugate NNS conjugate_solution O
vaccines NN vaccine T
in NN stopwords inch O
HIV CAPITAL NNP HIV O
seropositive NN O
adults DT adult O
and DT stopwords O
analysis DT analysis O
of NN stopwords O
predictors NN forecaster O
of NN stopwords O
vaccine NN vaccine O
response NN response O

However CAPITAL NNP however O
, , O
the NN stopwords O
etiology NN etiology O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
syndrome NN syndrome O
of NN stopwords O
m1/4llerian NN O
agenesis DT agenesis O
remains NN remains O
elusive NN elusive O

Cytochrome CAPITAL NNP cytochrome O
P450 CAPITAL NNP O
1A1 CD O
( ( O
CYP1A1 CAPITAL NNP O
) ) O
and DT stopwords O
glutathione NN O
S-transferase CAPITAL NNP O
M1 CAPITAL NNP M1 O
( ( O
GSTM1 CAPITAL NNP O
) ) O
genetic NN familial O
polymorphisms NN polymorphism O
are DT stopwords are O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
activation DT activation O
and DT stopwords O
detoxification NN detoxification O
of NN stopwords O
chemical NNS chemical O
carcinogens VB carcinogen O
found JJ found O
in NN stopwords inch O
tobacco NN tobacco O
smoke JJ smoke O
; : O
thus NN frankincense O
they NN stopwords O
may VB May O
influence NN influence O
host NN host O
susceptibility NN susceptibility O
to NN stopwords O
lung NN lung D
cancer VB cancer D

Neutrophil CAPITAL NNP neutrophil O
superoxide NN superoxide O
generation NN coevals O
, , O
a DT stopwords angstrom O
crucial NNS crucial O
part NN part O
of NN stopwords O
neutrophil JJ neutrophil O
bactericidal VB bactericidal O
activity DT activity O
, , O
is NN stopwords be O
impaired JJ impair O
in NN stopwords inch O
diabetes NN diabetes D

Both CAPITAL NNP both O
Msh2- CAPITAL NNP O
and DT stopwords O
p53-targeted NN O
knockout NN smasher O
mice NN mouse O
are DT stopwords are O
viable NN feasible O
and DT stopwords O
susceptible NN susceptible O
to NN stopwords O
cancer VB cancer D

Observation CAPITAL NNP observation O
of NN stopwords O
air DT air O
pollution NN pollution O
with NN stopwords O
the NN stopwords O
aid DT aid O
of NN stopwords O
continuous NNS continuous O
analysers DT analyzer O

Uptake CAPITAL NNP consumption O
on NN stopwords on O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
research NN research O

Management CAPITAL NNP management O
of NN stopwords O
polycythaemia NN D
in NN stopwords inch O
adults DT adult O
with NN stopwords O
cyanotic NNS D
congenital NNS congenital D
heart NN heart D
disease NN disease D

The CAPITAL NNP O
subjects NN subject O
were NN stopwords be O
matched VB match O
for NN stopwords O
age DT age O
, , O
ethnicity NN ethnicity O
, , O
parity NN parity O
, , O
and DT stopwords O
gestational NN gestational O
age DT age O

However CAPITAL NNP however O
, , O
a DT stopwords angstrom O
rigorous NN rigorous O
economic NN economic O
evaluation NN evaluation O
of NN stopwords O
possible NN possible O
screening NN screening O
strategies NN scheme O
is NN stopwords be O
needed JJ necessitate O
first NN first O

objective NN aim O
: : O
several NN several O
reports NN report O
emphasize NN stress O
the NN stopwords O
importance JJ importance O
of NN stopwords O
en-bloc NN T
resection NN resection T
as DT stopwords arsenic O
the NN stopwords O
optimal JJ optimum O
surgical NN surgical O
treatment NN treatment O
of NN stopwords O
lung NN lung D
cancer VB cancer D
with NN stopwords O
chest NNS thorax O
wall VB wall O
invasion NN invasion O

We CAPITAL NNP O
therefore NN therefore O
evaluated NN measure O
the NN stopwords O
effect NN consequence O
of NN stopwords O
cure NNS remedy O
of NN stopwords O
Helicobacter CAPITAL NNP D
pylori NN pylorus D
infection NN infection D
on NN stopwords on O
basal VB radical O
and DT stopwords O
pentagastrin-stimulated NN O
acid DT acid O
secretion NN secretion O

Clinical CAPITAL NNP clinical O
staging NN theatrical_production O
in NN stopwords inch O
cancer VB cancer D
of NN stopwords D
the NN stopwords D
larynx NN larynx D
: : O
a DT stopwords angstrom O
report NN report O
on NN stopwords on O
788 DIGITS CD O
cases VB case O
using JJ exploitation O
the NN stopwords O
American CAPITAL DT American O
Joint CAPITAL NNP joint O
Committee CAPITAL NNP committee O
's POS O
method NN method O
of NN stopwords O
stage NN phase O
classification NNS categorization O

hominis NN O
present NN present O
and DT stopwords O
stool NN stool O
characteristics NNS feature O

All CAPITAL DT all O
women NN woman O
were NN stopwords be O
expectantly NN expectantly O
managed VB pull_off O
without NN O
tocolytics NN O
until JJ stopwords O
37 DIGITS CD thirty-seven O
weeks NN week O
' '' O
gestation NN gestation O
unless JJ O
they NN stopwords O
developed NN develop O
clinical JJ clinical O
chorioamnionitis NNS O
, , O
or NN stopwords Oregon O
nonreassuring JJ O
fetal JJ fetal O
heart NN heart O
rate VB rate O
tracing NN tracing O
or NN stopwords Oregon O
biophysical NN O
profile NN profile O

DATA CAPITAL NNP data O
SYNTHESIS CAPITAL NNP synthesis O
: : O
Fenfluramines CAPITAL NNP T
cause VB cause O
dose-related NN O
, , O
long-lasting NN durable O
reductions NN decrease O
in NN stopwords inch O
serotonin NN serotonin O
axonal DT axonal O
markers NN marker O
in NN stopwords inch O
all DT stopwords all O
the NN stopwords O
animal DT animal O
species NN species O
tested NN test O
and DT stopwords O
with NN stopwords O
all DT stopwords all O
the NN stopwords O
routes NN path O
of NN stopwords O
drug NN drug O
administration DT administration O
used JJ use O

Comprehensive CAPITAL NNP comprehensive_examination T
modified NN modify T
diet NN diet T
simplifies NN simplify O
nutrition JJ nutrition T
management VB management T
of NN stopwords O
adults DT adult O
with NN stopwords O
short-bowel NN D
syndrome NN syndrome D

Munchausen CAPITAL NNP Munchhausen D
's POS D
syndrome NN syndrome D

The CAPITAL NNP O
objective NN aim O
of NN stopwords O
this NN stopwords O
article DT article O
is NN stopwords be O
to NN stopwords O
explore NN research O
attitudes DT attitude O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
inner-city NN O
, , O
pregnant NN pregnant O
cohort NNS cohort O
about DT stopwords about O
general NN general O
and DT stopwords O
HIV-related CAPITAL NNP O
prenatal NN prenatal O
care VB care O

Surface CAPITAL NNP surface O
plasmon NN O
resonance NN resonance O
analysis DT analysis O
of NN stopwords O
topoisomerase NN O
I-DNA CAPITAL PRP O
binding NN binding O
: : O
effect NN consequence O
of NN stopwords O
Mg2+ CAPITAL NNP O
and DT stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O
sequence NN sequence O

Smoking CAPITAL NNP smoke O
-- : O
good NN good O
or NN stopwords Oregon O
bad VB bad O
for NN stopwords O
semen NN semen O
? . O

Neutrophils CAPITAL NNP neutrophil O
from JJ stopwords O
the NN stopwords O
peripheral NN peripheral O
blood NN blood O
of NN stopwords O
these NN stopwords O
participants NN participant O
and DT stopwords O
from JJ stopwords O
healthy NN healthy O
controls NNS control O
were NN stopwords be O
stimulated JJ stimulate O
with NN stopwords O
opsonised JJ O
zymosan NN O
, , O
and DT stopwords O
superoxide NN superoxide O
production NN production O
was VB stopwords Washington O
measured NN measure O
by NN stopwords by O
a DT stopwords angstrom O
spectrophotometric NN O
assay DT assay O
( ( O
reduction NN decrease O
of NN stopwords O
ferricytochrome NN O
C CAPITAL SYM degree_centigrade O
) ) O

The CAPITAL NNP O
best NN best O
salespersons VB salesperson O
are DT stopwords are O
those NN stopwords O
who NN stopwords World_Health_Organization O
are DT stopwords are O
genuinely NN truly O
committed NNS perpetrate O
to NN stopwords O
their NN stopwords O
product NN merchandise O
and DT stopwords O
model NN model O
its NN stopwords information_technology O
benefits NN benefit O

This CAPITAL NNP O
is NN stopwords be O
the NN stopwords O
first NN first O
report NN report O
of NN stopwords O
the NN stopwords O
emergence NN emergence O
of NN stopwords O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
gag VB joke O
p7/p1 NN O
protease NN protease O
cleavage NNS cleavage O
sites NN site O
in NN stopwords inch O
patients VB patient O
receiving NN receive O
protease NN protease T
therapy NN therapy T
and DT stopwords O
identifies NN identify O
this NN stopwords O
change NNS change O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
important JJ important O
determinant NN determinant O
of NN stopwords O
HIV-1 CAPITAL NNP O
resistance NN resistance O
to NN stopwords O
protease NN protease O
inhibitors NN inhibitor O
in NN stopwords inch O
patient VB patient O
populations NN population O

One CAPITAL NNP one O
such NN stopwords such O
framework NN model O
for NN stopwords O
this NN stopwords O
is NN stopwords be O
referred NN mention O
to NN stopwords O
as DT stopwords arsenic O
the NN stopwords O
total NN sum O
quality NN quality O
recovery NN recovery O
( ( O
TQR CAPITAL NNP O
) ) O
process NN procedure O

In CAPITAL PRP inch O
closing NNS shutting O
, , O
the NN stopwords O
author DT writer O
presents NN present O
practical NN practical O
information NN information O
regarding NN see O
prevention NN prevention O
of NN stopwords O
dental NN alveolar_consonant O
phobia NN phobia O
and DT stopwords O
the NN stopwords O
merits NN merit O
of NN stopwords O
incorporating NN integrate O
this NN stopwords O
type NN type O
of NN stopwords O
patient VB patient O
into NN stopwords O
a DT stopwords angstrom O
dental NN alveolar_consonant O
practice NN practice O

Fluoride CAPITAL NNP fluoride T
increased NN increase O
the NN stopwords O
vertebral NN vertebral O
BV/TV CAPITAL NNP O
by NN stopwords by O
35 DIGITS CD thirty-five O
% NN O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
and DT stopwords O
tibial NN tibial O
ash DT ash O
weight NN weight O
by NN stopwords by O
10 DIGITS CD ten O
% NN O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O

It CAPITAL PRP information_technology O
is NN stopwords be O
possible NN possible O
that NN stopwords O
the NN stopwords O
calcium-binding VB O
motifs NN motif O
present NN present O
a DT stopwords angstrom O
secondary NN secondary O
structure NN structure O
similar NN similar O
to NN stopwords O
the NN stopwords O
parallel NN analogue O
beta NN beta O
roll NN axial_rotation O
structure NN structure O
described NN describe O
for NN stopwords O
an DT stopwords Associate_in_Nursing O
alkaline DT alkaline O
protease NN protease O
from JJ stopwords O
Pseudomonas CAPITAL NNP Pseudomonas O
aeruginosa DT O

Additional CAPITAL DT extra O
opinions IN opinion O
on NN stopwords on O
the NN stopwords O
mortality NN mortality O
of NN stopwords O
animal DT animal O
research NN research O

Unfortunately CAPITAL NNP unfortunately O
, , O
current NNS current O
dermatological NN dermatologic O
uses JJ use O
of NN stopwords O
hdIVIg NN O
have VB stopwords rich_person O
been NN stopwords be O
limited NN express O
to NN stopwords O
either NN either O
uncontrolled JJ uncontrolled O
trials NN test O
or NN stopwords Oregon O
anecdotal DT anecdotal O
case VB case O
reports NN report O
, , O
except NN demur O
for NN stopwords O
a DT stopwords angstrom O
single NN single O
controlled NNS control O
trial NN test O
of NN stopwords O
hdIVIg NN T
as DT stopwords arsenic O
adjunctive DT adjunctive O
therapy NN therapy O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
dermatomyositis NN dermatomyositis D
, , O
which NN stopwords O
documented NN document O
a DT stopwords angstrom O
significant NN significant O
benefit NN benefit O

The CAPITAL NNP O
comparison NNS comparison O
of NN stopwords O
the NN stopwords O
responsiveness NN responsiveness O
of NN stopwords O
human NN homo O
isolated NN isolate O
internal NN internal O
mammary VB mammary O
and DT stopwords O
gastroepiploic VB O
arteries DT artery O
to NN stopwords O
levcromakalim NN O
: : O
an DT stopwords Associate_in_Nursing O
alternative DT option O
approach DT approach O
to NN stopwords O
the NN stopwords O
management VB management O
of NN stopwords O
graft NN graft O
spasm NN spasm O

Outcomes CAPITAL NNP result O
were NN stopwords be O
documented NN document O
in NN stopwords inch O
675 DIGITS CD O
subjects NN subject O
( ( O
94 DIGITS CD ninety-four O
% NN O
) ) O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Antibody CAPITAL DT antibody O
class NNS class O
switch JJ switch O
recombinase NN O
activity DT activity O
is NN stopwords be O
B CAPITAL NN bacillus O
cell NNS cell O
stage NN phase O
specific NN particular O
and DT stopwords O
functions JJ function O
stochastically NN stochastically O
in NN stopwords inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
'targeted '' O
accessibility DT handiness O
' '' O
control NNS control O

in NN stopwords inch O
patients VB patient O
with NN stopwords O
advanced DT advance D
ovarian NN ovarian D
cancer VB cancer D
, , O
first-line NN O
therapy NN therapy O
with NN stopwords O
oxaliplatin/cyclophosphamide NN T
achieved DT achieve O
an DT stopwords Associate_in_Nursing O
objective NN aim O
response NN response O
rate VB rate O
which NN stopwords O
did NN stopwords make O
not JJ stopwords not O
differ NN differ O
significantly NN significantly O
from JJ stopwords O
that NN stopwords O
of NN stopwords O
cisplatin/cyclophosphamide NN T
( ( O
33 DIGITS CD thirty-three O
vs NN volt O
42 DIGITS CD forty-two O
% NN O
) ) O

Treatment CAPITAL NNP treatment O
of NN stopwords O
idiopathic JJ idiopathic D
thrombopenic NN D
purpura NN purpura D
in NN stopwords inch O
adolescents DT adolescent O
by NN stopwords by O
intravenous NN intravenous T
immunoglobulin JJ immunoglobulin T

DESIGN CAPITAL NNP design O
: : O
A CAPITAL DT angstrom O
prospective NN prospective O
clinical JJ clinical O
trial NN test O

< NN O
TO_SEE CAPITAL NNP O
> NN O
For CAPITAL NNP O
a DT stopwords angstrom O
subset NN subset O
of NN stopwords O
patients VB patient O
with NN stopwords O
Kaposi CAPITAL NNP D
's POS D
sarcoma VB sarcoma D
who NN stopwords World_Health_Organization O
were NN stopwords be O
treated NN treat O
with NN stopwords O
recombinant NN recombinant T
interferon NN interferon T
alfa-2a DT T
, , O
the NN stopwords O
disease NN disease O
is NN stopwords be O
in NN stopwords inch O
complete NNS complete O
remission NN remission O
, , O
without NN O
opportunistic JJ opportunist D
infection NN infection D
, , O
and DT stopwords O
they NN stopwords O
appear DT look O
to NN stopwords O
be NN stopwords beryllium O
culture-negative NNS O
for NN stopwords O
the NN stopwords O
etiologic NN etiological O
retrovirus NN retrovirus O
that NN stopwords O
causes VB cause O
their NN stopwords O
immune JJ immune D
deficiency NN lack D

Correction CAPITAL NNP correction O
of NN stopwords O
cardiac VB cardiac D
defects NN defect D
through NN stopwords done O
a DT stopwords angstrom O
right NN right T
thoracotomy NN thoracotomy T
in NN stopwords inch O
children JJ child O

PATIENTS CAPITAL VB patient O
: : O
Two CAPITAL NNP two O
patients VB patient O
who NN stopwords World_Health_Organization O
had VB stopwords have O
fatal VB fatal O
hyperammonemia NN D
after DT stopwords after O
orthotopic JJ O
lung NN lung T
transplantation NN transplant T
. . O

This CAPITAL NNP O
article DT article O
discusses NN discus O
dental NN alveolar_consonant O
anxiety DT anxiety O
and DT stopwords O
phobia NN phobia O

What CAPITAL NNP O
is NN stopwords be O
your NN stopwords O
diagnosis NN diagnosis O
? . O
Foreign CAPITAL NNP foreign O
body NN body O
in NN stopwords inch O
the NN stopwords O
abdomen DT abdomen O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Longitudinal CAPITAL NNP longitudinal D
melanonychia NN D
associated DT associate O
with NN stopwords O
hydroxyurea NN T
therapy NN therapy T
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
essential NN necessity D
thrombocytosis NN thrombocytosis D

Defects CAPITAL NNP defect O
of NN stopwords O
the NN stopwords O
interventricular NN O
septum NN septum O
not JJ stopwords not O
associated DT associate O
with NN stopwords O
other JJ stopwords other O
malformations VB deformity O

However CAPITAL NNP however O
, , O
3 DIGITS CD three O
characteristics NNS feature O
were NN stopwords be O
observed NN detect O
: : O
younger NN younger O
age DT age O
at DT stopwords astatine O
diagnosis NN diagnosis O
, , O
higher-grade NN O
tumors NN tumor D
, , O
and DT stopwords O
more NN stopwords More O
advanced-stage DT O
disease NN disease O

methods NN method O
: : O
we NN stopwords O
analyzed DT analyze O
34 DIGITS CD thirty-four O
patients VB patient O
who NN stopwords World_Health_Organization O
were NN stopwords be O
found JJ found O
to NN stopwords O
have VB stopwords rich_person O
malignant VB malignant D
pleural NN pleural D
effusions NN effusion D
in NN stopwords inch O
the NN stopwords O
course NNS course O
of NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
118 DIGITS CD O
patients VB patient O
enrolled NN enroll O
in NN stopwords inch O
three NN three O
consecutive NNS back-to-back O
clinical JJ clinical O
trials NN test O
on NN stopwords on O
advanced DT advance O
nsclc JJ D
assessing DT measure O
combination NNS combination T
chemotherapy NNS chemotherapy T
of NN stopwords T
cisplatin NN T
, , T
ifosfamide NN T
, , T
and DT stopwords T
irinotecan JJ T
with NN stopwords T
recombinant NN recombinant T
human NN homo T
granulocyte NN granulocyte T
colony-stimulating NNS T
factor VB factor T
support NN support T

Thalidomide CAPITAL NNP thalidomide O
in NN stopwords inch O
oral NN oral O
Crohn CAPITAL NNP Crohn O
's POS O
disease NN disease O
refractory NN furnace_lining O
to NN stopwords O
conventional NNS conventional O
medical NN checkup O
treatment NN treatment O

Surgical CAPITAL NNP surgical T
approaches DT approach T
to NN stopwords O
pediatric NN pediatric D
defecatory NN D
disorders NN disorder D

Is CAPITAL PRP be O
there NN stopwords there O
a DT stopwords angstrom O
rational VB rational_number O
therapy NN therapy O
for NN stopwords O
symptomatic NN diagnostic O
treatment NN treatment O
of NN stopwords O
benign NN benign D
prostatic NN prostate D
hyperplasia NN hyperplasia D
with NN stopwords O
phytogenic NN T
drugs NN drug T
? . O
Illustrated CAPITAL PRP exemplify O
with NN stopwords O
the NN stopwords O
example NN example O
of NN stopwords O
the NN stopwords O
prostate NN prostate_gland O
agent DT agent O
from JJ stopwords O
Serenoa CAPITAL NNP Serenoa O
repens NN O
( ( O
Sabal CAPITAL NNP Sabal O
fructus JJ O
) ) O

Delivery CAPITAL NNP delivery O
room NN room O
pediatrics NN pediatrics O

Radiocinematographic CAPITAL VB O
and DT stopwords O
clinical JJ clinical O
correlation NNS correlation O

Cyclin CAPITAL NNP O
D1 CAPITAL NNP O
, , O
the NN stopwords O
regulatory NN regulative O
subunit NN fractional_monetary_unit O
of NN stopwords O
certain NNS certain O
protein NN protein O
kinases NN kinase O
thought NN idea O
to NN stopwords O
advance DT progress O
the NN stopwords O
G1 CAPITAL NNP O
phase NN phase O
of NN stopwords O
the NN stopwords O
cell NNS cell O
cycle NNS cycle O
, , O
is NN stopwords be O
now JJ stopwords now O
established NN establish O
as DT stopwords arsenic O
a DT stopwords angstrom O
proto-oncogene NN proto-oncogene O
, , O
with NN stopwords O
evidence NN evidence O
indicating NN bespeak O
that NN stopwords O
its NN stopwords information_technology O
derangement NN derangement O
may VB May O
contribute NNS lend O
to NN stopwords O
the NN stopwords O
uncontrolled JJ uncontrolled O
cell NNS cell O
growth NN growth O
characteristic NNS feature O
of NN stopwords O
tumors NN tumor D

Vitamins CAPITAL NNP vitamin O
and DT stopwords O
minerals NN mineral O
: : O
efficacy NN efficacy O
and DT stopwords O
safety VB safety O

Methadone CAPITAL NNP methadone T
maintenance VB care T
treatment NN treatment T
: : O
a DT stopwords angstrom O
Canadian CAPITAL VB Canadian O
perspective NN position O

Use CAPITAL NNP use O
of NN stopwords O
protein-C NN T
concentrate NNS dressed_ore T
, , T
heparin NN heparin T
, , T
and DT stopwords T
haemodiafiltration VB T
in NN stopwords inch O
meningococcus-induced NN D
purpura NN purpura D
fulminans JJ D

Meta-analysis CAPITAL NNP O
of NN stopwords O
trials NN test O
comparing NNS comparison O
antidepressants DT antidepressant T
with NN stopwords O
active DT active_agent O
placebos NN placebo O

By CAPITAL NNP by O
in NN stopwords inch O
situ NN O
hybridization NN hybridization O
analysis DT analysis O
, , O
we NN stopwords O
show NN show O
that NN stopwords O
the NN stopwords O
Meis2 CAPITAL NNP O
gene NN gene O
displays NN display O
spatially NN spatially O
restricted NN restrict O
expression NN expression O
patterns VB form O
in NN stopwords inch O
the NN stopwords O
developing NN development O
nervous RB nervous O
system NN system O
, , O
limbs NN limb O
, , O
face VB face O
, , O
and DT stopwords O
in NN stopwords inch O
various NN assorted O
viscera NN viscera O

Ion CAPITAL PRP ion O
composition NNS composition O
of NN stopwords O
airway DT air_passage O
surface NN surface O
liquid NN liquid O
of NN stopwords O
patients VB patient O
with NN stopwords O
cystic NNS cystic D
fibrosis NN fibrosis D
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
normal RB convention O
and DT stopwords O
disease-control NN O
subjects NN subject O

Recently CAPITAL NNP recently O
, , O
many VB many O
advances DT progress O
have VB stopwords rich_person O
been NN stopwords be O
made VB make O
in NN stopwords inch O
the NN stopwords O
study NN survey O
of NN stopwords O
sexual NN sexual O
differentiation NN differentiation O
, , O
including NN include O
the NN stopwords O
discoveries NN discovery O
of NN stopwords O
the NN stopwords O
gene NN gene O
for NN stopwords O
antim1/4llerian DT O
hormone NN hormone O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
the NN stopwords O
gene NN gene O
for NN stopwords O
its NN stopwords information_technology O
receptor NN receptor O

Additional CAPITAL DT extra O
chemotherapy NNS chemotherapy T
may VB May O
thus NN frankincense O
have VB stopwords rich_person O
eradicated NN eliminate O
these NN stopwords O
micrometastases NN D
in NN stopwords inch O
the NN stopwords O
older JJ aged O
children JJ child O
, , O
since NN O
the NN stopwords O
age DT age O
influence NN influence O
on NN stopwords on O
Stage CAPITAL NNP phase O
II CAPITAL PRP two O
disease NN disease O
disappeared NN disappear O
when NN stopwords O
multimodal NN O
treatment NN treatment O
was VB stopwords Washington O
given NN given O
in NN stopwords inch O
this NN stopwords O
study NN survey O

hominis NN O
in NN stopwords inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
other JJ stopwords other O
pathogens VB pathogen O
clinical JJ clinical O
and DT stopwords O
epidemiological NN epidemiologic O
characteristics NNS feature O
were NN stopwords be O
evaluated NN measure O

During CAPITAL NNP O
one JJ one O
of NN stopwords O
his NN stopwords O
physical NN physical O
examinations NN examination O
, , O
routine NN routine O
sigmoidoscopy NN sigmoidoscopy O
showed NN show O
incidental NN incidental_expense O
colonic NNS colonic_irrigation D
polyps NN polyp D
which NN stopwords O
were NN stopwords be O
biopsied NN O

Immobilisation CAPITAL PRP immobilization T
after DT stopwords after O
first NN first O
anterior DT front_tooth O
shoulder NN shoulder D
dislocation NN dislocation D

The CAPITAL NNP O
effect NN consequence O
was VB stopwords Washington O
found JJ found O
predominantly NN predominantly O
among DT O
children JJ child O
whose NN O
body NN body O
mass VB mass O
index NN index O
at DT stopwords astatine O
assessment DT appraisal O
was VB stopwords Washington O
above DT stopwords above O
the NN stopwords O
median NN median O
for NN stopwords O
this NN stopwords O
population NN population O
( ( O
mean NN mean O
difference NN difference O
in NN stopwords inch O
systolic NN systolic O
blood NN blood O
pressure NN pressure O
-5.8 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
( ( O
-9.8 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
to NN stopwords O
-1.7 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
) ) O
for NN stopwords O
children JJ child O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
index NN index O
> NN O
17.5 CD O
and DT stopwords O
-3.2 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
( ( O
-6.3 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
to NN stopwords O
-0.1 : O
mm NNS millimeter O
Hg CAPITAL NNP mercury O
) ) O
for NN stopwords O
those NN stopwords O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
index NN index O
of NN stopwords O
> NN O
15.7 CD O
to NN stopwords O
17.5 CD O
) ) O

Online CAPITAL NNP on-line O

The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
neostigmine JJ neostigmine T
0.07 LS T
mg NN milligram T
kg-1 NN T
and DT stopwords T
edrophonium NN T
0.8 LS O
mg NN milligram O
kg-1 NN O
as DT stopwords arsenic O
antagonists DT adversary O
of NN stopwords O
profound NN profound D
neuromuscular JJ neuromuscular D
blockade NN blockade D
induced NN induce O
by NN stopwords by O
vecuronium NN O
0.1 LS O
mg NN milligram O
kg-1 NN O
or NN stopwords Oregon O
atracurium DT O
0.5 LS O
mg NN milligram O
kg-1 NN O
was VB stopwords Washington O
studied NN analyze O
in NN stopwords inch O
59 DIGITS CD fifty-nine O
healthy NN healthy O
patients VB patient O

3 DIGITS CD three O

The CAPITAL NNP O
women NN woman O
presented NN show O
with NN stopwords O
cardiovascular VB cardiovascular D
symptoms NN symptom D
or NN stopwords Oregon O
a DT stopwords angstrom O
heart NN heart D
murmur NN mutter D

Dipyridamole CAPITAL NNP T
plus NN asset T
aspirin DT aspirin T
in NN stopwords inch O
cerebrovascular NNS cerebrovascular D
disease NN disease D

patients VB patient O
who NN stopwords World_Health_Organization O
benefit NN benefit O
from JJ stopwords O
a DT stopwords angstrom O
surgical NN surgical T
resection NN resection T
for NN stopwords O
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
with NN stopwords O
aneuploid DT aneuploid O
dna NN deoxyribonucleic_acid O
content NNS content O
prove NN prove O
to NN stopwords O
have VB stopwords rich_person O
a DT stopwords angstrom O
higher NN higher O
risk NN hazard O
of NN stopwords O
death NN death O

The CAPITAL NNP O
serum NN serum O
cytokine NNS cytokine O
profile NN profile O
during NN stopwords O
the NN stopwords O
acute DT acute_accent O
phase NN phase O
of NN stopwords O
her NN stopwords O
illness NN illness O
showed NN show O
high NN high O
levels NN degree O
of NN stopwords O
tumor NN tumor O
necrosis JJ necrosis O
factor-alpha VB O
, , O
interleukin-6 NN O
and DT stopwords O
interferon-gamma NN O
, , O
as DT stopwords arsenic O
is NN stopwords be O
seen NN see O
during NN stopwords O
activation DT activation O
of NN stopwords O
the NN stopwords O
immune JJ immune O
system NN system O
by NN stopwords by O
TSS CAPITAL NNP toxic_shock D
toxin NN toxin O
1 DIGITS CD one O

Relationship CAPITAL NNP relationship O
of NN stopwords O
fractons NN O
of NN stopwords O
soybeans NN soy O
and DT stopwords O
a DT stopwords angstrom O
crystalline NNS crystalline O
soybean NN soy O
trypsin NN trypsin O
inhibitor NN inhibitor O
to NN stopwords O
the NN stopwords O
effects NN effects O
of NN stopwords O
feeding JJ eating O
unheated JJ unheated O
soybean NN soy O
meal NN meal O
to NN stopwords O
chicks JJ chick O

Only CAPITAL NNP lone O
20 DIGITS CD twenty O
% NN O
had VB stopwords have O
heard NN hear O
of NN stopwords O
a DT stopwords angstrom O
drug NN drug O
to NN stopwords O
reduce NN reduce O
this NN stopwords O
risk NN hazard O
, , O
but NN stopwords merely O
95 DIGITS CD ninety-five O
% NN O
would NN O
take VB return O
such NN stopwords such O
a DT stopwords angstrom O
therapy NN therapy O

Activation CAPITAL DT activation O
of NN stopwords O
Raf-1 CAPITAL VB O
kinase NN kinase O
resulted NN result O
in NN stopwords inch O
a DT stopwords angstrom O
delayed NN delay O
and DT stopwords O
sustained NN prolong O
increase NN addition O
of NN stopwords O
HMGI-C CAPITAL NNP O
expression NN expression O
in NN stopwords inch O
the NN stopwords O
Pa-4 CAPITAL VB O
cells NNS cell O

BACKGROUND CAPITAL IN background O
: : O
Thrombolytic CAPITAL NNP thrombolytic T
treatment NN treatment T
has VB stopwords hour_angle O
been NN stopwords be O
shown NN show O
to NN stopwords O
accelerate DT accelerate O
resolution NN resolution O
of NN stopwords O
major VB major D
pulmonary NN pneumonic D
embolism NN embolism D
and DT stopwords O
lead NN lead O
to NN stopwords O
a DT stopwords angstrom O
rapid VB rapid O
improvement JJ improvement O
of NN stopwords O
right-side NN O
hemodynamics NN hemodynamics O

< NN O
TO_SEE CAPITAL NNP O
> NN O
this NN stopwords O
report NN report O
describes NN describe O
our NN stopwords O
findings NN findings O
utilizing JJ use O
routine NN routine O
cervical NNS cervical O
mediastinoscopy NN O
in NN stopwords inch O
the NN stopwords O
evaluation NN evaluation O
of NN stopwords O
peripheral NN peripheral O
t1 NN O
( ( O
< NN O
3 DIGITS CD three O
cm NNS centimeter O
) ) O
lung NN lung O
tumors NN tumor O

Planned CAPITAL NNP plan O
parenthood NN parenthood O
and DT stopwords O
artifical DT O
selection NN choice O

The CAPITAL NNP O
protective NN protective O
effect NN consequence O
of NN stopwords O
condoms NNS condom T
and DT stopwords O
nonoxynol-9 JJ T
against DT stopwords O
HIV CAPITAL NNP HIV D
infection NN infection D

< NN O
TO_SEE CAPITAL NNP O
> NN O
Safety CAPITAL VB safety O
of NN stopwords O
intrathecal NN T
sodium NN sodium T
nitroprusside NN T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
and DT stopwords O
prevention NN prevention O
of NN stopwords O
refractory NN furnace_lining D
cerebral NNS cerebral D
vasospasm NN D
and DT stopwords D
ischemia NN ischemia D
in NN stopwords inch O
humans NN world O

Evidence CAPITAL NNP evidence O
for NN stopwords O
a DT stopwords angstrom O
new JJ new O
locus NN venue O
on NN stopwords on O
chromosome NN chromosome O
12 DIGITS CD twelve O

Origin CAPITAL NNP beginning O
of NN stopwords O
milk NN milk O
cholesterol NNS cholesterol O
in NN stopwords inch O
the NN stopwords O
rat VB rat O
: : O
dietary NN dietary O
versus NN O
endogenous NN endogenous O
sources NN beginning O

Right CAPITAL NN right O
temporal NN temporal_role O
and DT stopwords O
cerebellar NNS cerebellar O
hemorrhages NN bleeding O
were NN stopwords be O
present NN present O

A CAPITAL DT angstrom O
case VB case O
report NN report O
and DT stopwords O
a DT stopwords angstrom O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
literature NN literature O

The CAPITAL NNP O
focus JJ focus O
is NN stopwords be O
now JJ stopwords now O
on NN stopwords on O
standards NN standard O
and DT stopwords O
privacy NN privacy O
in NN stopwords inch O
electronic NN electronic O
patient VB patient O
records NN record O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Surgery CAPITAL NNP surgery T
for NN stopwords O
ectopia NN ectopia D
lentis NN D

A CAPITAL DT angstrom O
second NN second O
subset NN subset O
of NN stopwords O
38 DIGITS CD thirty-eight O
families VB family O
( ( O
216 DIGITS CD O
total NN sum O
family VB family O
members NN member O
, , O
89 DIGITS CD eighty-nine O
of NN stopwords O
whom NN stopwords O
were NN stopwords be O
patients VB patient O
with NN stopwords O
AD CAPITAL DT ad O
) ) O
was VB stopwords Washington O
used JJ use O
for NN stopwords O
the NN stopwords O
follow-up JJ follow-up O
analysis DT analysis O

Ischemic CAPITAL PRP ischemic D
infarction NN infarct D
resulted NN result O
in NN stopwords inch O
mild NN mild O
transient NN transient O
Broca CAPITAL NNP Broca D
's POS D
aphasia DT aphasia D
in NN stopwords inch O
one JJ one O
patient VB patient O
, , O
but NN stopwords merely O
there NN stopwords there O
was VB stopwords Washington O
no NNS stopwords no O
detectable NN detectable O
neurological JJ neurological O
deficit NN deficit O
in NN stopwords inch O
the NN stopwords O
other JJ stopwords other O
two NN two O

Atypical CAPITAL DT atypical O
antipsychotic DT major_tranquilizer T
agents DT agent T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
Schizophrenia CAPITAL NNP schizophrenia D
and DT stopwords D
other JJ stopwords other D
psychiatric NN psychiatric D
disorders NN disorder D

In CAPITAL PRP inch O
the NN stopwords O
case VB case O
of NN stopwords O
the NN stopwords O
12 DIGITS CD twelve O
base-pair VB O
DNA CAPITAL NNP deoxyribonucleic_acid O
duplex NN duplex_house O
, , O
torsion-angle NN O
molecular NN molecular O
dynamics NN dynamics O
had VB stopwords have O
a DT stopwords angstrom O
success NN success O
rate VB rate O
of NN stopwords O
52 DIGITS CD fifty-two O
% NN O
while NN stopwords while O
Cartesian CAPITAL VB Cartesian O
molecular NN molecular O
dynamics NN dynamics O
and DT stopwords O
metric-matrix NN O
distance NN distance O
geometry NN geometry O
always DT always O
failed VB fail O

Subcutaneous CAPITAL NNP hypodermic D
hematomas NN hematoma D
, , O
reduced NN reduce O
Quick CAPITAL NNP quick O
value NN value O

Interferon CAPITAL PRP interferon T
treatment NN treatment T
of NN stopwords O
renal NN nephritic D
cell NNS cell D
carcinoma VB carcinoma D

Limitations CAPITAL NNP restriction O
of NN stopwords O
diagnostic NN diagnostic O
criteria JJ standard O
and DT stopwords O
assessment DT appraisal O
instruments NN instrument O
for NN stopwords O
mental NN mental D
disorders NN disorder D

EU CAPITAL NN europium O
directive NN directive O
on NN stopwords on O
bovine NN bovine D
spongiform NN D
encephalopathy NN brain_disorder D
will NN stopwords volition O
not JJ stopwords not O
affect DT affect O
drugs NN drug O

In CAPITAL PRP inch O
contrast NNS contrast O
to NN stopwords O
known NN know O
bHLH NN O
genes NN gene O
, , O
detectable NN detectable O
transcription NN transcription O
of NN stopwords O
SHARP CAPITAL NNP sharp O
genes NN gene O
begins NN Begin O
at DT stopwords astatine O
the NN stopwords O
end NN end O
of NN stopwords O
embryonic NN embryonic O
development NN development O
marking NN marker O
differentiated NN distinguish O
neurons JJ nerve_cell O
that NN stopwords O
have VB stopwords rich_person O
reached NN reach O
a DT stopwords angstrom O
final NN final O
position NN position O
, , O
and DT stopwords O
increases NN addition O
as DT stopwords arsenic O
postnatal NN postnatal O
development NN development O
proceeds NN return O

Active CAPITAL DT active_agent T
forms NN form T
of NN stopwords T
vitamin NN vitamin T
D3 CAPITAL NNP T
, , T
1 DIGITS CD one T
alpha-hydroxyvitamin DT T
D3 CAPITAL NNP T
and DT stopwords T
1 DIGITS CD one T
alpha DT alpha T
, , T
25-dihydroxyvitamin CD T
D3 CAPITAL NNP T
, , O
were NN stopwords be O
administered DT administer O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
open-design JJ O
study NN survey O
to NN stopwords O
40 DIGITS CD forty O
patients VB patient O
with NN stopwords O
psoriasis NN psoriasis D
vulgaris NN D
in NN stopwords inch O
three NN three O
ways VB ways O
: : O
to NN stopwords O
17 DIGITS CD seventeen O
patients VB patient O
1 DIGITS CD one O
alpha-hydroxyvitamin DT O
D3 CAPITAL NNP O
was VB stopwords Washington O
given NN given O
orally NN orally O
at DT stopwords astatine O
a DT stopwords angstrom O
dose NN dose O
of NN stopwords O
1.0 CD O
micrograms/day NN O
for NN stopwords O
6 DIGITS CD six O
months NN calendar_month O
, , O
to NN stopwords O
four JJ four O
patients VB patient O
1 DIGITS CD one O
alpha DT alpha O
, , O
25-dihydroxyvitamin CD O
D3 CAPITAL NNP O
was VB stopwords Washington O
given NN given O
orally NN orally O
at DT stopwords astatine O
a DT stopwords angstrom O
dose NN dose O
of NN stopwords O
0.5 LS O
microgram/day NN O
for NN stopwords O
6 DIGITS CD six O
months NN calendar_month O
, , O
and DT stopwords O
19 DIGITS CD nineteen O
patients VB patient O
were NN stopwords be O
given NN given O
1 DIGITS CD one O
alpha DT alpha O
, , O
25-dihydroxyvitamin CD O
D3 CAPITAL NNP O
applied DT use O
topically NN locally O
at DT stopwords astatine O
concentration NNS concentration O
of NN stopwords O
0.5 LS O
microgram/g NN O
of NN stopwords O
base VB base O
for NN stopwords O
8 DIGITS CD eight O
weeks NN week O

Steroids CAPITAL NNP steroid T
in NN stopwords inch O
De CAPITAL NNP Delaware D
Quervain CAPITAL NNP D
's POS D
tenosynovitis NN tenosynovitis D

PROBLEM CAPITAL NNP problem O
: : O
To CAPITAL NNP O
compare NNS comparison O
the NN stopwords O
expression NN expression O
by NN stopwords by O
T-lymphocytes CAPITAL NNP O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
immunomodulatory JJ O
protein NN protein O
known NN know O
as DT stopwords arsenic O
progesterone-induced NN O
blocking NN blocking O
factor VB factor O
( ( O
PIBF CAPITAL NNP O
) ) O
in NN stopwords inch O
conception NNS concept O
versus NN O
non-conception JJ O
cycles NNS cycle O
even NN evening O
when NN stopwords O
there NN stopwords there O
has VB stopwords hour_angle O
been NN stopwords be O
definite NN definite O
fertilization NN fertilization O
and DT stopwords O
embryo NN embryo O
formation NN formation O

The CAPITAL NNP O
guide NN usher O
situates NN situate O
general NN general O
internal NN internal O
medicine NN medicine O
as DT stopwords arsenic O
the NN stopwords O
primary NN primary O
care VB care O
profession NN profession O
that NN stopwords O
focuses JJ focus O
on NN stopwords on O
preventive NN preventive O
, , O
short-term NN short-run O
, , O
and DT stopwords O
long-term NN long-run O
care VB care O
of NN stopwords O
adult DT adult O
patients VB patient O

Effect CAPITAL NNP consequence O
of NN stopwords O
dental NN alveolar_consonant T
treatment NN treatment T
on NN stopwords on O
the NN stopwords O
lung NN lung O
function JJ function O
of NN stopwords O
children JJ child O
with NN stopwords O
asthma DT asthma D
. . O

( ( O
4 DIGITS CD four O
) ) O
The CAPITAL NNP O
nurses RB nurse O
had VB stopwords have O
a DT stopwords angstrom O
positive NN positive O
attitude DT attitude O
about DT stopwords about O
their NN stopwords O
healthy NN healthy O
lifestyles NN life_style O
and DT stopwords O
felt JJ felt O
optimistic JJ optimistic O
about DT stopwords about O
being NN stopwords being O
role NN function O
models NN model O
for NN stopwords O
their NN stopwords O
patients VB patient O

Hemispheric CAPITAL NNP hemispheric O
difference NN difference O
in NN stopwords inch O
human NN homo O
skin JJ skin O
color NNS color O

The CAPITAL NNP O
authors DT writer O
suggest NN propose O
that NN stopwords O
changes NNS change O
in NN stopwords inch O
Ca2+ CAPITAL VB O
regulation NN regulation O
could NNS O
adjust DT adjust O
the NN stopwords O
thresholds NN threshold O
for NN stopwords O
synaptic NN synaptic O
modification NN alteration O
, , O
favoring VB prefer O
processes NN procedure O
for NN stopwords O
depression NN depression O
of NN stopwords O
synaptic NN synaptic O
strength NN strength O
during NN stopwords O
aging DT ripening O

The CAPITAL NNP O
search NN search O
of NN stopwords O
solutions NN solution O
needs JJ need O
multiple NN multiple O
competences NNS competence O
from JJ stopwords O
the NN stopwords O
physician NN doctor O
, , O
who NN stopwords World_Health_Organization O
has VB stopwords hour_angle O
to NN stopwords O
play NN play O
an DT stopwords Associate_in_Nursing O
essential NN necessity O
role NN function O

Cost-effectiveness CAPITAL NNP O
of NN stopwords O
interferon NN interferon T
treatment NN treatment T
for NN stopwords O
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D

Vision CAPITAL NNP vision O
versus NN O
touch NN touch O
in NN stopwords inch O
form NN form O
discrimination NN discrimination O

CONCLUSIONS CAPITAL NNP decision O
: : O
The CAPITAL NNP O
panel VB panel O
found JJ found O
sufficient NN sufficient O
acceptable DT acceptable O
long-term NN long-run O
outcomes JJ result O
data VB data O
( ( O
longer NN longer O
than NN stopwords O
48 DIGITS CD forty-eight O
months NN calendar_month O
) ) O
to NN stopwords O
conclude NNS reason O
that NN stopwords O
surgical NN surgical T
treatment NN treatment T
of NN stopwords O
female JJ female D
stress NN stress D
urinary JJ urinary D
incontinence NN incontinence D
is NN stopwords be O
effective NN effective O
, , O
offering JJ offer O
a DT stopwords angstrom O
long-term NN long-run O
cure NNS remedy O
in NN stopwords inch O
a DT stopwords angstrom O
significant NN significant O
percentage NN percentage O
of NN stopwords O
women NN woman O

Comparison CAPITAL NNP comparison O
of NN stopwords O
two NN two O
methods NN method O
of NN stopwords O
screening NN screening O
for NN stopwords O
genital NN genital O
chlamydial NNS chlamydial D
infection NN infection D
in NN stopwords inch O
women NN woman O
attending DT attention O
in NN stopwords inch O
general NN general O
practice NN practice O
: : O
cross NNS cross O
sectional NN sectional O
survey NN survey O

Simultaneous CAPITAL NNP coincident O
measurement NN measurement O
of NN stopwords O
stiffness JJ stiffness O
and DT stopwords O
energy NN energy O
absorptive DT absorbent O
properties NN property O
of NN stopwords O
articular DT articular O
cartilage VB cartilage O
and DT stopwords O
subchondral NN O
trabecular NN trabecular O
bone NN bone O

Epitome CAPITAL NNP prototype O
of NN stopwords O
myocarditis NN myocardial_inflammation D

Isolated CAPITAL PRP isolate O
axial DT axial O
lateral NN lateral_pass O
pulse NN pulsation O
as DT stopwords arsenic O
a DT stopwords angstrom O
sign NN sign O
of NN stopwords O
latero-bulbar NN D
ischemia NN ischemia D
: : O
clinical JJ clinical O
topographic NN topographical O
correlation NNS correlation O

Interferon-alpha-2b CAPITAL PRP T
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
patients VB patient O
with NN stopwords O
relapsed NN get_worse O
and/or DT O
refractory NN furnace_lining O
Hodgkin CAPITAL NNP Hodgkin D
's POS D
disease NN disease D

Primary CAPITAL NNP primary D
biliary NN bilious D
cirrhosis NN cirrhosis D

Tapered CAPITAL VB taper O
fibres NN fiber O
are DT stopwords are O
immobilized JJ immobilize O
with NN stopwords O
the NN stopwords O
purified NN purify O
cell NNS cell O
surface NN surface O
protein NN protein O
of NN stopwords O
L. CAPITAL NNP O
donovani NN O
by NN stopwords by O
covalent NNS covalent O
bonding NN bonding O

Novel CAPITAL NNP novel O
acceptor DT acceptor O
splice NN splice O
site NN site O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
invariant NN invariant O
AG CAPITAL DT silver O
of NN stopwords O
intron NN intron O
6 DIGITS CD six O
of NN stopwords O
alpha-galactosidase DT O
A CAPITAL DT angstrom O
gene NN gene O
, , O
causing VB causing O
Fabry CAPITAL NNP D
disease NN disease D

conclusions NNS decision O
: : O
endobronchial NN T
interventions NN intervention T
are DT stopwords are O
important JJ important O
adjuncts DT adjunct O
in NN stopwords inch O
the NN stopwords O
multimodality NN O
management VB management O
of NN stopwords O
lung NN lung D
cancer VB cancer D
and DT stopwords O
should NN stopwords O
become NN become O
standard NN standard O
considerations NNS consideration O
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance O
lung NN lung O
cancer VB cancer O

In CAPITAL PRP inch O
case VB case O
3 DIGITS CD three O
, , O
intravenous NN intravenous T
cidofovir NN T
therapy NN therapy T
was VB stopwords Washington O
started NN get_down O
both NN stopwords both O
for NN stopwords O
CMV CAPITAL NNP cytomegalovirus D
retinitis NN retinitis D
and DT stopwords O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
attempt DT attempt O
to NN stopwords O
clear NNS clear O
90 DIGITS CD ninety O
% NN O
facial VB facial O
MCV CAPITAL NNP D
involvement NN engagement O
; : O
after DT stopwords after O
1 DIGITS CD one O
month NN calendar_month O
of NN stopwords O
treatment NN treatment O
, , O
all DT stopwords all O
clinical JJ clinical O
evidence NN evidence O
of NN stopwords O
MCV CAPITAL NNP D
had VB stopwords have O
resolved NN decide O

Placebo-controlled CAPITAL NNP O
trials NN test O
have VB stopwords rich_person O
shown NN show O
that NN stopwords O
vitamin NN vitamin T
C CAPITAL SYM degree_centigrade T
supplementation NN supplement O
decreases NN decrease O
the NN stopwords O
duration NN duration O
and DT stopwords O
severity NN badness O
of NN stopwords O
common NNS park D
cold NNS cold D
infections NN infection D

Dipstick CAPITAL NNP dipstick O
only JJ stopwords lone O
urinalysis JJ urinalysis O
screen NN screen O
for NN stopwords O
the NN stopwords O
pediatric NN pediatric O
emergency NN emergency O
room NN room O

ETTIN CAPITAL NNP O
patterns VB form O
the NN stopwords O
Arabidopsis CAPITAL DT Arabidopsis O
floral JJ floral O
meristem NN meristem O
and DT stopwords O
reproductive NN generative O
organs JJ variety_meat O

The CAPITAL NNP O
pre- NN O
and DT stopwords O
postnatal NN postnatal O
prevalence NN prevalence O
of NN stopwords O
abuse DT maltreatment O
was VB stopwords Washington O
matched VB match O
with NN stopwords O
demographic NN demographic O
data VB data O

Management CAPITAL NNP management O
of NN stopwords O
vaginal NN vaginal D
vault NN vault D
prolapse NN prolapse D

METHODS CAPITAL NNP method O
: : O
Basal CAPITAL IN radical O
acid DT acid O
output JJ end_product O
( ( O
BAO CAPITAL IN O
) ) O
and DT stopwords O
maximal VB maximal O
acid DT acid O
output JJ end_product O
( ( O
MAO CAPITAL NNP monoamine_oxidase O
) ) O
were NN stopwords be O
assessed DT measure O
in NN stopwords inch O
11 DIGITS CD eleven O
H. CAPITAL NNP O
pylori-infected NN O
dyspeptic NN dyspeptic O
patients VB patient O
( ( O
8 DIGITS CD eight O
women NN woman O
and DT stopwords O
3 DIGITS CD three O
men NN work_force O
; : O
mean NN mean O
age DT age O
, , O
28 DIGITS CD twenty-eight O
years NN old_age O
) ) O
before NN stopwords earlier O
and DT stopwords O
after DT stopwords after O
successful NN successful O
anti-H DT O

Survey CAPITAL NNP survey O
on NN stopwords on O
rotavirus NN rotavirus D
infections NN infection D
in NN stopwords inch O
a DT stopwords angstrom O
German CAPITAL NNP German O
pediatric NN pediatric O
hospital NN hospital O

Correlation CAPITAL NNP correlation O
is NN stopwords be O
not JJ stopwords not O
causation VB causing O

Pellagra CAPITAL NNP pellagra D
and DT stopwords O
the NN stopwords O
origin IN beginning O
of NN stopwords O
a DT stopwords angstrom O
myth NN myth O
: : O
evidence NN evidence O
from JJ stopwords O
European CAPITAL NNP European O
literature NN literature O
and DT stopwords O
folklore JJ folklore O

V CAPITAL NN volt O

No CAPITAL NNP no O
objective NN aim O
evidence NN evidence O
of NN stopwords O
autonomic DT autonomic O
disturbance NN perturbation O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
cerebral NNS cerebral D
palsy VB paralysis D
was VB stopwords Washington O
found JJ found O
in NN stopwords inch O
this NN stopwords O
study NN survey O

Emergency CAPITAL NNP emergency O
! . O
Meningococcal CAPITAL NNP D
disease NN disease D

Initial CAPITAL PRP initial O
empiric NN empiric O
therapy NN therapy O
for NN stopwords O
community-acquired NNS O
bacterial VB bacterial D
meningitis NN meningitis D
should NN stopwords O
be NN stopwords beryllium O
based VB establish O
on NN stopwords on O
the NN stopwords O
possibility NN possibility O
that NN stopwords O
penicillin-resistant NN penicillin-resistant O
pneumococci NN pneumococcus O
may VB May O
be NN stopwords beryllium O
the NN stopwords O
etiologic NN etiological O
organisms JJ organism O
and DT stopwords O
, , O
hence NN therefore O
, , O
should NN stopwords O
include NN include O
a DT stopwords angstrom O
combination NNS combination O
of NN stopwords O
third-generation NN O
cephalosporin NNS cephalosporin T
( ( T
cefotaxime NNS cefotaxime T
or NN stopwords Oregon T
ceftriaxone NNS ceftriaxone T
) ) T
and DT stopwords T
vancomycin NN vancomycin T

Ropinirole-treated CAPITAL NNP O
patients VB patient O
had VB stopwords have O
a DT stopwords angstrom O
significantly NN significantly O
greater NN greater O
percentage NN percentage O
improvement JJ improvement O
in NN stopwords inch O
UPDRS CAPITAL NNP O
motor NN motor O
score JJ mark O
than NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
received NN receive O
placebo NN placebo O
( ( O
+24 RB O
% NN O
vs NN volt O
-3 : O
% NN O
; : O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O

reviewer NN reviewer O
's POS O
conclusions NNS decision O
: : O
prophylactic NN preventive T
cranial NNS cranial T
irradiation NN irradiation T
significantly NN significantly O
improves JJ better O
survival NN survival O
and DT stopwords O
disease-free NN O
survival NN survival O
for NN stopwords O
patients VB patient O
with NN stopwords O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
in NN stopwords inch O
complete NNS complete O
remission NN remission O

Usefulness CAPITAL NNP utility O
of NN stopwords O
percutaneous NN transdermal T
transhepatic NN T
biliary NN bilious T
drainage NN drain T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
surgical NN surgical D
jaundice NN jaundice D
-- : O
a DT stopwords angstrom O
prospective NN prospective O
randomised VB randomize O
study NN survey O

Comparison CAPITAL NNP comparison O
of NN stopwords O
AF-4 CAPITAL DT O
protein NN protein O
coding NNS cryptography O
sequences NN sequence O
with NN stopwords O
the NN stopwords O
LAF-4 CAPITAL VB O
and DT stopwords O
FMR-2 CAPITAL NNP O
sequences NN sequence O
revealed NN uncover O
five NN five O
highly NN highly O
conserved NNS conserve O
domains NN sphere O
of NN stopwords O
potential NN potential O
functional JJ functional O
relevance NN relevance O

BACKGROUND CAPITAL IN background O
: : O
Darier CAPITAL NNP D
disease NN disease D
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
uncommon JJ uncommon O
genodermatosis NN D
characterized NNS qualify O
by NN stopwords by O
the NN stopwords O
symmetrical NN symmetrical O
eruption NN volcanic_eruption O
of NN stopwords O
keratotic NN O
reddish-brown NN red-brown O
papules VB papule O
occurring JJ happen O
in NN stopwords inch O
the NN stopwords O
seborrheic NN O
areas DT area O
of NN stopwords O
the NN stopwords O
body NN body O

Tumor CAPITAL NNP tumor O
characteristics NNS feature O
of NN stopwords O
703 DIGITS CD O
cases VB case O
of NN stopwords O
newly JJ newly O
diagnosed NN diagnose O
invasive NN invasive O
colon NNS colon O
adenocarcinoma DT adenocarcinoma D
were NN stopwords be O
centrally NNS centrally O
evaluated NN measure O
by NN stopwords by O
a DT stopwords angstrom O
gastrointestinal VB gastrointestinal O
pathologist VB diagnostician O
, , O
blinded NN blind O
in NN stopwords inch O
regard NN respect O
to NN stopwords O
the NN stopwords O
age DT age O
, , O
race VB race O
, , O
and DT stopwords O
sex NN sexual_activity O
of NN stopwords O
the NN stopwords O
patients VB patient O

Research CAPITAL NNP research O
into NN stopwords O
the NN stopwords O
genetic NN familial O
component NNS component O
of NN stopwords O
some NN stopwords some O
complex NNS complex O
behaviors NN behavior O
often JJ frequently O
causes VB cause O
controversy NNS controversy O
, , O
depending NN depend O
on NN stopwords on O
the NN stopwords O
social NN sociable O
meaning NN meaning O
and DT stopwords O
significance NN significance O
of NN stopwords O
the NN stopwords O
behavior NN behavior O
under JJ stopwords nether O
study NN survey O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
a DT stopwords angstrom O
conference NNS conference O

Death CAPITAL NNP death O
rates VB rates O
of NN stopwords O
characters NNS fictional_character O
in NN stopwords inch O
soap NN soap O
operas JJ opera O
on NN stopwords on O
British CAPITAL NNP British O
television NN television O
: : O
is NN stopwords be O
a DT stopwords angstrom O
government NN government O
health NN health O
warning NN warning O
required NN necessitate O
? . O

The CAPITAL NNP O
Third CAPITAL NNP one-third O
International CAPITAL PRP International O
Study CAPITAL NNP survey O
of NN stopwords O
Infarct CAPITAL PRP infarct O
Survival CAPITAL NNP survival O
Collaborative CAPITAL NNP collaborative O
Group CAPITAL NNP group O

Randomised CAPITAL VB randomize O
trial NN test O
of NN stopwords O
interferon NN interferon T
alpha2b DT T
plus NN asset T
ribavirin NN ribavirin T
for NN stopwords O
48 DIGITS CD forty-eight O
weeks NN week O
or NN stopwords Oregon O
for NN stopwords O
24 DIGITS CD twenty-four O
weeks NN week O
versus NN O
interferon NN interferon T
alpha2b DT T
plus NN asset T
placebo NN placebo T
for NN stopwords O
48 DIGITS CD forty-eight O
weeks NN week O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
chronic NN chronic D
infection NN infection D
with NN stopwords D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D
virus NN virus D

Computer CAPITAL NNP computer O
science JJ science O
and DT stopwords O
biology NN biology O
-- : O
the NN stopwords O
German CAPITAL NNP German O
Conference CAPITAL NNP conference O
on NN stopwords on O
Bioinformatics CAPITAL NNP O
( ( O
GCB'96 CAPITAL NNP O
) ) O

Re CAPITAL NNP rhenium O
: : O
`` `` O
Biologic CAPITAL NNP biological O
synergism NN synergy O
and DT stopwords O
parallelism NN parallelism O
'' POS O

Whereas CAPITAL NNP O
by NN stopwords by O
TEFNA CAPITAL NNP T
spermatozoa NN sperm O
enabling NN enable O
performance NN performance O
of NN stopwords O
ICSI CAPITAL PRP O
were NN stopwords be O
found JJ found O
in NN stopwords inch O
only JJ stopwords lone O
four JJ four O
patients VB patient O
out JJ stopwords out O
of NN stopwords O
37 DIGITS CD thirty-seven O
( ( O
11 DIGITS CD eleven O
% NN O
) ) O
, , O
open JJ open T
biopsy NN biopsy T
and DT stopwords T
TESE CAPITAL NNP T
yielded NN yield O
spermatozoa NN sperm O
in NN stopwords inch O
16 DIGITS CD sixteen O
cases VB case O
( ( O
43 DIGITS CD forty-three O
% NN O
) ) O

A CAPITAL DT angstrom O
note JJ note O
on NN stopwords on O
the NN stopwords O
epidemiology NN epidemiology O
of NN stopwords O
Creutzfeldt-Jakob CAPITAL NNP D
syndrome NN syndrome D

Retinoblastoma CAPITAL NNP retinoblastoma D
patients VB patient O
should NN stopwords O
be NN stopwords beryllium O
examined NN analyze O
for NN stopwords O
new JJ new O
cancers VB cancer D
and DT stopwords O
followed JJ follow O
into NN stopwords O
later NN later O
life NN life O
to NN stopwords O
determine NN determine O
whether NN O
their NN stopwords O
extraordinary NN extraordinary O
cancer VB cancer O
risk NN hazard O
extends NN widen O
to NN stopwords O
common NNS park O
cancers VB cancer D
of NN stopwords O
adulthood DT adulthood O

Perforation CAPITAL NNP perforation D
of NN stopwords D
the NN stopwords D
postpartum NN postnatal D
uterus JJ uterus D
with NN stopwords O
an DT stopwords Associate_in_Nursing O
intrauterine NN intrauterine O
contraceptive NNS contraceptive O
device NN device O

A CAPITAL DT angstrom O
cDNA SYM complementary_DNA O
was VB stopwords Washington O
isolated NN isolate O
from JJ stopwords O
a DT stopwords angstrom O
lambdagt11 NN O
protoscolex NN O
expression NN expression O
library NN library O
and DT stopwords O
the NN stopwords O
deduced NN deduce O
amino DT amino O
acid DT acid O
sequence NN sequence O
has VB stopwords hour_angle O
at DT stopwords astatine O
least NN least O
fifteen NN fifteen O
sequentially NN consecutive O
repeated NN repeat O
twelve-residue NN O
repeats NN repeat O
that NN stopwords O
resemble NN resemble O
the NN stopwords O
calcium-binding VB O
loop NN cringle O
of NN stopwords O
EF-hands CAPITAL NNP O
; : O
however NN however O
, , O
the NN stopwords O
dodecamer NN O
motif NN motif O
has VB stopwords hour_angle O
no NNS stopwords no O
flanking NN flank O
helices NN helix O

GPs CAPITAL NNP Global_Positioning_System O
' '' O
perceptions NN percept O
of NN stopwords O
tolerability NN O
of NN stopwords O
selective NN selective O
serotonin NN serotonin O
reuptake NN reuptake O
inhibitors NN inhibitor O
and DT stopwords O
tricyclic NN tricyclic O
antidepressants DT antidepressant T

p53 NN O
mutations NN mutant O
in NN stopwords inch O
BRCA1-associated CAPITAL NNP O
familial VB familial O
breast NN breast D
cancer VB cancer D

DESIGN CAPITAL NNP design O
: : O
A CAPITAL DT angstrom O
complete NNS complete O
sequence NN sequence O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
BRCA1 CAPITAL NNP O
coding NNS cryptography O
sequence NN sequence O
and DT stopwords O
flanking NN flank O
intronic NN O
regions NN region O
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
798 DIGITS CD O
women NN woman O
in NN stopwords inch O
a DT stopwords angstrom O
collaborative NNS collaborative O
effort NN attempt O
involving NN involve O
institutions NN institution O
from JJ stopwords O
the NN stopwords O
United CAPITAL NNP unite O
States CAPITAL NNP state O
, , O
Italy CAPITAL PRP Italy O
, , O
Germany CAPITAL NNP Germany O
, , O
Finland CAPITAL NNP Finland O
, , O
and DT stopwords O
Switzerland CAPITAL NNP Switzerland O

Anesthesiology CAPITAL DT anesthesiology O

Effect CAPITAL NNP consequence O
of NN stopwords O
danaparoid VB T
sodium NN sodium T
on NN stopwords on O
hard NN difficult O
exudates NN exudate O
in NN stopwords inch O
diabetic NN diabetic D
retinopathy NN retinopathy D
. . O

Bilateral CAPITAL NNP bilateral O
sampling VB sampling O
of NN stopwords O
the NN stopwords O
internal NN internal O
jugular NN jugular_vein O
vein NN vein O
to NN stopwords O
distinguish NN distinguish O
between NN stopwords between O
mechanisms NN mechanism O
of NN stopwords O
adrenocorticotropic DT adrenocorticotropic O
hormone-dependent NN O
Cushing CAPITAL NNP Cushing D
syndrome NN syndrome D

In CAPITAL PRP inch O
seven NN seven O
subjects NN subject O
activation DT activation O
was VB stopwords Washington O
encountered NN meet O
in NN stopwords inch O
the NN stopwords O
hippocampal NN O
formation NN formation O

New CAPITAL NNP new O
diagnostic NN diagnostic O
criteria JJ standard O
lowered NN lower O
the NN stopwords O
cut NNS cut O
off JJ stopwords murder O
value NN value O
to NN stopwords O
126 DIGITS CD O
mg/dl NN O
, , O
in NN stopwords inch O
order JJ order O
to NN stopwords O
detect NN detect O
more NN stopwords More O
rapidly VB quickly O
diabetes NN diabetes D
and DT stopwords O
its NN stopwords information_technology O
complications NNS complication O

Investigation CAPITAL PRP probe O
of NN stopwords O
the NN stopwords O
yeast NN yeast O
mitochondrial NN O
unselective JJ unselective O
channel NNS channel O
in NN stopwords inch O
intact NN integral O
and DT stopwords O
permeabilized NN O
spheroplasts NN O

Recombinant CAPITAL NNP recombinant O
human NN homo O
DNase CAPITAL NNP O
( ( O
rhDNase NN O
) ) O
influences NN influence O
phospholipid NN phospholipid O
composition NNS composition O
, , O
surface NN surface O
activity DT activity O
, , O
rheology NN rheology O
and DT stopwords O
consecutively NNS consecutively O
clearance NNS clearance O
indices NN index O
of NN stopwords O
cystic NNS cystic D
fibrosis NN fibrosis D
sputum NN phlegm O

Analgesic CAPITAL DT analgesic D
nephropathy JJ kidney_disease D

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

A CAPITAL DT angstrom O
protein NN protein O
with NN stopwords O
a DT stopwords angstrom O
novel JJ novel O
calcium-binding VB O
domain NN sphere O
associated DT associate O
with NN stopwords O
calcareous VB calcareous O
corpuscles NNS atom O
in NN stopwords inch O
Echinococcus CAPITAL NNP echinococcus D
granulosus NN D

Various CAPITAL VB assorted O
aspects DT aspect O
of NN stopwords O
water-salt VB O
metabolism NN metamorphosis O
in NN stopwords inch O
heart NN heart D
congestive NNS congestive D
failure VB failure D

A CAPITAL DT angstrom O
case VB case O
of NN stopwords O
sarcoidosis VB sarcoidosis D
of NN stopwords O
the NN stopwords O
mastoid VB mastoid O

in NN stopwords inch O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
colorectal NNS colorectal D
cancer VB cancer D
, , O
intravenous NN intravenous T
oxaliplatin NN T
has VB stopwords hour_angle O
been NN stopwords be O
trialled NN O
as DT stopwords arsenic O
a DT stopwords angstrom O
monotherapy NN O
and DT stopwords O
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
other JJ stopwords other O
agents DT agent O

Effect CAPITAL NNP consequence O
of NN stopwords O
protein NN protein O
kinase NN kinase O
C CAPITAL SYM degree_centigrade O
inhibitors NN inhibitor O
on NN stopwords on O
cardioprotection VB O
by NN stopwords by O
ischemic NN ischemic O
preconditioning NN precondition O
depends NN depend O
on NN stopwords on O
the NN stopwords O
number JJ number O
of NN stopwords O
preconditioning NN precondition O
episodes NN episode O

Cytomegalovirus CAPITAL NNP cytomegalovirus D
( ( D
CMV CAPITAL NNP cytomegalovirus D
) ) D
infection NN infection D
was VB stopwords Washington O
one JJ one O
of NN stopwords O
the NN stopwords O
most NN stopwords most O
common NNS park O
opportunistic JJ opportunist O
infections NN infection O
in NN stopwords inch O
AIDS CAPITAL DT AIDS O
patients VB patient O
, , O
leading NN lead O
to NN stopwords O
blindness NN blindness O
or NN stopwords Oregon O
life-threatening NN dangerous O
disease NN disease O
in NN stopwords inch O
about DT stopwords about O
40 DIGITS CD forty O
% NN O
of NN stopwords O
patients VB patient O
in NN stopwords inch O
the NN stopwords O
later NN later O
stages NN phase O
of NN stopwords O
AIDS CAPITAL DT AIDS O
before NN stopwords earlier O
highly NN highly T
active DT active_agent T
antiretroviral DT T
therapy NN therapy T
( ( T
HAART CAPITAL NNP drug_cocktail T
) ) T

Thoracoscopy CAPITAL NNP T
for NN stopwords O
empyema NN empyema D
in NN stopwords inch O
children JJ child O

A CAPITAL DT angstrom O
hidden NN hide O
agenda DT agenda O

Anaesthesia CAPITAL DT anesthesia O
for NN stopwords O
laparoscopic NN T
cholecystectomy NNS cholecystectomy T
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
Eisenmenger CAPITAL NN D
's POS D
syndrome NN syndrome D

We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
the NN stopwords O
patient VB patient O
had VB stopwords have O
TSS CAPITAL NNP toxic_shock D
without NN O
rash VB rash D

RESULTS CAPITAL NNP consequence O
: : O
Test CAPITAL NNP trial O
results NN consequence O
for NN stopwords O
46 DIGITS CD forty-six O
ECMO-treated CAPITAL NNP O
infants NN baby O
( ( O
57.5 CD O
% NN O
) ) O
were NN stopwords be O
normal RB convention O
, , O
and DT stopwords O
those NN stopwords O
for NN stopwords O
34 DIGITS CD thirty-four O
infants NN baby O
( ( O
42.5 CD O
% NN O
) ) O
were NN stopwords be O
abnormal DT abnormal O
, , O
with NN stopwords O
either NN either O
elevated NN elevated_railway O
wave VB wave O
V CAPITAL NN volt O
threshold NN threshold O
, , O
prolonged NN prolong O
wave VB wave O
I-V CAPITAL PRP O
interval NN time_interval O
, , O
or NN stopwords Oregon O
both NN stopwords both O
on NN stopwords on O
neonatal JJ neonatal O
BAEP CAPITAL IN O
recordings NN recording O

Does CAPITAL NNP Department_of_Energy O
this NN stopwords O
patient VB patient O
have VB stopwords rich_person O
a DT stopwords angstrom O
mole NN gram_molecule O
or NN stopwords Oregon O
a DT stopwords angstrom O
melanoma NN melanoma D
? . O

The CAPITAL NNP O
display NN display O
of NN stopwords O
information NN information O
and DT stopwords O
the NN stopwords O
judgment NN judgment O
of NN stopwords O
contingency NNS eventuality O

We CAPITAL NNP O
identify NN identify O
three NN three O
different NN different O
mRNA NN messenger_RNA O
forms NN form O
of NN stopwords O
chLAMP NNS O
and DT stopwords O
show NN show O
that NN stopwords O
two NN two O
forms NN form O
with NN stopwords O
distinct NN distinct O
5'-termini CD O
are DT stopwords are O
differentially NN differentially O
transcribed NN transcribe O
in NN stopwords inch O
neural JJ nervous O
development NN development O

Microsurgical CAPITAL NNP T
treatment NN treatment T
of NN stopwords O
supratentorial NN D
cavernous VB cavernous D
malformations VB deformity D

While CAPITAL NNP while O
the NN stopwords O
demonstrated NN show O
antiviral DT antiviral O
, , O
antiproliferative DT O
, , O
and DT stopwords O
immunomodulatory JJ O
properties NN property O
of NN stopwords O
interferons NN interferon T
have VB stopwords rich_person O
led NN light-emitting_diode O
to NN stopwords O
a DT stopwords angstrom O
number JJ number O
of NN stopwords O
theories NN theory O
regarding NN see O
their NN stopwords O
potential NN potential O
use JJ use O
in NN stopwords inch O
treating NN treat O
individuals NN person O
with NN stopwords O
chronic NN chronic D
myelogenous NN D
leukemia NN leukemia D
( ( D
CML CAPITAL NNP D
) ) D
, , O
their NN stopwords O
limited NN express O
availability DT handiness O
has VB stopwords hour_angle O
prevented NN prevent O
thorough NN thorough O
clinical JJ clinical O
investigation NN probe O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
DNAS1L1 CAPITAL NNP O
, , O
DNAS1L2 CAPITAL NNP O
, , O
and DT stopwords O
DNAS1L3 CAPITAL NNP O
with NN stopwords O
the NN stopwords O
well-characterized NN O
DNase CAPITAL NNP O
I CAPITAL PRP iodine O
suggests NN propose O
that NN stopwords O
the NN stopwords O
DNAS1L CAPITAL NNP O
proteins NN protein O
are DT stopwords are O
unlikely JJ improbable O
to NN stopwords O
be NN stopwords beryllium O
glycosylated NN O
or NN stopwords Oregon O
bind NN bind O
actin DT actin O
; : O
however NN however O
, , O
catalytic VB catalytic O
and DT stopwords O
calcium- VB O
and DT stopwords O
DNA-binding CAPITAL NNP O
residues NN residue O
are DT stopwords are O
conserved NNS conserve O
, , O
and DT stopwords O
potentially NN potentially O
cleavable NNS cleavable O
signal NN signal O
peptides NN peptide O
are DT stopwords are O
present NN present O
among DT O
all DT stopwords all O
these NN stopwords O
proteins NN protein O

Only CAPITAL NNP lone O
patients VB patient O
whose NN O
primary NN primary D
head NN head D
and DT stopwords D
neck JJ neck D
tumor NN tumor D
shows NN show O
a DT stopwords angstrom O
response NN response O
to NN stopwords O
systemic NN systemic O
therapy NN therapy O
undergo JJ undergo O
Ommaya CAPITAL NNP T
placement NN placement T

background VB background O
: : O
the NN stopwords O
costs NNS costs O
of NN stopwords O
videothoracoscopic NN T
procedures NN procedure T
for NN stopwords O
patients VB patient O
with NN stopwords O
lung NN lung D
carcinoma VB carcinoma D
were NN stopwords be O
compared NNS compare O
with NN stopwords O
those NN stopwords O
of NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
open JJ open T
thoracotomy NN thoracotomy T
in NN stopwords inch O
japan NN Japan O

We CAPITAL NNP O
conducted NNS conduct O
a DT stopwords angstrom O
long-term NN long-run O
trial NN test O
of NN stopwords O
docosahexanoic NN T
acid DT acid T
( ( T
DHA CAPITAL NNP T
) ) T
-concentrated : T
fish NN fish T
oil NN oil T
capsules VB capsule T
for NN stopwords O
patients VB patient O
in NN stopwords inch O
a DT stopwords angstrom O
high-risk NN bad O
group NN group O
for NN stopwords O
colorectal NNS colorectal D
cancer VB cancer D

A CAPITAL DT angstrom O
novel JJ novel O
missense NN O
mutation NN mutant O
Ile538Val CAPITAL PRP O
in NN stopwords inch O
the NN stopwords O
fibroblast NN fibroblast O
growth NN growth O
factor VB factor O
receptor NN receptor O
3 DIGITS CD three O
in NN stopwords inch O
hypochondroplasia NN D

RESULTS CAPITAL NNP consequence O
: : O
Forty-four CAPITAL NNP forty-four O
patients VB patient O
were NN stopwords be O
enrolled NN enroll O
into NN stopwords O
the NN stopwords O
study NN survey O

2 DIGITS CD two O
students NN student O
at DT stopwords astatine O
Quo CAPITAL NNP O
Vadis CAPITAL VB O

Toward CAPITAL NNP O
a DT stopwords angstrom O
community NNS community O
alcoholism DT alcoholism O
program NN plan O

Mutation CAPITAL NNP mutant O
sharing NN sharing O
, , O
predominant NN prevailing O
involvement NN engagement O
of NN stopwords O
the NN stopwords O
MLH1 CAPITAL NNP O
gene NN gene O
and DT stopwords O
description NN description O
of NN stopwords O
four JJ four O
novel JJ novel O
mutations NN mutant O
in NN stopwords inch O
hereditary NN familial D
nonpolyposis JJ D
colorectal NNS colorectal D
cancer VB cancer D

Beyond CAPITAL NNP beyond O
a DT stopwords angstrom O
certain NNS certain O
intensity NN intensity O
of NN stopwords O
exercise NN exercise O
, , O
and DT stopwords O
coinciding JJ coincide O
with NN stopwords O
the NN stopwords O
accumulation DT accretion O
of NN stopwords O
blood NN blood O
lactate NN lactate O
( ( O
anaerobic DT anaerobic O
threshold NN threshold O
or NN stopwords Oregon O
AT CAPITAL DT astatine O
) ) O
, , O
a DT stopwords angstrom O
'saliva '' O
threshold NN threshold O
' '' O
( ( O
Tsa CAPITAL NNP Transportation_Security_Administration O
) ) O
does NN stopwords Department_of_Energy O
indeed NN indeed O
exist NN exist O

On CAPITAL NNP on O
socalled NN O
nervous RB nervous O
exhaustion NN exhaustion O

METHODS CAPITAL NNP method O
: : O
Fluvastatin CAPITAL NNP fluvastatin T
40 DIGITS CD forty O
mg NN milligram O
daily IN daily O
was VB stopwords Washington O
administered DT administer O
to NN stopwords O
25 DIGITS CD twenty-five O
patients VB patient O
with NN stopwords O
hypercholesterolaemia NN D
for NN stopwords O
up JJ stopwords up O
to NN stopwords O
24 DIGITS CD twenty-four O
weeks NN week O

Endoscopic CAPITAL NNP endoscopic T
hemostasis NN hemostasis T
of NN stopwords O
bleeding NN bleeding D
duodenal NN duodenal D
ulcer JJ ulcer D
in NN stopwords inch O
a DT stopwords angstrom O
child JJ child O
with NN stopwords O
Henoch-Schnlein CAPITAL NNP D
purpura NN purpura D

The CAPITAL NNP O
role NN function O
of NN stopwords O
the NN stopwords O
liver NN liver O
in NN stopwords inch O
serum-induced NN O
hypercoagulability NN D

Testing CAPITAL NNP testing O
for NN stopwords O
Helicobacter CAPITAL NNP D
pylori NN pylorus D
infection NN infection D
after DT stopwords after O
antibiotic DT antibiotic T
treatment NN treatment T
. . O

conclusions NNS decision O
: : O
the NN stopwords O
intensification NN intensification T
of NN stopwords T
platinum NN platinum T
dose NN dose T
( ( T
cisplatin NN T
plus NN asset T
carboplatin VB T
) ) T
in NN stopwords inch T
combination NNS combination T
chemotherapy NNS chemotherapy T
significantly NN significantly O
increased NN increase O
the NN stopwords O
complete NNS complete O
response NN response O
rate VB rate O
, , O
overall JJ overall O
survival NN survival O
and DT stopwords O
number JJ number O
of NN stopwords O
two-year NN biennial O
survivors NN survivor O
among DT O
sclc JJ D
patients VB patient O
with NN stopwords O
limited NN express O
disease NN disease O
compared NNS compare O
to NN stopwords O
combination NNS combination T
therapy NN therapy T
with NN stopwords T
carboplatin VB T
alone DT alone T
, , O
suggesting NN propose O
that NN stopwords O
a DT stopwords angstrom O
more NN stopwords More O
aggressive DT aggressive O
treatment NN treatment O
to NN stopwords O
this NN stopwords O
category VB class O
of NN stopwords O
patients VB patient O
is NN stopwords be O
worthwhile NN worthwhile O
, , O
while NN stopwords while O
no NNS stopwords no O
difference NN difference O
in NN stopwords inch O
treatment NN treatment O
outcome JJ result O
was VB stopwords Washington O
observed NN detect O
for NN stopwords O
patients VB patient O
with NN stopwords O
extensive NN extensive O
disease NN disease O

Arthrodesis CAPITAL DT arthrodesis T
of NN stopwords O
the NN stopwords O
first NN first O
metatarsophalangeal NN O
joint NN joint O
using JJ exploitation O
a DT stopwords angstrom O
bone NN bone T
graft NN graft T
to NN stopwords O
salvage VB salvage O
failed VB fail O
silicone NN silicone T
implant JJ implant T
arthroplasty DT arthroplasty T
produces NN produce O
acceptable DT acceptable O
subjective NN subjective O
and DT stopwords O
radiographic VB radiographic O
results NN consequence O

Arthrodesis CAPITAL DT arthrodesis T
of NN stopwords T
the NN stopwords T
first NN first T
metatarsophalangeal NN T
joint NN joint T
to NN stopwords O
salvage VB salvage O
failed VB fail D
silicone NN silicone D
implant JJ implant D
arthroplasty DT arthroplasty D

Our CAPITAL NNP O
results NN consequence O
provide NN supply O
evidence NN evidence O
that NN stopwords O
heterodimerization NN O
of NN stopwords O
receptors NN receptor O
can VB stopwords can O
be NN stopwords beryllium O
implicated JJ implicate O
either NN either O
in NN stopwords inch O
the NN stopwords O
positive NN positive O
or NN stopwords Oregon O
in NN stopwords inch O
negative JJ negative O
activation DT activation O
of NN stopwords O
gene NN gene O
transcription NN transcription O

The CAPITAL NNP O
surgical NN surgical T
treatment NN treatment T
of NN stopwords O
lung NN lung D
lacerations NN laceration D
and DT stopwords D
major VB major D
bronchial NN bronchial D
disruptions NN break D
caused VB cause O
by NN stopwords by O
blunt NN blunt O
thoracic NN pectoral O
trauma NN injury O

Washington CAPITAL WRB Washington O
, , O
DC CAPITAL NNP District_of_Columbia O
, , O
USA CAPITAL NNP United_States O

This CAPITAL NNP O
distinction NN differentiation O
becomes NN become O
critical JJ critical O
in NN stopwords inch O
the NN stopwords O
evaluation NN evaluation O
, , O
treatment NN treatment O
, , O
and DT stopwords O
management VB management O
of NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
a DT stopwords angstrom O
diagnosis NN diagnosis O
within NN inside O
the NN stopwords O
spectrum NN spectrum O
of NN stopwords O
the NN stopwords O
protein NN protein D
deposition NN deposition D
diseases NN disease D

Progressive CAPITAL NNP progressive O
sensorineural NN sensorineural O
hearing NN hearing D
loss NN loss D
, , O
subjective NN subjective O
tinnitus NN tinnitus D
and DT stopwords O
vertigo NN dizziness D
caused VB cause O
by NN stopwords by O
elevated NN elevated_railway O
blood NN blood O
lipids NN lipid O

119 DIGITS CD O

Massive CAPITAL NNP massive O
fetomaternal JJ D
hemorrhage NN bleeding D

The CAPITAL NNP O
chronological NN chronological O
parallelism NN parallelism O
with NN stopwords O
the NN stopwords O
appearance DT appearance O
of NN stopwords O
dioxins NN dioxin O
in NN stopwords inch O
the NN stopwords O
environment NN environment O
suggests NN propose O
that NN stopwords O
these NN stopwords O
might NN might O
exert NN exert O
biological NN biological O
effects NN effects O
at DT stopwords astatine O
the NN stopwords O
prevailing NN predominate O
level NN degree O
of NN stopwords O
exposure NN exposure O

In CAPITAL PRP inch O
the NN stopwords O
first NN first O
part NN part O
of NN stopwords O
this NN stopwords O
study NN survey O
only JJ stopwords lone O
the NN stopwords O
facial VB facial O
development NN development O
, , O
properly NN properly O
speaking NN speaking O
, , O
is NN stopwords be O
considered NNS see O
, , O
although DT O
it NN stopwords information_technology O
can VB stopwords can O
not JJ stopwords not O
be NN stopwords beryllium O
separate NN offprint O
of NN stopwords O
cervical NNS cervical O
development NN development O
to NN stopwords O
which NN stopwords O
a DT stopwords angstrom O
second NN second O
study NN survey O
will NN stopwords volition O
be NN stopwords beryllium O
reserved NN reserve O

The CAPITAL NNP O
radiological VB radiological O
investigation NN probe O
of NN stopwords O
suspected NN suspect O
lower NN lower_berth O
limb NN limb O
deep NN deep D
vein NN vein D
thrombosis NN thrombosis D

Transmural CAPITAL NNP T
drainage NN drain T
of NN stopwords O
pancreatic VB pancreatic D
fluid JJ fluid D
collections NNS collection D
without NN O
electrocautery NN electrocautery O
using JJ exploitation O
the NN stopwords O
Seldinger CAPITAL NNP O
technique NN technique O

Patients CAPITAL VB patient O
were NN stopwords be O
followed JJ follow O
up JJ stopwords up O
for NN stopwords O
6 DIGITS CD six O
months NN calendar_month O

Addressing CAPITAL DT address O
needle-stick JJ O
concerns NNS concern O

A CAPITAL DT angstrom O
native RB native O
protein NN protein O
of NN stopwords O
more NN stopwords More O
than NN stopwords O
300 DIGITS CD three_hundred O
kDa NN O
was VB stopwords Washington O
recognized NN acknowledge O
by NN stopwords by O
an DT stopwords Associate_in_Nursing O
anti-EgCaBP1 DT O
monoclonal NN monoclonal_antibody O
antibody DT antibody O
by NN stopwords by O
Western-blot CAPITAL NNP O
analysis DT analysis O

Telemedicine CAPITAL NNP O
gets NN get O
a DT stopwords angstrom O
chance NNS opportunity O
to NN stopwords O
prove NN prove O
itself NN stopwords O

A CAPITAL DT angstrom O
set NN set O
of NN stopwords O
recombinant NN recombinant O
phage NN bacteriophage O
carrying VB transport O
genomic NN O
fragments NN fragment O
for NN stopwords O
the NN stopwords O
coding NNS cryptography O
region NN region O
and DT stopwords O
flanking NN flank O
sequences NN sequence O
of NN stopwords O
the NN stopwords O
AF-4 CAPITAL DT O
gene NN gene O
were NN stopwords be O
isolated NN isolate O

In CAPITAL PRP inch O
all DT stopwords all O
cases VB case O
a DT stopwords angstrom O
coproparasitological NNS O
study NN survey O
was VB stopwords Washington O
performed NN perform O

They CAPITAL NNP O
received NN receive O
either NN either O
500 DIGITS CD five_hundred O
mg NN milligram O
of NN stopwords O
calcium VB calcium O
plus NN asset O
700 DIGITS CD O
IU CAPITAL PRP O
of NN stopwords O
vitamin NN vitamin O
D3 CAPITAL NNP O
( ( O
cholecalciferol NNS vitamin_D O
) ) O
per NN O
day VB day O
or NN stopwords Oregon O
placebo NN placebo O

European CAPITAL NNP European O
register NN register O
of NN stopwords O
patients VB patient O
with NN stopwords O
sickle NN sickle D
cell NNS cell D
disease NN disease D
treated NN treat O
with NN stopwords O
hydroxyurea NN T
is NN stopwords be O
being NN stopwords being O
set NN set O
up JJ stopwords up O

DESIGN CAPITAL NNP design O
: : O
Prospective CAPITAL NNP prospective O
community-based NNS O
study NN survey O

Recurrent CAPITAL NNP perennial D
strokes NN stroke D
in NN stopwords inch O
a DT stopwords angstrom O
34-year-old CD O
man VB man O

Some CAPITAL NNP some O
comments NNS remark O
on NN stopwords on O
awareness DT awareness O

Abnormal CAPITAL DT abnormal O
presentation NN presentation O
was VB stopwords Washington O
the NN stopwords O
most NN stopwords most O
common NNS park O
indication NN indication O
( ( O
25.6 CD O
% NN O
, , O
88 DIGITS CD eighty-eight O
of NN stopwords O
344 DIGITS CD O
) ) O

Helicobacter CAPITAL NNP O
pylori NN pylorus O
and DT stopwords O
abdominal DT abdominal O
symptoms NN symptom O
: : O
a DT stopwords angstrom O
population-based NN O
study NN survey O
among DT O
preschool NN preschool O
children JJ child O
in NN stopwords inch O
southern NN southern O
Germany CAPITAL NNP Germany O

Zinc CAPITAL NN zinc T
lozenges NN lozenge T
-- : O
a DT stopwords angstrom O
cure NNS remedy O
for NN stopwords O
common NNS park D
colds NNS cold D
? . O

Phototherapeutic CAPITAL NNP T
keratectomy NN T
in NN stopwords inch O
recurrent NN perennial D
corneal NNS corneal D
erosions NN erosion D
refractory NN furnace_lining O
to NN stopwords O
other JJ stopwords other O
forms NN form O
of NN stopwords O
treatment NN treatment O

Scientists CAPITAL NNP scientist O
at DT stopwords astatine O
major VB major O
and DT stopwords O
minor NN child O
universities JJ university O
: : O
a DT stopwords angstrom O
study NN survey O
of NN stopwords O
productivity NN productiveness O
and DT stopwords O
recognition NN recognition O

Pharmaceutical CAPITAL NNP pharmaceutical O
industry NN industry O
is NN stopwords be O
invited NN invite O
to NN stopwords O
respond NN react O
to NN stopwords O
amnesty DT amnesty O
for NN stopwords O
unreported JJ unreported O
trials NN test O

Cancer CAPITAL VB cancer D
therapy NN therapy T
and DT stopwords O
tumor NN tumor O
physiology NN physiology O

In CAPITAL PRP inch O
addition DT addition O
to NN stopwords O
a DT stopwords angstrom O
long NN hanker O
form NN form O
of NN stopwords O
591 DIGITS CD O
amino DT amino O
acids DT acid O
( ( O
aa DT aa O
) ) O
, , O
two NN two O
other JJ stopwords other O
forms NN form O
of NN stopwords O
PRL CAPITAL NNP O
receptor NN receptor O
( ( O
PRLR CAPITAL NNP O
) ) O
, , O
differing NN differ O
in NN stopwords inch O
the NN stopwords O
length NN length O
of NN stopwords O
their NN stopwords O
cytoplasmic NNS cytoplasmic O
domains NN sphere O
, , O
have VB stopwords rich_person O
been NN stopwords be O
identified NN identify O
in NN stopwords inch O
the NN stopwords O
rat VB rat O

The CAPITAL NNP O
diabetes NN diabetes D
audit DT audited_account O
and DT stopwords O
research NN research O
in NN stopwords inch O
Tayside CAPITAL VB O
Scotland CAPITAL NNP Scotland O
( ( O
DARTS CAPITAL NNP darts O
) ) O
study NN survey O
: : O
electronic NN electronic O
record NN record O
linkage NN linkage O
to NN stopwords O
create NNS make O
a DT stopwords angstrom O
diabetes NN diabetes O
register NN register O

chemotherapy NNS chemotherapy T
administered DT administer O
before NN stopwords earlier O
surgery NN surgery O
or NN stopwords Oregon O
definitive NN definitive O
irradiation NN irradiation O
has VB stopwords hour_angle O
improved JJ better O
survival NN survival O
rates VB rates O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
stage NN phase D
iii NN three D
nsclc JJ D

Randomised CAPITAL VB randomize O
study NN survey O
of NN stopwords O
radical VB group T
surgery NN surgery T
versus NN T
radiotherapy VB radiotherapy T
for NN stopwords O
stage NN phase D
Ib-IIa CAPITAL PRP D
cervical NNS cervical D
cancer VB cancer D

Emergency CAPITAL NNP emergency O
department NN department O
use JJ use O
as DT stopwords arsenic O
a DT stopwords angstrom O
component NNS component O
of NN stopwords O
total NN sum O
ambulatory DT ambulatory O
care VB care O
: : O
a DT stopwords angstrom O
population NN population O
perspective NN position O

A CAPITAL DT angstrom O
'normal POS O
' '' O
practice NN practice O

Studies CAPITAL NNP survey O
in NN stopwords inch O
infantile NN childish D
malnutrition VB malnutrition D

over JJ stopwords over O
the NN stopwords O
past VB past O
twenty NN twenty O
years NN old_age O
combination NNS combination T
chemotherapy NNS chemotherapy T
has VB stopwords hour_angle O
continued NNS continue O
to NN stopwords O
produce NN produce O
small JJ small O
survival NN survival O
gains NN addition O
for NN stopwords O
patients VB patient O
with NN stopwords O
sclc JJ D

This CAPITAL NNP O
model NN model O
can VB stopwords can O
be NN stopwords beryllium O
used JJ use O
to NN stopwords O
test NN trial O
the NN stopwords O
safety VB safety O
and DT stopwords O
efficacy NN efficacy O
of NN stopwords O
liver-assist NN T
devices NN devices T
aimed DT aim O
at DT stopwords astatine O
temporizing NN temporize O
the NN stopwords O
detoxification NN detoxification O
functions JJ function O
of NN stopwords O
the NN stopwords O
failing VB failing D
liver NN liver D

Underutilization CAPITAL NNP O
of NN stopwords O
aspirin DT aspirin T
in NN stopwords inch O
older JJ aged O
patients VB patient O
with NN stopwords O
prior NN prior D
myocardial NN myocardial D
infarction NN infarct D
at DT stopwords astatine O
the NN stopwords O
time NN time O
of NN stopwords O
admission DT admission O
to NN stopwords O
a DT stopwords angstrom O
nursing RB nursing O
home NN home O
. . O

Fulminant CAPITAL NNP fulminant O
hepatitis NN hepatitis T
associated DT associate O
with NN stopwords O
hepatitis NN hepatitis T
A CAPITAL DT angstrom T
virus NN virus T
superinfection NN superinfection T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic O
hepatitis NN hepatitis T
C CAPITAL SYM degree_centigrade T

Since CAPITAL NNP O
few JJ stopwords few O
trials NN test O
have VB stopwords rich_person O
examined NN analyze O
the NN stopwords O
effects NN effects O
of NN stopwords O
therapeutic NN remedy O
supplementation NN supplement O
and DT stopwords O
their NN stopwords O
results NN consequence O
have VB stopwords rich_person O
been NN stopwords be O
variable NN variable O
, , O
further NN stopwords foster O
therapeutic NN remedy O
trials NN test O
are DT stopwords are O
required NN necessitate O
to NN stopwords O
examine NN analyze O
the NN stopwords O
role NN function O
of NN stopwords O
vitamin NN vitamin T
C CAPITAL SYM degree_centigrade T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
colds NNS cold D

The CAPITAL NNP O
Gram CAPITAL NNP gram O
stain NN stain O

Recent CAPITAL NNP Holocene O
experimental NN experimental O
data VB data O
also DT besides O
indicate NN bespeak O
that NN stopwords O
dioxins NN dioxin O
can VB stopwords can O
cause VB cause O
dysfunction NN dysfunction D
of NN stopwords D
the NN stopwords D
sexual NN sexual D
and DT stopwords D
thyroid NN thyroid_gland D
hormone NN hormone D
systems NN system D
and DT stopwords O
that NN stopwords O
the NN stopwords O
administration DT administration O
of NN stopwords O
dioxins NN dioxin O
induces NN induce O
several NN several O
conditions NNS conditions O
related NN associate O
to NN stopwords O
hormonal NN hormonal D
dysfunction NN dysfunction D

The CAPITAL NNP O
trial NN test O
was VB stopwords Washington O
stopped NN stop O
prematurely NN prematurely O
because NN stopwords O
of NN stopwords O
concern NNS concern O
about DT stopwords about O
the NN stopwords O
safety VB safety O
of NN stopwords O
the NN stopwords O
double-bolus NN T
injection NN injection T

The CAPITAL NNP O
time NN time O
frame NN frame O
of NN stopwords O
training NN training O
and DT stopwords O
recovery NN recovery O
is NN stopwords be O
also DT besides O
important JJ important O
since NN O
the NN stopwords O
consequences NNS consequence O
of NN stopwords O
negative JJ negative O
overtraining JJ O
comprise NNS consist O
an DT stopwords Associate_in_Nursing O
overtraining-response JJ O
continuum NNS continuum O
from JJ stopwords O
short NN short O
to NN stopwords O
long NN hanker O
term NN term O
effects NN effects O

Clinically CAPITAL NNP clinically O
, , O
there NN stopwords there O
was VB stopwords Washington O
no NNS stopwords no O
evidence NN evidence O
of NN stopwords O
transfer NN transportation D
lesions NN lesion D
, , O
tenderness NN tenderness O
, , O
or NN stopwords Oregon O
hallux VB big_toe D
subluxation NN subluxation D

Sex CAPITAL NNP sexual_activity O
differences NN difference O
in NN stopwords inch O
the NN stopwords O
use JJ use O
of NN stopwords O
asthma DT asthma D
drugs NN drug T
: : O
cross NNS cross O
sectional NN sectional O
study NN survey O

A CAPITAL DT angstrom O
predetermined NN predetermine O
design NN design O
for NN stopwords O
easier VB easy O
aesthetic DT aesthetic T
abdominoplasty DT abdominoplasty T

over JJ stopwords over O
6 DIGITS CD six O
cycles NNS cycle O
of NN stopwords O
therapy NN therapy O
, , O
amifostine DT T
significantly NN significantly O
reduced NN reduce O
haematological VB hematologic D
, , D
renal NN nephritic D
and DT stopwords D
neurological JJ neurological D
toxicities NN toxicity D
: : O
treatment NN treatment O
delays NN delay O
, , O
treatment NN treatment O
discontinuation NN discontinuance O
and DT stopwords O
days VB days O
in NN stopwords inch O
hospital NN hospital O
related NN associate O
to NN stopwords O
these NN stopwords O
adverse DT adverse O
events NN event O
were NN stopwords be O
also DT besides O
significantly NN significantly O
reduced NN reduce O
in NN stopwords inch O
patients VB patient O
receiving NN receive O
amifostine DT O
versus NN O
patients VB patient O
receiving NN receive O
chemotherapy NNS chemotherapy O
alone DT alone O

The CAPITAL NNP O
conservation NNS conservation O
of NN stopwords O
a DT stopwords angstrom O
shape NN shape O
property NN property O
and DT stopwords O
a DT stopwords angstrom O
proposal NN proposal O
about DT stopwords about O
the NN stopwords O
origin IN beginning O
of NN stopwords O
the NN stopwords O
conservations NNS conservation O

Ostashevsky CAPITAL NNP O
, , O
Radiat CAPITAL VB O

Long-term CAPITAL NNP long-run O
therapy NN therapy O
with NN stopwords O
long-acting NN long-acting T
octreotide JJ T
( ( T
Sandostatin-LAR CAPITAL VB T
) ) T
for NN stopwords O
the NN stopwords O
management VB management O
of NN stopwords O
acromegaly DT acromegaly D

DESIGN CAPITAL NNP design O
: : O
Cohort CAPITAL NNP cohort O
incidence NN incidence O
study NN survey O
of NN stopwords O
patients VB patient O
with NN stopwords O
retinoblastoma NN retinoblastoma O
followed JJ follow O
for NN stopwords O
a DT stopwords angstrom O
median NN median O
of NN stopwords O
20 DIGITS CD twenty O
years NN old_age O
, , O
and DT stopwords O
nested JJ nest O
case-control VB O
study NN survey O
of NN stopwords O
a DT stopwords angstrom O
radiation VB radiation O
dose-response NN O
relationship NN relationship O
for NN stopwords O
bone NN bone O
and DT stopwords O
soft NN soft O
tissue NN tissue O
sarcomas VB sarcoma O

Safety CAPITAL VB safety O
and DT stopwords O
efficacy NN efficacy O
are DT stopwords are O
crucial NNS crucial O
but NN stopwords merely O
separate NN offprint O
issues NN issue O
for NN stopwords O
vitamin NN vitamin O
and DT stopwords O
mineral NN mineral O
supplements NN addendum O

We CAPITAL NNP O
tested NN test O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
double-bolus NN T
alteplase DT T
is NN stopwords be O
at DT stopwords astatine O
least NN least O
as DT stopwords arsenic O
effective NN effective O
as DT stopwords arsenic O
accelerated DT accelerate O
infusion NN infusion O

Human CAPITAL NNP homo O
herpesvirus NN O
8 DIGITS CD eight O
variants NN discrepancy O
in NN stopwords inch O
sarcoid VB fleshy O
tissues NN tissue O

A CAPITAL DT angstrom O
discussion NN discussion O
of NN stopwords O
evaluative NN appraising O
techniques NN technique O
for NN stopwords O
assessing DT measure O
anxiety DT anxiety O
levels NN degree O
follows JJ follow O

Both CAPITAL NNP both O
pregnancies NN pregnancy O
were NN stopwords be O
complicated NNS complicate O
by NN stopwords by O
preterm NN O
labor NN labor O
and DT stopwords O
hypertension NN high_blood_pressure D

These CAPITAL NNP O
results NN consequence O
clearly NNS clearly O
show NN show O
that NN stopwords O
the NN stopwords O
short NN short O
form NN form O
acts DT Acts_of_the_Apostles O
as DT stopwords arsenic O
a DT stopwords angstrom O
dominant NN dominant O
negative JJ negative O
inhibitor NN inhibitor O
through NN stopwords done O
the NN stopwords O
formation NN formation O
of NN stopwords O
inactive NN inactive O
heterodimers NN O
, , O
resulting NN result O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
inhibition NN inhibition O
of NN stopwords O
Janus CAPITAL NNP Janus O
kinase NN kinase O
2 DIGITS CD two O
( ( O
JAK2 CAPITAL NNP O
) ) O
activation DT activation O

By CAPITAL NNP by O
initially JJ initially O
selecting NN choose O
for NN stopwords O
proviral NN O
integrants NN O
in NN stopwords inch O
hygromycin NN O
followed JJ follow O
by NN stopwords by O
shifting NN shift O
into NN stopwords O
neomycin JJ neomycin O
+ NN O
ganciclovir VB O
to NN stopwords O
select NN choose O
for NN stopwords O
S CAPITAL NN second O
sequence-mediated NN O
deletions NN omission O
, , O
switch JJ switch O
recombinations NN recombination O
can VB stopwords can O
be NN stopwords beryllium O
specifically NN specifically O
forestalled NN prevent O
in NN stopwords inch O
B CAPITAL NN bacillus O
cell NNS cell O
lines NN line O
whilst NN O
most NN stopwords most O
switch-incompetent JJ O
cells NNS cell O
do NN stopwords bash O
not JJ stopwords not O
survive NN survive O
secondary NN secondary O
selection NN choice O

Current CAPITAL NNP current O
progress NN advancement O
in NN stopwords inch O
early VB early O
pregnancy NN pregnancy O
investigation NN probe O

the NN stopwords O
cancer VB cancer O
and DT stopwords O
leukemia NN leukemia O
group NN group O
b NN bacillus O
performed NN perform O
a DT stopwords angstrom O
series NN series O
of NN stopwords O
studies NN survey O
involving NN involve O
sequential NN consecutive T
chemotherapy NNS chemotherapy T
followed JJ follow T
by NN stopwords by T
radiation VB radiation T
for NN stopwords O
patients VB patient O
with NN stopwords O
unresectable JJ D
stage NN phase D
iii NN three D
nsclc JJ D

Platelet-derived CAPITAL NNP O
growth NN growth O
factor VB factor O
activates DT trip O
a DT stopwords angstrom O
mammalian VB mammal O
Ste20 CAPITAL NNP O
coupled NNS match O
mitogen-activated NN O
protein NN protein O
kinase NN kinase O
in NN stopwords inch O
airway DT air_passage O
smooth JJ smooth O
muscle NN muscle O

Here CAPITAL NNP here O
we NN stopwords O
show NN show O
that NN stopwords O
individual NN person O
amino-acid DT O
enantiomers NN enantiomorph O
from JJ stopwords O
Murchison CAPITAL NNP O
are DT stopwords are O
enriched NN enrich O
in NN stopwords inch O
15N CD O
relative NN relative O
to NN stopwords O
their NN stopwords O
terrestrial NN tellurian O
counterparts NNS counterpart O
, , O
so NN stopwords sol O
confirming NNS confirm O
an DT stopwords Associate_in_Nursing O
extraterrestrial NN extraterrestrial_being O
source NN beginning O
for NN stopwords O
an DT stopwords Associate_in_Nursing O
L-enantiomer CAPITAL NNP O
excess NN excess O
in NN stopwords inch O
the NN stopwords O
Solar CAPITAL NNP solar O
System CAPITAL NNP system O
that NN stopwords O
may VB May O
predate NN predate O
the NN stopwords O
origin IN beginning O
of NN stopwords O
life NN life O
on NN stopwords on O
the NN stopwords O
Earth CAPITAL NN Earth O

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

The CAPITAL NNP O
utility JJ utility O
of NN stopwords O
the NN stopwords O
sensor NN detector O
design NN design O
was VB stopwords Washington O
demonstrated NN show O
by NN stopwords by O
using JJ exploitation O
the NN stopwords O
penicillin-dual-analyte NN O
biosensor NN O
to NN stopwords O
quantitate NN O
penicillin NN penicillin T
produced NN produce O
during NN stopwords O
a DT stopwords angstrom O
Penicillium CAPITAL NNP Penicillium O
chrysogenum NN O
fermentation NN agitation O

Treating CAPITAL NNP treat O
shoulder NN shoulder O
complaints NNS ailment O
in NN stopwords inch O
general NN general O
practice NN practice O

Percutaneous CAPITAL NNP transdermal T
drainage NN drain T
of NN stopwords O
hydatid NN hydatid D
cysts NNS cyst D

METHODS CAPITAL NNP method O
: : O
Between CAPITAL NNP between O
September CAPITAL NNP September O
, , O
1986 DIGITS CD O
, , O
and DT stopwords O
December CAPITAL NNP December O
, , O
1991 DIGITS CD O
, , O
469 DIGITS CD O
women NN woman O
with NN stopwords O
newly JJ newly O
diagnosed NN diagnose O
stage NN phase O
Ib CAPITAL PRP O
and DT stopwords O
IIa CAPITAL PRP O
cervical NNS cervical T
carcinoma VB carcinoma T
were NN stopwords be O
referred NN mention O
to NN stopwords O
our NN stopwords O
institute NN institute O

we NN stopwords O
reviewed NN review O
our NN stopwords O
vats NN VAT O
experience NN experience O
for NN stopwords O
therapeutic NN remedy T
metastasectomy NN T
of NN stopwords O
peripheral NN peripheral D
colorectal NNS colorectal D
pulmonary NN pneumonic D
metastases NN metastasis D

< NN O
TO_SEE CAPITAL NNP O
> NN O
purpose NN purpose O
: : O
the NN stopwords O
benefit NN benefit O
of NN stopwords O
whole-lung NN T
irradiation NN irradiation T
( ( T
wli NN T
) ) T
for NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
pulmonary NN pneumonic D
metastases NN metastasis D
( ( D
pm NN autopsy D
) ) D
of NN stopwords D
ewing NN D
sarcoma VB sarcoma D
family VB family D
tumors NN tumor D
( ( D
esft NN D
) ) D
is NN stopwords be O
unclear JJ ill-defined O

How CAPITAL NNP O
to NN stopwords O
decide NN decide O
on NN stopwords on O
the NN stopwords O
applicability DT applicability O
of NN stopwords O
clinical JJ clinical O
trial NN test O
results NN consequence O
to NN stopwords O
your NN stopwords O
patient VB patient O

Antibiotic CAPITAL DT antibiotic T
management VB management T
of NN stopwords O
sore NN sore D
throat NN throat D

Heterologous CAPITAL NNP heterologous O
vaccines NN vaccine T
: : O
proponent NN advocate O
sparks NN flicker O
some NN stopwords some O
interest NN interest O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
identify NN identify O
additional DT extra O
genetic NN familial O
risk NN hazard O
factors VB factor O
for NN stopwords O
late-onset NN O
AD CAPITAL DT ad O

Water CAPITAL WRB water O
fluoridation JJ fluoridation O
, , O
tooth NN tooth D
decay NN decay D
in NN stopwords inch O
5 DIGITS CD five O
year NN year O
olds JJ old O
, , O
and DT stopwords O
social NN sociable O
deprivation NN privation O
measured NN measure O
by NN stopwords by O
the NN stopwords O
Jarman CAPITAL NNP O
score JJ mark O
: : O
analysis DT analysis O
of NN stopwords O
data VB data O
from JJ stopwords O
British CAPITAL NNP British O
dental NN alveolar_consonant O
surveys NN survey O

Managing CAPITAL NNP pull_off O
the NN stopwords O
anxious DT anxious O
and DT stopwords O
phobic NN phobic O
dental NN alveolar_consonant O
patient VB patient O

General CAPITAL NNP general O
practice NN practice O
is NN stopwords be O
characterized NNS qualify O
by NN stopwords by O
particular NN particular O
emphasis NN emphasis O
on NN stopwords on O
the NN stopwords O
doctor-patient NN O
relationship NN relationship O
and DT stopwords O
on NN stopwords on O
biomedical NN biomedical O
, , O
personal NN personal O
and DT stopwords O
contextual NNS contextual O
perspectives NN position O
in NN stopwords inch O
diagnosis NN diagnosis O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
The CAPITAL NNP O
results NN consequence O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
evaluation NN evaluation O
and DT stopwords O
DPL CAPITAL NNP O
were NN stopwords be O
compared NNS compare O
with NN stopwords O
the NN stopwords O
findings NN findings O
of NN stopwords O
the NN stopwords O
celiotomy NNS O

The CAPITAL NNP O
effects NN effects O
of NN stopwords O
alanine DT alanine O
and DT stopwords O
glycine NN glycine O
substitution NN substitution O
for NN stopwords O
tryptophan NN tryptophan O
upon JJ O
the NN stopwords O
species NN species O
heterogeneity NN heterogeneity O
of NN stopwords O
gramicidin NN gramicidin O
A CAPITAL DT angstrom O
analogs DT analogue O
incorporated NN integrate O
into NN stopwords O
SDS CAPITAL NNP South_Dakota O
micelles NN micelle O
have VB stopwords rich_person O
been NN stopwords be O
investigated NN investigate O

promising NN promise O
results NN consequence O
have VB stopwords rich_person O
also DT besides O
been NN stopwords be O
found JJ found O
with NN stopwords O
oxaliplatin NN T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
non-hodgkin JJ D
's POS D
lymphoma NN lymphoma D
, , D
breast NN breast D
cancer VB cancer D
, , D
mesothelioma NN mesothelioma D
and DT stopwords D
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D

Some CAPITAL NNP some O
factors VB factor O
affecting DT affect O
the NN stopwords O
response NN response O
of NN stopwords O
the NN stopwords O
immature JJ immature O
mouse NN mouse O
to NN stopwords O
pregnant NN pregnant O
mare NN mare O
serum NN serum O
gonadotrophin NN gonadotropin O
and DT stopwords O
human NN homo O
chorionic NNS chorionic O
gonadotrophin NN gonadotropin O

Techniques CAPITAL NNP technique O
for NN stopwords O
erbium NN erbium T
: : T
YAG CAPITAL VB T
laser NN laser T
skin JJ skin T
resurfacing NN resurface T
: : O
initial JJ initial O
pearls NN pearl O
from JJ stopwords O
the NN stopwords O
first NN first O
100 DIGITS CD hundred O
patients VB patient O

Point-counterpoint CAPITAL NNP O

Dual-fractal CAPITAL NNP O
analysis DT analysis O
for NN stopwords O
antigen DT antigen O
-- : O
antibody DT antibody O
binding NN binding O
kinetics NN dynamics O
for NN stopwords O
biosensor NN O
applications DT application O

Statistical CAPITAL NNP statistical O
significant NN significant O
association DT association O
was VB stopwords Washington O
found JJ found O
between NN stopwords between O
B CAPITAL NN bacillus O

Long-term CAPITAL NNP long-run O
mortality NN mortality O
in NN stopwords inch O
patients VB patient O
after DT stopwords after O
a DT stopwords angstrom O
British CAPITAL NNP British O
trial NN test O
of NN stopwords O
anticoagulants DT anticoagulant T
in NN stopwords inch O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

We CAPITAL NNP O
assessed DT measure O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
head NN head O
louse NN louse O
infestation NN infestation O
and DT stopwords O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
1 DIGITS CD one T
% NN T
permethrin NN T
against DT stopwords O
head NN head D
lice NN louse D
in NN stopwords inch O
Kosovar CAPITAL NNP O
refugees NN refugee O

Long-term CAPITAL NNP long-run O
safety VB safety O
and DT stopwords O
effectiveness NN effectiveness O
of NN stopwords O
iron-chelation NN T
therapy NN therapy T
with NN stopwords T
deferiprone NN T
for NN stopwords O
thalassemia NN thalassemia D
major VB major D

We CAPITAL NNP O
report NN report O
the NN stopwords O
cDNA SYM complementary_DNA O
cloning NNS cloning O
, , O
partial NN partial_derivative O
genomic NN O
organization JJ organization O
, , O
and DT stopwords O
expression NN expression O
pattern VB form O
of NN stopwords O
Stra10 CAPITAL NNP O
, , O
a DT stopwords angstrom O
novel JJ novel O
retinoic NN O
acid-inducible DT O
gene NN gene O
in NN stopwords inch O
P19 CAPITAL NNP O
embryonal NN embryonic D
carcinoma VB carcinoma D
cells NNS cell O

a DT stopwords angstrom O
phase NN phase O
ii NN two O
study NN survey O
of NN stopwords O
fractionated NN fractionate O
administration DT administration O
of NN stopwords O
irinotecan JJ T
( ( T
cpt-11 NNS T
) ) T
and DT stopwords T
cisplatin NN T
( ( T
cddp SYM T
) ) T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
was VB stopwords Washington O
conducted NNS conduct O

Peripheral CAPITAL NNP peripheral T
retinal NN retinene T
cryotherapy NNS T
for NN stopwords O
postvitrectomy NN D
diabetic NN diabetic D
vitreous NN vitreous D
hemorrhage NN bleeding D
in NN stopwords inch O
phakic NN O
patients VB patient O

Heavy CAPITAL NNP heavy O
caffeine VB caffeine O
intake NN consumption O
in NN stopwords inch O
pregnancy NN pregnancy O
and DT stopwords O
sudden NN sudden D
infant NN baby D
death NN death D
syndrome NN syndrome D

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Evidence CAPITAL NNP evidence O
for NN stopwords O
impairment JJ damage O
of NN stopwords O
elastin NN elastin O
formation NN formation O

Binding CAPITAL NNP binding O
of NN stopwords O
sulfobromophthalein NN O
( ( O
BSP CAPITAL NNP O
) ) O
sodium NN sodium O
by NN stopwords by O
plasma NN plasma O
albumin DT albumin O

Thirty-five CAPITAL NNP thirty-five O
per NN O
cent NNS cent O
of NN stopwords O
patients VB patient O
died NN die O
within NN inside O
1 DIGITS CD one O
week NN week O
of NN stopwords O
the NN stopwords O
stroke NN stroke O

Amniotic CAPITAL DT amniotic D
fluid JJ fluid D
embolism NN embolism D

Mitomycin CAPITAL NNP mitomycin T
, , T
ifosfamide NN T
, , T
and DT stopwords T
cisplatin NN T
in NN stopwords inch O
unresectable JJ D
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
: : O
effects NN effects O
on NN stopwords on O
survival NN survival O
and DT stopwords O
quality NN quality O
of NN stopwords O
life NN life O
. . O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Intraperitoneal CAPITAL PRP T
injection NN injection T
of NN stopwords T
irradiated NN enlighten T
LLC-IL2 CAPITAL NNP T
cured NNS bring_around O
pre-existing NN preexistent D
LLC CAPITAL NNP D
peritoneal NN peritoneal D
tumors NN tumor D
and DT stopwords O
extended NN widen O
the NN stopwords O
survival NN survival O
of NN stopwords O
the NN stopwords O
mice NN mouse O
but NN stopwords merely O
did NN stopwords make O
not JJ stopwords not O
affect DT affect O
survival NN survival O
of NN stopwords O
mice NN mouse O
bearing NN bearing O
lung NN lung D
tumors NN tumor D
nor RB stopwords O
did NN stopwords make O
it NN stopwords information_technology O
affect DT affect O
the NN stopwords O
growth NN growth O
of NN stopwords O
s.c. NN D
tumors NN tumor D

The CAPITAL NNP O
stimulatory JJ O
effect NN consequence O
of NN stopwords O
luteinizing NN O
hormone NN hormone O
on NN stopwords on O
adenosine DT adenosine O
3 DIGITS CD three O
' '' O
, , O
5'-monophosphate CD O
accumulation DT accretion O
in NN stopwords inch O
corpus NNS principal O
luteum NN O
slices JJ slice O

Treatment CAPITAL NNP treatment O
for NN stopwords O
low-grade NN low-grade D
NHL CAPITAL NNP D
during NN stopwords O
the NN stopwords O
past VB past O
30 DIGITS CD thirty O
yr NN year O
has VB stopwords hour_angle O
consisted NNS dwell O
of NN stopwords O
high-dose NN T
radiation VB radiation T
and DT stopwords O
cytotoxic NNS cytotoxic T
agents DT agent T
, , O
administered DT administer O
alone DT alone O
or NN stopwords Oregon O
in NN stopwords inch O
combination NNS combination O
, , O
and DT stopwords O
high-dose NN T
therapy NN therapy T
with NN stopwords T
stem NN root T
cell NNS cell T
transplant NN graft T

Modification CAPITAL NNP alteration O
of NN stopwords O
leukemia NN leukemia O
L1210 CAPITAL NNP O
growth NN growth O
kinetics NN dynamics O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
antimetabolite DT antimetabolite O

Tubularized CAPITAL NNP T
incised NN incise T
plate NN home_plate T
hypospadias NN hypospadias T
repair NN repair T
for NN stopwords O
proximal NN proximal D
hypospadias NN hypospadias D

Neostigmine CAPITAL NNP neostigmine T
for NN stopwords O
acute DT acute_accent D
colonic NNS colonic_irrigation D
pseudo-obstruction NN D

Characterization CAPITAL NNP word_picture O
of NN stopwords O
cDNA SYM complementary_DNA O
clones NNS ringer O
in NN stopwords inch O
size-fractionated NN O
cDNA SYM complementary_DNA O
libraries NN library O
from JJ stopwords O
human NN homo O
brain NN brain O

Changes CAPITAL NNP change O
of NN stopwords O
the NN stopwords O
biochemical NN biochemical O
parameters NN parameter O
were NN stopwords be O
observed NN detect O
in NN stopwords inch O
the NN stopwords O
bone-specific NN O
isoenzyme NN O
of NN stopwords O
alkaline DT alkaline O
phosphatase NN phosphatase O
, , O
a DT stopwords angstrom O
marker NN marker O
of NN stopwords O
osteoblastic JJ O
activity DT activity O
, , O
in NN stopwords inch O
group NN group O
I CAPITAL PRP iodine O
giving NN giving O
additional DT extra O
evidence NN evidence O
of NN stopwords O
increased NN increase O
bone NN bone O
formation NN formation O

The CAPITAL NNP O
road NN road O
to NN stopwords O
justice NN justice O

Additional CAPITAL DT extra O
analyses DT analysis O
are DT stopwords are O
necessary JJ necessity O
to NN stopwords O
identify NN identify O
the NN stopwords O
chromosome NN chromosome O
12 DIGITS CD twelve O
susceptibility NN susceptibility O
gene NN gene O
for NN stopwords O
AD CAPITAL DT ad O
and DT stopwords O
to NN stopwords O
follow JJ follow O
up JJ stopwords up O
the NN stopwords O
regions NN region O
of NN stopwords O
interest NN interest O
on NN stopwords on O
chromosomes NN chromosome O
4 DIGITS CD four O
, , O
6 DIGITS CD six O
, , O
and DT stopwords O
20 DIGITS CD twenty O

570 DIGITS CD O
patients VB patient O
with NN stopwords O
osteosarcoma JJ osteosarcoma D
of NN stopwords D
the NN stopwords D
extremities NN extremity D
were NN stopwords be O
treated NN treat O
with NN stopwords O
five NN five O
different NN different O
protocols NN protocol O
of NN stopwords O
neoadjuvant JJ T
chemotherapy NNS chemotherapy T
at DT stopwords astatine O
rizzoli NN O
institute NN institute O
between NN stopwords between O
1983 DIGITS CD O
and DT stopwords O
1995 DIGITS CD O

On CAPITAL NNP on O
the NN stopwords O
standardization NN standardization O
of NN stopwords O
plastic NN plastic T
suture NN suture T

On CAPITAL NNP on O
the NN stopwords O
other JJ stopwords other O
hand VB hand O
, , O
the NN stopwords O
mechanism NN mechanism O
for NN stopwords O
FFA CAPITAL NNP O
transport NN conveyance O
from JJ stopwords O
its NN stopwords information_technology O
storage NN storage O
as DT stopwords arsenic O
triglycerides NN triglyceride O
in NN stopwords inch O
adipose DT adipose O
tissue NN tissue O
and DT stopwords O
muscle NN muscle O
to NN stopwords O
its NN stopwords information_technology O
place NN topographic_point O
of NN stopwords O
utilisation JJ use O
in NN stopwords inch O
heart NN heart O
, , O
skeletal NN skeletal O
muscle NN muscle O
, , O
kidney NN kidney O
and DT stopwords O
liver NN liver O
is NN stopwords be O
more NN stopwords More O
clearly NNS clearly O
understood JJ understand O

American CAPITAL DT American O
Heart CAPITAL NNP heart O
Association CAPITAL DT association O
urges JJ urge O
caution VB caution O
on NN stopwords on O
new JJ new O
diet NN diet O
drug NN drug O

the NN stopwords O
use JJ use O
of NN stopwords O
topical NN topical T
corticosteroids NNS corticosteroid T
has VB stopwords hour_angle O
revolutionised NN revolutionize O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
inflammatory NN inflammatory D
skin JJ skin D
diseases NN disease D

Trisomy CAPITAL NNP trisomy O
10 DIGITS CD ten O
in NN stopwords inch O
leukemia NN leukemia D

141 DIGITS CD O

Double-blind CAPITAL NNP O
study NN survey O
of NN stopwords O
pulsing NN pulsation T
magnetic VB magnetic T
field NN field T
effects NN effects O
on NN stopwords on O
multiple NN multiple D
sclerosis JJ sclerosis D
. . O

ABC CAPITAL DT rudiment O
of NN stopwords O
mental NN mental O
health NN health O

As CAPITAL DT arsenic O
discoveries NN discovery O
unfold JJ blossom O
, , O
a DT stopwords angstrom O
new JJ new O
urgency JJ urgency O
to NN stopwords O
bring NN bring O
genetic NN familial O
literacy NN literacy O
to NN stopwords O
physicians NN doctor O

many VB many O
endobronchial NN T
treatment NN treatment T
modalities NN modality T
are DT stopwords are O
available DT available O
to NN stopwords O
supplement NN addendum O
traditional NN traditional O
therapies NN therapy O
for NN stopwords O
advanced DT advance D
lung NN lung D
cancer VB cancer D

The CAPITAL NNP O
results NN consequence O
underline JJ underscore O
the NN stopwords O
usefulness JJ utility O
of NN stopwords O
the NN stopwords O
BTA CAPITAL NNP O
6q21-31 CD O
library NN library O
for NN stopwords O
targeted VB target O
isolation NN isolation O
of NN stopwords O
unique JJ alone O
sequences NN sequence O
that NN stopwords O
are DT stopwords are O
specific NN particular O
for NN stopwords O
the NN stopwords O
dissected NN dissect O
chromosomal NN chromosomal O
region NN region O
as DT stopwords arsenic O
demonstrated NN show O
here NN stopwords here O
by NN stopwords by O
the NN stopwords O
isolation NN isolation O
of NN stopwords O
microsatellite NN O
markers NN marker O

Treatment CAPITAL NNP treatment O
strategy NN scheme O
for NN stopwords O
mucin-producing NN D
intrahepatic NN D
cholangiocarcinoma NNS D
: : O
value NN value O
of NN stopwords O
percutaneous NN transdermal T
transhepatic NN T
biliary NN bilious T
drainage NN drain T
and DT stopwords O
cholangioscopy NNS T

Sudden CAPITAL NNP sudden O
cryptococcal NNS D
deafness NN deafness D

prophylactic NN preventive T
cranial NNS cranial T
irradiation NN irradiation T
( ( T
pci NN T
) ) T
has VB stopwords hour_angle O
been NN stopwords be O
demonstrated NN show O
to NN stopwords O
significantly NN significantly O
reduce NN reduce O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
brain NN brain O
relapse NN backsliding O
from JJ stopwords O
limited NN express D
disease NN disease D
small-cell JJ D
lung NN lung D
cancer VB cancer D
( ( D
ld NN D
sclc JJ D
) ) D
, , O
but NN stopwords merely O
concerns NNS concern O
about DT stopwords about O
neurologic JJ neurological O
toxicity NN toxicity O
remain NN stay O

This CAPITAL NNP O
presentation NN presentation O
summarizes NN sum_up O
the NN stopwords O
debate NN argument O
on NN stopwords on O
the NN stopwords O
suggested NN propose O
progressive NN progressive O
impairment JJ damage O
of NN stopwords O
semen NN semen O
quality NN quality O
( ( O
the NN stopwords O
`` `` O
sperm NN sperm O
fall VB fall O
'' POS O
) ) O
in NN stopwords inch O
the NN stopwords O
last NN stopping_point O
forty NN forty O
years NN old_age O
in NN stopwords inch O
the NN stopwords O
developed NN develop O
countries NNS state O

CONCLUSION CAPITAL NNP decision O
: : O
Methylphenidate CAPITAL NNP methylphenidate T
is NN stopwords be O
effective NN effective O
in NN stopwords inch O
treating NN treat O
children JJ child O
with NN stopwords O
epilepsy NN epilepsy D
and DT stopwords O
ADHD CAPITAL DT attention_deficit_disorder D
and DT stopwords O
safe VB safe O
in NN stopwords inch O
children JJ child O
who NN stopwords World_Health_Organization O
are DT stopwords are O
seizure JJ seizure O
free JJ free O

Peptide CAPITAL NNP peptide O
nucleic JJ O
acid DT acid O
( ( O
PNA CAPITAL NNP O
) ) O
from JJ stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O
recognition NN recognition O
to NN stopwords O
antisense DT O
and DT stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O
structure NN structure O

Ethical CAPITAL NNP ethical O
issues NN issue O
in NN stopwords inch O
interventional NN T
radiology VB radiology T

< NN O
/TO_SEES JJ O
> NN O
OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
test NN trial O
the NN stopwords O
hypothesis NN hypothesis O
that NN stopwords O
liver NN liver O
glutamine NN glutamine O
synthetase NN O
deficiency NN lack O
may VB May O
explain NN explain O
hyperammonemia NN D
in NN stopwords inch O
patients VB patient O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
had VB stopwords have O
organ JJ organ T
transplantation NN transplant T
or NN stopwords Oregon O
are DT stopwords are O
receiving NN receive O
chemotherapy NNS chemotherapy T

the NN stopwords O
aim DT purpose O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
the NN stopwords O
evaluation NN evaluation O
of NN stopwords O
both NN stopwords both O
the NN stopwords O
antitumour DT anticancer O
activity DT activity O
and DT stopwords O
toxicity NN toxicity O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
immunochemotherapeutic JJ T
regimen NN regimen T
consisting NNS dwell T
of NN stopwords T
interferon-alpha2b NN T
and DT stopwords T
interleukin-2 NN T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
fotemustine JJ T
for NN stopwords O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
melanoma NN melanoma D

based VB establish O
on NN stopwords on O
these NN stopwords O
results NN consequence O
, , O
the NN stopwords O
irinotecan JJ T
and DT stopwords T
cisplatin NN T
combination NNS combination T
is NN stopwords be O
a DT stopwords angstrom O
new JJ new O
standard NN standard O
regimen NN regimen O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
extensive-disease NN D
small-cell JJ D
lung NN lung D
cancer VB cancer D

We CAPITAL NNP O
assessed DT measure O
G-CSF CAPITAL NNP T
as DT stopwords arsenic O
adjuvant DT adjuvant O
therapy NN therapy O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
severe NN severe D
foot JJ foot D
infections NN infection D
in NN stopwords inch D
diabetic NN diabetic D
patients VB patient D

Exposure CAPITAL NNP exposure O
to NN stopwords O
dioxins NN dioxin O
occurs JJ happen O
mainly VB chiefly O
via NN O
the NN stopwords O
ingestion NN consumption O
of NN stopwords O
contaminated NNS pollute O
food JJ food O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Repeated CAPITAL NNP repeat O
courses NNS course O
of NN stopwords O
steroids NN steroid O
in NN stopwords inch O
preterm NN O
membrane NN membrane O
rupture NN rupture O
do NN stopwords bash O
not JJ stopwords not O
increase NN addition O
the NN stopwords O
risk NN hazard O
of NN stopwords O
histologic NN histological O
chorioamnionitis NNS O

Toxic CAPITAL NNP toxic D
shock NN daze D
syndrome NN syndrome D
without NN O
rash VB rash D
in NN stopwords inch O
a DT stopwords angstrom O
young NN young O
child JJ child O
: : O
link NN link O
with NN stopwords O
syndrome NN syndrome O
of NN stopwords O
hemorrhagic NN hemorrhagic D
shock NN daze D
and DT stopwords O
encephalopathy NN brain_disorder D
? . O

Role CAPITAL NNP function O
of NN stopwords O
the NN stopwords O
ketogenic NN T
diet NN diet T
in NN stopwords inch O
children JJ child O
with NN stopwords O
intractable NN intractable D
seizures JJ seizure D
. . O

The CAPITAL NNP O
starting NN start O
dose NN dose O
of NN stopwords O
ropinirole NN T
was VB stopwords Washington O
0.25 LS O
mg NN milligram O
tid NN O
with NN stopwords O
titration NN titration O
to NN stopwords O
at DT stopwords astatine O
least NN least O
1.5 CD O
mg NN milligram O
tid NN O
( ( O
maximum VB maximum O
dose NN dose O
, , O
8 DIGITS CD eight O
mg NN milligram O
tid NN O
) ) O

RESULTS CAPITAL NNP consequence O
: : O
Clinical CAPITAL NNP clinical O
trials NN test O
of NN stopwords O
UFT CAPITAL NNP T
published NN print O
in NN stopwords inch O
the NN stopwords O
Western CAPITAL NNP Western O
world NN universe O
have VB stopwords rich_person O
included NN include O
581 DIGITS CD O
patients VB patient O
with NN stopwords O
colorectal NNS colorectal D
cancer VB cancer D

METHODS CAPITAL NNP method O
: : O
Thirty-seven CAPITAL NNP thirty-seven O
children JJ child O
with NN stopwords O
a DT stopwords angstrom O
history NN history O
of NN stopwords O
constipation NNS constipation D
( ( O
i.e NN O
. . O
, , O
pain IN pain O
and DT stopwords O
difficulty NN trouble O
or NN stopwords Oregon O
delay NN delay O
in NN stopwords inch O
defecation NN defecation O
for NN stopwords O
> NN O
3 DIGITS CD three O
months NN calendar_month O
) ) O
were NN stopwords be O
recruited NN enroll O
and DT stopwords O
randomly VB randomly O
assigned DT delegate O
to NN stopwords O
8 DIGITS CD eight O
weeks NN week O
of NN stopwords O
treatment NN treatment O
with NN stopwords O
either NN either O
cisapride NN T
, , O
0.2 LS O
mg/kg NN O
three NN three O
times NN times O
daily IN daily O
, , O
or NN stopwords Oregon O
matching VB match O
placebo NN placebo O
after DT stopwords after O
a DT stopwords angstrom O
2-week CD O
run-in NN quarrel O
period NN time_period O
in NN stopwords inch O
a DT stopwords angstrom O
double-blind NN O
, , O
parallel-group NN O
study NN survey O
design NN design O

Hormonal CAPITAL NNP hormonal O
phenomenon NN phenomenon O
after DT stopwords after O
the NN stopwords O
excision NN deletion O
of NN stopwords O
hydatiform NN O
mole NN gram_molecule O

amifostine DT T
has VB stopwords hour_angle O
also DT besides O
been NN stopwords be O
shown NN show O
to NN stopwords O
stimulate JJ stimulate O
haematopoietic VB hematopoietic O
stem NN root O
cells NNS cell O
and DT stopwords O
has VB stopwords hour_angle O
been NN stopwords be O
investigated NN investigate O
as DT stopwords arsenic O
a DT stopwords angstrom O
therapy NN therapy O
for NN stopwords O
patients VB patient O
with NN stopwords O
myelodysplastic NN D
syndrome NN syndrome D
in NN stopwords inch O
number JJ number O
of NN stopwords O
small JJ small O
preliminary NN preliminary O
studies NN survey O

PATIENTS CAPITAL VB patient O
: : O
36 DIGITS CD thirty-six O
patients VB patient O
with NN stopwords O
cardiac VB cardiac D
amyloid DT amyloid D
heart NN heart D
disease NN disease D
, , O
of NN stopwords O
whom NN stopwords O
12 DIGITS CD twelve O
had VB stopwords have O
familial VB familial O
and DT stopwords O
24 DIGITS CD twenty-four O
had VB stopwords have O
primary NN primary O
AL CAPITAL DT aluminum O
amyloidosis DT amyloidosis D

Polycystic CAPITAL NNP O
ovaries NN ovary O
associated DT associate O
with NN stopwords O
congenital NNS congenital D
adrenal DT adrenal_gland D
hyperplasia NN hyperplasia D

Quality-of-life CAPITAL NNP O
assessments DT appraisal O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
mild NN mild O
to NN stopwords O
moderate NN centrist O
disease NN disease O
show NN show O
that NN stopwords O
inhaled NN inhale T
fluticasone JJ T
propionate NN T
achieved DT achieve O
improvements JJ improvement O
which NN stopwords O
were NN stopwords be O
deemed NN deem O
to NN stopwords O
be NN stopwords beryllium O
clinically JJ clinically O
meaningful NN meaningful O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
mild NN mild O
to NN stopwords O
moderate NN centrist O
asthma DT asthma D
; : O
these NN stopwords O
changes NNS change O
were NN stopwords be O
significantly NN significantly O
greater NN greater O
than NN stopwords O
those NN stopwords O
achieved DT achieve O
with NN stopwords O
oral NN oral O
zafirlukast NN O
, , O
inhaled NN inhale O
triamcinolone NN triamcinolone O
acetonide DT O
or NN stopwords Oregon O
placebo NN placebo O

The CAPITAL NNP O
primary NN primary O
outcome JJ result O
measures NN measure O
were NN stopwords be O
5-year CD O
survival NN survival O
and DT stopwords O
the NN stopwords O
rate VB rate O
of NN stopwords O
complications NNS complication O

we NN stopwords O
attempted DT try O
a DT stopwords angstrom O
new JJ new O
regimen NN regimen O
of NN stopwords O
intermittent NN intermittent O
administration DT administration O
of NN stopwords O
5-fu CD T
and DT stopwords T
low-dose NN T
isovorin NN T
( ( T
f.i NN T
) ) T
to NN stopwords O
four JJ four O
patients VB patient O
with NN stopwords O
advanced DT advance O
and DT stopwords O
recurrent NN perennial O
colon NNS colon D
cancer VB cancer D

several NN several O
newer JJ new O
chemotherapeutic NNS chemotherapeutic T
drugs NN drug T
have VB stopwords rich_person O
recently NN recently O
been NN stopwords be O
shown NN show O
to NN stopwords O
have VB stopwords rich_person O
significant NN significant O
activity DT activity O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
untreated JJ untreated D
or NN stopwords Oregon D
relapsed NN get_worse D
sclc JJ D

A CAPITAL DT angstrom O
two-credits NN O
per NN O
semester NN semester O
clinical JJ clinical O
medicine NN medicine O
course NNS course O
was VB stopwords Washington O
established NN establish O
in NN stopwords inch O
the NN stopwords O
Department CAPITAL NNP department O
of NN stopwords O
Physical CAPITAL NNP physical O
Medicine CAPITAL NNP medicine O
and DT stopwords O
Rehabilitation CAPITAL NNP rehabilitation O
( ( O
PM CAPITAL NNP autopsy O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
R CAPITAL NN roentgen O
) ) O
in NN stopwords inch O
cooperation NNS cooperation O
with NN stopwords O
the NN stopwords O
Johns CAPITAL NNP Johns O
Hopkins CAPITAL NNP Hopkins O
University CAPITAL NNP university O
undergraduate JJ undergraduate O
Human CAPITAL NNP homo O
Biology CAPITAL NNP biology O
faculty VB faculty O
to NN stopwords O
present NN present O
the NN stopwords O
variety NN assortment O
of NN stopwords O
inpatient NN inpatient O
consultation NNS consultation O
personnel NN force O
, , O
units JJ unit_of_measurement O
, , O
patient VB patient O
diagnostic NN diagnostic O
groups NN group O
, , O
and DT stopwords O
functional JJ functional O
problems NN problem O

Intra-arterial CAPITAL PRP O
infusion NN infusion O
of NN stopwords O
the NN stopwords O
head NN head O
and DT stopwords O
neck JJ neck O

induction NN initiation T
chemotherapy NNS chemotherapy T
( ( T
cisplatin NN T
+ NN T
vinorelbine NN T
) ) T
is NN stopwords be O
found JJ found O
to NN stopwords O
be NN stopwords beryllium O
markedly NN markedly O
effective NN effective O
for NN stopwords O
squamous NN D
cell NNS cell D
lung NN lung D
carcinoma VB carcinoma D
with NN stopwords D
sarcoidosis VB sarcoidosis D
-- : O
a DT stopwords angstrom O
case VB case O
report NN report O

CONCLUSIONS CAPITAL NNP decision O
: : O
Using CAPITAL NNP exploitation O
logistic NN logistic O
regression NN arrested_development O
analysis DT analysis O
, , O
we NN stopwords O
provide NN supply O
a DT stopwords angstrom O
method NN method O
for NN stopwords O
evaluating NN measure O
the NN stopwords O
probability NN probability O
of NN stopwords O
a DT stopwords angstrom O
woman NN woman O
's POS O
carrying VB transport O
a DT stopwords angstrom O
deleterious NN deleterious O
BRCA1 CAPITAL NNP O
mutation NN mutant O
for NN stopwords O
a DT stopwords angstrom O
wide NN wide O
range VB scope O
of NN stopwords O
cases VB case O
, , O
which NN stopwords O
can VB stopwords can O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
important JJ important O
tool NN tool O
for NN stopwords O
clinicians JJ clinician O
as DT stopwords arsenic O
they NN stopwords O
incorporate NN integrate O
genetic NN familial O
susceptibility NN susceptibility O
testing NN testing O
into NN stopwords O
their NN stopwords O
medical NN checkup O
practice NN practice O

PURPOSE CAPITAL NNP purpose O
: : O
We CAPITAL NNP O
report NN report O
a DT stopwords angstrom O
multicenter NN O
experience NN experience O
using JJ exploitation O
tubularized NN T
incised NN incise T
plate NN home_plate T
urethroplastym JJ T
for NN stopwords O
proximal NN proximal D
hypospadias NN hypospadias D

Immunogenicity CAPITAL PRP immunogenicity O
of NN stopwords O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
vaccine NN vaccine T
in NN stopwords inch O
term NN term O
and DT stopwords O
preterm NN O
infants NN baby O

Both CAPITAL NNP both O
physiological NN physiological O
and DT stopwords O
pathological VB pathological O
materials VB material O
correlate NNS correlate O
well NN well O
with NN stopwords O
the NN stopwords O
declared NN declare O
values NN values O

INTERPRETATION CAPITAL PRP interpretation O
: : O
G-CSF CAPITAL NNP T
treatment NN treatment T
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
improved JJ better O
clinical JJ clinical O
outcome JJ result O
of NN stopwords O
foot JJ foot D
infection NN infection D
in NN stopwords inch D
diabetic NN diabetic D
patients VB patient D

We CAPITAL NNP O
describe NN describe O
2 DIGITS CD two O
cases VB case O
in NN stopwords inch O
which NN stopwords O
intraoperative NN O
transesophageal NN O
echocardiography NN echocardiography O
detected NN detect O
complications NNS complication O
related NN associate O
to NN stopwords O
the NN stopwords O
proximal NN proximal O
coronary NNS coronary_thrombosis O
arteries DT artery O
during NN stopwords O
homograft NN homograft T
aortic DT aortal T
valve NN valve T
and DT stopwords T
root NN root T
replacement NN replacement T

This CAPITAL NNP O
provides NN supply O
us JJ United_States O
with NN stopwords O
a DT stopwords angstrom O
unique JJ alone O
opportunity JJ opportunity O
to NN stopwords O
study NN survey O
the NN stopwords O
biological NN biological O
consequences NNS consequence O
of NN stopwords O
each VB stopwords each O
of NN stopwords O
these NN stopwords O
two NN two O
major VB major O
UV-induced CAPITAL NNP O
photoproducts NN O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
intact NN integral O
living NN life O
system NN system O

Excimer CAPITAL NNP T
laser NN laser T
assisted DT help T
in NN stopwords inch T
situ NN T
keratomileusis NN T
for NN stopwords O
hyperopia NN hyperopia D

Nagrestipen CAPITAL NNP O

Retrospective CAPITAL NNP retrospective O
comparison NNS comparison O
of NN stopwords O
techniques NN technique O
to NN stopwords O
prevent NN prevent O
secondary NN secondary D
cataract VB cataract D
formation NN formation D
after DT stopwords after O
posterior NN buttocks O
chamber NNS chamber O
intraocular NN O
lens NN lens T
implantation JJ implantation T
in NN stopwords inch O
infants NN baby O
and DT stopwords O
children JJ child O

Sida CAPITAL NNP Sida T
cordifolia NNS T
L. CAPITAL NNP T
( ( T
Malvaceae CAPITAL NNP Malvaceae T
) ) T
is NN stopwords be O
used JJ use O
in NN stopwords inch O
folk JJ folk O
medicine NN medicine O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
inflammation NN inflammation D
of NN stopwords D
the NN stopwords D
oral NN oral D
mucosa NN mucous_membrane D
, , D
blenorrhea NN D
, , D
asthmatic DT asthmatic D
bronchitis NN bronchitis D
and DT stopwords D
nasal RB nasal_consonant D
congestion NNS congestion D

Mutants CAPITAL NNP mutant O
of NN stopwords O
cholera NNS cholera O
toxin NN toxin O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
effective NN effective O
and DT stopwords O
safe VB safe O
adjuvant DT adjuvant O
for NN stopwords O
nasal RB nasal_consonant D
influenza NN influenza D
vaccine NN vaccine T

The CAPITAL NNP O
Federated CAPITAL NNP federate O
Council CAPITAL NNP council O
of NN stopwords O
Internal CAPITAL PRP internal O
Medicine CAPITAL NNP medicine O
has VB stopwords hour_angle O
developed NN develop O
a DT stopwords angstrom O
resource NN resource O
guide NN usher O
to NN stopwords O
help NN aid O
internal NN internal O
medicine NN medicine O
residency NN residency O
programs NN plan O
produce NN produce O
internists NN internist O
who NN stopwords World_Health_Organization O
are DT stopwords are O
prepared NN fix O
for NN stopwords O
today NN today O
's POS O
practice NN practice O
of NN stopwords O
internal NN internal O
medicine NN medicine O
and DT stopwords O
the NN stopwords O
challenges NNS challenge O
of NN stopwords O
practice NN practice O
in NN stopwords inch O
the NN stopwords O
future JJ future O

Traditionally CAPITAL NNP traditionally O
, , O
the NN stopwords O
therapy NN therapy O
of NN stopwords O
symptomatic NN diagnostic D
bronchiectasis NN D
is NN stopwords be O
based VB establish O
on NN stopwords on O
antibiotics DT antibiotic T
, , T
antibronchoobstructive DT T
medication NN medicine T
, , T
and DT stopwords T
chest NNS thorax T
physical NN physical T
therapy NN therapy T

The CAPITAL NNP O
early VB early O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
, , O
associated DT associate O
with NN stopwords O
tau VB tau O
( ( O
fast VB fast O
) ) O
, , O
is NN stopwords be O
predicted NN predict O
to NN stopwords O
be NN stopwords beryllium O
1.7 CD O
+/- NN O
0.7 LS O
h NN hydrogen O
, , O
and DT stopwords O
the NN stopwords O
late NN late O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
, , O
associated DT associate O
with NN stopwords O
tau VB tau O
( ( O
slow NN decelerate O
) ) O
, , O
is NN stopwords be O
predicted NN predict O
to NN stopwords O
be NN stopwords beryllium O
about DT stopwords about O
5 DIGITS CD five O
h. NN O
Both CAPITAL NNP both O
values NN values O
are DT stopwords are O
in NN stopwords inch O
excellent NN excellent O
agreement DT agreement O
with NN stopwords O
the NN stopwords O
times NN times O
at DT stopwords astatine O
which NN stopwords O
changing NNS change O
from JJ stopwords O
growth NN growth O
medium NN medium O
to NN stopwords O
conditioned NNS condition O
medium NN medium O
no NNS stopwords no O
longer NN longer O
gives NN give O
the NN stopwords O
full JJ full_moon O
recovery NN recovery O
seen NN see O
in NN stopwords inch O
conditioned NNS condition O
medium NN medium O
only JJ stopwords lone O
( ( O
the NN stopwords O
early VB early O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
) ) O
, , O
and DT stopwords O
the NN stopwords O
time NN time O
when NN stopwords O
changing NNS change O
from JJ stopwords O
growth NN growth O
medium NN medium O
to NN stopwords O
conditioned NNS condition O
medium NN medium O
produces NN produce O
no NNS stopwords no O
further NN stopwords foster O
increase NN addition O
in NN stopwords inch O
survival NN survival O
( ( O
the NN stopwords O
late NN late O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
) ) O
, , O
respectively NN respectively O

Although CAPITAL DT O
long-term NN long-run O
survival NN survival O
can VB stopwords can O
be NN stopwords beryllium O
achieved DT achieve O
by NN stopwords by O
successful NN successful O
corrective NNS corrective T
surgery NN surgery T
, , O
the NN stopwords O
associated DT associate O
structural NN structural O
defects NN defect O
such NN stopwords such O
as DT stopwords arsenic O
large NN large D
meningomyelocele NN D
and DT stopwords O
severe NN severe O
limb NN limb D
aplasia DT aplasia D
or NN stopwords Oregon O
hypoplasia NN hypoplasia D
, , O
as DT stopwords arsenic O
seen NN see O
in NN stopwords inch O
our NN stopwords O
patient VB patient O
, , O
can VB stopwords can O
influence NN influence O
the NN stopwords O
patient VB patient O
's POS O
quality NN quality O
of NN stopwords O
life NN life O
. . O

among DT O
these NN stopwords O
, , O
the NN stopwords O
gemcitabine/cisplatin NN T
study NN survey O
protocol NN protocol O
( ( O
gc NN gigahertz O
) ) O
, , O
set NN set O
up JJ stopwords up O
in NN stopwords inch O
a DT stopwords angstrom O
phase NN phase O
ii NN two O
study NN survey O
for NN stopwords O
patients VB patient O
with NN stopwords O
stage NN phase D
iiia NN D
n2 RB D
nsclc JJ D
, , O
was VB stopwords Washington O
very NN stopwords very O
effective NN effective O
( ( O
objective NN aim O
response NN response O
( ( O
or NN stopwords Oregon O
) ) O
: : O
70.2 CD O
% NN O
; : O
median NN median O
survival NN survival O
: : O
19 DIGITS CD nineteen O
months NN calendar_month O
) ) O
and DT stopwords O
should NN stopwords O
be NN stopwords beryllium O
promising NN promise O
for NN stopwords O
stages NN phase O
ib NN O
and DT stopwords O
ii NN two O

METHODS CAPITAL NNP method O
: : O
Hospital CAPITAL NNP hospital O
record NN record O
review NN reappraisal O
was VB stopwords Washington O
conducted NNS conduct O
of NN stopwords O
2 DIGITS CD two O
cases VB case O

For CAPITAL NNP O
example NN example O
, , O
during NN stopwords O
exercise NN exercise O
on NN stopwords on O
a DT stopwords angstrom O
cycle NNS cycle O
ergometer NN dynamometer O
, , O
nonplasma JJ O
FFAs CAPITAL NNP O
and DT stopwords O
plasma NN plasma O
FFAs CAPITAL NNP O
contribute NNS lend O
40 DIGITS CD forty O
% NN O
, , O
and DT stopwords O
carbohydrates VB carbohydrate O
60 DIGITS CD sixty O
% NN O
, , O
of NN stopwords O
the NN stopwords O
total NN sum O
calculated VB calculate O
amount DT sum O
of NN stopwords O
energy NN energy O
expenditure NN outgo O
before NN stopwords earlier O
exercise NN exercise O
and DT stopwords O
vice NN frailty O
versa NN O
after DT stopwords after O
exercise NN exercise O
( ( O
60 DIGITS CD sixty O
% NN O
nonplasma JJ O
and DT stopwords O
plasma NN plasma O
FFAs CAPITAL NNP O
and DT stopwords O
40 DIGITS CD forty O
% NN O
carbohydrates VB carbohydrate O
) ) O

Embryonic CAPITAL NNP embryonic O
stem NN root O
cells NNS cell O
and DT stopwords O
hematopoietic NN hematopoietic O
stem NN root O
cell NNS cell O
biology NN biology O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

A CAPITAL DT angstrom O
positive NN positive O
cannabinoids VB O
workplace NN workplace O
drug NN drug O
test NN trial O
following JJ following O
the NN stopwords O
ingestion NN consumption O
of NN stopwords O
commercially NNS commercially O
available DT available O
hemp NN hemp O
seed NN seed O
oil NN oil O

The CAPITAL NNP O
lesion NN lesion D
was VB stopwords Washington O
resected NN resect O
by NN stopwords by O
video-assisted NN T
thoracoscopic NN T
surgery NN surgery T
because NN stopwords O
it NN stopwords information_technology O
was VB stopwords Washington O
suspected NN suspect O
of NN stopwords O
being NN stopwords being O
a DT stopwords angstrom O
lung NN lung O
abscess DT abscess O
that NN stopwords O
had VB stopwords have O
caused VB cause O
repeated NN repeat O
episodes NN episode O
of NN stopwords O
inflammation NN inflammation O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
review NN reappraisal O
the NN stopwords O
clinical JJ clinical O
effectiveness NN effectiveness O
and DT stopwords O
cost-effectiveness NNS O
of NN stopwords O
combination NNS combination T
therapy NN therapy T
with NN stopwords T
interferon NN interferon T
alfa DT T
and DT stopwords T
ribavirin NN ribavirin T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D

Management CAPITAL NNP management O
of NN stopwords O
dyslipidemia NN D
in NN stopwords inch O
adults DT adult O
with NN stopwords O
diabetes NN diabetes D

Patient CAPITAL VB patient O
consent NNS consent O
for NN stopwords O
publication NN publication O
and DT stopwords O
the NN stopwords O
health NN health O
of NN stopwords O
the NN stopwords O
public NN populace O

Serotonin CAPITAL NNP serotonin O
as DT stopwords arsenic O
a DT stopwords angstrom O
regulator NN regulator O
of NN stopwords O
hypothalamic-pituitary-interrenal NN O
activity DT activity O
in NN stopwords inch O
teleost NN teleost_fish O
fish NN fish O

But CAPITAL NNP merely O
the NN stopwords O
origin IN beginning O
of NN stopwords O
life NN life O
required NN necessitate O
, , O
owing IN owe O
to NN stopwords O
conformational NNS O
constraints NNS constraint O
, , O
the NN stopwords O
almost DT about O
exclusive NN exclusive O
selection NN choice O
of NN stopwords O
either NN either O
L- CAPITAL NNP O
or NN stopwords Oregon O
D-enantiomers CAPITAL NNP O
, , O
and DT stopwords O
the NN stopwords O
question NN question O
of NN stopwords O
why NN stopwords why O
living NN life O
systems NN system O
on NN stopwords on O
the NN stopwords O
Earth CAPITAL NN Earth O
consist NNS dwell O
of NN stopwords O
L-enantiomers CAPITAL NNP O
rather VB rather O
than NN stopwords O
D-enantiomers CAPITAL NNP O
is NN stopwords be O
unresolved JJ unsolved O

Both CAPITAL NNP both O
hostfinding NN O
responses NN response O
in NN stopwords inch O
both NN stopwords both O
species NN species O
were NN stopwords be O
induced NN induce O
by NN stopwords by O
glycoconjugates NN O
with NN stopwords O
a DT stopwords angstrom O
molecular NN molecular O
weight NN weight O
of NN stopwords O
> NN O
30 DIGITS CD thirty O
kDa NN O
that NN stopwords O
were NN stopwords be O
sensitive NN medium O
to NN stopwords O
hydrolysis NN hydrolysis O
with NN stopwords O
pronase NN O
E CAPITAL NN vitamin_E O
and DT stopwords O
oxidation IN oxidation O
with NN stopwords O
NaIO4 CAPITAL IN O

The CAPITAL NNP O
sensitivity NN sensitivity O
and DT stopwords O
specificity NN specificity O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
elevated NN elevated_railway O
threshold NN threshold O
on NN stopwords on O
the NN stopwords O
neonatal JJ neonatal O
BAEP CAPITAL IN O
for NN stopwords O
detecting NN detection O
subsequent NN subsequent O
hearing NN hearing O
loss NN loss O
, , O
and DT stopwords O
the NN stopwords O
relationship NN relationship O
of NN stopwords O
any DT stopwords any O
neonatal JJ neonatal O
BAEP CAPITAL IN O
abnormality DT abnormality O
to NN stopwords O
language NN language O
or NN stopwords Oregon O
developmental NN developmental O
disorders NN disorder O
in NN stopwords inch O
infancy NN infancy O
, , O
were NN stopwords be O
calculated VB calculate O

`` `` O
Chronic CAPITAL NNP chronic D
pancreatitis VB pancreatitis D
`` `` O
and DT stopwords O
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
pancreas VB pancreas D

Ropinirole CAPITAL NNP T
monotherapy NN T
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
effective NN effective O
and DT stopwords O
well-tolerated NN O
therapeutic NN remedy O
option JJ option O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
early VB early D
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D

Pins CAPITAL NNP pin O
and DT stopwords O
Rubbers CAPITAL NNP rubber O
Traction CAPITAL NNP grip O
System CAPITAL NNP system O

Three CAPITAL NNP three O
consecutive NNS back-to-back O
phase NN phase O
II CAPITAL PRP two O
studies NN survey O
of NN stopwords O
recombinant NN recombinant T
interferon NN interferon T
alfa-2a DT T
in NN stopwords inch O
advanced DT advance D
malignant VB malignant D
melanoma NN melanoma D

conclusions NNS decision O
: : O
members NN member O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
ethnically NN ethnically O
diverse NN divers O
community NNS community O
believe NN believe O
antibiotics DT antibiotic T
are DT stopwords are O
effective NN effective O
for NN stopwords O
colds NNS cold D
, , O
are DT stopwords are O
very NN stopwords very O
likely NN likely O
to NN stopwords O
seek NN seek O
care VB care O
for NN stopwords O
colds NNS cold O
, , O
and DT stopwords O
often JJ frequently O
obtain NN obtain O
antibiotics DT antibiotic O
without NN O
a DT stopwords angstrom O
prescription NN prescription O

Putting CAPITAL NNP putt O
patients VB patient O
first NN first O
? . O

Thus CAPITAL NNP frankincense O
, , O
to NN stopwords O
date VB date O
, , O
four JJ four O
DNase CAPITAL NNP O
I-like CAPITAL PRP O
genes NN gene O
that NN stopwords O
show NN show O
different NN different O
tissue NN tissue O
expression NN expression O
patterns VB form O
are DT stopwords are O
known NN know O

In CAPITAL PRP inch O
the NN stopwords O
other JJ stopwords other O
clinical JJ clinical O
parameters NN parameter O
, , O
we NN stopwords O
found JJ found O
no NNS stopwords no O
significant NN significant O
differences NN difference O
between NN stopwords between O
the NN stopwords O
groups NN group O

Bradycardia CAPITAL NNP bradycardia D
: : O
an DT stopwords Associate_in_Nursing O
unrecognized JJ unrecognized O
complication NNS complication O
of NN stopwords O
some NN stopwords some O
epileptic NN epileptic O
crises JJ crisis O

The CAPITAL NNP O
analysis DT analysis O
of NN stopwords O
survival NN survival O
and DT stopwords O
recurrence NN recurrence O
was VB stopwords Washington O
by NN stopwords by O
intention NN purpose O
to NN stopwords O
treat NN dainty O
and DT stopwords O
analysis DT analysis O
of NN stopwords O
complications NNS complication O
was VB stopwords Washington O
by NN stopwords by O
treatment NN treatment O
delivered NN deliver O

methods NN method O
: : O
the NN stopwords O
author DT writer O
reviews NN reappraisal O
the NN stopwords O
use JJ use O
of NN stopwords O
several NN several O
endobronchial NN T
treatment NN treatment T
modalities NN modality T
that NN stopwords T
can VB stopwords can T
augment DT augment T
standard NN standard T
antitumor DT anticancer T
therapies NN therapy T
for NN stopwords O
advanced DT advance O
lung NN lung D
cancer VB cancer D
, , O
including NN include O
rigid NN rigid O
and DT stopwords O
flexible JJ flexible O
bronchoscopy NN O
, , O
laser NN laser O
therapy NN therapy O
, , O
endobronchial NN O
prosthesis NN prosthesis O
, , O
and DT stopwords O
photodynamic NN O
therapy NN therapy O

Better CAPITAL NNP better O
knowledge NN cognition O
of NN stopwords O
non JJ not O
lipidic NN O
effects NN effects O
of NN stopwords O
statins NN lipid-lowering_medicine O
on NN stopwords on O
the NN stopwords O
arterial DT arterial O
wall VB wall O
and DT stopwords O
the NN stopwords O
discovery NN discovery O
of NN stopwords O
the NN stopwords O
action DT action O
of NN stopwords O
fibrates NN O
on NN stopwords on O
PPAR CAPITAL NNP O
( ( O
Peroxisome CAPITAL NNP O
Proliferator CAPITAL NNP O
Activated CAPITAL DT trip O
Receptors CAPITAL NNP receptor O
) ) O
improved JJ better O
strongly NN strongly O
the NN stopwords O
therapeutic NN remedy O
management VB management O
of NN stopwords O
hyperlipidemias NN lipemia D

CONCLUSIONS CAPITAL NNP decision O
: : O
These CAPITAL NNP O
data VB data O
, , O
the NN stopwords O
first NN first O
evidence NN evidence O
that NN stopwords O
chronic NN chronic O
stress NN stress O
can VB stopwords can O
inhibit NN suppress O
the NN stopwords O
stability NN stability O
of NN stopwords O
the NN stopwords O
IgG CAPITAL PRP immunoglobulin_G O
antibody DT antibody O
response NN response O
to NN stopwords O
a DT stopwords angstrom O
bacterial VB bacterial T
vaccine NN vaccine T
for NN stopwords O
pneumonia NN pneumonia D
, , O
provide NN supply O
additional DT extra O
evidence NN evidence O
of NN stopwords O
health NN health O
risks NN hazard O
associated DT associate O
with NN stopwords O
dementia NN dementia O
caregiving VB O

Bethesda CAPITAL NNP O
, , O
Maryland CAPITAL NNP Maryland O
, , O
USA CAPITAL NNP United_States O

Use CAPITAL NNP use O
of NN stopwords O
scarred JJ scar O
flaps NN flap O
and DT stopwords O
secondary NN secondary O
flaps NN flap O
for NN stopwords O
reconstructive NN reconstructive T
surgery NN surgery T
of NN stopwords O
extensive NN extensive D
burns NN Burns D

Retropubic CAPITAL NNP T
suspensions NN suspension T
and DT stopwords O
slings JJ sling T
are DT stopwords are O
the NN stopwords O
most NN stopwords most O
efficacious NN efficacious O
procedures NN procedure O
for NN stopwords O
long-term NN long-run O
success NN success O
( ( O
based VB establish O
on NN stopwords on O
cure/dry NNS O
rates VB rates O
) ) O

Side CAPITAL NNP side O
effects NN effects O
of NN stopwords O
methylphenidate NN methylphenidate T
were NN stopwords be O
mild NN mild O
and DT stopwords O
transient NN transient O

We CAPITAL NNP O
suggest NN propose O
that NN stopwords O
1 DIGITS CD one T
alpha DT alpha T
, , T
24 DIGITS CD twenty-four T
( ( T
OH CAPITAL NNP Ohio T
) ) T
2D3 CD T
merits NN merit O
further NN stopwords foster O
investigation NN probe O
as DT stopwords arsenic O
a DT stopwords angstrom O
potentially NN potentially O
useful JJ useful O
topical NN topical O
therapy NN therapy O
for NN stopwords O
psoriasis NN psoriasis D

Dioxins CAPITAL NNP dioxin O
bind NN bind O
to NN stopwords O
a DT stopwords angstrom O
specific NN particular O
intracellular NN intracellular O
receptor NN receptor O
and DT stopwords O
the NN stopwords O
complex NNS complex O
acts DT Acts_of_the_Apostles O
as DT stopwords arsenic O
a DT stopwords angstrom O
transcription NN transcription O
factor VB factor O
that NN stopwords O
induces NN induce O
the NN stopwords O
production NN production O
of NN stopwords O
a DT stopwords angstrom O
great NN great O
number JJ number O
of NN stopwords O
proteins NN protein O

In CAPITAL PRP inch O
the NN stopwords O
adult DT adult O
, , O
SHARP CAPITAL NNP sharp O
genes NN gene O
are DT stopwords are O
expressed NN express O
in NN stopwords inch O
subregions NN O
of NN stopwords O
the NN stopwords O
CNS CAPITAL NNP central_nervous_system O
that NN stopwords O
have VB stopwords rich_person O
been NN stopwords be O
associated DT associate O
with NN stopwords O
adult DT adult O
plasticity NN malleability O

Cancer CAPITAL VB cancer D
incidence NN incidence O
after DT stopwords after O
retinoblastoma NN retinoblastoma D

Subsequently CAPITAL NNP subsequently O
, , O
recurrence NN recurrence O
of NN stopwords O
pleural NN pleural D
mesothelioma NN mesothelioma D
and DT stopwords O
peritoneal NN peritoneal O
involvement NN engagement O
by NN stopwords by O
mesothelioma NN mesothelioma D
was VB stopwords Washington O
documented NN document O

Identification CAPITAL PRP designation O
of NN stopwords O
a DT stopwords angstrom O
large NN large O
insertion NN interpolation O
and DT stopwords O
two NN two O
novel JJ novel O
point NN point O
mutations NN mutant O
( ( O
3671del8 CD O
and DT stopwords O
S1221X CAPITAL NNP O
) ) O
in NN stopwords inch O
tuberous NN tuberous D
sclerosis JJ sclerosis D
complex NNS complex D
( ( D
TSC CAPITAL NNP D
) ) D
patients VB patient O

Cologne CAPITAL NNP Cologne O
, , O
Germany CAPITAL NNP Germany O
, , O
March CAPITAL NNP March O
14-15 CD O
, , O
1998 DIGITS CD O

The CAPITAL NNP O
total NN sum O
cesarean NNS cesarean_delivery O
rate VB rate O
was VB stopwords Washington O
14.4 CD O
% NN O
( ( O
344 DIGITS CD O
of NN stopwords O
2395 DIGITS CD O
) ) O
, , O
and DT stopwords O
the NN stopwords O
primary NN primary O
rate VB rate O
was VB stopwords Washington O
11.4 CD O
% NN O
( ( O
244 DIGITS CD O
of NN stopwords O
2144 DIGITS CD O
) ) O

Prolonged CAPITAL NNP prolong O
use JJ use O
of NN stopwords O
methyldopa NN methyldopa T
in NN stopwords inch O
severe NN severe D
hypertension NN high_blood_pressure D
in NN stopwords inch O
pregnancy NN pregnancy O

Summary CAPITAL NNP summary O
of NN stopwords O
symposium NN symposium O
, , O
antisense DT O
oligonucleotides IN O
: : O
strategies NN scheme O
and DT stopwords O
successes NN success O

Res CAPITAL NNP reticuloendothelial_system O

Behavioral CAPITAL NNP behavioral O
audiometry DT audiology O
was VB stopwords Washington O
repeated NN repeat O
during NN stopwords O
periodic NN periodic O
follow-up JJ follow-up O
until JJ stopwords O
reliable NN reliable O
responses NN response O
were NN stopwords be O
obtained NN obtain O
for NN stopwords O
all DT stopwords all O
frequencies JJ frequency O
, , O
and DT stopwords O
standardized NN standardize O
developmental NN developmental O
testing NN testing O
was VB stopwords Washington O
also DT besides O
conducted NNS conduct O

Shifting CAPITAL NNP shift O
medical NN checkup O
education NN education O
from JJ stopwords O
the NN stopwords O
icebox JJ refrigerator O
to NN stopwords O
the NN stopwords O
refrigerator NN refrigerator O

CONTEXT CAPITAL NNP context O
: : O
Adolescents CAPITAL DT adolescent O
' '' O
concerns NNS concern O
about DT stopwords about O
privacy NN privacy O
in NN stopwords inch O
clinical JJ clinical O
settings NN setting O
decrease NN decrease O
their NN stopwords O
willingness NN willingness O
to NN stopwords O
seek NN seek O
health NN health O
care VB care O
for NN stopwords O
sensitive NN medium O
problems NN problem O
and DT stopwords O
may VB May O
inhibit NN suppress O
their NN stopwords O
communication NNS communication O
with NN stopwords O
physicians NN doctor O

The CAPITAL NNP O
four JJ four O
structurally NN structurally O
different NN different O
intercalators NN O
showed NN show O
significant NN significant O
distinction NN differentiation O
in NN stopwords inch O
binding NN binding O
kinetics NN dynamics O
and DT stopwords O
equilibrium NN equilibrium O
signals NN signal O

However CAPITAL NNP however O
, , O
thus NN frankincense O
far VB Army_for_the_Liberation_of_Rwanda O
, , O
no NNS stopwords no O
life-threatening NN dangerous O
sequelae NN sequela O
of NN stopwords O
these NN stopwords O
effects NN effects O
are DT stopwords are O
found JJ found O
in NN stopwords inch O
the NN stopwords O
literature NN literature O

This CAPITAL NNP O
article DT article O
summarises NN summarize O
the NN stopwords O
role NN function O
of NN stopwords O
fat VB fat O
metabolism NN metamorphosis O
during NN stopwords O
exercise NN exercise O

Legislative CAPITAL NNP legislative O
and DT stopwords O
legal NN legal O
vigilance NN watchfulness O

Recent CAPITAL NNP Holocene O
cocaine NNS cocaine O
use JJ use O
among DT O
women NN woman O
with NN stopwords O
preterm NN D
PROM CAPITAL NNP promenade D
is NN stopwords be O
common NNS park O
in NN stopwords inch O
only JJ stopwords lone O
some NN stopwords some O
segments NN section O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
urban JJ urban O
population NN population O

Assessment CAPITAL DT appraisal O
of NN stopwords O
atrioventricular DT atrioventricular T
junction NN junction T
ablation DT ablation T
and DT stopwords T
VVIR CAPITAL NNP T
pacemaker VB pacesetter T
versus NN O
pharmacological NN pharmacological T
treatment NN treatment T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
heart NN heart D
failure VB failure D
and DT stopwords D
chronic NN chronic D
atrial DT atrial D
fibrillation NN fibrillation D
: : O
a DT stopwords angstrom O
randomized VB randomize O
, , O
controlled NNS control O
study NN survey O

CONTEXT CAPITAL NNP context O
: : O
A CAPITAL DT angstrom O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
BRCA1 CAPITAL NNP O
gene NN gene O
may VB May O
confer NNS confer O
substantial NN significant O
risk NN hazard O
for NN stopwords O
breast NN breast O
and/or DT O
ovarian NN ovarian O
cancer VB cancer D

Antibiotics CAPITAL DT antibiotic T
for NN stopwords O
Salmonella CAPITAL VB salmonella D
meningitis NN meningitis D
in NN stopwords inch O
children JJ child O

these NN stopwords O
data VB data O
suggest NN propose O
that NN stopwords O
her2/erbb-2 NN O
should NN stopwords O
be NN stopwords beryllium O
evaluated NN measure O
prospectively NN O
as DT stopwords arsenic O
a DT stopwords angstrom O
prognostic NN omen O
indicator NN index O
and DT stopwords O
clinical JJ clinical O
trials NN test O
using JJ exploitation O
antibodies DT antibody T
that NN stopwords O
target VB target O
this NN stopwords O
receptor NN receptor O
should NN stopwords O
be NN stopwords beryllium O
considered NNS see O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
osteogenic JJ D
sarcoma VB sarcoma D

After CAPITAL DT after O
7 DIGITS CD seven O
days VB days O
' '' O
treatment NN treatment O
, , O
neutrophil JJ neutrophil O
superoxide NN superoxide O
production NN production O
was VB stopwords Washington O
significantly NN significantly O
higher NN higher O
in NN stopwords inch O
the NN stopwords O
G-CSF CAPITAL NNP O
group NN group O
than NN stopwords O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O
( ( O
16.1 CD O
( ( O
4.2-24.2 CD O
) ) O
vs NN volt O
7.3 CD O
( ( O
2.1-11.5 CD O
) ) O
nmol JJ O
per NN O
10 DIGITS CD ten O
( ( O
6 DIGITS CD six O
) ) O
neutrophils JJ neutrophil O
in NN stopwords inch O
30 DIGITS CD thirty O
min NN minute O
; : O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.0001 LS O
) ) O

In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
B CAPITAL NN bacillus O

Tests CAPITAL NNP trial O
were NN stopwords be O
carried VB transport O
out JJ stopwords out O
using JJ exploitation O
experimental NN experimental O
NMR CAPITAL NNP nuclear_magnetic_resonance O
data VB data O
for NN stopwords O
protein NN protein O
G CAPITAL NN gram O
, , O
interleukin-8 NN O
, , O
villin NN O
14T CD O
, , O
and DT stopwords O
a DT stopwords angstrom O
12 DIGITS CD twelve O
base-pair VB O
duplex NN duplex_house O
of NN stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O
, , O
and DT stopwords O
simulated NN imitate O
NMR CAPITAL NNP nuclear_magnetic_resonance O
data VB data O
for NN stopwords O
bovine NN bovine O
pancreatic VB pancreatic O
trypsin NN trypsin O
inhibitor NN inhibitor O

Ovine CAPITAL NNP ovine D
Johne CAPITAL NNP D
's POS D
disease NN disease D

The CAPITAL NNP O
recombinant NN recombinant O
fusion JJ fusion O
protein NN protein O
binds NN bind O
calcium VB calcium O
when NN stopwords O
assayed DT assay O
with NN stopwords O
45Ca CD O

DESIGN CAPITAL NNP design O
: : O
Randomized CAPITAL VB randomize O
controlled NNS control O
trial NN test O

The CAPITAL NNP O
advantages DT advantage O
and DT stopwords O
pitfalls NN pitfall O
of NN stopwords O
this NN stopwords O
new JJ new O
method NN method O
are DT stopwords are O
discussed NN discourse O
in NN stopwords inch O
the NN stopwords O
light NN light O
of NN stopwords O
the NN stopwords O
results NN consequence O
obtained NN obtain O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
infantile NN childish O
GSDII CAPITAL NNP O
patient VB patient O

Challenge CAPITAL NNP challenge O
with NN stopwords O
enzyme NN enzyme O
linked NN associate O
antigen DT antigen O
of NN stopwords O
oxygen JJ oxygen O
plasma NN plasma O
exposed NN expose O
antibody DT antibody O
layers NN layer O
demonstrated NN show O
that NN stopwords O
plasma NN plasma O
treatment NN treatment O
completely NNS wholly O
neutralized JJ neutralize O
antibody DT antibody O
capture VB capture O
ability DT ability O

Tested CAPITAL NNP test O
questionnaires NN questionnaire O
help NN aid O
administration DT administration O
learn NN learn O
if NN stopwords O
programs NN plan O
are DT stopwords are O
a DT stopwords angstrom O
success NN success O
, , O
and DT stopwords O
why NN stopwords why O

Inter-NICU CAPITAL PRP O
variability NN variability O
of NN stopwords O
thermal NN thermal O
equipment NN equipment O
use JJ use O
may VB May O
complicate NNS complicate O
fluid JJ fluid O
management VB management O

A CAPITAL DT angstrom O
radiation VB radiation O
risk NN hazard O
for NN stopwords O
all DT stopwords all O
sarcomas VB sarcoma O
combined NNS unite O
was VB stopwords Washington O
evident NN apparent O
at DT stopwords astatine O
doses NN dose O
above DT stopwords above O
5 DIGITS CD five O
Gy CAPITAL NNP gray O
, , O
rising NN rise O
to NN stopwords O
10.7-fold CD O
at DT stopwords astatine O
doses NN dose O
of NN stopwords O
60 DIGITS CD sixty O
Gy CAPITAL NNP gray O
or NN stopwords Oregon O
greater NN greater O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.05 . O
) ) O

The CAPITAL NNP O
recommendation NN recommendation O
of NN stopwords O
the NN stopwords O
Japan CAPITAL NNP Japan O
Diabetes CAPITAL NNP diabetes O
Society CAPITAL NNP society O
to NN stopwords O
measure NN measure O
only JJ stopwords lone O
the NN stopwords O
stable NN stable O
GHb CAPITAL NNP gamma_hydroxybutyrate O
component NNS component O
and DT stopwords O
to NN stopwords O
correct NNS correct O
the NN stopwords O
GHb CAPITAL NNP gamma_hydroxybutyrate O
percentage NN percentage O
by NN stopwords by O
two-point NN O
calibration VB calibration O
with NN stopwords O
assigned DT delegate O
values NN values O
, , O
was VB stopwords Washington O
effective NN effective O
but NN stopwords merely O
not JJ stopwords not O
sufficient NN sufficient O

BACKGROUND CAPITAL IN background O
: : O
Several CAPITAL NNP several O
randomized VB randomize O
trials NN test O
have VB stopwords rich_person O
demonstrated NN show O
the NN stopwords O
benefits NN benefit O
of NN stopwords O
primary NN primary T
angioplasty DT angioplasty T
in NN stopwords inch O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

< NN O
TO_SEE CAPITAL NNP O
> NN O
Prevention CAPITAL NNP prevention O
of NN stopwords O
a DT stopwords angstrom O
first NN first O
stroke NN stroke D
by NN stopwords by O
transfusions NN transfusion T
in NN stopwords inch O
children JJ child O
with NN stopwords O
sickle NN sickle O
cell NNS cell O
anemia DT anemia O
and DT stopwords O
abnormal DT abnormal O
results NN consequence O
on NN stopwords on O
transcranial NN O
Doppler CAPITAL NNP Doppler O
ultrasonography JJ sonography O

Female CAPITAL NNP female O
genital NN genital O
mutilation NN mutilation O
: : O
a DT stopwords angstrom O
contemporary NNS contemporary O
issue NN issue O
, , O
and DT stopwords O
a DT stopwords angstrom O
Victorian CAPITAL NNP Victorian O
obsession NN compulsion O

promising NN promise O
chemopreventive NNS T
agents DT agent T
also DT besides O
are DT stopwords are O
under JJ stopwords nether O
investigation NN probe O
currently NNS presently O
to NN stopwords O
reduce NN reduce O
the NN stopwords O
risk NN hazard O
of NN stopwords O
lung NN lung D
carcinoma VB carcinoma D
in NN stopwords inch O
high NN high O
risk NN hazard O
populations NN population O

Undergraduate CAPITAL NNP undergraduate O
orthodontic JJ orthodontic O
education NN education O
: : O
what NN stopwords O
should NN stopwords O
we NN stopwords O
teach NN Teach O
rather VB rather O
than NN stopwords O
what NN stopwords O
can VB stopwords can O
we NN stopwords O
teach NN Teach O
? . O

Recent CAPITAL NNP Holocene O
major VB major O
epidemiologic NN epidemiologic O
trends NN tendency O
in NN stopwords inch O
bacterial VB bacterial O
meningitis NN meningitis O
include NN include O
a DT stopwords angstrom O
dramatic NN dramatic O
decline NN decline O
in NN stopwords inch O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
Haemophilus CAPITAL NNP D
influenzae NN D
meningitis NN meningitis D
since NN O
the NN stopwords O
introduction NN introduction O
of NN stopwords O
the NN stopwords O
protein-conjugated NN T
H. CAPITAL NNP T
influenzae NN T
vaccines NN vaccine T
, , O
and DT stopwords O
a DT stopwords angstrom O
worldwide NN worldwide O
increase NN addition O
in NN stopwords inch O
infections NN infection O
with NN stopwords O
antibiotic-resistant DT O
strains NN strain O
of NN stopwords O
bacterial VB bacterial O
pathogens VB pathogen O

High-dose CAPITAL NNP T
intravenous NN intravenous T
immunoglobulin JJ immunoglobulin T
( ( T
hdIVIg NN T
) ) T
is NN stopwords be O
increasingly NN increasingly O
used JJ use O
to NN stopwords O
treat NN dainty O
a DT stopwords angstrom O
range VB scope O
of NN stopwords O
inflammatory NN inflammatory D
and DT stopwords D
autoimmune DT autoimmune D
diseases NN disease D

methods NN method O
: : O
forty-four NN forty-four O
patients VB patient O
with NN stopwords O
limited NN express D
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
were NN stopwords be O
treated NN treat O
with NN stopwords O
etoposide-ifosfamide-cisplatin NN T
and DT stopwords T
concurrent NNS coincident T
thoracic NN pectoral T
irradiation NN irradiation T

A CAPITAL DT angstrom O
retrospective NN retrospective O
sequential NN consecutive O
review NN reappraisal O
was VB stopwords Washington O
made VB make O
of NN stopwords O
the NN stopwords O
last NN stopping_point O
100 DIGITS CD hundred O
physical NN physical O
medicine NN medicine O
and DT stopwords O
rehabilitation NN rehabilitation O
consultations NNS consultation O
with NN stopwords O
student NN student O
attendance DT attendance O

Short-term CAPITAL NNP short-run O
retention NN retention O
as DT stopwords arsenic O
a DT stopwords angstrom O
function JJ function O
of NN stopwords O
method NN method O
of NN stopwords O
measurement NN measurement O
, , O
recording NN recording O
time NN time O
, , O
and DT stopwords O
meaningfulness NN meaningfulness O
of NN stopwords O
the NN stopwords O
material VB material O

The CAPITAL NNP O
average DT average O
postoperative NN postoperative O
metatarsophalangeal NN O
dorsiflexion NN dorsiflexion O
angle DT angle O
was VB stopwords Washington O
15.6 CD O
degrees NN degree O
and DT stopwords O
the NN stopwords O
first NN first O
metatarsophalangeal NN O
angle DT angle O
was VB stopwords Washington O
3.1 LS O
degrees NN degree O

Identification CAPITAL PRP designation O
of NN stopwords O
tranquillizers NN tranquilizer T
by NN stopwords by O
thin-layer NN O
chromatography NN chromatography O

Also CAPITAL DT besides O
, , O
no NNS stopwords no O
false VB false O
positive NN positive O
result NN consequence O
was VB stopwords Washington O
obtained NN obtain O
with NN stopwords O
serum NN serum O
samples VB sample O
of NN stopwords O
patients VB patient O
infected NN infect O
with NN stopwords O
leprosy NN leprosy D
, , O
tuberculosis NN tuberculosis D
, , O
typhoid NN typhoid D
and DT stopwords O
malaria VB malaria D
, , O
showing NN screening O
the NN stopwords O
specificity NN specificity O
of NN stopwords O
the NN stopwords O
sensor NN detector O
and DT stopwords O
efficacy NN efficacy O
of NN stopwords O
the NN stopwords O
technique NN technique O

We CAPITAL NNP O
performed NN perform O
a DT stopwords angstrom O
prospective NN prospective O
study NN survey O
over JJ stopwords over O
a12-mo DT O
period NN time_period O
on NN stopwords on O
bone NN bone O
density NN density O
at DT stopwords astatine O
a DT stopwords angstrom O
spinal JJ spinal_anesthesia O
and DT stopwords O
peripheral NN peripheral O
measuring NN measurement O
site NN site O
in NN stopwords inch O
28 DIGITS CD twenty-eight O
female JJ female O
senior NN senior O
members NN member O
( ( O
mean NN mean O
age DT age O
: : O
67 DIGITS CD sixty-seven O
+/- NN O
2 DIGITS CD two O
yr NN year O
) ) O
of NN stopwords O
a DT stopwords angstrom O
dancing VB dancing O
group NN group O
in NN stopwords inch O
Vienna CAPITAL NNP Vienna O

Long-term CAPITAL NNP long-run O
survival NN survival O
and DT stopwords O
morbidity NN morbidity O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
malignant VB malignant D
germ NN source D
cell NNS cell D
tumors NN tumor D
treated NN treat O
with NN stopwords O
cisplatin-based NN T
combination NNS combination T
chemotherapy NNS chemotherapy T

Several CAPITAL NNP several O
forms NN form O
of NN stopwords O
hippocampal NN O
synaptic NN synaptic O
plasticity NN malleability O
are DT stopwords are O
dependent NN dependant O
on NN stopwords on O
Ca2+ CAPITAL VB O
, , O
providing NN supply O
a DT stopwords angstrom O
potential NN potential O
link NN link O
between NN stopwords between O
altered DT change O
Ca2+ CAPITAL VB O
homeostasis NN homeostasis O
and DT stopwords O
memory NN memory O
deficits NN deficit O
associated DT associate O
with NN stopwords O
aging DT ripening O

Weekly CAPITAL NNP weekly O
clinicopathological JJ O
exercises NN exercise O

Of CAPITAL NNP O
75 DIGITS CD seventy-five O
women NN woman O
, , O
drug NN drug O
users JJ user O
( ( O
51 DIGITS CD fifty-one O
% NN O
) ) O
were NN stopwords be O
more NN stopwords More O
likely NN likely O
to NN stopwords O
say VB say O
that NN stopwords O
they NN stopwords O
would NN O
defer NN postpone O
initiating JJ originate O
prenatal NN prenatal O
care VB care O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.03 LS O
) ) O
and DT stopwords O
to NN stopwords O
minimize NN minimize O
the NN stopwords O
risk NN hazard O
of NN stopwords O
drug NN drug O
or NN stopwords Oregon O
alcohol DT alcohol O
use JJ use O
to NN stopwords O
the NN stopwords O
fetus JJ fetus O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.04 LS O
) ) O

CONCLUSIONS CAPITAL NNP decision O
: : O
Calcium CAPITAL VB calcium O
quantities NN measure O
from JJ stopwords O
the NN stopwords O
3-mm LS O
and DT stopwords O
the NN stopwords O
more NN stopwords More O
reproducible NN reproducible O
6-mm CD O
scanning JJ scanning O
are DT stopwords are O
equally NN equally O
accurate DT accurate O
for NN stopwords O
predicting NN predict O
events NN event O

The CAPITAL NNP O
current NNS current O
dermatological NN dermatologic O
uses JJ use O
of NN stopwords O
hdIVIg NN T
include NN include O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
dermatomyositis NN dermatomyositis D
and DT stopwords O
the NN stopwords O
autoimmune DT autoimmune D
bullous NN D
disorders NN disorder D
, , O
epidermolysis NN D
bullosa NN D
acquisita DT D
, , O
pemphigoid NN D
, , O
and DT stopwords O
pemphigus NN pemphigus D

Limitation CAPITAL NNP restriction O
of NN stopwords O
intakes NN consumption O
to NN stopwords O
the NN stopwords O
RDAs CAPITAL NNP O
would NN O
preclude NN prevent O
reductions NN decrease O
in NN stopwords inch O
disease NN disease O
risk NN hazard O
from JJ stopwords O
these NN stopwords O
nutrients JJ food O

Income CAPITAL PRP income O
inequality NN inequality O
and DT stopwords O
population NN population O
health NN health O

The CAPITAL NNP O
occurrence JJ happening O
of NN stopwords O
the NN stopwords O
2 DIGITS CD two O
thresholds NN threshold O
( ( O
AT CAPITAL DT astatine O
and DT stopwords O
Tsa CAPITAL NNP Transportation_Security_Administration O
) ) O
might NN might O
, , O
in NN stopwords inch O
turn NN bend O
, , O
be NN stopwords beryllium O
attributable DT attributable O
to NN stopwords O
the NN stopwords O
same VB stopwords Lapp O
underlying JJ underlie O
mechanism NN mechanism O
, , O
that NN stopwords O
of NN stopwords O
increased NN increase O
adrenal DT adrenal_gland O
sympathetic NN sympathetic O
activity DT activity O
at DT stopwords astatine O
high NN high O
exercise NN exercise O
intensities NN intensity O

methods NN method O
: : O
between NN stopwords between O
1981 DIGITS CD O
and DT stopwords O
1998 DIGITS CD O
, , O
100 DIGITS CD hundred O
patients VB patient O
( ( O
90 DIGITS CD ninety O
male VB male O
; : O
ten NN ten O
female JJ female O
) ) O
, , O
with NN stopwords O
a DT stopwords angstrom O
median NN median O
age DT age O
of NN stopwords O
60 DIGITS CD sixty O
years NN old_age O
( ( O
36-84 CD O
) ) O
, , O
underwent JJ undergo O
radical VB group T
en-bloc NN T
resection NN resection T
of NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
with NN stopwords O
chest NNS thorax O
wall VB wall O
involvement NN engagement O

Ultramicro-analysis CAPITAL NNP O
of NN stopwords O
cyclohexylamine NNS O
and DT stopwords O
low NN low O
fatty VB fatso O
amines DT amine O
by NN stopwords by O
gas VB gas O
chromatography NN chromatography O

Internet CAPITAL PRP internet O
resources NN resource O
for NN stopwords O
medical NN checkup O
genetics NN genetics O

Sodium CAPITAL NNP sodium O
in NN stopwords inch O
heart NN heart D
failure VB failure D

In CAPITAL PRP inch O
our NN stopwords O
study NN survey O
, , O
we NN stopwords O
specifically NN specifically O
analyzed DT analyze O
the NN stopwords O
role NN function O
played NN play O
by NN stopwords by O
advanced DT advance O
maternal VB maternal O
age DT age O
and DT stopwords O
sonographically NN O
discovered NN detect O
abnormalities DT abnormality O
in NN stopwords inch O
the NN stopwords O
detection NN detection O
of NN stopwords O
autosomal DT autosomal D
trisomies NN trisomy D

Single-breath CAPITAL NNP O
diffusing NN diffuse O
capacities VB capacity O
for NN stopwords O
NO CAPITAL NNP no O
, , O
CO CAPITAL NNP carbon_monoxide O
and DT stopwords O
C18O2 CAPITAL NNP O
in NN stopwords inch O
rabbits NN rabbit O

Gas CAPITAL VB gas O
chromatographic NN chromatographic O
studies NN survey O
on NN stopwords on O
organic JJ organic O
mercurials NN O

Testicular CAPITAL NNP testicular T
sperm NN sperm T
retrieval NN retrieval T
by NN stopwords by T
percutaneous NN transdermal T
fine NN fine T
needle JJ acerate_leaf T
sperm NN sperm T
aspiration DT aspiration T
compared NNS compare O
with NN stopwords O
testicular NN testicular T
sperm NN sperm T
extraction NN extraction T
by NN stopwords by T
open JJ open T
biopsy NN biopsy T
in NN stopwords inch O
men NN work_force O
with NN stopwords O
non-obstructive JJ D
azoospermia DT D

Although CAPITAL DT O
it NN stopwords information_technology O
was VB stopwords Washington O
many VB many O
years NN old_age O
before NN stopwords earlier O
it NN stopwords information_technology O
was VB stopwords Washington O
fully JJ fully O
demonstrated NN show O
, , O
fat VB fat O
is NN stopwords be O
now JJ stopwords now O
known NN know O
to NN stopwords O
be NN stopwords beryllium O
transported NN transport O
in NN stopwords inch O
the NN stopwords O
blood NN blood O
as DT stopwords arsenic O
FFA CAPITAL NNP O
bound NN boundary O
to NN stopwords O
the NN stopwords O
protein NN protein O
carrier VB carrier O
albumin DT albumin O

Thus CAPITAL NNP frankincense O
, , O
with NN stopwords O
this NN stopwords O
sensitive NN medium O
method NN method O
, , O
no NNS stopwords no O
correlation NNS correlation O
was VB stopwords Washington O
detectable NN detectable O
between NN stopwords between O
the NN stopwords O
external NN external O
osmolarity JJ O
, , O
the NN stopwords O
electrical NN electrical O
charge NNS charge O
and DT stopwords O
the NN stopwords O
preferential NN discriminatory O
direction NN direction O
of NN stopwords O
migration NN migration O
of NN stopwords O
a DT stopwords angstrom O
microinjected NN O
probe NN probe O

Individuals CAPITAL PRP person O
who NN stopwords World_Health_Organization O
develop NN develop O
schizophrenic JJ schizophrenic D
symptoms NN symptom D
show NN show O
lesser NN lesser O
anatomical DT anatomical_reference O
and DT stopwords O
functional JJ functional O
asymmetries DT asymmetry O
than NN stopwords O
the NN stopwords O
population NN population O
as DT stopwords arsenic O
a DT stopwords angstrom O
whole NN whole O
; : O
such NN stopwords such O
symptoms NN symptom O
may VB May O
reflect NN reflect O
'dominance POS O
failure VB failure O
' '' O
for NN stopwords O
language NN language O

Supportive CAPITAL NNP supportive O
role NN function O
of NN stopwords O
nurse RB nurse O
in NN stopwords inch O
first NN first O
stage NN phase O
of NN stopwords O
labor NN labor O
`` `` O
can VB stopwords can O
not JJ stopwords not O
be NN stopwords beryllium O
emphasized NN stress O
enough NN enough O
'' POS O
, , O
according DT harmonize O
to NN stopwords O
patient VB patient O

Extra-gastrointestinal CAPITAL NNP D
diseases NN disease D
and DT stopwords O
Helicobacter CAPITAL NNP O
pylori NN pylorus O

Mesenteric CAPITAL NNP mesenteric D
venous NN venous D
thrombosis NN thrombosis D
: : O
successful NN successful O
treatment NN treatment O
by NN stopwords by O
intraarterial NN T
lytic NN T
therapy NN therapy T

Clear CAPITAL NNP clear D
cell NNS cell D
papulosis VB D
: : O
case VB case O
report NN report O
and DT stopwords O
literature NN literature O
review NN reappraisal O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
a DT stopwords angstrom O
conference NNS conference O

Mike CAPITAL NNP microphone O
Grace CAPITAL NNP grace O
talks VB negotiation O
to NN stopwords O
Mike CAPITAL NNP microphone O
Joy CAPITAL NNP joy O

An CAPITAL DT Associate_in_Nursing O
athlete DT athlete O
failing VB failing O
to NN stopwords O
recover NN recover O
within NN inside O
72 DIGITS CD seventy-two O
hours NN hours O
has VB stopwords hour_angle O
presumably NN presumably O
negatively JJ negatively O
overtrained JJ O
and DT stopwords O
is NN stopwords be O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
overreached JJ overreach O
state NN state O

Effect CAPITAL NNP consequence O
of NN stopwords O
diabetes NN diabetes D
and DT stopwords O
starvation NN starvation O
on NN stopwords on O
myocardial NN myocardial O
triglyceride NN triglyceride O
and DT stopwords O
free JJ free O
fatty VB fatso O
acid DT acid O
utilization JJ use O

Toxemia CAPITAL NNP toxemia_of_pregnancy D
of NN stopwords O
pregnancy NN pregnancy O

Coronary CAPITAL NNP coronary_thrombosis D
endothelial NN endothelial D
dysfunction NN dysfunction D
in NN stopwords inch O
humans NN world O
is NN stopwords be O
associated DT associate O
with NN stopwords O
myocardial NN myocardial D
perfusion NN perfusion D
defects NN defect D

Twelve CAPITAL NNP twelve O
patients VB patient O
with NN stopwords O
intractable NN intractable D
rheumatoid NN arthritic D
arthritis DT arthritis D
were NN stopwords be O
treated NN treat O
with NN stopwords O
antilymphocyte DT T
globulin NN globulin T
( ( T
ALG CAPITAL DT T
) ) T
, , T
prednisolone NN prednisolone T
and DT stopwords T
a DT stopwords angstrom T
cytotoxic NNS cytotoxic T
agent DT agent T
, , T
usually JJ normally T
azathioprine DT azathioprine T
, , O
and DT stopwords O
were NN stopwords be O
followed JJ follow O
for NN stopwords O
1 DIGITS CD one O
year NN year O

OBJECTIVES CAPITAL NNP aim O
: : O
Obesity CAPITAL NNP fleshiness D
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
important JJ important O
clinical JJ clinical O
problem NN problem O
, , O
and DT stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
dexfenfluramine NN T
hydrochloride NN hydrochloride T
for NN stopwords O
weight NN weight O
reduction NN decrease O
has VB stopwords hour_angle O
been NN stopwords be O
widely NN widely O
publicized NN publicize O
since NN O
its NN stopwords information_technology O
approval DT blessing O
by NN stopwords by O
the NN stopwords O
Food CAPITAL NNP food O
and DT stopwords O
Drug CAPITAL NNP drug O
Administration CAPITAL DT administration O

this NN stopwords O
conjugated NNS conjugate T
vaccine NN vaccine T
against DT stopwords O
pneumococcus NN pneumococcus D
uses JJ use O
the NN stopwords O
same VB stopwords Lapp O
technology NN technology O
as DT stopwords arsenic O
the NN stopwords O
successful NN successful O
vaccine NN vaccine T
against DT stopwords O
haemophilus VB D
influenzae NN D
type NN type D
b NN bacillus D

In CAPITAL PRP inch O
11 DIGITS CD eleven O
out JJ stopwords out O
of NN stopwords O
12 DIGITS CD twelve O
normal RB convention O
healthy NN healthy O
volunteers NN volunteer O
this NN stopwords O
task VB undertaking O
resulted NN result O
in NN stopwords inch O
activation DT activation O
in NN stopwords inch O
posterior NN buttocks O
portions NN part O
of NN stopwords O
the NN stopwords O
parahippocampal NN O
region NN region O
, , O
close NNS stopping_point O
to NN stopwords O
the NN stopwords O
collateral NNS collateral O
sulcus NN sulcus O

Translocations CAPITAL NNP translocation O
of NN stopwords O
11q13 CD O
in NN stopwords inch O
mantle VB mantle D
cell NNS cell D
lymphoma NN lymphoma D
fail VB fail O
to NN stopwords O
disrupt NN interrupt O
the NN stopwords O
S CAPITAL NN second O
mu NN mu O
bp-2 NN O
gene NN gene O

in NN stopwords inch O
the NN stopwords O
gks NN O
group NN group O
, , O
large NN large O
lesions NN lesion O
( ( O
> NN O
30 DIGITS CD thirty O
mm NNS millimeter O
) ) O
were NN stopwords be O
removed NN remove O
surgically NN surgically O
and DT stopwords O
all DT stopwords all O
other JJ stopwords other O
small JJ small D
lesions NN lesion D
( ( O
< NN O
or NN stopwords Oregon O
= NN O
30 DIGITS CD thirty O
mm NNS millimeter O
) ) O
were NN stopwords be O
treated NN treat O
by NN stopwords by O
gks NN T

In CAPITAL PRP inch O
order JJ order O
to NN stopwords O
understand JJ understand O
and DT stopwords O
model NN model O
cochlear NNS cochlear O
processes NN procedure O
involved NN involve O
in NN stopwords inch O
TEOAE CAPITAL NNP O
generation NN coevals O
, , O
it NN stopwords information_technology O
needs JJ need O
to NN stopwords O
be NN stopwords beryllium O
known NN know O
whether NN O
the NN stopwords O
presence NN presence O
of NN stopwords O
normal RB convention O
hearing NN hearing O
leads NN lead O
automatically DT automatically O
to NN stopwords O
generation NN coevals O
of NN stopwords O
TEOAEs CAPITAL NNP O

Etiology CAPITAL NNP etiology O
and DT stopwords O
incidence NN incidence O
of NN stopwords O
renal NN nephritic D
stones NN rock D

The CAPITAL NNP O
nonstress JJ O
test NN trial O
was VB stopwords Washington O
abnormal DT abnormal O
with NN stopwords O
low NN low O
biophysical NN O
profile NN profile O
and DT stopwords O
decreased NN decrease O
beat-to-beat NN O
variability NN variability O

Effects CAPITAL NNP effects O
of NN stopwords O
tolcapone NN T
, , T
a DT stopwords angstrom T
catechol-O-methyltransferase VB T
inhibitor NN inhibitor T
, , O
on NN stopwords on O
motor NN motor O
symptoms NN symptom O
and DT stopwords O
pharmacokinetics NN pharmacokinetics O
of NN stopwords O
levodopa NN L-dopa T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
. . O

Other CAPITAL NNP other O
studies NN survey O
have VB stopwords rich_person O
found JJ found O
that NN stopwords O
during NN stopwords O
prolonged NN prolong O
exercise NN exercise O
, , O
muscle NN muscle O
TGs CAPITAL NNP O
become NN become O
the NN stopwords O
predominant NN prevailing O
source NN beginning O
of NN stopwords O
energy NN energy O
obtained NN obtain O
from JJ stopwords O
fat VB fat O

Eradication CAPITAL NNP eradication O

conclusions NNS decision O
: : O
the NN stopwords O
comparable NNS comparable O
survival NN survival O
of NN stopwords O
patients VB patient O
with NN stopwords O
poor NN poor_people O
and DT stopwords O
good NN good O
response NN response O
of NN stopwords O
pm NN autopsy D
to NN stopwords O
induction NN initiation T
chemotherapy NNS chemotherapy T
suggests NN propose O
that NN stopwords O
wli NN T
may VB May O
benefit NN benefit O
poor NN poor_people O
responders NN respondent O

A CAPITAL DT angstrom O
systematic NN systematic O
review NN reappraisal O
of NN stopwords O
five NN five O
systemic NN systemic T
treatments NN treatment T
for NN stopwords O
severe NN severe D
psoriasis NN psoriasis D

CONCLUSIONS CAPITAL NNP decision O
: : O
This CAPITAL NNP O
study NN survey O
indicates NN bespeak O
that NN stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
a DT stopwords angstrom O
computerized NNS computerize O
physician NN doctor O
reminder NN reminder O
and DT stopwords O
a DT stopwords angstrom O
mailed VB mail O
patient VB patient O
reminder NN reminder O
had VB stopwords have O
a DT stopwords angstrom O
positive NN positive O
impact JJ impact O
on NN stopwords on O
influenza NN influenza D
immunizations JJ immunization T
for NN stopwords O
older JJ aged O
adults DT adult O
in NN stopwords inch O
a DT stopwords angstrom O
large NN large O
family VB family O
practice NN practice O
office JJ office O

Black CAPITAL NNP black O
patients VB patient O
with NN stopwords O
colon NNS colon D
cancer VB cancer D
in NN stopwords inch O
the NN stopwords O
Black/White CAPITAL NNP O
Cancer CAPITAL VB cancer O
Survival CAPITAL NNP survival O
Study CAPITAL NNP survey O
were NN stopwords be O
found JJ found O
to NN stopwords O
have VB stopwords rich_person O
a DT stopwords angstrom O
poorer NN hapless O
survival NN survival O
than NN stopwords O
white NN White O
patients VB patient O

In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
myeloid NN myeloid D
leukemia NN leukemia D
( ( D
CML CAPITAL NNP D
) ) D
, , O
the NN stopwords O
neoplastic JJ neoplastic O
( ( O
BCR-ABL+ CAPITAL NNP O
) ) O
progenitor NN progenitor O
cells NNS cell O
are DT stopwords are O
characterized NNS qualify O
by NN stopwords by O
an DT stopwords Associate_in_Nursing O
increased NN increase O
proliferative NN O
activity DT activity O

The CAPITAL NNP O
systemic NN systemic O
amyloidoses DT T

Rigid CAPITAL NN rigid T
ureteroscopy JJ T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
ureteric JJ D
calculi VB calculus D
: : O
experience NN experience O
in NN stopwords inch O
120 DIGITS CD long_hundred O
cases VB case O

System CAPITAL NNP system O
acknowledging DT admit O
roles NN function O
of NN stopwords O
contributors NNS subscriber O
is NN stopwords be O
best NN best O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
investigate NN investigate O
several NN several O
loci NN venue O
spanning NN cross O
3 DIGITS CD three O
candidate VB campaigner O
regions NN region O
for NN stopwords O
a DT stopwords angstrom O
role NN function O
in NN stopwords inch O
multiple NN multiple D
sclerosis JJ sclerosis D
( ( D
MS CAPITAL NNP multiple_sclerosis D
) ) D
susceptibility NN susceptibility O
in NN stopwords inch O
2 DIGITS CD two O
ethnic NN ethnic O
groups NN group O
using JJ exploitation O
both NN stopwords both O
single-locus NN O
and DT stopwords O
haplotype VB haplotype O
analyses DT analysis O

Congenital CAPITAL NNP congenital D
anomalies DT anomaly D
of NN stopwords D
tracheobronchial NN D
branching NN branching D
patterns VB form D
: : O
spiral JJ spiral O
CT CAPITAL NNP Connecticut O
aspects DT aspect O
in NN stopwords inch O
adults DT adult O

Large CAPITAL VB large D
airway DT air_passage D
disease NN disease D
associated DT associate O
with NN stopwords O
inflammatory NN inflammatory D
bowel NN intestine D
disease NN disease D

the NN stopwords O
available DT available O
inactivated NN demobilize O
vaccine NN vaccine T
is NN stopwords be O
effective NN effective O
for NN stopwords O
preventing NN prevent O
influenza NN influenza D
and DT stopwords O
the NN stopwords O
serious NN serious O
disease NN disease O
and DT stopwords O
death NN death O
that NN stopwords O
can VB stopwords can O
accompany DT attach_to O
it NN stopwords information_technology O

Authorship CAPITAL DT writing O

Two CAPITAL NNP two O
novel JJ novel O
cDNAs SYM complementary_DNA O
, , O
DNAS1L2 CAPITAL NNP O
and DT stopwords O
DNAS1L3 CAPITAL NNP O
, , O
are DT stopwords are O
predicted NN predict O
to NN stopwords O
encode NN encode O
proteins NN protein O
of NN stopwords O
299 DIGITS CD O
and DT stopwords O
305 DIGITS CD O
amino DT amino O
acids DT acid O
with NN stopwords O
56 DIGITS CD fifty-six O
and DT stopwords O
46 DIGITS CD forty-six O
% NN O
residue NN residue O
identity NN identity O
( ( O
71 DIGITS CD seventy-one O
and DT stopwords O
63 DIGITS CD sixty-three O
% NN O
similarity NN similarity O
) ) O
, , O
respectively NN respectively O
, , O
to NN stopwords O
deoxyribonuclease NN O
I CAPITAL PRP iodine O
( ( O
DNase CAPITAL NNP O
I CAPITAL PRP iodine O
) ) O

Public CAPITAL NNP populace O
health NN health O
approach DT approach O
to NN stopwords O
activated DT trip O
protein NN protein O
C CAPITAL SYM degree_centigrade O
resistance NN resistance O
assay DT assay O

Malignancy CAPITAL NNP malignancy O

An CAPITAL DT Associate_in_Nursing O
experimental NN experimental O
and DT stopwords O
a DT stopwords angstrom O
clinical JJ clinical O
study NN survey O

Bethesda CAPITAL NNP O
, , O
Maryland CAPITAL NNP Maryland O
, , O
USA CAPITAL NNP United_States O

This CAPITAL NNP O
case VB case O
shows NN show O
the NN stopwords O
importance JJ importance O
of NN stopwords O
clinical JJ clinical O
history NN history O
and DT stopwords O
ancillary DT accessory O
laboratory NN lab O
procedures NN procedure O
such NN stopwords such O
as DT stopwords arsenic O
immunohistochemistry JJ immunohistochemistry O
and DT stopwords O
electron NN electron O
microscopy NN microscopy O
to NN stopwords O
avoid DT avoid O
diagnostic NN diagnostic O
pitfalls NN pitfall O

object NN object O
: : O
the NN stopwords O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
retrospective NN retrospective O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
gamma VB gamma T
knife NN knife T
radiosurgery VB T
( ( T
gks NN T
) ) T
for NN stopwords O
multiple NN multiple D
cerebral NNS cerebral D
metastases NN metastasis D
with NN stopwords O
that NN stopwords O
of NN stopwords O
whole-brain NN T
radiation VB radiation T
therapy NN therapy T
( ( T
wbrt NN T
) ) T

Patients CAPITAL VB patient O
were NN stopwords be O
randomly VB randomly O
assigned DT delegate O
either NN either O
roxithromycin NN T
150 DIGITS CD one_hundred_fifty O
mg NN milligram O
orally NN orally O
twice NN twice O
a DT stopwords angstrom O
day VB day O
( ( O
n NN nitrogen O
= NN O
102 DIGITS CD O
) ) O
or NN stopwords Oregon O
placebo NN placebo O
orally NN orally O
twice NN twice O
a DT stopwords angstrom O
day VB day O
( ( O
n NN nitrogen O
= NN O
100 DIGITS CD hundred O
) ) O

Contralateral CAPITAL NNP contralateral O
modification NN alteration O
of NN stopwords O
transitory NN ephemeral O
evoked NN arouse O
otoacoustic JJ O
emissions NN emission O

Molecular CAPITAL NNP molecular O
distances NN distance O
from JJ stopwords O
dipolar NN dipolar O
coupled NNS match O
spin-labels JJ O
: : O
the NN stopwords O
global NN global O
analysis DT analysis O
of NN stopwords O
multifrequency NN O
continuous NNS continuous O
wave VB wave O
electron NN electron O
paramagnetic NN paramagnetic O
resonance NN resonance O
data VB data O

Supramaximal CAPITAL NNP T
horizontal NN horizontal T
rectus NN rectus T
surgery NN surgery T
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
third NN one-third D
and DT stopwords D
sixth NN sixth D
nerve RB nerve D
palsy VB paralysis D

April CAPITAL DT April O
21 DIGITS CD twenty-one O
, , O
1995 DIGITS CD O

The CAPITAL NNP O
procedure NN procedure O
involves NN involve O
directed NN direct O
microdissection NN O
of NN stopwords O
one JJ one O
defined NN specify O
subchromosomal NN O
area DT area O
, , O
its NN stopwords information_technology O
DOP-PCR-amplification CAPITAL NNP O
and DT stopwords O
cloning NNS cloning O

Signals CAPITAL NNP signal O
have VB stopwords rich_person O
qualitative NN qualitative O
and DT stopwords O
quantitative NN quantitative O
aspects DT aspect O

The CAPITAL NNP O
3 DIGITS CD three O
regions NN region O
include NN include O
HLA CAPITAL NNP O
on NN stopwords on O
chromosome NN chromosome O
6p21.3 CD O
, , O
APOE CAPITAL DT O
on NN stopwords on O
chromosome NN chromosome O
19ql CD O
3.2 LS O
, , O
and DT stopwords O
MBP CAPITAL NNP O
( ( O
myelin NN myelin O
basic VB BASIC O
protein NN protein O
) ) O
on NN stopwords on O
chromosome NN chromosome O
18q23 CD O

to NN stopwords O
examine NN analyze O
whether NN O
efficacy NN efficacy O
of NN stopwords O
postoperative NN postoperative O
oral NN oral O
administration DT administration O
of NN stopwords O
uft JJ T
, , T
a DT stopwords angstrom T
5-fluorouracil CD T
derivative NN derived_function T
chemotherapeutic NNS chemotherapeutic T
agent DT agent T
, , O
may VB May O
be NN stopwords beryllium O
influenced NN influence O
by NN stopwords by O
incidence NN incidence O
of NN stopwords O
apoptosis DT apoptosis O
( ( O
apoptosis DT apoptosis O
index NN index O
) ) O
or NN stopwords Oregon O
apoptosis-related DT O
gene NN gene O
status NN status O
( ( O
p53 NN O
and DT stopwords O
bcl-2 NN O
) ) O
of NN stopwords O
the NN stopwords O
tumour NN tumor O
, , O
a DT stopwords angstrom O
total NN sum O
of NN stopwords O
162 DIGITS CD O
patients VB patient O
with NN stopwords O
pathologic VB diseased D
stage NN phase D
i NN stopwords iodine D
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
were NN stopwords be O
retrospectively NN retrospectively O
reviewed NN review O

The CAPITAL NNP O
contribution NNS contribution O
of NN stopwords O
thoracic NN pectoral T
surgery NN surgery T
to NN stopwords O
our NN stopwords O
discipline NN discipline O

Amylase CAPITAL DT amylase O
production NN production O
by NN stopwords by O
Streptomyces CAPITAL NNP streptomyces O
species NN species O

University CAPITAL NNP university O
College CAPITAL NNP college O
of NN stopwords O
Rhodesia CAPITAL NNP Zimbabwe O

Athens CAPITAL DT Athens O
, , O
Greece CAPITAL NNP Greece O
, , O
December CAPITAL NNP December O
6-9 CD O
, , O
1995 DIGITS CD O

As CAPITAL DT arsenic O
the NN stopwords O
clinical JJ clinical O
availability DT handiness O
of NN stopwords O
glycohaemoglobin/GHb NN O
measurement NN measurement O
increases NN addition O
, , O
so NN stopwords sol O
does NN stopwords Department_of_Energy O
the NN stopwords O
need JJ need O
for NN stopwords O
comparable NNS comparable O
and DT stopwords O
accurate DT accurate O
values NN values O
among DT O
different NN different O
laboratories NN lab O
and DT stopwords O
different NN different O
methods NN method O

Appetite CAPITAL DT appetite O
suppressants-most NN O
commonly NNS normally O
fenfluramines JJ T
-increase : O
the NN stopwords O
risk NN hazard O
of NN stopwords O
developing NN development O
PPH CAPITAL NNP D
( ( O
odds JJ odds O
ratio VB ratio O
, , O
6.3 CD O
) ) O
, , O
particularly NN particularly O
when NN stopwords O
used JJ use O
for NN stopwords O
more NN stopwords More O
than NN stopwords O
3 DIGITS CD three O
months NN calendar_month O
( ( O
odds JJ odds O
ratio VB ratio O
, , O
> NN O
20 DIGITS CD twenty O
) ) O

The CAPITAL NNP O
method NN method O
is NN stopwords be O
rapid VB rapid O
and DT stopwords O
complementary NNS complementary_color O
to NN stopwords O
the NN stopwords O
automated DT automatize O
sequencing NN sequence O
of NN stopwords O
all DT stopwords all O
the NN stopwords O
19 DIGITS CD nineteen O
, , O
PCR CAPITAL NNP O
amplified DT magnify O
, , O
coding NNS cryptography O
exons NN exon O
of NN stopwords O
the NN stopwords O
GAA CAPITAL VB O
gene NN gene O

By CAPITAL NNP by O
some NN stopwords some O
estimates NN estimate O
, , O
the NN stopwords O
disorder NN disorder O
may VB May O
account DT history O
for NN stopwords O
upwards JJ up O
of NN stopwords O
10 DIGITS CD ten O
% NN O
of NN stopwords O
hereditary NN familial D
deafness NN deafness D

Update CAPITAL NNP update O
on NN stopwords on O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
research NN research O

Vesico-uterine CAPITAL NNP D
fistula NN fistulous_withers D
-- : O
a DT stopwords angstrom O
rare NN rare O
complication NNS complication O
of NN stopwords O
vacuum NN vacuum T
extraction NN extraction T
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
previous NN previous O
caesarean VB cesarean_delivery T
section NN section T

In CAPITAL PRP inch O
this NN stopwords O
respect NN respect O
, , O
the NN stopwords O
response NN response O
of NN stopwords O
salivary VB salivary O
amylase DT amylase O
and DT stopwords O
salivary VB salivary O
electrolytes NN electrolyte O
to NN stopwords O
incremental NN incremental O
levels NN degree O
of NN stopwords O
exercise NN exercise O
is NN stopwords be O
of NN stopwords O
particular NN particular O
interest NN interest O

thus NN frankincense O
, , O
twice-daily NN O
pci NN T
should NN stopwords O
be NN stopwords beryllium O
considered NNS see O
for NN stopwords O
patients VB patient O
with NN stopwords O
ld NN D
sclc JJ D
who NN stopwords World_Health_Organization O
achieve DT achieve O
a DT stopwords angstrom O
complete NNS complete O
response NN response O
to NN stopwords O
chemoirradiation NNS O

XIX CAPITAL NN nineteen O

Other CAPITAL NNP other O
studies NN survey O
showed NN show O
that NN stopwords O
radiation VB radiation O
levels NN degree O
in NN stopwords inch O
Newbury CAPITAL NNP O
area DT area O
were NN stopwords be O
low NN low O

In CAPITAL PRP inch O
addition DT addition O
, , O
blacks NN black O
were NN stopwords be O
less NN lupus_erythematosus O
likely NN likely O
to NN stopwords O
have VB stopwords rich_person O
high-grade NN high-grade O
( ( O
grade NN class O
3 DIGITS CD three O
) ) O
nuclear JJ nuclear D
atypia DT D
, , O
mitotic NN mitotic O
activity DT activity O
, , O
and DT stopwords O
tubule NN tubule O
formation NN formation O
, , O
although DT O
these NN stopwords O
ORs CAPITAL NNP Oregon O
did NN stopwords make O
not JJ stopwords not O
reach NN range O
a DT stopwords angstrom O
statistical NN statistical O
significance NN significance O
level NN degree O
of NN stopwords O
0.05 LS O

1 DIGITS CD one O
: : O
Antiepileptic CAPITAL DT anticonvulsant T
drugs NN drug T

Phase CAPITAL NNP phase O
1 DIGITS CD one O
safety VB safety O
and DT stopwords O
immune JJ immune O
response NN response O
studies NN survey O
of NN stopwords O
a DT stopwords angstrom O
DNA CAPITAL NNP deoxyribonucleic_acid T
vaccine NN vaccine T
encoding NN encoding O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
surface NN surface O
antigen DT antigen O
delivered NN deliver O
by NN stopwords by O
a DT stopwords angstrom O
gene NN gene O
delivery NN delivery O
device NN device O

Human CAPITAL NNP homo O
leukocyte NN leukocyte O
antigen DT antigen O
frequencies JJ frequency O
in NN stopwords inch O
a DT stopwords angstrom O
selected NN choose O
group NN group O
of NN stopwords O
Lebanese CAPITAL NNP Lebanese O
Greek CAPITAL NNP Greek O
Orthodox CAPITAL NNP Orthodox O

It CAPITAL PRP information_technology O
is NN stopwords be O
concluded NNS reason O
that NN stopwords O
ENS CAPITAL NNP en T
is NN stopwords be O
more NN stopwords More O
effective NN effective O
for NN stopwords O
immediate JJ immediate O
relief NN relief O
of NN stopwords O
myofascial NN D
trigger NN gun_trigger D
point NN point D
pain IN pain D
than NN stopwords O
EMS CAPITAL NNP em T
, , O
and DT stopwords O
EMS CAPITAL NNP em T
has VB stopwords hour_angle O
a DT stopwords angstrom O
better NN better O
effect NN consequence O
on NN stopwords on O
immediate JJ immediate O
release NN release O
of NN stopwords O
muscle NN muscle D
tightness NN stringency D
than NN stopwords O
ENS CAPITAL NNP en T

The CAPITAL NNP O
naming RB naming O
of NN stopwords O
a DT stopwords angstrom O
syndrome NN syndrome O

Demographic CAPITAL NNP demographic O
information NN information O
, , O
hours NN hours O
from JJ stopwords O
rupture NN rupture O
of NN stopwords O
membranes NN membrane O
to NN stopwords O
delivery NN delivery O
, , O
gestational NN gestational O
age DT age O
, , O
and DT stopwords O
birth NN birth O
weight NN weight O
at DT stopwords astatine O
delivery NN delivery O
were NN stopwords be O
compared NNS compare O
using JJ exploitation O
Fisher CAPITAL NNP fisherman O
's POS O
exact NN demand O
, , O
Mann-Whitney CAPITAL NNP O
U CAPITAL NN uracil O
, , O
and DT stopwords O
randomization VB randomization O
tests NN trial O
where NN stopwords O
appropriate DT allow O

Importantly CAPITAL PRP importantly O
, , O
the NN stopwords O
clinical JJ clinical O
benefits NN benefit O
offered JJ offer O
by NN stopwords by O
fluticasone JJ T
propionate NN T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
persistent NN persistent D
asthma DT asthma D
are DT stopwords are O
accompanied DT attach_to O
by NN stopwords by O
clinically JJ clinically O
significant NN significant O
improvements JJ improvement O
in NN stopwords inch O
quality NN quality O
of NN stopwords O
life NN life O

STUDY CAPITAL NNP survey O
DESIGN CAPITAL NNP design O
: : O
This CAPITAL NNP O
was VB stopwords Washington O
a DT stopwords angstrom O
retrospective NN retrospective O
cohort NNS cohort O
study NN survey O

The CAPITAL NNP O
histone NN histone O
H1 CAPITAL $ O
genes NN gene O
of NN stopwords O
the NN stopwords O
dipteran NN dipterous_insect O
insect NN insect O
, , O
Chironomus CAPITAL NNP Chironomus O
thummi NN O
, , O
fall VB fall O
under JJ stopwords nether O
two NN two O
divergent NN divergent O
classes NNS class O
and DT stopwords O
encode NN encode O
proteins NN protein O
with NN stopwords O
distinct NN distinct O
intranuclear NN O
distribution NN distribution O
and DT stopwords O
potentially NN potentially O
different NN different O
functions JJ function O

Blood CAPITAL NNP blood O
volume NN volume O
measurements NN measurement O
in NN stopwords inch O
burn NN burn D
therapy NN therapy T

From CAPITAL NNP O
June CAPITAL NNP June O
11 DIGITS CD eleven O
to NN stopwords O
August CAPITAL DT August O
16 DIGITS CD sixteen O
, , O
1993 DIGITS CD O
, , O
during NN stopwords O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
unusual JJ unusual O
high NN high O
heat NN heat O
, , O
42 DIGITS CD forty-two O
women NN woman O
with NN stopwords O
singleton NN singleton O
pregnancies NN pregnancy O
between NN stopwords between O
27 DIGITS CD twenty-seven O
and DT stopwords O
40 DIGITS CD forty O
weeks NN week O
' '' O
gestation NN gestation O
undergoing JJ undergo O
serial NN serial O
antenatal DT prenatal O
testing NN testing O
had VB stopwords have O
AFI CAPITAL DT O
determinations NN determination O
recorded NN record O
at DT stopwords astatine O
least NN least O
weekly NN weekly O

Phenylbutazone CAPITAL NNP phenylbutazone T
and DT stopwords O
acute DT acute_accent D
leukemia NN leukemia D
. . O

Generalised CAPITAL NNP generalize O
caseous VB caseous D
lymphadenitis NN lymphadenitis D

Comparison CAPITAL NNP comparison O
of NN stopwords O
three NN three O
methods NN method O
used JJ use O
for NN stopwords O
assessment DT appraisal O
of NN stopwords O
pain IN pain D
in NN stopwords inch O
dogs NN dog O

A CAPITAL DT angstrom O
tentative NN probationary O
draft NN draft O
of NN stopwords O
qualitative NN qualitative O
test NN trial O
of NN stopwords O
fluoride JJ fluoride O
for NN stopwords O
adoption DT adoption O
to NN stopwords O
the NN stopwords O
general NN general O
tests NN trial O
of NN stopwords O
eighth NN eighth O
revised NN revise O
edition NN edition O
of NN stopwords O
the NN stopwords O
Pharmacopoeia CAPITAL NNP pharmacopoeia O
of NN stopwords O
Japan CAPITAL NNP Japan O

Haemodynamic CAPITAL NNP O
performance NN performance O
of NN stopwords O
a DT stopwords angstrom O
16-mm CD O
Carbomedics CAPITAL VB O
aortic DT aortal O
prosthesis NN prosthesis O

As CAPITAL DT arsenic O
culture NNS culture O
solutions NN solution O
, , O
we NN stopwords O
used JJ use O
four JJ four O
simple NN simple O
salines VB saline_solution O
( ( O
IMADS CAPITAL PRP O
) ) O
and DT stopwords O
a DT stopwords angstrom O
complex NNS complex O
tissue-culture NN O
medium NN medium O
( ( O
R-14 CAPITAL NNP O
) ) O
that NN stopwords O
matched VB match O
the NN stopwords O
osmolarity JJ O
of NN stopwords O
adult DT adult O
hemolymph NN O

Descriptive CAPITAL NNP descriptive O
statistics NN statistics O
were NN stopwords be O
used JJ use O
to NN stopwords O
analyze DT analyze O
the NN stopwords O
data VB data O
retrieved NN recover O
from JJ stopwords O
the NN stopwords O
questionnaires NN questionnaire O

Generation CAPITAL NNP coevals O
of NN stopwords O
diversity NN diverseness O
in NN stopwords inch O
mammalian VB mammal O
gut-associated NN O
lymphoid NN lymphoid O
tissues NN tissue O
: : O
restricted NN restrict O
V CAPITAL NN volt O
gene NN gene O
usage JJ use O
does NN stopwords Department_of_Energy O
not JJ stopwords not O
preclude NN prevent O
complex NNS complex O
V CAPITAL NN volt O
gene NN gene O
organization JJ organization O

Voluntary CAPITAL NNP volunteer O
death NN death O
: : O
a DT stopwords angstrom O
comparison NNS comparison O
of NN stopwords O
terminal NN terminal O
dehydration NN dehydration D
and DT stopwords O
physician-assisted NN O
suicide JJ suicide O

Inferences CAPITAL PRP inference O
from JJ stopwords O
symphysiotomy NN T
experience NN experience O

1981 DIGITS CD O

The CAPITAL NNP O
Biopsychosocial CAPITAL NNP O
Model CAPITAL NNP model O
of NN stopwords O
medical NN checkup O
practice NN practice O
is NN stopwords be O
demonstrated NN show O
through NN stopwords done O
multiple NN multiple O
interdisciplinary NN interdisciplinary O
perspectives NN position O
of NN stopwords O
needs JJ need O
and DT stopwords O
interventions NN intervention O
for NN stopwords O
patients VB patient O
with NN stopwords O
obvious NN obvious O
functional JJ functional O
deficits NN deficit O

She CAPITAL NNP O
was VB stopwords Washington O
admitted DT admit O
with NN stopwords O
high NN high D
fever JJ fever D
, , O
shock NN daze D
, , O
and DT stopwords O
multiorgan NN O
involvement NN engagement O

The CAPITAL NNP O
combination NNS combination O
of NN stopwords O
surgery NN surgery D
and DT stopwords O
radiotherapy VB radiotherapy D
has VB stopwords hour_angle O
the NN stopwords O
worst NN worst O
morbidity NN morbidity O
, , O
especially NN particularly O
urological JJ O
complications NNS complication O

DATA CAPITAL NNP data O
EXTRACTION CAPITAL NNP extraction O
: : O
Reports CAPITAL NNP report O
were NN stopwords be O
reviewed NN review O
by NN stopwords by O
individuals NN person O
with NN stopwords O
expertise NN expertness O
in NN stopwords inch O
serotonin NN serotonin O
neurobiology JJ neurobiology O
, , O
neurotoxicity JJ O
, , O
neuropsychiatry JJ neuropsychiatry O
, , O
and DT stopwords O
pulmonary NN pneumonic O
medicine NN medicine O
and DT stopwords O
evaluated NN measure O
for NN stopwords O
appropriateness DT appropriateness O
for NN stopwords O
inclusion NN inclusion O
in NN stopwords inch O
this NN stopwords O
review NN reappraisal O

amifostine DT T
( ( T
wr-2721 NN T
) ) T
is NN stopwords be O
a DT stopwords angstrom O
cytoprotective NNS O
agent DT agent O
that NN stopwords O
protects NN protect O
a DT stopwords angstrom O
broad NN broad O
range VB scope O
of NN stopwords O
normal RB convention O
tissues NN tissue O
from JJ stopwords O
the NN stopwords O
toxic NN toxic D
effects NN effects D
of NN stopwords D
chemotherapy NNS chemotherapy D
and DT stopwords D
radiotherapy VB radiotherapy D
without NN O
attenuating DT rarefy O
tumour NN tumor O
response NN response O

Safety CAPITAL VB safety O
and DT stopwords O
potential NN potential O
effectiveness NN effectiveness O
of NN stopwords O
daunorubicin-containing VB T
liposomes NN liposome T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
advanced DT advance D
recurrent NN perennial D
malignant VB malignant D
CNS CAPITAL NNP central_nervous_system D
tumors NN tumor D

radiotherapy VB radiotherapy T
is NN stopwords be O
effective NN effective O
for NN stopwords O
palliation VB palliation O
of NN stopwords O
symptoms NN symptom D
associated DT associate D
with NN stopwords D
sblc NN D

Combined CAPITAL NNP unite T
interferon NN interferon T
and DT stopwords T
lamivudine NN lamivudine T
therapy NN therapy T
: : O
is NN stopwords be O
this NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
choice NNS choice O
for NN stopwords O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
virus NN virus D
infection NN infection D
? . O

Structure CAPITAL NNP structure O
and DT stopwords O
expression NN expression O
of NN stopwords O
the NN stopwords O
chicken JJ chicken O
calmodulin VB O
I CAPITAL PRP iodine O
gene NN gene O

A CAPITAL DT angstrom O
single NN single O
training NN training O
bout NN turn O
per NN O
day VB day O
was VB stopwords Washington O
previously NN previously O
considered NNS see O
sufficient NN sufficient O
, , O
whereas NN O
today NN today O
athletes DT athlete O
regularly NN regularly O
train NN train O
twice NN twice O
a DT stopwords angstrom O
day VB day O
or NN stopwords Oregon O
more NN stopwords More O

CONCLUSIONS CAPITAL NNP decision O
: : O
B CAPITAL NN bacillus O

Tissue CAPITAL NNP tissue O
adhesives DT adhesive_material O
-- : O
revisited NN revisit O

Mouse CAPITAL NNP mouse O
LIM-kinase CAPITAL NNP O
2 DIGITS CD two O
gene NN gene O
: : O
cDNA SYM complementary_DNA O
cloning NNS cloning O
, , O
genomic NN O
organization JJ organization O
, , O
and DT stopwords O
tissue-specific NN O
expression NN expression O
of NN stopwords O
two NN two O
alternatively DT alternatively O
initiated JJ originate O
transcripts NN transcript O

118 DIGITS CD O
, , O
437-466 CD O
, , O
1989 DIGITS CD O
) ) O
models NN model O

Delayed CAPITAL NNP delay O
healing NN healing O
of NN stopwords O
rhytidectomy NN face_lift T
flap NN flap O
resurfaced NN resurface O
with NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
laser NN laser O

Influence CAPITAL PRP influence O
of NN stopwords O
environmental NN environmental O
factors VB factor O
on NN stopwords on O
fertility NN birthrate O
: : O
example NN example O
of NN stopwords O
the NN stopwords O
diminution NN decline O
of NN stopwords O
sperm NN sperm O
quality NN quality O

A CAPITAL DT angstrom O
combined NNS unite T
therapy NN therapy T
results NN consequence O
in NN stopwords inch O
eradication NN eradication O
of NN stopwords O
the NN stopwords O
bacterium VB bacteria D
and DT stopwords O
in NN stopwords inch O
improvement JJ improvement O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
symptoms NN symptom O
in NN stopwords inch O
a DT stopwords angstrom O
significant NN significant O
majority VB majority O
of NN stopwords O
the NN stopwords O
patients VB patient O

Chronic CAPITAL NNP chronic D
histiocytosis NN histiocytosis D
X CAPITAL NN ten D
associated DT associate O
with NN stopwords O
pregnancy NN pregnancy O

We CAPITAL NNP O
varied NN change O
the NN stopwords O
composition NNS composition O
and DT stopwords O
the NN stopwords O
osmolarity JJ O
of NN stopwords O
the NN stopwords O
culture NNS culture O
solution NN solution O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
the NN stopwords O
electrical NN electrical O
charge NNS charge O
and DT stopwords O
the NN stopwords O
molecular NN molecular O
mass VB mass O
of NN stopwords O
the NN stopwords O
microinjected NN O
fluorescent JJ fluorescent O
probe NN probe O

Primary CAPITAL NNP primary O
efficacy NN efficacy O
endpoint NN end_point O
was VB stopwords Washington O
the NN stopwords O
percentage NN percentage O
improvement JJ improvement O
in NN stopwords inch O
Unified CAPITAL NNP unify O
Parkinson CAPITAL VB Parkinson D
's POS D
Disease CAPITAL NNP disease D
Rating CAPITAL VB evaluation O
Scale CAPITAL NNP scale O
( ( O
UPDRS CAPITAL NNP O
) ) O
motor NN motor O
score JJ mark O

The CAPITAL NNP O
mean NN mean O
volume NN volume O
of NN stopwords O
late-phase NN O
( ( O
6 DIGITS CD six O
months NN calendar_month O
) ) O
lesions NN lesion O
was VB stopwords Washington O
22 DIGITS CD twenty-two O
+/- NN O
28.8 CD O
mm3 NN O

Amyloidosis CAPITAL DT amyloidosis D
of NN stopwords O
the NN stopwords O
cornea NNS cornea O

Conflict CAPITAL NNP conflict O
and DT stopwords O
conditioned NNS condition O
aversive DT aversive O
stimuli JJ stimulation O
in NN stopwords inch O
the NN stopwords O
development NN development O
of NN stopwords O
experimental NN experimental O
neuroses JJ neurosis O

Seven CAPITAL NNP seven O
basic VB BASIC O
considerations NNS consideration O
can VB stopwords can O
be NN stopwords beryllium O
identified NN identify O
that NN stopwords O
determine NN determine O
the NN stopwords O
evidence NN evidence O
contained NNS incorporate O
in NN stopwords inch O
a DT stopwords angstrom O
signal NN signal O
: : O
quantitative NN quantitative O
strength NN strength O
of NN stopwords O
the NN stopwords O
association DT association O
, , O
consistency NNS consistency O
of NN stopwords O
the NN stopwords O
data VB data O
, , O
exposure NN exposure O
response NN response O
relationship NN relationship O
, , O
biological NN biological O
plausibility NN plausibility O
, , O
experimental NN experimental O
findings NN findings O
, , O
possible NN possible O
analogies DT analogy O
and DT stopwords O
the NN stopwords O
nature RB nature O
and DT stopwords O
quality NN quality O
of NN stopwords O
the NN stopwords O
data VB data O

What CAPITAL NNP O
investigations NN probe O
and DT stopwords O
procedures NN procedure O
do NN stopwords bash O
patients VB patient O
in NN stopwords inch O
hospices NN hospice O
want VB privation O
? . O
Interview CAPITAL PRP interview O
based VB establish O
survey NN survey O
of NN stopwords O
patients VB patient O
and DT stopwords O
their NN stopwords O
nurses RB nurse O

OBJECTIVE CAPITAL NNP aim O
: : O
This CAPITAL NNP O
retrospective NN retrospective O
study NN survey O
was VB stopwords Washington O
designed NN plan O
to NN stopwords O
confirm NNS confirm O
that NN stopwords O
aggressive DT aggressive T
pulmonary NN pneumonic T
resection NN resection T
can VB stopwords can O
provide NN supply O
effective NN effective O
long-term NN long-run O
palliation VB palliation O
of NN stopwords O
disease NN disease O
for NN stopwords O
patients VB patient O
with NN stopwords O
pulmonary NN pneumonic D
aspergilloma DT D

< NN O
TO_SEE CAPITAL NNP O
> NN O
Fatal CAPITAL NNP fatal O
spontaneous NN spontaneous O
spinal JJ spinal_anesthesia O
epidural NN epidural_anesthesia O
hematoma NN hematoma O
following JJ following O
thrombolysis NN thrombolysis O
for NN stopwords O
myocardial NN myocardial O
infarction NN infarct O

In CAPITAL PRP inch O
humans NN world O
a DT stopwords angstrom O
series NN series O
of NN stopwords O
conditions NNS conditions O
related NN associate O
to NN stopwords O
hormonal NN hormonal D
dysfunction NN dysfunction D
as DT stopwords arsenic O
undescended JJ undescended O
testis NN testis O
, , O
decreased NN decrease O
spermatogenesis NN spermatogenesis O
, , O
testicular NN testicular D
cancer VB cancer D
and DT stopwords O
endometriosis NN endometriosis D
have VB stopwords rich_person O
increased NN increase O
in NN stopwords inch O
incidence NN incidence O
during NN stopwords O
the NN stopwords O
last NN stopping_point O
decades NN decade O

The CAPITAL NNP O
dry NN dry O
stored NN store O
lactate NN lactate O
catheter VB catheter O
needs JJ need O
about DT stopwords about O
10 DIGITS CD ten O
min NN minute O
for NN stopwords O
hydration NN hydration O
and DT stopwords O
is NN stopwords be O
characterized NNS qualify O
by NN stopwords by O
response NN response O
times NN times O
t98 RB O
% NN O
of NN stopwords O
less NN lupus_erythematosus O
than NN stopwords O
2 DIGITS CD two O
min NN minute O

Intrapartum CAPITAL PRP O
sonography NN sonography O
of NN stopwords O
the NN stopwords O
lower NN lower_berth O
uterine JJ uterine O
segment NN section O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
breech-presenting NN O
fetuses JJ fetus O

small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
is NN stopwords be O
a DT stopwords angstrom O
frequently JJ frequently O
relapsing NN backsliding O
tumor NN tumor O
despite NN contempt O
a DT stopwords angstrom O
high NN high O
rate VB rate O
of NN stopwords O
response NN response O
after DT stopwords after O
first-line NN O
chemotherapy NNS chemotherapy T

tumor NN tumor T
vaccines NN vaccine T
against DT stopwords O
gangliosides VB O
that NN stopwords O
are DT stopwords are O
expressed NN express O
on NN stopwords on O
almost DT about O
all DT stopwords all O
human NN homo O
sclc JJ D
cells NNS cell O
have VB stopwords rich_person O
been NN stopwords be O
recently NN recently O
developed NN develop O

The CAPITAL NNP O
rehabilitation NN rehabilitation O
consultation NNS consultation O
service NN service O
is NN stopwords be O
particularly NN particularly O
effective NN effective O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
introduction NN introduction O
to NN stopwords O
hospital-based NN O
medical NN checkup O
practice NN practice O
due NN due O
to NN stopwords O
the NN stopwords O
diagnostic NN diagnostic O
variety NN assortment O
of NN stopwords O
the NN stopwords O
patients VB patient O
, , O
the NN stopwords O
functional JJ functional O
approach DT approach O
of NN stopwords O
rehabilitation NN rehabilitation O
, , O
and DT stopwords O
student NN student O
exposure NN exposure O
to NN stopwords O
multiple NN multiple O
hospital NN hospital O
settings NN setting O

Despite CAPITAL NNP contempt O
this NN stopwords O
, , O
cholecystectomy NNS cholecystectomy T
as DT stopwords arsenic O
a DT stopwords angstrom O
treatment NN treatment O
for NN stopwords O
biliary NN bilious D
dyskinesia NN dyskinesia D
remains NN remains O
controversial NNS controversial O

The CAPITAL NNP O
protein NN protein O
was VB stopwords Washington O
found JJ found O
on NN stopwords on O
a DT stopwords angstrom O
subset NN subset O
of NN stopwords O
axons DT axon O
in NN stopwords inch O
the NN stopwords O
central NNS central O
and DT stopwords O
peripheral NN peripheral O
nervous RB nervous O
system NN system O
and DT stopwords O
is NN stopwords be O
likely NN likely O
to NN stopwords O
be NN stopwords beryllium O
involved NN involve O
in NN stopwords inch O
specific NN particular O
cell-cell NNS O
interactions NN interaction O
in NN stopwords inch O
neurohistogenesis JJ O

Consensus CAPITAL NNP consensus O
of NN stopwords O
the NN stopwords O
Surgical CAPITAL NNP surgical O
Working CAPITAL NNP working O
Group CAPITAL NNP group O
for NN stopwords O
Oncology CAPITAL NNP oncology O
, , O
the NN stopwords O
Working CAPITAL NNP working O
Group CAPITAL NNP group O
for NN stopwords O
Medical CAPITAL NNP checkup O
Oncology CAPITAL NNP oncology O
and DT stopwords O
the NN stopwords O
Working CAPITAL NNP working O
Group CAPITAL NNP group O
for NN stopwords O
Radiologic CAPITAL VB O
Oncology CAPITAL NNP oncology O

Various CAPITAL VB assorted O
aspects DT aspect O
of NN stopwords O
diuresis NN diuresis D
in NN stopwords inch O
heart NN heart D
congestive NNS congestive D
failure VB failure D

Ectopic CAPITAL NNP ectopic D
pregnancy NN pregnancy D
recurrence NN recurrence O
: : O
role NN function O
of NN stopwords O
gynecologic NN gynecological O
, , O
obstetric NN obstetric O
, , O
contraceptive NNS contraceptive O
and DT stopwords O
smoking JJ smoke O
history NN history O

Res CAPITAL NNP reticuloendothelial_system O

However CAPITAL NNP however O
, , O
an DT stopwords Associate_in_Nursing O
exercise NN exercise O
intensity NN intensity O
of NN stopwords O
65 DIGITS CD sixty-five O
% NN O
VO2max CAPITAL NNP O
results NN consequence O
in NN stopwords inch O
a DT stopwords angstrom O
slight JJ rebuff O
decrease NN decrease O
in NN stopwords inch O
the NN stopwords O
amount DT sum O
of NN stopwords O
plasma NN plasma O
FFA CAPITAL NNP O
uptake JJ consumption O
by NN stopwords by O
muscle NN muscle O
tissue NN tissue O

A CAPITAL DT angstrom O
simplified NN simplify O
laparoscopic NN T
technique NN technique T
for NN stopwords T
mesh NN mesh T
placement NN placement T
in NN stopwords inch O
ventral NN ventral D
hernia NN hernia D
repair NN repair O

we NN stopwords O
further NN stopwords foster O
developed NN develop O
a DT stopwords angstrom O
vaccine NN vaccine O
model NN model O
based VB establish O
on NN stopwords on O
s.c.injection NN O
of NN stopwords O
infected NN infect O
, , O
irradiated NN enlighten O
rm-9 NN O
cells NNS cell O
and DT stopwords O
found JJ found O
that NN stopwords O
both NN stopwords both O
admil-12 DT T
and DT stopwords T
admil-12/b7 DT T
are DT stopwords are O
effective NN effective O
at DT stopwords astatine O
suppressing NN suppress O
the NN stopwords O
development NN development O
and DT stopwords O
growth NN growth O
of NN stopwords O
challenge NNS challenge D
orthotopic JJ D
tumors NN tumor D
using JJ exploitation O
this NN stopwords O
protocol NN protocol O

Significance CAPITAL NNP significance O
of NN stopwords O
revision NN revision O
of NN stopwords O
the NN stopwords O
occupational JJ occupational O
illness NN illness O
legislation NN legislation O
for NN stopwords O
evaluating NN measure O
intervertebral NN intervertebral D
disk NN disk D
damage VB damage D

The CAPITAL NNP O
comfort NNS comfort O
movements NN motion O
of NN stopwords O
Anatidae CAPITAL DT Anatidae O

Report CAPITAL NNP report O
of NN stopwords O
a DT stopwords angstrom O
case VB case O
without NN O
conjunctival NNS conjunctival O
involvement NN engagement O

Receptor CAPITAL NNP receptor O
Classification CAPITAL NNP categorization O
: : O
The CAPITAL NNP O
Integration CAPITAL PRP integration O
of NN stopwords O
Operational CAPITAL NNP operational O
, , O
Structural CAPITAL NNP structural O
, , O
and DT stopwords O
Transductional CAPITAL NNP O
Information CAPITAL PRP information O

The CAPITAL NNP O
initial JJ initial O
hemoglobin NN hemoglobin O
was VB stopwords Washington O
2.2 CD O
g/dL NN O
, , O
the NN stopwords O
Kleihauer-Betke CAPITAL NNP O
stain NN stain O
was VB stopwords Washington O
27.6 CD O
% NN O
( ( O
highest NN high O
level NN degree O
ever NN ever O
reported NN report O
) ) O

A CAPITAL DT angstrom O
specialist NN specialist O
nurse RB nurse O
can VB stopwords can O
replace NN replace O
pre-registration NN O
house NN house O
officers JJ military_officer O
in NN stopwords inch O
the NN stopwords O
surgical NN surgical O
pre-admission NN O
clinic JJ clinic O

Rethink CAPITAL NNP reconsideration O
on NN stopwords on O
screening NN screening O
for NN stopwords O
breast NN breast D
cancer VB cancer D

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
The CAPITAL NNP O
families VB family O
were NN stopwords be O
divided NN divide O
into NN stopwords O
2 DIGITS CD two O
groups NN group O
: : O
either NN either O
potentially NN potentially O
linked NN associate O
( ( O
33 DIGITS CD thirty-three O
families VB family O
with NN stopwords O
133 DIGITS CD O
men NN work_force O
with NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
) ) O
, , O
and DT stopwords O
thus NN frankincense O
likely NN likely O
to NN stopwords O
be NN stopwords beryllium O
carrying VB transport O
an DT stopwords Associate_in_Nursing O
altered DT change O
HPC1 CAPITAL NNP O
gene NN gene O
, , O
or NN stopwords Oregon O
potentially NN potentially O
unlinked JJ O
( ( O
41 DIGITS CD forty-one O
families VB family O
with NN stopwords O
172 DIGITS CD O
men NN work_force O
with NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
) ) O
, , O
on NN stopwords on O
the NN stopwords O
basis VB footing O
of NN stopwords O
haplotype VB haplotype O
analysis DT analysis O
in NN stopwords inch O
the NN stopwords O
region NN region O
of NN stopwords O
HPC1 CAPITAL NNP O

Outpatient CAPITAL NNP outpatient O
care VB care O
-- : O
the NN stopwords O
role NN function O
of NN stopwords O
the NN stopwords O
nurse RB nurse O

As CAPITAL DT arsenic O
the NN stopwords O
overview JJ overview O
shows NN show O
, , O
both NN stopwords both O
groups NN group O
of NN stopwords O
substances NN substance O
are DT stopwords are O
useful JJ useful O
for NN stopwords O
individualized NN individualize O
treatment NN treatment O
of NN stopwords O
benign NN benign D
prostatic NN prostate D
hyperplasia NN hyperplasia D
( ( D
BPH CAPITAL NNP benign_prostatic_hyperplasia D
) ) D
, , O
provided NN supply O
that NN stopwords O
conservative NNS conservative O
pharmacological NN pharmacological T
treatment NN treatment T
of NN stopwords O
BPH CAPITAL NNP benign_prostatic_hyperplasia D
is NN stopwords be O
basically VB basically O
accepted DT accept O
and DT stopwords O
that NN stopwords O
the NN stopwords O
patients VB patient O
' '' O
quality NN quality O
of NN stopwords O
life NN life O
is NN stopwords be O
also DT besides O
considered NNS see O

Post-acquisition CAPITAL NNP O
solvent NN solvent O
suppression NN suppression O
by NN stopwords by O
singular-value NN O
decomposition NN decomposition O

Thrombolytic CAPITAL NNP thrombolytic T
therapy NN therapy T
has VB stopwords hour_angle O
been NN stopwords be O
accepted DT accept O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D

Current CAPITAL NNP current O
results NN consequence O
suggest NN propose O
that NN stopwords O
RHBP CAPITAL NNP T
remains NN remains O
the NN stopwords O
gold NN gold O
standard NN standard O
for NN stopwords O
severe NN severe D
RV CAPITAL NNP recreational_vehicle D
failure VB failure D
, , O
but NN stopwords merely O
further NN stopwords foster O
clinical JJ clinical O
experience NN experience O
with NN stopwords O
PABC CAPITAL VB O
may VB May O
more NN stopwords More O
clearly NNS clearly O
define NN specify O
its NN stopwords information_technology O
role NN function O
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
RV CAPITAL NNP recreational_vehicle O
failure VB failure O

METHODS CAPITAL NNP method O
AND CAPITAL DT O
RESULTS CAPITAL NNP consequence O
: : O
In CAPITAL PRP inch O
1994 DIGITS CD O
, , O
24 DIGITS CD twenty-four O
months NN calendar_month O
after DT stopwords after O
enrollment NN registration O
in NN stopwords inch O
a DT stopwords angstrom O
longitudinal NN longitudinal O
study NN survey O
, , O
326 DIGITS CD O
high-risk NN bad O
adults DT adult O
underwent JJ undergo O
both NN stopwords both O
3- CD O
and DT stopwords O
6-mm CD O
image-slice NN O
thickness NN thickness O
EBCT CAPITAL NN O
scanning JJ scanning O
and DT stopwords O
were NN stopwords be O
followed JJ follow O
up JJ stopwords up O
for NN stopwords O
32.0+/-4.0 CD O
additional DT extra O
months NN calendar_month O

Consumption CAPITAL NNP consumption O
of NN stopwords O
alcohol DT alcohol O
and DT stopwords O
mortality NN mortality O
in NN stopwords inch O
Russia CAPITAL NNP Soviet_Union O

Epidemiology CAPITAL NNP epidemiology O
of NN stopwords O
hypertension NN high_blood_pressure D

Effect CAPITAL NNP consequence O
of NN stopwords O
iodixanol NN D
on NN stopwords on O
renal NN nephritic O
function JJ function O
immediately JJ immediately O
after DT stopwords after O
abdominal DT abdominal T
angiography DT angiography T
. . O

The CAPITAL NNP O
somatic NN bodily O
cells NNS cell O
become NN become O
senescent NN aging O
because NN stopwords O
during NN stopwords O
cell NNS cell O
division NN division O
, , O
they NN stopwords O
lose NN lose O
the NN stopwords O
mechanisms NN mechanism O
for NN stopwords O
the NN stopwords O
lengthening NN prolongation O
of NN stopwords O
the NN stopwords O
telomere NN telomere O

Mortality CAPITAL NNP mortality O
and DT stopwords O
refusal NN refusal O
of NN stopwords O
ICU CAPITAL PRP intensive_care_unit O
admission DT admission O

However CAPITAL NNP however O
, , O
these NN stopwords O
results NN consequence O
have VB stopwords rich_person O
to NN stopwords O
be NN stopwords beryllium O
confirmed NNS confirm O
by NN stopwords by O
larger NN bigger O
trials NN test O
, , O
currently NNS presently O
underway JJ afoot O
, , O
before NN stopwords earlier O
to NN stopwords O
consider NNS see O
that NN stopwords O
beta-blockade NN O
should NN stopwords O
definitely NN decidedly O
be NN stopwords beryllium O
incorporated NN integrate O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
heart NN heart O
failure VB failure O

Diagnostic CAPITAL NNP diagnostic O
evaluation NN evaluation O
of NN stopwords O
the NN stopwords O
patient VB patient O
with NN stopwords O
high NN high D
blood NN blood D
pressure NN pressure D

the NN stopwords O
only JJ stopwords lone O
specific NN particular O
antidote DT antidote O
for NN stopwords O
dosage-dependent NN D
hepatotoxicity NN D
is NN stopwords be O
n-acetylcysteine SYM T
( ( T
and DT stopwords T
some NN stopwords some T
other JJ stopwords other T
sulfhydryl NN T
donors NN donor T
) ) T
, , O
which NN stopwords O
is NN stopwords be O
highly NN highly O
effective NN effective O
for NN stopwords O
the NN stopwords O
prevention NN prevention O
of NN stopwords O
significant NN significant O
hepatotoxicity NN O
after DT stopwords after O
acetaminophen DT acetaminophen O
overdose JJ overdose O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
evaluate NN measure O
the NN stopwords O
performance NN performance O
of NN stopwords O
DPL CAPITAL NNP O
in NN stopwords inch O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
intra-abdominal NN D
injury NN injury D
in NN stopwords inch O
hemodynamically NN O
stable NN stable O
patients VB patient O
with NN stopwords O
gunshot NN gunfire D
wounds NN wound D
to NN stopwords O
the NN stopwords O
abdomen DT abdomen O

Data CAPITAL NNP data O
on NN stopwords on O
the NN stopwords O
actual DT actual O
state NN state O
of NN stopwords O
inter-laboratory NN O
and DT stopwords O
inter-assay NN O
differences NN difference O
of NN stopwords O
observed NN detect O
values NN values O
were NN stopwords be O
useful JJ useful O
for NN stopwords O
comparing NNS comparison O
results NN consequence O
among DT O
facilities VB facility O

Type CAPITAL NNP type O
C CAPITAL SYM degree_centigrade O
effects NN effects O
( ( O
those NN stopwords O
effects NN effects O
related NN associate O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
increased NN increase O
frequency JJ frequency O
of NN stopwords O
'spontaneous POS O
' '' O
disease NN disease O
) ) O
are DT stopwords are O
difficult NN difficult O
to NN stopwords O
study NN survey O
, , O
however NN however O
, , O
and DT stopwords O
continue NNS continue O
to NN stopwords O
pose NN airs O
a DT stopwords angstrom O
pharmacoepidemiological NN O
challenge NNS challenge O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
assess DT buttocks O
the NN stopwords O
medicalising NN O
effect NN consequence O
of NN stopwords O
prescribing NN order O
antibiotics DT antibiotic T
for NN stopwords O
sore NN sore D
throat NN throat D

Complete CAPITAL NNP complete O
genomic NN O
screen NN screen O
in NN stopwords inch O
late-onset NN O
familial VB familial O
Alzheimer CAPITAL DT D
disease NN disease D

Compared CAPITAL NNP compare O
to NN stopwords O
two NN two O
other JJ stopwords other O
commonly NNS normally O
used JJ use O
algorithms DT algorithm O
, , O
molecular NN molecular O
dynamics NN dynamics O
in NN stopwords inch O
Cartesian CAPITAL VB Cartesian O
space NN space O
and DT stopwords O
metric-matrix NN O
geometry NN geometry O
combined NNS unite O
with NN stopwords O
Cartesian CAPITAL VB Cartesian O
molecular NN molecular O
dynamics NN dynamics O
, , O
the NN stopwords O
method NN method O
shows NN show O
increased NN increase O
computational NNS computational O
efficiency NN efficiency O
and DT stopwords O
success NN success O
rate VB rate O
for NN stopwords O
large NN large O
proteins NN protein O
, , O
and DT stopwords O
it NN stopwords information_technology O
shows NN show O
a DT stopwords angstrom O
dramatically NN dramatically O
increased NN increase O
radius VB radius O
of NN stopwords O
convergence NNS convergence O
for NN stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O

Patients CAPITAL VB patient O
with NN stopwords O
evidence NN evidence O
of NN stopwords O
infection NN infection D
with NN stopwords D
H. CAPITAL NNP D
pylori NN pylorus D
were NN stopwords be O
treated NN treat O
with NN stopwords O
a DT stopwords angstrom O
combination NNS combination T
of NN stopwords T
omeprazole JJ omeprazole T
, , T
amoxicillin DT amoxicillin T
, , T
and DT stopwords T
clarithromycin NNS T

STUDY CAPITAL NNP survey O
DESIGN CAPITAL NNP design O
: : O
Thirty CAPITAL NNP thirty O
children JJ child O
, , O
aged DT aged O
6.4 CD O
to NN stopwords O
16.4 CD O
years NN old_age O
, , O
with NN stopwords O
epilepsy NN epilepsy D
and DT stopwords O
ADHD CAPITAL DT attention_deficit_disorder D
were NN stopwords be O
studied NN analyze O
during NN stopwords O
a DT stopwords angstrom O
4-month CD O
period NN time_period O

Lamaze CAPITAL VB O
and DT stopwords O
Bradley CAPITAL NNP Bradley O
childbirth JJ childbirth O
classes NNS class O

< NN O
TO_SEE CAPITAL NNP O
> NN O
We CAPITAL NNP O
describe NN describe O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
left NN left D
cardiac VB cardiac D
herniation NN hernia D
presenting NN show O
after DT stopwords after O
intrapericardial NN T
pulmonectomy NN T
for NN stopwords O
primary NN primary D
lung NN lung D
cancer VB cancer D

Electrophysiological CAPITAL NNP O
evidence NN evidence O
on NN stopwords on O
the NN stopwords O
time NN time O
course NNS course O
of NN stopwords O
semantic NN semantic O
and DT stopwords O
phonological NN phonological O
processes NN procedure O
in NN stopwords inch O
speech NN address O
production NN production O

Commentary CAPITAL NNP comment O
: : O
are DT stopwords are O
nurses RB nurse O
effective NN effective O
providers NN supplier O
of NN stopwords O
labor NN labor O
support NN support O
? . O
Should CAPITAL NNP O
they NN stopwords O
be NN stopwords beryllium O
? . O
Can CAPITAL VB can O
they NN stopwords O
be NN stopwords beryllium O
? . O

Other CAPITAL NNP other O
studies NN survey O
have VB stopwords rich_person O
reported NN report O
TEOAEs CAPITAL NNP O
in NN stopwords inch O
all DT stopwords all O
normal RB convention O
ears VB ear O

CONCLUSIONS CAPITAL NNP decision O
: : O
The CAPITAL NNP O
majority VB majority O
of NN stopwords O
the NN stopwords O
nurses RB nurse O
reported NN report O
practicing NN practice O
a DT stopwords angstrom O
healthy NN healthy O
lifestyle NN life_style O
and DT stopwords O
thought NN idea O
that NN stopwords O
they NN stopwords O
were NN stopwords be O
good NN good O
role NN function O
models NN model O
for NN stopwords O
patients VB patient O

The CAPITAL NNP O
US CAPITAL NNP United_States O
attack DT attack O
on NN stopwords on O
Cuba CAPITAL NNP Cuba O
's POS O
health NN health O

standard NN standard O
treatment NN treatment O
of NN stopwords O
sclc JJ D
consists NNS dwell O
of NN stopwords O
platinum-based NN T
combination NNS combination T
chemotherapy NNS chemotherapy T
, , O
with NN stopwords O
thoracic NN pectoral O
irradiation NN irradiation O
added DT add O
for NN stopwords O
patients VB patient O
with NN stopwords O
limited-stage NN O
disease NN disease O

Trisomy CAPITAL NNP trisomy D
18 DIGITS CD eighteen D
fetuses JJ fetus O
showed NN show O
hydramnios NN hydramnios O
, , O
intrauterine NN intrauterine O
growth NN growth O
retardation NN deceleration O
, , O
microcephaly NN microcephaly D
, , O
spina JJ D
bifida NN D
, , O
and DT stopwords O
nonimmune JJ liable D
hydrops NN edema D
fetalis JJ D

Visual CAPITAL NNP ocular O
analog DT analogue O
scales JJ scale O
( ( O
VAS CAPITAL VB vessel O
, , O
0-100 CD O
mm NNS millimeter O
) ) O
were NN stopwords be O
used JJ use O
to NN stopwords O
assess DT buttocks O
pain IN pain O
and DT stopwords O
sedation NN sedation O
at DT stopwords astatine O
baseline VB baseline O
; : O
at DT stopwords astatine O
3 DIGITS CD three O
, , O
6 DIGITS CD six O
, , O
9 DIGITS CD nine O
, , O
12 DIGITS CD twelve O
, , O
15 DIGITS CD fifteen O
, , O
20 DIGITS CD twenty O
, , O
25 DIGITS CD twenty-five O
, , O
30 DIGITS CD thirty O
, , O
45 DIGITS CD forty-five O
, , O
and DT stopwords O
60 DIGITS CD sixty O
min NN minute O
; : O
and DT stopwords O
every NN every O
30 DIGITS CD thirty O
min NN minute O
until JJ stopwords O
further NN stopwords foster O
analgesia DT analgesia O
was VB stopwords Washington O
requested NN request O

Randomised CAPITAL VB randomize O
controlled NNS control O
trial NN test O
of NN stopwords O
magnetic-resonance VB T
pelvimetry NN pelvimetry T
in NN stopwords inch O
breech NN breech D
presentation NN presentation D
at DT stopwords astatine D
term NN term D

Different CAPITAL NNP different O
categories VB class O
of NN stopwords O
adverse DT adverse O
effects NN effects O
need JJ need O
different NN different O
methods NN method O
for NN stopwords O
detection NN detection O

Paris CAPITAL VB Paris O
, , O
France CAPITAL NNP France O
, , O
March CAPITAL NNP March O
6-7 CD O
, , O
1997 DIGITS CD O

Isolated CAPITAL PRP isolate O
persistent NN persistent O
fetal JJ fetal O
bradycardia NN bradycardia O
in NN stopwords inch O
complete NNS complete O
A-V CAPITAL DT O
block NN block O
: : O
a DT stopwords angstrom O
conservative NNS conservative O
approach DT approach O
is NN stopwords be O
appropriate DT allow O

This CAPITAL NNP O
study NN survey O
examined NN analyze O
the NN stopwords O
aggressiveness DT aggressiveness O
of NN stopwords O
colon NNS colon D
tumors NN tumor D
in NN stopwords inch O
blacks NN black O
and DT stopwords O
whites NN White O
to NN stopwords O
explore NN research O
its NN stopwords information_technology O
role NN function O
in NN stopwords inch O
the NN stopwords O
racial VB racial O
survival NN survival O
differences NN difference O

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
diagnostic NN diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
in NN stopwords inch O
stable NN stable O
patients VB patient O
with NN stopwords O
gunshot NN gunfire D
wounds NN wound D
to NN stopwords O
the NN stopwords O
abdomen DT abdomen O

Pendred CAPITAL NNP D
syndrome NN syndrome D
is NN stopwords be O
caused VB cause O
by NN stopwords by O
mutations NN mutant O
in NN stopwords inch O
a DT stopwords angstrom O
putative NN putative O
sulphate NN sulfate O
transporter NN transporter O
gene NN gene O
( ( O
PDS CAPITAL NNP palladium O
) ) O

patients VB patient O
and DT stopwords O
methods NN method O
: : O
forty-two NN forty-two O
chemo-naive NNS O
extensive NN extensive O
disease NN disease O
sclc JJ D
patients VB patient O
were NN stopwords be O
enrolled NN enroll O
to NN stopwords O
receive NN receive O
gemcitabine NN T
1000 DIGITS CD thousand O
mg/m2 NN O
, , O
days VB days O
1 DIGITS CD one O
, , O
8 DIGITS CD eight O
and DT stopwords O
15 DIGITS CD fifteen O
, , O
and DT stopwords O
etoposide NN T
80 DIGITS CD eighty O
mg/m2 NN O
, , O
days VB days O
8 DIGITS CD eight O
, , O
9 DIGITS CD nine O
and DT stopwords O
10 DIGITS CD ten O
of NN stopwords O
a DT stopwords angstrom O
28-day CD O
cycle NNS cycle O

treatment NN treatment T
( ( O
within NN inside O
24 DIGITS CD twenty-four O
hours NN hours O
of NN stopwords O
diagnosis NN diagnosis O
) ) O
was VB stopwords Washington O
given NN given O
to NN stopwords O
169 DIGITS CD O
patients VB patient O
( ( O
23.5 CD O
% NN O
) ) O
, , O
whereas NN O
the NN stopwords O
remaining NN stay O
550 DIGITS CD O
patients VB patient O
were NN stopwords be O
initially JJ initially O
treated NN treat O
with NN stopwords O
heparin NN heparin T
alone DT alone O

Bolstering CAPITAL NNP bolster O
Sisyphus CAPITAL NNP Sisyphus O

Case CAPITAL VB case O
records NN record O
of NN stopwords O
the NN stopwords O
Massachusetts CAPITAL NNP Massachusetts O
General CAPITAL NNP general O
Hospital CAPITAL NNP hospital O

SETTING CAPITAL NNP setting O
: : O
Three CAPITAL NNP three O
suburban NN suburban O
public NN populace O
high NN high O
schools JJ school O
in NN stopwords inch O
California CAPITAL VB California O

Previous CAPITAL NNP previous O
genetic NN familial O
linkage NN linkage O
studies NN survey O
localized NN place O
the NN stopwords O
gene NN gene O
to NN stopwords O
a DT stopwords angstrom O
broad NN broad O
interval NN time_interval O
on NN stopwords on O
human NN homo O
chromosome NN chromosome O
7q22-31.1 CD O

Careful CAPITAL VB careful O
inspection NN inspection O
of NN stopwords O
the NN stopwords O
delivered NN deliver O
placenta NN placenta O
revealed NN uncover O
that NN stopwords O
there NN stopwords there O
was VB stopwords Washington O
a DT stopwords angstrom O
yellowish NN yellow O
lesion NN lesion O
of NN stopwords O
fibrin NN fibrin O
deposits NN deposit O
below NN stopwords below O
the NN stopwords O
cord NNS cord O
insertion NN interpolation O
site NN site O
, , O
which NN stopwords O
resulted NN result O
from JJ stopwords O
the NN stopwords O
absorption DT absorption O
of NN stopwords O
hematoma NN hematoma O

Use CAPITAL NNP use O
of NN stopwords O
surface NN surface O
plasmon NN O
resonance NN resonance O
to NN stopwords O
probe NN probe O
the NN stopwords O
equilibrium NN equilibrium O
and DT stopwords O
dynamic NN moral_force O
aspects DT aspect O
of NN stopwords O
interactions NN interaction O
between NN stopwords between O
biological NN biological O
macromolecules VB macromolecule O

Clinical CAPITAL NNP clinical O
problem-solving NN O
-- : O
where NN stopwords O
did NN stopwords make O
good NN good O
old JJ old O
clinical JJ clinical O
diagnosis NN diagnosis O
go NN go O
? . O

Candidates CAPITAL VB campaigner O
for NN stopwords O
fenfluramine-phentermine JJ T
therapy NN therapy T
should NN stopwords O
be NN stopwords beryllium O
informed NN inform O
about DT stopwords about O
serious NN serious O
potential NN potential O
adverse DT adverse O
effects NN effects O
, , O
including NN include O
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D
and DT stopwords O
valvular NN valvular D
heart NN heart D
disease NN disease D

$ $ O
12 DIGITS CD twelve O

Genetic CAPITAL NNP familial O
findings NN findings O
in NN stopwords inch O
congenital NNS congenital D
bilateral NN bilateral D
aplasia DT aplasia D
of NN stopwords O
vas NN vessel O
deferens NN O
patients VB patient O
and DT stopwords O
identification NN designation O
of NN stopwords O
six NN six O
novel JJ novel O
mutatations NN O

The CAPITAL NNP O
growing NN growth O
use JJ use O
of NN stopwords O
automated DT automatize T
night-time NN T
dialysis NN dialysis T
( ( T
APD CAPITAL DT T
) ) T
in NN stopwords inch O
peritoneal NN peritoneal D
dialysis NN dialysis D
over JJ stopwords over O
the NN stopwords O
last NN stopping_point O
few JJ stopwords few O
years NN old_age O
shows NN show O
that NN stopwords O
this NN stopwords O
method NN method O
represents NN represent O
a DT stopwords angstrom O
valid NN valid O
alternative DT option O
to NN stopwords O
continuous NNS continuous T
ambulatory DT ambulatory T
peritoneal NN peritoneal T
dialysis NN dialysis T
( ( T
CAPD CAPITAL VB T
) ) T

Users CAPITAL NNP user O
in NN stopwords inch O
clinical JJ clinical O
practice NN practice O
must NN must O
recognize NN acknowledge O
these NN stopwords O
problems NN problem O
, , O
and DT stopwords O
, , O
before NN stopwords earlier O
supply NN supply O
, , O
the NN stopwords O
providers NN supplier O
should NN stopwords O
check NNS check O
their NN stopwords O
method NN method O
and DT stopwords O
keep NN support O
records NN record O
that NN stopwords O
are DT stopwords are O
readily NN readily O
traceable NN traceable O

This CAPITAL NNP O
condition NNS condition O
was VB stopwords Washington O
aggravated DT worsen O
by NN stopwords by O
sunlight NN sunlight O
, , O
heat NN heat O
, , O
or NN stopwords Oregon O
sweating NN perspiration O
in NN stopwords inch O
42 DIGITS CD forty-two O
% NN O
( ( O
19/40 CD O
) ) O
of NN stopwords O
reported NN report O
cases VB case O
, , O
and DT stopwords O
38 DIGITS CD thirty-eight O
% NN O
( ( O
15/40 CD O
) ) O
of NN stopwords O
the NN stopwords O
patients VB patient O
responded NN react O
to NN stopwords O
treatment NN treatment O
with NN stopwords O
topical NN topical O
tretinoin NN T

Albumin CAPITAL DT albumin O
synthesis NN synthesis O
rates VB rates O
are DT stopwords are O
not JJ stopwords not O
decreased NN decrease O
in NN stopwords inch O
hypoalbuminemic NN D
cachectic VB cachectic D
cancer VB cancer D
patients VB patient O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
ongoing JJ ongoing O
acute-phase DT O
protein NN protein O
response NN response O

Loss CAPITAL NNP loss O
of NN stopwords O
function JJ function O
of NN stopwords O
p53 NN O
has VB stopwords hour_angle O
also DT besides O
been NN stopwords be O
proposed NN propose O
to NN stopwords O
increase NN addition O
cellular NNS cellular O
hypermutability NN O
, , O
thereby NN thereby O
accelerating DT accelerate O
carcinogenesis VB O
, , O
although DT O
a DT stopwords angstrom O
clear NNS clear O
role NN function O
for NN stopwords O
p53 NN O
in NN stopwords inch O
genomic NN O
instability NN instability O
remains NN remains O
controversial NNS controversial O

Folate CAPITAL NNP vitamin_Bc T
and DT stopwords O
heart NN heart D
disease NN disease D
: : O
theoretical NN theoretical O
link NN link O
needs JJ need O
study NN survey O
. . O

Second CAPITAL NNP second O
of NN stopwords O
two NN two O
parts NN parts O

We CAPITAL NNP O
describe NN describe O
such NN stopwords such O
an DT stopwords Associate_in_Nursing O
event NN event O
in NN stopwords inch O
a DT stopwords angstrom O
man VB man O
who NN stopwords World_Health_Organization O
underwent JJ undergo O
allogeneic DT allogeneic T
BMT CAPITAL NNP T
for NN stopwords O
APL CAPITAL DT D
in NN stopwords inch O
second NN second O
relapse NN backsliding O
and DT stopwords O
4 DIGITS CD four O
years NN old_age O
later NN later O
presented NN show O
with NN stopwords O
testicular NN testicular O
relapse NN backsliding O

dverse NN O
outcomes JJ result O
and DT stopwords O
opioid IN T
analgesic DT analgesic T
administration DT administration T
in NN stopwords inch O
acute DT acute_accent D
abdominal DT abdominal D
pain IN pain D

Management CAPITAL NNP management O
of NN stopwords O
ileosigmoid NN D
knotting NN knot D

II CAPITAL PRP two O

The CAPITAL NNP O
vacuolar NN O
form NN form O
was VB stopwords Washington O
the NN stopwords O
predominant NN prevailing O
morphological NN morphologic O
type NN type O

we NN stopwords O
aimed DT aim O
to NN stopwords O
investigate NN investigate O
whether NN O
biological NN biological O
factors VB factor O
related NN associate O
to NN stopwords O
radiosensitivity VB photosensitivity O
and DT stopwords O
chemosensitivity NNS O
have VB stopwords rich_person O
prognostic NN omen O
significance NN significance O
in NN stopwords inch O
non-small-cell-lung-cancer JJ D
( ( D
nsclc JJ D
) ) D
patients VB patient O
treated NN treat O
with NN stopwords O
daily IN daily O
low NN low O
doses NN dose O
of NN stopwords O
cisplatin NN T
and DT stopwords T
radiotherapy VB radiotherapy T

Early CAPITAL NN early O
introduction NN introduction O
of NN stopwords O
enteral NN enteric O
feeds JJ feed O
and DT stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
nutritional JJ nutritional O
modulation NN transition O
are DT stopwords are O
emphasized NN stress O

Thoracic CAPITAL NNP pectoral T
surgery NN surgery T
for NN stopwords O
hydatid NN hydatid D
disease NN disease D

This CAPITAL NNP O
process NN procedure O
develops NN develop O
a DT stopwords angstrom O
rudimentary NN fundamental O
understanding JJ understanding O
of NN stopwords O
the NN stopwords O
effect NN consequence O
of NN stopwords O
illness NN illness O
on NN stopwords on O
the NN stopwords O
person NN person O
and DT stopwords O
the NN stopwords O
variety NN assortment O
of NN stopwords O
medically NN medically O
effective NN effective O
therapeutic NN remedy O
modalities NN modality O

Eight CAPITAL NN eight O
women NN woman O
also DT besides O
had VB stopwords have O
newly JJ newly O
documented NN document O
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D

Renal CAPITAL NNP nephritic O
ultrasonography JJ sonography O
: : O
a DT stopwords angstrom O
procedure NN procedure O
for NN stopwords O
nephrologists JJ O

Structure-activity CAPITAL NNP O
and DT stopwords O
mechanism NN mechanism O
studies NN survey O
on NN stopwords on O
silicon NN silicon O
phthalocyanines NN O
with NN stopwords O
Plasmodium CAPITAL NNP plasmodium O
falciparum VB O
in NN stopwords inch O
the NN stopwords O
dark VB dark O
and DT stopwords O
under JJ stopwords nether O
red NN red O
light NN light O

Analysis CAPITAL DT analysis O
of NN stopwords O
steroids NN steroid O

About CAPITAL DT about O
genital NN genital O
discharge NN discharge O
with NN stopwords O
special NN special O
consideration NNS consideration O
of NN stopwords O
its NN stopwords information_technology O
cervical NNS cervical O
manifestation VB manifestation O

Sensitivity CAPITAL NNP sensitivity O
of NN stopwords O
temporal NN temporal_role O
artery DT artery O
biopsy NN biopsy O
varies NN change O
with NN stopwords O
biopsy NN biopsy O
length NN length O
and DT stopwords O
sectioning NN segment O
strategy NN scheme O

Fathers CAPITAL NNP father O
in NN stopwords inch O
the NN stopwords O
delivery NN delivery O
room NN room O
-- : O
long NN hanker O
experience NN experience O
molds NN cast O
one JJ one O
viewpoint NN point_of_view O

After CAPITAL DT after O
a DT stopwords angstrom O
rapid VB rapid O
examination NN examination O
of NN stopwords O
a DT stopwords angstrom O
few JJ stopwords few O
basic VB BASIC O
concepts NNS concept O
concerning NNS refer O
cellular NNS cellular O
aging DT ripening O
and DT stopwords O
programmed NN program O
cell NNS cell O
death NN death O
, , O
the NN stopwords O
aging DT ripening O
of NN stopwords O
the NN stopwords O
tissues NN tissue O
and DT stopwords O
organs JJ variety_meat O
, , O
the NN stopwords O
authors DT writer O
discuss NN discus O
the NN stopwords O
principal NN principal O
theories NN theory O
on NN stopwords on O
senescence NN aging O

combined NNS unite T
modality NN modality T
treatment NN treatment T
has VB stopwords hour_angle O
'come POS O
out JJ stopwords out O
of NN stopwords O
age DT age O
' '' O
and DT stopwords O
increasingly NN increasingly O
represents NN represent O
standard NN standard O
of NN stopwords O
care VB care O
for NN stopwords O
a DT stopwords angstrom O
rapidly VB quickly O
growing NN growth O
number JJ number O
of NN stopwords O
patients VB patient O
in NN stopwords inch O
locally NN locally O
advanced DT advance O
stages NN phase O
of NN stopwords O
nsclc JJ D

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
explore NN research O
the NN stopwords O
long-term NN long-run O
effect NN consequence O
of NN stopwords O
calcium VB calcium T
supplementation NN supplement T
during NN stopwords O
pregnancy NN pregnancy O
on NN stopwords on O
the NN stopwords O
offspring JJ offspring O
's POS O
blood NN blood O
pressure NN pressure O
during NN stopwords O
childhood JJ childhood O

The CAPITAL NNP O
course NNS course O
includes NN include O
simulations NN simulation O
of NN stopwords O
physical NN physical O
impairments JJ damage O
, , O
demonstrations NN presentation O
of NN stopwords O
adaptive DT adaptive O
equipment NN equipment O
, , O
interactive NN synergistic O
chart NNS chart O
reviews NN reappraisal O
, , O
readings NN reading O
, , O
and DT stopwords O
audio DT audio O
lectures NN lecture O

Diagnostic CAPITAL NNP diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
correctly NNS correctly O
identified NN identify O
the NN stopwords O
presence NN presence O
or NN stopwords Oregon O
absence DT absence O
of NN stopwords O
intra-abdominal NN D
injury NN injury D
in NN stopwords inch O
40 DIGITS CD forty O
( ( O
91 DIGITS CD ninety-one O
% NN O
) ) O
of NN stopwords O
the NN stopwords O
patients VB patient O
( ( O
positive NN positive O
predictive NN predictive O
value NN value O
= NN O
96.7 CD O
% NN O
, , O
negative JJ negative O
predictive NN predictive O
value NN value O
= NN O
78.6 CD O
% NN O
, , O
phi NN phi O
= NN O
0.79 LS O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.01 . O
) ) O

After CAPITAL DT after O
6 DIGITS CD six O
months NN calendar_month O
of NN stopwords O
fluoride JJ fluoride T
dosing NN dose T
, , O
all DT stopwords all O
rabbits NN rabbit O
were NN stopwords be O
euthanized NN O
and DT stopwords O
bone NN bone O
and DT stopwords O
blood NN blood O
samples VB sample O
were NN stopwords be O
taken VB take O
for NN stopwords O
analyses DT analysis O

Touch CAPITAL NNP touch O
sensibility NN sensibility O
was VB stopwords Washington O
assessed DT measure O
with NN stopwords O
von NN O
Frey CAPITAL NNP Frey O
's POS O
monofilaments NN O
in NN stopwords inch O
the NN stopwords O
breasts NN breast O
of NN stopwords O
10 DIGITS CD ten O
healthy NN healthy O
women NN woman O
( ( O
controls NNS control O
) ) O
and DT stopwords O
of NN stopwords O
80 DIGITS CD eighty O
women NN woman O
with NN stopwords O
breast NN breast D
cancer VB cancer D
who NN stopwords World_Health_Organization O
at DT stopwords astatine O
least NN least O
1 DIGITS CD one O
year NN year O
previously NN previously O
had VB stopwords have O
undergone JJ undergo O
subcutaneous NN hypodermic T
mastectomy VB mastectomy T
and DT stopwords O
immediate JJ immediate O
reconstruction NN Reconstruction O
with NN stopwords O
a DT stopwords angstrom O
prosthesis NN prosthesis O

Haplotype CAPITAL NNP haplotype O
frequencies JJ frequency O
were NN stopwords be O
estimated NN estimate O
with NN stopwords O
standard NN standard O
maximum VB maximum O
likelihood NN likelihood O
methods NN method O

Tobias CAPITAL NNP O
, , O
Radiat CAPITAL VB O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
evaluate NN measure O
the NN stopwords O
efficacy NN efficacy O
of NN stopwords O
oral NN oral T
tacrolimus VB T
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
induction NN initiation O
agent DT agent O
in NN stopwords inch O
steroid-refractory NN D
severe NN severe D
colitis NNS colitis D
.Study . O
design NN design O
: : O
Open-label CAPITAL NNP O
, , O
multicenter NN O
trial NN test O
of NN stopwords O
oral NN oral O
tacrolimus VB O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
severe NN severe O
colitis NNS colitis O

Plasma CAPITAL NNP plasma O
PAI-1 CAPITAL VB O
activity DT activity O
was VB stopwords Washington O
measured NN measure O
by NN stopwords by O
a DT stopwords angstrom O
spectrophotometric NN O
assay DT assay O
and DT stopwords O
PAI-1 CAPITAL VB O
4G/5G CD O
promoter NN promoter O
genotype NN genotype O
by NN stopwords by O
the NN stopwords O
polymerase NN polymerase O
chain NNS chain O
reaction NN chemical_reaction O
( ( O
PCR CAPITAL NNP O
) ) O
using JJ exploitation O
allele-specific DT O
primers NN primer O

In CAPITAL PRP inch O
women NN woman O
with NN stopwords O
primary NN primary O
infertility NN sterility D
all DT stopwords all O
pregnancies NN pregnancy O
achieved DT achieve O
by NN stopwords by O
either NN either O
partner NN spouse O
or NN stopwords Oregon O
donor NN donor O
intrauterine NN intrauterine T
insemination NN insemination T
carried VB transport O
to NN stopwords O
birth NN birth O
of NN stopwords O
a DT stopwords angstrom O
fetus JJ fetus O
( ( O
> NN O
20 DIGITS CD twenty O
weeks NN week O
) ) O
were NN stopwords be O
identified NN identify O

Differences CAPITAL NNP difference O
in NN stopwords inch O
the NN stopwords O
chemical NNS chemical O
characteristics NNS feature O
of NN stopwords O
SCW CAPITAL NNP O
from JJ stopwords O
the NN stopwords O
intermediate NN intermediate O
hosts NN host O
L. CAPITAL NNP O
truncatula NN O
and DT stopwords O
L. CAPITAL NNP O
stagnalis NN O
could NNS O
be NN stopwords beryllium O
shown NN show O
by NN stopwords by O
sodium NN sodium O
dodecyl NN O
sulfate-polyacrylamide NN O
gel NN gel O
electrophoresis NN electrophoresis O
, , O
blotting NN blot O
, , O
and DT stopwords O
subsequent NN subsequent O
carbohydrate VB carbohydrate O
detection NN detection O

conclusions NNS decision O
: : O
apc DT armored_personnel_carrier T
is NN stopwords be O
effective NN effective O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
endoluminal NN D
hemoptysis NN hemoptysis D
and DT stopwords O
airway DT air_passage D
obstruction NN obstruction D

Frequency CAPITAL NNP frequency O
and DT stopwords O
significance NN significance O
of NN stopwords O
antinuclear DT O
antibodies DT antibody O
in NN stopwords inch O
multiple NN multiple D
sclerosis JJ sclerosis D

Inter-method CAPITAL PRP O
differences NN difference O
among DT O
11 DIGITS CD eleven O
available DT available O
assay DT assay O
methods NN method O
were NN stopwords be O
great NN great O
even NN evening O
after DT stopwords after O
correction NNS correction O
and DT stopwords O
depended NN depend O
on NN stopwords on O
not JJ stopwords not O
only JJ stopwords lone O
the NN stopwords O
methods NN method O
but NN stopwords merely O
the NN stopwords O
samples VB sample O
used JJ use O
for NN stopwords O
the NN stopwords O
determination NN determination O

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
gastritis VB gastritis O
index NN index O
was VB stopwords Washington O
significantly NN significantly O
lower NN lower_berth O
after DT stopwords after O
therapy NN therapy O
and DT stopwords O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
both NN stopwords both O
BAO CAPITAL IN O
and DT stopwords O
MAO CAPITAL NNP monoamine_oxidase O
after DT stopwords after O
cure NNS remedy O
of NN stopwords O
the NN stopwords O
H. CAPITAL NNP D
pylori NN pylorus D
infection NN infection D
( ( O
BAO CAPITAL IN O
from JJ stopwords O
0.3 LS O
mmol/h NN O
and DT stopwords O
MAO CAPITAL NNP monoamine_oxidase O
from JJ stopwords O
4.8 CD O
mmol/h NN O
to NN stopwords O
19 DIGITS CD nineteen O
mmol/ NN O
h NN hydrogen O
) ) O

Physicians CAPITAL NNP doctor O
disciplined NN discipline O
for NN stopwords O
sex-related NN O
offenses JJ discourtesy O

This CAPITAL NNP O
partial NN partial_derivative O
recovery NN recovery O
is NN stopwords be O
also DT besides O
parallel NN analogue O
to NN stopwords O
the NN stopwords O
partial NN partial_derivative O
activation DT activation O
of NN stopwords O
JAK2 CAPITAL NNP O
, , O
indicating NN bespeak O
that NN stopwords O
the NN stopwords O
signal NN signal O
transduction NN transduction O
pathway VB nerve_pathway O
implicated JJ implicate O
JAK2 CAPITAL NNP O

One-lung CAPITAL NNP T
ventilation NN ventilation T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
difficult NN difficult D
airways DT air_passage D

Eosinophilic CAPITAL NNP eosinophilic D
meningitis NN meningitis D
due NN due O
to NN stopwords O
Angiostrongylus CAPITAL DT O
cantonensis VB O

Induction CAPITAL PRP initiation O
of NN stopwords O
apoptosis DT apoptosis O
in NN stopwords inch O
tumor NN tumor O
cells NNS cell O
is NN stopwords be O
possible NN possible O
with NN stopwords O
a DT stopwords angstrom O
biologically NN biologically O
active DT active_agent O
TRAIL CAPITAL NNP trail T
, , O
and DT stopwords O
suggests NN propose O
that NN stopwords O
this NN stopwords O
cytokine NNS cytokine O
is NN stopwords be O
a DT stopwords angstrom O
promising NN promise O
antitumor DT anticancer O
agent DT agent O
against DT stopwords O
human NN homo D
cholangiocarcinoma NNS D

AIDS CAPITAL DT AIDS O
: : O
a DT stopwords angstrom O
world NN universe O
, , O
a DT stopwords angstrom O
desire NN desire O

Run-in CAPITAL NNP quarrel O
periods NN time_period O
in NN stopwords inch O
randomized VB randomize O
trials NN test O
: : O
implications JJ deduction O
for NN stopwords O
the NN stopwords O
application DT application O
of NN stopwords O
results NN consequence O
in NN stopwords inch O
clinical JJ clinical O
practice NN practice O

Ultrasound CAPITAL NNP ultrasound O
measurements NN measurement O
of NN stopwords O
the NN stopwords O
newborn JJ neonate O
hip NN hip O

Characteristics CAPITAL NNP feature O
of NN stopwords O
a DT stopwords angstrom O
patient VB patient O
's POS O
specific NN particular O
diagnosis NN diagnosis O
( ( O
unilateral JJ unilateral O
or NN stopwords Oregon O
bilateral NN bilateral O
breast NN breast D
cancer VB cancer D
, , O
with NN stopwords O
or NN stopwords Oregon O
without NN O
ovarian NN ovarian D
cancer VB cancer D
) ) O
, , O
early VB early O
age DT age O
at DT stopwords astatine O
diagnosis NN diagnosis O
, , O
Ashkenazi CAPITAL DT Ashkenazi O
Jewish CAPITAL NNP Jewish O
ethnicity NN ethnicity O
, , O
and DT stopwords O
family VB family O
history NN history O
of NN stopwords O
cancer VB cancer O
were NN stopwords be O
positively NN positively O
associated DT associate O
with NN stopwords O
the NN stopwords O
probability NN probability O
of NN stopwords O
her NN stopwords O
carrying VB transport O
a DT stopwords angstrom O
deleterious NN deleterious O
BRCA1 CAPITAL NNP O
mutation NN mutant O

The CAPITAL NNP O
fast VB fast O
reaction NN chemical_reaction O
of NN stopwords O
peroxynitrite NN O
with NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
and DT stopwords O
the NN stopwords O
high NN high O
concentration NNS concentration O
of NN stopwords O
dissolved NN dissolve O
CO2 CAPITAL NNP carbon_dioxide O
in NN stopwords inch O
vivo NN O
( ( O
ca VB calcium O

Drug CAPITAL NNP drug O
resistance NN resistance O
markers NN marker O
: : O
are DT stopwords are O
they NN stopwords O
bad VB bad O
or NN stopwords Oregon O
good NN good O
? . O

Three CAPITAL NNP three O
patients VB patient O
with NN stopwords O
FAP CAPITAL NNP D
and DT stopwords O
two NN two O
patients VB patient O
with NN stopwords O
multiple NN multiple O
( ( O
more NN stopwords More O
than NN stopwords O
30 DIGITS CD thirty O
) ) O
colorectal NNS colorectal D
polyps NN polyp D
were NN stopwords be O
administered DT administer O
DHA-concentrated CAPITAL NNP T
fish NN fish T
oil NN oil T
capsules_Hlk427554600 VB T
( ( T
2.2 CD T
g NN gram T
of NN stopwords T
DHA CAPITAL NNP T
and DT stopwords T
0.6 LS T
g NN gram T
of NN stopwords T
eicosapentanoic NN T
acid DT acid T
( ( T
EPA CAPITAL NNP Environmental_Protection_Agency T
) ) T
per NN T
day VB day T
) ) T
for NN stopwords O
one JJ one O
or NN stopwords Oregon O
two NN two O
years NN old_age O

Sensitivity CAPITAL NNP sensitivity O
and DT stopwords O
specificity NN specificity O
of NN stopwords O
the NN stopwords O
neonatal JJ neonatal O
brain-stem NN brainstem O
auditory DT auditory O
evoked NN arouse O
potential NN potential O
for NN stopwords O
hearing NN hearing O
and DT stopwords O
language NN language O
deficits NN deficit O
in NN stopwords inch O
survivors NN survivor O
of NN stopwords O
extracorporeal NN O
membrane NN membrane O
oxygenation JJ oxygenation O

conclusions NNS decision O
: : O
both NN stopwords both O
the NN stopwords O
response NN response O
rate VB rate O
and DT stopwords O
survival NN survival O
data VB data O
in NN stopwords inch O
this NN stopwords O
retrospective NN retrospective O
study NN survey O
suggest NN propose O
a DT stopwords angstrom O
high NN high O
degree NN degree O
of NN stopwords O
activity DT activity O
of NN stopwords O
this NN stopwords O
combination NNS combination T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
brain NN brain D
metastases NN metastasis D
from JJ stopwords D
nsclc JJ D

OBJECTIVES CAPITAL NNP aim O
: : O
The CAPITAL NNP O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
analysis DT analysis O
was VB stopwords Washington O
to NN stopwords O
determine NN determine O
the NN stopwords O
influence NN influence O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
additional DT extra O
treatment NN treatment O
delay NN delay O
inherent NN built-in O
in NN stopwords inch O
transfer NN transportation O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
angioplasty DT angioplasty O
center NNS center O
for NN stopwords O
primary NN primary T
angioplasty DT angioplasty T
of NN stopwords O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
who NN stopwords World_Health_Organization O
are DT stopwords are O
first NN first O
admitted DT admit O
to NN stopwords O
hospitals NN hospital O
without NN O
angioplasty DT angioplasty O
facilities VB facility O

Requirements CAPITAL NNP requirement O
for NN stopwords O
training NN training O
to NN stopwords O
ensure NN guarantee O
competence NNS competence O
of NN stopwords O
endoscopists NN O
performing NN acting O
invasive NN invasive O
procedures NN procedure O
in NN stopwords inch O
children JJ child O

The CAPITAL NNP O
electrochemical NN electrochemical O
behaviour NN behavior O
of NN stopwords O
the NN stopwords O
1 DIGITS CD one O
x NN ten O
3 DIGITS CD three O
mm NNS millimeter O
Pt-Ag/AgCl CAPITAL NNP O
thin NN thin O
film NN movie O
electrode NN electrode O
is NN stopwords be O
not JJ stopwords not O
significantly NN significantly O
influenced NN influence O
by NN stopwords by O
lactate NN lactate O
oxidase-polyurethane IN O
covering NNS covering O

Online CAPITAL NNP on-line O

146 DIGITS CD O

We CAPITAL NNP O
report NN report O
4 DIGITS CD four O
new JJ new O
cases VB case O
of NN stopwords O
localized NN place O
Darier CAPITAL NNP D
disease NN disease D
and DT stopwords O
review NN reappraisal O
the NN stopwords O
English-language CAPITAL NNP O
literature NN literature O

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
the NN stopwords O
microparticle NN O
enzyme NN enzyme O
immunoassay JJ immunoassay O
Abbott CAPITAL DT O
IMx CAPITAL PRP O
Select CAPITAL NNP choose O
Chlamydia CAPITAL NNP chlamydia O
and DT stopwords O
the NN stopwords O
importance JJ importance O
of NN stopwords O
urethral JJ urethral O
site NN site O
sampling VB sampling O
to NN stopwords O
detect NN detect O
Chlamydia CAPITAL NNP chlamydia D
trachomatis NN D
in NN stopwords inch O
women NN woman O

SETTING CAPITAL NNP setting O
: : O
Black CAPITAL NNP black O
residents NN resident O
of NN stopwords O
Harare CAPITAL NNP Harare O
, , O
Zimbabwe CAPITAL NN Zimbabwe O

To CAPITAL NNP O
avoid DT avoid O
medicalising NN O
a DT stopwords angstrom O
self NN self O
limiting NN modification O
illness NN illness O
doctors NN doctor O
should NN stopwords O
avoid DT avoid O
antibiotics DT antibiotic T
or NN stopwords Oregon O
offer JJ offer O
a DT stopwords angstrom O
delayed NN delay O
prescription NN prescription O
for NN stopwords O
most NN stopwords most O
patients VB patient O
with NN stopwords O
sore NN sore D
throat NN throat D

The CAPITAL NNP O
visual NN ocular O
association DT association O
task VB undertaking O
as DT stopwords arsenic O
adapted DT adapt O
for NN stopwords O
this NN stopwords O
study NN survey O
may VB May O
provide NN supply O
a DT stopwords angstrom O
sensitive NN medium O
measure NN measure O
to NN stopwords O
study NN survey O
anterograde DT anterograde O
amnesia DT amnesia O
prevalent NN prevailing O
in NN stopwords inch O
Alzheimer CAPITAL DT O
's POS O
disease NN disease O

We CAPITAL NNP O
hypothesize NN speculate O
that NN stopwords O
activating DT energizing O
mutations NN mutant O
of NN stopwords O
either NN either O
the NN stopwords O
antim1/4llerian DT O
hormone NN hormone O
gene NN gene O
or NN stopwords Oregon O
its NN stopwords information_technology O
receptor NN receptor O
gene NN gene O
may VB May O
cause VB cause O
m1/4llerian NN O
duct NN duct O
regression NN arrested_development O
in NN stopwords inch O
a DT stopwords angstrom O
genetic NN familial O
female JJ female O
during NN stopwords O
embryogenesis NN O

The CAPITAL NNP O
infant NN baby O
presented NN show O
with NN stopwords O
extreme NN extreme O
pallor VB lividness O
, , O
hypotonia NN hypotonia D
, , O
hepatosplenomegaly NN D
, , O
and DT stopwords O
ascites DT ascites D

PATIENTS CAPITAL VB patient O
AND CAPITAL DT O
METHODS CAPITAL NNP method O
: : O
Twenty-three CAPITAL NNP twenty-three O
previously NN previously O
untreated JJ untreated O
patients VB patient O
with NN stopwords O
stage NN phase D
III CAPITAL PRP three D
or NN stopwords Oregon D
IV CAPITAL PRP four D
SCCHN CAPITAL NNP D
and DT stopwords O
Eastern CAPITAL VB eastern O
Cooperative CAPITAL NNP cooperative O
Oncology CAPITAL NNP oncology O
Group CAPITAL NNP group O
functional JJ functional O
status NN status O
less NN lupus_erythematosus O
than NN stopwords O
or NN stopwords Oregon O
equal NN peer O
to NN stopwords O
2 DIGITS CD two O
were NN stopwords be O
treated NN treat O
with NN stopwords O
TPFL5 CAPITAL NNP T

Multicenter CAPITAL NNP O
study NN survey O
of NN stopwords O
surfactant NN wetting_agent T
( ( T
beractant NN T
) ) T
use JJ use O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
term NN term O
infants NN baby O
with NN stopwords O
severe NN severe D
respiratory NN respiratory D
failure VB failure D

Mouse CAPITAL NNP mouse O
monoclonal NN monoclonal_antibody O
antibodies DT antibody O
specific NN particular O
for NN stopwords O
thiabendazole NN thiabendazole T
( ( O
a DT stopwords angstrom O
post-harvest NN O
fungicide JJ antifungal O
and DT stopwords O
veterinary NN veterinarian O
anthelmintic DT vermifuge O
) ) O
were NN stopwords be O
covalently NNS O
linked NN associate O
through NN stopwords done O
free JJ free O
amine DT amine O
groups NN group O
to NN stopwords O
aminosilanized DT O
silicon NN silicon O
dioxide NN dioxide O
films NN movie O
using JJ exploitation O
glutaraldehyde NN O

Immunotherapy CAPITAL PRP immunotherapy T
of NN stopwords O
mice NN mouse O
with NN stopwords O
preexisting NN preexist O
cancers VB cancer D
with NN stopwords O
heat NN heat T
shock NN daze T
protein NN protein T
preparations NN preparation T
derived NN deduce T
from JJ stopwords T
autologous DT autologous T
cancer VB cancer T
resulted NN result O
in NN stopwords inch O
retarded NN mentally_retarded O
progression NN progression O
of NN stopwords O
the NN stopwords O
primary NN primary O
cancer VB cancer D
, , O
a DT stopwords angstrom O
reduced NN reduce O
metastatic NN metastatic O
load NN load O
, , O
and DT stopwords O
prolongation NN prolongation O
of NN stopwords O
life-span NN O

DESIGN CAPITAL NNP design O
: : O
Blinded CAPITAL NNP blind O
group NN group O
comparison NNS comparison O
of NN stopwords O
randomly VB randomly O
selected NN choose O
cases VB case O
of NN stopwords O
cardiac VB cardiac D
amyloidosis DT amyloidosis D

these NN stopwords O
results NN consequence O
suggested NN propose O
that NN stopwords O
the NN stopwords O
sp1 NN T
decoy NN decoy T
strategy NN scheme T
would NN O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
regulating NN regulation O
tumor NN tumor D
growth NN growth D
by NN stopwords by O
simultaneously NN simultaneously O
reducing NN reduction O
cancer VB cancer O
cell NNS cell O
( ( O
a DT stopwords angstrom O
) ) O
angiogenic DT O
growth NN growth O
factor VB factor O
expression NN expression O
, , O
( ( O
b NN bacillus O
) ) O
proliferation NN proliferation O
, , O
and DT stopwords O
( ( O
c NNS degree_centigrade O
) ) O
invasiveness NN O

The CAPITAL NNP O
Ropinirole CAPITAL NNP O
Study CAPITAL NNP survey O
Group CAPITAL NNP group O

BACKGROUND CAPITAL IN background O
: : O
Fenfluramine CAPITAL NNP T
and DT stopwords O
phentermine NN T
have VB stopwords rich_person O
been NN stopwords be O
individually NN individually O
approved DT approve O
as DT stopwords arsenic O
anorectic DT anorexic T
agents DT agent T
by NN stopwords by O
the NN stopwords O
Food CAPITAL NNP food O
and DT stopwords O
Drug CAPITAL NNP drug O
Administration CAPITAL DT administration O
( ( O
FDA CAPITAL NNP Food_and_Drug_Administration O
) ) O

silicone NN silicone T
stents NN stent T
were NN stopwords be O
used JJ use O
for NN stopwords O
the NN stopwords O
tracheobronchial NN D
stenoses NN stenosis D

Varying CAPITAL VB change O
the NN stopwords O
position NN position O
of NN stopwords O
the NN stopwords O
critical JJ critical O
phoneme NN phoneme O
in NN stopwords inch O
the NN stopwords O
picture NN picture O
name RB name O
did NN stopwords make O
not JJ stopwords not O
affect DT affect O
the NN stopwords O
onset JJ onset O
of NN stopwords O
the NN stopwords O
LRP CAPITAL NNP O
but NN stopwords merely O
rather VB rather O
influenced NN influence O
when NN stopwords O
the NN stopwords O
LRP CAPITAL NNP O
began NN get_down O
to NN stopwords O
differ NN differ O
on NN stopwords on O
go NN go O
and DT stopwords O
no-go RB no-go O
trials NN test O
and DT stopwords O
allowed DT let O
the NN stopwords O
duration NN duration O
of NN stopwords O
phonological NN phonological O
encoding NN encoding O
of NN stopwords O
a DT stopwords angstrom O
word NN word O
to NN stopwords O
be NN stopwords beryllium O
estimated NN estimate O

The CAPITAL NNP O
objective NN aim O
of NN stopwords O
this NN stopwords O
review NN reappraisal O
was VB stopwords Washington O
to NN stopwords O
assess DT buttocks O
the NN stopwords O
effects NN effects O
of NN stopwords O
zinc NN zinc T
lozenges NN lozenge T
for NN stopwords O
cold NNS cold D
symptoms NN symptom D

Doctors CAPITAL NNP doctor O
-- : O
we NN stopwords O
need JJ need O
you NN stopwords O

Thoracoscopic CAPITAL NNP T
surgery NN surgery T
for NN stopwords O
pulmonary NN pneumonic D
tuberculosis NN tuberculosis D

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
prevalence NN prevalence O
of NN stopwords O
chemical NNS chemical O
substance NN substance O
misuse NN misuse O
in NN stopwords inch O
the NN stopwords O
antenatal DT prenatal O
population NN population O
was VB stopwords Washington O
2.8 CD O
% NN O
and DT stopwords O
5.6 CD O
% NN O
in NN stopwords inch O
the NN stopwords O
postnatal NN postnatal O
population NN population O

In CAPITAL PRP inch O
hospitals NN hospital O
where NN stopwords O
venography NN venography O
was VB stopwords Washington O
routinely NN routinely O
used JJ use O
as DT stopwords arsenic O
the NN stopwords O
first NN first O
line NN line O
investigation NN probe O
, , O
the NN stopwords O
most NN stopwords most O
common NNS park O
reasons NN reason O
were NN stopwords be O
: : O
the NN stopwords O
perceived NN perceive O
inferiority NN inferiority O
of NN stopwords O
ultrasound JJ ultrasound O
( ( O
US CAPITAL NNP United_States O
) ) O
in NN stopwords inch O
demonstrating NN show O
below-knee NN O
clot NNS clot D
, , O
its NN stopwords information_technology O
time-consuming NN time-consuming O
nature RB nature O
and DT stopwords O
the NN stopwords O
limited NN express O
access DT entree O
to NN stopwords O
suitable JJ suitable O
ultrasound JJ ultrasound O
machines VB machine O

When CAPITAL NNP O
can VB stopwords can O
odds JJ odds O
ratios VB ratio O
mislead NN mislead O
? . O

Family CAPITAL NNP family O
history NN history O
and DT stopwords O
genetic NN familial O
risk NN hazard O
factors VB factor O
: : O
forward NN forward O
to NN stopwords O
the NN stopwords O
future JJ future O

GAPS CAPITAL VB gap O
( ( O
AMA CAPITAL DT O
Guidelines CAPITAL NNP guideline O
for NN stopwords O
Adolescent CAPITAL DT adolescent O
Preventive CAPITAL NNP preventive O
Services CAPITAL NNP services O
) ) O

Substantial CAPITAL NNP significant O
evidence NN evidence O
indicates NN bespeak O
that NN stopwords O
intakes NN consumption O
greater NN greater O
than NN stopwords O
the NN stopwords O
recommended NN recommend O
dietary NN dietary O
allowances DT allowance O
( ( O
RDAs CAPITAL NNP O
) ) O
of NN stopwords O
certain NNS certain O
vitamins NN vitamin O
and DT stopwords O
minerals NN mineral O
such NN stopwords such O
as DT stopwords arsenic O
calcium VB calcium O
, , O
folic JJ O
acid DT acid O
, , O
vitamin NN vitamin O
E CAPITAL NN vitamin_E O
, , O
selenium NN selenium O
, , O
and DT stopwords O
chromium NN chromium O
reduce NN reduce O
the NN stopwords O
risk NN hazard O
of NN stopwords O
certain NNS certain O
diseases NN disease O
for NN stopwords O
some NN stopwords some O
people NN people O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
a DT stopwords angstrom O
conference NNS conference O

Methadone CAPITAL NNP methadone T
maintenance VB care T
vs NN volt O
180-day CD O
psychosocially NN O
enriched NN enrich O
detoxification NN detoxification T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
opioid IN D
dependence NN dependence D
: : O
a DT stopwords angstrom O
randomized VB randomize O
controlled NNS control O
trial NN test O

Alkaline CAPITAL DT alkaline O
phosphatase NN phosphatase O
in NN stopwords inch O
neutrophil JJ neutrophil O
leukocytes NN leukocyte O
of NN stopwords O
patients VB patient O
with NN stopwords O
infectious NN infectious D
mononucleosis NN infectious_mononucleosis D
and DT stopwords O
the NN stopwords O
effect NN consequence O
of NN stopwords O
corticosteroid NNS corticosteroid T
therapy NN therapy T

The CAPITAL NNP O
prevalence NN prevalence O
of NN stopwords O
retinopathy NN retinopathy D
in NN stopwords inch O
the NN stopwords O
three NN three O
genotype NN genotype O
groups NN group O
differed NN differ O
significantly NN significantly O
( ( O
4G/4G CD O
, , O
4G/5G CD O
, , O
and DT stopwords O
5G/5G CD O
were NN stopwords be O
44 DIGITS CD forty-four O
, , O
49 DIGITS CD forty-nine O
, , O
and DT stopwords O
24 DIGITS CD twenty-four O
% NN O
, , O
respectively NN respectively O
; : O
chi JJ qi O
2 DIGITS CD two O
= NN O
8.22 CD O
, , O
df NN O
= NN O
2 DIGITS CD two O
, , O
P CAPITAL NN phosphorus O
= NN O
0.016 LS O
) ) O
and DT stopwords O
remained NN stay O
significant NN significant O
after DT stopwords after O
controlling NNS control O
for NN stopwords O
age DT age O
, , O
sex NN sexual_activity O
, , O
BMI CAPITAL NNP body_mass_index O
, , O
duration NN duration O
of NN stopwords O
diabetes NN diabetes D
, , O
glycated NN O
hemoglobin NN hemoglobin O
, , O
and DT stopwords O
urine JJ urine O
albumin-to-creatine DT O
ratio VB ratio O
in NN stopwords inch O
a DT stopwords angstrom O
logistic NN logistic O
regression NN arrested_development O
analysis DT analysis O

Local CAPITAL NNP local O
injection NN injection O
of NN stopwords O
corticosteroids NNS corticosteroid T
into NN stopwords O
refractory NN furnace_lining O
esophageal NN esophageal O
strictures NN stenosis O
to NN stopwords O
decrease NN decrease O
the NN stopwords O
restenosis NN D
rate VB rate O
has VB stopwords hour_angle O
been NN stopwords be O
reported NN report O

< NN O
TO_SEE CAPITAL NNP O
> NN O
conclusion NNS decision O
: : O
the NN stopwords O
results NN consequence O
of NN stopwords O
phase NN phase O
iii NN three O
trials NN test O
have VB stopwords rich_person O
confirmed NNS confirm O
the NN stopwords O
safety VB safety O
and DT stopwords O
efficacy NN efficacy O
of NN stopwords O
amifostine DT T
as DT stopwords arsenic O
a DT stopwords angstrom O
cytoprotectant NNS O
to NN stopwords O
ameliorate DT better O
cisplatin-induced NN D
cumulative NNS accumulative D
renal NN nephritic D
toxicity NN toxicity D
, , O
for NN stopwords O
which NN stopwords O
it NN stopwords information_technology O
is NN stopwords be O
the NN stopwords O
only JJ stopwords lone O
agent DT agent O
proven NN prove O
to NN stopwords O
be NN stopwords beryllium O
effective NN effective O
, , O
and DT stopwords O
neutropenia JJ neutropenia D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
advanced DT advance O
ovarian NN ovarian O
cancer VB cancer O
, , O
and DT stopwords O
to NN stopwords O
reduce NN reduce O
xerostomia NN xerostomia D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
head NN head D
and DT stopwords D
neck JJ neck D
cancer VB cancer D
receiving NN receive O
irradiation NN irradiation T
therapy NN therapy T

Epidurals CAPITAL NNP epidural_anesthesia T
and DT stopwords O
breastfeeding NN breastfeed O

The CAPITAL NNP O
importance JJ importance O
of NN stopwords O
being NN stopwords being O
where NN stopwords O
? . O
Balancing CAPITAL IN reconciliation O
the NN stopwords O
perspective NN position O
on NN stopwords on O
practice NN practice O
coverage NNS coverage O

404 DIGITS CD O

American CAPITAL DT American O
Academy CAPITAL DT academy O
of NN stopwords O
Child CAPITAL NNP child O
and DT stopwords O
Adolescent CAPITAL DT adolescent O
Psychiatry CAPITAL NNP psychiatry O

History CAPITAL NNP history O
-- : O
a DT stopwords angstrom O
living NN life O
museum NN museum O

The CAPITAL NNP O
findings NN findings O
, , O
therefore NN therefore O
, , O
are DT stopwords are O
the NN stopwords O
opposite JJ antonym O
of NN stopwords O
those NN stopwords O
hypothesized NN speculate O

we NN stopwords O
report NN report O
the NN stopwords O
use JJ use O
of NN stopwords O
paclitaxel VB T
in NN stopwords inch O
the NN stopwords O
successful NN successful O
treatment NN treatment O
of NN stopwords O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
recurrent NN perennial D
adenocarcinoma DT adenocarcinoma D
of NN stopwords D
the NN stopwords D
cervix NNS neck D

Serologic CAPITAL NNP serologic O
evidence NN evidence O
for NN stopwords O
mother-to-child NN O
transmission NN transmission O
of NN stopwords O
Kaposi CAPITAL NNP D
sarcoma-associated VB D
herpesvirus NN D
infection NN infection D

A CAPITAL DT angstrom O
novel JJ novel O
frameshift NN O
mutation NN mutant O
840delA CD O
and DT stopwords O
a DT stopwords angstrom O
novel JJ novel O
polymorphism NN polymorphism O
D203A CAPITAL NNP O
in NN stopwords inch O
the NN stopwords O
steroidogenic NN O
acute DT acute_accent O
regulatory NN regulative O
protein NN protein O
gene NN gene O
in NN stopwords inch O
a DT stopwords angstrom O
Japanese CAPITAL NNP Japanese O
patient VB patient O
with NN stopwords O
congenital NNS congenital D
lipoid NN lipid D
adrenal DT adrenal_gland D
hyperplasia NN hyperplasia D

We CAPITAL NNP O
monitored NN monitor O
these NN stopwords O
subjects NN subject O
for NN stopwords O
the NN stopwords O
32-month CD O
postscanning NN O
period NN time_period O
with NN stopwords O
yearly NN annual O
phone NN telephone O
calls VB call O
and DT stopwords O
acquisition DT acquisition O
of NN stopwords O
records NN record O
for NN stopwords O
all DT stopwords all O
hospital NN hospital O
admissions DT admission O

Cocaine-positive CAPITAL NNP O
women NN woman O
presented NN show O
at DT stopwords astatine O
an DT stopwords Associate_in_Nursing O
earlier VB earlier O
gestational NN gestational O
age DT age O
( ( O
32 DIGITS CD thirty-two O
weeks NN week O
' '' O
, , O
( ( O
24-34 CD O
) ) O
vs. NN O
33 DIGITS CD thirty-three O
weeks NN week O
' '' O
, , O
( ( O
23-36 CD O
) ) O
, , O
p NN phosphorus O
= NN O
0.02 LS O
) ) O
and DT stopwords O
had VB stopwords have O
a DT stopwords angstrom O
significantly NN significantly O
longer NN longer O
membrane NN membrane O
rupture NN rupture O
to NN stopwords O
delivery NN delivery O
interval NN time_interval O
than NN stopwords O
women NN woman O
with NN stopwords O
a DT stopwords angstrom O
negative JJ negative O
urine JJ urine O
drug NN drug O
screen NN screen O
( ( O
174 DIGITS CD O
hr NN hour O
, , O
( ( O
6-475 CD O
) ) O
vs. NN O
33 DIGITS CD thirty-three O
hours NN hours O
( ( O
1-833 CD O
) ) O
, , O
p NN phosphorus O
= NN O
0.01 LS O
) ) O

Synergism CAPITAL NNP synergy O
in NN stopwords inch O
tumorigenesis NN O
and DT stopwords O
independent NN mugwump O
segregation NN segregation O
of NN stopwords O
the NN stopwords O
MSI CAPITAL NNP O
phenotype NN phenotype O
suggest NN propose O
that NN stopwords O
Msh2 CAPITAL NNP O
and DT stopwords O
p53 NN O
are DT stopwords are O
not JJ stopwords not O
genetically NN genetically O
epistatic NN O

Frequent CAPITAL NNP patronize O
users JJ user O
of NN stopwords O
emergency NN emergency O
services NN services O

The CAPITAL NNP O
effects NN effects O
of NN stopwords O
oral NN oral T
liarozole NN T
on NN stopwords on O
epidermal NN cuticular O
proliferation NN proliferation O
and DT stopwords O
differentiation NN differentiation O
in NN stopwords inch O
severe NN severe D
plaque NN plaque D
psoriasis NN psoriasis D
are DT stopwords are O
comparable NNS comparable O
with NN stopwords O
those NN stopwords O
of NN stopwords O
acitretin DT T
. . O

The CAPITAL NNP O
efficiency NN efficiency O
of NN stopwords O
testicular NN testicular T
sperm NN sperm T
retrieval NN retrieval T
by NN stopwords by T
testicular NN testicular T
fine NN fine T
needle JJ acerate_leaf T
aspiration DT aspiration T
( ( T
TEFNA CAPITAL NNP T
) ) T
was VB stopwords Washington O
compared NNS compare O
with NN stopwords O
open JJ open T
biopsy NN biopsy T
and DT stopwords T
testicular NN testicular T
sperm NN sperm T
extraction NN extraction T
( ( T
TESE CAPITAL NNP T
) ) T
, , O
in NN stopwords inch O
37 DIGITS CD thirty-seven O
rigorously NN rigorously O
selected NN choose O
patients VB patient O
with NN stopwords O
non-obstructive JJ D
azoospermia DT D

Are CAPITAL DT are O
the NN stopwords O
products NN merchandise O
of NN stopwords O
CD44 CAPITAL NNP O
exons NN exon O
v5 NN O
and DT stopwords O
v6 NN O
markers NN marker O
for NN stopwords O
metastasis NN metastasis O
of NN stopwords O
laryngeal NN laryngeal D
carcinomas VB carcinoma D
? . O

These CAPITAL NNP O
studies NN survey O
provide NN supply O
compelling NNS compel O
evidence NN evidence O
that NN stopwords O
defects NN defect O
in NN stopwords inch O
pendrin NN O
cause VB cause O
Pendred CAPITAL NNP D
syndrome NN syndrome D
thereby NN thereby O
launching NN launching O
a DT stopwords angstrom O
new JJ new O
area DT area O
of NN stopwords O
investigation NN probe O
into NN stopwords O
thyroid NN thyroid_gland O
physiology NN physiology O
, , O
the NN stopwords O
pathogenesis VB pathogenesis O
of NN stopwords O
congenital NNS congenital D
deafness NN deafness D
and DT stopwords O
the NN stopwords O
role NN function O
of NN stopwords O
altered DT change O
sulphate NN sulfate O
transport NN conveyance O
in NN stopwords inch O
human NN homo O
disease NN disease O

Agonist CAPITAL DT protagonist O
efficacy NN efficacy O
and DT stopwords O
allosteric DT O
models NN model O
of NN stopwords O
receptor NN receptor O
action DT action O

No CAPITAL NNP no O
G-CSF-treated CAPITAL NNP O
patient VB patient O
needed JJ necessitate O
surgery NN surgery T
, , O
whereas NN O
two NN two O
placebo NN placebo O
recipients NN recipient O
underwent JJ undergo O
to NN stopwords O
amputation DT amputation T
and DT stopwords O
two NN two O
had VB stopwords have O
extensive NN extensive O
debridement NN debridement T
under JJ stopwords nether O
anaesthesia DT anesthesia O

The CAPITAL NNP O
sequential NN consecutive O
replacement NN replacement O
of NN stopwords O
the NN stopwords O
four JJ four O
tryptophan NN tryptophan O
residues NN residue O
in NN stopwords inch O
gramicidin NN gramicidin O
A CAPITAL DT angstrom O
at DT stopwords astatine O
positions NN position O
15 DIGITS CD fifteen O
, , O
13 DIGITS CD thirteen O
, , O
11 DIGITS CD eleven O
, , O
and DT stopwords O
9 DIGITS CD nine O
with NN stopwords O
glycine NN glycine O
showed NN show O
that NN stopwords O
there NN stopwords there O
was VB stopwords Washington O
no NNS stopwords no O
detectable NN detectable O
effect NN consequence O
at DT stopwords astatine O
position NN position O
15 DIGITS CD fifteen O
but NN stopwords merely O
increasing NN increase O
heterogeneity NN heterogeneity O
of NN stopwords O
species NN species O
in NN stopwords inch O
the NN stopwords O
micelles NN micelle O
proceeding NN proceeding O
toward NN O
the NN stopwords O
interior NN inside O
of NN stopwords O
the NN stopwords O
micelle NN micelle O
at DT stopwords astatine O
position NN position O
9 DIGITS CD nine O

Pendred CAPITAL NNP D
syndrome NN syndrome D
is NN stopwords be O
a DT stopwords angstrom O
recessively NN O
inherited NN inherit O
disorder NN disorder O
with NN stopwords O
the NN stopwords O
hallmark VB hallmark O
features NN feature O
of NN stopwords O
congenital NNS congenital D
deafness NN deafness D
and DT stopwords O
thyroid NN thyroid_gland D
goitre NN goiter D

Pregnancy CAPITAL NNP pregnancy O
in NN stopwords inch O
chronic NN chronic O
progressive NN progressive O
external NN external O
ophthalmoplegia JJ ophthalmoplegia D
: : O
a DT stopwords angstrom O
case VB case O
report NN report O

Polyclonal CAPITAL NNP O
antisera DT antiserum O
directed NN direct O
against DT stopwords O
three NN three O
different NN different O
portions NN part O
of NN stopwords O
the NN stopwords O
AF-4 CAPITAL DT O
protein NN protein O
were NN stopwords be O
produced NN produce O
and DT stopwords O
used JJ use O
to NN stopwords O
detect NN detect O
a DT stopwords angstrom O
116 DIGITS CD O
kD NN O
protein NN protein O
in NN stopwords inch O
cellular NNS cellular O
extracts NN infusion O
of NN stopwords O
human NN homo O
B-lymphoblastoid CAPITAL NNP O
and DT stopwords O
proB NN O
cell NNS cell O
lines NN line O

Electronic CAPITAL NNP electronic O
computers NNS computer O
in NN stopwords inch O
medical NN checkup O
education NN education O
of NN stopwords O
the NN stopwords O
future JJ future O

The CAPITAL NNP O
rationale VB rationale O
for NN stopwords O
antileukemic DT T
therapy NN therapy T
in NN stopwords inch O
hairy NN hairy D
cell NNS cell D
leukemia NN leukemia D
is NN stopwords be O
to NN stopwords O
reduce NN reduce O
the NN stopwords O
significant NN significant O
risk NN hazard O
of NN stopwords O
infection NN infection O
and DT stopwords O
other JJ stopwords other O
potential NN potential O
serious NN serious O
complications NNS complication O

Multianalyte CAPITAL NNP O
biosensors NN O
on NN stopwords on O
optical JJ optical O
imaging NN imagination O
bundles NN package O

Treated CAPITAL NNP treat O
fibres NN fiber O
are DT stopwords are O
incubated NN incubate O
with NN stopwords O
the NN stopwords O
patient VB patient O
serum NN serum O
for NN stopwords O
10 DIGITS CD ten O
min NN minute O
followed JJ follow O
by NN stopwords by O
incubation NN incubation O
with NN stopwords O
goat NN goat O
anti DT anti O
human NN homo O
IgG CAPITAL PRP immunoglobulin_G O
tagged VB tag O
FITC CAPITAL NNP O

Repair CAPITAL NNP repair O
of NN stopwords O
ventral NN ventral D
hernias NN hernia D
with NN stopwords O
expanded NN expand T
polytetrafluoroethylene NN Teflon T
patch VB spot T

The CAPITAL NNP O
one JJ one O
year NN year O
survival NN survival O
for NN stopwords O
familial VB familial O
and DT stopwords O
AL CAPITAL DT aluminum O
forms NN form O
was VB stopwords Washington O
92 DIGITS CD ninety-two O
% NN O
( ( O
11/12 CD O
) ) O
nu NNS nu O
38 DIGITS CD thirty-eight O
% NN O
( ( O
6/24 CD O
) ) O
, , O
respectively NN respectively O
, , O
with NN stopwords O
virtually NN virtually O
all DT stopwords all O
deaths NN death O
due NN due O
to NN stopwords O
cardiac VB cardiac O
causes VB cause O

A CAPITAL DT angstrom O
2- CD O
, , O
3- CD O
, , O
and DT stopwords O
4-day CD O
mean NN mean O
temperature NN temperature O
prior NN prior O
to NN stopwords O
the NN stopwords O
test NN trial O
date VB date O
was VB stopwords Washington O
compared NNS compare O
to NN stopwords O
AFI CAPITAL DT O
using JJ exploitation O
a DT stopwords angstrom O
Spearman-rank CAPITAL NNP O
Correlation CAPITAL NNP correlation O

Substance CAPITAL NNP substance O
abusers DT abuser O
in NN stopwords inch O
pregnancy NN pregnancy O
are DT stopwords are O
more NN stopwords More O
likely NN likely O
to NN stopwords O
be NN stopwords beryllium O
single NN single O
, , O
unemployed JJ unemployed_people O
, , O
and DT stopwords O
to NN stopwords O
have VB stopwords rich_person O
had VB stopwords have O
a DT stopwords angstrom O
previous NN previous O
pregnancy NN pregnancy O

Chemotherapeutic CAPITAL NNP chemotherapeutic O
effects NN effects O
on NN stopwords on O
mammalian VB mammal D
tumor NN tumor D
cells NNS cell D

Rationale CAPITAL VB rationale O
for NN stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
antiplatelet DT T
drugs NN drug T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
peripheral NN peripheral D
vascular NN vascular D
disease NN disease D

Role CAPITAL NNP function O
of NN stopwords O
beta-blockers NN T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
cardiac VB cardiac D
insufficiency NN insufficiency D

Studies CAPITAL NNP survey O
on NN stopwords on O
nitrogen NN nitrogen O
metabolism NN metamorphosis O
of NN stopwords O
Penicillium CAPITAL NNP Penicillium O
chrysogenum NN O
Thom CAPITAL NNP O
. . O
II CAPITAL PRP two O

A CAPITAL DT angstrom O
statistical NN statistical O
evaluation NN evaluation O

Absorption CAPITAL DT absorption O
of NN stopwords O
medium NN medium O
and DT stopwords O
long NN hanker O
chain NNS chain O
triglycerides NN triglyceride O
: : O
factors VB factor O
influencing NN influence O
their NN stopwords O
hydrolysis NN hydrolysis O
and DT stopwords O
transport NN conveyance O

The CAPITAL NNP O
clinical JJ clinical O
and DT stopwords O
roentgenographic NN roentgenographic O
features NN feature O
of NN stopwords O
patients VB patient O
with NN stopwords O
thoracic NN pectoral O
manifestations VB manifestation O
of NN stopwords O
the NN stopwords O
growing NN growth O
teratoma NN teratoma D
syndrome NN syndrome D
, , O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
its NN stopwords information_technology O
management VB management O
, , O
are DT stopwords are O
reviewed NN review O

Drugs CAPITAL NNP drug O
for NN stopwords O
the NN stopwords O
Third CAPITAL NNP one-third O
World CAPITAL NNP universe O

The CAPITAL NNP O
effect NN consequence O
was VB stopwords Washington O
most NN stopwords most O
pronounced NN pronounce O
in NN stopwords inch O
the NN stopwords O
central NNS central O
part NN part O
of NN stopwords O
the NN stopwords O
treated NN treat O
area DT area O
, , O
where NN stopwords O
no NNS stopwords no O
positive NN positive O
fox JJ fox O
was VB stopwords Washington O
found JJ found O
in NN stopwords inch O
the NN stopwords O
2 DIGITS CD two O
months NN calendar_month O
before NN stopwords earlier O
the NN stopwords O
end NN end O
of NN stopwords O
the NN stopwords O
trial NN test O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Increased CAPITAL PRP increase O
incidence NN incidence O
of NN stopwords O
preeclampsia NN preeclampsia D
in NN stopwords inch O
women NN woman O
conceiving NNS gestate O
by NN stopwords by O
intrauterine NN intrauterine T
insemination NN insemination T
with NN stopwords T
donor NN donor T
versus NN T
partner NN spouse T
sperm NN sperm T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
primary NN primary D
infertility NN sterility D

Signs CAPITAL NNP sign O
observed NN detect O
in NN stopwords inch O
fetuses JJ fetus O
with NN stopwords O
trisomy NN trisomy D
13 DIGITS CD thirteen D
were NN stopwords be O
: : O
hydrocephalus NN hydrocephalus O
, , O
intrauterine NN intrauterine O
growth NN growth O
retardation NN deceleration O
, , O
oligoanhydramnios IN O
, , O
complex NNS complex O
malformations VB deformity O
, , O
severe NN severe O
fetal JJ fetal O
bradycardia NN bradycardia D
and DT stopwords O
hydronephrosis NN hydronephrosis D

Significant CAPITAL NNP significant O
factors VB factor O
for NN stopwords O
survival NN survival O
in NN stopwords inch O
univariate JJ O
and DT stopwords O
multivariate NN multivariate O
analyses DT analysis O
were NN stopwords be O
: : O
cervical NNS cervical O
diameter NN diameter O
, , O
positive NN positive O
lymphangiography NN lymphangiography O
, , O
and DT stopwords O
adeno-carcinomatous DT O
histotype NN O

The CAPITAL NNP O
results NN consequence O
confirm NNS confirm O
student NN student O
exposure NN exposure O
to NN stopwords O
many VB many O
ward NN ward O
settings NN setting O
( ( O
surgery NN surgery O
, , O
30 DIGITS CD thirty O
% NN O
; : O
neurology/neurosurgery JJ O
, , O
28 DIGITS CD twenty-eight O
% NN O
; : O
medicine NN medicine O
, , O
24 DIGITS CD twenty-four O
% NN O
; : O
intensive NN intensifier O
care VB care O
, , O
15 DIGITS CD fifteen O
% NN O
; : O
oncology JJ oncology O
, , O
2 DIGITS CD two O
% NN O
; : O
and DT stopwords O
psychiatry NN psychiatry O
, , O
1 DIGITS CD one O
% NN O
) ) O
, , O
patient VB patient O
complexity NNS complexity O
( ( O
averaging DT average O
10 DIGITS CD ten O
problems NN problem O
) ) O
, , O
and DT stopwords O
multiple NN multiple O
ICD-9 CAPITAL PRP O
diagnosis NN diagnosis O
categories VB class O
( ( O
circulatory NN circulative O
, , O
36 DIGITS CD thirty-six O
% NN O
; : O
neurologic JJ neurological O
, , O
22 DIGITS CD twenty-two O
% NN O
; : O
musculoskeletal NN musculoskeletal O
, , O
17 DIGITS CD seventeen O
% NN O
; : O
neoplasms JJ tumor O
, , O
10 DIGITS CD ten O
% NN O
; : O
injury NN injury O
, , O
5 DIGITS CD five O
% NN O
; : O
endocrine NN hormone O
, , O
4 DIGITS CD four O
% NN O
; : O
infections NN infection O
, , O
3 DIGITS CD three O
% NN O
; : O
and DT stopwords O
others JJ O
, , O
3 DIGITS CD three O
% NN O
) ) O

After CAPITAL DT after O
a DT stopwords angstrom O
median NN median O
follow-up JJ follow-up O
of NN stopwords O
87 DIGITS CD eighty-seven O
( ( O
range VB scope O
57-120 CD O
) ) O
months NN calendar_month O
, , O
5-year CD O
overall JJ overall O
and DT stopwords O
disease-free NN O
survival NN survival O
were NN stopwords be O
identical NN identical O
in NN stopwords inch O
the NN stopwords O
surgery NN surgery O
and DT stopwords O
radiotherapy VB radiotherapy O
groups NN group O
( ( O
83 DIGITS CD eighty-three O
% NN O
and DT stopwords O
74 DIGITS CD seventy-four O
% NN O
, , O
respectively NN respectively O
, , O
for NN stopwords O
both NN stopwords both O
groups NN group O
) ) O
, , O
86 DIGITS CD eighty-six O
women NN woman O
developed NN develop O
recurrent NN perennial O
disease NN disease O
: : O
42 DIGITS CD forty-two O
( ( O
25 DIGITS CD twenty-five O
% NN O
) ) O
in NN stopwords inch O
the NN stopwords O
surgery NN surgery O
group NN group O
and DT stopwords O
44 DIGITS CD forty-four O
( ( O
26 DIGITS CD twenty-six O
% NN O
) ) O
in NN stopwords inch O
the NN stopwords O
radiotherapy VB radiotherapy O
group NN group O

New CAPITAL NNP new O
Zealand CAPITAL NNP Zealand O
Cot CAPITAL NNP fingerstall O
Death CAPITAL NNP death O
Study CAPITAL NNP survey O
Group CAPITAL NNP group O

Thirty-four CAPITAL NNP thirty-four O
( ( O
94 DIGITS CD ninety-four O
% NN O
) ) O
of NN stopwords O
the NN stopwords O
36 DIGITS CD thirty-six O
patients VB patient O
enjoyed NN enjoy O
sustained NN prolong O
moderate NN centrist O
or NN stopwords Oregon O
marked NN tag O
improvement JJ improvement O
of NN stopwords O
their NN stopwords O
parkinsonian NN D
symptoms NN symptom D
6 DIGITS CD six O
months NN calendar_month O
postoperatively NN postoperatively O

Autosomal CAPITAL DT autosomal O
dominant NN dominant O
nocturnal JJ nocturnal O
frontal JJ frontlet O
lobe NN lobe O
epilepsy NN epilepsy D

To CAPITAL NNP O
show NN show O
this NN stopwords O
, , O
it NN stopwords information_technology O
is NN stopwords be O
necessary JJ necessity O
to NN stopwords O
study NN survey O
systems NN system O
with NN stopwords O
limiting NN modification O
concentrations NNS concentration O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O

BACKGROUND CAPITAL IN background O
: : O
Few CAPITAL NNP few O
studies NN survey O
have VB stopwords rich_person O
explored NN research O
the NN stopwords O
health NN health O
practices NN practice O
of NN stopwords O
critical JJ critical O
care VB care O
nurses RB nurse O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Fatal CAPITAL NNP fatal D
acute DT acute_accent D
haemolysis VB hemolysis D
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
AIDS CAPITAL DT AIDS D
patient VB patient O
treated NN treat O
with NN stopwords O
lindinavir NN T

BACKGROUND CAPITAL IN background O
: : O
Adrenalectomy CAPITAL DT adrenalectomy T
is NN stopwords be O
the NN stopwords O
current NNS current O
treatment NN treatment O
for NN stopwords O
phaeochromocytoma NN pheochromocytoma D

Electrolyte CAPITAL NNP electrolyte O
abnormalities DT abnormality O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
renal NN nephritic D
failure VB failure D
receiving NN receive O
parenteral NN parenteral O
nutrition JJ nutrition O

Algae CAPITAL DT alga O
or NN stopwords Oregon O
protozoa NN Protozoa O
: : O
phylogenetic NN phylogenetic O
position NN position O
of NN stopwords O
euglenophytes NN euglenoid O
and DT stopwords O
dinoflagellates NN dinoflagellate O
as DT stopwords arsenic O
inferred NN deduce O
from JJ stopwords O
mitochondrial NN O
sequences NN sequence O

Zinc CAPITAL NN zinc T
gluconate NN T
lozenges NN lozenge T
for NN stopwords O
treating NN treat O
the NN stopwords O
common NNS park D
cold NNS cold D

METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
studied NN analyze O
the NN stopwords O
effects NN effects O
of NN stopwords O
three NN three O
years NN old_age O
of NN stopwords O
dietary NN dietary O
supplementation NN supplement O
with NN stopwords O
calcium VB calcium O
and DT stopwords O
vitamin NN vitamin O
D CAPITAL NN vitamin_D O
on NN stopwords on O
bone NN bone O
mineral NN mineral O
density NN density O
, , O
biochemical NN biochemical O
measures NN measure O
of NN stopwords O
bone NN bone O
metabolism NN metamorphosis O
, , O
and DT stopwords O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
nonvertebral JJ O
fractures NN fracture O
in NN stopwords inch O
176 DIGITS CD O
men NN work_force O
and DT stopwords O
213 DIGITS CD O
women NN woman O
65 DIGITS CD sixty-five O
years NN old_age O
of NN stopwords O
age DT age O
or NN stopwords Oregon O
older JJ aged O
who NN stopwords World_Health_Organization O
were NN stopwords be O
living NN life O
at DT stopwords astatine O
home NN home O

Corticosteroids CAPITAL NNP corticosteroid T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
croup NNS croup D

The CAPITAL NNP O
clinical JJ clinical O
application DT application O
of NN stopwords O
therapeutic NN remedy T
hysteroscopy NN hysteroscopy T
, , O
mainly VB chiefly O
in NN stopwords inch O
the NN stopwords O
field NN field O
of NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
abnormal DT abnormal D
uterine JJ uterine D
bleeding NN bleeding D
, , O
started NN get_down O
in NN stopwords inch O
the NN stopwords O
1980s CD eighties O

Effect CAPITAL NNP consequence O
of NN stopwords O
calcium VB calcium O
and DT stopwords O
vitamin NN vitamin O
D CAPITAL NN vitamin_D O
supplementation NN supplement O
on NN stopwords on O
bone NN bone O
density NN density O
in NN stopwords inch O
men NN work_force O
and DT stopwords O
women NN woman O
65 DIGITS CD sixty-five O
years NN old_age O
of NN stopwords O
age DT age O
or NN stopwords Oregon O
older JJ aged O

Koch CAPITAL NNP Koch O
's POS O
or NN stopwords Oregon O
Crohn CAPITAL NNP Crohn O
's POS O
? . O

The CAPITAL NNP O
mutator NN O
hypothesis NN hypothesis O
of NN stopwords O
tumorigenesis NN O
suggests NN propose O
that NN stopwords O
loss NN loss O
of NN stopwords O
chromosomal NN chromosomal O
stability NN stability O
or NN stopwords Oregon O
maintenance VB care O
functions JJ function O
results NN consequence O
in NN stopwords inch O
elevated NN elevated_railway O
mutation NN mutant O
rates VB rates O
, , O
leading NN lead O
to NN stopwords O
the NN stopwords O
accumulation DT accretion O
of NN stopwords O
the NN stopwords O
numerous JJ numerous O
mutations NN mutant O
required NN necessitate O
for NN stopwords O
multistep NN O
carcinogenesis VB O

Absence CAPITAL DT absence O
of NN stopwords O
renal NN nephritic O
and DT stopwords O
hepatic NN liverwort O
toxicity NN toxicity O
after DT stopwords after O
four JJ four O
hours NN hours O
of NN stopwords O
1.25 CD O
minimum NN minimum O
alveolar DT alveolar_consonant O
anesthetic DT anesthetic O
concentration NNS concentration O
sevoflurane NN O
anesthesia DT anesthesia O
in NN stopwords inch O
volunteers NN volunteer O

Lumbar CAPITAL NNP lumbar O
bone NN bone O
mineral NN mineral O
density NN density O
was VB stopwords Washington O
assessed DT measure O
by NN stopwords by O
quantitative NN quantitative O
computed NNS calculate O
tomography NN imaging O
( ( O
qCT JJ O
) ) O
and DT stopwords O
radial VB radial O
bone NN bone O
density NN density O
by NN stopwords by O
single NN single O
photon NN photon O
absorptiometry DT O
of NN stopwords O
the NN stopwords O
distal NN distal O
forearm NN forearm O

BACKGROUND CAPITAL IN background O
: : O
An CAPITAL DT Associate_in_Nursing O
increasing NN increase O
number JJ number O
of NN stopwords O
reports NN report O
indicate NN bespeak O
symptomatic NN diagnostic O
relief NN relief O
of NN stopwords O
biliary NN bilious O
colic NNS colic O
symptoms NN symptom O
after DT stopwords after O
cholecystectomy NNS cholecystectomy T
for NN stopwords O
biliary NN bilious D
dyskinesia NN dyskinesia D

More CAPITAL NNP More O
than NN stopwords O
20 DIGITS CD twenty O
years NN old_age O
second-look NN O
surgery NN surgery T
in NN stopwords inch O
advanced DT advance D
epithelial NN epithelial D
ovarian NN ovarian D
cancer VB cancer D
: : O
what NN stopwords O
did NN stopwords make O
we NN stopwords O
learn NN learn O
? . O

Standard CAPITAL NNP standard T
versus NN T
high-dose NN T
therapy NN therapy T
in NN stopwords inch O
10+ CD O
breast NN breast D
cancer VB cancer D

The CAPITAL NNP O
chicken JJ chicken O
calmodulin VB O
I CAPITAL PRP iodine O
( ( O
CaMI CAPITAL VB O
) ) O
gene NN gene O
has VB stopwords hour_angle O
been NN stopwords be O
isolated NN isolate O
and DT stopwords O
characterized NNS qualify O
on NN stopwords on O
the NN stopwords O
level NN degree O
of NN stopwords O
cDNA SYM complementary_DNA O
and DT stopwords O
genomic NN O
DNA CAPITAL NNP deoxyribonucleic_acid O

The CAPITAL NNP O
art DT art O
of NN stopwords O
medicine NN medicine O
is NN stopwords be O
founded JJ establish O
on NN stopwords on O
context NNS context O
, , O
anecdote DT anecdote O
, , O
patient VB patient O
stories NN narrative O
of NN stopwords O
illness NN illness O
and DT stopwords O
personal NN personal O
experience NN experience O
, , O
and DT stopwords O
we NN stopwords O
should NN stopwords O
continue NNS continue O
to NN stopwords O
blend NN blend O
this NN stopwords O
with NN stopwords O
good NN good O
quality NN quality O
and DT stopwords O
appropriate DT allow O
research NN research O
findings NN findings O
in NN stopwords inch O
patient VB patient O
care VB care O

We CAPITAL NNP O
did NN stopwords make O
not JJ stopwords not O
find NN discovery O
a DT stopwords angstrom O
statistically NN statistically O
significant NN significant O
association DT association O
between NN stopwords between O
the NN stopwords O
number JJ number O
of NN stopwords O
B CAPITAL NN bacillus O

PL CAPITAL NNP T
granule NN granule T
is NN stopwords be O
one JJ one O
of NN stopwords O
the NN stopwords O
most NN stopwords most O
common NNS park O
forms NN form O
of NN stopwords O
composite NNS complex O
medicine NN medicine O
for NN stopwords O
colds NNS cold D
in NN stopwords inch O
Japan CAPITAL NNP Japan O
, , O
including NN include O
acetaminophen DT acetaminophen O

Ribosomal CAPITAL NN O
S6 CAPITAL CD O
kinase NN kinase O
p90rsk NN O
and DT stopwords O
mRNA NN messenger_RNA O
cap-binding VB O
protein NN protein O
eIF4E NN O
phosphorylations NN O
correlate NNS correlate O
with NN stopwords O
MAP CAPITAL NNP map O
kinase NN kinase O
activation DT activation O
during NN stopwords O
meiotic NN meiotic O
reinitiation NN O
of NN stopwords O
mouse NN mouse O
oocytes JJ oocyte O

Fathers CAPITAL NNP father O
in NN stopwords inch O
the NN stopwords O
delivery NN delivery O
-- : O
'' POS O
helpful NN helpful O
and DT stopwords O
supportive NN supportive O
'' POS O

Molecular CAPITAL NNP molecular O
neurogenetics JJ O
: : O
the NN stopwords O
genome NN genome O
is NN stopwords be O
settling NN settling O
the NN stopwords O
issue NN issue O

methods NN method O
: : O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
cells NNS cell O
were NN stopwords be O
treated NN treat O
with NN stopwords O
gemcitabine NN T
, , O
harvested NN reap O
, , O
and DT stopwords O
nuclear JJ nuclear O
extracts NN infusion O
analyzed DT analyze O
for NN stopwords O
nf-kappab RB O
dna NN deoxyribonucleic_acid O
binding NN binding O
by NN stopwords by O
electrophoretic NN electrophoretic O
mobility NN mobility O
shift NN shift O
assays DT assay O

Vaccination CAPITAL VB inoculation T
against DT stopwords O
Schistosoma CAPITAL NNP Schistosoma D
mansoni VB D
infection NN infection D
using JJ exploitation O
74 DIGITS CD seventy-four O
kDa NN O
Schistosoma CAPITAL NNP Schistosoma O
protein NN protein O
antigen DT antigen O

The CAPITAL NNP O
transport NN conveyance O
of NN stopwords O
prey NN prey O
by NN stopwords by O
ants DT ant O

From CAPITAL NNP O
these NN stopwords O
results NN consequence O
Gingyo-san CAPITAL NNP T
was VB stopwords Washington O
shown NN show O
to NN stopwords O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
antiviral DT antiviral O
agent DT agent O
in NN stopwords inch O
mice NN mouse O
infected NN infect O
with NN stopwords O
a DT stopwords angstrom O
lethal NN deadly O
amount DT sum O
of NN stopwords O
a DT stopwords angstrom O
mouse-adopted NN D
strain NN strain D
of NN stopwords D
influenza NN influenza D
A2 CAPITAL DT D
virus NN virus D

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Quo CAPITAL NNP O
vadis NN O
`` `` O
suprema NN O
lex NN O
'' POS O
? . O

Influence CAPITAL PRP influence O
of NN stopwords O
treatment NN treatment O
delay NN delay O
on NN stopwords on O
infarct NN infarct O
size NN size O
and DT stopwords O
clinical JJ clinical O
outcome JJ result O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
treated NN treat O
with NN stopwords O
primary NN primary T
angioplasty DT angioplasty T

The CAPITAL NNP O
optimum JJ optimum O
therapy NN therapy O
for NN stopwords O
each VB stopwords each O
patient VB patient O
should NN stopwords O
take VB return O
account DT history O
of NN stopwords O
clinical JJ clinical O
factors VB factor O
such NN stopwords such O
as DT stopwords arsenic O
menopausal NN menopausal O
status NN status O
, , O
age DT age O
, , O
medical NN checkup O
illness NN illness O
, , O
histological NN histological O
type NN type O
, , O
and DT stopwords O
cervical NNS cervical O
diameter NN diameter O
to NN stopwords O
yield NN output O
the NN stopwords O
best NN best O
cure NNS remedy O
with NN stopwords O
minimum NN minimum O
complications NNS complication O

Coronary CAPITAL NNP coronary_thrombosis O
calcium VB calcium O
amount DT sum O
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
a DT stopwords angstrom O
weak NN weak O
predictor NN forecaster O
of NN stopwords O
coronary NNS coronary_thrombosis O
death NN death O
and DT stopwords O
infarction NN infarct D

Patients CAPITAL VB patient O
with NN stopwords O
classical NNS classical_music O
symptoms NN symptom O
such NN stopwords such O
as DT stopwords arsenic O
heartburn NN heartburn D
and DT stopwords D
regurgitation NN regurgitation D
may VB May O
be NN stopwords beryllium O
treated NN treat O
pharmaceutically NN T
combined NNS unite T
with NN stopwords T
life NN life T
style NN manner T
counselling NNS guidance T

All CAPITAL DT all O
live NN populate O
births NN birth O
> NN O
or NN stopwords Oregon O
= NN O
23 DIGITS CD twenty-three O
weeks NN week O
at DT stopwords astatine O
the NN stopwords O
University CAPITAL NNP university O
of NN stopwords O
Vermont CAPITAL NNP Vermont O
in NN stopwords inch O
1995 DIGITS CD O
( ( O
n NN nitrogen O
= NN O
2395 DIGITS CD O
) ) O
were NN stopwords be O
retrospectively NN retrospectively O
analyzed DT analyze O
for NN stopwords O
delivery NN delivery O
route NN path O
, , O
indication NN indication O
for NN stopwords O
cesarean NNS cesarean_delivery O
, , O
gestational NN gestational O
age DT age O
, , O
parity NN parity O
, , O
and DT stopwords O
practice NN practice O
group NN group O
( ( O
to NN stopwords O
reflect NN reflect O
risk NN hazard O
status NN status O
) ) O

Intravascular-catheter-related CAPITAL PRP D
infections NN infection D

Evidence CAPITAL NNP evidence O
for NN stopwords O
double NN double O
resistance NN resistance O
to NN stopwords O
permethrin NN T
and DT stopwords T
malathion VB Malathion T
in NN stopwords inch O
head NN head D
lice NN louse D

Chromosome CAPITAL NNP chromosome O
19 DIGITS CD nineteen O
single-locus NN O
and DT stopwords O
multilocus NN O
haplotype VB haplotype O
associations DT association O
with NN stopwords O
multiple NN multiple D
sclerosis JJ sclerosis D

Use CAPITAL NNP use O
of NN stopwords O
fenfluramines JJ T
is NN stopwords be O
associated DT associate O
with NN stopwords O
an DT stopwords Associate_in_Nursing O
increased NN increase O
risk NN hazard O
of NN stopwords O
PPH CAPITAL NNP D

There CAPITAL NNP there O
were NN stopwords be O
no NNS stopwords no O
differences NN difference O
among DT O
groups NN group O
in NN stopwords inch O
sedation NN sedation O
scores JJ tons O
or NN stopwords Oregon O
side NN side O
effects NN effects O

Coumadin CAPITAL NNP warfarin O
Aspirin CAPITAL DT aspirin O
Reinfarction CAPITAL NNP O
Study CAPITAL NNP survey O
( ( O
CARS CAPITAL VB car O
) ) O
Investigators CAPITAL PRP research_worker O

After CAPITAL DT after O
completion NNS completion O
of NN stopwords O
chemotherapy NNS chemotherapy T
and DT stopwords O
normalization RB standardization O
of NN stopwords O
tumor NN tumor O
markers NN marker O
, , O
both NN stopwords both O
patients VB patient O
presented NN show O
with NN stopwords O
pulmonary NN pneumonic D
symptoms NN symptom D
attributable DT attributable O
to NN stopwords O
their NN stopwords O
massively VB massively O
enlarging NN enlarge O
mediastinal NN D
teratomas NN teratoma D
. . O

A CAPITAL DT angstrom O
65-year-old CD O
woman NN woman O
, , O
who NN stopwords World_Health_Organization O
had VB stopwords have O
been NN stopwords be O
undergoing JJ undergo O
immunotherapy JJ immunotherapy T
for NN stopwords O
inoperably NN D
disseminated NN circulate D
renal NN nephritic D
carcinoma VB carcinoma D
and DT stopwords D
lung NN lung D
metastases NN metastasis D
, , O
presented NN show O
with NN stopwords O
severe NN severe O
abdominal DT abdominal O
pain IN pain O
in NN stopwords inch O
a DT stopwords angstrom O
state NN state O
of NN stopwords O
hypovolemic NN hypovolemic O
shock NN daze O

High-dose CAPITAL NNP O
fluoride JJ fluoride T
treatment NN treatment T
did NN stopwords make O
not JJ stopwords not O
improve JJ better O
, , O
but NN stopwords merely O
decreased NN decrease O
, , O
bone NN bone O
strength NN strength O
in NN stopwords inch O
rabbits NN rabbit O
, , O
even NN evening O
in NN stopwords inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
impaired JJ impair O
mineralization NN O

Spinal CAPITAL NNP spinal_anesthesia D
muscular NN muscular D
atrophy DT atrophy D
: : O
where NN stopwords O
are DT stopwords are O
we NN stopwords O
in NN stopwords inch O
1998 DIGITS CD O
? . O

Management CAPITAL NNP management O
of NN stopwords O
patients VB patient O
with NN stopwords O
HIV/AIDS CAPITAL NNP D

Another CAPITAL DT another O
use JJ use O
of NN stopwords O
androgens DT androgen T
: : O
treatment NN treatment O
of NN stopwords O
anemia DT anemia D
of NN stopwords D
end-stage NN D
renal NN nephritic D
disease NN disease D

Longer CAPITAL NNP longer O
duration NN duration O
of NN stopwords O
illness NN illness O
( ( O
> NN O
5 DIGITS CD five O
days VB days O
) ) O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
increased NN increase O
return NN tax_return O
within NN inside O
six NN six O
weeks NN week O
( ( O
hazard NN hazard O
ratio VB ratio O
2.90 CD O
, , O
1.70 CD O
to NN stopwords O
4.92 CD O
) ) O

The CAPITAL NNP O
audit DT audited_account O
demonstrated NN show O
inconsistent NN inconsistent O
use JJ use O
of NN stopwords O
plastic NN plastic O
covers NNS screen O
, , O
warming NN heating O
mattresses VB mattress O
, , O
and DT stopwords O
added DT add O
humidity NN humidity O
under JJ stopwords nether O
radiant VB beaming O
warmers NN heater O
, , O
and DT stopwords O
discrepancies NN discrepancy O
between NN stopwords between O
survey NN survey O
responses NN response O
and DT stopwords O
actual DT actual O
use JJ use O
within NN inside O
NICUs CAPITAL NNP neonatal_intensive_care_unit O

In CAPITAL PRP inch O
doing NN stopwords make O
so NN stopwords sol O
, , O
it NN stopwords information_technology O
( ( O
i NN stopwords iodine O
) ) O
aims DT purpose O
to NN stopwords O
differentiate NN distinguish O
between NN stopwords between O
the NN stopwords O
types NN type O
of NN stopwords O
stress NN stress O
affecting DT affect O
an DT stopwords Associate_in_Nursing O
athlete DT athlete O
's POS O
performance NN performance O
: : O
( ( O
ii NN two O
) ) O
identifies NN identify O
factors VB factor O
influencing NN influence O
an DT stopwords Associate_in_Nursing O
athlete DT athlete O
's POS O
ability DT ability O
to NN stopwords O
adapt DT adapt O
to NN stopwords O
physical NN physical O
training NN training O
: : O
( ( O
iii NN three O
) ) O
structures NN structure O
the NN stopwords O
recovery NN recovery O
process NN procedure O

It CAPITAL PRP information_technology O
assumes DT assume O
that NN stopwords O
a DT stopwords angstrom O
single NN single O
pathway VB nerve_pathway O
is NN stopwords be O
sufficient NN sufficient O
for NN stopwords O
educating NN educate O
general NN general O
internists NN internist O
and DT stopwords O
subspecialty-bound NN O
trainees NN trainee O

Long-term CAPITAL NNP long-run O
effect NN consequence O
of NN stopwords O
calcium VB calcium O
supplementation NN supplement O
during NN stopwords O
pregnancy NN pregnancy O
on NN stopwords on O
the NN stopwords O
blood NN blood O
pressure NN pressure O
of NN stopwords O
offspring JJ offspring O
: : O
follow JJ follow O
up JJ stopwords up O
of NN stopwords O
a DT stopwords angstrom O
randomised VB randomize O
controlled NNS control O
trial NN test O

Sera CAPITAL NNP serum O
were NN stopwords be O
drawn NN pull O
12 DIGITS CD twelve O
days VB days O
from JJ stopwords O
ovulation JJ ovulation O
in NN stopwords inch O
non-IVF JJ O
cycles NNS cycle O
or NN stopwords Oregon O
9 DIGITS CD nine O
days VB days O
after DT stopwords after O
ET CAPITAL NN O
and DT stopwords O
were NN stopwords be O
assayed DT assay O
for NN stopwords O
PIBF CAPITAL NNP O
and DT stopwords O
beta NN beta O
human NN homo O
chorionic NNS chorionic O
gondotropin NN O

Both CAPITAL NNP both O
current NNS current O
and DT stopwords O
previous NN previous O
prescribing NN order O
for NN stopwords O
sore NN sore D
throat NN throat D
increase NN addition O
reattendance NN O

H2NCO-E.COSY CAPITAL $ O
, , O
a DT stopwords angstrom O
simple NN simple O
method NN method O
for NN stopwords O
the NN stopwords O
sterospecific NN O
assignment DT assignment O
of NN stopwords O
side-chain NN O
amide DT amide O
protons NN proton O
in NN stopwords inch O
proteins NN protein O

1995 DIGITS CD O
coronary NNS coronary_thrombosis T
artery DT artery T
bypass NN beltway T
risk NN hazard O
model NN model O
: : O
The CAPITAL NNP O
Society CAPITAL NNP society O
of NN stopwords O
Thoracic CAPITAL NNP pectoral O
Surgeons CAPITAL NNP surgeon O
Adult CAPITAL DT adult O
Cardiac CAPITAL VB cardiac O
National CAPITAL NNP national O
Database CAPITAL NNP database O

OBJECTIVES CAPITAL NNP aim O
: : O
To CAPITAL NNP O
identify NN identify O
BRCA1 CAPITAL NNP O
mutations NN mutant O
and DT stopwords O
to NN stopwords O
determine NN determine O
factors VB factor O
that NN stopwords O
best NN best O
predict NN predict O
presence NN presence O
of NN stopwords O
a DT stopwords angstrom O
deleterious NN deleterious O
BRCA1 CAPITAL NNP O
mutation NN mutant O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
breast NN breast O
and/or DT O
ovarian NN ovarian O
cancer VB cancer D

Overall CAPITAL NNP overall O
30-day CD O
mortality NN mortality O
was VB stopwords Washington O
significantly NN significantly O
lower NN lower_berth O
in NN stopwords inch O
the NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
received NN receive O
thrombolytic NN thrombolytic T
agents DT agent T
( ( O
4.7 CD O
versus NN O
11.1 CD O
% NN O
, , O
P=.016 CAPITAL NNP O
) ) O

Physician CAPITAL NNP doctor O
assistants DT assistant O
and DT stopwords O
nurse RB nurse O
practitioners NN practitioner O
in NN stopwords inch O
hospital NN hospital O
outpatient JJ outpatient O
departments NN department O
, , O
1993-1994 CD O

Classification CAPITAL NNP categorization O
of NN stopwords O
malignant VB malignant D
lymphomas NN lymphoma D
: : O
the NN stopwords O
updated JJ update O
Kiel CAPITAL NNP O
classification NNS categorization O

Single CAPITAL NNP single O
or NN stopwords Oregon O
double NN double O
lung NN lung T
transplantation NN transplant T
for NN stopwords O
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
epinephrine NN epinephrine O
on NN stopwords on O
immunoreactive JJ O
insulin NN insulin O
levels NN degree O
in NN stopwords inch O
man VB man O

Which CAPITAL NNP O
calcium VB calcium T
antagonists DT adversary T
for NN stopwords O
hypertension NN high_blood_pressure D
? . O

International CAPITAL PRP International O
Committee CAPITAL NNP committee O
of NN stopwords O
Medical CAPITAL NNP checkup O
Journal CAPITAL NNP diary O
Editors CAPITAL NNP editor O

FINDINGS CAPITAL NNP findings O
: : O
170 DIGITS CD one_hundred_seventy O
patients VB patient O
in NN stopwords inch O
the NN stopwords O
surgery NN surgery O
group NN group O
and DT stopwords O
167 DIGITS CD O
in NN stopwords inch O
the NN stopwords O
radiotherapy VB radiotherapy O
group NN group O
were NN stopwords be O
included NN include O
in NN stopwords inch O
the NN stopwords O
intention-to-treat NN O
analysis DT analysis O
; : O
scheduled JJ schedule O
treatment NN treatment O
was VB stopwords Washington O
delivered NN deliver O
to NN stopwords O
169 DIGITS CD O
and DT stopwords O
158 DIGITS CD O
women NN woman O
, , O
respectively NN respectively O
, , O
62 DIGITS CD sixty-two O
of NN stopwords O
114 DIGITS CD O
women NN woman O
with NN stopwords O
cervical NNS cervical O
diameters NN diameter O
of NN stopwords O
4 DIGITS CD four O
cm NNS centimeter O
or NN stopwords Oregon O
smaller JJ smaller O
and DT stopwords O
46 DIGITS CD forty-six O
of NN stopwords O
55 DIGITS CD fifty-five O
with NN stopwords O
diameters NN diameter O
larger NN bigger O
than NN stopwords O
4 DIGITS CD four O
cm NNS centimeter O
received NN receive O
adjuvant DT adjuvant O
therapy NN therapy O

Cell-based CAPITAL NNP T
vaccination NN inoculation T
against DT stopwords O
melanoma NN melanoma D
-- : O
background VB background O
, , O
preliminary NN preliminary O
results NN consequence O
, , O
and DT stopwords O
perspective NN position O

Application CAPITAL DT application O
to NN stopwords O
prenatal NN prenatal O
diagnosis NN diagnosis O

Parameter CAPITAL VB parameter O
sensitivity NN sensitivity O
of NN stopwords O
a DT stopwords angstrom O
mathematical VB mathematical O
model NN model O
of NN stopwords O
the NN stopwords O
anterior DT front_tooth O
cruciate NNS cruciate O
ligament NN ligament O

Altogether CAPITAL DT raw O
, , O
these NN stopwords O
findings NN findings O
support NN support O
the NN stopwords O
notion JJ impression O
that NN stopwords O
the NN stopwords O
Raf/MEK/ERK CAPITAL VB O
signaling NN signal O
module NN faculty O
, , O
at DT stopwords astatine O
least NN least O
in NN stopwords inch O
part NN part O
, , O
regulates NN regulate O
transcriptional NN O
activation DT activation O
of NN stopwords O
the NN stopwords O
chromosomal NN chromosomal O
architectural DT architectural O
protein NN protein O
HMGI-C CAPITAL NNP O

Women CAPITAL NNP woman O
in NN stopwords inch O
the NN stopwords O
cocaine NNS cocaine O
positive NN positive O
group NN group O
were NN stopwords be O
of NN stopwords O
higher NN higher O
parity NN parity O
( ( O
3 DIGITS CD three O
, , O
( ( O
0-7 CD O
) ) O
vs. NN O
1 DIGITS CD one O
, , O
( ( O
0-6 CD O
) ) O
, , O
p NN phosphorus O
= NN O
0.001 LS O
) ) O
and DT stopwords O
tended NN tend O
to NN stopwords O
be NN stopwords beryllium O
older JJ aged O
( ( O
27 DIGITS CD twenty-seven O
, , O
( ( O
23-42 CD O
) ) O
vs. NN O
25 DIGITS CD twenty-five O
, , O
( ( O
14-40 CD O
) ) O
) ) O

Receptor CAPITAL NNP receptor O
Classification CAPITAL NNP categorization O
: : O
The CAPITAL NNP O
Integration CAPITAL PRP integration O
of NN stopwords O
Operational CAPITAL NNP operational O
, , O
Structural CAPITAL NNP structural O
, , O
and DT stopwords O
Transductional CAPITAL NNP O
Information CAPITAL PRP information O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
rectal NN rectal T
diazepam NN diazepam T
gel NN gel T
and DT stopwords O
placebo NN placebo O
for NN stopwords O
acute DT acute_accent D
repetitive NN insistent D
seizures JJ seizure D

Possibilities CAPITAL NNP possibility O
of NN stopwords O
surgical NN surgical T
correction NNS correction T
of NN stopwords O
malformations VB deformity D
of NN stopwords D
the NN stopwords D
bones NN bones D
of NN stopwords D
the NN stopwords D
foot JJ foot D

Dubowitz CAPITAL NNP O
assessment DT appraisal O
of NN stopwords O
gestational NN gestational O
age DT age O
and DT stopwords O
agreement DT agreement O
with NN stopwords O
prenatal NN prenatal O
methods NN method O

p53 NN O
is NN stopwords be O
mutated NN mutate O
frequently JJ frequently O
in NN stopwords inch O
a DT stopwords angstrom O
wide NN wide O
range VB scope O
of NN stopwords O
human NN homo O
cancers VB cancer D
, , O
including NN include O
colonic NNS colonic_irrigation D
tumours NN tumor D

The CAPITAL NNP O
return NN tax_return O
of NN stopwords O
gross NN gross O
blood NN blood O
on NN stopwords on O
aspiration DT aspiration O
or NN stopwords Oregon O
a DT stopwords angstrom O
lavage NN lavage O
red NN red O
blood NN blood O
cell NNS cell O
count NNS count O
greater NN greater O
than NN stopwords O
10 DIGITS CD ten O
x NN ten O
10 DIGITS CD ten O
( ( O
9 DIGITS CD nine O
) ) O
/L NN O
should NN stopwords O
prompt NN prompt O
an DT stopwords Associate_in_Nursing O
urgent JJ pressing O
celiotomy NNS O

In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
combination NNS combination T
therapy NN therapy T
, , O
a DT stopwords angstrom O
further NN stopwords foster O
reduction NN decrease O
of NN stopwords O
viremia NN viremia D
level NN degree O
could NNS O
be NN stopwords beryllium O
observed NN detect O
, , O
whereas NN O
viremia NN viremia O
levels NN degree O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
IFN CAPITAL PRP O
alpha DT alpha O
alone DT alone O
slightly JJ slightly O
increased NN increase O

However CAPITAL NNP however O
, , O
recent NN Holocene O
clinical JJ clinical O
use JJ use O
of NN stopwords O
monoclonal NN monoclonal_antibody T
antibodies DT antibody T
( ( T
mAbs NN T
) ) T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
low-grade NN low-grade D
or NN stopwords Oregon D
transformed NN transform D
low-grade NN low-grade D
NHL CAPITAL NNP D
has VB stopwords hour_angle O
resulted NN result O
in NN stopwords inch O
less NN lupus_erythematosus O
toxicity NN toxicity O
than NN stopwords O
conventional NNS conventional O
treatments NN treatment O
, , O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
response NN response O
rates VB rates O
that NN stopwords O
are DT stopwords are O
comparable NNS comparable O
or NN stopwords Oregon O
superior NN superior O
to NN stopwords O
those NN stopwords O
achieved DT achieve O
with NN stopwords O
chemotherapy NNS chemotherapy T

Pregnancy CAPITAL NNP pregnancy O
outcomes JJ result O
in NN stopwords inch O
women NN woman O
with NN stopwords O
gestational NN gestational D
diabetes NN diabetes D
compared NNS compare O
with NN stopwords O
the NN stopwords O
general NN general O
obstetric NN obstetric O
population NN population O

Zoonotic CAPITAL NNP zoonotic O
and DT stopwords O
viral NN viral D
infection NN infection D
in NN stopwords inch O
fetal JJ fetal O
loss NN loss O
after DT stopwords after O
12 DIGITS CD twelve O
weeks NN week O

In CAPITAL PRP inch O
the NN stopwords O
six NN six O
patients VB patient O
in NN stopwords inch O
this NN stopwords O
group NN group O
, , O
there NN stopwords there O
was VB stopwords Washington O
also DT besides O
an DT stopwords Associate_in_Nursing O
identical NN identical O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
gag VB joke O
p7/p1 NN O
gag VB joke O
protease NN protease O
cleavage NNS cleavage O
site NN site O

Thalidomide CAPITAL NNP thalidomide T
for NN stopwords O
aphthous DT D
ulcers JJ ulcer D
in NN stopwords inch O
HIV CAPITAL NNP HIV D
infection NN infection D

OBJECTIVES CAPITAL NNP aim O
: : O
Interest CAPITAL PRP interest O
in NN stopwords inch O
zinc NN zinc T
as DT stopwords arsenic O
a DT stopwords angstrom O
treatment NN treatment O
for NN stopwords O
the NN stopwords O
common NNS park D
cold NNS cold D
has VB stopwords hour_angle O
grown NN turn O
following JJ following O
the NN stopwords O
recent NN Holocene O
publication NN publication O
of NN stopwords O
several NN several O
controlled NNS control O
trials NN test O

Effect CAPITAL NNP consequence O
of NN stopwords O
photodynamic NN T
therapy NN therapy T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
mitomycin NN mitomycin T
C CAPITAL SYM degree_centigrade T
on NN stopwords on O
a DT stopwords angstrom O
mitomycin-resistant NN D
bladder NN bladder D
cancer VB cancer D
cell NNS cell O
line NN line O

A CAPITAL DT angstrom O
clinical JJ clinical O
joint NN joint O
study NN survey O
on NN stopwords on O
insulin NN insulin T
therapy NN therapy T
, , O
a DT stopwords angstrom O
survey NN survey O
of NN stopwords O
the NN stopwords O
actual DT actual O
inter-laboratory NN O
differences NN difference O
in NN stopwords inch O
GHb CAPITAL NNP gamma_hydroxybutyrate O
measurement NN measurement O
among DT O
41 DIGITS CD forty-one O
institutions NN institution O
and DT stopwords O
an DT stopwords Associate_in_Nursing O
assessment DT appraisal O
of NN stopwords O
11 DIGITS CD eleven O
assay DT assay O
methods NN method O
for NN stopwords O
the NN stopwords O
determination NN determination O
of NN stopwords O
GHb CAPITAL NNP gamma_hydroxybutyrate O
were NN stopwords be O
performed NN perform O
using JJ exploitation O
commercial NNS commercial O
calibrators VB O
and DT stopwords O
fresh JJ fresh O
blood NN blood O
samples VB sample O

Physician-assisted CAPITAL NNP O
suicide JJ suicide O
in NN stopwords inch O
Oregon CAPITAL NNP Oregon O

clinically JJ clinically O
, , O
oral NN oral T
administration DT administration T
of NN stopwords T
uft JJ T
has VB stopwords hour_angle O
proved NN prove O
to NN stopwords O
be NN stopwords beryllium O
effective NN effective O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
adjuvant DT adjuvant T
therapy NN therapy T
after DT stopwords after O
surgery NN surgery O
for NN stopwords O
some NN stopwords some O
malignant VB malignant D
tumors NN tumor D
such NN stopwords such D
as DT stopwords arsenic D
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D

The CAPITAL NNP O
objective NN aim O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
determine NN determine O
if NN stopwords O
the NN stopwords O
rate VB rate O
of NN stopwords O
preeclampsia NN preeclampsia D
is NN stopwords be O
increased NN increase O
in NN stopwords inch O
triplet NN three O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
twin NN twin O
gestations NN gestation O

Issues CAPITAL PRP issue O
and DT stopwords O
challenges NNS challenge O
with NN stopwords O
antithrombotic DT T
therapy NN therapy T
in NN stopwords inch O
diabetic NN diabetic O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
coronary NNS coronary_thrombosis D
syndromes NN syndrome D

These CAPITAL NNP O
levels NN degree O
were NN stopwords be O
determined NN determine O
in NN stopwords inch O
patients VB patient O
undergoing JJ undergo O
three NN three O
types NN type O
of NN stopwords O
therapy NN therapy O
: : O
non-in JJ O
vitro NN O
fertilization NN fertilization O
( ( O
IVF CAPITAL PRP O
) ) O
, , O
IVF-embryo CAPITAL PRP O
transfer NN transportation O
( ( O
ET CAPITAL NN O
) ) O
, , O
and DT stopwords O
frozen JJ freeze O
ET CAPITAL NN O

Open CAPITAL NNP open T
capsulorrhaphy VB T
with NN stopwords T
suture NN suture T
anchors DT anchor T
for NN stopwords O
recurrent NN perennial D
anterior DT front_tooth D
dislocation NN dislocation D
of NN stopwords D
the NN stopwords D
shoulder NN shoulder D

Urgent CAPITAL NNP pressing O
colonoscopy NNS colonoscopy T
for NN stopwords O
the NN stopwords O
diagnosis NN diagnosis O
and DT stopwords O
treatment NN treatment O
of NN stopwords O
severe NN severe D
diverticular NN D
hemorrhage NN bleeding D

Cryogen CAPITAL NNP cryogen O
spray NN spray O
cooling NNS cooling O
during NN stopwords O
Nd CAPITAL NNP neodymium T
: : T
YAG CAPITAL VB T
laser NN laser T
treatment NN treatment T
of NN stopwords O
hemangiomas NN hemangioma D

Higher-grade CAPITAL NNP O
cancers VB cancer D
( ( O
grade NN class O
3 DIGITS CD three O
) ) O
were NN stopwords be O
more NN stopwords More O
common NNS park O
in NN stopwords inch O
potentially NN potentially O
linked NN associate O
families VB family O
, , O
and DT stopwords O
advanced-stage DT O
disease NN disease O
was VB stopwords Washington O
found JJ found O
in NN stopwords inch O
41 DIGITS CD forty-one O
% NN O
of NN stopwords O
the NN stopwords O
case VB case O
patients VB patient O
in NN stopwords inch O
potentially NN potentially O
linked NN associate O
families VB family O
compared NNS compare O
with NN stopwords O
31 DIGITS CD thirty-one O
% NN O
in NN stopwords inch O
both NN stopwords both O
the NN stopwords O
potentially NN potentially O
unlinked JJ O
families VB family O
and DT stopwords O
the NN stopwords O
reference NN mention O
groups NN group O
( ( O
P=.03 CAPITAL NNP O
for NN stopwords O
the NN stopwords O
latter NN latter O
comparison NNS comparison O
) ) O

Racial CAPITAL VB racial O
discrimination NN discrimination O
in NN stopwords inch O
the NN stopwords O
allocation DT allotment O
of NN stopwords O
distinction NN differentiation O
awards DT award O
? . O
Analysis CAPITAL DT analysis O
of NN stopwords O
list NN list O
of NN stopwords O
award DT award O
holders NN holder O
by NN stopwords by O
type NN type O
of NN stopwords O
award DT award O
, , O
specialty NN forte O
and DT stopwords O
region NN region O

Report CAPITAL NNP report O
of NN stopwords O
the NN stopwords O
61st CD O
National CAPITAL NNP national O
Scientific CAPITAL NNP scientific O
Meeting CAPITAL NNP meeting O
of NN stopwords O
the NN stopwords O
American CAPITAL DT American O
College CAPITAL NNP college O
of NN stopwords O
Rheumatology CAPITAL NNP rheumatology O
, , O
Washington CAPITAL WRB Washington O
DC CAPITAL NNP District_of_Columbia O
, , O
8-12 CD O
November CAPITAL NNP November O
1997 DIGITS CD O

The CAPITAL NNP O
roots NN roots O

MATERIALS CAPITAL NNP material O
AND CAPITAL DT O
METHODS CAPITAL NNP method O
: : O
From CAPITAL NNP O
August CAPITAL DT August O
1993 DIGITS CD O
to NN stopwords O
December CAPITAL NNP December O
1996 DIGITS CD O
tubularized NN T
incised NN incise T
plate NN home_plate T
urethroplasty JJ T
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
27 DIGITS CD twenty-seven O
boys NN male_child O
6 DIGITS CD six O
months NN calendar_month O
to NN stopwords O
3 DIGITS CD three O
years NN old_age O
old JJ old O
with NN stopwords O
mid NN mid D
shaft NN shaft D
and DT stopwords D
penoscrotal NN D
hypospadias NN hypospadias D

Pathological CAPITAL VB pathological O
staging NN theatrical_production O
and DT stopwords O
biochemical NN biochemical O
recurrence NN recurrence O
after DT stopwords after O
neoadjuvant JJ T
androgen DT androgen T
deprivation NN privation T
therapy NN therapy T
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
radical VB group T
prostatectomy NN prostatectomy T
in NN stopwords inch O
clinically JJ clinically O
localized NN place O
prostate NN prostate_gland D
cancer VB cancer D

Sales CAPITAL VB gross_sales O
of NN stopwords O
food JJ food O
aid DT aid O
as DT stopwords arsenic O
sign NN sign O
of NN stopwords O
distress NN distress O
, , O
not JJ stopwords not O
excess NN excess O

Bone CAPITAL NNP bone O
registration NN registration O
method NN method O
for NN stopwords O
robot NN automaton T
assisted DT help T
surgery NN surgery T
: : O
pedicle NN pedicel O
screw NN prison_guard O
insertion NN interpolation O

Continuous CAPITAL NNP continuous T
renal NN nephritic T
replacement NN replacement T
therapy NN therapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
renal NN nephritic D
dysfunction NN dysfunction D
undergoing JJ undergo O
intraaortic NN O
balloon VB balloon O
pump NN pump O
and/or DT O
left NN left O
ventricular NN ventricular O
device NN device O
support NN support O

Interferon CAPITAL PRP interferon T
beta NN beta T
treatment NN treatment T
for NN stopwords O
multiple NN multiple D
sclerosis JJ sclerosis D

Modulation CAPITAL NNP transition O
of NN stopwords O
ultraviolet JJ ultraviolet O
light-induced NN O
epidermal NN cuticular D
damage VB damage D
: : O
beneficial NN beneficial O
effects NN effects O
of NN stopwords O
tocopherol NN vitamin_E T

These CAPITAL NNP O
preliminary NN preliminary O
findings NN findings O
indicate NN bespeak O
that NN stopwords O
in NN stopwords inch O
Pima CAPITAL NNP Pima O
Indians CAPITAL PRP Indian O
with NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D
, , O
presence NN presence O
of NN stopwords O
the NN stopwords O
4G CD O
allele DT allele O
of NN stopwords O
the NN stopwords O
PAI-1 CAPITAL VB O
gene NN gene O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
higher NN higher O
risk NN hazard O
of NN stopwords O
diabetic NN diabetic D
retinopathy NN retinopathy D

Amnioinfusion CAPITAL DT T
for NN stopwords O
prevention NN prevention O
of NN stopwords O
pulmonary NN pneumonic D
hypoplasia NN hypoplasia D
in NN stopwords inch O
second-trimester NN O
rupture NN rupture O
of NN stopwords O
membranes NN membrane O

An CAPITAL DT Associate_in_Nursing O
under-recognised JJ O
cause VB cause O
of NN stopwords O
idiopathic JJ idiopathic D
learning NN learning D
disability NN disability D

METHODS CAPITAL NNP method O
: : O
The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
roxithromycin NN T
was VB stopwords Washington O
assessed DT measure O
in NN stopwords inch O
a DT stopwords angstrom O
double-blind NN O
, , O
randomised VB randomize O
, , O
prospective NN prospective O
, , O
multicentre NN O
, , O
parallel-group NN O
, , O
placebo-controlled NN O
pilot NN pilot O
study NN survey O
of NN stopwords O
202 DIGITS CD O
patients VB patient O
with NN stopwords O
unstable JJ unstable D
angina DT angina D
or NN stopwords Oregon O
non-Q-wave JJ D
myocardial NN myocardial D
infarction NN infarct D

Synthesis CAPITAL NNP synthesis O
of NN stopwords O
lysergic NN O
acid DT acid O
diethylamide NN O
( ( O
LSD CAPITAL NNP lysergic_acid_diethylamide O
) ) O

RESULTS CAPITAL NNP consequence O
: : O
Results CAPITAL NNP consequence O
of NN stopwords O
first NN first O
tune-up NN warm-up O
show NN show O
an DT stopwords Associate_in_Nursing O
open JJ open O
set NN set O
speech NN address O
understanding JJ understanding O
in NN stopwords inch O
approximately DT approximately O
50 DIGITS CD fifty O
% NN O
of NN stopwords O
patients VB patient O

Strucutre CAPITAL NNP O
of NN stopwords O
the NN stopwords O
influenza NN influenza D
virus NN virus D

In CAPITAL PRP inch O
addition DT addition O
, , O
we NN stopwords O
are DT stopwords are O
able DT able O
to NN stopwords O
generate NN generate O
plants NN plant O
in NN stopwords inch O
which NN stopwords O
only JJ stopwords lone O
CPDs CAPITAL NNP O
or NN stopwords Oregon O
6-4 CD O
products NN merchandise O
are DT stopwords are O
photoreactivated NN O
in NN stopwords inch O
the NN stopwords O
nuclear JJ nuclear O
genome NN genome O
by NN stopwords by O
exposing NN expose O
these NN stopwords O
mutants NN mutant O
to NN stopwords O
UV CAPITAL NNP ultraviolet O
light NN light O
and DT stopwords O
then NN stopwords then O
allowing DT let O
them NN stopwords O
to NN stopwords O
repair NN repair O
one JJ one O
or NN stopwords Oregon O
the NN stopwords O
other JJ stopwords other O
class NNS class O
of NN stopwords O
dimers NN dimer O

Fluorescent CAPITAL NNP fluorescent O
imaging NN imagination O
demonstrated NN show O
smallest JJ small O
line NN line O
widths NN width O
of NN stopwords O
2-3 CD O
microns NN micron O

The CAPITAL NNP O
respective NN respective O
rates VB rates O
of NN stopwords O
any DT stopwords any O
stroke NN stroke D
and DT stopwords O
of NN stopwords O
hemorrhagic NN hemorrhagic D
stroke NN stroke D
were NN stopwords be O
1.92 CD O
and DT stopwords O
1.12 CD O
percent NN percentage O
after DT stopwords after O
double-bolus NN O
alteplase DT T
, , O
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
1.53 CD O
and DT stopwords O
0.81 LS O
percent NN percentage O
after DT stopwords after O
an DT stopwords Associate_in_Nursing O
accelerated DT accelerate O
infusion NN infusion O
of NN stopwords O
alteplase DT T
( ( O
P=0.24 CAPITAL NNP O
and DT stopwords O
P=0.23 CAPITAL NNP O
, , O
respectively NN respectively O
) ) O

BAP CAPITAL IN bap O
was VB stopwords Washington O
increased NN increase O
37 DIGITS CD thirty-seven O
% NN O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
by NN stopwords by O
fluoride JJ fluoride O
; : O
serum NN serum O
TRAP CAPITAL NNP trap O
was VB stopwords Washington O
increased NN increase O
42 DIGITS CD forty-two O
% NN O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
; : O
serum NN serum O
IGF-1 CAPITAL PRP O
was VB stopwords Washington O
increased NN increase O
40 DIGITS CD forty O
% NN O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O

When CAPITAL NNP O
comparing NNS comparison O
the NN stopwords O
unconditional JJ unconditional O
with NN stopwords O
the NN stopwords O
conditional NNS conditional O
groups NN group O
, , O
assurances DT assurance O
of NN stopwords O
unconditional JJ unconditional O
confidentiality NNS confidentiality O
increased NN increase O
the NN stopwords O
number JJ number O
of NN stopwords O
adolescents DT adolescent O
willing NN volition O
to NN stopwords O
return NN tax_return O
for NN stopwords O
a DT stopwords angstrom O
future JJ future O
visit NN visit O
by NN stopwords by O
10 DIGITS CD ten O
percentage NN percentage O
points NN point O
, , O
from JJ stopwords O
62 DIGITS CD sixty-two O
% NN O
( ( O
122/196 CD O
) ) O
to NN stopwords O
72 DIGITS CD seventy-two O
% NN O
( ( O
137/190 CD O
) ) O
( ( O
beta=.14 NN O
, , O
P=.001 CAPITAL NNP O
) ) O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Between CAPITAL NNP between O
1987 DIGITS CD O
and DT stopwords O
1992 DIGITS CD O
, , O
all DT stopwords all O
patients VB patient O
presenting NN show O
to NN stopwords O
the NN stopwords O
senior NN senior O
author DT writer O
with NN stopwords O
a DT stopwords angstrom O
symptomatic NN diagnostic O
failed VB fail O
silicone NN silicone O
implant JJ implant O
arthroplasty DT arthroplasty O
refractory NN furnace_lining O
to NN stopwords O
conservative NNS conservative O
treatment NN treatment O
were NN stopwords be O
converted NNS convert O
to NN stopwords O
a DT stopwords angstrom O
metatarsophalangeal NN O
joint NN joint O
arthrodesis DT arthrodesis O

New CAPITAL NNP new O
vaccine NN vaccine T
targets VB target O
childhood JJ childhood D
pneumonia NN pneumonia D

Role CAPITAL NNP function O
of NN stopwords O
fine NN fine T
needle JJ acerate_leaf T
aspiration DT aspiration T
cytology NNS cytology T
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
the NN stopwords O
discrete NN discrete D
parotid NN parotid D
lump NN ball D

Glasgow CAPITAL NNP Glasgow O
has VB stopwords hour_angle O
already DT already O
produced NN produce O
strategy NN scheme O
for NN stopwords O
treatment NN treatment O

PATIENTS CAPITAL VB patient O
: : O
> NN O
From CAPITAL NNP O
a DT stopwords angstrom O
series NN series O
of NN stopwords O
multiplex NN multiplex O
families VB family O
affected DT affect O
with NN stopwords O
late-onset NN O
( ( O
> NN O
or NN stopwords Oregon O
=60 RB O
years NN old_age O
) ) O
AD CAPITAL DT ad O
ascertained DT determine O
during NN stopwords O
the NN stopwords O
last NN stopping_point O
14 DIGITS CD fourteen O
years NN old_age O
( ( O
National CAPITAL NNP national O
Insititute CAPITAL PRP O
of NN stopwords O
Neurological CAPITAL NNP neurological O
Disorders CAPITAL NNP disorder O
and DT stopwords O
Stroke-Alzheimer CAPITAL NNP O
's POS O
Disease CAPITAL NNP disease O
and DT stopwords O
Related CAPITAL NNP associate O
Disorders CAPITAL NNP disorder O
Association CAPITAL DT association O
diagnostic NN diagnostic O
criteria JJ standard O
) ) O
and DT stopwords O
for NN stopwords O
which NN stopwords O
DNA CAPITAL NNP deoxyribonucleic_acid O
has VB stopwords hour_angle O
been NN stopwords be O
obtained NN obtain O
, , O
a DT stopwords angstrom O
subset NN subset O
of NN stopwords O
16 DIGITS CD sixteen O
families VB family O
( ( O
135 DIGITS CD one_hundred_thirty-five O
total NN sum O
family VB family O
members NN member O
, , O
52 DIGITS CD fifty-two O
of NN stopwords O
whom NN stopwords O
were NN stopwords be O
patients VB patient O
with NN stopwords O
AD CAPITAL DT ad O
) ) O
was VB stopwords Washington O
used JJ use O
for NN stopwords O
the NN stopwords O
genomic NN O
screen NN screen O

combination NNS combination T
chemotherapy NNS chemotherapy T
is NN stopwords be O
the NN stopwords O
cornerstone NNS basis O
of NN stopwords O
treatment NN treatment O
that NN stopwords O
confers NNS confer O
a DT stopwords angstrom O
meaningful NN meaningful O
survival NN survival O
benefit NN benefit O
for NN stopwords O
patients VB patient O
with NN stopwords O
small-cell JJ D
lung NN lung D
cancer VB cancer D

However CAPITAL NNP however O
, , O
psychological NN psychological O
testing NN testing O
may VB May O
reveal NN uncover O
early-warning VB O
signs NN sign O
more NN stopwords More O
readily NN readily O
than NN stopwords O
the NN stopwords O
various NN assorted O
physiological NN physiological O
or NN stopwords Oregon O
immunological JJ immunological O
markers NN marker O

Alterations CAPITAL DT change O
of NN stopwords O
monocyte NN monocyte O
function JJ function O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
growth NN growth D
hormone NN hormone D
( ( D
GH CAPITAL NNP D
) ) D
deficiency NN lack D
: : O
effect NN consequence O
of NN stopwords O
substitutive NN O
GH CAPITAL NNP T
therapy NN therapy T

More CAPITAL NNP More O
of NN stopwords O
those NN stopwords O
initially JJ initially O
prescribed NN order O
antibiotics DT antibiotic T
initially JJ initially O
returned NN return O
to NN stopwords O
the NN stopwords O
surgery NN surgery O
with NN stopwords O
sore NN sore D
throat NN throat D
( ( O
38 DIGITS CD thirty-eight O
% NN O
v NN volt O
27 DIGITS CD twenty-seven O
% NN O
, , O
adjusted DT adjust O
hazard NN hazard O
ratio VB ratio O
for NN stopwords O
return NN tax_return O
1.39 CD O
% NN O
, , O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
1.03 CD O
to NN stopwords O
1.89 CD O
) ) O

Research CAPITAL NNP research O
past VB past O
and DT stopwords O
present NN present O
, , O
with NN stopwords O
particular NN particular O
reference NN mention O
to NN stopwords O
the NN stopwords O
application DT application O
of NN stopwords O
the NN stopwords O
techniques NN technique O
of NN stopwords O
basic VB BASIC O
science JJ science O
to NN stopwords O
the NN stopwords O
problems NN problem O
of NN stopwords O
adrenal DT adrenal_gland O
pathology VB pathology O

The CAPITAL NNP O
results NN consequence O
show NN show O
that NN stopwords O
87 DIGITS CD eighty-seven O
% NN O
of NN stopwords O
hospitals NN hospital O
possess NN posse O
colour NNS coloring_material O
Doppler CAPITAL NNP Doppler O
ultrasound JJ ultrasound O
( ( O
CDUS CAPITAL NNP O
) ) O
machines VB machine O
and DT stopwords O
that NN stopwords O
46 DIGITS CD forty-six O
% NN O
of NN stopwords O
departments NN department O
perform NN perform O
ultrasound JJ ultrasound O
as DT stopwords arsenic O
the NN stopwords O
first NN first O
line NN line O
investigation NN probe O
in NN stopwords inch O
over JJ stopwords over O
90 DIGITS CD ninety O
% NN O
of NN stopwords O
cases VB case O

Urine CAPITAL NNP urine O
specimens NN specimen O
collected NNS roll_up O
from JJ stopwords O
the NN stopwords O
volunteer NN volunteer O
were NN stopwords be O
subjected NN subject O
to NN stopwords O
standard NN standard O
workplace NN workplace O
urine JJ urine O
drug NN drug O
testing NN testing O
procedures NN procedure O
, , O
and DT stopwords O
the NN stopwords O
following JJ following O
concentrations NNS concentration O
of NN stopwords O
11-nor-delta9- CD O
tetrahydrocannabinol NN tetrahydrocannabinol O
carboxylic VB carboxyl O
acid DT acid O
( ( O
9-THCA CD O
) ) O
were NN stopwords be O
detected NN detect O
: : O
41 DIGITS CD forty-one O
ng/mL JJ O
9-THCA CD O
at DT stopwords astatine O
45 DIGITS CD forty-five O
h NN hydrogen O
, , O
49 DIGITS CD forty-nine O
ng/mL JJ O
at DT stopwords astatine O
69 DIGITS CD sixty-nine O
h NN hydrogen O
, , O
and DT stopwords O
55 DIGITS CD fifty-five O
ng/mL JJ O
at DT stopwords astatine O
93 DIGITS CD ninety-three O
h. NN O
Ingestion CAPITAL PRP consumption O
was VB stopwords Washington O
discontinued NN discontinue O
after DT stopwords after O
93 DIGITS CD ninety-three O
h NN hydrogen O
, , O
and DT stopwords O
the NN stopwords O
following JJ following O
concentrations NNS concentration O
were NN stopwords be O
detected NN detect O
: : O
68 DIGITS CD sixty-eight O
ng/mL JJ O
at DT stopwords astatine O
108 DIGITS CD O
h NN hydrogen O
, , O
57 DIGITS CD fifty-seven O
ng/mL JJ O
at DT stopwords astatine O
117 DIGITS CD O
h NN hydrogen O
, , O
31 DIGITS CD thirty-one O
ng/mL JJ O
at DT stopwords astatine O
126 DIGITS CD O
h NN hydrogen O
, , O
and DT stopwords O
20 DIGITS CD twenty O
ng/mL JJ O
at DT stopwords astatine O
142 DIGITS CD O
h. NN O
The CAPITAL NNP O
first NN first O
specimen NN specimen O
that NN stopwords O
tested NN test O
negative JJ negative O
( ( O
50 DIGITS CD fifty O
ng/mL JJ O
initial JJ initial O
immunoassay JJ immunoassay O
test NN trial O
, , O
15 DIGITS CD fifteen O
ng/mL JJ O
confirmatory NNS collateral O
gas VB gas O
chromatographic-mass NN O
spectrometric NN spectrometric O
test NN trial O
) ) O
was VB stopwords Washington O
at DT stopwords astatine O
146 DIGITS CD O
h NN hydrogen O
, , O
which NN stopwords O
was VB stopwords Washington O
53 DIGITS CD fifty-three O
h NN hydrogen O
after DT stopwords after O
the NN stopwords O
last NN stopping_point O
hemp NN hemp O
seed NN seed O
oil NN oil O
ingestion NN consumption O

Online CAPITAL NNP on-line O

The CAPITAL NNP O
Meis2 CAPITAL NNP O
homeodomain NN O
is NN stopwords be O
identical NN identical O
to NN stopwords O
that NN stopwords O
of NN stopwords O
Meis1 CAPITAL NNP O
, , O
and DT stopwords O
is NN stopwords be O
most NN stopwords most O
closely NNS closely O
related NN associate O
to NN stopwords O
those NN stopwords O
of NN stopwords O
the NN stopwords O
Pbx/TGIF CAPITAL NNP O
homeobox NN homeobox O
gene NN gene O
products NN merchandise O

Is CAPITAL PRP be O
prevaccination NN O
screening NN screening O
for NN stopwords O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
among DT O
sexually NN sexually O
active DT active_agent O
adolescents DT adolescent O
cost-effective NNS cost-efficient O
? . O

In CAPITAL PRP inch O
addition DT addition O
, , O
a DT stopwords angstrom O
2-choice CD O
reaction NN chemical_reaction O
go/no-go NN O
procedure NN procedure O
was VB stopwords Washington O
included NN include O
, , O
involving NN involve O
a DT stopwords angstrom O
semantic NN semantic O
and DT stopwords O
a DT stopwords angstrom O
phonological NN phonological O
categorization VB classification O
of NN stopwords O
the NN stopwords O
picture NN picture O
name RB name O

CONCLUSIONS CAPITAL NNP decision O
: : O
Tubularized CAPITAL NNP T
incised NN incise T
plate NN home_plate T
urethroplasty JJ T
is NN stopwords be O
a DT stopwords angstrom O
versatile NN versatile O
operation JJ operation O
that NN stopwords O
corrects NNS correct O
proximal NN proximal D
hypospadias NN hypospadias D
defects NN defect D
with NN stopwords O
few JJ stopwords few O
complications NNS complication O
and DT stopwords O
superior NN superior O
cosmetic NNS cosmetic O
results NN consequence O

Therefore CAPITAL NNP therefore O
, , O
prudent NN prudent O
management VB management O
and DT stopwords O
use JJ use O
of NN stopwords O
washed VB wash T
red NN red T
blood NN blood T
cells NNS cell T
transfusion NN transfusion T
would NN O
prevent NN prevent O
hemolytic NN hemolytic D
aggravation DT aggravation D
even NN evening O
in NN stopwords inch O
open JJ open O
heart NN heart O
surgery NN surgery O

In CAPITAL PRP inch O
some NN stopwords some O
cases VB case O
, , O
the NN stopwords O
binding NN binding O
curve NNS curve O
exhibits NN exhibit O
complexities NNS complexity O

methods NN method O
: : O
over JJ stopwords over O
90 DIGITS CD ninety O
months NN calendar_month O
, , O
therapeutic NN remedy T
vats NN VAT T
metastasectomy NN T
was VB stopwords Washington O
accomplished DT carry_through O
upon JJ O
80 DIGITS CD eighty O
patients VB patient O
with NN stopwords O
colorectal NNS colorectal D
metastases NN metastasis D

Single-dose CAPITAL NNP O
pharmacokinetics NN pharmacokinetics O
of NN stopwords O
felbamate JJ O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
renal NN nephritic O
dysfunction NN dysfunction O

The CAPITAL NNP O
performance NN performance O
of NN stopwords O
some NN stopwords some O
methods NN method O
or NN stopwords Oregon O
instruments NN instrument O
used JJ use O
are DT stopwords are O
only JJ stopwords lone O
poor NN poor_people O
at DT stopwords astatine O
distinguishing NN distinguish O
the NN stopwords O
stable NN stable O
glycated NN O
haemoglobin VB hemoglobin O
itself NN stopwords O

< NN O
TO_SEE CAPITAL NNP O
> NN O
tracheal NN tracheal O
stent NN stent O
insertion NN interpolation O
is NN stopwords be O
a DT stopwords angstrom O
useful JJ useful O
method NN method O
for NN stopwords O
patients VB patient O
with NN stopwords O
malignant VB malignant O
tracheal NN tracheal O
stenosis NN stenosis O

Kinetic CAPITAL NNP kinetic O
models NN model O
of NN stopwords O
ion NN ion O
channels NNS channels O

< NN O
TO_SEE CAPITAL NNP O
> NN O
With CAPITAL NNP O
regard NN respect O
to NN stopwords O
the NN stopwords O
high NN high O
rate VB rate O
of NN stopwords O
recurrent NN perennial D
ulcer JJ ulcer D
Roux-en-Y CAPITAL NNP T
reconstruction NN Reconstruction T
after DT stopwords after O
partial NN partial_derivative T
gastrectomy VB gastrectomy T
for NN stopwords O
primary NN primary D
ulcer JJ ulcer D
surgery NN surgery D
should NN stopwords O
be NN stopwords beryllium O
avoided DT avoid O
and DT stopwords O
reconstruction NN Reconstruction O
procedures NN procedure O
preferred NN prefer O
, , O
which NN stopwords O
guarantee NN guarantee O
duodenogastric NN O
reflux NN reflux O

Discontinuation CAPITAL NNP discontinuance O
of NN stopwords O
secondary NN secondary O
prophylaxis NN prophylaxis O
for NN stopwords O
cryptococcal NNS D
meningitis NN meningitis D
in NN stopwords inch O
HIV-infected CAPITAL NNP O
patients VB patient O
responding NN react O
to NN stopwords O
highly NN highly O
active DT active_agent O
antiretroviral DT T
therapy NN therapy T

Lung CAPITAL NNP lung D
cancer VB cancer D
, , O
tobacco NN tobacco O
smoking JJ smoke O
and DT stopwords O
environmental NN environmental O
factors VB factor O
in NN stopwords inch O
Denmark CAPITAL NNP Denmark O

The CAPITAL NNP O
present NN present O
study NN survey O
evaluated NN measure O
the NN stopwords O
effects NN effects O
of NN stopwords O
TJ-135 CAPITAL NNP T
on NN stopwords on O
concanavalin NNS D
A CAPITAL DT angstrom D
( ( D
con NNS con D
A CAPITAL DT angstrom D
) ) D
-induced : D
hepatitis NN hepatitis D
in NN stopwords inch O
mice NN mouse O
in NN stopwords inch O
vivo NN O
and DT stopwords O
con NNS con O
A-induced CAPITAL DT O
cytokine NNS cytokine O
production NN production O
in NN stopwords inch O
vitro NN O

OBJECTIVE CAPITAL NNP aim O
: : O
The CAPITAL NNP O
aim DT purpose O
of NN stopwords O
these NN stopwords O
studies NN survey O
was VB stopwords Washington O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
pharmacokinetics NN pharmacokinetics O
of NN stopwords O
inhaled NN inhale T
fluticasone JJ T
propionate NN T
( ( T
FP CAPITAL NNP T
) ) T
after DT stopwords after O
repeated NN repeat O
administration DT administration O
via NN O
the NN stopwords O
Diskus CAPITAL NNP O
or NN stopwords Oregon O
Diskhaler CAPITAL NNP O
dry NN dry O
powder NN powder O
inhalers NN inhaler O
( ( O
DPIs CAPITAL NNP O
) ) O
to NN stopwords O
patients VB patient O
with NN stopwords O
mild-to-moderate NN D
asthma DT asthma D

274 DIGITS CD O
, , O
111-122 CD O
, , O
1992 DIGITS CD O
) ) O

Lactate CAPITAL VB lactate O
values NN values O
obtained NN obtain O
by NN stopwords by O
continuous NNS continuous O
catheter VB catheter O
operation JJ operation O
ex NN ex-husband O
vivo NN O
correlate NNS correlate O
well NN well O
with NN stopwords O
those NN stopwords O
obtained NN obtain O
by NN stopwords by O
BIOSEN CAPITAL NNP O
Med CAPITAL NNP Master_of_Education O
L. CAPITAL NNP O
First CAPITAL NNP first O
subcutaneous NN hypodermic O
implantation JJ implantation O
( ( O
dog NN dog O
) ) O
underlines JJ underscore O
the NN stopwords O
characteristics NNS feature O
obtained NN obtain O
ex NN ex-husband O
vivo NN O
: : O
after DT stopwords after O
30 DIGITS CD thirty O
min NN minute O
hydration NN hydration O
the NN stopwords O
lactate NN lactate O
catheter VB catheter O
follows JJ follow O
the NN stopwords O
lactate NN lactate O
concentration NNS concentration O
measured NN measure O
ex NN ex-husband O
vivo NN O
with NN stopwords O
samples VB sample O
from JJ stopwords O
the NN stopwords O
leg NN leg O
vein NN vein O
by NN stopwords by O
BIOSEN CAPITAL NNP O
Med CAPITAL NNP Master_of_Education O
L. CAPITAL NNP O

We CAPITAL NNP O
report NN report O
the NN stopwords O
first NN first O
case VB case O
( ( O
to NN stopwords O
our NN stopwords O
knowledge NN cognition O
) ) O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
endoscopic NN endoscopic T
removal NN removal T
of NN stopwords O
a DT stopwords angstrom O
forehead NN brow D
soft NN soft D
tissue NN tissue D
mass VB mass D

Effect CAPITAL NNP consequence O
of NN stopwords O
tranquilizing NN calm T
drugs NN drug T
on NN stopwords on O
postnatal NN postnatal O
behavior NN behavior O

We CAPITAL NNP O
now JJ stopwords now O
show NN show O
that NN stopwords O
highly NN highly O
purified NN purify O
populations NN population O
of NN stopwords O
very NN stopwords very O
primitive NN primitive O
neoplastic JJ neoplastic O
progenitor NN progenitor O
cells NNS cell O
obtained NN obtain O
directly NN directly O
from JJ stopwords O
CML CAPITAL NNP O
patients VB patient O
survive NN survive O
and DT stopwords O
proliferate NN proliferate O
in NN stopwords inch O
vitro NN O
for NN stopwords O
several NN several O
weeks NN week O
in NN stopwords inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
any DT stopwords any O
added DT add O
growth NN growth O
factors VB factor O
( ( O
except NN demur O
insulin NN insulin O
) ) O

Moreover CAPITAL NNP furthermore O
, , O
such NN stopwords such O
research NN research O
may VB May O
lead NN lead O
to NN stopwords O
prenatal NN prenatal O
tests NN trial O
that NN stopwords O
claim NNS claim O
to NN stopwords O
predict NN predict O
for NN stopwords O
homosexuality NN homosexuality O

Levofloxacin CAPITAL NNP T
versus NN T
intravenous NN intravenous T
ceftriaxone NNS ceftriaxone T
and DT stopwords T
amoxicillin/clavulanate DT T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
community-acquired NNS O
pneumonia NN pneumonia D
that NN stopwords O
require NN necessitate O
hospitalization NN hospitalization O

The CAPITAL NNP O
effects NN effects O
on NN stopwords on O
health NN health O
are DT stopwords are O
as DT stopwords arsenic O
various NN assorted O
as DT stopwords arsenic O
the NN stopwords O
pollutants NN pollutant O
, , O
going NN departure O
from JJ stopwords O
sharp NN sharp O
intoxication NN poisoning O
to NN stopwords O
irritations NN irritation O
or NN stopwords Oregon O
simply NN merely O
desagreements NN O

Cesarean CAPITAL NNP cesarean_delivery O
rates VB rates O
at DT stopwords astatine O
tertiary NN Tertiary O
care VB care O
hospitals NN hospital O
should NN stopwords O
be NN stopwords beryllium O
compared NNS compare O
with NN stopwords O
rates VB rates O
at DT stopwords astatine O
community NNS community O
hospitals NN hospital O
only JJ stopwords lone O
after DT stopwords after O
correcting NNS correct O
for NN stopwords O
dissimilar NN dissimilar O
patient VB patient O
groups NN group O
or NN stopwords Oregon O
gestational NN gestational O
age DT age O

hominis NN O
, , O
in NN stopwords inch O
absence DT absence O
of NN stopwords O
other JJ stopwords other O
pathogens VB pathogen O
and DT stopwords O
the NN stopwords O
presence NN presence O
of NN stopwords O
clinical JJ clinical O
manifestations VB manifestation O
( ( O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.0001 LS O
) ) O
, , O
the NN stopwords O
most NN stopwords most O
common NNS park O
of NN stopwords O
which NN stopwords O
were NN stopwords be O
diarrhoea NN diarrhea D
and DT stopwords O
abdominal DT abdominal D
pain IN pain D

Oxytocin CAPITAL NNP oxytocin O
induction NN initiation O
in NN stopwords inch O
pregnant NN pregnant O
rabbits NN rabbit O
, , O
with NN stopwords O
special NN special O
reference NN mention O
to NN stopwords O
the NN stopwords O
stillbirth JJ spontaneous_abortion O
rate VB rate O

Significance CAPITAL NNP significance O
of NN stopwords O
a DT stopwords angstrom O
single NN single O
umbilical JJ umbilical_cord O
artery DT artery O

Chicago CAPITAL NNP Chicago O
report NN report O
profiles NN profile O

We CAPITAL NNP O
demonstrate NN show O
that NN stopwords O
the NN stopwords O
CPD CAPITAL NNP O
photolyase NN O
mutation NN mutant O
is NN stopwords be O
genetically NN genetically O
linked NN associate O
to NN stopwords O
a DT stopwords angstrom O
DNA CAPITAL NNP deoxyribonucleic_acid O
sequence NN sequence O
encoding NN encoding O
a DT stopwords angstrom O
type NN type O
II CAPITAL PRP two O
( ( O
metazoan NN metazoan O
) ) O
CPD CAPITAL NNP O
photolyase NN O

A CAPITAL DT angstrom O
factor VB factor O
analytic DT analytic O
exploration NN exploration O
of NN stopwords O
the NN stopwords O
alienation DT alienation O
, , O
anomia DT nominal_aphasia O
and DT stopwords O
authoritarianism DT dictatorship O
domain NN sphere O

Treatment CAPITAL NNP treatment O
of NN stopwords O
childhood JJ childhood D
schizophrenia JJ schizophrenia D

Should CAPITAL NNP O
we NN stopwords O
screen NN screen O
for NN stopwords O
gestational NN gestational D
diabetes NN diabetes D
? . O

A CAPITAL DT angstrom O
three-step NN O
treatment NN treatment O
algorithm DT algorithm O
for NN stopwords O
refractory NN furnace_lining D
AOM CAPITAL DT D
that NN stopwords O
employs NN employment O
amoxicillin DT amoxicillin T
, , T
trimethoprim/sulfamethoxazole NN T
( ( T
TMP/SMX CAPITAL NNP T
) ) T
, , T
or NN stopwords Oregon T
high-dose NN T
amoxicillin/clavulanate DT T
( ( T
depending NN depend T
on NN stopwords on T
the NN stopwords T
prior NN prior T
dose NN dose T
of NN stopwords T
and DT stopwords T
adherence DT attachment T
to NN stopwords T
amoxicillin DT amoxicillin T
therapy NN therapy T
) ) T
, , T
and DT stopwords T
ceftriaxone NNS ceftriaxone T
or NN stopwords Oregon T
tympanocentesis NN T
at DT stopwords astatine O
steps NN stairs O
1 DIGITS CD one O
, , O
2 DIGITS CD two O
, , O
and DT stopwords O
3 DIGITS CD three O
, , O
respectively NN respectively O
, , O
appears DT look O
rational VB rational_number O
and DT stopwords O
cost-effective NNS cost-efficient O

background VB background O
: : O
to NN stopwords O
find NN discovery O
the NN stopwords O
maximum VB maximum O
tolerated NN digest O
dose NN dose O
for NN stopwords O
ifosfamide NN T
in NN stopwords inch T
combination NNS combination T
with NN stopwords T
paclitaxel VB T
and DT stopwords T
carboplatin VB T
in NN stopwords inch O
small-cell JJ D
lung NN lung D
cancer VB cancer D
patients VB patient O
( ( O
sclc JJ O
) ) O
, , O
who NN stopwords World_Health_Organization O
are DT stopwords are O
resistant NN immune O
to NN stopwords O
cyclophosphamide NNS O
, , O
doxorubicin NN doxorubicin O
and DT stopwords O
etoposide NN O
( ( O
cde SYM O
) ) O

Torsion-angle CAPITAL NNP O
molecular NN molecular O
dynamics NN dynamics O
as DT stopwords arsenic O
a DT stopwords angstrom O
new JJ new O
efficient NN efficient O
tool NN tool O
for NN stopwords O
NMR CAPITAL NNP nuclear_magnetic_resonance O
structure NN structure O
calculation VB calculation O

Antimicrobials CAPITAL DT disinfectant T
were NN stopwords be O
prescribed NN order O
to NN stopwords O
175 DIGITS CD one_hundred_seventy-five O
( ( O
83.73 CD O
per NN O
cent NNS cent O
) ) O
patients VB patient O
with NN stopwords O
common NNS park D
cold NNS cold D
and DT stopwords O
78 DIGITS CD seventy-eight O
( ( O
82.11 CD O
per NN O
cent NNS cent O
) ) O
patients VB patient O
with NN stopwords O
diarrhea NN diarrhea D

Administration CAPITAL DT administration O
of NN stopwords O
dexamethasone NN dexamethasone T
induces NN induce O
proteinuria NN albuminuria D
of NN stopwords O
glomerular NN glomerular O
origin IN beginning O
in NN stopwords inch O
mice NN mouse O

There CAPITAL NNP there O
was VB stopwords Washington O
a DT stopwords angstrom O
significant NN significant O
correlation NNS correlation O
between NN stopwords between O
the NN stopwords O
2- CD O
, , O
3- CD O
, , O
and DT stopwords O
4-day CD O
mean NN mean O
temperature NN temperature O
and DT stopwords O
AFI CAPITAL DT O
, , O
with NN stopwords O
the NN stopwords O
4-day CD O
mean NN mean O
being NN stopwords being O
the NN stopwords O
most NN stopwords most O
significant NN significant O
( ( O
r NN roentgen O
= NN O
0.31 LS O
, , O
p NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O

A CAPITAL DT angstrom O
randomized VB randomize O
, , O
controlled NNS control O
study NN survey O
in NN stopwords inch O
adults DT adult O
of NN stopwords O
the NN stopwords O
immunogenicity JJ immunogenicity O
of NN stopwords O
a DT stopwords angstrom O
novel JJ novel O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
vaccine NN vaccine T
containing NNS incorporate O
MF59 CAPITAL NNP O
adjuvant DT adjuvant O

1981 DIGITS CD O

Some CAPITAL NNP some O
alternative DT option O
measurement NN measurement O
system NN system O
with NN stopwords O
comparability NNS comparison O
, , O
commutability NNS replaceability O
and DT stopwords O
precision NN preciseness O
should NN stopwords O
be NN stopwords beryllium O
established NN establish O

The CAPITAL NNP O
authors DT writer O
monitored NN monitor O
clinical JJ clinical O
outcome JJ result O
and DT stopwords O
lung NN lung O
function JJ function O
of NN stopwords O
43 DIGITS CD forty-three O
children JJ child O
with NN stopwords O
acute DT acute_accent D
lymphoblastic NN D
leukemia NN leukemia D
and DT stopwords D
non-Hodgkin JJ D
lymphoma NN lymphoma D
who NN stopwords World_Health_Organization O
received NN receive O
chemotherapy NNS chemotherapy T
at DT stopwords astatine O
the NN stopwords O
University CAPITAL NNP university O
Children CAPITAL NNP child O
's POS O
Hospital CAPITAL NNP hospital O
of NN stopwords O
Greifswald CAPITAL NNP O
between NN stopwords between O
1993 DIGITS CD O
and DT stopwords O
1998 DIGITS CD O

Conventional CAPITAL NNP conventional T
treatments NN treatment T
for NN stopwords O
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D
: : O
the NN stopwords O
need JJ need O
for NN stopwords O
new JJ new O
therapies NN therapy O

Ticarcillin/clavulanate CAPITAL NNP T
versus NN O
imipenem/cilistatin JJ T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
infections NN infection D
associated DT associate D
with NN stopwords D
gangrenous VB gangrenous D
and DT stopwords D
perforated NN punch D
appendicitis DT appendicitis D

A CAPITAL DT angstrom O
case VB case O
of NN stopwords O
biliary NN bilious D
stenosis NN stenosis D
in NN stopwords inch O
polycystic NN O
liver NN liver O
improved JJ better O
by NN stopwords by O
injection NN injection T
of NN stopwords T
minocycline NN minocycline T
hydrochloride NN hydrochloride T
to NN stopwords O
a DT stopwords angstrom O
hepatic NN liverwort O
cyst NNS cyst O

in NN stopwords inch O
conclusion NNS decision O
, , O
fractionated NN fractionate O
administration DT administration O
of NN stopwords O
cpt-11 NNS T
and DT stopwords T
cddp SYM T
was VB stopwords Washington O
highly NN highly O
effective NN effective O
for NN stopwords O
advanced DT advance D
nsclc JJ D
with NN stopwords O
manageable VB manageable O
toxicities NN toxicity O

Meta-analysis CAPITAL NNP O
of NN stopwords O
typhoid NN typhoid D
vaccine NN vaccine T
efficacy NN efficacy O
trials NN test O
showed NN show O
that NN stopwords O
whole NN whole O
cell NNS cell O
vaccines NN vaccine O
are DT stopwords are O
more NN stopwords More O
effective NN effective O
than NN stopwords O
either NN either O
the NN stopwords O
oral NN oral O
, , O
attenuated DT rarefy O
vaccine NN vaccine O
or NN stopwords Oregon O
the NN stopwords O
Vi CAPITAL NNP six O
polysaccharide NN polysaccharide O
vaccine NN vaccine O

Environmental CAPITAL NNP environmental O
tobacco NN tobacco O
smoke JJ smoke O
and DT stopwords O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D

Valvular CAPITAL VB valvular D
heart NN heart D
disease NN disease D
associated DT associate O
with NN stopwords O
fenfluramine-phentermine JJ T

Statins CAPITAL NNP lipid-lowering_medicine T
for NN stopwords O
prevention NN prevention O
of NN stopwords O
stroke NN stroke D

Cerebral CAPITAL NNP cerebral D
bleeding NN bleeding D
occurred JJ happen O
in NN stopwords inch O
2 DIGITS CD two O
patients VB patient O
in NN stopwords inch O
each VB stopwords each O
treatment NN treatment O
group NN group O
, , O
and DT stopwords O
1 DIGITS CD one O
patient VB patient O
in NN stopwords inch O
each VB stopwords each O
group NN group O
died NN die O
of NN stopwords O
a DT stopwords angstrom O
bleeding NN bleeding D
complication NNS complication O

19 DIGITS CD nineteen O
September CAPITAL NNP September O
1996 DIGITS CD O

Alkaline CAPITAL DT alkaline O
cleavage NNS cleavage O
revealed NN uncover O
that NN stopwords O
they NN stopwords O
contained NNS incorporate O
carbohydrates VB carbohydrate O
linked NN associate O
O-glycosidically CAPITAL NNP O
via NN O
serine NN serine O
and DT stopwords O
N-acetylgalactosamine CAPITAL NNP O

The CAPITAL NNP O
use JJ use O
of NN stopwords O
implantable JJ O
venous NN venous O
access DT entree O
devices NN devices O
( ( O
IVADs CAPITAL PRP O
) ) O
in NN stopwords inch O
children JJ child O
with NN stopwords O
hemophilia NN hemophilia D

Enthesopathy CAPITAL NNP D
in NN stopwords inch O
a DT stopwords angstrom O
case VB case O
of NN stopwords O
primary NN primary D
biliary NN bilious D
cirrhosis NN cirrhosis D
with NN stopwords O
positive NN positive O
HLA-B27 CAPITAL NNP O

Radiotherapy CAPITAL VB radiotherapy T
of NN stopwords O
soft NN soft D
tissue NN tissue D
sarcomas VB sarcoma D

Double CAPITAL NNP double O
blind NN blind O
, , O
cluster NNS bunch O
randomised VB randomize O
trial NN test O
of NN stopwords O
low NN low O
dose NN dose O
supplementation NN supplement O
with NN stopwords O
vitamin NN vitamin T
A CAPITAL DT angstrom T
or NN stopwords Oregon O
beta NN beta T
carotene VB provitamin_A T
on NN stopwords on O
mortality NN mortality D
related NN associate D
to NN stopwords D
pregnancy NN pregnancy D
in NN stopwords inch O
Nepal CAPITAL NNP Nepal O
. . O

Because CAPITAL NNP O
the NN stopwords O
symptoms NN symptom O
of NN stopwords O
rhinovirus NN rhinovirus O
colds NNS cold O
are DT stopwords are O
attributed DT impute O
to NN stopwords O
the NN stopwords O
inflammatory NN inflammatory O
response NN response O
to NN stopwords O
infection NN infection O
, , O
we NN stopwords O
studied NN analyze O
the NN stopwords O
effects NN effects O
of NN stopwords O
treatment NN treatment O
with NN stopwords O
clarithromycin NNS T
on NN stopwords on O
the NN stopwords O
symptomatic NN diagnostic O
and DT stopwords O
inflammatory NN inflammatory O
response NN response O
to NN stopwords O
nasal RB nasal_consonant O
inoculation NN inoculation O
with NN stopwords O
rhinovirus NN rhinovirus D

Palliative CAPITAL VB palliative O
options JJ option O
of NN stopwords O
last NN stopping_point O
resort NN resort O
: : O
a DT stopwords angstrom O
comparison NNS comparison O
of NN stopwords O
voluntarily NN voluntarily O
stopping NN fillet O
eating VB eating O
and DT stopwords O
drinking NN drinking O
, , O
terminal NN terminal O
sedation NN sedation O
, , O
physician-assisted NN O
suicide JJ suicide O
, , O
and DT stopwords O
voluntary NN volunteer O
active DT active_agent O
euthanasia NN euthanasia O

CONCLUSIONS CAPITAL NNP decision O
: : O
Adolescents CAPITAL DT adolescent O
are DT stopwords are O
more NN stopwords More O
willing NN volition O
to NN stopwords O
communicate NNS communicate O
with NN stopwords O
and DT stopwords O
seek NN seek O
health NN health O
care VB care O
from JJ stopwords O
physicians NN doctor O
who NN stopwords World_Health_Organization O
assure DT guarantee O
confidentiality NNS confidentiality O

A CAPITAL DT angstrom O
family VB family O
of NN stopwords O
highly NN highly O
repetitive NN insistent O
DNAs CAPITAL NNP deoxyribonucleic_acid O
from JJ stopwords O
`` `` O
ginbuna NN O
'' POS O
( ( O
Carassius CAPITAL VB Carassius O
auratus DT O
langsdorfi NN O
) ) O
genome NN genome O
common NNS park O
to NN stopwords O
Carassius CAPITAL VB Carassius O
auratus DT O
populations NN population O

Surgical CAPITAL NNP surgical T
treatment NN treatment T
for NN stopwords O
lung NN lung D
hydatid NN hydatid D
disease NN disease D

Suppression CAPITAL NNP suppression O
of NN stopwords O
erythema NN erythema D
also DT besides O
occurred JJ happen O
when NN stopwords O
application DT application O
of NN stopwords O
indomethacin NN indomethacin T
was VB stopwords Washington O
delayed NN delay O
until JJ stopwords O
24 DIGITS CD twenty-four O
h NN hydrogen O
after DT stopwords after O
irradiation NN irradiation O
, , O
showing NN screening O
that NN stopwords O
for NN stopwords O
both NN stopwords both O
wavelengths VB wavelength O
prostaglandin NN prostaglandin O
synthesis NN synthesis O
remains NN remains O
increased NN increase O
throughout NN throughout O
this NN stopwords O
period NN time_period O

Clinical CAPITAL NNP clinical O
course NNS course O
of NN stopwords O
breast NN breast O
cancer VB cancer O
patients VB patient O
with NN stopwords O
osseous JJ osseous D
metastasis NN metastasis D
treated NN treat O
with NN stopwords O
combination NNS combination T
chemotherapy NNS chemotherapy T

The CAPITAL NNP O
use JJ use O
of NN stopwords O
radioactive VB radioactive O
isotopes NN isotope O
in NN stopwords inch O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
hypertension NN high_blood_pressure D

In CAPITAL PRP inch O
both NN stopwords both O
cases VB case O
detection NN detection O
of NN stopwords O
the NN stopwords O
binding NN binding O
event NN event O
was VB stopwords Washington O
successful NN successful O

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
mean NN mean O
age DT age O
at DT stopwords astatine O
diagnosis NN diagnosis O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
for NN stopwords O
men NN work_force O
in NN stopwords inch O
potentially NN potentially O
linked NN associate O
families VB family O
was VB stopwords Washington O
significantly NN significantly O
lower NN lower_berth O
than NN stopwords O
for NN stopwords O
men NN work_force O
in NN stopwords inch O
potentially NN potentially O
unlinked JJ O
families VB family O
( ( O
63.7 CD O
vs NN volt O
65.9 CD O
years NN old_age O
, , O
respectively NN respectively O
, , O
P=.01 CAPITAL NNP O
; : O
mean NN mean O
age DT age O
at DT stopwords astatine O
diagnosis NN diagnosis O
in NN stopwords inch O
the NN stopwords O
reference NN mention O
population NN population O
was VB stopwords Washington O
71.6 CD O
years NN old_age O
) ) O

Enzyme CAPITAL NNP enzyme O
structure NN structure O
with NN stopwords O
two NN two O
catalytic VB catalytic O
sites NN site O
for NN stopwords O
double-sieve NN O
selection NN choice O
of NN stopwords O
substrate NN substrate O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

To CAPITAL NNP O
identify NN identify O
novel JJ novel O
members NN member O
of NN stopwords O
this NN stopwords O
superfamily NN superfamily O
in NN stopwords inch O
the NN stopwords O
chick JJ chick O
nervous RB nervous O
system NN system O
, , O
we NN stopwords O
developed NN develop O
a DT stopwords angstrom O
polymerase NN polymerase O
chain NNS chain O
reaction-based NN O
approach DT approach O
making NN devising O
use JJ use O
of NN stopwords O
sequence NN sequence O
motifs NN motif O
of NN stopwords O
immunoglobulin-like JJ O
domains NN sphere O

The CAPITAL NNP O
project NN undertaking O
of NN stopwords O
a DT stopwords angstrom O
national RB national O
control NNS control O
program NN plan O
for NN stopwords O
tuberculosis NN tuberculosis D
in NN stopwords inch O
Spain CAPITAL NNP Spain O

Brain CAPITAL NNP brain D
serotonin NN serotonin D
neurotoxicity JJ D
and DT stopwords O
primary NN primary D
pulmonary NN pneumonic D
hypertension NN high_blood_pressure D
from JJ stopwords O
fenfluramine JJ T
and DT stopwords O
dexfenfluramine NN T

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
overall JJ overall O
preeclampsia NN preeclampsia D
was VB stopwords Washington O
not JJ stopwords not O
significantly NN significantly O
different NN different O
in NN stopwords inch O
the NN stopwords O
triplet NN three O
18 DIGITS CD eighteen O
of NN stopwords O
53 DIGITS CD fifty-three O
( ( O
33.96 CD O
% NN O
) ) O
or NN stopwords Oregon O
twin NN twin O
12 DIGITS CD twelve O
of NN stopwords O
53 DIGITS CD fifty-three O
( ( O
22.6 CD O
% NN O
) ) O
groups NN group O

Long-term CAPITAL NNP long-run O
survival NN survival O
of NN stopwords O
patients VB patient O
with NN stopwords O
unresectable JJ D
colorectal NNS colorectal D
cancer VB cancer D
liver NN liver D
metastases NN metastasis D
following JJ following O
infusional NN T
chemotherapy NNS chemotherapy T
with NN stopwords T
5-fluorouracil CD T
, , T
leucovorin NN T
, , T
oxaliplatin NN T
and DT stopwords T
surgery NN surgery T

This CAPITAL NNP O
study NN survey O
indicates NN bespeak O
that NN stopwords O
a DT stopwords angstrom O
workplace NN workplace O
urine JJ urine O
drug NN drug O
test NN trial O
positive NN positive O
for NN stopwords O
cannabinoids VB O
may VB May O
arise DT originate O
from JJ stopwords O
the NN stopwords O
consumption NNS consumption O
of NN stopwords O
commercially NNS commercially O
available DT available O
cold-pressed NNS O
hemp NN hemp O
seed NN seed O
oil NN oil O

Introduction CAPITAL PRP introduction O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
additional DT extra O
mutation NN mutant O
at DT stopwords astatine O
the NN stopwords O
gag VB joke O
p7/p1 NN O
protease NN protease O
cleavage NNS cleavage O
site NN site O
compensated NNS compensate O
for NN stopwords O
the NN stopwords O
partially NN partially O
defective NN defective O
protease NN protease O
gene NN gene O

Potential CAPITAL NNP potential O
biases NN bias O
were NN stopwords be O
not JJ stopwords not O
taken VB take O
into NN stopwords O
account DT history O
in NN stopwords inch O
study NN survey O
of NN stopwords O
waiting IN wait O
times NN times O

Our CAPITAL NNP O
aim DT purpose O
was VB stopwords Washington O
to NN stopwords O
determine NN determine O
efficacy NN efficacy O
of NN stopwords O
cholecystectomy NNS cholecystectomy T
in NN stopwords inch O
alleviating DT relieve O
biliary NN bilious D
dyskinesia NN dyskinesia D
symptoms NN symptom D
and DT stopwords O
the NN stopwords O
correlation NNS correlation O
with NN stopwords O
histologic NN histological O
findings NN findings O

In CAPITAL PRP inch O
the NN stopwords O
tissue-culture NN O
medium NN medium O
, , O
within NN inside O
a DT stopwords angstrom O
few JJ stopwords few O
seconds NN second O
following JJ following O
microinjection NN O
, , O
all DT stopwords all O
tested NN test O
dyes NN dye O
passed VB pass O
through NN stopwords done O
the NN stopwords O
intercellular NN intercellular O
bridges NN Bridges O
in NN stopwords inch O
both NN stopwords both O
the NN stopwords O
anterior DT front_tooth O
direction NN direction O
( ( O
to NN stopwords O
the NN stopwords O
nurse RB nurse O
cells NNS cell O
) ) O
and DT stopwords O
the NN stopwords O
posterior NN buttocks O
direction NN direction O
( ( O
to NN stopwords O
the NN stopwords O
oocyte JJ oocyte O
) ) O
, , O
independent NN mugwump O
of NN stopwords O
their NN stopwords O
electrical NN electrical O
charge NNS charge O
or NN stopwords Oregon O
molecular NN molecular O
mass VB mass O

However CAPITAL NNP however O
, , O
the NN stopwords O
association DT association O
of NN stopwords O
parvovirus NN parvovirus D
and DT stopwords O
fetal JJ fetal O
pleural NN pleural O
or NN stopwords Oregon O
pericardial NN pericardial D
effusions NN effusion D
has VB stopwords hour_angle O
not JJ stopwords not O
been NN stopwords be O
reported NN report O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Chi2 CAPITAL NNP O
Testing CAPITAL NNP testing O
of NN stopwords O
loci NN venue O
and DT stopwords O
individual NN person O
alleles DT allele O
and DT stopwords O
haplotypes VB haplotype O

September CAPITAL NNP September O
7-10 CD O
, , O
1996 DIGITS CD O

Cumulative CAPITAL NNP accumulative O
incidence NN incidence O
( ( O
+/-SE NN O
) ) O
of NN stopwords O
a DT stopwords angstrom O
second NN second O
cancer VB cancer D
at DT stopwords astatine O
50 DIGITS CD fifty O
years NN old_age O
after DT stopwords after O
diagnosis NN diagnosis O
was VB stopwords Washington O
51.0 CD O
% NN O
( ( O
+/-6.2 NN O
% NN O
) ) O
for NN stopwords O
hereditary NN familial O
retinoblastoma NN retinoblastoma D
, , O
and DT stopwords O
5.0 CD O
% NN O
( ( O
+/-3.0 NN O
% NN O
) ) O
for NN stopwords O
nonhereditary JJ nonhereditary O
retinoblastoma NN retinoblastoma D

Current CAPITAL NNP current O
surgical NN surgical T
therapy NN therapy T
for NN stopwords O
bronchiectasis NN D

Randomized CAPITAL VB randomize O
phase NN phase O
II CAPITAL PRP two O
study NN survey O
of NN stopwords O
the NN stopwords O
neurokinin JJ T
1 DIGITS CD one T
receptor NN receptor T
antagonist DT adversary T
CJ-11 CAPITAL NNP T
, , T
974 DIGITS CD T
in NN stopwords inch O
the NN stopwords O
control NNS control O
of NN stopwords O
cisplatin-induced NN D
emesis NN vomit D

A CAPITAL DT angstrom O
simple NN simple O
selective NN selective O
screening NN screening O
strategy NN scheme O
might NN might O
be NN stopwords beryllium O
appropriate DT allow O
and DT stopwords O
would NN O
be NN stopwords beryllium O
able DT able O
to NN stopwords O
detect NN detect O
most NN stopwords most O
cases VB case O
of NN stopwords O
infection NN infection D

Background CAPITAL IN background O
: : O
N-acetylcysteine CAPITAL NNP T
( ( T
NAC CAPITAL NNP North_Atlantic_Council T
) ) T
and DT stopwords T
ambroxol DT T
( ( T
AMB CAPITAL DT T
) ) T
have VB stopwords rich_person O
recently NN recently O
been NN stopwords be O
proposed NN propose O
as DT stopwords arsenic O
possible NN possible O
therapeutic NN remedy O
agents DT agent O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
pulmonary NN pneumonic D
disorders NN disorder D

Abstracts CAPITAL DT abstraction O

Both CAPITAL NNP both O
groups NN group O
received NN receive O
similar NN similar O
antibiotic DT antibiotic T
and DT stopwords T
insulin NN insulin T
treatment NN treatment T

It CAPITAL PRP information_technology O
is NN stopwords be O
of NN stopwords O
interest NN interest O
to NN stopwords O
note JJ note O
the NN stopwords O
effect NN consequence O
of NN stopwords O
different NN different O
parameters NN parameter O
on NN stopwords on O
the NN stopwords O
extent NN extent O
or NN stopwords Oregon O
heterogeneity NN heterogeneity O
that NN stopwords O
exists NN exist O
on NN stopwords on O
the NN stopwords O
surface NN surface O
and DT stopwords O
how NN stopwords O
this NN stopwords O
influences NN influence O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficients NNS coefficient O

The CAPITAL NNP O
odds JJ odds O
ratios VB ratio O
for NN stopwords O
retinopathy NN retinopathy D
in NN stopwords inch O
subjects NN subject O
with NN stopwords O
4G/4G CD O
and DT stopwords O
4G/5G CD O
, , O
compared NNS compare O
with NN stopwords O
the NN stopwords O
5G/5G CD O
genotype NN genotype O
, , O
were NN stopwords be O
2.0 CD O
and DT stopwords O
3.1 LS O
, , O
respectively NN respectively O

Early CAPITAL NN early O
and DT stopwords O
long-term NN long-run O
results NN consequence O
of NN stopwords O
rehabilitation NN rehabilitation O
of NN stopwords O
cochlear NNS cochlear T
implant JJ implant T
patients VB patient O
) ) O

Here CAPITAL NNP here O
we NN stopwords O
demonstrate NN show O
that NN stopwords O
combined NNS unite O
Msh2 CAPITAL NNP O
and DT stopwords O
p53 NN O
ablation DT ablation O
( ( O
Msh2-/-p53-/- CAPITAL NNP O
) ) O
results NN consequence O
in NN stopwords inch O
developmental NN developmental O
arrest DT apprehension O
of NN stopwords O
all DT stopwords all O
female JJ female O
embryos NN embryo O
at DT stopwords astatine O
9.5 CD O
days VB days O

Metabolism CAPITAL NNP metamorphosis O
of NN stopwords O
polyunsaturated NN polyunsaturated O
fatty VB fatso O
acids DT acid O
and DT stopwords O
serum NN serum O
cholesterol NNS cholesterol O
levels NN degree O
in NN stopwords inch O
the NN stopwords O
rat VB rat O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Surgical-site CAPITAL NNP D
complications NNS complication D
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
morphine NN morphine T
nerve RB nerve T
paste VB paste T
used JJ use O
for NN stopwords O
postoperative NN postoperative D
pain IN pain D
control NNS control D
after DT stopwords after D
laminectomy NN laminectomy D

Through CAPITAL NNP done O
this NN stopwords O
approach DT approach O
, , O
the NN stopwords O
gene NN gene O
encoding NN encoding O
non-histone JJ O
chromosomal NN chromosomal O
protein NN protein O
HMGI-C CAPITAL NNP O
was VB stopwords Washington O
identified NN identify O
as DT stopwords arsenic O
one JJ one O
of NN stopwords O
the NN stopwords O
target VB target O
genes NN gene O
activated DT trip O
by NN stopwords by O
oncogenic JJ O
Raf-1 CAPITAL VB O
kinase NN kinase O

Ten-year CAPITAL NNP O
disease NN disease O
free JJ free O
survival NN survival O
after DT stopwords after O
transperineal NN T
sonography-guided NN T
iodine-125 NN iodine-125 T
brachytherapy NN T
with NN stopwords O
or NN stopwords Oregon O
without NN O
45-Gray CD T
external NN external T
beam NN radio_beam T
irradiation NN irradiation T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
clinically JJ clinically O
localized NN place O
, , O
low NN low O
to NN stopwords O
high NN high O
Gleason CAPITAL NNP D
grade NN class D
prostate NN prostate_gland D
carcinoma VB carcinoma D

The CAPITAL NNP O
women NN woman O
were NN stopwords be O
tested NN test O
for NN stopwords O
C CAPITAL SYM degree_centigrade D
trachomatis NN D
with NN stopwords O
confirmed NNS confirm O
enzyme NN enzyme O
immunoassay JJ immunoassay O
( ( O
endocervical NN O
specimens NN specimen O
) ) O
and DT stopwords O
ligase NN O
chain NNS chain O
reaction NN chemical_reaction O
assay DT assay O
on NN stopwords on O
urine JJ urine O
specimens NN specimen O

background VB background O
: : O
the NN stopwords O
objective NN aim O
of NN stopwords O
this NN stopwords O
phase NN phase O
ii NN two O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
concept NNS concept O
of NN stopwords O
sequential NN consecutive T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
nonsmall JJ D
cell NNS cell D
lung NN lung D
carcinoma VB carcinoma D
( ( D
nsclc JJ D
) ) D
by NN stopwords by O
the NN stopwords O
administration DT administration O
of NN stopwords O
carboplatin VB T
plus NN asset T
gemcitabine NN T
followed JJ follow T
by NN stopwords by T
of NN stopwords T
paclitaxel VB T

The CAPITAL NNP O
distinction NN differentiation O
is NN stopwords be O
important JJ important O
, , O
however NN however O
, , O
for NN stopwords O
proper NN proper O
management VB management O
of NN stopwords O
the NN stopwords O
two NN two O
conditions NNS conditions O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
6th CD sixth O
Congress CAPITAL NNP Congress O
of NN stopwords O
the NN stopwords O
Soci CAPITAL NNP O
( ( O
c NNS degree_centigrade O
) ) O
t NN O
( ( O
c NNS degree_centigrade O
) ) O
de NN Delaware O
Pharmaco-Toxicologie CAPITAL NNP O
Cellulaire CAPITAL NNP O
and DT stopwords O
the NN stopwords O
Soci CAPITAL NNP O
( ( O
c NNS degree_centigrade O
) ) O
t NN O
( ( O
c NNS degree_centigrade O
) ) O
Franaise CAPITAL NNP O
de NN Delaware O
Toxicologie CAPITAL NNP O
G CAPITAL NNP O
( ( O
c NNS degree_centigrade O
) ) O
n NNS O
( ( O
c NNS degree_centigrade O
) ) O
tique NN O

Diurnal CAPITAL NNP diurnal O
periodicity NN cyclicity O
in NN stopwords inch O
the NN stopwords O
metabolic NN metabolic O
activity DT activity O
of NN stopwords O
bone NN bone O
tissue NN tissue O

In CAPITAL PRP inch O
order JJ order O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
applicability DT applicability O
of NN stopwords O
anthelminthic DT vermifuge T
treatment NN treatment T
of NN stopwords O
wild NN wild O
foxes JJ fox O
( ( O
Vulpes CAPITAL NNP Vulpes O
vulpes NN Vulpes O
) ) O
to NN stopwords O
limit NN limit O
their NN stopwords O
infection NN infection D
with NN stopwords D
Echinococcus CAPITAL NNP echinococcus D
multilocularis NN D
, , O
bait IN bait O
pellets NN pellet O
, , O
each VB stopwords each O
containing NNS incorporate O
50 DIGITS CD fifty O
mg NN milligram O
praziquantel NN T
, , O
were NN stopwords be O
repeatedly NN repeatedly O
distributed NN distribute O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
area DT area O
of NN stopwords O
566 DIGITS CD O
km2 NN O
where NN stopwords O
many VB many O
foxes JJ fox O
are DT stopwords are O
infected NN infect O
, , O
in NN stopwords inch O
southern NN southern O
Germany CAPITAL NNP Germany O

What CAPITAL NNP O
's POS O
new JJ new O
in NN stopwords inch O
protein NN protein O
folding JJ protein_folding O
? . O
EMBO CAPITAL NNP O
workshop NN workshop O
: : O
protein NN protein O
folding JJ protein_folding O
and DT stopwords O
misfolding NN O
inside NN inside O
and DT stopwords O
outside JJ outside O
the NN stopwords O
cell NNS cell O

Phylogeographic CAPITAL NNP O
structure NN structure O
was VB stopwords Washington O
determined NN determine O
for NN stopwords O
the NN stopwords O
yellow NN yellow O
mongoose NN mongoose O
, , O
Cynictis CAPITAL NNP O
penicillata NN O
, , O
using JJ exploitation O
mtDNA NN O
RFLPs CAPITAL NNP O
and DT stopwords O
control NNS control O
region NN region O
sequences NN sequence O

Use CAPITAL NNP use O
of NN stopwords O
food JJ food O
in NN stopwords inch O
child JJ child T
psychotherapy NN psychotherapy T

American CAPITAL DT American O
Academy CAPITAL DT academy O
of NN stopwords O
Child CAPITAL NNP child O
and DT stopwords O
Adolescent CAPITAL DT adolescent O
Psychiatry CAPITAL NNP psychiatry O

The CAPITAL NNP O
postprandial NN postprandial O
period NN time_period O
of NN stopwords O
the NN stopwords O
gastrectomized VB O
patient VB patient O

The CAPITAL NNP O
senior NN senior O
surgery NN surgery O
resident NN resident O
correctly NNS correctly O
predicted NN predict O
the NN stopwords O
presence NN presence O
of NN stopwords O
intra-abdominal NN D
injury NN injury D
in NN stopwords inch O
36 DIGITS CD thirty-six O
( ( O
82 DIGITS CD eighty-two O
% NN O
) ) O
of NN stopwords O
the NN stopwords O
patients VB patient O
( ( O
sensitivity NN sensitivity O
= NN O
90.0 CD O
% NN O
, , O
specificity NN specificity O
= NN O
58.3 CD O
% NN O
, , O
positive NN positive O
predictive NN predictive O
value NN value O
= NN O
85.3 CD O
% NN O
, , O
negative JJ negative O
predictive NN predictive O
value NN value O
= NN O
63.6 CD O
% NN O
, , O
phi NN phi O
= NN O
0.52 LS O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.01 . O
) ) O
in NN stopwords inch O
the NN stopwords O
emergency NN emergency O
department NN department O
before NN stopwords earlier O
DPL CAPITAL NNP O
and DT stopwords O
celiotomy NNS O
were NN stopwords be O
performed NN perform O

Postoperative CAPITAL NNP postoperative D
peritonitis NN peritonitis D
originating IN originate O
from JJ stopwords O
the NN stopwords O
duodenum NN duodenum O
: : O
operative JJ secret_agent O
management VB management O
by NN stopwords by O
intubation NN cannulation T
and DT stopwords T
continuous NNS continuous T
intraluminal NN T
irrigation NN irrigation T

Urine CAPITAL NNP urine O
was VB stopwords Washington O
also DT besides O
obtained NN obtain O
from JJ stopwords O
subjects NN subject O
who NN stopwords World_Health_Organization O
had VB stopwords have O
received NN receive O
the NN stopwords O
maximum VB maximum O
dosage NN dose O
of NN stopwords O
inhaled NN inhale O
salbutamol VB T
advisable DT advisable O
for NN stopwords O
competing NNS compete O
athletes DT athlete O
to NN stopwords O
provide NN supply O
protection NN protection O
from JJ stopwords O
exercise-induced NN O
asthma DT asthma O
and DT stopwords O
treatment NN treatment O
of NN stopwords O
asthma DT asthma D
( ( O
1600 DIGITS CD O
microg NN O
in NN stopwords inch O
24 DIGITS CD twenty-four O
h NN hydrogen O
, , O
800 DIGITS CD O
microg NN O
being NN stopwords being O
in NN stopwords inch O
the NN stopwords O
last NN stopping_point O
4 DIGITS CD four O
h NN hydrogen O
) ) O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Jaw CAPITAL NNP jaw D
clenching NNS clench D
following JJ following O
Gamma CAPITAL VB gamma T
Knife CAPITAL NNP knife T
treatment NN treatment T
for NN stopwords O
trigeminal NN trigeminal D
neuralgia JJ neuralgia D

In CAPITAL PRP inch O
this NN stopwords O
work NN work O
we NN stopwords O
investigated NN investigate O
the NN stopwords O
use JJ use O
of NN stopwords O
enzyme NN enzyme O
amplification DT amplification O
systems NN system O
to NN stopwords O
enhance NN enhance O
the NN stopwords O
direct NN direct O
transduction NN transduction O
of NN stopwords O
immune JJ immune O
cell NNS cell O
responses NN response O
to NN stopwords O
analyte DT O

CONCLUSIONS CAPITAL NNP decision O
: : O
The CAPITAL NNP O
significant NN significant O
chromosome NN chromosome O
19q13.2 CD O
single-locus NN O
and DT stopwords O
multilocus NN O
haplotype VB haplotype O
associations DT association O
with NN stopwords O
MS CAPITAL NNP multiple_sclerosis O
in NN stopwords inch O
Caucasian CAPITAL VB White O
and DT stopwords O
Chinese CAPITAL NNP Chinese O
patient VB patient O
samples VB sample O
indicate NN bespeak O
an DT stopwords Associate_in_Nursing O
effect NN consequence O
from JJ stopwords O
a DT stopwords angstrom O
nearby RB nearby O
disease NN disease O
susceptibility NN susceptibility O
locus NN venue O

PURPOSE CAPITAL NNP purpose O
: : O
The CAPITAL NNP O
American CAPITAL DT American O
Urological CAPITAL NNP O
Association CAPITAL DT association O
convened NNS convene O
the NN stopwords O
Female CAPITAL NNP female D
Stress CAPITAL NNP stress D
Urinary CAPITAL NNP urinary D
Incontinence CAPITAL PRP incontinence D
Clinical CAPITAL NNP clinical O
Guidelines CAPITAL NNP guideline O
Panel CAPITAL VB panel O
to NN stopwords O
analyze DT analyze O
the NN stopwords O
literature NN literature O
regarding NN see O
surgical NN surgical T
procedures NN procedure T
for NN stopwords O
treating NN treat O
stress NN stress D
urinary JJ urinary D
incontinence NN incontinence D
in NN stopwords inch O
the NN stopwords O
otherwise JJ otherwise O
healthy NN healthy O
female JJ female O
subject NN subject O
and DT stopwords O
to NN stopwords O
make NN brand O
practice NN practice O
recommendations NN recommendation O
based VB establish O
on NN stopwords on O
the NN stopwords O
treatment NN treatment O
outcomes JJ result O
data VB data O

Role CAPITAL NNP function O
of NN stopwords O
a DT stopwords angstrom O
p53 NN O
polymorphism NN polymorphism O
in NN stopwords inch O
the NN stopwords O
development NN development O
of NN stopwords O
human NN homo D
papillomavirus-associated VB D
cancer VB cancer D

Evidence CAPITAL NNP evidence O
for NN stopwords O
an DT stopwords Associate_in_Nursing O
immunological JJ immunological O
reaction NN chemical_reaction O
of NN stopwords O
the NN stopwords O
host NN host O
directed NN direct O
against DT stopwords O
its NN stopwords information_technology O
own JJ stopwords own O
actively DT actively O
growing NN growth O
primary NN primary D
tumor NN tumor D

Sequence CAPITAL NNP sequence O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
36-kb CD O
region NN region O
between NN stopwords between O
gntZ NN O
and DT stopwords O
trnY NN O
genes NN gene O
of NN stopwords O
Bacillus CAPITAL IN bacillus O
subtilis NN O
genome NN genome O

Recent CAPITAL NNP Holocene O
studies NN survey O
demonstrated NN show O
that NN stopwords O
immunohistochemical JJ O
detection NN detection O
in NN stopwords inch O
paraffin-embedded NN O
material VB material O
, , O
using JJ exploitation O
a DT stopwords angstrom O
monoclonal NN monoclonal_antibody O
antibody DT antibody O
, , O
is NN stopwords be O
very NN stopwords very O
useful JJ useful O
for NN stopwords O
routine NN routine O
diagnosis NN diagnosis O

Joint CAPITAL NNP joint O
meeting NN meeting O
of NN stopwords O
the NN stopwords O
Benelux CAPITAL NNP Benelux O
Society CAPITAL NNP society O
for NN stopwords O
Microcirculation CAPITAL NNP O
and DT stopwords O
the NN stopwords O
Gesellschaft CAPITAL NNP O
f1/4r JJ O
Mikrozirkulation CAPITAL NNP O
e.V NN O

This CAPITAL NNP O
clinical JJ clinical O
commentary NNS comment O
discusses NN discus O
the NN stopwords O
current NNS current O
management VB management O
of NN stopwords O
the NN stopwords O
syndrome NN syndrome O
including NN include O
the NN stopwords O
Abbe-McIndoe CAPITAL DT T
procedure NN procedure T
, , O
the NN stopwords O
most NN stopwords most O
commonly NNS normally O
used JJ use O
method NN method O
of NN stopwords O
surgical NN surgical T
correction NNS correction T
, , O
and DT stopwords O
the NN stopwords O
Frank CAPITAL NNP Frank T
vaginal NN vaginal T
dilation NN dilation T
method NN method T
, , O
the NN stopwords O
most NN stopwords most O
common NNS park O
nonsurgical JJ nonsurgical O
method NN method O
of NN stopwords O
correction NNS correction O

Echocardiography CAPITAL NNP echocardiography O
demonstrated NN show O
unusual JJ unusual O
valvular NN valvular O
morphology NN morphology O
and DT stopwords O
regurgitation NN regurgitation O
in NN stopwords inch O
all DT stopwords all O
patients VB patient O

Our CAPITAL NNP O
data VB data O
did NN stopwords make O
not JJ stopwords not O
provide NN supply O
enough NN enough O
evidence NN evidence O
for NN stopwords O
a DT stopwords angstrom O
substantial NN significant O
modification NN alteration O
of NN stopwords O
the NN stopwords O
effect NN consequence O
of NN stopwords O
pack-years VB O
on NN stopwords on O
lung NN lung D
cancer VB cancer D
risk NN hazard O
by NN stopwords by O
the NN stopwords O
CYP1A1 CAPITAL NNP O
MspI CAPITAL NNP O
and DT stopwords O
GSTM1 CAPITAL NNP O
genotypes NN genotype O

Very CAPITAL NNP very O
high NN high O
intakes NN consumption O
of NN stopwords O
vitamins NN vitamin O
A CAPITAL DT angstrom O
and DT stopwords O
D CAPITAL NN vitamin_D O
, , O
niacin NN niacin O
, , O
pyridoxine NN vitamin_B6 O
, , O
and DT stopwords O
selenium NN selenium O
have VB stopwords rich_person O
produced NN produce O
adverse DT adverse O
effects NN effects O

This CAPITAL NNP O
suggests NN propose O
that NN stopwords O
there NN stopwords there O
may VB May O
be NN stopwords beryllium O
racial VB racial O
differences NN difference O
in NN stopwords inch O
environmental NN environmental O
exposure NN exposure O
, , O
and DT stopwords O
that NN stopwords O
the NN stopwords O
intensity NN intensity O
and DT stopwords O
mode NN manner O
of NN stopwords O
delivery NN delivery O
of NN stopwords O
carcinogen VB carcinogen O
insult NN abuse O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
host NN host O
susceptibility NN susceptibility O
may VB May O
differ NN differ O
by NN stopwords by O
race VB race O
and DT stopwords O
anatomical DT anatomical_reference O
subsite NN O

The CAPITAL NNP O
mean NN mean O
age DT age O
of NN stopwords O
the NN stopwords O
male VB male O
patients VB patient O
was VB stopwords Washington O
32.7 CD O
years NN old_age O
( ( O
range VB scope O
24-47 CD O
) ) O

When CAPITAL NNP O
used JJ use O
in NN stopwords inch O
combination NNS combination O
the NN stopwords O
drugs NN drug O
may VB May O
be NN stopwords beryllium O
just NN stopwords just O
as DT stopwords arsenic O
effective NN effective O
as DT stopwords arsenic O
either NN either O
drug NN drug O
alone DT alone O
, , O
with NN stopwords O
the NN stopwords O
added DT add O
advantages DT advantage O
of NN stopwords O
the NN stopwords O
need JJ need O
for NN stopwords O
lower NN lower_berth O
doses NN dose O
of NN stopwords O
each VB stopwords each O
agent DT agent O
and DT stopwords O
perhaps NN possibly O
fewer JJ fewer O
side NN side O
effects NN effects O

When CAPITAL NNP O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
treatment NN treatment O
was VB stopwords Washington O
compared NNS compare O
with NN stopwords O
that NN stopwords O
of NN stopwords O
the NN stopwords O
placebo NN placebo O
group NN group O
( ( O
group NN group O
A CAPITAL DT angstrom O
) ) O
, , O
there NN stopwords there O
was VB stopwords Washington O
significant NN significant O
improvement JJ improvement O
in NN stopwords inch O
PI CAPITAL NN pi O
and DT stopwords O
PT CAPITAL NNP platinum O
in NN stopwords inch O
group NN group O
B CAPITAL NN bacillus O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.01 LS O
) ) O
but NN stopwords merely O
not JJ stopwords not O
in NN stopwords inch O
group NN group O
C CAPITAL SYM degree_centigrade O
( ( O
P CAPITAL NN phosphorus O
> NN O
0.05 LS O
) ) O

Curtis CAPITAL NNP Curtis O
, , O
Radiat CAPITAL VB O

Analysis CAPITAL DT analysis O
of NN stopwords O
five NN five O
mutations NN mutant O
in NN stopwords inch O
20 DIGITS CD twenty O
mucopolysaccharidois NN D
type NN type O
1 DIGITS CD one O
patients VB patient O
: : O
high NN high O
prevalence NN prevalence O
of NN stopwords O
the NN stopwords O
W402X CAPITAL NNP O
mutation NN mutant O

Aspirin CAPITAL DT aspirin T
therapy NN therapy T
in NN stopwords inch O
diabetes NN diabetes D
mellitus NN D

Case CAPITAL VB case O
complexity NNS complexity O

Practice CAPITAL NNP practice O
parameters NN parameter O
for NN stopwords O
the NN stopwords O
assessment DT appraisal O
and DT stopwords O
treatment NN treatment O
of NN stopwords O
children JJ child O
and DT stopwords O
adolescents DT adolescent O
with NN stopwords O
schizophrenia JJ schizophrenia D

The CAPITAL NNP O
presence NN presence O
of NN stopwords O
clinical JJ clinical O
autonomic DT autonomic D
dysfunction NN dysfunction D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
neurologic JJ neurological D
diseases NN disease D
, , O
such NN stopwords such O
as DT stopwords arsenic O
multiple NN multiple D
sclerosis JJ sclerosis D
, , O
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
, , O
and DT stopwords O
cerebrovascular NNS cerebrovascular O
accident DT accident O
, , O
has VB stopwords hour_angle O
become NN become O
increasingly NN increasingly O
recognized NN acknowledge O
in NN stopwords inch O
the NN stopwords O
past VB past O
decade NN decade O

CONCLUSIONS CAPITAL NNP decision O
: : O
We CAPITAL NNP O
conclude NNS reason O
that NN stopwords O
LTG CAPITAL NNP T
is NN stopwords be O
effective NN effective O
and DT stopwords O
well NN well O
tolerated NN digest O
when NN stopwords O
administered DT administer O
as DT stopwords arsenic O
monotherapy NN O
in NN stopwords inch O
adult DT adult O
patients VB patient O
with NN stopwords O
partial NN partial_derivative D
seizures JJ seizure D

Genetic CAPITAL NNP familial O
testing NN testing O
in NN stopwords inch O
hereditary NN familial O
colorectal NNS colorectal D
cancer VB cancer D

Colonoscopic CAPITAL NNP O
removal NN removal O
of NN stopwords O
chicken JJ chicken O
bones NN bones O
impacted JJ impact O
in NN stopwords inch O
the NN stopwords O
sigmoid NN sigmoid O
in NN stopwords inch O
two NN two O
patients VB patient O

Bone CAPITAL NNP bone T
grafting NN graft T
was VB stopwords Washington O
used JJ use O
to NN stopwords O
maintain VB keep O
hallux VB big_toe O
length NN length O

Four CAPITAL NNP four O
patients VB patient O
developed NN develop O
mild NN mild O
pancreatitis VB pancreatitis D
, , O
one JJ one O
had VB stopwords have O
moderate NN centrist O
pancreatitis VB pancreatitis D
and DT stopwords O
one JJ one O
had VB stopwords have O
leak NN leak O
of NN stopwords O
contrast NNS contrast O
, , O
which NN stopwords O
was VB stopwords Washington O
treated NN treat O
by NN stopwords by O
administration DT administration T
of NN stopwords T
clear NNS clear T
fluids JJ fluid T
orally NN orally O
for NN stopwords O
one JJ one O
day VB day O

Wegener CAPITAL NNP Wegener D
's POS D
granulomatosis NN D
from JJ stopwords O
infancy NN infancy O
to NN stopwords O
adolescence DT adolescence O

CONCLUSIONS CAPITAL NNP decision O
: : O
The CAPITAL NNP O
results NN consequence O
of NN stopwords O
our NN stopwords O
study NN survey O
suggest NN propose O
that NN stopwords O
thrombolysis NN thrombolysis T
may VB May O
favorably VB favorably O
affect DT affect O
the NN stopwords O
clinical JJ clinical O
outcome JJ result O
of NN stopwords O
hemodynamically NN O
stable NN stable O
patients VB patient O
with NN stopwords O
major VB major D
pulmonary NN pneumonic D
embolism NN embolism D

She CAPITAL NNP O
had VB stopwords have O
been NN stopwords be O
taking VB pickings O
amitriptyline DT amitriptyline T
75 DIGITS CD seventy-five O
mg NN milligram O
at DT stopwords astatine O
night NN night O
for NN stopwords O
depression NN depression D
for NN stopwords O
four JJ four O
months NN calendar_month O
before NN stopwords earlier O
her NN stopwords O
admission DT admission O

Iatrogenic CAPITAL PRP iatrogenic T
ruptures NN rupture T
of NN stopwords O
the NN stopwords O
tracheobronchial NN O
tree NN tree O

No CAPITAL NNP no O
significant NN significant O
differences NN difference O
were NN stopwords be O
found JJ found O
between NN stopwords between O
the NN stopwords O
two NN two O
groups NN group O
in NN stopwords inch O
the NN stopwords O
mode NN manner O
of NN stopwords O
delivery NN delivery O
or NN stopwords Oregon O
Apgar CAPITAL DT O
scores JJ tons O

Patient CAPITAL VB patient O
safety VB safety O
and DT stopwords O
scented JJ odorize O
pediatric NN pediatric O
anesthesia DT anesthesia O
facemasks VB O

This CAPITAL NNP O
49-year-old CD O
woman NN woman O
did NN stopwords make O
not JJ stopwords not O
experience NN experience O
sustained NN prolong O
benefit NN benefit O

Further CAPITAL NNP foster O
prospective NN prospective O
studies NN survey O
are DT stopwords are O
warranted NN justify O
to NN stopwords O
test NN trial O
the NN stopwords O
efficacy NN efficacy O
of NN stopwords O
this NN stopwords O
discriminant NN O
function JJ function O
in NN stopwords inch O
predicting NN predict O
preeclampsia NN preeclampsia D

Lonomia CAPITAL NNP O
obliqua NN O
caterpillar VB caterpillar O
spicules JJ spicule O
trigger NN gun_trigger O
human NN homo O
blood NN blood O
coagulation NNS curdling O
via NN O
activation DT activation O
of NN stopwords O
factor VB factor O
X CAPITAL NN ten O
and DT stopwords O
prothrombin NN prothrombin O

Improvement CAPITAL PRP improvement O
of NN stopwords O
experimental NN experimental O
parameters NN parameter O
is NN stopwords be O
required NN necessitate O
to NN stopwords O
obtain NN obtain O
more NN stopwords More O
reliable NN reliable O
kinetic NN kinetic O
data VB data O

Successful CAPITAL NNP successful O
treatment NN treatment O
of NN stopwords O
anaerobic DT anaerobic D
pleuropulmonary NN D
infections NN infection D
requires NN necessitate O
a DT stopwords angstrom O
combination NNS combination T
of NN stopwords T
antibiotic DT antibiotic T
therapy NN therapy T
and DT stopwords T
surgical NN surgical T
interventions NN intervention T

Winning CAPITAL NNP winning O
the NN stopwords O
war NN war O
on NN stopwords on O
cancer VB cancer D

Our CAPITAL NNP O
aim DT purpose O
was VB stopwords Washington O
to NN stopwords O
investigate NN investigate O
the NN stopwords O
contribution NNS contribution O
of NN stopwords O
certain NNS certain O
antenatally DT O
detectable NN detectable O
markers NN marker O
leading NN lead O
to NN stopwords O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
trisomic NN O
fetuses JJ fetus O
we NN stopwords O
observed NN detect O
over JJ stopwords over O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
6 DIGITS CD six O
years NN old_age O

Twinning CAPITAL NNP twin O
in NN stopwords inch O
relation NN relation O
to NN stopwords O
birth NN birth O
weight NN weight O
, , O
mortality NN mortality O
, , O
and DT stopwords O
congenital NNS congenital D
anomalies DT anomaly D

The CAPITAL NNP O
importance JJ importance O
of NN stopwords O
patient VB patient O
registration NN registration O
and DT stopwords O
processing NN processing O

The CAPITAL NNP O
effects NN effects O
of NN stopwords O
social NN sociable O
class NNS class O
and DT stopwords O
friends JJ friend O
' '' O
expectations NN expectation O
on NN stopwords on O
oral NN oral O
polio NN poliomyelitis D
vaccination NN inoculation T
participation NN engagement O

Malignancies CAPITAL NNP malignancy O

EMS CAPITAL NNP em O
could NNS O
significantly NN significantly O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
improve JJ better O
ROM CAPITAL NNP read-only_memory O
, , O
but NN stopwords merely O
not JJ stopwords not O
PT CAPITAL NNP platinum O
, , O
better NN better O
than NN stopwords O
the NN stopwords O
placebo NN placebo O
groups NN group O
, , O
for NN stopwords O
either NN either O
subgroup NN subgroup O

The CAPITAL NNP O
medical NN checkup O
records NN record O
were NN stopwords be O
examined NN analyze O
for NN stopwords O
the NN stopwords O
maternal VB maternal O
and DT stopwords O
pregnancy NN pregnancy O
outcome JJ result O
data VB data O

Still CAPITAL NNP still O
hard NN difficult O
to NN stopwords O
know NN know O
how NN stopwords O
large NN large O
the NN stopwords O
benefits NN benefit O
will NN stopwords volition O
really NN truly O
be NN stopwords beryllium O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
endothelin-receptor NN T
antagonist DT adversary T
, , T
bosentan NN T
, , O
on NN stopwords on O
blood NN blood O
pressure NN pressure O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
essential NN necessity D
hypertension NN high_blood_pressure D
. . O

Anesthesiology CAPITAL DT anesthesiology O

The CAPITAL NNP O
AF-4 CAPITAL DT O
gene NN gene O
is NN stopwords be O
a DT stopwords angstrom O
member NN member O
of NN stopwords O
the NN stopwords O
AF-4 CAPITAL DT O
, , O
LAF-4 CAPITAL VB O
and DT stopwords O
FMR-2 CAPITAL NNP O
gene NN gene O
family VB family O

because NN stopwords O
placement NN placement O
of NN stopwords O
stents NN stent O
in NN stopwords inch O
both NN stopwords both O
the NN stopwords O
esophagus NN esophagus O
and DT stopwords O
tracheobronchus NN O
has VB stopwords hour_angle O
a DT stopwords angstrom O
high NN high O
risk NN hazard O
of NN stopwords O
enlargement NN expansion O
of NN stopwords O
the NN stopwords O
fistula NN fistulous_withers O
, , O
a DT stopwords angstrom O
covered NNS cover T
metallic NN metallic T
stent NN stent T
is NN stopwords be O
preferable NN preferable O
for NN stopwords O
esophageal NN esophageal D
cancer VB cancer D
involving NN involve D
the NN stopwords D
tracheobronchus NN D

results NN consequence O
: : O
we NN stopwords O
have VB stopwords rich_person O
performed NN perform O
60 DIGITS CD sixty O
carinal VB carinal T
resections NN resection T
for NN stopwords O
bronchogenic NN D
carcinoma VB carcinoma D
: : O
18 DIGITS CD eighteen O
isolated NN isolate T
carinal VB carinal T
resections NN resection T
for NN stopwords O
tumor NN tumor D
confined NNS restrict D
to NN stopwords D
the NN stopwords D
carinal VB carinal D
or NN stopwords Oregon D
proximal NN proximal D
main VB main D
stem NN root D
bronchus NN bronchus D
; : O
35 DIGITS CD thirty-five O
carinal VB carinal T
pneumonectomies NN pneumonectomy T
; : O
5 DIGITS CD five O
carinal VB carinal T
plus NN asset T
lobar NN lobar T
resections NN resection T
, , O
and DT stopwords O
2 DIGITS CD two O
carinal VB carinal T
resections NN resection T
for NN stopwords O
stump NN stump D
recurrence NN recurrence D
after DT stopwords after D
prior NN prior D
pneumonectomy NN pneumonectomy D

SUBJECTS CAPITAL NNP subject O
: : O
591 DIGITS CD O
children JJ child O
at DT stopwords astatine O
a DT stopwords angstrom O
mean NN mean O
age DT age O
of NN stopwords O
7 DIGITS CD seven O
years NN old_age O
whose NN O
mothers NN mother O
were NN stopwords be O
randomly VB randomly O
assigned DT delegate O
during NN stopwords O
pregnancy NN pregnancy O
to NN stopwords O
receive NN receive O
2 DIGITS CD two O
g/day NN O
of NN stopwords O
elemental NN elemental O
calcium VB calcium O
( ( O
n NN nitrogen O
= NN O
298 DIGITS CD O
) ) O
or NN stopwords Oregon O
placebo NN placebo O
( ( O
n NN nitrogen O
= NN O
293 DIGITS CD O
) ) O

A CAPITAL DT angstrom O
new JJ new O
method NN method O
is NN stopwords be O
described NN describe O
for NN stopwords O
detection NN detection O
of NN stopwords O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
lysosomal NN O
alpha-glucosidase DT O
gene NN gene O
( ( O
GAA CAPITAL VB O
) ) O
leading NN lead O
to NN stopwords O
Glycogen CAPITAL NNP glycogen D
Storage CAPITAL NNP storage D
Disease CAPITAL NNP disease D
type NN type D
II CAPITAL PRP two D
( ( D
GSDII CAPITAL NNP D
) ) D

The CAPITAL NNP O
responsibilities NN duty O
of NN stopwords O
the NN stopwords O
obstetrician NN obstetrician O

Besides CAPITAL NNP besides O
the NN stopwords O
well-known NN well-known O
nonsteroidal JJ nonsteroid T
antiinflammatory DT T
drugs NN drug T
( ( T
NSAID CAPITAL NNP nonsteroidal_anti-inflammatory T
) ) T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
rheumatic NN rheumatic D
pain IN pain D
herbal NN herb_tea T
medicine NN medicine T
can VB stopwords can O
also DT besides O
be NN stopwords beryllium O
applied DT use O
successfully NN successfully O

Genetic CAPITAL NNP familial O
population NN population O
structure NN structure O
in NN stopwords inch O
the NN stopwords O
yellow NN yellow O
mongoose NN mongoose O
, , O
Cynictis CAPITAL NNP O
penicillata NN O

March CAPITAL NNP March O
14-17 CD O
, , O
1996 DIGITS CD O

Where CAPITAL NNP O
next JJ following O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
rectal NN rectal D
cancer VB cancer D
? . O

Steroid CAPITAL NNP steroid T
delivery NN delivery T
in NN stopwords inch O
croup NNS croup D

Positive CAPITAL NNP positive O
patch VB spot O
test NN trial O
to NN stopwords O
cocamidopropyl NNS O
betaine NN betaine O
in NN stopwords inch O
a DT stopwords angstrom O
hairdresser NN hairdresser O

Biology CAPITAL NNP biology O
of NN stopwords O
non-conventional JJ O
transmissible NN catching O
agents DT agent O
or NN stopwords Oregon O
prions NN prion O

Our CAPITAL NNP O
data VB data O
suggest NN propose O
that NN stopwords O
the NN stopwords O
relative NN relative O
analgesic DT analgesic O
potency NN authority O
of NN stopwords O
epidural NN epidural_anesthesia O
S CAPITAL NN second O
: : O
F CAPITAL NN degree_Fahrenheit O
is NN stopwords be O
approximately DT approximately O
5 DIGITS CD five O
and DT stopwords O
that NN stopwords O
there NN stopwords there O
are DT stopwords are O
no NNS stopwords no O
differences NN difference O
between NN stopwords between O
the NN stopwords O
opioids IN O
in NN stopwords inch O
the NN stopwords O
onset JJ onset O
, , O
duration NN duration O
, , O
and DT stopwords O
effectiveness NN effectiveness O
of NN stopwords O
analgesia DT analgesia O
when NN stopwords O
equianalgesic NN O
doses NN dose O
are DT stopwords are O
administered DT administer O
postoperatively NN postoperatively O
after DT stopwords after O
lidocaine NN Lidocaine O
anesthesia DT anesthesia O
for NN stopwords O
C/S CAPITAL NNP O

Given CAPITAL NNP given O
that NN stopwords O
the NN stopwords O
predisposition NN sensitivity O
( ( O
which NN stopwords O
presumably NN presumably O
is NN stopwords be O
genetic NN familial O
) ) O
is NN stopwords be O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
procreative NN generative O
disadvantage NN disadvantage O
why NN stopwords why O
do NN stopwords bash O
such NN stopwords such O
illnesses NN illness O
persist NN prevail O
? . O
Here CAPITAL NNP here O
it NN stopwords information_technology O
is NN stopwords be O
suggested NN propose O
that NN stopwords O
these NN stopwords O
conditions NNS conditions O
are DT stopwords are O
a DT stopwords angstrom O
manifestation VB manifestation O
of NN stopwords O
genetic NN familial O
diversity NN diverseness O
in NN stopwords inch O
the NN stopwords O
evolution NN development O
of NN stopwords O
the NN stopwords O
specifically NN specifically O
human NN homo O
characteristic NNS feature O
of NN stopwords O
language NN language O
, , O
an DT stopwords Associate_in_Nursing O
innovation NN invention O
that NN stopwords O
has VB stopwords hour_angle O
occurred JJ happen O
by NN stopwords by O
a DT stopwords angstrom O
process NN procedure O
of NN stopwords O
progressive NN progressive O
hemispheric NN hemispheric O
specialization-the NN O
establishment NN constitution O
of NN stopwords O
dominance NN laterality O
for NN stopwords O
some NN stopwords some O
critical JJ critical O
component NNS component O
of NN stopwords O
language NN language O
in NN stopwords inch O
one JJ one O
or NN stopwords Oregon O
the NN stopwords O
other JJ stopwords other O
hemisphere NN hemisphere O

A CAPITAL DT angstrom O
three-year NN O
comparison NNS comparison O
of NN stopwords O
day VB day O
and DT stopwords O
residental NN O
treatment NN treatment O

They CAPITAL NNP O
have VB stopwords rich_person O
been NN stopwords be O
combined NNS unite O
with NN stopwords O
a DT stopwords angstrom O
nonlinear JJ nonlinear O
regression NN arrested_development O
analysis DT analysis O
method NN method O
and DT stopwords O
tested NN test O
on NN stopwords on O
both NN stopwords both O
simulated NN imitate O
and DT stopwords O
real NN real_number O
sets NN set O
of NN stopwords O
biomedical NN biomedical O
MRS CAPITAL NNP Mrs O
data VB data O
selected NN choose O
with NN stopwords O
respect NN respect O
to NN stopwords O
the NN stopwords O
main VB main O
problems NN problem O
usually JJ normally O
encountered NN meet O
in NN stopwords inch O
quantifying NN quantify O
biomedical NN biomedical O
MRS CAPITAL NNP Mrs O
, , O
specifically NN specifically O
`` `` O
chemical NNS chemical O
noise JJ noise O
, , O
'' POS O
resulting NN result O
from JJ stopwords O
overlapping JJ imbrication O
resonances NN resonance O
, , O
and DT stopwords O
baseline VB baseline O
distortion NN distortion O

PAI-1 CAPITAL VB O
activity DT activity O
was VB stopwords Washington O
negatively JJ negatively O
correlated NNS correlate O
with NN stopwords O
duration NN duration O
of NN stopwords O
diabetes NN diabetes D
( ( O
rs NN roentgen O
= NN O
-0.18 : O
, , O
P CAPITAL NN phosphorus O
= NN O
0.02 LS O
) ) O

Early CAPITAL NN early O
returns NN tax_return O
( ( O
within NN inside O
two NN two O
weeks NN week O
) ) O
and DT stopwords O
complications NNS complication O
( ( O
otitis IN otitis D
media NN medium D
, , O
sinusitis NN sinusitis D
, , O
quinsy NN quinsy D
) ) O

August CAPITAL DT August O
17-22 CD O
, , O
1996 DIGITS CD O

Inpatient CAPITAL PRP inpatient O
rehabilitation NN rehabilitation O
after DT stopwords after O
total NN sum O
joint NN joint T
replacement NN replacement T

RESULTS CAPITAL NNP consequence O
: : O
Forty-four CAPITAL NNP forty-four O
patients VB patient O
in NN stopwords inch O
the NN stopwords O
partner NN spouse O
intrauterine NN intrauterine T
insemination NN insemination T
group NN group O
and DT stopwords O
37 DIGITS CD thirty-seven O
in NN stopwords inch O
the NN stopwords O
donor NN donor T
insemination NN insemination T
group NN group O
were NN stopwords be O
identified NN identify O
as DT stopwords arsenic O
having VB stopwords have O
primary NN primary O
infertility NN sterility D

Using CAPITAL NNP exploitation O
video-intensified NN O
fluorescence JJ fluorescence O
microscopy NN microscopy O
and DT stopwords O
a DT stopwords angstrom O
pseudocolor NN O
display NN display O
of NN stopwords O
fluorescence JJ fluorescence O
intensity NN intensity O
, , O
we NN stopwords O
analyzed DT analyze O
the NN stopwords O
distribution NN distribution O
of NN stopwords O
microinjected NN O
molecules NN molecule O
within NN inside O
the NN stopwords O
nurse-cell/oocyte RB O
syncytium NN syncytium O
of NN stopwords O
Drosophila CAPITAL NNP drosophila O
ovarian NN ovarian O
follicles JJ follicle O

He CAPITAL NNP helium O
needed JJ necessitate O
mechanical NN mechanical T
ventilation NN ventilation T
for NN stopwords O
severe NN severe D
hypoxemia NN D
, , O
but NN stopwords merely O
recovered NN recover O
with NN stopwords O
glucocorticoid NN glucocorticoid T
pulse NN pulsation T
therapy NN therapy T

Association CAPITAL DT association O
of NN stopwords O
parvovirus NN parvovirus D
infection NN infection D
with NN stopwords O
isolated NN isolate O
fetal JJ fetal O
effusions NN effusion O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Effects CAPITAL NNP effects O
of NN stopwords O
anal DT anal T
invasive NN invasive T
treatment NN treatment T
and DT stopwords O
incontinence NN incontinence D
on NN stopwords on O
mental NN mental O
health NN health O
and DT stopwords O
psychosocial NN O
functioning JJ operation O
of NN stopwords O
adolescents DT adolescent O
with NN stopwords O
Hirshsprung CAPITAL NNP D
's POS D
disease NN disease D
and DT stopwords O
low NN low O
anorectal DT anorectal D
anomalies DT anomaly D

The CAPITAL NNP O
group NN group O
classified NNS classified_ad O
as DT stopwords arsenic O
dancers VB dancer O
with NN stopwords O
osteoporosis JJ osteoporosis O
( ( O
group NN group O
I CAPITAL PRP iodine O
) ) O
showed NN show O
a DT stopwords angstrom O
significant NN significant O
increase NN addition O
in NN stopwords inch O
lumbar NN lumbar O
bone NN bone O
density NN density O
, , O
whereas NN O
in NN stopwords inch O
the NN stopwords O
group NN group O
of NN stopwords O
dancers VB dancer O
without NN O
signs NN sign O
of NN stopwords O
osteoporosis JJ osteoporosis D
( ( O
group NN group O
II CAPITAL PRP two O
) ) O
, , O
BMD CAPITAL NNP O
remained NN stay O
unchanged JJ unchanged O

< NN O
TO_SEE CAPITAL NNP O
> NN O
amantadine DT T
, , O
rimantadine NN T
, , O
and DT stopwords O
the NN stopwords O
newly JJ newly O
available DT available O
drugs NN drug O
zanamivir NN T
and DT stopwords O
oseltamivir JJ T
are DT stopwords are O
effective NN effective O
for NN stopwords O
influenza NN influenza D
prevention NN prevention D
and DT stopwords D
treatment NN treatment D
( ( O
the NN stopwords O
former NN former O
two NN two O
for NN stopwords O
influenza NN influenza O
a DT stopwords angstrom O
only JJ stopwords lone O
) ) O

Res CAPITAL NNP reticuloendothelial_system O

Radiotherapy CAPITAL VB radiotherapy T
in NN stopwords inch O
breast-conserving NN T
treatment NN treatment T
for NN stopwords O
ductal NN D
carcinoma VB carcinoma D
in NN stopwords inch O
situ NN O
: : O
first NN first O
results NN consequence O
of NN stopwords O
the NN stopwords O
EORTC CAPITAL NNP O
randomised VB randomize O
phase NN phase O
III CAPITAL PRP three O
trial NN test O
10853 DIGITS CD O

Gene CAPITAL NNP gene O
technology NN technology O
and DT stopwords O
democracy NN democracy O

Positron CAPITAL NNP positron O
emission NN emission O
tomography NN imaging O
in NN stopwords inch O
assessing DT measure O
response NN response O
to NN stopwords O
neoadjuvant JJ T
chemotherapy NNS chemotherapy T
for NN stopwords O
non-small-cell JJ D
lung NN lung D
cancer VB cancer D

A CAPITAL DT angstrom O
bias NN bias O
in NN stopwords inch O
prior NN prior O
reports NN report O
for NN stopwords O
mutations NN mutant O
in NN stopwords inch O
exon NN exon O
11 DIGITS CD eleven O
was VB stopwords Washington O
revealed NN uncover O

Successful CAPITAL NNP successful O
treatment NN treatment O
of NN stopwords O
psoriasis NN psoriasis D
with NN stopwords O
topical NN topical O
application DT application O
of NN stopwords O
active DT active_agent T
vitamin NN vitamin T
D3 CAPITAL NNP T
analogue DT analogue T
, , T
1 DIGITS CD one T
alpha DT alpha T
, , T
24-dihydroxycholecalciferol CD T

The CAPITAL NNP O
most NN stopwords most O
common NNS park O
indication NN indication O
leading NN lead O
to NN stopwords O
diagnosis NN diagnosis O
was VB stopwords Washington O
abnormal DT abnormal O
ultrasound JJ ultrasound O
finding NN determination O
( ( O
48.2 CD O
% NN O
) ) O
, , O
followed JJ follow O
by NN stopwords by O
advanced DT advance O
maternal VB maternal O
age DT age O
( ( O
44.4 CD O
% NN O
) ) O

reviewer NN reviewer O
's POS O
conclusions NNS decision O
: : O
a DT stopwords angstrom O
single NN single O
dose NN dose O
of NN stopwords O
nasal RB nasal_consonant T
decongestant NN decongestant T
in NN stopwords inch O
the NN stopwords O
common NNS park O
cold NNS cold O
is NN stopwords be O
moderately NN reasonably O
effective NN effective O
for NN stopwords O
the NN stopwords O
short NN short O
term NN term O
relief NN relief O
of NN stopwords O
congestion NNS congestion D
in NN stopwords inch O
adults DT adult O
, , O
while NN stopwords while O
there NN stopwords there O
is NN stopwords be O
no NNS stopwords no O
evidence NN evidence O
available DT available O
to NN stopwords O
show NN show O
benefit NN benefit O
after DT stopwords after O
repeated NN repeat O
use JJ use O
over JJ stopwords over O
several NN several O
days VB days O

the NN stopwords O
administration DT administration O
of NN stopwords O
mitomycin NN mitomycin T
c NNS degree_centigrade T
in NN stopwords inch O
addition DT addition O
to NN stopwords O
cisplatin-based NN T
regimens NN regimen T
for NN stopwords O
patients VB patient O
with NN stopwords O
lung NN lung D
cancer VB cancer D
should NN stopwords O
be NN stopwords beryllium O
carefully VB carefully O
considered NNS see O

Genomic CAPITAL NNP O
sequence NN sequence O
of NN stopwords O
a DT stopwords angstrom O
Lyme CAPITAL NNP D
disease NN disease D
spirochaete JJ spirochete O
, , O
Borrelia CAPITAL NNP borrelia O
burgdorferi NN O

Brandon/Hill CAPITAL NNP O
selected NN choose O
list NN list O
of NN stopwords O
nursing RB nursing O
books NN book O
and DT stopwords O
journals NN diary O

Linear CAPITAL NNP linear D
lichen NN lichen D
planopilaris NN D
of NN stopwords O
the NN stopwords O
face VB face O

Wavelet CAPITAL WRB ripple O
transformation NN transformation O
is NN stopwords be O
a DT stopwords angstrom O
time-frequency NN O
representation NN representation O
which NN stopwords O
separates NN offprint O
each VB stopwords each O
component NNS component O
from JJ stopwords O
the NN stopwords O
FID CAPITAL NNP O
, , O
then NN stopwords then O
successively NN successively O
quantifies NN quantify O
it NN stopwords information_technology O
and DT stopwords O
subtracts NN subtract O
it NN stopwords information_technology O
from JJ stopwords O
the NN stopwords O
raw VB raw O
signal NN signal O

Ancient CAPITAL DT ancient O
DNA CAPITAL NNP deoxyribonucleic_acid O
from JJ stopwords O
amber DT amber O
fossil JJ dodo O
bees NN bee O
? . O

In CAPITAL PRP inch O
this NN stopwords O
prospective NN prospective O
randomised VB randomize O
trial NN test O
of NN stopwords O
radiotherapy VB radiotherapy T
versus NN O
surgery NN surgery T
, , O
our NN stopwords O
aim DT purpose O
was VB stopwords Washington O
to NN stopwords O
assess DT buttocks O
the NN stopwords O
5-year CD O
survival NN survival O
and DT stopwords O
the NN stopwords O
rate VB rate O
and DT stopwords O
pattern VB form O
of NN stopwords O
complications NNS complication O
and DT stopwords O
recurrences NN recurrence O
associated DT associate O
with NN stopwords O
each VB stopwords each O
treatment NN treatment O

However CAPITAL NNP however O
, , O
animal DT animal O
and DT stopwords O
human NN homo O
studies NN survey O
have VB stopwords rich_person O
demonstrated NN show O
toxic NN toxic O
effects NN effects O
of NN stopwords O
fenfluramines JJ T
that NN stopwords O
clinicians JJ clinician O
should NN stopwords O
be NN stopwords beryllium O
aware DT aware O
of NN stopwords O
when NN stopwords O
considering NNS see O
prescribing NN order O
the NN stopwords O
drugs NN drug O

We CAPITAL NNP O
systematically NN systematically O
reviewed NN review O
the NN stopwords O
evidence NN evidence O
concerning NNS refer O
the NN stopwords O
ability DT ability O
of NN stopwords O
five NN five O
systemic NN systemic T
treatments NN treatment T
to NN stopwords O
induce NN induce O
remission NN remission O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
severe NN severe D
psoriasis NN psoriasis D
: : O
ultraviolet JJ ultraviolet T
B CAPITAL NN bacillus T
( ( T
UVB CAPITAL NNP T
) ) T
, , O
photochemotherapy NN T
( ( T
PUVA CAPITAL NNP T
) ) T
, , O
methotrexate NN methotrexate T
( ( T
MTX CAPITAL NNP T
) ) T
, , O
retinoids NN T
( ( T
RET CAPITAL NNP ret T
) ) T
and DT stopwords O
cyclosporin NNS T
A CAPITAL DT angstrom T
( ( T
CYA CAPITAL NNP T
) ) T

An CAPITAL DT Associate_in_Nursing O
economic NN economic O
analysis DT analysis O
of NN stopwords O
different NN different O
strategies NN scheme O
of NN stopwords O
immunization JJ immunization T
against DT stopwords O
hepatitis NN hepatitis D
A CAPITAL DT angstrom D
virus NN virus D
in NN stopwords inch O
developed NN develop O
countries NNS state O

Fluorescent CAPITAL NNP fluorescent O
intensity NN intensity O
from JJ stopwords O
the NN stopwords O
fibre NN fiber O
has VB stopwords hour_angle O
been NN stopwords be O
shown NN show O
to NN stopwords O
be NN stopwords beryllium O
proportional NN proportional O
to NN stopwords O
L. CAPITAL NNP O
donovani NN O
specific NN particular O
antibodies DT antibody O
present NN present O
in NN stopwords inch O
the NN stopwords O
test NN trial O
sera NN serum O

The CAPITAL NNP O
role NN function O
of NN stopwords O
procedures NN procedure O
in NN stopwords inch O
family VB family O
practice NN practice O
: : O
is NN stopwords be O
there NN stopwords there O
a DT stopwords angstrom O
right NN right O
answer DT answer O
? . O

Touch CAPITAL NNP touch O
sensibility NN sensibility O
in NN stopwords inch O
the NN stopwords O
breast NN breast O
after DT stopwords after O
subcutaneous NN hypodermic T
mastectomy VB mastectomy T
and DT stopwords O
immediate JJ immediate O
reconstruction NN Reconstruction O
with NN stopwords O
a DT stopwords angstrom O
prosthesis NN prosthesis O

A CAPITAL DT angstrom O
randomised VB randomize O
comparison NNS comparison O
of NN stopwords O
the NN stopwords O
EuroQol CAPITAL NNP O
and DT stopwords O
Short CAPITAL NNP short O
Form-36 CAPITAL NNP O
after DT stopwords after O
stroke NN stroke D

Association CAPITAL DT association O
between NN stopwords between O
5-HT2A CD O
gene NN gene O
promoter NN promoter O
polymorphism NN polymorphism O
and DT stopwords O
anorexia DT anorexia D
nervosa RB D

He CAPITAL NNP helium O
was VB stopwords Washington O
followed JJ follow O
regularly NN regularly O
with NN stopwords O
chest NNS thorax O
computed NNS calculate O
tomography NN imaging O
( ( O
CT CAPITAL NNP Connecticut O
) ) O
scan JJ scan O
and DT stopwords O
had VB stopwords have O
been NN stopwords be O
asymptomatic DT asymptomatic O

Surgical CAPITAL NNP surgical T
treatment NN treatment T
is NN stopwords be O
a DT stopwords angstrom O
good NN good O
alternative DT option O
for NN stopwords O
patients VB patient O
with NN stopwords O
persistent NN persistent D
severe NN severe D
regurgitation NN regurgitation D
during NN stopwords O
medical NN checkup O
therapy NN therapy O
and DT stopwords O
for NN stopwords O
young NN young O
patients VB patient O
who NN stopwords World_Health_Organization O
prefer NN prefer O
surgery NN surgery O
to NN stopwords O
lifelong NN lifelong O
medication NN medicine O

We CAPITAL NNP O
support NN support O
the NN stopwords O
use JJ use O
of NN stopwords O
conjugate NNS conjugate_solution T
pneumococcal NN pneumococcal T
vaccine NN vaccine T
per NN O
guidelines NN guideline O
for NN stopwords O
prevention NN prevention O
of NN stopwords O
Raom CAPITAL VB D
from JJ stopwords O
the NN stopwords O
Advisory CAPITAL DT advisory O
Committee CAPITAL NNP committee O
on NN stopwords on O
Immunization CAPITAL PRP immunization O
Practice CAPITAL NNP practice O
of NN stopwords O
the NN stopwords O
Centers CAPITAL NNP center O
for NN stopwords O
Disease CAPITAL NNP disease O
Control CAPITAL NNP control O
and DT stopwords O
Prevention CAPITAL NNP prevention O
, , O
with NN stopwords O
consideration NNS consideration O
given NN given O
to NN stopwords O
influenza NN influenza D
vaccine NN vaccine T
for NN stopwords O
cases VB case O
of NN stopwords O
rAOM VB O
that NN stopwords O
historically NN historically O
worsen NN worsen O
during NN stopwords O
the NN stopwords O
flu JJ influenza O
season NN season O

Initially CAPITAL PRP initially O
, , O
all DT stopwords all O
eyes NN eyes O
that NN stopwords O
had VB stopwords have O
optic JJ eye T
capture VB capture T
without NN O
vitrectomy NN vitrectomy T
also DT besides O
remained NN stay O
clear NNS clear O
, , O
but NN stopwords merely O
after DT stopwords after O
6 DIGITS CD six O
months NN calendar_month O
, , O
four JJ four O
of NN stopwords O
five NN five O
developed NN develop O
opacification NN opacification D

Synergism CAPITAL NNP synergy O
in NN stopwords inch O
the NN stopwords O
chemotherapy NNS chemotherapy T
of NN stopwords O
Eimeria CAPITAL NN coccidium D
infections NN infection D
of NN stopwords O
chicks JJ chick O

Winning CAPITAL NNP winning O
health NN health O
victories NN victory O
with NN stopwords O
community NNS community O
commitment NNS committedness O

Ionized CAPITAL PRP ionize O
magnesium VB magnesium O
in NN stopwords inch O
serum NN serum O
and DT stopwords O
ultrafiltrate JJ O
: : O
pH NN pH O
and DT stopwords O
bicarbonate NN bicarbonate O
effect NN consequence O
on NN stopwords on O
measurements NN measurement O
with NN stopwords O
the NN stopwords O
AVL CAPITAL DT O
988-4 CD O
electrolyte NN electrolyte O
analyzer DT analyzer O

Breastfeeding CAPITAL NNP breastfeed O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
0.36 LS O
and DT stopwords O
0.64 LS O
standard NN standard O
deviation NN deviation O
( ( O
SD CAPITAL NNP South_Dakota O
) ) O
increase NN addition O
in NN stopwords inch O
weight NN weight O
at DT stopwords astatine O
2 DIGITS CD two O
weeks NN week O
and DT stopwords O
3 DIGITS CD three O
months NN calendar_month O
of NN stopwords O
age DT age O
, , O
respectively NN respectively O
, , O
which NN stopwords O
persisted NN prevail O
beyond NN beyond O
the NN stopwords O
breastfeeding NN breastfeed O
period NN time_period O
( ( O
0.64 LS O
SD CAPITAL NNP South_Dakota O
at DT stopwords astatine O
1 DIGITS CD one O
y NN stopwords yttrium O
) ) O

Diagnostic CAPITAL NNP diagnostic O
criteria JJ standard O
must NN must O
be NN stopwords beryllium O
used JJ use O
and DT stopwords O
therapeutic NN remedy O
regimens NN regimen O
standardised NN standardize O

< NN O
TO_SEE CAPITAL NNP O
> NN O
the NN stopwords O
standard NN standard O
care VB care O
for NN stopwords O
patients VB patient O
with NN stopwords O
non-small-cell JJ D
lung NN lung D
cancer VB cancer D
is NN stopwords be O
chemotherapy NNS chemotherapy T
of NN stopwords T
supportive NN supportive T
care VB care T
, , O
with NN stopwords O
surgery NN surgery T
being NN stopwords being O
reserved NN reserve O
for NN stopwords O
palliation VB palliation O
of NN stopwords O
symptoms NN symptom O
; : O
however NN however O
, , O
there NN stopwords there O
is NN stopwords be O
a DT stopwords angstrom O
small JJ small O
group NN group O
of NN stopwords O
patients VB patient O
with NN stopwords O
a DT stopwords angstrom O
finite NN finite O
number JJ number O
of NN stopwords O
extrathoracic NN D
metastases NN metastasis D
( ( D
oligometastases IN D
) ) D
who NN stopwords World_Health_Organization O
may VB May O
experience NN experience O
improved JJ better O
survival NN survival O
by NN stopwords by O
resection NN resection T
of NN stopwords T
their NN stopwords T
metastases NN metastasis T
and DT stopwords T
the NN stopwords T
primary NN primary T
site NN site T
, , O
with NN stopwords O
or NN stopwords Oregon O
without NN O
systemic NN systemic O
treatment NN treatment O

Coronary CAPITAL NNP coronary_thrombosis T
angioplasty DT angioplasty T
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
53 DIGITS CD fifty-three O
patients VB patient O
in NN stopwords inch O
whom NN stopwords O
unstable JJ unstable D
angina DT angina D
had VB stopwords have O
reoccurred NN O
after DT stopwords after O
48 DIGITS CD forty-eight O
hr NN hour O
and DT stopwords O
within NN inside O
30 DIGITS CD thirty O
days VB days O
after DT stopwords after O
sustained NN prolong O
myocardial NN myocardial O
infarction NN infarct O

More CAPITAL NNP More O
on NN stopwords on O
infertility NN sterility D

Online CAPITAL NNP on-line O

Treatment CAPITAL NNP treatment O
of NN stopwords O
hydrocele NN hydrocele D
and DT stopwords D
cysts NNS cyst D
of NN stopwords D
the NN stopwords D
epididymis NN epididymis D
with NN stopwords O
sclerosing JJ T
injections NN injection T
of NN stopwords T
quinine NN quinine T
and DT stopwords T
urea JJ urea T
chlorhydrolactate NNS T
in NN stopwords inch O
a DT stopwords angstrom O
30 DIGITS CD thirty O
per NN O
cent NNS cent O
solution NN solution O

There CAPITAL NNP there O
is NN stopwords be O
no NNS stopwords no O
evidence NN evidence O
of NN stopwords O
adverse DT adverse O
effects NN effects O
from JJ stopwords O
beta-carotene NN beta-carotene O
supplements NN addendum O
except NN demur O
in NN stopwords inch O
current NNS current O
heavy NN heavy O
smokers JJ smoker O

These CAPITAL NNP O
last NN stopping_point O
drugs NN drug O
seem NN look O
very NN stopwords very O
attractive DT attractive O
because NN stopwords O
they NN stopwords O
decrease NN decrease O
insulin NN insulin O
resistance NN resistance O
in NN stopwords inch O
obese NN corpulent O
, , O
diabetics NN diabetic O

BACKGROUND CAPITAL IN background O
: : O
The CAPITAL NNP O
administration DT administration O
of NN stopwords O
salbutamol VB T
is NN stopwords be O
permitted NN permit O
only JJ stopwords lone O
by NN stopwords by O
inhalation NN inhalation O
by NN stopwords by O
the NN stopwords O
International CAPITAL PRP International O
Olympic CAPITAL NNP Olympic O
Committee CAPITAL NNP committee O
( ( O
IOC CAPITAL PRP O
) ) O
for NN stopwords O
the NN stopwords O
management VB management O
of NN stopwords O
asthma DT asthma D
and DT stopwords D
exercise-induced NN D
asthma DT asthma D
in NN stopwords inch O
athletes DT athlete O

) ) O

Moxonidine CAPITAL NNP T
for NN stopwords O
hypertension NN high_blood_pressure D

Today CAPITAL NNP today O
's POS O
technology NN technology O
links NN links O
health NN health O
care VB care O
providers NN supplier O
and DT stopwords O
patients VB patient O
across DT across O
town NN town O
, , O
in NN stopwords inch O
the NN stopwords O
next JJ following O
state NN state O
or NN stopwords Oregon O
even NN evening O
another DT another O
country NNS state O

While CAPITAL NNP while O
TEOAE CAPITAL NNP O
strength NN strength O
varies NN change O
widely NN widely O
among DT O
ears VB ear O
, , O
no NNS stopwords no O
clear NNS clear O
evidence NN evidence O
was VB stopwords Washington O
found JJ found O
to NN stopwords O
show NN show O
that NN stopwords O
TEOAEs CAPITAL NNP O
can VB stopwords can O
be NN stopwords beryllium O
absent DT absent O
when NN stopwords O
HTLs CAPITAL NNP O
are DT stopwords are O
normal RB convention O

Keys CAPITAL NNP key O
to NN stopwords O
receptor NN receptor O
active DT active_agent O
states NN state O
? . O

Surgical CAPITAL NNP surgical T
clearance NNS clearance T
of NN stopwords O
CBD CAPITAL NNP D
stones NN rock D
was VB stopwords Washington O
achieved DT achieve O
in NN stopwords inch O
58 DIGITS CD fifty-eight O
patients VB patient O
( ( O
93.5 CD O
% NN O
; : O
group NN group O
Ia CAPITAL PRP Iowa O
) ) O

These CAPITAL NNP O
results NN consequence O
verified NN verify O
the NN stopwords O
synergistic NN synergistic O
effect NN consequence O
fludarabine JJ T
exhibited NN exhibit O
in NN stopwords inch O
augmenting DT augment O
ara-CTP DT T
concentrations NNS concentration O
in NN stopwords inch O
patients VB patient O
' '' O
leukemic NN O
blasts NN blast O
, , O
thus NN frankincense O
improving JJ better O
the NN stopwords O
clinical JJ clinical O
response NN response O
in NN stopwords inch O
relapsed NN get_worse D
pediatric NN pediatric D
leukemias NN leukemia D

CONCLUSIONS CAPITAL NNP decision O
: : O
Clinical CAPITAL NNP clinical O
judgment NN judgment O
is NN stopwords be O
highly NN highly O
accurate DT accurate O
in NN stopwords inch O
separating NN separate O
patients VB patient O
with NN stopwords O
tangential VB digressive O
gunshot NN gunfire D
wounds NN wound D
to NN stopwords O
the NN stopwords O
abdomen DT abdomen O
from JJ stopwords O
those NN stopwords O
with NN stopwords O
intra-abdominal NN D
injury NN injury D
but NN stopwords merely O
may VB May O
miss NN girl O
patients VB patient O
with NN stopwords O
intra-abdominal NN D
hemorrhage NN bleeding D

Proposed CAPITAL NNP propose O
new JJ new O
bacterial VB bacterial O
taxa VB taxonomic_group O
and DT stopwords O
proposed NN propose O
changes NNS change O
of NN stopwords O
bacterial VB bacterial O
names RB name_calling O
published NN print O
during NN stopwords O
1995 DIGITS CD O
and DT stopwords O
considered NNS see O
to NN stopwords O
be NN stopwords beryllium O
of NN stopwords O
interest NN interest O
to NN stopwords O
medical NN checkup O
or NN stopwords Oregon O
veterinary NN veterinarian O
bacteriology VB bacteriology O

Clinical CAPITAL NNP clinical O
problem-solving NN O

Evidence CAPITAL NNP evidence O
that NN stopwords O
the NN stopwords O
expression NN expression O
of NN stopwords O
progesterone-induced NN O
blocking NN blocking O
factor VB factor O
by NN stopwords by O
maternal VB maternal O
T-lymphocytes CAPITAL NNP O
is NN stopwords be O
positively NN positively O
correlated NNS correlate O
with NN stopwords O
conception NNS concept O

Depression CAPITAL NNP depression D
in NN stopwords inch O
the NN stopwords O
chronically NN chronically O
ill NN ailment O
needs JJ need O
separate NN offprint O
treatment NN treatment O

INTERPRETATION CAPITAL PRP interpretation O
: : O
Low CAPITAL NNP low O
, , O
fixed-dose NN O
warfarin NN warfarin T
( ( T
1 DIGITS CD one T
mg NN milligram T
or NN stopwords Oregon T
3 DIGITS CD three T
mg NN milligram T
) ) T
combined NNS unite T
with NN stopwords T
low-dose NN T
aspirin DT aspirin T
( ( T
80 DIGITS CD eighty T
mg NN milligram T
) ) T
in NN stopwords inch O
patients VB patient O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
had VB stopwords have O
myocardial NN myocardial D
infarction NN infarct D
does NN stopwords Department_of_Energy O
not JJ stopwords not O
provide NN supply O
clinical JJ clinical O
benefit NN benefit O
beyond NN beyond O
that NN stopwords O
achievable DT accomplishable O
with NN stopwords O
160 DIGITS CD one_hundred_sixty O
mg NN milligram O
aspirin DT aspirin T
monotherapy NN T

Lake CAPITAL VB lake O
Como CAPITAL NNP O
, , O
Italy CAPITAL PRP Italy O
, , O
September CAPITAL NNP September O
9-12 CD O
, , O
1996 DIGITS CD O

INTERPRETATION CAPITAL PRP interpretation O
: : O
Antichlamydial CAPITAL DT T
antibiotics DT antibiotic T
may VB May O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
therapeutic NN remedy O
intervention NN intervention O
in NN stopwords inch O
addition DT addition O
to NN stopwords O
standard NN standard O
medication NN medicine O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
coronary-artery NNS D
disease NN disease D

F CAPITAL NN degree_Fahrenheit O
25 DIGITS CD twenty-five O
microg NN O
and DT stopwords O
S CAPITAL NN second O
5 DIGITS CD five O
microg NN O
were NN stopwords be O
ineffective NN ineffective O
, , O
with NN stopwords O
significantly NN significantly O
fewer JJ fewer O
women NN woman O
achieving DT achieve O
VAS CAPITAL VB vessel O
scores JJ tons O
& CC O
# # O
60 DIGITS CD sixty O
; : O
10 DIGITS CD ten O
mm NNS millimeter O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
compared NNS compare O
with NN stopwords O
F CAPITAL NN degree_Fahrenheit O
100 DIGITS CD hundred O
or NN stopwords Oregon O
200 DIGITS CD two_hundred O
microg NN O
and DT stopwords O
S CAPITAL NN second O
20 DIGITS CD twenty O
or NN stopwords Oregon O
30 DIGITS CD thirty O
microg NN O
) ) O

Guidelines CAPITAL NNP guideline O
for NN stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
antiretroviral DT T
agents DT agent T
in NN stopwords inch O
HIV CAPITAL NNP HIV D
-infected : O
adults DT adult O
and DT stopwords O
adolescents DT adolescent O

Central CAPITAL NNP central O
and DT stopwords O
East CAPITAL VB east O
European CAPITAL NNP European O
Regional CAPITAL NNP regional O
INTERASMA CAPITAL PRP O
Conference CAPITAL NNP conference O

Scientific CAPITAL NNP scientific O
evidence NN evidence O
in NN stopwords inch O
family VB family O
and DT stopwords O
community NNS community O
medicine NN medicine O

Genomic CAPITAL NNP O
medicine NN medicine O

The CAPITAL NNP O
fight NN battle O
against DT stopwords O
hemolytic NN hemolytic D
disease NN disease D
of NN stopwords O
the NN stopwords O
newborn JJ neonate O
in NN stopwords inch O
general NN general O
practice NN practice O

Disparate CAPITAL NNP disparate O
sequence NN sequence O
characteristics NNS feature O
of NN stopwords O
the NN stopwords O
Erysiphe CAPITAL NNP Erysiphe O
graminis NN O
f.sp NN O

Western CAPITAL NNP Western O
blot NN smudge O
assays DT assay O
for NN stopwords O
hepatic NN liverwort O
glutamine NN glutamine O
synthetase NN O
were NN stopwords be O
performed NN perform O
to NN stopwords O
determine NN determine O
whether NN O
glutamine NN glutamine O
synthetase NN O
deficiency NN lack O
resulted NN result O
from JJ stopwords O
reduced NN reduce O
enzyme NN enzyme O
levels NN degree O

The CAPITAL NNP O
family VB family O
medicine NN medicine O
program NN plan O
of NN stopwords O
the NN stopwords O
University CAPITAL NNP university O
of NN stopwords O
Miami CAPITAL NNP Miami O

Effect CAPITAL NNP consequence O
of NN stopwords O
sodium NN sodium O
ions NN ion O
on NN stopwords on O
the NN stopwords O
behavior NN behavior O
of NN stopwords O
rest NN remainder O
and DT stopwords O
action DT action O
potentials NN potential O
of NN stopwords O
the NN stopwords O
cell NNS cell O
membrane NN membrane O
of NN stopwords O
the NN stopwords O
rat VB rat O
myometrium NN myometrium O

Case CAPITAL VB case O
30-1997 CD O
: : O
pulmonary NN pneumonic D
interstitial NN interstitial D
emphysema NN emphysema D
in NN stopwords inch O
infancy NN infancy O

The CAPITAL NNP O
characterization NNS word_picture O
of NN stopwords O
low NN low O
molecular NN molecular O
weight NN weight O
ligand NN ligand O
interaction NN interaction O
with NN stopwords O
receptor NN receptor O
molecules NN molecule O
is NN stopwords be O
of NN stopwords O
importance JJ importance O
for NN stopwords O
the NN stopwords O
investigation NN probe O
of NN stopwords O
biological NN biological O
processes NN procedure O
and DT stopwords O
for NN stopwords O
drug NN drug O
research NN research O

Variables CAPITAL VB variable O
differing NN differ O
significantly NN significantly O
between NN stopwords between O
groups NN group O
included NN include O
increases NN addition O
in NN stopwords inch O
uric JJ uric O
acid DT acid O
( ( O
UA CAPITAL IN O
) ) O
, , O
low-density NN low-density O
lipoproteins NN lipoprotein O
( ( O
LDL CAPITAL NNP low-density_lipoprotein O
) ) O
, , O
phosphoglycerate NN O
kinase NN kinase O
( ( O
PGK CAPITAL NNP O
) ) O
, , O
and DT stopwords O
mean NN mean O
platelet NN platelet O
volume NN volume O
( ( O
MPV CAPITAL NNP O
) ) O
, , O
and DT stopwords O
decreases NN decrease O
in NN stopwords inch O
glyceraldehyde NN glyceraldehyde O
phosphate NN phosphate O
dehydrogenase NN O
( ( O
G3PD CAPITAL NNP O
) ) O
in NN stopwords inch O
preeclamptic NN O
women NN woman O
compared NNS compare O
to NN stopwords O
normal RB convention O
controls NNS control O

For CAPITAL NNP O
refractory NN furnace_lining D
right NN right D
ventricular NN ventricular D
failure VB failure D
following JJ following O
the NN stopwords O
surgical NN surgical O
repair NN repair O
of NN stopwords O
congenital NNS congenital O
cardiac VB cardiac O
defects NN defect O
in NN stopwords inch O
which NN stopwords O
the NN stopwords O
placement NN placement O
of NN stopwords O
right NN right O
atrial DT atrial O
and DT stopwords O
pulmonary NN pneumonic O
artery DT artery O
cannulae VB O
is NN stopwords be O
not JJ stopwords not O
technically NN technically O
feasible NN feasible O
, , O
use JJ use T
of NN stopwords T
high-frequency NN T
high-volume NN T
ventilation NN ventilation T
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
quite NN quite O
promising NN promise O

A CAPITAL DT angstrom O
gross NN gross O
and DT stopwords O
microscopic NN microscopic O
study NN survey O
of NN stopwords O
cerebral NNS cerebral D
injuries NN injury D
accompanying DT attach_to O
maxillofacial VB maxillofacial O
high-velocity NN high-speed O
projectile NN projectile D
wounding NN wound D
in NN stopwords inch O
dogs NN dog O

The CAPITAL NNP O
TQR CAPITAL NNP O
scale JJ scale O
emphasises NN emphasis O
both NN stopwords both O
the NN stopwords O
athlete DT athlete O
's POS O
perception NN percept O
of NN stopwords O
recovery NN recovery O
and DT stopwords O
the NN stopwords O
importance JJ importance O
of NN stopwords O
active DT active_agent O
measures NN measure O
to NN stopwords O
improve JJ better O
the NN stopwords O
recovery NN recovery O
process NN procedure O

OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Number CAPITAL NNP number O
and DT stopwords O
rate VB rate O
of NN stopwords O
patients VB patient O
making NN devising O
a DT stopwords angstrom O
first NN first O
return NN tax_return O
with NN stopwords O
sore NN sore D
throat NN throat D
, , O
pharyngitis NN sore_throat D
, , O
or NN stopwords Oregon O
tonsillitis NN tonsillitis D

3rd CD third O
Congress CAPITAL NNP Congress O
of NN stopwords O
the NN stopwords O
French CAPITAL NNP French O
Society CAPITAL NNP society O
of NN stopwords O
Blood CAPITAL NNP blood T
Transfusion CAPITAL NNP transfusion T

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
adjuvant DT adjuvant T
psychological NN psychological T
therapy NN therapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
testicular NN testicular D
cancer VB cancer D
: : O
randomised VB randomize O
controlled NNS control O
trial NN test O

Who CAPITAL NNP World_Health_Organization O
should NN stopwords O
care VB care O
? . O

Hyaluronidase CAPITAL NNP hyaluronidase O
activity DT activity O
of NN stopwords O
macaque VB macaque O
sperm NN sperm O
assessed DT measure O
by NN stopwords by O
an DT stopwords Associate_in_Nursing O
in NN stopwords inch O
vitro NN O
cumulus NNS cumulus O
penetration NN penetration O
assay DT assay O

CONCLUSIONS CAPITAL NNP decision O
: : O
There CAPITAL NNP there O
is NN stopwords be O
a DT stopwords angstrom O
higher NN higher O
incidence NN incidence O
of NN stopwords O
preeclampsia NN preeclampsia D
in NN stopwords inch O
women NN woman O
conceiving NNS gestate O
by NN stopwords by O
intrauterine NN intrauterine T
insemination NN insemination T
with NN stopwords O
washed VB wash O
donor NN donor O
sperm NN sperm O
compared NNS compare O
with NN stopwords O
intrauterine NN intrauterine T
insemination NN insemination T
with NN stopwords O
washed VB wash O
partner NN spouse O
sperm NN sperm O
. . O

The CAPITAL NNP O
Italian CAPITAL PRP Italian O
Association CAPITAL DT association O
for NN stopwords O
the NN stopwords O
Study CAPITAL NNP survey O
of NN stopwords O
Glaucoma CAPITAL NNP glaucoma D

Ethics CAPITAL NNP ethical_motive O
of NN stopwords O
HIV CAPITAL NNP HIV O
trials NN test O

Mortality CAPITAL NNP mortality O
and DT stopwords O
length NN length O
of NN stopwords O
stay NN stay O
in NN stopwords inch O
teaching NN teaching O
vs NN volt O
nonteaching JJ O
hospitals NN hospital O

Surgical CAPITAL NNP surgical T
treatment NN treatment T
of NN stopwords O
urinary JJ urinary D
stones NN rock D

Informed CAPITAL PRP inform O
consent NNS consent O
: : O
edging NN edging O
forwards NN forward O
( ( O
and DT stopwords O
backwards VB back O
) ) O

Women CAPITAL NNP woman O
's POS O
views NN position O
of NN stopwords O
different NN different O
models NN model O
of NN stopwords O
antenatal DT prenatal O
care VB care O
in NN stopwords inch O
Victoria CAPITAL NNP Victoria O
, , O
Australia CAPITAL DT Australia O

The CAPITAL NNP O
`` `` O
corrected NNS correct O
'' POS O
cesarean NNS cesarean_delivery O
rate VB rate O
( ( O
maternal-fetal VB O
medicine NN medicine O
and DT stopwords O
transported NN transport O
patients VB patient O
excluded NN exclude O
) ) O
was VB stopwords Washington O
12.4 CD O
% NN O
( ( O
273 DIGITS CD O
of NN stopwords O
2194 DIGITS CD O
) ) O
, , O
and DT stopwords O
the NN stopwords O
`` `` O
corrected NNS correct O
'' POS O
primary NN primary O
rate VB rate O
was VB stopwords Washington O
9.6 CD O
% NN O
( ( O
190 DIGITS CD one_hundred_ninety O
of NN stopwords O
1975 DIGITS CD O
) ) O

additional DT extra O
clinical JJ clinical O
investigation NN probe O
of NN stopwords O
oxaliplatin NN T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
other JJ stopwords other O
cancers VB cancer D
is NN stopwords be O
warranted NN justify O
given NN given O
the NN stopwords O
promising NN promise O
results NN consequence O
achieved DT achieve O
in NN stopwords inch O
early VB early O
trials NN test O
, , O
most NN stopwords most O
notably JJ notably O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
platinum-pretreated NN O
ovarian NN ovarian O
cancer VB cancer O

Online CAPITAL NNP on-line O

SUBJECTS CAPITAL NNP subject O
: : O
890 DIGITS CD O
women NN woman O
aged DT aged O
18-35 CD O
years NN old_age O
attending DT attention O
general NN general O
practice NN practice O
for NN stopwords O
a DT stopwords angstrom O
cervical NNS cervical O
smear JJ smear O
or NN stopwords Oregon O
a DT stopwords angstrom O
`` `` O
young NN young O
well NN well O
woman NN woman O
'' POS O
check NNS check O
between NN stopwords between O
October CAPITAL NNP October O
1994 DIGITS CD O
and DT stopwords O
January CAPITAL NNP January O
1996 DIGITS CD O

The CAPITAL NNP O
American CAPITAL DT American O
Urological CAPITAL NNP O
Association CAPITAL DT association O

Connecting CAPITAL NNP connect O
peptide NN peptide O
, , O
correcting NNS correct O
peptide NN peptide O
? . O

Treatment CAPITAL NNP treatment O
of NN stopwords O
postmenopausal NN postmenopausal D
osteoporosis JJ osteoporosis D

< NN O
TO_SEE CAPITAL NNP O
> NN O
Safety CAPITAL VB safety O
trial NN test O
with NN stopwords O
the NN stopwords O
5HT1B/1D CD T
agonist DT protagonist T
avitriptan DT T
( ( O
BMS-180048 CAPITAL NNP O
) ) O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
migraine NN migraine D
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
experienced NN experience O
pressure NN pressure D
, , D
tightness NN stringency D
, , D
and/or DT D
pain IN pain D
in NN stopwords inch O
the NN stopwords O
chest NNS thorax O
, , O
neck JJ neck O
, , O
and/or DT O
throat NN throat O
following JJ following O
sumatriptan NN T

is NN stopwords be O
prolonged NN prolong O
survival NN survival O
possible NN possible O
for NN stopwords O
patients VB patient O
with NN stopwords O
supraclavicular NN D
node JJ node D
metastases NN metastasis D
in NN stopwords inch D
nsclc JJ D
treated NN treat O
with NN stopwords O
chemoradiotherapy NNS T
? . O
ijrobp NN O
1999 DIGITS CD O
; : O
44 DIGITS CD forty-four O
( ( O
4 DIGITS CD four O
) ) O
: : O
847-853 CD O

BCL1B1 CAPITAL NNP O
mature VB mature O
B CAPITAL NN bacillus O
cells NNS cell O
have VB stopwords rich_person O
the NN stopwords O
highest NN high O
level NN degree O
of NN stopwords O
recombinase NN O
activity DT activity O
with NN stopwords O
25 DIGITS CD twenty-five O
% NN O
or NN stopwords Oregon O
more NN stopwords More O
of NN stopwords O
proviral NN O
integrants NN O
accumulating DT roll_up O
S CAPITAL NN second O
mu/S NN O
gamma VB gamma O
2b CD O
substrate NN substrate O
recombinations NN recombination O
within NN inside O
10-14 CD O
cell NNS cell O
generations NN coevals O

Patient-centered CAPITAL VB O
ethics NN ethical_motive O
reclaiming NN reclaim O
center NNS center O
stage NN phase O

Current CAPITAL NNP current O
knowledge NN cognition O
of NN stopwords O
cyclin NNS O
D1 CAPITAL NNP O
overexpression JJ O
in NN stopwords inch O
malignant VB malignant D
lymphomas NN lymphoma D
, , O
with NN stopwords O
emphasis NN emphasis O
on NN stopwords on O
its NN stopwords information_technology O
clinicopathologic JJ O
significance NN significance O
, , O
is NN stopwords be O
reviewed NN review O

RESULTS CAPITAL NNP consequence O
: : O
Mean CAPITAL NNP mean O
follow JJ follow O
up JJ stopwords up O
time NN time O
was VB stopwords Washington O
similar NN similar O
( ( O
antibiotic DT antibiotic O
group NN group O
1.07 CD O
years NN old_age O
, , O
other JJ stopwords other O
two NN two O
groups NN group O
1.03 CD O
years NN old_age O
) ) O

Stereotactic CAPITAL NNP T
radiosurgery VB T
for NN stopwords O
acoustic DT acoustic D
neuroma JJ neuroma D
: : O
a DT stopwords angstrom O
Canadian CAPITAL VB Canadian O
perspective NN position O

Long-term CAPITAL NNP long-run O
results NN consequence O
also DT besides O
reveal NN uncover O
further NN stopwords foster O
improvement JJ improvement O
in NN stopwords inch O
patients VB patient O
who NN stopwords World_Health_Organization O
had VB stopwords have O
no NNS stopwords no O
open JJ open O
set NN set O
speech NN address O
understanding JJ understanding O

Immunotherapy CAPITAL PRP immunotherapy T
of NN stopwords O
tumors NN tumor D
with NN stopwords O
autologous DT autologous T
tumor-derived NN T
heat NN heat T
shock NN daze T
protein NN protein T
preparations NN preparation T

Intramedullary CAPITAL PRP O
metastases NN metastasis O
of NN stopwords O
bronchogenic NN D
carcinoma VB carcinoma D

Effects CAPITAL NNP effects O
of NN stopwords O
tryptophan NN tryptophan O
mustard NN mustard O
on NN stopwords on O
incorporation NN incorporation O
of NN stopwords O
amino DT amino O
acids DT acid O
into NN stopwords O
proteins NN protein O
in NN stopwords inch O
tumor-bearing NN O
rats VB rat O

Randomised CAPITAL VB randomize O
trial NN test O
of NN stopwords O
irinotecan JJ T
versus NN O
fluorouracil JJ fluorouracil T
by NN stopwords by O
continuous NNS continuous O
infusion NN infusion O
after DT stopwords after O
fluorouracil JJ fluorouracil O
failure VB failure O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
colorectal NNS colorectal D
cancer VB cancer D

Update CAPITAL NNP update O
: : O
influenza NN influenza D
activity DT activity O
-- : O
worldwide NN worldwide O
, , O
March-August CAPITAL NNP O
1997 DIGITS CD O

No CAPITAL NNP no O
participant NN participant O
was VB stopwords Washington O
from JJ stopwords O
a DT stopwords angstrom O
family VB family O
in NN stopwords inch O
which NN stopwords O
genetic NN familial O
markers NN marker O
showed NN show O
linkage NN linkage O
to NN stopwords O
the NN stopwords O
BRCA1 CAPITAL NNP O
locus NN venue O

Therefore CAPITAL NNP therefore O
the NN stopwords O
sensitivity NN sensitivity O
of NN stopwords O
neonatal JJ neonatal O
BAEP CAPITAL IN O
testing NN testing O
for NN stopwords O
predicting NN predict O
subsequent NN subsequent O
hearing NN hearing D
loss NN loss D
was VB stopwords Washington O
only JJ stopwords lone O
42 DIGITS CD forty-two O
% NN O

The CAPITAL NNP O
role NN function O
of NN stopwords O
fibric NN T
acid DT acid T
derivatives NN derived_function T
in NN stopwords inch O
the NN stopwords O
secondary NN secondary O
prevention NN prevention O
of NN stopwords O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D

In CAPITAL PRP inch O
the NN stopwords O
absence DT absence O
of NN stopwords O
structural NN structural O
or NN stopwords Oregon O
karyotypic VB O
abnormalities DT abnormality O
, , O
spontaneous NN spontaneous O
resolution NN resolution O
of NN stopwords O
the NN stopwords O
effusion NN effusion O
portends NN bode O
for NN stopwords O
a DT stopwords angstrom O
successful NN successful O
pregnancy NN pregnancy O
outcome JJ result O

In CAPITAL PRP inch O
the NN stopwords O
second NN second O
group NN group O
, , O
a DT stopwords angstrom O
rebound NN recoil O
in NN stopwords inch O
virus NN virus O
levels NN degree O
in NN stopwords inch O
plasma NN plasma O
followed JJ follow O
the NN stopwords O
initial JJ initial O
sharp NN sharp O
decline NN decline O
observed NN detect O
at DT stopwords astatine O
the NN stopwords O
start NN start O
of NN stopwords O
therapy NN therapy O

A CAPITAL DT angstrom O
rapid VB rapid O
molecular NN molecular O
method NN method O
( ( O
polymerase NN polymerase O
chain NNS chain O
reaction NN chemical_reaction O
with NN stopwords O
sequence-specific NN O
primers NN primer O
) ) O
to NN stopwords O
genotype NN genotype O
for NN stopwords O
ABO CAPITAL DT Aborigine O
blood NN blood O
group NN group O
and DT stopwords O
secretor NN gland O
status NN status O
and DT stopwords O
its NN stopwords information_technology O
potential NN potential O
for NN stopwords O
organ JJ organ T
transplants NN graft T

Meta-analyses CAPITAL NNP O
and DT stopwords O
large NN large O
randomized VB randomize O
, , O
controlled NNS control O
trials NN test O

Catania CAPITAL VB O
, , O
Italy CAPITAL PRP Italy O
, , O
May CAPITAL NNP May O
27-31 CD O
, , O
1998 DIGITS CD O

background VB background O
: : O
prophylactic NN preventive T
cranial NNS cranial T
irradiation NN irradiation T
halves VB one-half O
the NN stopwords O
rate VB rate O
of NN stopwords O
brain NN brain O
metastases NN metastasis O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D

Metronidazole CAPITAL NNP metronidazole T
( ( O
Flagyl CAPITAL NNP metronidazole O
) ) O

Lymphatics CAPITAL NNP O
of NN stopwords O
the NN stopwords O
mouth NN mouth O
and DT stopwords O
neck JJ neck O

A CAPITAL DT angstrom O
commercially NNS commercially O
available DT available O
health NN health O
food JJ food O
product NN merchandise O
of NN stopwords O
cold-pressed NNS O
hemp NN hemp O
seed NN seed O
oil NN oil O
ingested NN consume O
by NN stopwords by O
one JJ one O
volunteer NN volunteer O
twice NN twice O
a DT stopwords angstrom O
day VB day O
for NN stopwords O
4 DIGITS CD four O
1/2 CD O
days VB days O
( ( O
135 DIGITS CD one_hundred_thirty-five O
mL NN milliliter O
total NN sum O
) ) O

Atrial CAPITAL DT atrial D
fibrillation NN fibrillation D
begets NN beget O
trouble NN trouble O

New CAPITAL NNP new O
technique NN technique O
for NN stopwords O
mesh NN mesh T
repair NN repair T
of NN stopwords O
paracolostomy NN D
hernias NN hernia D

Recombinant CAPITAL NNP recombinant O
and DT stopwords O
natural RB natural O
forms NN form O
of NN stopwords O
interferon NN interferon T
alpha DT alpha T
have VB stopwords rich_person O
been NN stopwords be O
shown NN show O
to NN stopwords O
bring NN bring O
about DT stopwords about O
tumor NN tumor O
regressions NN arrested_development O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
low-grade NN low-grade D
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D

Abstracts CAPITAL DT abstraction O

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
crude NNS petroleum O
incidence NN incidence O
rate VB rate O
was VB stopwords Washington O
estimated NN estimate O
to NN stopwords O
be NN stopwords beryllium O
30.7 CD O
per NN O
100000 DIGITS CD hundred_thousand O
( ( O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
27.1-34.4 CD O
) ) O
and DT stopwords O
the NN stopwords O
standardised NN standardize O
rate VB rate O
was VB stopwords Washington O
68 DIGITS CD sixty-eight O
per NN O
100000 DIGITS CD hundred_thousand O

Quality CAPITAL NNP quality O
framework NN model O
for NN stopwords O
force NN force O
plate NN home_plate O
testing NN testing O

Some CAPITAL NNP some O
functional JJ functional O
and DT stopwords O
morphological NN morphologic O
alterations DT change O
occurring JJ happen O
during NN stopwords O
and DT stopwords O
after DT stopwords after O
the NN stopwords O
adaptation DT adaptation O
of NN stopwords O
BHK CAPITAL NNP O
21 DIGITS CD twenty-one O
clone NNS ringer O
13 DIGITS CD thirteen O
cells NNS cell O
to NN stopwords O
suspension NN suspension O
culture NNS culture O

All CAPITAL DT all O
together NN together O
, , O
27 DIGITS CD twenty-seven O
fetuses JJ fetus O
had VB stopwords have O
this NN stopwords O
disorder NN disorder O
, , O
representing NN represent O
28.7 CD O
% NN O
( ( O
27 DIGITS CD twenty-seven O
of NN stopwords O
94 DIGITS CD ninety-four O
) ) O
of NN stopwords O
all DT stopwords all O
cytogenetic NNS cytogenetic D
aberrations DT aberrance D
detected NN detect O
at DT stopwords astatine O
our NN stopwords O
center NNS center O
over JJ stopwords over O
the NN stopwords O
same VB stopwords Lapp O
period NN time_period O

Lignocaine CAPITAL NNP T
or NN stopwords Oregon O
bupivacaine NN T
for NN stopwords O
digital NN digital D
ring NN ring D
block NN block D

Comparison CAPITAL NNP comparison O
of NN stopwords O
two NN two O
methods NN method O
in NN stopwords inch O
657 DIGITS CD O
newborns JJ neonate O

OBJECTIVE CAPITAL NNP aim O
: : O
This CAPITAL NNP O
study NN survey O
was VB stopwords Washington O
designed NN plan O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
safety VB safety O
and DT stopwords O
estimate NN estimate O
the NN stopwords O
efficacy NN efficacy O
of NN stopwords O
oral NN oral T
budesonide NN T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
primary NN primary D
sclerosing JJ D
cholangitis NNS cholangitis D
( ( D
PSC CAPITAL NNP D
) ) D

METHODS CAPITAL NNP method O
: : O
BAEP CAPITAL IN O
studies NN survey O
were NN stopwords be O
performed NN perform O
before NN stopwords earlier O
discharge NN discharge O
in NN stopwords inch O
infants NN baby O
treated NN treat O
with NN stopwords O
extracorporeal NN T
membrane NN membrane T
oxygenation JJ oxygenation T
( ( T
ECMO CAPITAL NNP T
) ) T
, , O
and DT stopwords O
two NN two O
specific NN particular O
abnormalities DT abnormality O
were NN stopwords be O
analyzed DT analyze O
: : O
elevated NN elevated_railway O
threshold NN threshold O
and DT stopwords O
delayed NN delay O
central NNS central O
auditory DT auditory O
conduction NNS conduction O

The CAPITAL NNP O
AACC CAPITAL DT O
Lectureship CAPITAL NNP lectureship O
Award CAPITAL DT award O
Address CAPITAL DT address O

Photolithographic CAPITAL NNP O
patterning VB model O
was VB stopwords Washington O
performed NN perform O
with NN stopwords O
a DT stopwords angstrom O
positive NN positive O
photoresist NN O
with NN stopwords O
modified NN modify O
bake NN bake O
temperatures NN temperature O
and DT stopwords O
times NN times O
, , O
selective NN selective O
UV CAPITAL NNP ultraviolet O
exposure NN exposure O
with NN stopwords O
a DT stopwords angstrom O
contact NNS contact O
mask VB mask O
, , O
and DT stopwords O
aqueous DT aqueous O
alkaline DT alkaline O
solubilization NN O
of NN stopwords O
exposed NN expose O
resist NN defy O

In CAPITAL PRP inch O
the NN stopwords O
group NN group O
C CAPITAL SYM degree_centigrade O
the NN stopwords O
presence NN presence O
of NN stopwords O
non-parasitic JJ O
enteropathogens NN O
was VB stopwords Washington O
also DT besides O
investigated NN investigate O

We CAPITAL NNP O
describe NN describe O
the NN stopwords O
isolation NN isolation O
and DT stopwords O
characterization NNS word_picture O
of NN stopwords O
two NN two O
new JJ new O
classes NNS class O
of NN stopwords O
mutants NN mutant O
of NN stopwords O
Arabidopsis CAPITAL DT Arabidopsis O
, , O
termed NN term O
uvr2 JJ O
and DT stopwords O
uvr3 JJ O
, , O
that NN stopwords O
are DT stopwords are O
defective NN defective O
in NN stopwords inch O
the NN stopwords O
photoreactivation NN O
of NN stopwords O
CPDs CAPITAL NNP O
and DT stopwords O
6-4 CD O
products NN merchandise O
, , O
respectively NN respectively O

Changes CAPITAL NNP change O
in NN stopwords inch O
the NN stopwords O
mechanism NN mechanism O
of NN stopwords O
renal NN nephritic O
acidification DT acidification O
in NN stopwords inch O
congestive NNS congestive D
heart NN heart D
failure VB failure D
: : O
effects NN effects O
of NN stopwords O
diuretic NN diuretic_drug T
treatment NN treatment T
on NN stopwords on O
the NN stopwords O
acid-base DT O
equilibrium NN equilibrium O

The CAPITAL NNP O
study NN survey O
involved NN involve O
117 DIGITS CD O
infants NN baby O
( ( O
mean NN mean O
age DT age O
2.6 CD O
months NN calendar_month O
) ) O
, , O
who NN stopwords World_Health_Organization O
needed JJ necessitate O
hospital NN hospital T
treatment NN treatment T
because NN stopwords O
of NN stopwords O
RSV CAPITAL NNP D
bronchiolitis NN bronchiolitis D

Thoracoscopic CAPITAL NNP T
surgery NN surgery T
for NN stopwords O
spontaneous NN spontaneous D
pneumothorax NN pneumothorax D

A CAPITAL DT angstrom O
new JJ new O
informative NN enlightening O
Alw CAPITAL DT O
26 DIGITS CD twenty-six O
I CAPITAL PRP iodine O
polymorphism NN polymorphism O
in NN stopwords inch O
exon NN exon O
10 DIGITS CD ten O
of NN stopwords O
the NN stopwords O
human NN homo O
low NN low O
density NN density O
lipoprotein NN lipoprotein O
receptor NN receptor O
gene NN gene O

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
ephedrine NN ephedrine O
on NN stopwords on O
the NN stopwords O
onset JJ onset O
time NN time O
of NN stopwords O
rocuronium NN O

Leukaemia CAPITAL NNP leukemia D
and DT stopwords O
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D
in NN stopwords inch O
children JJ child O
and DT stopwords O
young NN young O
adults DT adult O
: : O
are DT stopwords are O
prenatal NN prenatal O
and DT stopwords O
neonatal JJ neonatal O
factors VB factor O
important JJ important O
determinants NN determinant O
of NN stopwords O
disease NN disease O
? . O

Leprosy CAPITAL NNP leprosy D
beyond NN beyond O
the NN stopwords O
year NN year O
2000 DIGITS CD O

Analysis CAPITAL DT analysis O
of NN stopwords O
these NN stopwords O
27 DIGITS CD twenty-seven O
families VB family O
resulted NN result O
in NN stopwords inch O
MLSs CAPITAL NNP Master_of_Library_Science O
of NN stopwords O
1.0 CD O
, , O
2.4 CD O
, , O
3.7 LS O
, , O
and DT stopwords O
3.3 LS O
and DT stopwords O
a DT stopwords angstrom O
peak NN extremum O
multipoint NN O
MLS CAPITAL NNP Master_of_Library_Science O
of NN stopwords O
3.9 LS O

Furthermore CAPITAL NNP furthermore O
, , O
when NN stopwords O
all DT stopwords all O
deliveries NN delivery O
were NN stopwords be O
analyzed DT analyze O
, , O
regardless NN careless O
of NN stopwords O
risk NN hazard O
status NN status O
but NN stopwords merely O
limited NN express O
to NN stopwords O
gestational NN gestational O
age DT age O
> NN O
or NN stopwords Oregon O
= NN O
36 DIGITS CD thirty-six O
weeks NN week O
, , O
the NN stopwords O
rates VB rates O
did NN stopwords make O
not JJ stopwords not O
change NNS change O
( ( O
12.6 CD O
% NN O
, , O
280 DIGITS CD O
of NN stopwords O
2214 DIGITS CD O
; : O
primary NN primary O
9.2 CD O
% NN O
, , O
183 DIGITS CD O
of NN stopwords O
1994 DIGITS CD O
) ) O

Corpora CAPITAL NNP principal D
lutea NN D
in NN stopwords inch O
proven NN prove O
mules NN mule O

There CAPITAL NNP there O
were NN stopwords be O
no NNS stopwords no O
significant NN significant O
changes NNS change O
in NN stopwords inch O
AED CAPITAL DT O
levels NN degree O
or NN stopwords Oregon O
electroencephalographic NN electroencephalographic O
findings NN findings O

PARTICIPANTS CAPITAL VB participant O
: : O
Two CAPITAL NNP two O
hundred NN hundred O
and DT stopwords O
seventy-three NN seventy-three O
'first-ever POS O
' '' O
strokes NN stroke D
prospectively NN O
identified NN identify O
over JJ stopwords over O
a DT stopwords angstrom O
12-month CD O
period NN time_period O

Dumping CAPITAL NNP dumping D
syndrome NN syndrome D
following JJ following O
pyloroplasty NN T
. . O

Antiplatelet CAPITAL DT T
therapy NN therapy T
in NN stopwords inch O
acute DT acute_accent D
cerebral NNS cerebral D
ischemia NN ischemia D

Two CAPITAL NNP two O
patients VB patient O
with NN stopwords O
metastatic NN metastatic D
dysgerminoma NN D
of NN stopwords D
the NN stopwords D
ovary NN ovary D
were NN stopwords be O
treated NN treat O
with NN stopwords O
a DT stopwords angstrom T
combination NNS combination T
of NN stopwords T
etoposide NN T
, , T
bleomycin NN T
, , T
and DT stopwords T
cisplatin NN T
at DT stopwords astatine O
The CAPITAL NNP O
University CAPITAL NNP university O
of NN stopwords O
Texas CAPITAL NNP Texas O
M.D CAPITAL NNP O

The CAPITAL NNP O
primary NN primary O
end NN end O
point NN point O
was VB stopwords Washington O
death NN death O
from JJ stopwords O
any DT stopwords any O
cause VB cause O
at DT stopwords astatine O
30 DIGITS CD thirty O
days VB days O

Cholesterol-lowering CAPITAL NNP T
therapy NN therapy T

Splenectomy CAPITAL NNP splenectomy T
presumably NN presumably O
alleviates DT relieve O
the NN stopwords O
pancytopenic VB O
effect NN consequence O
of NN stopwords O
hypersplenism NN hypersplenism D
by NN stopwords by O
removing NN remove O
the NN stopwords O
preferred NN prefer O
site NN site O
of NN stopwords O
leukemic NN O
cell NNS cell O
proliferation NN proliferation O

The CAPITAL NNP O
average DT average O
age DT age O
at DT stopwords astatine O
onset JJ onset O
was VB stopwords Washington O
27 DIGITS CD twenty-seven O
years NN old_age O

After CAPITAL DT after O
adjusting DT adjust O
for NN stopwords O
stage NN phase O
, , O
more NN stopwords More O
aggressive DT aggressive O
tumor NN tumor O
characteristics NNS feature O
do NN stopwords bash O
not JJ stopwords not O
explain NN explain O
the NN stopwords O
adverse DT adverse O
survival NN survival O
differential NN derived_function O
in NN stopwords inch O
blacks NN black O

The CAPITAL NNP O
screening NN screening O
muddle NN clutter O

Furthermore CAPITAL NNP furthermore O
, , O
the NN stopwords O
frequency JJ frequency O
of NN stopwords O
microsatellite NN O
instability NN instability O
( ( O
MSI CAPITAL NNP O
) ) O
in NN stopwords inch O
tumours NN tumor O
from JJ stopwords O
Msh2-/-p53-/- CAPITAL NNP O
mice NN mouse O
is NN stopwords be O
not JJ stopwords not O
significantly NN significantly O
different NN different O
than NN stopwords O
in NN stopwords inch O
Msh2-/- CAPITAL NNP O
mice NN mouse O

A CAPITAL DT angstrom O
diffuse NN diffuse O
macular VB D
erythroderma NN erythroderma D
and DT stopwords O
subsequent NN subsequent O
desquamation NN desquamation D
after DT stopwords after O
1 DIGITS CD one O
to NN stopwords O
2 DIGITS CD two O
weeks NN week O
are DT stopwords are O
two NN two O
of NN stopwords O
the NN stopwords O
five NN five O
major VB major O
diagnostic NN diagnostic O
criteria JJ standard O
of NN stopwords O
toxic NN toxic D
shock NN daze D
syndrome NN syndrome D
( ( D
TSS CAPITAL NNP toxic_shock D
) ) D

Without CAPITAL NNP O
the NN stopwords O
evidence NN evidence O
implicating JJ implicate O
a DT stopwords angstrom O
TSS CAPITAL NNP toxic_shock D
toxin NN toxin O
1-producing CD O
strain NN strain O
of NN stopwords O
S. CAPITAL NNP O
aureus DT O
as DT stopwords arsenic O
the NN stopwords O
cause VB cause O
of NN stopwords O
her NN stopwords O
disease NN disease O
, , O
a DT stopwords angstrom O
diagnosis NN diagnosis O
of NN stopwords O
syndrome NN syndrome O
of NN stopwords O
hemorrhagic NN hemorrhagic D
shock NN daze D
and DT stopwords O
encephalopathy NN brain_disorder D
would NN O
have VB stopwords rich_person O
been NN stopwords be O
made VB make O

There CAPITAL NNP there O
was VB stopwords Washington O
a DT stopwords angstrom O
higher NN higher O
rate VB rate O
of NN stopwords O
recent NN Holocene O
cocaine NNS cocaine O
use JJ use O
among DT O
African-American CAPITAL DT African-American O
women NN woman O
( ( O
20.4 CD O
% NN O
) ) O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
non-African-Americans JJ O
( ( O
1.2 CD O
% NN O
, , O
p NN phosphorus O
= NN O
0.0001 LS O
) ) O

Bolus CAPITAL NNP bolus T
thrombolytic NN thrombolytic T
infusions NN infusion T
during NN stopwords O
CPR CAPITAL NNP cardiopulmonary_resuscitation O
for NN stopwords O
patients VB patient O
with NN stopwords O
refractory NN furnace_lining D
arrest DT apprehension D
rhythms NN rhythm D
: : O
outcome JJ result O
of NN stopwords O
a DT stopwords angstrom O
case VB case O
series NN series O

Gastrointestinal CAPITAL VB gastrointestinal O
absorption DT absorption O
of NN stopwords O
metals NN metallic_element O

SETTING CAPITAL NNP setting O
: : O
Clinic CAPITAL NNP clinic O
populations NN population O
in NN stopwords inch O
the NN stopwords O
continental NNS Continental O
United CAPITAL NNP unite O
States CAPITAL NNP state O

The CAPITAL NNP O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
investigate NN investigate O
the NN stopwords O
autonomic DT autonomic O
function JJ function O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
cerebral NNS cerebral D
palsy VB paralysis D
using JJ exploitation O
two NN two O
noninvasive JJ noninvasive O
tests NN trial O
: : O
sympathetic NN sympathetic O
skin JJ skin O
response NN response O
( ( O
SSR CAPITAL NNP O
) ) O
and DT stopwords O
R-R CAPITAL NNP O
interval NN time_interval O
variation NN variation O
( ( O
RRIV CAPITAL NNP O
) ) O

Breastfed CAPITAL NNP O
infants NN baby O
also DT besides O
showed NN show O
greater NN greater O
catch-up VB O
growth NN growth O
in NN stopwords inch O
head NN head O
circumference NN circumference O
( ( O
SD CAPITAL NNP South_Dakota O
score JJ mark O
( ( O
SDS CAPITAL NNP South_Dakota O
) ) O
0.53 LS O
higher NN higher O
at DT stopwords astatine O
3 DIGITS CD three O
months NN calendar_month O
) ) O
, , O
and DT stopwords O
greater NN greater O
body NN body O
length NN length O
gain NN addition O
( ( O
SDS CAPITAL NNP South_Dakota O
0.68 LS O
higher NN higher O
at DT stopwords astatine O
6 DIGITS CD six O
months NN calendar_month O
) ) O

Current CAPITAL NNP current O
status NN status O
of NN stopwords O
mitochondrial NN D
diseases NN disease D

CONCLUSIONS CAPITAL NNP decision O
: : O
These CAPITAL NNP O
cases VB case O
arouse DT arouse O
concern NNS concern O
that NN stopwords O
fenfluramine-phentermine JJ T
therapy NN therapy T
may VB May O
be NN stopwords beryllium O
associated DT associate O
with NN stopwords O
valvular NN valvular D
heart NN heart D
disease NN disease D

The CAPITAL NNP O
lesions NN lesion O
in NN stopwords inch O
bovine NN bovine O
udders JJ udder O
shedding NN shedding O
nonhemolytic JJ O
coagulase-negative NNS O
staphylococci NN staphylococcus O

Cellular CAPITAL NNP cellular O
and DT stopwords O
in NN stopwords inch O
vitro NN O
transport NN conveyance O
of NN stopwords O
glutathione NN O
conjugates NNS conjugate_solution O
by NN stopwords by O
MRP CAPITAL NNP O

In CAPITAL PRP inch O
this NN stopwords O
study NN survey O
at DT stopwords astatine O
Massachusetts CAPITAL NNP Massachusetts O
General CAPITAL NNP general O
Hospital CAPITAL NNP hospital O
( ( O
Boston CAPITAL NNP Boston O
, , O
MA CAPITAL NNP ma O
, , O
USA CAPITAL NNP United_States O
) ) O
of NN stopwords O
416 DIGITS CD O
cases VB case O
and DT stopwords O
446 DIGITS CD O
controls NNS control O
( ( O
mostly NN largely O
White CAPITAL NNP White O
) ) O
we NN stopwords O
evaluated NN measure O
the NN stopwords O
association DT association O
between NN stopwords between O
the NN stopwords O
CYP1A1 CAPITAL NNP O
MspI CAPITAL NNP O
and DT stopwords O
GSTM1 CAPITAL NNP O
polymorphisms NN polymorphism O
and DT stopwords O
lung NN lung D
cancer VB cancer D
risk NN hazard O
, , O
and DT stopwords O
their NN stopwords O
interaction NN interaction O
with NN stopwords O
cigarette NN cigarette O
smoke JJ smoke O

An CAPITAL DT Associate_in_Nursing O
experimental NN experimental O
application DT application O
of NN stopwords O
gene NN gene T
therapy NN therapy T
for NN stopwords O
human NN homo D
retinoblastoma NN retinoblastoma D

Current CAPITAL NNP current O
studies NN survey O
using JJ exploitation O
interferon NN interferon T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
low-grade NN low-grade D
non-Hodgkin JJ D
's POS D
lymphomas NN lymphoma D
are DT stopwords are O
evaluating NN measure O
lower NN lower_berth O
, , O
and DT stopwords O
perhaps NN possibly O
better NN better O
tolerated NN digest O
doses NN dose O
of NN stopwords O
interferon NN interferon T

Scientists CAPITAL NNP scientist O
revel NN revel O
in NN stopwords inch O
new JJ new O
research NN research O
tool NN tool O
: : O
an DT stopwords Associate_in_Nursing O
online JJ on-line O
index NN index O
of NN stopwords O
cancer VB cancer O
genes NN gene O

Regional CAPITAL NNP regional O
follow-up JJ follow-up O
included NN include O
analysis DT analysis O
of NN stopwords O
additional DT extra O
markers NN marker O
and DT stopwords O
a DT stopwords angstrom O
second NN second O
data VB data O
set NN set O

At CAPITAL DT astatine O
least NN least O
there NN stopwords there O
should NN stopwords O
be NN stopwords beryllium O
comparability NNS comparison O
, , O
i.e NN O
. . O
, , O
commutability NNS replaceability O
or NN stopwords Oregon O
feasibility NN feasibility O
of NN stopwords O
providing NN supply O
comparable NNS comparable O
results NN consequence O
from JJ stopwords O
different NN different O
assays DT assay O
in NN stopwords inch O
different NN different O
laboratories NN lab O

( ( O
Part CAPITAL VB part O
1 DIGITS CD one O
: : O
facial VB facial O
morphogenesis NN morphogenesis O
) ) O

CONCLUSION CAPITAL NNP decision O
: : O
UFT CAPITAL NNP T
is NN stopwords be O
a DT stopwords angstrom O
fluoropyrimidine JJ T
active DT active_agent O
in NN stopwords inch O
colorectal NNS colorectal D
cancer VB cancer D

The CAPITAL NNP O
influence NN influence O
of NN stopwords O
patients VB patient O
' '' O
hopes NN hope O
of NN stopwords O
receiving NN receive O
a DT stopwords angstrom O
prescription NN prescription O
on NN stopwords on O
doctors NN doctor O
' '' O
perceptions NN percept O
and DT stopwords O
the NN stopwords O
decision NN decision O
to NN stopwords O
prescribe NN order O
: : O
a DT stopwords angstrom O
questionnaire NN questionnaire O
survey NN survey O

Fluoride CAPITAL NNP fluoride O
decreased NN decrease O
bone NN bone O
strength NN strength O
by NN stopwords by O
about DT stopwords about O
19 DIGITS CD nineteen O
% NN O
in NN stopwords inch O
the NN stopwords O
L5 CAPITAL $ O
vertebra NN vertebra O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.01 LS O
) ) O
and DT stopwords O
25 DIGITS CD twenty-five O
% NN O
in NN stopwords inch O
the NN stopwords O
femoral JJ femoral O
neck JJ neck O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0 DIGITS CD zero O

Reduction CAPITAL NNP decrease O
of NN stopwords O
vasoreactivity NN D
and DT stopwords O
thrombogenicity NN D
with NN stopwords O
laser-thermal NN T
angioplasty DT angioplasty T
: : O
comparison NNS comparison O
with NN stopwords O
balloon VB balloon T
angioplasty DT angioplasty T

Rapid CAPITAL VB rapid O
and DT stopwords O
ultrarapid JJ O
opioid IN T
detoxification NN detoxification T
techniques NN technique O

Epilepsy CAPITAL NNP epilepsy D
-- : O
a DT stopwords angstrom O
guide NN usher O
to NN stopwords O
medical NN checkup O
treatment NN treatment O

Nutritional CAPITAL NNP nutritional O
assessment DT appraisal O
, , O
substrate NN substrate O
immunonutrition JJ O
, , O
and DT stopwords O
disease NN disease O
specific NN particular O
issues NN issue O
are DT stopwords are O
presented NN show O

Blood CAPITAL NNP blood O
samples VB sample O
were NN stopwords be O
taken VB take O
at DT stopwords astatine O
the NN stopwords O
time NN time O
of NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
preeclampsia NN preeclampsia D
and DT stopwords O
at DT stopwords astatine O
comparable NNS comparable O
gestational NN gestational O
ages DT age O
for NN stopwords O
matched VB match O
normal RB convention O
controls NNS control O

for NN stopwords O
intrathoracic NN D
relapse NN backsliding D
and DT stopwords D
severe NN severe D
obstruction NN obstruction D
of NN stopwords D
main VB main D
bronchus NN bronchus D
and/or DT D
superior NN superior D
caval VB D
vein NN vein D
, , O
radiotherapy VB radiotherapy T
is NN stopwords be O
a DT stopwords angstrom O
possibility NN possibility O
if NN stopwords O
not JJ stopwords not O
given NN given O
as DT stopwords arsenic O
part NN part O
of NN stopwords O
first-line NN O
treatment NN treatment O

ABC CAPITAL DT rudiment O
of NN stopwords O
mental NN mental O
health NN health O

Leaders CAPITAL NNP leadership O
or NN stopwords Oregon O
lemmings NN lemming O
? . O

Sequential CAPITAL NNP consecutive O
estrogen-progestogen NN T
therapy NN therapy T
in NN stopwords inch O
gynecology NN gynecology O

DESIGN CAPITAL NNP design O
: : O
Retrospective CAPITAL NNP retrospective O
case VB case O
study NN survey O
in NN stopwords inch O
which NN stopwords O
clinical JJ clinical O
data VB data O
were NN stopwords be O
extracted NN extract O
from JJ stopwords O
medical NN checkup O
and DT stopwords O
pathological VB pathological O
records NN record O

Gamma-irradiation CAPITAL VB O
( ( O
25 DIGITS CD twenty-five O
kGy NN O
) ) O
is NN stopwords be O
suitable JJ suitable O
for NN stopwords O
the NN stopwords O
sterilization NN sterilization O
procedure NN procedure O

How CAPITAL NNP O
often JJ frequently O
does NN stopwords Department_of_Energy O
surgery NN surgery T
for NN stopwords O
peptic NN peptic D
ulceration JJ ulcer D
eradicate NN eliminate O
Helicobacter CAPITAL NNP O
pylori NN pylorus O
? . O
Systematic CAPITAL NNP systematic O
review NN reappraisal O
of NN stopwords O
36 DIGITS CD thirty-six O
studies NN survey O

The CAPITAL NNP O
translocation NN translocation O
breakpoint NN O
cluster NNS bunch O
region NN region O
is NN stopwords be O
flanked NN flank O
by NN stopwords by O
exons NN exon O
3 DIGITS CD three O
and DT stopwords O
6 DIGITS CD six O
and DT stopwords O
two NN two O
different NN different O
polyadenylation NN O
signals NN signal O
were NN stopwords be O
identified NN identify O

It CAPITAL PRP information_technology O
offers JJ offer O
potential NN potential O
as DT stopwords arsenic O
a DT stopwords angstrom O
non-invasive JJ O
screening NN screening O
tool NN tool O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
a DT stopwords angstrom O
conference NNS conference O

The CAPITAL NNP O
veracious NN veracious O
etiology NN etiology O
of NN stopwords O
ectopic NN ectopic D
pregnancy NN pregnancy D

The CAPITAL NNP O
origin IN beginning O
and DT stopwords O
glyceride NN glyceride O
distribution NN distribution O
of NN stopwords O
fatty VB fatso O
acids DT acid O
in NN stopwords inch O
rat VB rat O
adipose DT adipose O
tissue NN tissue O

Dominant CAPITAL NNP dominant O
negative JJ negative O
and DT stopwords O
cooperative NNS cooperative O
effects NN effects O
of NN stopwords O
mutant NN mutant O
forms NN form O
of NN stopwords O
prolactin NN prolactin O
receptor NN receptor O

Role CAPITAL NNP function O
of NN stopwords O
phosphatidylinositol NN O
3-kinase LS O
in NN stopwords inch O
degranulation NN O
induced NN induce O
by NN stopwords by O
IgE-dependent CAPITAL PRP O
and DT stopwords O
-independent : O
mechanisms NN mechanism O
in NN stopwords inch O
rat VB rat O
basophilic VB basophilic O
RBL-2H3 CAPITAL NN O
( ( O
ml NN milliliter O
) ) O
cells NNS cell O

Of CAPITAL NNP O
the NN stopwords O
5 DIGITS CD five O
children JJ child O
with NN stopwords O
seizures JJ seizure D
, , O
3 DIGITS CD three O
had VB stopwords have O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
attacks DT attack O
, , O
whereas NN O
the NN stopwords O
other JJ stopwords other O
2 DIGITS CD two O
showed NN show O
no NNS stopwords no O
change NNS change O
or NN stopwords Oregon O
a DT stopwords angstrom O
reduction NN decrease O

It CAPITAL PRP information_technology O
is NN stopwords be O
still JJ still O
unclear JJ ill-defined O
, , O
however NN however O
, , O
how NN stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
these NN stopwords O
substrates NN substrate O
is NN stopwords be O
regulated NN regulate O
during NN stopwords O
exercise NN exercise O

SCIM CAPITAL NNP O
-- : O
spinal JJ spinal_anesthesia O
cord NNS cord O
independence NN independence O
measure NN measure O
: : O
a DT stopwords angstrom O
new JJ new O
disability NN disability O
scale JJ scale O
for NN stopwords O
patients VB patient O
with NN stopwords O
spinal JJ spinal_anesthesia D
cord NNS cord D
lesions NN lesion D

Waiting CAPITAL IN wait O
for NN stopwords O
the NN stopwords O
definitive NN definitive O
trial NN test O
of NN stopwords O
hepatic NN liverwort T
arterial DT arterial T
chemotherapy NNS chemotherapy T
for NN stopwords O
colorectal NNS colorectal D
cancer VB cancer D

Support CAPITAL NNP support O
in NN stopwords inch O
first NN first O
stage NN phase O
of NN stopwords O
labor NN labor O

Presenilin CAPITAL NNP O
polymorphisms NN polymorphism O
in NN stopwords inch O
Alzheimer CAPITAL DT D
's POS D
disease NN disease D

Evaluation CAPITAL NNP evaluation O
and DT stopwords O
management VB management O
of NN stopwords O
traumatic NN traumatic D
lacerations NN laceration D

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
data VB data O
indicate NN bespeak O
that NN stopwords O
after DT stopwords after O
48 DIGITS CD forty-eight O
months NN calendar_month O
retropubic NN T
suspensions NN suspension T
and DT stopwords O
slings JJ sling T
appear DT look O
to NN stopwords O
be NN stopwords beryllium O
more NN stopwords More O
efficacious NN efficacious O
than NN stopwords O
transvaginal NN T
suspensions NN suspension T
, , O
and DT stopwords O
also DT besides O
more NN stopwords More O
efficacious NN efficacious O
than NN stopwords O
anterior DT front_tooth T
repairs NN repair T

In CAPITAL PRP inch O
three NN three O
of NN stopwords O
the NN stopwords O
patients VB patient O
, , O
this NN stopwords O
change NNS change O
was VB stopwords Washington O
seen NN see O
as DT stopwords arsenic O
early VB early O
as DT stopwords arsenic O
6 DIGITS CD six O
to NN stopwords O
10 DIGITS CD ten O
weeks NN week O
after DT stopwords after O
the NN stopwords O
start NN start O
of NN stopwords O
therapy NN therapy O

These CAPITAL NNP O
initial JJ initial O
observations NN observation O
are DT stopwords are O
an DT stopwords Associate_in_Nursing O
encouraging NN promote O
step NN measure O
toward NN O
the NN stopwords O
description NN description O
of NN stopwords O
non-HLA JJ O
genetic NN familial O
susceptibility NN susceptibility O
to NN stopwords O
MS CAPITAL NNP multiple_sclerosis O

New CAPITAL NNP new T
drug NN drug T
treatment NN treatment T
for NN stopwords O
Alzheimer CAPITAL DT D
's POS D
disease NN disease D
: : O
lessons NN lesson O
for NN stopwords O
healthcare NN healthcare O
policy NN policy O

Correlation CAPITAL NNP correlation O
between NN stopwords between O
the NN stopwords O
concentration NNS concentration O
of NN stopwords O
various NN assorted O
kinds NN kind O
of NN stopwords O
pollutants NN pollutant O
in NN stopwords inch O
atmosphere DT atmosphere O
and DT stopwords O
wind NN wind O
direction NN direction O
and DT stopwords O
velocity NN speed O
at DT stopwords astatine O
Kasumigaseki CAPITAL NNP O
, , O
central NNS central O
district NN district O
of NN stopwords O
Tokyo CAPITAL NNP Tokyo O

The CAPITAL NNP O
average DT average O
walking VB walk O
tolerance NN tolerance O
improved JJ better O
from JJ stopwords O
1.11 CD O
to NN stopwords O
4.80 CD O
, , O
and DT stopwords O
the NN stopwords O
overall JJ overall O
level NN degree O
of NN stopwords O
satisfaction VB satisfaction O
improved JJ better O
from JJ stopwords O
0.0 LS O
to NN stopwords O
4.79 CD O

Patient CAPITAL VB patient O
1 DIGITS CD one O
demonstrated NN show O
dramatic NN dramatic O
clearing NNS clearing O
of NN stopwords O
his NN stopwords O
MCV CAPITAL NNP D
lesions NN lesion D
when NN stopwords O
intravenous NN intravenous T
cidofovir NN T
therapy NN therapy T
was VB stopwords Washington O
started NN get_down O
for NN stopwords O
his NN stopwords O
treatment-resistant NN D
bilateral NN bilateral D
CMV CAPITAL NNP cytomegalovirus D
retinitis NN retinitis D
and DT stopwords O
because NN stopwords O
of NN stopwords O
cidofovir NN T
's POS T
possible NN possible O
activity DT activity O
against DT stopwords O
MCV CAPITAL NNP D

the NN stopwords O
drug NN drug O
is NN stopwords be O
currently NNS presently O
in NN stopwords inch O
phase NN phase O
iii NN three O
clinical JJ clinical O
trials NN test O
for NN stopwords O
patients VB patient O
with NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
paclitaxel VB T
and DT stopwords T
carboplatin VB T
, , O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
in NN stopwords inch O
advanced DT advance D
hormone NN hormone D
refractory NN furnace_lining D
prostate NN prostate_gland D
cancer VB cancer D
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
mitoxantrone NN T

Seven CAPITAL NNP seven O
primer NN primer O
pairs IN pair O
generated NN generate O
bovine-specific NN O
PCR CAPITAL NNP O
products NN merchandise O
and DT stopwords O
provided NN supply O
a DT stopwords angstrom O
set NN set O
of NN stopwords O
microsatellite NN O
markers NN marker O
that NN stopwords O
generally NN by_and_large O
revealed NN uncover O
high NN high O
informativity NN O
in NN stopwords inch O
the NN stopwords O
HF CAPITAL NNP hafnium O
breed NN breed O

Meis2 CAPITAL NNP O
, , O
a DT stopwords angstrom O
novel JJ novel O
mouse NN mouse O
Pbx-related CAPITAL NNP O
homeobox NN homeobox O
gene NN gene O
induced NN induce O
by NN stopwords by O
retinoic NN O
acid DT acid O
during NN stopwords O
differentiation NN differentiation O
of NN stopwords O
P19 CAPITAL NNP O
embryonal NN embryonic O
carcinoma VB carcinoma O
cells NNS cell O

After CAPITAL DT after O
adjusting DT adjust O
for NN stopwords O
stage NN phase O
, , O
factors VB factor O
such NN stopwords such O
as DT stopwords arsenic O
poverty NN poverty O
, , O
other JJ stopwords other O
socioeconomic NN socioeconomic O
conditions NNS conditions O
, , O
and DT stopwords O
treatment NN treatment O
did NN stopwords make O
not JJ stopwords not O
further NN stopwords foster O
explain NN explain O
the NN stopwords O
remaining NN stay O
survival NN survival O
deficit NN deficit O

The CAPITAL NNP O
miracidia NN O
of NN stopwords O
Fasciola CAPITAL NNP Fasciola O
hepatica NN hepatica O
and DT stopwords O
Trichobilharzia CAPITAL NNP O
ocellata JJ O
approach DT approach O
their NN stopwords O
host NN host O
snails NN snail O
Lymnaea CAPITAL NNP O
truncatula NN O
and DT stopwords O
L. CAPITAL NNP O
stagnalis NN O
by NN stopwords by O
increasing NN increase O
their NN stopwords O
rate VB rate O
of NN stopwords O
change NNS change O
of NN stopwords O
direction NN direction O
( ( O
RCD CAPITAL NNP O
) ) O
in NN stopwords inch O
increasing NN increase O
gradients NN gradient O
of NN stopwords O
snail-conditioned NN O
water VB water O
( ( O
SCW CAPITAL NNP O
) ) O
, , O
and DT stopwords O
they NN stopwords O
perform NN perform O
a DT stopwords angstrom O
turnback NN O
swimming JJ swimming O
in NN stopwords inch O
decreasing NN decrease O
gradients NN gradient O

On CAPITAL NNP on O
the NN stopwords O
day VB day O
of NN stopwords O
delivery NN delivery O
, , O
they NN stopwords O
were NN stopwords be O
absent DT absent O

Inositol CAPITAL PRP inositol T
treatment NN treatment O
of NN stopwords O
autism DT autism D

Sequential CAPITAL NNP consecutive O
MR CAPITAL NNP Mister O
studies NN survey O
were NN stopwords be O
obtained NN obtain O
within NN inside O
1 DIGITS CD one O
to NN stopwords O
3 DIGITS CD three O
days VB days O
postoperatively NN postoperatively O
and DT stopwords O
at DT stopwords astatine O
6-month CD O
follow-up JJ follow-up O
examination NN examination O

Diagnosis CAPITAL NNP diagnosis O
of NN stopwords O
stone NN rock D
disease NN disease D

When CAPITAL NNP O
right NN right D
ventricular NN ventricular D
failure VB failure D
prohibits NN forbid O
separation NN separation O
from JJ stopwords O
cardiopulmonary VB cardiopulmonary O
bypass NN beltway O
, , O
standard NN standard T
methods NN method T
of NN stopwords T
increasing NN increase T
pulmonary NN pneumonic T
blood NN blood T
flow JJ flow T
should NN stopwords O
be NN stopwords beryllium O
employed NN use O
, , O
including NN include O
correction NNS correction O
of NN stopwords O
hypoxia NN hypoxia O
and DT stopwords O
acidosis DT acidosis O
, , O
volume NN volume O
loading NN load O
, , O
and DT stopwords O
inotropic NN O
support NN support O
of NN stopwords O
the NN stopwords O
right NN right O
ventricle NN ventricle O

purpose/objectives NN O
: : O
to NN stopwords O
describe NN describe O
the NN stopwords O
relationship NN relationship O
between NN stopwords between O
fatigue VB fatigue O
and DT stopwords O
nutritional JJ nutritional O
status NN status O
in NN stopwords inch O
patients VB patient O
receiving NN receive O
radiation VB radiation T
therapy NN therapy T
for NN stopwords O
lung NN lung D
cancer VB cancer D

Differences CAPITAL NNP difference O
between NN stopwords between O
studies NN survey O
may VB May O
arise DT originate O
directly NN directly O
from JJ stopwords O
criteria JJ standard O
for NN stopwords O
TEOAE CAPITAL NNP O
identification NN designation O
, , O
criteria JJ standard O
for NN stopwords O
selection NN choice O
of NN stopwords O
normals RB convention O
, , O
or NN stopwords Oregon O
statistically NN statistically O
due NN due O
to NN stopwords O
limited NN express O
sample VB sample O
sizes NN size O

Two CAPITAL NNP two O
hundred NN hundred O
and DT stopwords O
seventy-seven NN seventy-seven O
patients VB patient O
with NN stopwords O
advanced DT advance D
prostatic NN prostate D
cancer VB cancer D
were NN stopwords be O
treated NN treat O
by NN stopwords by O
either NN either O
orchiectomy JJ orchidectomy T
or NN stopwords Oregon T
oestrogen JJ estrogen T

RESULTS CAPITAL NNP consequence O
: : O
Thirty-day CAPITAL NNP O
mortality NN mortality O
was VB stopwords Washington O
higher NN higher O
in NN stopwords inch O
the NN stopwords O
double-bolus NN O
group NN group O
than NN stopwords O
in NN stopwords inch O
the NN stopwords O
accelerated-infusion DT O
group NN group O
: : O
7.98 CD O
percent NN percentage O
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
7.53 CD O
percent NN percentage O

Additional CAPITAL DT extra O
edema NN edema D
spreading NN spread O
to NN stopwords O
the NN stopwords O
internal NN internal O
capsule VB capsule O
was VB stopwords Washington O
noted JJ note O
in NN stopwords inch O
32 DIGITS CD thirty-two O
of NN stopwords O
34 DIGITS CD thirty-four O
cases VB case O
and DT stopwords O
to NN stopwords O
the NN stopwords O
optic JJ eye O
tract NN tract O
in NN stopwords inch O
11 DIGITS CD eleven O
of NN stopwords O
34 DIGITS CD thirty-four O
cases VB case O

The CAPITAL NNP O
most NN stopwords most O
common NNS park O
toxicity NN toxicity O
is NN stopwords be O
bone NN bone D
pain IN pain D
, , O
and DT stopwords O
other JJ stopwords other O
reactions NN chemical_reaction O
such NN stopwords such O
as DT stopwords arsenic O
inflammation NN inflammation D
at DT stopwords astatine O
the NN stopwords O
site NN site O
of NN stopwords O
injection NN injection T
have VB stopwords rich_person O
also DT besides O
occurred JJ happen O

Special CAPITAL NNP special O
report NN report O
: : O
comparative NNS comparative O
efficacy NN efficacy O
of NN stopwords O
different NN different O
types NN type O
of NN stopwords O
pneumatic NN pneumatic T
compression NNS compaction T
pumps NN pump T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
lymphedema NN lymphedema D

Conglutination CAPITAL NNP union O
of NN stopwords O
the NN stopwords O
labia NN labium O
minora NN O

These CAPITAL NNP O
variables NN variable O
and DT stopwords O
standard NN standard O
clinical JJ clinical O
tests NN trial O
were NN stopwords be O
analyzed DT analyze O
as DT stopwords arsenic O
discriminators NN differentiator O
between NN stopwords between O
preeclamptic NN O
and DT stopwords O
control NNS control O
women NN woman O

< NN O
TO_SEE CAPITAL NNP O
> NN O
In CAPITAL PRP inch O
patients VB patient O
with NN stopwords O
non-obstructive JJ O
azoospermia DT O
, , O
TEFNA CAPITAL NNP O
has VB stopwords hour_angle O
a DT stopwords angstrom O
significantly NN significantly O
lower NN lower_berth O
yield NN output O
compared NNS compare O
to NN stopwords O
TESE CAPITAL NNP O

Effectiveness CAPITAL NNP effectiveness O
of NN stopwords O
casein VB casein T
hydrolysate NN hydrolysate T
feedings JJ eating O
in NN stopwords inch O
infants NN baby O
with NN stopwords O
colic NNS colic D
( ( O
see NN see O
comments NNS remark O
) ) O

we NN stopwords O
have VB stopwords rich_person O
documented NN document O
previously NN previously O
that NN stopwords O
adenovirus-mediated DT T
interleukin NN interleukin T
12 DIGITS CD twelve T
( ( T
il-12 NN T
) ) T
gene NN gene T
therapy NN therapy T
is NN stopwords be O
effective NN effective O
for NN stopwords O
orthotopic JJ D
tumor NN tumor D
control NNS control O
and DT stopwords O
suppression NN suppression O
of NN stopwords O
pre-established NN D
metastases NN metastasis D
in NN stopwords inch D
a DT stopwords angstrom D
preclinical NN preclinical D
prostate NN prostate_gland D
cancer VB cancer D
model NN model D
( ( O
y. NN stopwords O
nasu RB O
et NN O
al DT aluminum O
. . O
, , O
gene NN gene O
ther NN O

This CAPITAL NNP O
molecule NN molecule O
has VB stopwords hour_angle O
91 DIGITS CD ninety-one O
% NN O
sequence NN sequence O
identity NN identity O
with NN stopwords O
the NN stopwords O
limbic NN limbic O
system-associated NN O
membrane NN membrane O
protein NN protein O
( ( O
LAMP CAPITAL VB lamp O
) ) O
characterized NNS qualify O
in NN stopwords inch O
the NN stopwords O
rat VB rat O
and DT stopwords O
is NN stopwords be O
therefore NN therefore O
referred NN mention O
to NN stopwords O
as DT stopwords arsenic O
the NN stopwords O
chicken JJ chicken O
homologue NN O
of NN stopwords O
the NN stopwords O
latter NN latter O
( ( O
chLAMP NNS O
) ) O

Starfish CAPITAL NNP starfish O
oocytes JJ oocyte O
can VB stopwords can O
be NN stopwords beryllium O
fertilized NN fertilize O
after DT stopwords after O
germinal NN Germinal O
vesicle NN vesicle O
breakdown NN dislocation O
( ( O
GVBD CAPITAL NNP O
) ) O
and DT stopwords O
artificial DT artificial O
parthenogenesis NN parthenogenesis O
can VB stopwords can O
be NN stopwords beryllium O
induced NN induce O
by NN stopwords by O
activating DT energizing O
the NN stopwords O
oocytes JJ oocyte O
after DT stopwords after O
GVBD CAPITAL NNP O
( ( O
post-GVBD NN O
activation DT activation O
) ) O

Fetal CAPITAL NNP fetal O
movements NN motion O
were NN stopwords be O
decreased NN decrease O
48 DIGITS CD forty-eight O
hr NN hour O
prior NN prior O
to NN stopwords O
delivery NN delivery O

Substances CAPITAL NNP substance O
identified NN identify O
included NN include O
benzodiazepines NN benzodiazepine O
, , O
cannabis VB cannabis O
, , O
amphetamines DT amphetamine O
, , O
opiates IN opiate O
and DT stopwords O
cocaine NNS cocaine O

Also CAPITAL DT besides O
, , O
the NN stopwords O
magnitude VB magnitude O
of NN stopwords O
the NN stopwords O
changes NNS change O
in NN stopwords inch O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficients NNS coefficient O
( ( O
k1 NN O
and DT stopwords O
k2 NN K2 O
) ) O
and DT stopwords O
in NN stopwords inch O
the NN stopwords O
fractal NN fractal O
dimensions NN dimension O
( ( O
Df1 CAPITAL NNP O
and DT stopwords O
Df2 CAPITAL NNP O
) ) O
as DT stopwords arsenic O
different NN different O
parameters NN parameter O
are DT stopwords are O
changed NNS change O
for NN stopwords O
the NN stopwords O
different NN different O
biosensor NN O
applications DT application O
are DT stopwords are O
of NN stopwords O
particular NN particular O
value NN value O
, , O
since NN O
they NN stopwords O
provide NN supply O
us JJ United_States O
with NN stopwords O
a DT stopwords angstrom O
measure NN measure O
or NN stopwords Oregon O
extent NN extent O
of NN stopwords O
changes NNS change O
in NN stopwords inch O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficient NNS coefficient O
on NN stopwords on O
changing NNS change O
different NN different O
experimental NN experimental O
parameter NN parameter O
values NN values O

CONCLUSION CAPITAL NNP decision O
: : O
Although CAPITAL DT O
tacrolimus VB T
is NN stopwords be O
effective NN effective O
induction NN initiation O
therapy NN therapy O
for NN stopwords O
severe NN severe D
ulcerative JJ ulcerative D
or NN stopwords Oregon D
Crohn CAPITAL NNP Crohn D
's POS D
colitis NNS colitis D
, , O
fewer JJ fewer O
than NN stopwords O
50 DIGITS CD fifty O
% NN O
of NN stopwords O
patients VB patient O
treated NN treat O
will NN stopwords volition O
successfully NN successfully O
achieve DT achieve O
a DT stopwords angstrom O
long-term NN long-run O
remission NN remission O

Challenges CAPITAL NNP challenge O
to NN stopwords O
Native CAPITAL NNP native O
American CAPITAL DT American O
health NN health O
care VB care O

Intra- CAPITAL PRP O
and DT stopwords O
inter-individual NN O
biological NN biological O
variability NN variability O
data VB data O
bank VB bank O

A CAPITAL DT angstrom O
novel JJ novel O
technique NN technique O
for NN stopwords O
patterning VB model O
immobilized JJ immobilize O
antibody DT antibody O
layers NN layer O
based VB establish O
upon JJ O
photolithography NN photolithography O
and DT stopwords O
oxygen JJ oxygen O
plasma NN plasma O
exposure NN exposure O
has VB stopwords hour_angle O
been NN stopwords be O
developed NN develop O

This CAPITAL NNP O
study NN survey O
investigated NN investigate O
whether NN O
intensive NN intensifier O
chemotherapy NNS chemotherapy T
might NN might O
have VB stopwords rich_person O
a DT stopwords angstrom O
positive NN positive O
effect NN consequence O
on NN stopwords on O
asthma DT asthma D
in NN stopwords inch O
these NN stopwords O
special NN special O
cases VB case O
and DT stopwords O
whether NN O
asthma DT asthma O
generally NN by_and_large O
relapses NN backsliding O
after DT stopwords after O
completion NNS completion O
of NN stopwords O
chemotherapy NNS chemotherapy O

moreover NN furthermore O
, , O
uft JJ T
has VB stopwords hour_angle O
proved NN prove O
to NN stopwords O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
inoperable NN inoperable D
advanced DT advance D
malignancies VB malignancy D
such NN stopwords such D
as DT stopwords arsenic D
colorectal NNS colorectal D
cancer VB cancer D
, , O
especially NN particularly O
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
leucovorin NN T
or NN stopwords Oregon T
cisplatin NN T

I CAPITAL PRP iodine O
. . O
The CAPITAL NNP O
behavior NN behavior O
of NN stopwords O
chicks JJ chick O
which NN stopwords O
do NN stopwords bash O
not JJ stopwords not O
eat VB eat O
the NN stopwords O
mealworm NN mealworm O

SETTING CAPITAL NNP setting O
: : O
Cullen CAPITAL NNP O
Eye CAPITAL NNP eye O
Institute CAPITAL PRP institute O
, , O
Baylor CAPITAL IN O
College CAPITAL NNP college O
of NN stopwords O
Medicine CAPITAL NNP medicine O
, , O
Houston CAPITAL NNP Houston O
, , O
Texas CAPITAL NNP Texas O
, , O
USA CAPITAL NNP United_States O

conclusions NNS decision O
: : O
the NN stopwords O
heptavalent NN T
pneumococcal NN pneumococcal T
conjugate NNS conjugate_solution T
vaccine NN vaccine T
is NN stopwords be O
safe VB safe O
and DT stopwords O
highly NN highly O
effective NN effective O
in NN stopwords inch O
preventing NN prevent O
pneumococcal NN pneumococcal D
meningitis NN meningitis D
and DT stopwords D
bacteremic VB bacteremic D
pneumonia NN pneumonia D
in NN stopwords inch O
young NN young O
children JJ child O
< NN O
2 DIGITS CD two O
years NN old_age O
of NN stopwords O
age DT age O
; : O
it NN stopwords information_technology O
is NN stopwords be O
less NN lupus_erythematosus O
effective NN effective O
in NN stopwords inch O
preventing NN prevent O
otitis IN otitis O
media NN medium O

Then CAPITAL NNP then O
, , O
for NN stopwords O
these NN stopwords O
cases VB case O
, , O
the NN stopwords O
dual-fractal NN O
analysis DT analysis O
provides NN supply O
an DT stopwords Associate_in_Nursing O
improved JJ better O
fit NN fit O
when NN stopwords O
compared NNS compare O
with NN stopwords O
a DT stopwords angstrom O
single-fractal NN O
analysis DT analysis O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Despite CAPITAL NNP contempt O
Beta-blockade CAPITAL NNP T
therapy NN therapy T
has VB stopwords hour_angle O
been NN stopwords be O
considered NNS see O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
absolute DT absolute O
contraindication NNS contraindication O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
heart NN heart D
failure VB failure D
, , O
it NN stopwords information_technology O
has VB stopwords hour_angle O
been NN stopwords be O
shown NN show O
that NN stopwords O
they NN stopwords O
could NNS O
have VB stopwords rich_person O
a DT stopwords angstrom O
beneficial NN beneficial O
effect NN consequence O
, , O
provided NN supply O
that NN stopwords O
they NN stopwords O
were NN stopwords be O
introduced NN introduce O
at DT stopwords astatine O
very NN stopwords very O
low NN low O
dose NN dose O
, , O
and DT stopwords O
very NN stopwords very O
progressively NN increasingly O
in NN stopwords inch O
addition DT addition O
of NN stopwords O
the NN stopwords O
traditional NN traditional O
treatment NN treatment O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Reduced CAPITAL NNP reduce D
bone NN bone D
density NN density D
at DT stopwords astatine O
completion NNS completion O
of NN stopwords O
chemotherapy NNS chemotherapy T
for NN stopwords O
a DT stopwords angstrom O
malignancy VB malignancy D

RESULTS CAPITAL NNP consequence O
: : O
Two CAPITAL NNP two O
male VB male O
patients VB patient O
are DT stopwords are O
presented NN show O
, , O
1 DIGITS CD one O
with NN stopwords O
a DT stopwords angstrom O
metastatic NN metastatic D
germ NN source D
cell NNS cell D
tumor NN tumor D
of NN stopwords O
both NN stopwords both O
the NN stopwords O
retroperitoneum NN O
and DT stopwords O
mediastinum NN mediastinum O
( ( O
with NN stopwords O
elevated NN elevated_railway O
alpha-fetoprotein DT O
level NN degree O
) ) O
and DT stopwords O
1 DIGITS CD one O
with NN stopwords O
a DT stopwords angstrom O
primary NN primary D
germ NN source D
cell NNS cell D
tumor NN tumor D
of NN stopwords O
the NN stopwords O
mediastinum NN mediastinum O
( ( O
with NN stopwords O
elevated NN elevated_railway O
alpha-fetoprotein DT O
and DT stopwords O
beta-human NN O
chorionic NNS chorionic O
gonadotropin NN gonadotropin O
levels NN degree O
) ) O

Transiently CAPITAL NNP transiently O
evolked NN O
otoacoustic JJ O
emissions NN emission O
( ( O
TEOAE CAPITAL NNP O
) ) O
have VB stopwords rich_person O
been NN stopwords be O
reported NN report O
in NN stopwords inch O
several NN several O
studies NN survey O
as DT stopwords arsenic O
absent DT absent O
in NN stopwords inch O
a DT stopwords angstrom O
small JJ small O
minority NN minority O
of NN stopwords O
normal RB convention O
ears VB ear O

extracorporeal NN T
photopheresis NN T
has VB stopwords hour_angle O
evolved NN evolve O
as DT stopwords arsenic O
a DT stopwords angstrom O
possible NN possible O
therapy NN therapy O
for NN stopwords O
patients VB patient O
with NN stopwords O
acute DT acute_accent D
nd RB neodymium D
chronic NN chronic D
lung NN lung D
allograft DT homograft D
rejection NN rejection D

The CAPITAL NNP O
practical NN practical O
use JJ use O
of NN stopwords O
PCR CAPITAL NNP O
for NN stopwords O
rapid VB rapid O
detection NN detection O
of NN stopwords O
methicillin NN methicillin T
resistance NN resistance O
among DT O
staphylococcal NN staphylococcal O
clinical JJ clinical O
isolates NN isolate O
from JJ stopwords O
Turkish CAPITAL NNP Turkish O
hospitals NN hospital O

< NN O
TO_SEE CAPITAL NNP O
> NN O
CONCLUSIONS CAPITAL NNP decision O
: : O
After CAPITAL DT after O
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
primary NN primary D
or NN stopwords Oregon D
metastatic NN metastatic D
mediastinal NN D
germ NN source D
cell NNS cell D
tumors NN tumor D
whose NN O
tumor NN tumor O
markers NN marker O
normalize RB normalize O
, , O
a DT stopwords angstrom O
growing NN growth O
mass VB mass O
in NN stopwords inch O
the NN stopwords O
mediastinum NN mediastinum O
may VB May O
represent NN represent O
the NN stopwords O
growing NN growth O
teratoma NN teratoma D
syndrome NN syndrome D

Comparison CAPITAL NNP comparison O
of NN stopwords O
the NN stopwords O
sensitivity NN sensitivity O
of NN stopwords O
normal RB convention O
hematopoietic NN hematopoietic O
and DT stopwords O
transplanted NN transplant O
lymphoma NN lymphoma O
colony-forming NNS O
cells NNS cell O
of NN stopwords O
mice NN mouse O
to NN stopwords O
vinblastine NN vinblastine O
administered DT administer O
in NN stopwords inch O
vivo NN O

The CAPITAL NNP O
negative JJ negative O
predictive NN predictive O
value NN value O
of NN stopwords O
high NN high O
serum NN serum O
follicle JJ follicle O
stimulating JJ stimulate O
hormone NN hormone O
( ( O
FSH CAPITAL NNP follicle-stimulating_hormone O
) ) O
concentrations NNS concentration O
( ( O
> NN O
or NN stopwords Oregon O
=10 RB O
IU/l CAPITAL PRP O
) ) O
( ( O
predicting NN predict O
failure VB failure O
to NN stopwords O
find NN discovery O
spermatozoa NN sperm O
for NN stopwords O
ICSI CAPITAL PRP O
) ) O
was VB stopwords Washington O
low NN low O
( ( O
38.4 CD O
% NN O
) ) O

Surgical CAPITAL NNP surgical T
treatment NN treatment T
of NN stopwords O
postpneumonic NN D
empyema NN empyema D

Ropinirole CAPITAL NNP T
was VB stopwords Washington O
well NN well O
tolerated NN digest O
and DT stopwords O
patient VB patient O
withdrawals NN withdrawal O
were NN stopwords be O
infrequent NN infrequent O

Gynaecological CAPITAL NNP gynecological O
pain IN pain O

Laryngeal CAPITAL VB laryngeal D
obstruction NN obstruction D
caused VB cause O
by NN stopwords by O
lingual NN lingual D
thyroglossal NN D
duct NN duct D
cyst NNS cyst D
presenting NN show O
at DT stopwords astatine O
birth NN birth O

Karolinska CAPITAL NNP O
Institute CAPITAL PRP institute O
rocked NN rock O
by NN stopwords by O
research NN research O
misconduct NN misconduct O

The CAPITAL NNP O
treatment NN treatment O
of NN stopwords O
autoimmune DT autoimmune D
hemolytic NN hemolytic D
anemia DT anemia D
with NN stopwords O
heparin NN heparin T

The CAPITAL NNP O
effects NN effects O
of NN stopwords O
physical NN physical O
activity DT activity O
( ( O
with NN stopwords O
reference NN mention O
to NN stopwords O
factors VB factor O
such NN stopwords such O
as DT stopwords arsenic O
exercise NN exercise O
intensity NN intensity O
and DT stopwords O
duration NN duration O
, , O
or NN stopwords Oregon O
type NN type O
of NN stopwords O
exercise NN exercise O
protocol NN protocol O
) ) O
on NN stopwords on O
salivary VB salivary O
composition NNS composition O
are DT stopwords are O
then NN stopwords then O
considered NNS see O

The CAPITAL NNP O
purpose NN purpose O
of NN stopwords O
the NN stopwords O
present NN present O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
analyze DT analyze O
the NN stopwords O
association DT association O
of NN stopwords O
recurrent NN perennial O
abdominal DT abdominal O
pain IN pain O
and DT stopwords O
H. CAPITAL NNP O
pylori NN pylorus O
infection NN infection O
in NN stopwords inch O
children JJ child O
and DT stopwords O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
efficacy NN efficacy O
of NN stopwords O
antimicrobial DT disinfectant T
treatment NN treatment T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
evidence NN evidence O
of NN stopwords O
infection NN infection D

A CAPITAL DT angstrom O
prospective NN prospective O
, , O
randomized VB randomize O
, , O
placebo-controlled NN O
, , O
double-blind NN O
, , O
parallel-group NN O
, , O
6-month CD O
study NN survey O
assessed DT measure O
the NN stopwords O
efficacy NN efficacy O
and DT stopwords O
safety VB safety O
of NN stopwords O
ropinirole NN T
, , T
a DT stopwords angstrom T
nonergoline JJ T
D2-dopamine CAPITAL NNP T
agonist DT protagonist T
, , O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
early VB early D
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
( ( O
n NN nitrogen O
= NN O
241 DIGITS CD O
; : O
Hoehn CAPITAL NNP O
& CC O
# # O
38 DIGITS CD thirty-eight O
; : O
Yahr CAPITAL VB O
stages NN phase O
I CAPITAL PRP iodine O
to NN stopwords O
III CAPITAL PRP three O
) ) O
with NN stopwords O
limited NN express O
or NN stopwords Oregon O
no NNS stopwords no O
prior NN prior O
dopaminergic NN T
therapy NN therapy T

Urinary CAPITAL NNP urinary O
calculi VB calculus O

Specific CAPITAL NNP particular O
binding NN binding O
of NN stopwords O
low NN low O
molecular NN molecular O
weight NN weight O
ligands NN ligand O
with NN stopwords O
direct NN direct O
optical JJ optical O
detection NN detection O

NICE CAPITAL NNP Nice O
to NN stopwords O
rule NN rule O
on NN stopwords on O
influenza NN influenza D
flu JJ influenza D
drug NN drug O
zanamivir NN T

Experimental CAPITAL NNP experimental O
vaccination NN inoculation T
against DT stopwords O
Mycoplasma CAPITAL NNP mycoplasma D
agalactiae DT D
using JJ exploitation O
different NN different O
inactivated NN demobilize O
vaccines NN vaccine O

These CAPITAL NNP O
effects NN effects O
can VB stopwords can O
cause VB cause O
deviations NN deviation O
from JJ stopwords O
predicted NN predict O
kinetic NN kinetic O
behavior NN behavior O
in NN stopwords inch O
studies NN survey O
of NN stopwords O
peroxynitrite NN O
in NN stopwords inch O
noncarbonate JJ O
buffers NN buffer O
in NN stopwords inch O
vitro NN O
, , O
and DT stopwords O
since NN O
1 DIGITS CD one O
and DT stopwords O
other JJ stopwords other O
intermediates NN intermediate O
derived NN deduce O
from JJ stopwords O
it NN stopwords information_technology O
are DT stopwords are O
oxidants IN oxidant O
and/or DT O
nitrating NN nitrate O
agents DT agent O
, , O
some NN stopwords some O
of NN stopwords O
the NN stopwords O
reactions NN chemical_reaction O
attributed DT impute O
to NN stopwords O
peroxynitrite NN O
may VB May O
depend NN depend O
on NN stopwords on O
the NN stopwords O
availability DT handiness O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O

Comparison CAPITAL NNP comparison O
of NN stopwords O
radical VB group T
prostatectomy NN prostatectomy T
and DT stopwords O
iodine NN iodine T
125 DIGITS CD one_hundred_twenty-five T
interstitial NN interstitial T
radiotherapy VB radiotherapy T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
clinically JJ clinically D
localized NN place D
prostate NN prostate_gland D
cancer VB cancer D
: : O
a DT stopwords angstrom O
7-year CD O
biochemical NN biochemical O
( ( O
PSA CAPITAL NNP prostate_specific_antigen O
) ) O
progression NN progression O
analysis DT analysis O

Transabdominal CAPITAL NNP T
extensive NN extensive T
esophagogastric NN T
devascularization NN T
with NN stopwords T
gastroesophageal VB gastroesophageal T
stapling NN staple T
for NN stopwords O
management VB management O
of NN stopwords O
noncirrhotic JJ D
portal NN portal D
hypertension NN high_blood_pressure D
: : O
long-term NN long-run O
results NN consequence O

In CAPITAL PRP inch O
the NN stopwords O
present NN present O
study NN survey O
we NN stopwords O
recall NN recall O
the NN stopwords O
particular NN particular O
aspects DT aspect O
of NN stopwords O
the NN stopwords O
neurulation JJ O
in NN stopwords inch O
the NN stopwords O
cephalic NNS cephalic O
area DT area O
, , O
then NN stopwords then O
the NN stopwords O
establishment NN constitution O
of NN stopwords O
the NN stopwords O
facial VB facial O
processes NN procedure O

Using CAPITAL NNP exploitation O
YPLL CAPITAL NNP O
in NN stopwords inch O
health NN health O
planning NN planning O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Antiplatelet CAPITAL DT T
therapy NN therapy T
to NN stopwords O
prevent NN prevent O
stroke NN stroke D
: : O
risk NN hazard O
of NN stopwords O
brain NN brain D
hemorrhage NN bleeding D
and DT stopwords O
efficacy NN efficacy O
in NN stopwords inch O
atrial DT atrial T
fibrillation NN fibrillation T

Prior CAPITAL NNP prior O
attendance DT attendance O
with NN stopwords O
upper JJ upper_berth D
respiratory NN respiratory D
conditions NNS conditions D
was VB stopwords Washington O
also DT besides O
associated DT associate O
with NN stopwords O
increased NN increase O
reattendance NN O

Methylphenidate CAPITAL NNP methylphenidate T
benefited NN profit O
70 DIGITS CD seventy O
% NN O
of NN stopwords O
children JJ child O
according DT harmonize O
to NN stopwords O
parental NN parental O
report NN report O
; : O
methylphenidate NN methylphenidate T
also DT besides O
enhanced NN enhance O
performance NN performance O
on NN stopwords on O
the NN stopwords O
CPT CAPITAL NNP O

objectives NN aim O
: : O
this NN stopwords O
study NN survey O
aims DT purpose O
to NN stopwords O
test NN trial O
whether NN O
prophylactic NN preventive T
cranial NNS cranial T
irradiation NN irradiation T
prolongs NN prolong O
survival NN survival O
of NN stopwords O
patients VB patient O
with NN stopwords O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
in NN stopwords inch O
complete NNS complete O
remission NN remission O

These CAPITAL NNP O
results NN consequence O
suggest NN propose O
that NN stopwords O
con NNS con D
A-induced CAPITAL DT D
hepatitis NN hepatitis D
was VB stopwords Washington O
ameliorated DT better O
by NN stopwords by O
pretreatment NN O
with NN stopwords O
TJ-135 CAPITAL NNP T

Two CAPITAL NNP two O
different NN different O
responses NN response O
to NN stopwords O
the NN stopwords O
therapy NN therapy O
were NN stopwords be O
observed NN detect O
in NN stopwords inch O
a DT stopwords angstrom O
group NN group O
of NN stopwords O
patients VB patient O
receiving NN receive O
the NN stopwords O
protease NN protease T
inhibitor NN inhibitor T
indinavir NN indinavir T

An CAPITAL DT Associate_in_Nursing O
active-control DT O
trial NN test O
of NN stopwords O
lamotrigine NN T
monotherapy NN T
for NN stopwords O
partial NN partial_derivative D
seizures JJ seizure D

The CAPITAL NNP O
treatment NN treatment O
of NN stopwords O
diabetes NN diabetes D
2 DIGITS CD two D
by NN stopwords by O
the NN stopwords O
classic NNS classic T
oral NN oral T
antidiabetic DT antidiabetic T
drugs NN drug T
( ( T
sulfamides NN T
and DT stopwords T
biguanides NN T
) ) T
is NN stopwords be O
completed NNS complete O
by NN stopwords by O
intestinal NN intestinal T
glycosidases NN T
inhibitors NN inhibitor T
and DT stopwords O
thiazolidendiones NN T

Most CAPITAL NNP most O
significantly NN significantly O
, , O
7 DIGITS CD seven O
( ( O
58 DIGITS CD fifty-eight O
% NN O
) ) O
of NN stopwords O
the NN stopwords O
12 DIGITS CD twelve O
children JJ child O
with NN stopwords O
subsequent NN subsequent O
sensorineural NN sensorineural D
hearing NN hearing D
loss NN loss D
had VB stopwords have O
left NN left O
the NN stopwords O
hospital NN hospital O
after DT stopwords after O
showing NN screening O
normal RB convention O
results NN consequence O
on NN stopwords on O
threshold NN threshold O
tests NN trial O

Effect CAPITAL NNP consequence O
of NN stopwords O
long-term NN long-run O
salmeterol VB T
treatment NN treatment T
on NN stopwords on O
exercise-induced NN D
asthma DT asthma D

If CAPITAL PRP O
the NN stopwords O
medial NN medial O
region NN region O
of NN stopwords O
the NN stopwords O
temporal NN temporal_role O
lobes NN lobe O
, , O
including NN include O
the NN stopwords O
hippocampus NN hippocampus O
and DT stopwords O
related NN associate O
structures NN structure O
, , O
is NN stopwords be O
critical JJ critical O
for NN stopwords O
establishing NN establish O
these NN stopwords O
new JJ new O
memories NN memory O
, , O
then NN stopwords then O
this NN stopwords O
brain NN brain O
region NN region O
should NN stopwords O
be NN stopwords beryllium O
active DT active_agent O
whenever NN O
events NN event O
are DT stopwords are O
experienced NN experience O
, , O
regardless NN careless O
of NN stopwords O
whether NN O
subjects NN subject O
are DT stopwords are O
asked DT ask O
explicitly NN explicitly O
to NN stopwords O
learn NN learn O
and DT stopwords O
remember NN remember O

new JJ new O
distant NN distant D
lesions NN lesion D
were NN stopwords be O
treated NN treat O
by NN stopwords by O
repeated NN repeat O
gks NN T
without NN O
prophylactic NN preventive O
wbrt NN O

Medical CAPITAL NNP checkup O
centers NNS center O
tackle VB tackle O
delays NN delay O
, , O
reduce NN reduce O
wait IN delay O
times NN times O

The CAPITAL NNP O
literature NN literature O
suggests NN propose O
higher NN higher O
complication NNS complication O
rates VB rates O
when NN stopwords O
synthetic NN synthetic O
materials VB material O
are DT stopwords are O
used JJ use O
for NN stopwords O
slings JJ sling T

PARTICIPANTS CAPITAL VB participant O
: : O
The CAPITAL NNP O
562 DIGITS CD O
participating NN participate O
adolescents DT adolescent O
represented NN represent O
92 DIGITS CD ninety-two O
% NN O
of NN stopwords O
students NN student O
in NN stopwords inch O
mandatory VB mandatary O
classes NNS class O

CONCLUSION CAPITAL NNP decision O
: : O
The CAPITAL NNP O
treatment NN treatment O
paradigm NN paradigm O
for NN stopwords O
NHL CAPITAL NNP D
is NN stopwords be O
expected NN expect O
to NN stopwords O
change NNS change O
over JJ stopwords over O
the NN stopwords O
next JJ following O
few JJ stopwords few O
years NN old_age O
to NN stopwords O
include NN include O
radiolabeled VB T
mAbs NN T
, , O
administered DT administer O
alone DT alone O
or NN stopwords Oregon O
in NN stopwords inch O
combination NNS combination O
with NN stopwords O
cytotoxic NNS cytotoxic T
agents DT agent T

efforts NN attempt O
at DT stopwords astatine O
improving JJ better O
survival NN survival O
for NN stopwords O
early-stage VB D
nsclc JJ D
patients VB patient O
have VB stopwords rich_person O
focused JJ concentrate O
on NN stopwords on O
the NN stopwords O
use JJ use O
of NN stopwords O
chemotherapy NNS chemotherapy T
administered DT administer O
postoperatively NN postoperatively O
( ( O
adjuvant DT adjuvant O
) ) O
or NN stopwords Oregon O
preoperatively NN O
( ( O
neoadjuvant JJ O
or NN stopwords Oregon O
induction NN initiation O
) ) O
to NN stopwords O
eradicate NN eliminate O
micrometastatic NN D
disease NN disease D

Histopathological CAPITAL NNP O
findings NN findings O
included NN include O
plaque-like NN O
encasement NN encasement O
of NN stopwords O
the NN stopwords O
leaflets NN cusp O
and DT stopwords O
chordal NNS chordal O
structures NN structure O
with NN stopwords O
intact NN integral O
valve NN valve O
architecture DT architecture O

Ovarian CAPITAL NNP ovarian D
carcinoma VB carcinoma D

Early CAPITAL NN early T
surgical NN surgical T
treatment NN treatment T
for NN stopwords O
supratentorial NN D
intracerebral NN intracerebral D
hemorrhage NN bleeding D
: : O
a DT stopwords angstrom O
randomized VB randomize O
feasibility NN feasibility O
study NN survey O

Online CAPITAL NNP on-line O

They CAPITAL NNP O
underwent JJ undergo O
neurologic JJ neurological O
assessment DT appraisal O
, , O
brain NN brain O
computed NNS calculate O
tomography NN imaging O
, , O
IQ CAPITAL PRP intelligence_quotient O
testing NN testing O
, , O
and DT stopwords O
assessment DT appraisal O
with NN stopwords O
the NN stopwords O
Childhood CAPITAL NNP childhood O
Behavior CAPITAL NNP behavior O
Checklist CAPITAL NNP checklist O
at DT stopwords astatine O
baseline VB baseline O
before NN stopwords earlier O
methylphenidate NN methylphenidate T
therapy NN therapy T

Fibromyalgia CAPITAL NNP D
-- : O
out JJ stopwords out O
of NN stopwords O
control NNS control O
? . O

Stereotactic CAPITAL NNP T
radiosurgery VB T
for NN stopwords O
management VB management O
of NN stopwords O
deep NN deep D
brain NN brain D
cavernous VB cavernous D
malformations VB deformity D

Fetal CAPITAL NNP fetal O
nuchal JJ O
translucency NN translucence O
test NN trial O
for NN stopwords O
Down CAPITAL NNP down D
's POS D
syndrome NN syndrome D

The CAPITAL NNP O
activity DT activity O
of NN stopwords O
oral NN oral T
UFT CAPITAL NNP T
in NN stopwords inch O
large-bowel NN D
cancer VB cancer D
when NN stopwords O
administered DT administer O
with NN stopwords O
oral NN oral T
LV CAPITAL NNP fifty-five T
( ( O
approximately DT approximately O
50 DIGITS CD fifty O
mg/dose NN O
) ) O
has VB stopwords hour_angle O
resulted NN result O
in NN stopwords inch O
objective NN aim O
response NN response O
rates VB rates O
of NN stopwords O
approximately DT approximately O
40 DIGITS CD forty O
% NN O

The CAPITAL NNP O
immediate JJ immediate O
effectiveness NN effectiveness O
of NN stopwords O
electrical NN electrical T
nerve RB nerve T
stimulation JJ stimulation T
and DT stopwords O
electrical NN electrical T
muscle NN muscle T
stimulation JJ stimulation T
on NN stopwords on O
myofascial NN D
trigger NN gun_trigger D
points NN point D

Triglycerides CAPITAL NNP triglyceride O
( ( O
TGs CAPITAL NNP O
) ) O
, , O
stored NN store O
in NN stopwords inch O
adipose DT adipose O
tissue NN tissue O
and DT stopwords O
within NN inside O
muscle NN muscle O
fibres NN fiber O
, , O
are DT stopwords are O
considered NNS see O
to NN stopwords O
be NN stopwords beryllium O
the NN stopwords O
main VB main O
source NN beginning O
of NN stopwords O
the NN stopwords O
free JJ free O
fatty VB fatso O
acids DT acid O
( ( O
FFAs CAPITAL NNP O
) ) O
oxidised IN oxidize O
during NN stopwords O
exercise NN exercise O

CONCLUSIONS CAPITAL NNP decision O
: : O
A CAPITAL DT angstrom O
complete NNS complete O
genomic NN O
screen NN screen O
in NN stopwords inch O
families VB family O
affected DT affect O
with NN stopwords O
late-onset NN O
AD CAPITAL DT ad O
identified NN identify O
4 DIGITS CD four O
regions NN region O
of NN stopwords O
interest NN interest O
after DT stopwords after O
follow-up JJ follow-up O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
determine NN determine O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
illicit NN illicit O
drug NN drug O
abuse DT maltreatment O
and DT stopwords O
alcohol DT alcohol O
use JJ use O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
obstetric NN obstetric O
population NN population O
based VB establish O
in NN stopwords inch O
an DT stopwords Associate_in_Nursing O
urban JJ urban O
maternity VB pregnancy O
hospital NN hospital O

Group CAPITAL NNP group O
I CAPITAL PRP iodine O
showed NN show O
a DT stopwords angstrom O
significant NN significant O
correlation NNS correlation O
between NN stopwords between O
basal VB radical O
spinal JJ spinal_anesthesia O
BMD CAPITAL NNP O
and DT stopwords O
the NN stopwords O
percentage NN percentage O
change NNS change O
of NN stopwords O
BMD CAPITAL NNP O
during NN stopwords O
the NN stopwords O
observation NN observation O
period NN time_period O
( ( O
r NN roentgen O
= NN O
0.7 LS O
, , O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O

Cardiac CAPITAL VB cardiac O
monitors NN proctor O
work NN work O
-- : O
but NN stopwords merely O
they NN stopwords O
should NN stopwords O
report NN report O
more NN stopwords More O
than NN stopwords O
they NN stopwords O
do NN stopwords bash O

Acute CAPITAL DT acute_accent D
sciatica JJ sciatica D
with NN stopwords O
an DT stopwords Associate_in_Nursing O
infective NN infective O
cause VB cause O

Effects CAPITAL NNP effects O
of NN stopwords O
transpupillary NN T
thermotherapy NN thermotherapy T
on NN stopwords on O
immunological JJ immunological O
parameters NN parameter O
and DT stopwords O
apoptosis DT apoptosis O
in NN stopwords inch O
a DT stopwords angstrom O
case VB case O
of NN stopwords O
primary NN primary D
uveal JJ uveal D
melanoma NN melanoma D

Flucticasone CAPITAL NNP T
propionate NN T
is NN stopwords be O
safe VB safe O
in NN stopwords inch O
recommended NN recommend O
doses NN dose O

despite NN contempt O
the NN stopwords O
marked NN tag O
toxicity NN toxicity O
of NN stopwords O
the NN stopwords O
initial JJ initial O
intensive NN intensifier T
chemotherapy NNS chemotherapy T
, , O
the NN stopwords O
treatments NN treatment O
are DT stopwords are O
tolerable NN tolerable O
and DT stopwords O
effective NN effective O
in NN stopwords inch O
the NN stopwords O
control NNS control O
of NN stopwords O
extra-thoracic NN D
micrometastases NN D
, , O
whereas NN O
they NN stopwords O
are DT stopwords are O
less NN lupus_erythematosus O
effective NN effective O
for NN stopwords O
thoracic NN pectoral O
primary NN primary O
tumor NN tumor O

Medical CAPITAL NNP checkup O
devices NN devices O
and DT stopwords O
the NN stopwords O
year NN year O
2000 DIGITS CD O
problem NN problem O

Steroid CAPITAL NNP steroid T
therapy NN therapy T
was VB stopwords Washington O
also DT besides O
used JJ use O
in NN stopwords inch O
two NN two O
patients VB patient O
with NN stopwords O
NSAID-induced CAPITAL NNP D
proteinuria NN albuminuria D

The CAPITAL NNP O
psychological NN psychological O
profiles NN profile O
of NN stopwords O
patients VB patient O
with NN stopwords O
whiplash-associated NN D
headache NN concern D

conclusions NNS decision O
: : O
this NN stopwords O
study NN survey O
is NN stopwords be O
the NN stopwords O
first NN first O
to NN stopwords O
evaluate NN measure O
planned NN plan T
sequential NN consecutive T
chemotherapy NNS chemotherapy T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
nsclc JJ D

118 DIGITS CD O

She CAPITAL NNP O
was VB stopwords Washington O
diagnosed NN diagnose O
as DT stopwords arsenic O
miliary NN D
tuberculosis NN tuberculosis D
and DT stopwords O
treated NN treat O
with NN stopwords O
antituberculous DT T
drugs NN drug T

Isolated CAPITAL PRP isolate O
internal NN internal D
ophthalmoplegia JJ ophthalmoplegia D
associated DT associate O
with NN stopwords O
IgG CAPITAL PRP immunoglobulin_G O
anti-GQ1b DT O
antibody DT antibody O

Causing CAPITAL VB causing O
death NN death O
or NN stopwords Oregon O
allowing DT let O
to NN stopwords O
die NN die O
? . O
Developments CAPITAL NNP development O
in NN stopwords inch O
the NN stopwords O
law NN law O

CONCLUSION CAPITAL NNP decision O
: : O
The CAPITAL NNP O
WDTA CAPITAL NNP O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
intrinsically NN intrinsically O
motivating NN motivation O
educational NN educational O
program NN plan O
that NN stopwords O
has VB stopwords hour_angle O
the NN stopwords O
ability DT ability O
to NN stopwords O
effect NN consequence O
determinants NN determinant O
of NN stopwords O
asthma DT asthma D
self-management NN T
behavior NN behavior O
in NN stopwords inch O
9- CD O
to NN stopwords O
13-year-old CD O
children JJ child O
with NN stopwords O
asthma DT asthma O

144 DIGITS CD gross O

Double-blind CAPITAL NNP O
placebo-controlled NN O
trial NN test O
of NN stopwords O
Mycobacterium CAPITAL NNP mycobacteria T
vaccae NN T
immunotherapy JJ immunotherapy T
for NN stopwords O
tuberculosis NN tuberculosis D
in NN stopwords inch O
KwaZulu CAPITAL NNP O
, , O
South CAPITAL NNP South O
Africa CAPITAL DT Africa O
, , O
1991-97 CD O

Diagnostic CAPITAL NNP diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
objective NN aim O
test NN trial O
that NN stopwords O
may VB May O
augment DT augment O
clinical JJ clinical O
judgment NN judgment O
in NN stopwords inch O
selecting NN choose O
hemodynamically NN O
stable NN stable O
patients VB patient O
with NN stopwords O
potential NN potential O
tangential VB digressive O
gunshot NN gunfire D
wounds NN wound D
for NN stopwords O
observation NN observation O
and DT stopwords O
is NN stopwords be O
especially NN particularly O
useful JJ useful O
in NN stopwords inch O
identifying NN identify O
intra-abdominal NN D
hemorrhage NN bleeding D

An CAPITAL DT Associate_in_Nursing O
informational NN informational O
note JJ note O

The CAPITAL NNP O
patient VB patient O
had VB stopwords have O
previously NN previously O
been NN stopwords be O
immunized JJ immunize O
with NN stopwords O
two NN two O
doses NN dose O
of NN stopwords O
Hib CAPITAL NNP D
conjugate NNS conjugate_solution O
vaccine NN vaccine T
( ( O
PRP-T CAPITAL NNP O
) ) O

A CAPITAL DT angstrom O
radiation VB radiation O
dose-response NN O
relationship NN relationship O
is NN stopwords be O
demonstrated NN show O
for NN stopwords O
all DT stopwords all O
sarcomas VB sarcoma O
and DT stopwords O
, , O
for NN stopwords O
the NN stopwords O
first NN first O
time NN time O
in NN stopwords inch O
humans NN world O
, , O
for NN stopwords O
soft NN soft O
tissue NN tissue O
sarcomas VB sarcoma O

Northern CAPITAL NNP Northern O
analysis DT analysis O
revealed NN uncover O
DNAS1L3 CAPITAL NNP O
expression NN expression O
nearly RB about O
exclusively NN entirely O
in NN stopwords inch O
liver NN liver O
, , O
while NN stopwords while O
DNAS1L2 CAPITAL NNP O
expression NN expression O
was VB stopwords Washington O
detected NN detect O
in NN stopwords inch O
brain NN brain O
by NN stopwords by O
RT-PCR CAPITAL NNP O

At CAPITAL DT astatine O
the NN stopwords O
time NN time O
of NN stopwords O
scanning JJ scanning O
, , O
11 DIGITS CD eleven O
subjects NN subject O
( ( O
3 DIGITS CD three O
% NN O
) ) O
had VB stopwords have O
already DT already O
suffered NN suffer O
12 DIGITS CD twelve O
events NN event O
( ( O
5 DIGITS CD five O
infarctions NN infarct D
and DT stopwords O
7 DIGITS CD seven O
revascularizations NN D
) ) O
during NN stopwords O
the NN stopwords O
24-month CD O
prescanning NN O
period NN time_period O

The CAPITAL NNP O
persistent NN persistent O
vegetative NN vegetative O
state NN state O
after DT stopwords after O
closed NNS close D
head NN head D
injury NN injury D
: : O
clinical JJ clinical O
and DT stopwords O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O
findings NN findings O
in NN stopwords inch O
42 DIGITS CD forty-two O
patients VB patient O

Sumatriptan CAPITAL NNP T
and DT stopwords O
other JJ stopwords other O
selective NN selective O
serotonin NN serotonin T
agonists DT protagonist T
represent NN represent O
a DT stopwords angstrom O
major VB major O
breakthrough NN discovery O
in NN stopwords inch O
acute DT acute_accent D
migraine NN migraine D
treatment NN treatment O

Patients CAPITAL VB patient O
took NN take O
a DT stopwords angstrom O
single NN single O
tablet VB tablet O
daily IN daily O
, , O
and DT stopwords O
attended DT attend O
for NN stopwords O
prothrombin NN prothrombin O
time NN time O
( ( O
PT CAPITAL NNP platinum O
) ) O
measurements NN measurement O
at DT stopwords astatine O
weeks NN week O
1 DIGITS CD one O
, , O
2 DIGITS CD two O
, , O
3 DIGITS CD three O
, , O
4 DIGITS CD four O
, , O
6 DIGITS CD six O
, , O
and DT stopwords O
12 DIGITS CD twelve O
, , O
and DT stopwords O
then NN stopwords then O
every NN every O
3 DIGITS CD three O
months NN calendar_month O

weekly NN weekly O
paclitaxel VB T
was VB stopwords Washington O
very NN stopwords very O
well NN well O
tolerated NN digest O
, , O
yet NN yet O
was VB stopwords Washington O
effective NN effective O
for NN stopwords O
recurrent NN perennial D
cervical NNS cervical D
adenocarcinoma DT adenocarcinoma D

Screening CAPITAL NNP screening O
for NN stopwords O
Chlamydia CAPITAL NNP chlamydia D
trachomatis NN D
? . O

Leprosy CAPITAL NNP leprosy D
type NN type D
1 DIGITS CD one D
reaction NN chemical_reaction O
as DT stopwords arsenic O
the NN stopwords O
first NN first O
manifestation VB manifestation O
of NN stopwords O
borderline NN boundary_line O
lepromatous NN D
leprosy NN leprosy D
in NN stopwords inch O
a DT stopwords angstrom O
young NN young O
native RB native O
German CAPITAL NNP German O

In CAPITAL PRP inch O
21 DIGITS CD twenty-one O
patients VB patient O
B CAPITAL NN bacillus O

BACKGROUND CAPITAL IN background O
: : O
We CAPITAL NNP O
assessed DT measure O
the NN stopwords O
accuracy DT accuracy O
of NN stopwords O
two NN two O
electron NN electron O
beam NN radio_beam O
computed NNS calculate O
tomography NN imaging O
( ( O
EBCT CAPITAL NN O
) ) O
protocols NN protocol O
for NN stopwords O
predicting NN predict O
coronary NNS coronary_thrombosis D
events NN event D

Effects CAPITAL NNP effects O
of NN stopwords O
smoking JJ smoke O
on NN stopwords on O
selected NN choose O
clinical JJ clinical O
obstetric NN obstetric O
factors VB factor O

Does CAPITAL NNP Department_of_Energy O
blinding NN blind O
of NN stopwords O
readers NN reader O
affect DT affect O
results NN consequence O
of NN stopwords O
meta-analyses NN O
? . O

Facial CAPITAL NNP facial D
palsy VB paralysis O
relevant NN relevant O
to NN stopwords O
HIV CAPITAL NNP HIV O
seropositivity NN O

METHODS CAPITAL NNP method O
AND CAPITAL DT O
RESULTS CAPITAL NNP consequence O
: : O
Platelet CAPITAL NNP platelet O
P-selectin CAPITAL NNP O
( ( O
CD62 CAPITAL NNP O
) ) O
and DT stopwords O
activated DT trip O
GP CAPITAL NNP general_practitioner O
IIb/IIIa CAPITAL PRP O
( ( O
PAC-1 CAPITAL VB O
) ) O
expression NN expression O
on NN stopwords on O
platelet NN platelet O
membrane NN membrane O
was VB stopwords Washington O
quantified NN quantify O
in NN stopwords inch O
whole NN whole O
blood NN blood O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
platelet NN platelet O
aggregation DT collection O
in NN stopwords inch O
platelet-rich NN O
plasma NN plasma O
in NN stopwords inch O
43 DIGITS CD forty-three O
patients VB patient O
with NN stopwords O
unstable JJ unstable D
angina DT angina D
before NN stopwords earlier O
and DT stopwords O
during NN stopwords O
treatment NN treatment O
with NN stopwords O
UFH CAPITAL NNP T
or NN stopwords Oregon O
enoxaparin NN T

An CAPITAL DT Associate_in_Nursing O
informational NN informational O
note JJ note O

Treatment CAPITAL NNP treatment O
of NN stopwords O
renal NN nephritic D
failure VB failure D
in NN stopwords inch O
idiopathic JJ idiopathic D
membranous NN membranous D
nephropathy JJ kidney_disease D
with NN stopwords O
azathioprine DT azathioprine T
and DT stopwords T
prednisolone NN prednisolone T

Lutein CAPITAL NNP xanthophyll T
improves JJ better O
visual NN ocular O
function JJ function O
in NN stopwords inch O
some NN stopwords some O
patients VB patient O
with NN stopwords O
retinal NN retinene D
degeneration NN degeneration D
: : O
a DT stopwords angstrom O
pilot NN pilot O
study NN survey O
via NN O
the NN stopwords O
Internet CAPITAL PRP internet O

In CAPITAL PRP inch O
a DT stopwords angstrom O
follow-up JJ follow-up O
study NN survey O
operative JJ secret_agent O
risk NN hazard O
, , O
postoperative NN postoperative O
functional JJ functional O
disorders NN disorder O
and DT stopwords O
incidence NN incidence O
of NN stopwords O
anastomotic DT anastomotic O
( ( O
recurrent NN perennial O
) ) O
ulcer JJ ulcer O
after DT stopwords after O
partial NN partial_derivative T
gastrectomy VB gastrectomy T
with NN stopwords T
Roux-en-Y CAPITAL NNP T
gastrojejunostomy VB T
for NN stopwords O
gastroduodenal VB gastroduodenal D
ulcer JJ ulcer D
were NN stopwords be O
evaluated NN measure O
in NN stopwords inch O
52 DIGITS CD fifty-two O
patients VB patient O

purpose NN purpose O
: : O
a DT stopwords angstrom O
prospective NN prospective O
randomized VB randomize O
trial NN test O
in NN stopwords inch O
small-cell JJ O
lung NN lung O
cancer VB cancer O
( ( O
sclc JJ O
) ) O
was VB stopwords Washington O
performed NN perform O
to NN stopwords O
determine NN determine O
if NN stopwords O
intensification NN intensification O
of NN stopwords O
the NN stopwords O
platinum NN platinum O
dose NN dose O
by NN stopwords by O
giving NN giving O
cisplatin NN T
and DT stopwords T
carboplatin VB T
in NN stopwords inch O
combination NNS combination O
to NN stopwords O
patients VB patient O
with NN stopwords O
sclc JJ D
yields NN output O
higher NN higher O
response NN response O
rates VB rates O
and DT stopwords O
survival NN survival O
, , O
than NN stopwords O
carboplatin VB T
alone DT alone T
in NN stopwords inch T
a DT stopwords angstrom T
combination NNS combination T
chemotherapy NNS chemotherapy T
regimen NN regimen T

multilocularis NN O
from JJ stopwords O
wild NN wild O
hosts NN host O
has VB stopwords hour_angle O
been NN stopwords be O
demonstrated NN show O
, , O
the NN stopwords O
question NN question O
of NN stopwords O
its NN stopwords information_technology O
long-term NN long-run O
efficacy NN efficacy O
and DT stopwords O
other JJ stopwords other O
unresolved JJ unsolved O
problems NN problem O
have VB stopwords rich_person O
to NN stopwords O
be NN stopwords beryllium O
addressed DT address O
by NN stopwords by O
consecutive NNS back-to-back O
studies NN survey O
before NN stopwords earlier O
routine NN routine O
application DT application O
can VB stopwords can O
be NN stopwords beryllium O
recommended NN recommend O

Causes CAPITAL VB cause O
of NN stopwords O
this NN stopwords O
kind NN kind O
of NN stopwords O
pollution NN pollution O
are DT stopwords are O
partially NN partially O
linked NN associate O
to NN stopwords O
the NN stopwords O
external NN external O
pollution NN pollution O
and DT stopwords O
the NN stopwords O
outdoor JJ outdoor O
environment NN environment O
and DT stopwords O
also DT besides O
are DT stopwords are O
function JJ function O
of NN stopwords O
human NN homo O
activities DT activity O
and DT stopwords O
introduced NN introduce O
products NN merchandise O
in NN stopwords inch O
the NN stopwords O
habitat NN habitat O
( ( O
heating NN heating O
, , O
tabagisme VB O
, , O
handywork VB O
, , O
products NN merchandise O
of NN stopwords O
maintenance VB care O
, , O
coatings NNS coating O
, , O
materials VB material O
of NN stopwords O
construction NNS construction O
, , O
etc NN O

Ninety-six CAPITAL NNP ninety-six O
patients VB patient O
with NN stopwords O
disseminated NN circulate D
malignant VB malignant D
melanoma NN melanoma D
received NN receive O
thrice NN thrice O
weekly NN weekly O
intramuscular NN intramuscular O
injections NN injection O
of NN stopwords O
leukocyte NN leukocyte T
A CAPITAL DT angstrom T
recombinant NN recombinant T
interferon NN interferon T
( ( T
rIFN-alpha NN T
A CAPITAL DT angstrom T
, , T
Roferon-A CAPITAL NNP T
, , T
Hoffmann CAPITAL NNP Hoffmann T
La CAPITAL VB lanthanum T
Roche CAPITAL NNP T
) ) T
at DT stopwords astatine O
doses NN dose O
of NN stopwords O
12 DIGITS CD twelve O
X CAPITAL NN ten O
10 DIGITS CD ten O
( ( O
6 DIGITS CD six O
) ) O
U/m2 CAPITAL NNP O
or NN stopwords Oregon O
50 DIGITS CD fifty O
X CAPITAL NN ten O
10 DIGITS CD ten O
( ( O
6 DIGITS CD six O
) ) O
U/m2 CAPITAL NNP O
with NN stopwords O
or NN stopwords Oregon O
without NN O
cimetidine NN cimetidine O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
immunorestorative JJ O
agent DT agent O

There CAPITAL NNP there O
were NN stopwords be O
no NNS stopwords no O
differences NN difference O
in NN stopwords inch O
PIBF CAPITAL NNP O
levels NN degree O
by NN stopwords by O
therapy NN therapy O
used JJ use O
in NN stopwords inch O
non-pregnant JJ O
cases VB case O
or NN stopwords Oregon O
in NN stopwords inch O
the NN stopwords O
pregnant NN pregnant O
group NN group O

China CAPITAL NNP China O
's POS O
human-organ NN O
trade NN trade O
highlighted NN foreground O
by NN stopwords by O
US CAPITAL NNP United_States O
arrest DT apprehension O
of NN stopwords O
`` `` O
salesman VB salesman O
'' POS O

MATERIALS CAPITAL NNP material O
AND CAPITAL DT O
METHODS CAPITAL NNP method O
: : O
The CAPITAL NNP O
panel VB panel O
searched NN search O
the NN stopwords O
MEDLINE CAPITAL NNP MEDLINE O
data VB data O
base VB base O
for NN stopwords O
all DT stopwords all O
articles DT article O
through NN stopwords done O
1993 DIGITS CD O
on NN stopwords on O
surgical NN surgical T
treatment NN treatment T
of NN stopwords O
female JJ female D
stress NN stress D
urinary JJ urinary D
incontinence NN incontinence D

Our CAPITAL NNP O
data VB data O
( ( O
Reddy CAPITAL NNP O
et NN O
al DT aluminum O
. . O
, , O
Radiat CAPITAL VB O

Effectiveness CAPITAL NNP effectiveness O
of NN stopwords O
pseudoephedrine NN pseudoephedrine T
plus NN asset T
acetaminophen DT acetaminophen T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
symptoms NN symptom O
attributed DT impute O
to NN stopwords O
the NN stopwords O
paranasal NN paranasal O
sinuses NN fistula O
associated DT associate O
with NN stopwords O
the NN stopwords O
common NNS park D
cold NNS cold D

Online CAPITAL NNP on-line O

Comparison CAPITAL NNP comparison O
of NN stopwords O
neutral JJ neutral O
fat VB fat O
and DT stopwords O
free JJ free O
fatty VB fatso O
acids DT acid O
in NN stopwords inch O
high NN high O
lipid-low NN O
carbohydrate VB carbohydrate O
diets NN diet O
for NN stopwords O
the NN stopwords O
growing NN growth O
chicken JJ chicken O

November CAPITAL NNP November O
13-15 CD O
, , O
1996 DIGITS CD O

Immobilized CAPITAL PRP immobilize O
antibody DT antibody O
layers NN layer O
were NN stopwords be O
stabilized NN stabilize O
with NN stopwords O
sucrose NN sucrose O
, , O
dehydrated NN dehydrate O
, , O
and DT stopwords O
stored NN store O
refrigerated NN refrigerate O
with NN stopwords O
desiccant NN desiccant O

Clinical CAPITAL NNP clinical O
physiopathology NN O
of NN stopwords O
the NN stopwords O
patency VB patency O
of NN stopwords O
the NN stopwords O
interatrial NN O
septum NN septum O

They CAPITAL NNP O
underline JJ underscore O
that NN stopwords O
it NN stopwords information_technology O
is NN stopwords be O
necessary JJ necessity O
to NN stopwords O
agree DT agree O
in NN stopwords inch O
considering NNS see O
the NN stopwords O
various NN assorted O
genetic NN familial O
and DT stopwords O
epigenetic NN O
, , O
endogenous NN endogenous O
and DT stopwords O
exogenous NN exogenous O
mechanisms NN mechanism O
that NN stopwords O
lead NN lead O
to NN stopwords O
the NN stopwords O
complex NNS complex O
aging DT ripening O
phenomenon NN phenomenon O
multiple NN multiple O
and DT stopwords O
interrelated NN relate O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Acute CAPITAL DT acute_accent D
hydrocephalus NN hydrocephalus D
and DT stopwords O
brain NN brain D
abscess DT abscess D
in NN stopwords inch O
Listeria CAPITAL NNP listeria D
monocytogenes NN D
meningitis NN meningitis D

Alcohol CAPITAL DT alcohol O
and DT stopwords O
the NN stopwords O
heart NN heart O

Most CAPITAL NNP most O
adverse DT adverse O
experiences NN experience O
were NN stopwords be O
related NN associate O
to NN stopwords O
peripheral NN peripheral O
dopaminergic NN O
activity DT activity O

Fludarabine CAPITAL NNP T
and DT stopwords O
ara-C DT T
successfully NN successfully O
eradicated NN eliminate O
bone NN bone D
marrow NN marrow D
disease NN disease D
in NN stopwords inch O
16 DIGITS CD sixteen O
of NN stopwords O
27 DIGITS CD twenty-seven O
patients VB patient O
( ( O
59 DIGITS CD fifty-nine O
% NN O
) ) O
, , O
23 DIGITS CD twenty-three O
patients VB patient O
of NN stopwords O
which NN stopwords O
had VB stopwords have O
been NN stopwords be O
treated NN treat O
previously NN previously O
with NN stopwords O
high-dose NN O
ara-C DT T

Resolution CAPITAL NNP resolution O
of NN stopwords O
recalcitrant NN fractious D
molluscum NN molluscum D
contagiosum NNS D
virus NN virus D
lesions NN lesion D
in NN stopwords inch O
human NN homo O
immunodeficiency JJ immunodeficiency O
virus-infected NN O
patients VB patient O
treated NN treat O
with NN stopwords O
cidofovir NN T

A CAPITAL DT angstrom O
subchorial NN O
placental NN placental O
hematoma NN hematoma D
, , O
which NN stopwords O
detected NN detect O
as DT stopwords arsenic O
a DT stopwords angstrom O
subchorial NN O
placental NN placental O
lucencies NN D
by NN stopwords by O
ultrasonography JJ sonography O
, , O
can VB stopwords can O
be NN stopwords beryllium O
a DT stopwords angstrom O
cause VB cause O
of NN stopwords O
reversible NN reversible O
nonimmune JJ liable D
hydrops NN edema D
fetalis JJ D

Cytokines CAPITAL NNP cytokine O
and DT stopwords O
peripheral NN peripheral O
neuropathies JJ neuropathy O

Comparison CAPITAL NNP comparison O
of NN stopwords O
the NN stopwords O
frequency JJ frequency O
of NN stopwords O
lymphocyte NN lymphocyte O
expression NN expression O
of NN stopwords O
PIBF CAPITAL NNP O
in NN stopwords inch O
pregnant NN pregnant O
versus NN O
non-pregnant JJ O
women NN woman O
were NN stopwords be O
made VB make O

Human CAPITAL NNP homo O
cervico-facial NNS O
morphogenesis NN morphogenesis O

Presentations CAPITAL NNP presentation O
from JJ stopwords O
the NN stopwords O
2nd CD second O
NIH CAPITAL NNP National_Institutes_of_Health O
Symposium CAPITAL NNP symposium O
on NN stopwords on O
Therapeutic CAPITAL NNP remedy O
Oligonucleotides CAPITAL NNP O
: : O
Targeting CAPITAL VB target O
Transcription CAPITAL NNP transcription O
Factors CAPITAL NNP factor O
and DT stopwords O
Signaling CAPITAL NNP signal O
Pathways CAPITAL VB nerve_pathway O

Carbon CAPITAL VB carbon D
monoxide NN monoxide D
poisoning NN poisoning D
treated NN treat O
with NN stopwords O
hyperbaric NN T
oxygen JJ oxygen T
: : O
metabolic NN metabolic O
acidosis DT acidosis O
as DT stopwords arsenic O
a DT stopwords angstrom O
predictor NN forecaster O
of NN stopwords O
treatment NN treatment O
requirements NN requirement O

New CAPITAL NNP new O
authorship DT writing O
practices NN practice O
are DT stopwords are O
needed JJ necessitate O
in NN stopwords inch O
developing NN development O
countries NNS state O

The CAPITAL NNP O
relationship NN relationship O
to NN stopwords O
fatty VB fatso O
acids DT acid O

Platelet CAPITAL NNP platelet O
Receptor CAPITAL NNP receptor O
Inhibition CAPITAL PRP inhibition O
in NN stopwords inch O
Ischemic CAPITAL PRP ischemic O
Syndrome CAPITAL NNP syndrome O
Management CAPITAL NNP management O
( ( O
PRISM CAPITAL NNP prism O
) ) O
Study CAPITAL NNP survey O
Investigators CAPITAL PRP research_worker O

Plasma CAPITAL NNP plasma T
exchange NN exchange T
and DT stopwords T
tacrolimus-mycophenolate VB T
rescue NN rescue T
for NN stopwords O
acute DT acute_accent D
humoral NN humoral D
rejection NN rejection D
in NN stopwords inch O
kidney NN kidney O
transplantation NN transplant O

Mean CAPITAL NNP mean O
heart NN heart O
rate VB rate O
under JJ stopwords nether O
relaxed NN relax O
sitting NN sitting O
condition NNS condition O
was VB stopwords Washington O
significantly NN significantly O
higher NN higher O
in NN stopwords inch O
the NN stopwords O
study NN survey O
group NN group O

PATIENTS CAPITAL VB patient O
: : O
Patients CAPITAL VB patient O
with NN stopwords O
gunshot NN gunfire D
wounds NN wound D
to NN stopwords O
the NN stopwords O
abdomen DT abdomen O
and DT stopwords O
a DT stopwords angstrom O
systolic NN systolic O
blood NN blood O
pressure NN pressure O
of NN stopwords O
at DT stopwords astatine O
least NN least O
90 DIGITS CD ninety O
mm NNS millimeter O
Hg CAPITAL NNP mercury O

Treatment CAPITAL NNP treatment O
of NN stopwords O
Barrett CAPITAL IN D
esophagus NN esophagus D
with NN stopwords O
argon DT argon T
plasma NN plasma T
coagulation NNS curdling T
with NN stopwords T
acid DT acid T
suppression NN suppression T
-- : O
a DT stopwords angstrom O
prospective NN prospective O
study NN survey O

Teaching CAPITAL NNP teaching O
irritable NN cranky D
bowel NN intestine D
syndrome NN syndrome D
patients VB patient O
to NN stopwords O
care VB care O
for NN stopwords O
themselves NN stopwords O

Report CAPITAL NNP report O
of NN stopwords O
spores NN spore O
of NN stopwords O
Henneguya CAPITAL NNP O
salminicola VB O
( ( O
Myxozoa CAPITAL NNP O
) ) O
in NN stopwords inch O
human NN homo O
stool NN stool O
specimens NN specimen O
: : O
possible NN possible O
source NN beginning O
of NN stopwords O
confusion NNS confusion O
with NN stopwords O
human NN homo O
spermatozoa NN sperm O

Research CAPITAL NNP research O
in NN stopwords inch O
complementary NNS complementary_color O
medicine NN medicine O
: : O
results NN consequence O
and DT stopwords O
problems NN problem O

Gene CAPITAL NNP gene T
therapy NN therapy T
of NN stopwords O
malignant VB malignant D
brain NN brain D
tumors NN tumor D

This CAPITAL NNP O
clinical JJ clinical O
scenario JJ scenario O
must NN must O
be NN stopwords beryllium O
differentiated NN distinguish O
from JJ stopwords O
that NN stopwords O
in NN stopwords inch O
which NN stopwords O
germ NN source D
cell NNS cell D
tumors NN tumor D
maintain VB keep O
their NN stopwords O
malignant VB malignant O
characteristics NNS feature O
with NN stopwords O
elevated NN elevated_railway O
levels NN degree O
of NN stopwords O
serum NN serum O
tumor NN tumor O
markers NN marker O

Screening CAPITAL NNP screening O
tests NN trial O
of NN stopwords O
microorganisms NN microorganism O
for NN stopwords O
the NN stopwords O
microbial NN microbial O
transformation NN transformation O
of NN stopwords O
griseophenone NN O
A CAPITAL DT angstrom O
, , O
N-methylcoclaurine CAPITAL NNP O
and DT stopwords O
sparteine NN O

Decrease CAPITAL NNP decrease O
in NN stopwords inch O
antibiotic DT antibiotic O
susceptibility NN susceptibility O
or NN stopwords Oregon O
increase NN addition O
in NN stopwords inch O
resistance NN resistance O
? . O

The CAPITAL NNP O
mean NN mean O
volume NN volume O
of NN stopwords O
the NN stopwords O
middle NN center O
zone NN zone O
, , O
corresponding NNS match O
to NN stopwords O
the NN stopwords O
area DT area O
of NN stopwords O
hemorrhagic NN hemorrhagic D
coagulation NNS curdling D
necrosis JJ necrosis D
, , O
was VB stopwords Washington O
44.4 CD O
+/- NN O
17.6 CD O
mm3 NN O
; : O
the NN stopwords O
mean NN mean O
lesion NN lesion O
volume NN volume O
as DT stopwords arsenic O
defined NN specify O
by NN stopwords by O
the NN stopwords O
outer JJ outer O
zone NN zone O
, , O
corresponding NNS match O
to NN stopwords O
perilesional NN D
edema NN edema D
, , O
was VB stopwords Washington O
262.2 CD O
+/- NN O
111.6 CD O
mm3 NN O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Frontal CAPITAL NNP frontlet D
dysfunction NN dysfunction D
blocks NN block O
the NN stopwords O
therapeutic NN remedy O
effect NN consequence O
of NN stopwords O
THA CAPITAL NNP T
on NN stopwords on O
attention DT attention O
in NN stopwords inch O
Alzheimer CAPITAL DT D
's POS D
disease NN disease D

Dosing CAPITAL NNP dose O
of NN stopwords O
amoxicillin/clavulanate DT T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
lower NN lower_berth D
respiratory NN respiratory D
tract NN tract D
infection NN infection D

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
investigate NN investigate O
phenotypic NN phenotypical O
characteristics NNS feature O
of NN stopwords O
families VB family O
potentially NN potentially O
linked NN associate O
to NN stopwords O
the NN stopwords O
hereditary NN familial O
prostate NN prostate_gland O
cancer VB cancer O
1 DIGITS CD one O
( ( O
HPC1 CAPITAL NNP O
) ) O
locus NN venue O
on NN stopwords on O
chromosome NN chromosome O
1q24-25 CD O

Are CAPITAL DT are O
Japanese CAPITAL NNP Japanese O
researchers NN research_worker O
exploiting NN exploit O
Thai CAPITAL NNP Thai O
HIV CAPITAL NNP HIV O
patients VB patient O
? . O

As CAPITAL DT arsenic O
noted JJ note O
previously NN previously O
, , O
using JJ exploitation O
chemotherapy NNS chemotherapy O
, , O
a DT stopwords angstrom O
small JJ small O
proportion NN proportion O
of NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
malignant VB malignant D
melanoma NN melanoma D
, , O
despite NN contempt O
prior NN prior O
therapy NN therapy O
, , O
may VB May O
achieve DT achieve O
prolonged NN prolong O
objective NN aim O
regression NN arrested_development O
with NN stopwords O
rIFN-alpha NN T
A CAPITAL DT angstrom T

1-year CD O
life-table NN O
estimates NN estimate O
for NN stopwords O
the NN stopwords O
primary NN primary O
event NN event O
were NN stopwords be O
8.6 CD O
% NN O
( ( O
95 DIGITS CD ninety-five O
% NN O
CI CAPITAL NNP curie O
7.6-9.6 CD O
) ) O
for NN stopwords O
160 DIGITS CD one_hundred_sixty O
mg NN milligram O
aspirin DT aspirin T
, , O
8.4 CD O
% NN O
( ( O
7.4-9.4 CD O
) ) O
for NN stopwords O
3 DIGITS CD three O
mg NN milligram O
warfarin NN warfarin T
with NN stopwords O
80 DIGITS CD eighty O
mg NN milligram O
aspirin DT aspirin T
, , O
and DT stopwords O
8.8 CD O
% NN O
( ( O
7.6-10 CD O
) ) O
for NN stopwords O
1 DIGITS CD one O
mg NN milligram O
warfarin NN warfarin T
with NN stopwords O
80 DIGITS CD eighty O
mg NN milligram O
aspirin DT aspirin T

Evidence CAPITAL NNP evidence O
on NN stopwords on O
effectiveness NN effectiveness O
is NN stopwords be O
stronger NN strong O
for NN stopwords O
statins NN lipid-lowering_medicine T
than NN stopwords O
for NN stopwords O
other JJ stopwords other O
treatments NN treatment O

Late CAPITAL VB late O
prenatal NN prenatal O
ultrasound JJ ultrasound O
features NN feature O
of NN stopwords O
hydrometrocolpos NN O
secondary NN secondary O
to NN stopwords O
cloacal NNS D
anomaly DT anomaly D
: : O
case VB case O
reports NN report O
and DT stopwords O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
literature NN literature O

Genetic CAPITAL NNP familial O
testing NN testing O
for NN stopwords O
cancer VB cancer D
risk NN hazard O
: : O
how NN stopwords O
to NN stopwords O
reconcile NN accommodate O
the NN stopwords O
conflicts NNS conflict O

On CAPITAL NNP on O
admission DT admission O
, , O
patients VB patient O
were NN stopwords be O
randomly VB randomly O
assigned DT delegate O
G-CSF CAPITAL NNP T
( ( T
filgrastim NN T
) ) T
therapy NN therapy T
( ( O
n NN nitrogen O
= NN O
20 DIGITS CD twenty O
) ) O
or NN stopwords Oregon O
placebo NN placebo O
( ( O
n NN nitrogen O
= NN O
20 DIGITS CD twenty O
) ) O
for NN stopwords O
7 DIGITS CD seven O
days VB days O

Is CAPITAL PRP be O
concomitant NNS accompaniment T
radiotherapy VB radiotherapy T
and DT stopwords T
chemotherapy NNS chemotherapy T
superior NN superior O
to NN stopwords O
optimal JJ optimum O
radiotherapy VB radiotherapy T
alone DT alone O
in NN stopwords inch O
anal DT anal D
cancer VB cancer D
? . O

Second CAPITAL NNP second O
, , O
children JJ child O
in NN stopwords inch O
the NN stopwords O
first NN first O
year NN year O
of NN stopwords O
life NN life O
are DT stopwords are O
at DT stopwords astatine O
highest NN high O
risk NN hazard O
of NN stopwords O
progression NN progression O
and DT stopwords O
should NN stopwords O
be NN stopwords beryllium O
treated NN treat O
with NN stopwords O
trimethoprim-sulfamethoxazole NN T
to NN stopwords O
prevent NN prevent O
Pneumocystis CAPITAL NNP D
carinii VB D
pneumonia NN pneumonia D
, , O
and DT stopwords O
targeted VB target O
for NN stopwords O
receiving NN receive O
antiretrovirals DT O

Directly CAPITAL NNP directly O
observed NN detect O
therapy NN therapy O
and DT stopwords O
treatment NN treatment O
completion NNS completion O
for NN stopwords O
tuberculosis NN tuberculosis D
in NN stopwords inch O
the NN stopwords O
United CAPITAL NNP unite O
States CAPITAL NNP state O
: : O
is NN stopwords be O
universal JJ universal O
supervised NN oversee O
therapy NN therapy O
necessary JJ necessity O
? . O

Oncogenic CAPITAL NNP O
raf-1 VB O
induces NN induce O
the NN stopwords O
expression NN expression O
of NN stopwords O
non-histone JJ O
chromosomal NN chromosomal O
architectural DT architectural O
protein NN protein O
HMGI-C CAPITAL NNP O
via NN O
a DT stopwords angstrom O
p44/p42 NN O
mitogen-activated NN O
protein NN protein O
kinase-dependent NN O
pathway VB nerve_pathway O
in NN stopwords inch O
salivary VB salivary O
epithelial NN epithelial O
cells NNS cell O

However CAPITAL NNP however O
, , O
coronary NNS coronary_thrombosis O
death NN death O
and DT stopwords O
infarction NN infarct D
were NN stopwords be O
not JJ stopwords not O
significantly NN significantly O
more NN stopwords More O
frequent JJ patronize O
in NN stopwords inch O
higher NN higher O
quartiles NN quartile O

A CAPITAL DT angstrom O
randomized VB randomize O
, , O
double-blind NN O
, , O
dose-response NN O
comparison NNS comparison O
of NN stopwords O
epidural NN epidural_anesthesia T
fentanyl JJ Fentanyl T
versus NN O
sufentanil NN T
analgesia DT analgesia T
after DT stopwords after O
cesarean NNS cesarean_delivery T
section NN section T

SETTING/PARTICIPANTS CAPITAL NNP O
: : O
A CAPITAL DT angstrom O
total NN sum O
of NN stopwords O
1604 DIGITS CD O
patients VB patient O
with NN stopwords O
retinoblastoma NN retinoblastoma D
who NN stopwords World_Health_Organization O
survived NN survive O
at DT stopwords astatine O
least NN least O
1 DIGITS CD one O
year NN year O
after DT stopwords after O
diagnosis NN diagnosis O
, , O
identified NN identify O
from JJ stopwords O
hospital NN hospital O
records NN record O
in NN stopwords inch O
Massachusetts CAPITAL NNP Massachusetts O
and DT stopwords O
New CAPITAL NNP new O
York CAPITAL NNP York O
during NN stopwords O
1914 DIGITS CD O
to NN stopwords O
1984 DIGITS CD O

It CAPITAL PRP information_technology O
is NN stopwords be O
not JJ stopwords not O
known NN know O
if NN stopwords O
such NN stopwords such O
damage VB damage O
occurs JJ happen O
in NN stopwords inch O
humans NN world O
or NN stopwords Oregon O
if NN stopwords O
there NN stopwords there O
are DT stopwords are O
clinical JJ clinical O
consequences NNS consequence O

An CAPITAL DT Associate_in_Nursing O
open-label JJ O
study NN survey O
of NN stopwords O
lamivudine NN lamivudine T
for NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
in NN stopwords inch O
six NN six O
patients VB patient O
with NN stopwords O
chronic NN chronic O
renal NN nephritic O
failure VB failure O
before NN stopwords earlier O
and DT stopwords O
after DT stopwords after O
kidney NN kidney O
transplantation NN transplant O

The CAPITAL NNP O
mechanisms NN mechanism O
of NN stopwords O
dioxin NN dioxin O
action DT action O
are DT stopwords are O
similar NN similar O
to NN stopwords O
those NN stopwords O
of NN stopwords O
a DT stopwords angstrom O
hormone NN hormone O

Adverse CAPITAL DT adverse O
drug NN drug O
effects NN effects O
are DT stopwords are O
manifold VB manifold O
and DT stopwords O
heterogenous NN heterogeneous O

In CAPITAL PRP inch O
contrast NNS contrast O
, , O
male VB male O
Msh2-/-p53-/- CAPITAL NNP O
mice NN mouse O
are DT stopwords are O
viable NN feasible O
, , O
but NN stopwords merely O
succumb NN yield O
to NN stopwords O
tumours NN tumor D
significantly NN significantly O
earlier VB earlier O
( ( O
t1-2 NN O
is NN stopwords be O
73 DIGITS CD seventy-three O
days VB days O
) ) O
than NN stopwords O
either NN either O
Msh2-/- CAPITAL NNP O
or NN stopwords Oregon O
p53-/- NN O
littermates NN O

Needle-exchange CAPITAL NNP O
programmes NN program O
in NN stopwords inch O
the NN stopwords O
USA CAPITAL NNP United_States O

Corticosteroid CAPITAL NNP corticosteroid T
injections NN injection T
for NN stopwords O
sciatica JJ sciatica D

Medical CAPITAL NNP checkup T
treatments NN treatment T
for NN stopwords O
balding VB bald D
in NN stopwords inch O
men NN work_force O

PDS CAPITAL NNP palladium O
produces NN produce O
a DT stopwords angstrom O
transcript NN transcript O
of NN stopwords O
approximately DT approximately O
5 DIGITS CD five O
kb NN kilobit O
that NN stopwords O
was VB stopwords Washington O
found JJ found O
to NN stopwords O
be NN stopwords beryllium O
expressed NN express O
at DT stopwords astatine O
significant NN significant O
levels NN degree O
only JJ stopwords lone O
in NN stopwords inch O
the NN stopwords O
thyroid NN thyroid_gland O

140 DIGITS CD one_hundred_forty O

Hyperbaric CAPITAL NNP T
or NN stopwords Oregon T
normobaric RB T
oxygen JJ oxygen T
for NN stopwords O
acute DT acute_accent D
carbon VB carbon D
monoxide NN monoxide D
poisoning NN poisoning D
: : O
a DT stopwords angstrom O
randomised VB randomize O
controlled NNS control O
clinical JJ clinical O
trial NN test O

Mutual CAPITAL NNP common O
relationships NN relationship O
based VB establish O
on NN stopwords on O
equality NN equality O

Help CAPITAL NNP aid O
wanted VB desire O
: : O
ultrasonographers JJ O

The CAPITAL NNP O
urine JJ urine O
screen NN screen O
did NN stopwords make O
not JJ stopwords not O
influence NN influence O
management VB management O
decisions NN decision O

SETTING CAPITAL NNP setting O
: : O
Two CAPITAL NNP two O
urban JJ urban O
trauma NN injury O
centers NNS center O

Intracranial CAPITAL PRP intracranial D
teratomas NN teratoma D
in NN stopwords inch O
fetal JJ fetal O
life NN life O
and DT stopwords O
infancy NN infancy O

In CAPITAL PRP inch O
conclusion NNS decision O
, , O
fluoride JJ fluoride O
's POS O
effects NN effects O
on NN stopwords on O
bone NN bone O
mass VB mass O
and DT stopwords O
bone NN bone O
turnover NN employee_turnover O
were NN stopwords be O
not JJ stopwords not O
mediated NN intercede O
by NN stopwords by O
PTH CAPITAL NNP O

In CAPITAL PRP inch O
fact VB fact O
, , O
time NN time O
course NNS course O
studies NN survey O
demonstrated NN show O
an DT stopwords Associate_in_Nursing O
even NN evening O
faster VB fast O
onset JJ onset O
of NN stopwords O
apoptosis DT apoptosis O
in NN stopwords inch O
ceramide-treated NNS O
BCR-ABL+ CAPITAL NNP O
BAF3 CAPITAL IN O
cells NNS cell O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
normal RB convention O
controls NNS control O

Hormonal CAPITAL NNP hormonal O
responses NN response O
to NN stopwords O
restraint NN restraint O
in NN stopwords inch O
rhesus NN rhesus O
monkeys NN monkey O

conclusions NNS decision O
: : O
therapeutic NN remedy T
vats NN VAT T
resection NN resection T
of NN stopwords O
colorectal NNS colorectal D
metastases NN metastasis D
appears DT look O
efficacious NN efficacious O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
estimate NN estimate O
the NN stopwords O
crude NNS petroleum O
incidence NN incidence O
rates VB rates O
of NN stopwords O
cerebrovascular NNS cerebrovascular D
accidents DT accident D
among DT O
the NN stopwords O
black NN black O
residents NN resident O
of NN stopwords O
Harare CAPITAL NNP Harare O

Four CAPITAL NNP four O
subsequent NN subsequent O
specimens NN specimen O
taken VB take O
to NN stopwords O
177 DIGITS CD O
h NN hydrogen O
were NN stopwords be O
also DT besides O
negative JJ negative O

Emphasis CAPITAL NNP emphasis O
on NN stopwords on O
the NN stopwords O
biomedical NN biomedical O
domain NN sphere O
and DT stopwords O
the NN stopwords O
randomized VB randomize O
controlled NNS control O
trial NN test O
( ( O
RCT CAPITAL NNP O
) ) O
alone DT alone O
reflects NN reflect O
a DT stopwords angstrom O
reductionist NN reductionist O
approach DT approach O
that NN stopwords O
fails VB fail O
to NN stopwords O
do NN stopwords bash O
justice NN justice O
to NN stopwords O
the NN stopwords O
philosophy NN doctrine O
of NN stopwords O
general NN general O
practice NN practice O

FAMILIES CAPITAL NNP family O
: : O
A CAPITAL DT angstrom O
total NN sum O
of NN stopwords O
74 DIGITS CD seventy-four O
North CAPITAL NNP North O
American CAPITAL DT American O
families VB family O
with NN stopwords O
hereditary NN familial O
prostate NN prostate_gland D
cancer VB cancer D

Managing CAPITAL NNP pull_off O
endophthalmitis NN D

Prostate CAPITAL NNP prostate_gland O
cancer VB cancer O
cases VB case O
from JJ stopwords O
the NN stopwords O
National CAPITAL NNP national O
Cancer CAPITAL VB cancer O
Data CAPITAL NNP data O
Base CAPITAL IN base O
were NN stopwords be O
used JJ use O
as DT stopwords arsenic O
a DT stopwords angstrom O
reference NN mention O
population NN population O
for NN stopwords O
comparison NNS comparison O

Diagnosing CAPITAL NNP diagnosis O
and DT stopwords O
managing VB pull_off O
polymyalgia NN D
rheumatica NN D
and DT stopwords O
temporal NN temporal_role D
arteritis DT arteritis D

Proceedings CAPITAL NNP proceeding O

With CAPITAL NNP O
this NN stopwords O
approach DT approach O
, , O
a DT stopwords angstrom O
library NN library O
specific NN particular O
to NN stopwords O
the NN stopwords O
BTA CAPITAL NNP O
6q21-31 CD O
chromosomal NN chromosomal O
region NN region O
was VB stopwords Washington O
constructed NNS construct O

We CAPITAL NNP O
report NN report O
on NN stopwords on O
the NN stopwords O
investigation NN probe O
of NN stopwords O
the NN stopwords O
binding NN binding O
of NN stopwords O
low NN low O
molecular NN molecular O
weight NN weight O
ligands NN ligand O
to NN stopwords O
immobilized JJ immobilize O
receptors NN receptor O
by NN stopwords by O
label-free NN O
detection NN detection O

Serum CAPITAL NNP serum O
urate JJ urate O
during NN stopwords O
bouts NN turn O
of NN stopwords O
acute DT acute_accent D
gouty NN gouty D
arthritis DT arthritis D

Their CAPITAL NNP O
hepatic NN liverwort O
side NN side O
effects NN effects O
must NN must O
be NN stopwords beryllium O
however NN however O
under JJ stopwords nether O
control NNS control O

Radical CAPITAL VB group T
prostatectomy NN prostatectomy T
for NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
: : O
the NN stopwords O
perineal NN perineal O
approach DT approach O
increases NN addition O
the NN stopwords O
risk NN hazard O
of NN stopwords O
surgically NN surgically O
induced NN induce O
positive NN positive O
margins NN margin O
and DT stopwords O
capsular VB capsular O
incisions NN incision O

Growth CAPITAL NNP growth O
hormone NN hormone O
secretion NN secretion O
in NN stopwords inch O
HIV-positive CAPITAL NNP O
versus NN O
HIV-negative CAPITAL NNP O
hemophilic NN haemophilic O
males VB male O
with NN stopwords O
abnormal DT abnormal O
growth NN growth O
and DT stopwords O
pubertal NN pubertal O
development NN development O

Most CAPITAL NNP most O
of NN stopwords O
the NN stopwords O
caffeine-treated VB O
eggs NN egg O
developed NN develop O
as DT stopwords arsenic O
tetraploids NN O
, , O
as DT stopwords arsenic O
parthenogenotes NN O
produced NN produce O
by NN stopwords by O
the NN stopwords O
post-GVBD NN O
activation DT activation O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Case CAPITAL VB case O
report NN report O

Chemotherapy CAPITAL NNP chemotherapy T
alone DT alone T
compared NNS compare O
with NN stopwords O
chemotherapy NNS chemotherapy T
plus NN asset T
radiotherapy VB radiotherapy T
for NN stopwords O
localized NN place O
intermediate- NN O
and DT stopwords O
high-grade NN high-grade O
non-Hodgkin JJ D
's POS D
lymphoma NN lymphoma D

Misinterpretation CAPITAL NNP misinterpretation O
of NN stopwords O
`` `` O
safe VB safe O
and DT stopwords O
adequate DT adequate O
'' POS O
to NN stopwords O
mean NN mean O
`` `` O
safety VB safety O
limit NN limit O
'' POS O
would NN O
impose JJ enforce O
restrictions NN restriction O
on NN stopwords on O
vitamin NN vitamin O
and DT stopwords O
mineral NN mineral O
intakes NN consumption O
that NN stopwords O
are DT stopwords are O
not JJ stopwords not O
needed JJ necessitate O
to NN stopwords O
ensure NN guarantee O
safety VB safety O

Fifty CAPITAL NNP fifty O
new JJ new O
genetic NN familial O
alterations DT change O
were NN stopwords be O
found JJ found O
including NN include O
24 DIGITS CD twenty-four O
deleterious NN deleterious O
mutations NN mutant O
, , O
24 DIGITS CD twenty-four O
variants NN discrepancy O
of NN stopwords O
unknown JJ unknown O
significance NN significance O
, , O
and DT stopwords O
2 DIGITS CD two O
rare NN rare O
polymorphisms NN polymorphism O

Our CAPITAL NNP O
results NN consequence O
in NN stopwords inch O
the NN stopwords O
surgical NN surgical T
treatment NN treatment T
of NN stopwords O
habitual NN accustomed D
shoulder NN shoulder D
dislocation NN dislocation D
with NN stopwords O
special NN special O
reference NN mention O
to NN stopwords O
occupational JJ occupational O
disability NN disability O

The CAPITAL NNP O
practice NN practice O
of NN stopwords O
recapping NN recapitulate O
needles JJ acerate_leaf O
with NN stopwords O
fingers NN finger O
and DT stopwords O
some NN stopwords some O
inadequate NN inadequate O
washing VB wash O
facilities VB facility O
are DT stopwords are O
areas DT area O
that NN stopwords O
require NN necessitate O
particular NN particular O
attention DT attention O

Evidence CAPITAL NNP evidence O
based VB establish O
advertising DT ad O
? . O
Half CAPITAL NNP one-half O
of NN stopwords O
drug NN drug O
advertisements DT ad O
in NN stopwords inch O
BMJ CAPITAL NNP O
over JJ stopwords over O
six NN six O
months NN calendar_month O
cited NN mention O
no NNS stopwords no O
supporting NN support O
evidence NN evidence O

Protean CAPITAL NNP protean O
agonists DT protagonist O

A CAPITAL DT angstrom O
better NN better O
understanding JJ understanding O
of NN stopwords O
the NN stopwords O
conditions NNS conditions O
and DT stopwords O
mechanisms NN mechanism O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
detection NN detection O
of NN stopwords O
adverse DT adverse O
drug NN drug O
effects NN effects O
may VB May O
further NN stopwords foster O
improve JJ better O
strategies NN scheme O
for NN stopwords O
pharmacovigilance NN O

Proposed CAPITAL NNP propose O
new JJ new O
bacterial VB bacterial O
taxa VB taxonomic_group O
and DT stopwords O
proposed NN propose O
changes NNS change O
of NN stopwords O
bacterial VB bacterial O
names RB name_calling O
published NN print O
during NN stopwords O
1996 DIGITS CD O
and DT stopwords O
considered NNS see O
to NN stopwords O
be NN stopwords beryllium O
of NN stopwords O
interest NN interest O
to NN stopwords O
medical NN checkup O
or NN stopwords Oregon O
veterinary NN veterinarian O
bacteriology VB bacteriology O

The CAPITAL NNP O
lesions NN lesion O
were NN stopwords be O
placed NN put O
within NN inside O
1 DIGITS CD one O
mm NNS millimeter O
of NN stopwords O
the NN stopwords O
ventral NN ventral O
border NN boundary_line O
of NN stopwords O
the NN stopwords O
globus NN O
pallidus VB O
internus NN O
( ( O
GPi CAPITAL NNP O
) ) O
to NN stopwords O
include NN include O
pallidothalamic VB O
outflow JJ escape O
pathways VB nerve_pathway O

Mononucleosis CAPITAL NNP infectious_mononucleosis D
infectiosa NN D
( ( O
Epstein-Barr CAPITAL NNP D
virus NN virus D
infection NN infection D

Whether CAPITAL NNP O
these NN stopwords O
cells NNS cell O
are DT stopwords are O
also DT besides O
resistant NN immune O
to NN stopwords O
apoptosis DT apoptosis O
and DT stopwords O
if NN stopwords O
so NN stopwords sol O
, , O
under JJ stopwords nether O
what NN stopwords O
conditions NNS conditions O
remains NN remains O
controversial NNS controversial O

> NN O
From CAPITAL NNP O
the NN stopwords O
Centers CAPITAL NNP center O
for NN stopwords O
Disease CAPITAL NNP disease O
Control CAPITAL NNP control O
and DT stopwords O
Prevention CAPITAL NNP prevention O

A CAPITAL DT angstrom O
key NN key O
feature NN feature O
of NN stopwords O
the NN stopwords O
method NN method O
is NN stopwords be O
isolation NN isolation O
and DT stopwords O
reverse NN reverse O
transcription NN transcription O
of NN stopwords O
mRNA NN messenger_RNA O
followed JJ follow O
by NN stopwords by O
PCR CAPITAL NNP O
amplification DT amplification O
of NN stopwords O
lysosomal NN O
alpha-glucosidase DT O
cDNA SYM complementary_DNA O
with NN stopwords O
M13-extended CAPITAL NNP O
primers NN primer O

None CAPITAL NNP none O
of NN stopwords O
the NN stopwords O
women NN woman O
yielding NN giving_up O
positive NN positive O
samples VB sample O
had VB stopwords have O
been NN stopwords be O
pre-identified NN O
on NN stopwords on O
the NN stopwords O
basis VB footing O
of NN stopwords O
history NN history O

A CAPITAL DT angstrom O
new JJ new O
splice NN splice O
site NN site O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
GAA CAPITAL VB O
gene NN gene O
of NN stopwords O
this NN stopwords O
patient VB patient O
was VB stopwords Washington O
identified NN identify O
, , O
IVS16 CAPITAL PRP O
( ( O
+2T RB O
-- : O
> NN O
C CAPITAL SYM degree_centigrade O
) ) O
, , O
resulting NN result O
in NN stopwords inch O
the NN stopwords O
deletion NN omission O
of NN stopwords O
16 DIGITS CD sixteen O
base VB base O
pairs IN pair O
of NN stopwords O
exon NN exon O
16 DIGITS CD sixteen O

Aspirin CAPITAL DT aspirin T
therapy NN therapy T
for NN stopwords O
cardiovascular VB cardiovascular D
disease NN disease D

To CAPITAL NNP O
ascertain DT determine O
the NN stopwords O
results NN consequence O
of NN stopwords O
standard NN standard T
ABVD CAPITAL DT T
chemotherapy NNS chemotherapy T
( ( T
doxorubicin NN doxorubicin T
, , T
bleomycin NN T
, , T
vinblastine NN vinblastine T
, , T
dacarbazine VB T
) ) T
in NN stopwords inch O
HIV-infected CAPITAL NNP O
patients VB patient O
with NN stopwords O
newly JJ newly D
diagnosed NN diagnose D
Hodgkin CAPITAL NNP Hodgkin D
's POS D
disease NN disease D
( ( D
HD CAPITAL NNP D
) ) D
, , O
a DT stopwords angstrom O
nonrandomized JJ O
, , O
prospective NN prospective O
, , O
multiinstitutional NN O
clinical JJ clinical O
trial NN test O
was VB stopwords Washington O
conducted NNS conduct O
by NN stopwords by O
the NN stopwords O
AIDS CAPITAL DT AIDS O
Clinical CAPITAL NNP clinical O
Trials CAPITAL NNP test O
Group CAPITAL NNP group O
( ( O
ACTG CAPITAL DT O
) ) O
, , O
in NN stopwords inch O
HIV-infected CAPITAL NNP O
patients VB patient O
with NN stopwords O
Hodgkin CAPITAL NNP Hodgkin O
's POS O
disease NN disease O

Second CAPITAL NNP second O
, , O
data VB data O
for NN stopwords O
split-dose NN O
recovery NN recovery O
are DT stopwords are O
used JJ use O
to NN stopwords O
predict NN predict O
the NN stopwords O
first-order NN O
kinetics NN dynamics O
time NN time O
constant NNS constant O
for NN stopwords O
DSB CAPITAL NNP O
repair NN repair O
( ( O
tau VB tau O
( ( O
DSBR CAPITAL NNP O
) ) O
) ) O
using JJ exploitation O
the NN stopwords O
DSB CAPITAL NNP O
model NN model O
( ( O
24 DIGITS CD twenty-four O
+/- NN O
1.5 CD O
min NN minute O
) ) O

X CAPITAL NN ten O
inactivation NN inactivation O
in NN stopwords inch O
females JJ female O
with NN stopwords O
X-linked CAPITAL LS X-linked D
disease NN disease D

Intravenous CAPITAL PRP intravenous T
immunoglobulin JJ immunoglobulin T
treatment NN treatment T
in NN stopwords inch O
multiple NN multiple D
sclerosis JJ sclerosis D

Occupation CAPITAL NNP occupation O
: : O
the NN stopwords O
keystone NN anchor O
of NN stopwords O
a DT stopwords angstrom O
curriculum NNS course_of_study O
for NN stopwords O
a DT stopwords angstrom O
self-defined NN O
profession NN profession O

Penicillin CAPITAL NNP penicillin T
can VB stopwords can O
be NN stopwords beryllium O
measured NN measure O
in NN stopwords inch O
the NN stopwords O
range VB scope O
0.25-10.0 LS O
mM NNS millimeter O
in NN stopwords inch O
the NN stopwords O
pH NN pH O
range VB scope O
6.2-7.5 CD O

objectives NN aim O
: : O
the NN stopwords O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
study NN survey O
is NN stopwords be O
to NN stopwords O
review NN reappraisal O
our NN stopwords O
experience NN experience O
with NN stopwords O
the NN stopwords O
spectrum NN spectrum O
of NN stopwords O
neuroendocrine JJ neuroendocrine D
neoplasms JJ tumor D
of NN stopwords D
the NN stopwords D
lung NN lung D
with NN stopwords O
emphasis NN emphasis O
on NN stopwords on O
the NN stopwords O
histopathologic NN O
classification NNS categorization O
and DT stopwords O
surgical NN surgical T
therapy NN therapy T
of NN stopwords O
each VB stopwords each O
class NNS class O
of NN stopwords O
neoplasm JJ tumor O

Breast CAPITAL NNP breast O
engorgement NN engorgement O
and DT stopwords O
postpartum NN postnatal D
fever JJ fever D

Indoor CAPITAL PRP indoor O
pollution NN pollution O
and DT stopwords O
health NN health O

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

Pharmacological CAPITAL NNP pharmacological O
blockade NN blockade O
of NN stopwords O
ovulation JJ ovulation O
in NN stopwords inch O
the NN stopwords O
ewe NN Ewe O

However CAPITAL NNP however O
, , O
an DT stopwords Associate_in_Nursing O
abnormal DT abnormal O
neonatal JJ neonatal O
BAEP CAPITAL IN O
significantly NN significantly O
increased NN increase O
the NN stopwords O
probability NN probability O
of NN stopwords O
finding NN determination O
a DT stopwords angstrom O
receptive NN receptive O
language NN language O
delay NN delay O
during NN stopwords O
early VB early O
childhood JJ childhood O
, , O
even NN evening O
in NN stopwords inch O
those NN stopwords O
with NN stopwords O
subsequently NN subsequently O
normal RB convention O
audiometry DT audiology O
findings NN findings O

Role CAPITAL NNP function O
of NN stopwords O
free JJ free O
radicals VB group O
, , O
telomeres NN telomere O
, , O
and DT stopwords O
telomerases NN telomerase O
in NN stopwords inch O
aging DT ripening O
and DT stopwords O
cancerogenesis VB O

The CAPITAL NNP O
1996 DIGITS CD O
list NN list O

BACKGROUND CAPITAL IN background O
: : O
Stage CAPITAL NNP phase D
Ib CAPITAL PRP D
and DT stopwords D
IIa CAPITAL PRP D
cervical NNS cervical D
carcinoma VB carcinoma D
can VB stopwords can O
be NN stopwords beryllium O
cured NNS bring_around O
by NN stopwords by O
radical VB group T
surgery NN surgery T
or NN stopwords Oregon O
radiotherapy VB radiotherapy T

Postnatal CAPITAL NNP postnatal O
growth NN growth O
was VB stopwords Washington O
prospectively NN O
measured NN measure O
from JJ stopwords O
birth NN birth O
to NN stopwords O
1 DIGITS CD one O
y NN stopwords yttrium O
in NN stopwords inch O
54 DIGITS CD fifty-four O
term NN term O
infants NN baby O
born NN Born O
small JJ small O
for NN stopwords O
gestational NN gestational O
age DT age O
( ( O
SGA CAPITAL NNP O
) ) O
, , O
fed JJ Federal O
either NN either O
breast NN breast O
milk NN milk O
or NN stopwords Oregon O
a DT stopwords angstrom O
standard NN standard O
term NN term O
infant NN baby O
formula NN formula O

Abandonment CAPITAL DT abandonment O
: : O
deepest NN deep O
fear NN fear O
of NN stopwords O
hospitalized NN hospitalize O
children JJ child O

for NN stopwords O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
sclc JJ D
) ) D
, , O
which NN stopwords O
accounts DT history O
for NN stopwords O
approximately DT approximately O
20 DIGITS CD twenty O
% NN O
of NN stopwords O
cases VB case O
of NN stopwords O
lung NN lung O
cancer VB cancer O
, , O
the NN stopwords O
primary NN primary O
treatment NN treatment O
is NN stopwords be O
chemotherapy NNS chemotherapy T
and DT stopwords O
in NN stopwords inch O
the NN stopwords O
majority VB majority O
of NN stopwords O
cases VB case O
the NN stopwords O
primary NN primary O
aim DT purpose O
is NN stopwords be O
to NN stopwords O
control NNS control O
the NN stopwords O
disease NN disease O
which NN stopwords O
generally NN by_and_large O
would NN O
have VB stopwords rich_person O
spread NN spread O
beyond NN beyond O
the NN stopwords O
lungs NN lung O
at DT stopwords astatine O
the NN stopwords O
time NN time O
of NN stopwords O
presentation NN presentation O

We CAPITAL NNP O
have VB stopwords rich_person O
previously NN previously O
determined NN determine O
that NN stopwords O
mast VB mast O
cell NNS cell O
metabolic NN metabolic O
responses NN response O
can VB stopwords can O
be NN stopwords beryllium O
thermally NN thermally O
transduced NN transduce O
in NN stopwords inch O
real NN real_number O
time NN time O
, , O
thus NN frankincense O
indicating NN bespeak O
the NN stopwords O
possibility NN possibility O
of NN stopwords O
whole NN whole O
cell NNS cell O
thermoelectric NN thermoelectric O
immunobiosensing JJ O

object NN object O
: : O
the NN stopwords O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
retrospective NN retrospective O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
compare NNS comparison O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
gamma VB gamma T
knife NN knife T
radiosurgery VB T
( ( T
gks NN T
) ) T
for NN stopwords O
multiple NN multiple D
cerebral NNS cerebral D
metastases NN metastasis D
with NN stopwords O
that NN stopwords O
of NN stopwords O
whole-brain NN T
radiation VB radiation T
therapy NN therapy T
( ( T
wbrt NN T
) ) T

A CAPITAL DT angstrom O
case-control VB O
study NN survey O
was VB stopwords Washington O
performed NN perform O
in NN stopwords inch O
eight NN eight O
pairs IN pair O
of NN stopwords O
women NN woman O
to NN stopwords O
determine NN determine O
whether NN O
preeclamptic NN O
women NN woman O
developed NN develop O
abnormalities DT abnormality O
in NN stopwords inch O
minor NN child O
hemoglobins NN hemoglobin O
, , O
glycolytic NN O
enzymes NN enzyme O
, , O
or NN stopwords Oregon O
other JJ stopwords other O
blood NN blood O
components NNS component O
that NN stopwords O
might NN might O
provide NN supply O
insight NN penetration O
into NN stopwords O
the NN stopwords O
pathophysiology VB O
of NN stopwords O
preeclampsia NN preeclampsia D
, , O
or NN stopwords Oregon O
that NN stopwords O
in NN stopwords inch O
combination NNS combination O
might NN might O
be NN stopwords beryllium O
used JJ use O
as DT stopwords arsenic O
a DT stopwords angstrom O
marker NN marker O
for NN stopwords O
the NN stopwords O
condition NNS condition O

Researchers CAPITAL NNP research_worker O
puzzle NN puzzle O
over JJ stopwords over O
origin IN beginning O
of NN stopwords O
type NN type O
2 DIGITS CD two O
diabetes NN diabetes D

Practice CAPITAL NNP practice O
parameters NN parameter O
for NN stopwords O
the NN stopwords O
psychiatric NN psychiatric O
assessment DT appraisal O
of NN stopwords O
infants NN baby O
and DT stopwords O
toddlers NN toddler O
( ( O
0-36 CD O
months NN calendar_month O
) ) O

These CAPITAL NNP O
were NN stopwords be O
matched VB match O
for NN stopwords O
maternal VB maternal O
age DT age O
, , O
parity NN parity O
, , O
and DT stopwords O
race VB race O
to NN stopwords O
twin NN twin O
gestations NN gestation O
( ( O
N CAPITAL NN nitrogen O
= NN O
53 DIGITS CD fifty-three O
) ) O
from JJ stopwords O
the NN stopwords O
same VB stopwords Lapp O
population NN population O

Trauma CAPITAL NNP injury O
and DT stopwords O
pregnancy NN pregnancy O

Magnetic CAPITAL NNP magnetic O
resonance NN resonance O
imaging NN imagination O
of NN stopwords O
the NN stopwords O
bone NN bone O
marrow NN marrow O
in NN stopwords inch O
hematologic NN hematologic D
malignancies VB malignancy D

RESULTS CAPITAL NNP consequence O
: : O
Prevalence CAPITAL NNP prevalence O
of NN stopwords O
confirmed NNS confirm O
infection NN infection O
was VB stopwords Washington O
2.6 CD O
% NN O
( ( O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
1.6 CD O
% NN O
to NN stopwords O
3.6 LS O
% NN O
) ) O
in NN stopwords inch O
all DT stopwords all O
women NN woman O

Online CAPITAL NNP on-line O

On CAPITAL NNP on O
the NN stopwords O
peripheral NN peripheral O
effects NN effects O
of NN stopwords O
endotoxin NN endotoxin O
and DT stopwords O
leucocyte NN leukocyte O
pyrogen NN pyrogen O
in NN stopwords inch O
rabbit NN rabbit O

The CAPITAL NNP O
article DT article O
stresses NN stress O
behavioral NN behavioral O
treatment NN treatment O
modalities NN modality O
that NN stopwords O
eliminate NN extinguish O
the NN stopwords O
debilitating NN enfeeble O
phobia NN phobia O

Induction CAPITAL PRP initiation T
chemotherapy NNS chemotherapy T
with NN stopwords T
docetaxel NN T
, , T
cisplatin NN T
, , T
fluorouracil JJ fluorouracil T
, , T
and DT stopwords T
leucovorin NN T
for NN stopwords O
squamous NN D
cell NNS cell D
carcinoma VB carcinoma D
of NN stopwords O
the NN stopwords O
head NN head O
and DT stopwords O
neck JJ neck O
: : O
a DT stopwords angstrom O
phase NN phase O
I/II CAPITAL PRP O
trial NN test O

The CAPITAL NNP O
most NN stopwords most O
frequent JJ patronize O
site NN site O
of NN stopwords O
involvement NN engagement O
was VB stopwords Washington O
the NN stopwords O
trunk NN trunk O
( ( O
40 DIGITS CD forty O
% NN O
( ( O
16/40 CD O
) ) O
) ) O

We CAPITAL NNP O
present NN present O
an DT stopwords Associate_in_Nursing O
optical JJ optical O
biosensor NN O
design NN design O
that NN stopwords O
expands NN expand O
the NN stopwords O
utility JJ utility O
of NN stopwords O
enzyme NN enzyme O
biosensors NN O

< NN O
TO_SEE CAPITAL NNP O
> NN O
thus NN frankincense O
influenza NN influenza D
vaccination NN inoculation T
is NN stopwords be O
effective NN effective O
for NN stopwords O
preventing NN prevent O
influenza NN influenza D
disease NN disease D
in NN stopwords inch O
persons NN person O
aged DT aged O
65 DIGITS CD sixty-five O
years NN old_age O
and DT stopwords O
over JJ stopwords over O
, , O
and DT stopwords O
should NN stopwords O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
integral NN integral O
part NN part O
of NN stopwords O
the NN stopwords O
care VB care O
of NN stopwords O
this NN stopwords O
population NN population O
residing NN reside O
in NN stopwords inch O
nursing RB nursing O
homes NN home O

In CAPITAL PRP inch O
this NN stopwords O
report NN report O
, , O
we NN stopwords O
document NN document O
the NN stopwords O
perinatal NN perinatal O
features NN feature O
of NN stopwords O
two NN two O
cases VB case O
of NN stopwords O
OEIS CAPITAL NNP D
complex NNS complex D
associated DT associate O
with NN stopwords O
meningomyeloceles NN D
and DT stopwords O
severe NN severe O
lower NN lower_berth O
limb NN limb O
defects NN defect O
, , O
and DT stopwords O
discuss NN discus O
the NN stopwords O
prenatal NN prenatal O
diagnosis NN diagnosis O
, , O
inheritance NN inheritance O
, , O
and DT stopwords O
differential NN derived_function O
diagnosis NN diagnosis O
of NN stopwords O
this NN stopwords O
association DT association O
of NN stopwords O
malformations VB deformity O

The CAPITAL NNP O
activity DT activity O
of NN stopwords O
hepatic NN liverwort O
glutamine NN glutamine O
synthetase NN O
was VB stopwords Washington O
markedly NN markedly O
reduced NN reduce O
( ( O
in NN stopwords inch O
patient VB patient O
1 DIGITS CD one O
, , O
12 DIGITS CD twelve O
% NN O
of NN stopwords O
the NN stopwords O
mean NN mean O
value NN value O
in NN stopwords inch O
controls NNS control O
; : O
in NN stopwords inch O
patient VB patient O
2 DIGITS CD two O
, , O
28 DIGITS CD twenty-eight O
% NN O
of NN stopwords O
the NN stopwords O
mean NN mean O
value NN value O
in NN stopwords inch O
controls NNS control O
) ) O
, , O
and DT stopwords O
a DT stopwords angstrom O
concomitant NNS accompaniment O
reduction NN decrease O
in NN stopwords inch O
the NN stopwords O
amount DT sum O
of NN stopwords O
glutamine NN glutamine O
synthetase NN O
protein NN protein O
was VB stopwords Washington O
observed NN detect O

Celecoxib CAPITAL NNP celecoxib T
for NN stopwords O
arthritis DT arthritis D

Quality CAPITAL NNP quality O
in NN stopwords inch O
general NN general O
practice NN practice O

< NN O
TO_SEE CAPITAL NNP O
> NN O
METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
identified NN identify O
valvular NN valvular O
heart NN heart O
diseasein NN O
24 DIGITS CD twenty-four O
women NN woman O
treated NN treat O
with NN stopwords O
fenfluramine-phentermine JJ O
who NN stopwords World_Health_Organization O
had VB stopwords have O
no NNS stopwords no O
history NN history O
of NN stopwords O
cardiac VB cardiac O
disease NN disease O

Dye CAPITAL NNP dye O
labeled NN label O
primers NN primer O
are DT stopwords are O
used JJ use O
for NN stopwords O
cycle NNS cycle O
sequencing NN sequence O
and DT stopwords O
an DT stopwords Associate_in_Nursing O
ABI CAPITAL DT O
PRISM CAPITAL NNP prism O
377 DIGITS CD O
DNA CAPITAL NNP deoxyribonucleic_acid O
sequencing NN sequence O
system NN system O
for NN stopwords O
analysis DT analysis O

Effect CAPITAL NNP consequence O
of NN stopwords O
magnesium VB magnesium O
sulfate NN sulfate O
on NN stopwords on O
the NN stopwords O
development NN development O
of NN stopwords O
cystic NNS cystic O
periventricular NN O
leukomalacia NN D
in NN stopwords inch O
preterm NN O
infants NN baby O

Combined CAPITAL NNP unite T
pancreas-/kidney VB T
transplantation NN transplant T
as DT stopwords arsenic O
a DT stopwords angstrom O
standard NN standard O
procedure NN procedure O
in NN stopwords inch O
therapy NN therapy O
of NN stopwords O
kidney NN kidney D
failure VB failure D
in NN stopwords inch D
type NN type D
I CAPITAL PRP iodine D
diabetic NN diabetic D
patients VB patient D

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
study NN survey O
the NN stopwords O
relationship NN relationship O
between NN stopwords between O
interleukin-2 NN O
( ( O
IL-2 CAPITAL PRP O
) ) O
, , O
soluble NN soluble O
interleukin-2 NN O
receptor NN receptor O
( ( O
sIL-2R NN O
) ) O
and DT stopwords O
the NN stopwords O
non-and-hypo-responsiveness JJ O
to NN stopwords O
hepatitis NN hepatitis D
B CAPITAL NN bacillus D
vaccine NN vaccine T

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
severe NN severe O
preeclampsia NN preeclampsia D
is NN stopwords be O
increased NN increase O
in NN stopwords inch O
triplet NN three O
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
twin NN twin O
gestations NN gestation O

Prevalence CAPITAL NNP prevalence O
on NN stopwords on O
the NN stopwords O
basis VB footing O
of NN stopwords O
enzyme NN enzyme O
immunoassay JJ immunoassay O
was VB stopwords Washington O
1.6 CD O
% NN O
( ( O
0.8 LS O
% NN O
to NN stopwords O
2.7 CD O
% NN O
) ) O
, , O
with NN stopwords O
a DT stopwords angstrom O
sensitivity NN sensitivity O
of NN stopwords O
60 DIGITS CD sixty O
% NN O
and DT stopwords O
a DT stopwords angstrom O
specificity NN specificity O
of NN stopwords O
100 DIGITS CD hundred O
% NN O

Overall CAPITAL NNP overall O
, , O
the NN stopwords O
age-specific DT O
rates VB rates O
for NN stopwords O
both NN stopwords both O
sexes NN sexual_activity O
rose NN rose O
with NN stopwords O
age DT age O
, , O
with NN stopwords O
the NN stopwords O
rates VB rates O
for NN stopwords O
women NN woman O
being NN stopwords being O
higher NN higher O
at DT stopwords astatine O
all DT stopwords all O
age DT age O
strata NN stratum O
except NN demur O
for NN stopwords O
the NN stopwords O
group NN group O
45-54 CD O
years NN old_age O

Death CAPITAL NNP death O
is NN stopwords be O
a DT stopwords angstrom O
journey NN journey O
to NN stopwords O
be NN stopwords beryllium O
undertaken JJ undertake O

The CAPITAL NNP O
plug NN plug O
and DT stopwords O
patch VB spot O
repair NN repair O
for NN stopwords O
managing VB pull_off O
the NN stopwords O
inguinal NN inguinal O
hernia NN hernia O
of NN stopwords O
the NN stopwords O
adult DT adult O

OBJECTIVE CAPITAL NNP aim O
: : O
This CAPITAL NNP O
study NN survey O
aimed DT aim O
to NN stopwords O
determine NN determine O
the NN stopwords O
effect NN consequence O
of NN stopwords O
external NN external T
beam NN radio_beam T
radiation VB radiation T
therapy NN therapy T
on NN stopwords on O
choroidal NNS D
neovascularization JJ D
( ( D
CNV CAPITAL NNP D
) ) D
secondary NN secondary O
to NN stopwords O
age-related DT age-related D
macular VB D
degeneration NN degeneration D
( ( D
AMD CAPITAL DT age-related_macular_degeneration D
) ) D

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Linkage CAPITAL NNP linkage O
analysis DT analysis O
results NN consequence O
generated NN generate O
using JJ exploitation O
both NN stopwords both O
genetic NN familial O
model-dependent NN O
( ( O
lod NN O
score JJ mark O
) ) O
and DT stopwords O
model-independent NN O
methods NN method O

How CAPITAL NNP O
critical JJ critical O
are DT stopwords are O
critical JJ critical O
values NN values O
? . O

This CAPITAL NNP O
study NN survey O
indicates NN bespeak O
that NN stopwords O
BAM-M CAPITAL IN T
is NN stopwords be O
effective NN effective O
therapy NN therapy O
for NN stopwords O
advanced DT advance D
stage NN phase D
mycosis NN fungal_infection D
fungoides JJ D
and DT stopwords O
suggests NN propose O
that NN stopwords O
the NN stopwords O
therapeutic NN remedy O
role NN function O
of NN stopwords O
splenectomy NN splenectomy O
should NN stopwords O
be NN stopwords beryllium O
evaluated NN measure O
further NN stopwords foster O

On CAPITAL NNP on O
the NN stopwords O
significance NN significance O
of NN stopwords O
histologic NN histological O
findings NN findings O
in NN stopwords inch O
neoplasms JJ tumor D
of NN stopwords O
the NN stopwords O
trophoblast NN trophoblast O
( ( O
case VB case O
contributions NNS contribution O
) ) O

It CAPITAL PRP information_technology O
is NN stopwords be O
possible NN possible O
that NN stopwords O
some NN stopwords some O
cases VB case O
of NN stopwords O
syndrome NN syndrome O
of NN stopwords O
hemorrhagic NN hemorrhagic D
shock NN daze D
and DT stopwords O
encephalopathy NN brain_disorder D
represent NN represent O
a DT stopwords angstrom O
variant NN discrepancy O
of NN stopwords O
TSS CAPITAL NNP toxic_shock D
in NN stopwords inch O
small JJ small O
children JJ child O

121 DIGITS CD O

It CAPITAL PRP information_technology O
is NN stopwords be O
generally NN by_and_large O
assumed DT assume O
that NN stopwords O
abiotic DT O
synthesis NN synthesis O
of NN stopwords O
amino DT amino O
acids DT acid O
on NN stopwords on O
the NN stopwords O
early VB early O
Earth CAPITAL NN Earth O
resulted NN result O
in NN stopwords inch O
racemic VB O
mixtures NN mixture O
( ( O
L- CAPITAL NNP O
and DT stopwords O
D-enantiomers CAPITAL NNP O
in NN stopwords inch O
equal NN peer O
abundance DT abundance O
) ) O

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
severe NN severe O
recurrent NN perennial O
ischaemia NN ischemia O
, , O
myocardial NN myocardial O
infarction NN infarct O
, , O
and DT stopwords O
ischaemic NN ischemic O
death NN death O
was VB stopwords Washington O
5.4 CD O
% NN O
, , O
2.2 CD O
% NN O
, , O
and DT stopwords O
2.2 CD O
% NN O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O
and DT stopwords O
1.1 CD O
% NN O
, , O
0 DIGITS CD zero O
% NN O
, , O
and DT stopwords O
0 DIGITS CD zero O
% NN O
, , O
in NN stopwords inch O
the NN stopwords O
roxithromycin NN O
group NN group O
, , O
respectively NN respectively O

Bifid CAPITAL NNP bifid O
T CAPITAL NN thymine O
waves VB wave O
induced NN induce O
by NN stopwords by O
isoprenaline NN T
in NN stopwords inch O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
Brugada CAPITAL NNP D
syndrome NN syndrome D
. . O

intravenous NN intravenous T
injection NN injection T
of NN stopwords T
pb2-as NN T
, , T
as DT stopwords arsenic T
a DT stopwords angstrom T
complex NNS complex T
with NN stopwords T
dmrie-c NN T
, , T
a DT stopwords angstrom T
cationic VB cationic T
liposome NN liposome T
, , O
was VB stopwords Washington O
most NN stopwords most O
effective NN effective O
for NN stopwords O
prolonging NN prolong O
the NN stopwords O
mean NN mean O
survival NN survival O
time NN time O
in NN stopwords inch O
days VB days O
( ( O
msds NN O
) ) O
and DT stopwords O
increasing NN increase O
the NN stopwords O
survival NN survival O
rates VB rates O
of NN stopwords O
mice NN mouse O
infected NN infect O
with NN stopwords O
the NN stopwords O
influenza NN influenza D
a DT stopwords angstrom D
virus NN virus D

To CAPITAL NNP O
determine NN determine O
if NN stopwords O
microscopic NN microscopic O
urinalysis JJ urinalysis O
is NN stopwords be O
needed JJ necessitate O
in NN stopwords inch O
all DT stopwords all O
pediatric NN pediatric O
emergency NN emergency O
room NN room O
patients VB patient O
screened NN screen O
for NN stopwords O
urinary JJ urinary D
tract NN tract D
infections NN infection D
( ( D
UTI CAPITAL NNP D
) ) D
, , O
we NN stopwords O
compared NNS compare O
the NN stopwords O
dipstick NN dipstick O
urinalysis JJ urinalysis O
and DT stopwords O
complete NNS complete O
urinalysis JJ urinalysis O
( ( O
dipstick NN dipstick O
and DT stopwords O
microscopy NN microscopy O
) ) O
with NN stopwords O
urine JJ urine O
cultures NNS culture O
in NN stopwords inch O
236 DIGITS CD O
children JJ child O
, , O
aged DT aged O
3 DIGITS CD three O
weeks NN week O
to NN stopwords O
21 DIGITS CD twenty-one O
years NN old_age O

Missed CAPITAL NNP miss O
injuries NN injury O
are DT stopwords are O
rare NN rare O
and DT stopwords O
most NN stopwords most O
likely NN likely O
to NN stopwords O
be NN stopwords beryllium O
bowel NN intestine D
perforations NN perforation D

Profiting CAPITAL NNP profit O
from JJ stopwords O
closure NNS closing O
: : O
the NN stopwords O
private NN private O
finance NN finance O
initiative JJ enterprise O
and DT stopwords O
the NN stopwords O
NHS CAPITAL NNP New_Hampshire O

we NN stopwords O
present NN present O
the NN stopwords O
case VB case O
of NN stopwords O
a DT stopwords angstrom O
patient VB patient O
with NN stopwords O
metastatic NN metastatic D
transitional NN transitional D
cell NNS cell D
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
bladder NN bladder D
and DT stopwords D
renal NN nephritic D
failure VB failure D
who NN stopwords World_Health_Organization O
underwent JJ undergo O
successful NN successful O
systemic NN systemic T
chemotherapy NNS chemotherapy T
with NN stopwords T
paclitaxel VB T
and DT stopwords T
carboplatin VB T

in NN stopwords inch O
single-agent NN O
phase NN phase O
ii NN two O
studies NN survey O
, , O
irinotecan JJ T
yielded NN yield O
response NN response O
rates VB rates O
between NN stopwords between O
16 DIGITS CD sixteen O
% NN O
and DT stopwords O
47 DIGITS CD forty-seven O
% NN O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
previously NN previously O
treated NN treat O
small-cell JJ D
lung NN lung D
cancer VB cancer D

In CAPITAL PRP inch O
this NN stopwords O
study NN survey O
, , O
we NN stopwords O
investigated NN investigate O
the NN stopwords O
expression NN expression O
and DT stopwords O
therapeutic NN remedy O
potential NN potential O
of NN stopwords O
TRAIL CAPITAL NNP trail T
in NN stopwords inch O
cholangiocarcinoma NNS D
, , O
one JJ one O
of NN stopwords O
the NN stopwords O
most NN stopwords most O
devastating NN lay_waste_to O
human NN homo O
hepatic NN liverwort O
malignancies VB malignancy O

A CAPITAL DT angstrom O
discriminant NN O
score JJ mark O
of NN stopwords O
> NN O
or NN stopwords Oregon O
= NN O
275 DIGITS CD O
indicated NN bespeak O
a DT stopwords angstrom O
> NN O
or NN stopwords Oregon O
= NN O
90 DIGITS CD ninety O
% NN O
probability NN probability O
of NN stopwords O
preeclampsia NN preeclampsia D

The CAPITAL NNP O
rationale VB rationale O
of NN stopwords O
extended NN widen T
resection NN resection T
for NN stopwords O
complicated NNS complicate D
cancer VB cancer D
of NN stopwords D
the NN stopwords D
large NN large D
bowel NN intestine D

$ $ O
32 DIGITS CD thirty-two O
to NN stopwords O
U.S CAPITAL NNP O

in NN stopwords inch O
a DT stopwords angstrom O
pivotal NN pivotal O
phase NN phase O
iii NN three O
trial NN test O
, , O
242 DIGITS CD O
patients VB patient O
with NN stopwords O
advanced DT advance D
ovarian NN ovarian D
cancer VB cancer D
were NN stopwords be O
randomised VB randomize O
to NN stopwords O
receive NN receive O
treatment NN treatment O
with NN stopwords O
cisplatin NN T
100 DIGITS CD hundred O
mg/m2 NN O
and DT stopwords O
cyclophosphamide NNS T
1000 DIGITS CD thousand O
mg/m2 NN O
every NN every O
3 DIGITS CD three O
weeks NN week O
with NN stopwords O
or NN stopwords Oregon O
without NN O
pretreatment NN O
with NN stopwords O
intravenous NN intravenous O
amifostine DT O
910 DIGITS CD O
mg/m2 NN O

Memphis CAPITAL NNP Memphis O
, , O
Tennessee CAPITAL NNP Tennessee O
, , O
USA CAPITAL NNP United_States O

therefore NN therefore O
, , O
patients VB patient O
with NN stopwords O
radiation-induced VB D
spinal JJ spinal_anesthesia D
cord NNS cord D
injury NN injury D
may VB May O
benefit NN benefit O
from JJ stopwords O
anticoagulant DT anticoagulant T
therapy NN therapy T

Brain-gut CAPITAL NNP O
axis DT axis O
in NN stopwords inch O
health NN health O
and DT stopwords O
disease NN disease O

RESULTS CAPITAL NNP consequence O
: : O
Fifteen CAPITAL NNP fifteen O
chromosomal NN chromosomal O
regions NN region O
warranted NN justify O
initial JJ initial O
follow-up JJ follow-up O

Both CAPITAL NNP both O
salivary VB salivary O
output JJ end_product O
and DT stopwords O
composition NNS composition O
depend NN depend O
on NN stopwords on O
the NN stopwords O
activity DT activity O
of NN stopwords O
the NN stopwords O
autonomic DT autonomic O
nervous RB nervous O
system NN system O
and DT stopwords O
any DT stopwords any O
modification NN alteration O
of NN stopwords O
this NN stopwords O
activity DT activity O
can VB stopwords can O
be NN stopwords beryllium O
observed NN detect O
indirectly NN indirectly O
by NN stopwords by O
alternations DT alternation O
in NN stopwords inch O
the NN stopwords O
salivary VB salivary O
excretion NN elimination O

conclusion NNS decision O
: : O
nyt JJ T
has VB stopwords hour_angle O
a DT stopwords angstrom O
positive NN positive O
effect NN consequence O
on NN stopwords on O
life NN life O
expectancy NN anticipation O
for NN stopwords O
patients VB patient O
with NN stopwords O
malignancy VB malignancy D

Examination CAPITAL NNP examination O
of NN stopwords O
neonatal JJ neonatal O
archaic DT antediluvian O
( ( O
primitive NN primitive O
) ) O
reflexes NN reflex O
in NN stopwords inch O
icterus JJ jaundice D
gravis NN D

The CAPITAL NNP O
age DT age O
at DT stopwords astatine O
diagnosis NN diagnosis O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
, , O
serum NN serum O
prostate-specific NN O
antigen DT antigen O
levels NN degree O
, , O
digital NN digital O
rectal NN rectal O
examination NN examination O
status NN status O
, , O
stage NN phase O
, , O
grade NN class O
, , O
primary NN primary O
treatment NN treatment O
of NN stopwords O
prostate NN prostate_gland D
cancers VB cancer D
, , O
and DT stopwords O
occurrence JJ happening O
of NN stopwords O
other JJ stopwords other O
cancers VB cancer D
were NN stopwords be O
compared NNS compare O
between NN stopwords between O
the NN stopwords O
groups NN group O

OBJECTIVE CAPITAL NNP aim O
: : O
We CAPITAL NNP O
determined NN determine O
the NN stopwords O
sensitivity NN sensitivity O
and DT stopwords O
specificity NN specificity O
of NN stopwords O
neonatal JJ neonatal O
brain-stem NN brainstem O
auditory DT auditory O
evoked NN arouse O
potentials NN potential O
( ( O
BAEP CAPITAL IN O
) ) O
as DT stopwords arsenic O
markers NN marker O
for NN stopwords O
subsequent NN subsequent O
hearing NN hearing D
impairment JJ damage D
and DT stopwords O
for NN stopwords O
developmental NN developmental D
problems NN problem D
found JJ found O
later NN later O
in NN stopwords inch O
infancy NN infancy O
and DT stopwords O
childhood JJ childhood O

Who CAPITAL NNP World_Health_Organization O
understands JJ understand O
the NN stopwords O
menopause NN menopause O
? . O

Drug CAPITAL NNP drug O
resistance NN resistance O
during NN stopwords O
indinavir NN indinavir T
therapy NN therapy T
is NN stopwords be O
caused VB cause O
by NN stopwords by O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
protease NN protease O
gene NN gene O
and DT stopwords O
in NN stopwords inch O
its NN stopwords information_technology O
Gag CAPITAL VB joke O
substrate NN substrate O
cleavage NNS cleavage O
sites NN site O

Low-molecular-weight CAPITAL NNP T
heparin NN heparin T
for NN stopwords O
immediate JJ immediate O
management VB management O
of NN stopwords O
thromboembolic NN D
disease NN disease D
in NN stopwords inch O
pregnancy NN pregnancy O

Strasbourg CAPITAL NNP Strasbourg O
, , O
France CAPITAL NNP France O
, , O
3-6 LS O
September CAPITAL NNP September O
1997 DIGITS CD O

This CAPITAL NNP O
report NN report O
describes NN describe O
a DT stopwords angstrom O
full-term JJ full-term O
newborn JJ neonate O
with NN stopwords O
massive VB massive D
fetomaternal JJ D
hemorrhage NN bleeding D

Overtraining CAPITAL NNP O
and DT stopwords O
recovery NN recovery O

Death CAPITAL NNP death O
in NN stopwords inch O
springtime NN spring O

139 DIGITS CD O

Risk CAPITAL NN hazard O
factors VB factor O
for NN stopwords O
hemiretinal NN D
vein NN vein D
occlusion JJ occlusion D
: : O
comparison NNS comparison O
with NN stopwords O
risk NN hazard O
factors VB factor O
for NN stopwords O
central NNS central D
and DT stopwords D
branch NN branch D
retinal NN retinene D
vein NN vein D
occlusion JJ occlusion D
: : O
the NN stopwords O
eye NN eye O
disease NN disease O
case-control VB O
study NN survey O

Intralesional CAPITAL PRP T
therapy NN therapy T
with NN stopwords T
betamethasone NN T

Studies CAPITAL NNP survey O
on NN stopwords on O
the NN stopwords O
radioimmunoassay VB radioimmunoassay O
of NN stopwords O
insulin NN insulin T

Removal CAPITAL NNP removal O
of NN stopwords O
a DT stopwords angstrom O
broken NN interrupt O
solid-core NN O
intramedullary NN O
femoral JJ femoral O
nail IN nail O
using JJ exploitation O
both NN stopwords both O
antegrade DT O
and DT stopwords O
retrograde NN retrograde O
starting NN start O
points NN point O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Freeze-dried CAPITAL NNP freeze-dry O
cortical NNS cortical O
allograft DT homograft O
in NN stopwords inch O
posterior NN buttocks O
spinal JJ spinal_anesthesia O
arthrodesis DT arthrodesis O
: : O
use JJ use O
with NN stopwords O
segmental NN segmental O
instrumentation NN instrumentality O
for NN stopwords O
idiopathic JJ idiopathic O
adolescent DT adolescent O
scoliosis JJ scoliosis O

Human CAPITAL NNP homo D
papillomavirus VB D
types NN type O
52 DIGITS CD fifty-two O
and DT stopwords O
58 DIGITS CD fifty-eight O
are DT stopwords are O
prevalent NN prevailing O
in NN stopwords inch O
cervical NNS cervical D
cancer VB cancer D
from JJ stopwords O
Chinese CAPITAL NNP Chinese O
women NN woman O

Our CAPITAL NNP O
results NN consequence O
indicate NN bespeak O
that NN stopwords O
the NN stopwords O
electrical NN electrical O
gradient NN gradient O
described NN describe O
by NN stopwords by O
other JJ stopwords other O
authors DT writer O
does NN stopwords Department_of_Energy O
not JJ stopwords not O
exert NN exert O
significant NN significant O
influence NN influence O
on NN stopwords on O
the NN stopwords O
migration NN migration O
of NN stopwords O
charged NNS charge O
molecules NN molecule O
through NN stopwords done O
intercellular NN intercellular O
bridges NN Bridges O
in NN stopwords inch O
situ NN O

Evanescent CAPITAL NNP evanescent O
wave VB wave O
fibre NN fiber O
optic JJ eye O
sensor NN detector O
for NN stopwords O
detection NN detection O
of NN stopwords O
L. CAPITAL NNP O
donovani NN O
specific NN particular O
antibodies DT antibody O
in NN stopwords inch O
sera NN serum O
of NN stopwords O
kala VB O
azar DT O
patients VB patient O

Spontaneous CAPITAL NNP spontaneous D
ovarian NN ovarian D
hyperstimulation NN D
syndrome NN syndrome D
with NN stopwords O
pregnancy NN pregnancy O

Prevalence CAPITAL NNP prevalence O
on NN stopwords on O
the NN stopwords O
basis VB footing O
of NN stopwords O
ligase NN O
chain NNS chain O
reaction NN chemical_reaction O
was VB stopwords Washington O
2.5 CD O
% NN O
( ( O
1.5 CD O
% NN O
to NN stopwords O
3.9 LS O
% NN O
) ) O
, , O
with NN stopwords O
90 DIGITS CD ninety O
% NN O
sensitivity NN sensitivity O
and DT stopwords O
99.8 CD O
% NN O
specificity NN specificity O

in NN stopwords inch O
particular NN particular O
, , O
tacrolimus VB T
and DT stopwords T
ascomycin DT T
derivatives NN derived_function T
have VB stopwords rich_person O
been NN stopwords be O
shown NN show O
to NN stopwords O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
treating NN treat O
atopic DT D
dermatitism NN D
with NN stopwords O
a DT stopwords angstrom O
surprising NN surprise O
lack NN lack O
of NN stopwords O
side NN side O
effects NN effects O

Authors CAPITAL DT writer O
' '' O
reply NN answer O

Characteristics CAPITAL NNP feature O
of NN stopwords O
prostate NN prostate_gland D
cancer VB cancer D
in NN stopwords inch O
families VB family O
potentially NN potentially O
linked NN associate O
to NN stopwords O
the NN stopwords O
hereditary NN familial O
prostate NN prostate_gland O
cancer VB cancer O
1 DIGITS CD one O
( ( O
HPC1 CAPITAL NNP O
) ) O
locus NN venue O

The CAPITAL NNP O
APOE CAPITAL DT O
variation NN variation O
, , O
prominent NN outstanding O
in NN stopwords inch O
other JJ stopwords other O
neurological JJ neurological O
diseases NN disease O
, , O
showed NN show O
no NNS stopwords no O
influence NN influence O
on NN stopwords on O
MS CAPITAL NNP multiple_sclerosis O
susceptibility NN susceptibility O
, , O
despite NN contempt O
its NN stopwords information_technology O
location NN location O
within NN inside O
the NN stopwords O
chromosome NN chromosome O
19q13.2 CD O
region NN region O

Study CAPITAL NNP survey O
of NN stopwords O
the NN stopwords O
effect NN consequence O
of NN stopwords O
newer JJ new O
analeptic DT analeptic O
( ( O
Micoren CAPITAL NNP O
) ) O
in NN stopwords inch O
hypoventilation NN O
syndrome NN syndrome O

between NN stopwords between O
july NN July O
1992 DIGITS CD O
and DT stopwords O
december NN December O
1997 DIGITS CD O
, , O
1799 DIGITS CD O
patients VB patient O
were NN stopwords be O
diagnosed NN diagnose O
as DT stopwords arsenic O
having VB stopwords have O
lung NN lung D
cancer VB cancer D
in NN stopwords inch O
our NN stopwords O
hospital NN hospital O
and DT stopwords O
926 DIGITS CD O
patients VB patient O
received NN receive O
chemotherapy NNS chemotherapy T
and/or DT T
thoracic NN pectoral T
radiotherapy VB radiotherapy T

hominis NN O
( ( O
group NN group O
C CAPITAL SYM degree_centigrade O
) ) O
was VB stopwords Washington O
observed NN detect O
in NN stopwords inch O
absence DT absence O
of NN stopwords O
other JJ stopwords other O
enteropathogens NN O

Preterm CAPITAL NNP O
premature NN premature O
rupture NN rupture D
of NN stopwords D
the NN stopwords D
membranes NN membrane D
associated DT associate O
with NN stopwords O
recent NN Holocene O
cocaine NNS cocaine O
use JJ use O

in NN stopwords inch O
summary NN summary O
, , O
gemifloxacin NN T
was VB stopwords Washington O
found JJ found O
to NN stopwords O
be NN stopwords beryllium O
well NN well O
tolerated NN digest O
and DT stopwords O
effective NN effective O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
aecb DT D
, , O
suggesting NN propose O
it NN stopwords information_technology O
is NN stopwords be O
well NN well O
suited JJ suit O
for NN stopwords O
empirical NN empirical O
treatment NN treatment O
of NN stopwords O
this NN stopwords O
common NNS park O
respiratory NN respiratory O
condition NNS condition O
in NN stopwords inch O
the NN stopwords O
current NNS current O
clinical JJ clinical O
environment NN environment O

The CAPITAL NNP O
study NN survey O
population NN population O
included NN include O
84 DIGITS CD eighty-four O
women NN woman O
with NN stopwords O
gestational NN gestational D
diabetes NN diabetes D
, , O
ascertained DT determine O
by NN stopwords by O
universal JJ universal O
screening NN screening O
of NN stopwords O
all DT stopwords all O
women NN woman O
attending DT attention O
the NN stopwords O
antenatal DT prenatal O
clinic JJ clinic O
of NN stopwords O
the NN stopwords O
Hadassah CAPITAL NNP O
Medical CAPITAL NNP checkup O
Center CAPITAL NNP center O
, , O
over JJ stopwords over O
a DT stopwords angstrom O
2-year CD O
period NN time_period O

Fate CAPITAL NNP destiny O
of NN stopwords O
the NN stopwords O
2d CD second O
twin NN twin O

< NN O
TO_SEE CAPITAL NNP O
> NN O
CASE CAPITAL VB case O
SUMMARY CAPITAL NNP summary O
: : O
A CAPITAL DT angstrom O
92-year CD O
old JJ old O
white NN White O
woman NN woman O
who NN stopwords World_Health_Organization O
was VB stopwords Washington O
receiving NN receive O
venlafaxine NN T
for NN stopwords O
management VB management O
of NN stopwords O
depression NN depression D
was VB stopwords Washington O
found JJ found O
to NN stopwords O
have VB stopwords rich_person O
hyponatremia NN hyponatremia O

The CAPITAL NNP O
lesion NN lesion O
was VB stopwords Washington O
located NN locate O
in NN stopwords inch O
the NN stopwords O
posteroventral NN O
GPi CAPITAL NNP O
in NN stopwords inch O
all DT stopwords all O
cases VB case O
except NN demur O
in NN stopwords inch O
one JJ one O
patient VB patient O
in NN stopwords inch O
whom NN stopwords O
it NN stopwords information_technology O
was VB stopwords Washington O
confined NNS restrict O
to NN stopwords O
the NN stopwords O
GP CAPITAL NNP general_practitioner O
externus NN O
( ( O
GPe CAPITAL NNP O
) ) O

Moxonidine CAPITAL NNP T
( ( T
Physiotens-Solvay CAPITAL NNP T
) ) T
was VB stopwords Washington O
introduced NN introduce O
last NN stopping_point O
year NN year O
as DT stopwords arsenic O
the NN stopwords O
first NN first O
of NN stopwords O
a DT stopwords angstrom O
new JJ new O
class NNS class O
of NN stopwords O
centrally-acting NNS O
antihypertensive DT antihypertensive T
agents DT agent T
, , O
the NN stopwords O
selective NN selective O
imidazoline JJ O
receptor NN receptor O
agonists DT protagonist O

Ellipsometry CAPITAL NNP O
measurements NN measurement O
of NN stopwords O
oxygen JJ oxygen O
plasma NN plasma O
exposed NN expose O
antibody DT antibody O
layers NN layer O
indicated NN bespeak O
complete NNS complete O
removal NN removal O
of NN stopwords O
immobilized JJ immobilize O
antibodies DT antibody O

Treatment CAPITAL NNP treatment O
of NN stopwords O
advanced DT advance D
stage NN phase D
mycosis NN fungal_infection D
fungoides JJ D
with NN stopwords O
bleomycin NN T
, , T
doxorubicin NN doxorubicin T
, , T
and DT stopwords T
methotrexate NN methotrexate T
with NN stopwords T
topical NN topical T
nitrogen NN nitrogen T
mustard NN mustard T
( ( T
BAM-M CAPITAL IN T
) ) T

A CAPITAL DT angstrom O
cause VB cause O
of NN stopwords O
portal NN portal D
vein NN vein D
thrombosis NN thrombosis D
and DT stopwords O
portal NN portal D
hypertension NN high_blood_pressure D

Specialists CAPITAL NNP specialist O
and DT stopwords O
nurses RB nurse O
: : O
the NN stopwords O
pillars NN pillar O
of NN stopwords O
hospital NN hospital O
care VB care O

More CAPITAL NNP More O
advanced-stage DT O
disease NN disease O
at DT stopwords astatine O
diagnosis NN diagnosis O
was VB stopwords Washington O
the NN stopwords O
primary NN primary O
determinant NN determinant O
, , O
accounting DT accounting O
for NN stopwords O
60 DIGITS CD sixty O
% NN O
of NN stopwords O
the NN stopwords O
excess NN excess O
mortality NN mortality O

< NN O
TO_SEE CAPITAL NNP O
> NN O
PURPOSE CAPITAL NNP purpose O
: : O
To CAPITAL NNP O
review NN reappraisal O
reported NN report O
inflammatory NN inflammatory D
reactions NN chemical_reaction D
occurring JJ happen O
after DT stopwords after O
initiation JJ initiation O
of NN stopwords O
highly NN highly O
active DT active_agent O
antiretroviral DT T
therapy NN therapy T
( ( T
HAART CAPITAL NNP drug_cocktail T
) ) T
in NN stopwords inch O
persons NN person O
infected NN infect O
with NN stopwords O
HIV-1 CAPITAL NNP D
and DT stopwords O
to NN stopwords O
explore NN research O
the NN stopwords O
mechanisms NN mechanism O
leading NN lead O
to NN stopwords O
these NN stopwords O
reactions NN chemical_reaction O

Eleven CAPITAL NNP eleven O
patients VB patient O
with NN stopwords O
vesicoureteric NN D
reflux NN reflux D
secondary NN secondary O
to NN stopwords O
neuropathic JJ O
bladder NN bladder O
were NN stopwords be O
treated NN treat O
by NN stopwords by O
endoscopic NN endoscopic T
injection NN injection T
of NN stopwords T
pyrolised NN T
polytetrafluoroethylene NN Teflon T
( ( T
Polytef CAPITAL NNP T
) ) T
paste VB paste T

`` `` O
Children CAPITAL NNP child O
are DT stopwords are O
not JJ stopwords not O
supposed NN suppose O
to NN stopwords O
die NN die O

Understanding CAPITAL NNP understanding O
the NN stopwords O
culture NNS culture O
of NN stopwords O
prescribing NN order O
: : O
qualitative NN qualitative O
study NN survey O
of NN stopwords O
general NN general O
practitioners NN practitioner O
' '' O
and DT stopwords O
patients VB patient O
' '' O
perceptions NN percept O
of NN stopwords O
antibiotics DT antibiotic T
for NN stopwords O
sore NN sore D
throats NN throat D

Consultation CAPITAL NNP consultation O
section NN section O

It CAPITAL PRP information_technology O
is NN stopwords be O
noted JJ note O
that NN stopwords O
attempts DT attempt O
to NN stopwords O
correlate NNS correlate O
radiosensitivity VB photosensitivity O
with NN stopwords O
the NN stopwords O
rates VB rates O
of NN stopwords O
DSB CAPITAL NNP O
repair NN repair O
, , O
rather VB rather O
than NN stopwords O
using JJ exploitation O
an DT stopwords Associate_in_Nursing O
explicit NN explicit O
model NN model O
such NN stopwords such O
as DT stopwords arsenic O
the NN stopwords O
DSB CAPITAL NNP O
model NN model O
, , O
are DT stopwords are O
unlikely JJ improbable O
to NN stopwords O
be NN stopwords beryllium O
productive NN productive O
since NN O
survival NN survival O
depends NN depend O
on NN stopwords on O
both NN stopwords both O
tau VB tau O
( ( O
DSBR CAPITAL NNP O
) ) O
and DT stopwords O
t NN stopwords thymine O
( ( O
rep NN rep O
) ) O
( ( O
as DT stopwords arsenic O
defined NN specify O
in NN stopwords inch O
the NN stopwords O
DSB CAPITAL NNP O
model NN model O
) ) O
and DT stopwords O
the NN stopwords O
latter NN latter O
may VB May O
be NN stopwords beryllium O
the NN stopwords O
more NN stopwords More O
important JJ important O
determinant NN determinant O
of NN stopwords O
radiosensitivity VB photosensitivity O
( ( O
as DT stopwords arsenic O
it NN stopwords information_technology O
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
for NN stopwords O
ataxia DT ataxia O
telangiectasia NN O
cells NNS cell O
compared NNS compare O
to NN stopwords O
normal RB convention O
fibroblasts NN fibroblast O
and DT stopwords O
for NN stopwords O
irs NN Internal_Revenue_Service O
compared NNS compare O
to NN stopwords O
V79 CAPITAL NNP O
cells NNS cell O
) ) O

HIV CAPITAL NNP HIV O
and DT stopwords O
AIDS CAPITAL DT AIDS D
awareness DT awareness O
: : O
an DT stopwords Associate_in_Nursing O
evaluation NN evaluation O
of NN stopwords O
a DT stopwords angstrom O
short NN short O
training NN training O
programme NN program O
for NN stopwords O
midwives NN midwife O

Female CAPITAL NNP female O
embryonic NN embryonic O
lethality NN deadliness O
in NN stopwords inch O
mice NN mouse O
nullizygous JJ O
for NN stopwords O
both NN stopwords both O
Msh2 CAPITAL NNP O
and DT stopwords O
p53 NN O

Using CAPITAL NNP exploitation O
cross NNS cross O
correlation NNS correlation O
between NN stopwords between O
replicate NN retroflex O
nonlinear JJ nonlinear O
waveforms VB wave_form O
as DT stopwords arsenic O
the NN stopwords O
criterion JJ standard O
, , O
TEOAEs CAPITAL NNP O
were NN stopwords be O
present NN present O
in NN stopwords inch O
99.2 CD O
% NN O
of NN stopwords O
the NN stopwords O
sample VB sample O
( ( O
lower NN lower_berth O
CI CAPITAL NNP curie O
98.1 CD O
% NN O
) ) O

All CAPITAL DT all O
had VB stopwords have O
undergone JJ undergo O
Billroth CAPITAL NNP T
II CAPITAL PRP two T
subtotal NN subtotal T
gastrectomy VB gastrectomy T
( ( O
20 DIGITS CD twenty O
for NN stopwords O
ulcer JJ ulcer D
and DT stopwords O
1 DIGITS CD one O
for NN stopwords O
gastric VB gastric D
cancer VB cancer D
) ) O

Two CAPITAL NNP two O
of NN stopwords O
the NN stopwords O
polyps NN polyp O
showed NN show O
metastatic NN metastatic D
malignant VB malignant D
mesothelioma NN mesothelioma D
in NN stopwords inch O
the NN stopwords O
lamina NN lamina O
propia NN O
which NN stopwords O
strongly NN strongly O
resembled NN resemble O
adenocarcinoma DT adenocarcinoma D
histologically NN histologically O
causing VB causing O
difficulty NN trouble O
in NN stopwords inch O
making NN devising O
definitive NN definitive O
diagnosis NN diagnosis O

Back CAPITAL IN back O
from JJ stopwords O
the NN stopwords O
dead NN dead O
: : O
extracorporeal NN T
rewarming NN T
of NN stopwords O
severe NN severe D
accidental DT accidental D
hypothermia NN hypothermia D
victims NN victim O
in NN stopwords inch O
accident DT accident O
and DT stopwords O
emergency NN emergency O

Molecular CAPITAL NNP molecular O
dynamics NN dynamics O
in NN stopwords inch O
torsion-angle NN O
space NN space O
was VB stopwords Washington O
applied DT use O
to NN stopwords O
nuclear JJ nuclear O
magnetic VB magnetic O
resonance NN resonance O
structure NN structure O
calculation VB calculation O
using JJ exploitation O
nuclear JJ nuclear O
Overhauser CAPITAL NNP O
effect-derived NN O
distances NN distance O
and DT stopwords O
J-coupling-constant-derived CAPITAL NNP O
dihedral NN O
angle DT angle O
restraints NN restraint O

Assessment CAPITAL DT appraisal O
of NN stopwords O
fetal JJ fetal O
nuchal JJ O
translucency NN translucence O
test NN trial O
for NN stopwords O
Down CAPITAL NNP down D
's POS D
syndrome NN syndrome D

the NN stopwords O
food JJ food O
and DT stopwords O
drug NN drug O
administration DT administration O
( ( O
fda NN Food_and_Drug_Administration O
) ) O
recently NN recently O
approved DT approve O
the NN stopwords O
first NN first O
protein-polysaccharide NN T
conjugate NNS conjugate_solution T
vaccine NN vaccine T
to NN stopwords O
prevent NN prevent O
invasive NN invasive D
pneumococcal NN pneumococcal D
diseases NN disease D
in NN stopwords inch O
infants NN baby O
and DT stopwords O
toddlers NN toddler O
< NN O
2 DIGITS CD two O
years NN old_age O
of NN stopwords O
age DT age O

This CAPITAL NNP O
analysis DT analysis O
also DT besides O
identifies NN identify O
regions NN region O
of NN stopwords O
high NN high O
conservation NNS conservation O
among DT O
these NN stopwords O
proteins NN protein O
with NN stopwords O
no NNS stopwords no O
currently NNS presently O
assigned DT delegate O
function JJ function O

a DT stopwords angstrom O
growing NN growth O
body NN body O
of NN stopwords O
evidence NN evidence O
suggests NN propose O
that NN stopwords O
postoperative NN postoperative T
irradiation NN irradiation T
for NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
may VB May O
cause VB cause O
life-threatening NN dangerous O
toxicity NN toxicity O
and DT stopwords O
, , O
when NN stopwords O
the NN stopwords O
risk NN hazard O
of NN stopwords O
local-regional NN O
recurrence NN recurrence O
is NN stopwords be O
low NN low O
, , O
the NN stopwords O
toxicity NN toxicity O
of NN stopwords O
irradiation NN irradiation O
may VB May O
outweight JJ O
the NN stopwords O
benefit NN benefit O

The CAPITAL NNP O
hemorrhage NN bleeding D
was VB stopwords Washington O
successfully NN successfully O
stopped NN stop O
by NN stopwords by O
microcoil NN T
embolization NN T

methods NN method O
and DT stopwords O
materials VB material O
: : O
eleven NN eleven O
patients VB patient O
with NN stopwords O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
sclc JJ D
) ) D
, , O
who NN stopwords World_Health_Organization O
had VB stopwords have O
presented NN show O
complete NNS complete O
response NN response O
of NN stopwords O
disease NN disease O
after DT stopwords after O
chemotherapy NNS chemotherapy T
and DT stopwords O
radical VB group T
radiotherapy VB radiotherapy T
in NN stopwords inch T
the NN stopwords T
lung NN lung T
, , O
were NN stopwords be O
prescribed NN order O
to NN stopwords O
receive NN receive O
a DT stopwords angstrom O
prophylacting NN O
cranial NNS cranial O
irradiation NN irradiation O
( ( O
pci NN O
) ) O
with NN stopwords O
a DT stopwords angstrom O
6 DIGITS CD six O
mev NN O
linear NN linear O
accelerator DT accelerator O

Significant CAPITAL NNP significant O
negative JJ negative O
correlation NNS correlation O
between NN stopwords between O
heart NN heart O
rate VB rate O
and DT stopwords O
age DT age O
was VB stopwords Washington O
noted JJ note O
in NN stopwords inch O
the NN stopwords O
control NNS control O
group NN group O
but NN stopwords merely O
was VB stopwords Washington O
not JJ stopwords not O
present NN present O
in NN stopwords inch O
the NN stopwords O
study NN survey O
group NN group O

Hypertension CAPITAL NNP high_blood_pressure D
treatment NN treatment O
and DT stopwords O
control NNS control O
in NN stopwords inch O
sub-Saharan NN sub-Saharan O
Africa CAPITAL DT Africa O
: : O
the NN stopwords O
epidemiological NN epidemiologic O
basis VB footing O
for NN stopwords O
policy NN policy O

Antimicrobial CAPITAL DT disinfectant T
treatment NN treatment T
options JJ option O
in NN stopwords inch O
the NN stopwords O
management VB management O
of NN stopwords O
odontogenic JJ D
infections NN infection D

3 DIGITS CD three O

Factor CAPITAL NNP factor D
VII CAPITAL NNP seven D
deficiency NN lack D

Death CAPITAL NNP death O
rates VB rates O
from JJ stopwords O
childhood JJ childhood D
leukaemia NN leukemia D
near RB approach O
nuclear JJ nuclear O
sites NN site O

Gastric CAPITAL VB gastric O
site NN site O
of NN stopwords O
epidermoid NN D
carcinoma VB carcinoma D

Complications CAPITAL NNP complication O
included NN include O
one JJ one O
case VB case O
of NN stopwords O
testicular NN testicular D
bleeding NN bleeding D
following JJ following O
fine NN fine T
needle JJ acerate_leaf T
aspiration DT aspiration T
, , O
treated NN treat O
locally NN locally O
, , O
and DT stopwords O
two NN two O
cases VB case O
of NN stopwords O
extratunical NN D
haematomata VB hematoma D
following JJ following O
TESE CAPITAL NNP O
requiring NN necessitate O
no NNS stopwords no O
intervention NN intervention O

Beta-propiolactone CAPITAL NNP T
as DT stopwords arsenic O
used JJ use O
in NN stopwords inch O
sterilization NN sterilization O
of NN stopwords O
homografts NN homograft O
not JJ stopwords not O
carcinogenic VB carcinogenic O
for NN stopwords O
mice NN mouse O

several NN several O
studies NN survey O
have VB stopwords rich_person O
suggested NN propose O
that NN stopwords O
non-small JJ D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
patients VB patient O
whose NN O
tumors NN tumor O
have VB stopwords rich_person O
neuroendocrine JJ neuroendocrine O
( ( O
ne NNS neon O
) ) O
features NN feature O
may VB May O
be NN stopwords beryllium O
more NN stopwords More O
responsive NN responsive O
to NN stopwords O
chemotherapy NNS chemotherapy T
in NN stopwords inch O
addition DT addition O
, , O
increased NN increase O
expression NN expression O
of NN stopwords O
p53 NN O
and DT stopwords O
her2 NN O
may VB May O
confer NNS confer O
relative NN relative O
chemotherapy NNS chemotherapy O
resistance NN resistance O
and DT stopwords O
shortened NN shorten O
survival NN survival O

Laerdal CAPITAL VB O
infant NN baby O
resuscitators NN resuscitator O
are DT stopwords are O
unreliable JJ undependable O
as DT stopwords arsenic O
free-flow JJ O
oxygen JJ oxygen O
delivery NN delivery O
devices NN devices O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Eighty CAPITAL NN eighty O
women NN woman O
undergoing JJ undergo O
cesarean NNS cesarean_delivery O
section NN section O
( ( O
C/S CAPITAL NNP O
) ) O
with NN stopwords O
epidural NN epidural_anesthesia O
2 DIGITS CD two O
% NN O
lidocaine NN Lidocaine O
with NN stopwords O
epinephrine NN epinephrine O
( ( O
1 DIGITS CD one O
: : O
200 DIGITS CD two_hundred O
, , O
000 DIGITS CD O
) ) O
were NN stopwords be O
randomly VB randomly O
assigned DT delegate O
to NN stopwords O
receive NN receive O
double-blind NN O
epidural NN epidural_anesthesia O
administration DT administration O
of NN stopwords O
F CAPITAL NN degree_Fahrenheit O
( ( O
25 DIGITS CD twenty-five O
, , O
50 DIGITS CD fifty O
, , O
100 DIGITS CD hundred O
, , O
or NN stopwords Oregon O
200 DIGITS CD two_hundred O
microg NN O
) ) O
or NN stopwords Oregon O
S CAPITAL NN second O
( ( O
5 DIGITS CD five O
, , O
10 DIGITS CD ten O
, , O
20 DIGITS CD twenty O
, , O
or NN stopwords Oregon O
30 DIGITS CD thirty O
microg NN O
) ) O
( ( O
n NN nitrogen O
= NN O
10 DIGITS CD ten O
per NN O
group NN group O
) ) O
upon JJ O
complaint NNS ailment O
of NN stopwords O
pain IN pain O
postoperatively NN postoperatively O

Existential CAPITAL NNP experiential O
phenomenology NN phenomenology O
and DT stopwords O
the NN stopwords O
sociological NN sociological O
tradition NN tradition O

The CAPITAL NNP O
outcome JJ result O
of NN stopwords O
arthroscopic DT T
treatment NN treatment T
of NN stopwords O
temporomandibular NN D
joint NN joint D
arthropathy DT arthropathy D

Evidence CAPITAL NNP evidence O
for NN stopwords O
the NN stopwords O
presence NN presence O
of NN stopwords O
a DT stopwords angstrom O
serotonin1A NN O
( ( O
5-HT1A CD O
) ) O
receptor NN receptor O
subtype NN O
in NN stopwords inch O
the NN stopwords O
salmonid VB salmonid O
fish NN fish O
brain NN brain O
has VB stopwords hour_angle O
recently NN recently O
been NN stopwords be O
presented NN show O

Morbidity CAPITAL NNP morbidity O
and DT stopwords O
healthcare NN healthcare O
utilisation JJ use O
of NN stopwords O
children JJ child O
in NN stopwords inch O
households NN family O
with NN stopwords O
one JJ one O
adult DT adult O
: : O
comparative NNS comparative O
observational NN experimental O
study NN survey O

Recombinant CAPITAL NNP recombinant O
HIV-1 CAPITAL NNP O
variants NN discrepancy O
containing NNS incorporate O
two NN two O
or NN stopwords Oregon O
three NN three O
mutations NN mutant O
in NN stopwords inch O
the NN stopwords O
protease NN protease O
gene NN gene O
were NN stopwords be O
constructed NNS construct O
either NN either O
with NN stopwords O
mutations NN mutant O
at DT stopwords astatine O
the NN stopwords O
p7/p1 NN O
cleavage NNS cleavage O
site NN site O
or NN stopwords Oregon O
with NN stopwords O
wild-type NN O
( ( O
WT CAPITAL NNP O
) ) O
gag VB joke O
sequences NN sequence O

A CAPITAL DT angstrom O
substantial NN significant O
fraction NN fraction O
of NN stopwords O
the NN stopwords O
organic JJ organic O
compounds NNS compound O
on NN stopwords on O
the NN stopwords O
early VB early O
Earth CAPITAL NN Earth O
may VB May O
have VB stopwords rich_person O
been NN stopwords be O
derived NN deduce O
from JJ stopwords O
comet NNS comet O
and DT stopwords O
meteorite NN meteorite O
impacts JJ impact O

Cloning CAPITAL NNP cloning O
and DT stopwords O
characterization NNS word_picture O
of NN stopwords O
a DT stopwords angstrom O
neural JJ nervous O
cell NNS cell O
recognition NN recognition O
molecule NN molecule O
on NN stopwords on O
axons DT axon O
of NN stopwords O
the NN stopwords O
retinotectal NN O
system NN system O
and DT stopwords O
spinal JJ spinal_anesthesia O
cord NNS cord O

Fetal CAPITAL NNP fetal O
chondrodystrophy NNS achondroplasia O

Measured CAPITAL NNP measure O
subtotal NN subtotal O
gastrectomy VB gastrectomy O
for NN stopwords O
duodenal NN duodenal O
ulcer JJ ulcer O

Ultrasonographic CAPITAL NNP O
evaluation NN evaluation O
of NN stopwords O
parathyroid NN parathyroid_gland D
hyperplasia NN hyperplasia D

Basal CAPITAL IN radical O
and DT stopwords O
stimulated JJ stimulate O
acid DT acid O
concentrations NNS concentration O
also DT besides O
increased NN increase O
( ( O
29.1 CD O
+/- NN O
36.6 CD O
to NN stopwords O
54 DIGITS CD fifty-four O
+/- NN O
31 DIGITS CD thirty-one O
mmol/l NN O
and DT stopwords O
72.5 CD O
+/- NN O
46 DIGITS CD forty-six O
to NN stopwords O
120.1 CD O
+/- NN O
30 DIGITS CD thirty O
mmol/l NN O
, , O
respectively NN respectively O
, , O
for NN stopwords O
basal VB radical O
and DT stopwords O
stimulated JJ stimulate O
acid DT acid O
concentrations NNS concentration O
; : O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
for NN stopwords O
peak NN extremum O
and DT stopwords O
MAO CAPITAL NNP monoamine_oxidase O
, , O
P CAPITAL NN phosphorus O
= NN O
0.07 LS O
for NN stopwords O
BAO CAPITAL IN O
) ) O

Methicillin-resistant CAPITAL NNP O
Staphylococcus CAPITAL NNP staphylococcus O
aureus DT O
clinical JJ clinical O
strain NN strain O
with NN stopwords O
reduced NN reduce O
vancomycin NN vancomycin T
susceptibility NN susceptibility O

Traditional CAPITAL NNP traditional O
therapy NN therapy O
for NN stopwords O
malignant VB malignant D
pleural NN pleural D
effusions NN effusion D
includes NN include O
thoracentesis NN thoracocentesis T
or NN stopwords Oregon T
tube NN tube T
drainage NN drain T
with NN stopwords O
instillation NN instillation O
of NN stopwords O
irritants NN irritant O
to NN stopwords O
achieve DT achieve O
pleurodesis NN O

Responses CAPITAL NNP response O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
interview NN interview O
at DT stopwords astatine O
initial JJ initial O
prenatal NN prenatal O
care VB care O
enrollment NN registration O
were NN stopwords be O
compared NNS compare O
using JJ exploitation O
Chi-square CAPITAL NNP O
and DT stopwords O
Fisher CAPITAL NNP fisherman O
's POS O
exact NN demand O
tests NN trial O

Down CAPITAL NNP down D
syndrome NN syndrome D
fetuses JJ fetus O
( ( O
41.7 CD O
% NN O
) ) O
had VB stopwords have O
prenatally NN O
detected NN detect O
sonographic NN O
anomalies DT anomaly O
, , O
63.6 CD O
% NN O
for NN stopwords O
Edward CAPITAL NNP Edward D
syndrome NN syndrome D
, , O
and DT stopwords O
all DT stopwords all O
fetuses JJ fetus O
with NN stopwords O
Patau CAPITAL VB D
syndrome NN syndrome D
( ( O
4 DIGITS CD four O
of NN stopwords O
4 DIGITS CD four O
) ) O
showed NN show O
abnormal DT abnormal O
sonographic NN O
signs NN sign O

Plasma CAPITAL NNP plasma O
PAI-1 CAPITAL VB O
activity DT activity O
was VB stopwords Washington O
not JJ stopwords not O
significantly NN significantly O
different NN different O
among DT O
subjects NN subject O
with NN stopwords O
and DT stopwords O
without NN O
retinopathy NN retinopathy D
( ( O
17.1 CD O
+/- NN O
vs. NN O
19.7 CD O
+/- NN O
9.1 CD O
arbitrary DT arbitrary O
units JJ unit_of_measurement O
( ( O
AU CAPITAL DT gold O
) ) O
/ml JJ O
, , O
P CAPITAL NN phosphorus O
= NN O
0.09 LS O
) ) O

There CAPITAL NNP there O
are DT stopwords are O
many VB many O
methods NN method O
used JJ use O
to NN stopwords O
measure NN measure O
the NN stopwords O
training NN training O
process NN procedure O
but NN stopwords merely O
few JJ stopwords few O
with NN stopwords O
which NN stopwords O
to NN stopwords O
match VB match O
the NN stopwords O
recovery NN recovery O
process NN procedure O
against DT stopwords O
it NN stopwords information_technology O

Strategy CAPITAL NNP scheme O
for NN stopwords O
surgical NN surgical T
management VB management T
of NN stopwords O
ileocolonic NN D
anastomotic DT anastomotic D
recurrence NN recurrence D
in NN stopwords inch D
Crohn CAPITAL NNP Crohn D
's POS D
disease NN disease D

Low CAPITAL NNP low O
prenatal NN prenatal O
weight NN weight O
gain NN addition O
among DT O
low-income NN O
women NN woman O
: : O
what NN stopwords O
are DT stopwords are O
the NN stopwords O
risk NN hazard O
factors VB factor O
? . O

There CAPITAL NNP there O
was VB stopwords Washington O
also DT besides O
a DT stopwords angstrom O
slightly JJ slightly O
higher NN higher O
rate VB rate O
of NN stopwords O
intracranial NN intracranial D
hemorrhage NN bleeding D
with NN stopwords O
the NN stopwords O
double-bolus NN T
method NN method T

Cerebrospinal CAPITAL NNP cerebrospinal O
fluid JJ fluid O
and DT stopwords O
plasma NN plasma O
insulin NN insulin O
levels NN degree O
in NN stopwords inch O
Alzheimer CAPITAL DT D
's POS D
disease NN disease D
: : O
relationship NN relationship O
to NN stopwords O
severity NN badness O
of NN stopwords O
dementia NN dementia D
and DT stopwords O
apolipoprotein DT O
E CAPITAL NN vitamin_E O
genotype NN genotype O

Treatment CAPITAL NNP treatment O
of NN stopwords O
suicidal JJ self-destructive O
patients VB patient O

Hyperbaric CAPITAL NNP T
oxygen JJ oxygen T
therapy NN therapy T
for NN stopwords O
children JJ child O
with NN stopwords O
cerebral NNS cerebral D
palsy VB paralysis D

All CAPITAL DT all O
patients VB patient O
were NN stopwords be O
hemodynamically NN O
stable NN stable O
( ( O
ie NN Internet_Explorer O
, , O
without NN O
evidence NN evidence O
of NN stopwords O
cardiogenic VB D
shock NN daze D
) ) O
at DT stopwords astatine O
presentation NN presentation O

We CAPITAL NNP O
now JJ stopwords now O
show NN show O
that NN stopwords O
the NN stopwords O
formation NN formation O
of NN stopwords O
1 DIGITS CD one O
is NN stopwords be O
followed JJ follow O
by NN stopwords by O
reformation NN reformation O
of NN stopwords O
CO2 CAPITAL NNP carbon_dioxide O
( ( O
rather VB rather O
than NN stopwords O
another DT another O
carbonate VB carbonate O
species NN species O
such NN stopwords such O
as DT stopwords arsenic O
CO3 CAPITAL NNP O
= NN O
or NN stopwords Oregon O
HCO3- CAPITAL NNP O
) ) O

Increase CAPITAL PRP addition O
in NN stopwords inch O
ambient DT ambient O
temperature NN temperature O
may VB May O
explain NN explain O
decrease NN decrease O
in NN stopwords inch O
amniotic DT amniotic O
fluid JJ fluid O
index NN index O

Connexin-26 CAPITAL NNP O
mutations NN mutant O
in NN stopwords inch O
sporadic NN sporadic O
non-syndromal JJ D
sensorineural NN sensorineural D
deafness NN deafness D

schizophrenia JJ schizophrenia D
as DT stopwords arsenic O
failure VB failure O
of NN stopwords O
hemispheric NN hemispheric O
dominance NN laterality O
for NN stopwords O
language NN language O

On CAPITAL NNP on O
the NN stopwords O
examination NN examination O
of NN stopwords O
ginseng NN ginseng O
and DT stopwords O
powdered NN powderize O
ginseng NN ginseng O
in NN stopwords inch O
1969 DIGITS CD O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
12th CD twelfth O
annual DT annual O
general NN general O
meeting NN meeting O

We CAPITAL NNP O
cotransfected NNS O
Chinese CAPITAL NNP Chinese O
hamster VB hamster O
ovary NN ovary O
cells NNS cell O
with NN stopwords O
two NN two O
cDNA SYM complementary_DNA O
constructs NNS concept O
: : O
a DT stopwords angstrom O
cytoplasmic NNS cytoplasmic O
( ( O
soluble NN soluble O
) ) O
form NN form O
of NN stopwords O
the NN stopwords O
receptor NN receptor O
with NN stopwords O
a DT stopwords angstrom O
deleted NN delete O
signal NN signal O
peptide NN peptide O
( ( O
delta-19 NN O
) ) O
, , O
which NN stopwords O
is NN stopwords be O
unable JJ unable O
to NN stopwords O
bind NN bind O
PRL CAPITAL NNP O
, , O
and DT stopwords O
a DT stopwords angstrom O
functionally JJ functionally O
inactive NN inactive O
receptor NN receptor O
mutant NN mutant O
( ( O
lacking NN miss O
box NN box O
1 DIGITS CD one O
) ) O
, , O
which NN stopwords O
is NN stopwords be O
anchored DT anchor O
in NN stopwords inch O
the NN stopwords O
plasma NN plasma O
membrane NN membrane O
and DT stopwords O
able DT able O
to NN stopwords O
bind NN bind O
PRL CAPITAL NNP O

Low-dose CAPITAL NNP T
clozapine NNS clozapine T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
drug-induced NN D
psychosis NN psychosis D
in NN stopwords inch D
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D

Moreover CAPITAL NNP furthermore O
, , O
the NN stopwords O
girl NN girl O
had VB stopwords have O
no NNS stopwords no O
antibodies DT antibody O
against DT stopwords O
this NN stopwords O
toxin NN toxin O

An CAPITAL DT Associate_in_Nursing O
urgent JJ pressing O
and DT stopwords O
worldwide NN worldwide O
problem NN problem O
to NN stopwords O
remove NN remove O
inter-laboratory NN O
differences NN difference O
in NN stopwords inch O
the NN stopwords O
measurement NN measurement O
of NN stopwords O
GHb CAPITAL NNP gamma_hydroxybutyrate O
needs JJ need O
to NN stopwords O
be NN stopwords beryllium O
solved NN solve O

Incidence CAPITAL PRP incidence O
of NN stopwords O
dog NN dog D
bite NN bite D
injuries NN injury D
treated NN treat O
in NN stopwords inch O
emergency NN emergency O
departments NN department O

Genetic CAPITAL NNP familial O
variation NN variation O
in NN stopwords inch O
the NN stopwords O
dimorphic NN dimorphic O
regions NN region O
of NN stopwords O
RAP-1 CAPITAL VB O
genes NN gene O
and DT stopwords O
rap-1 VB O
loci NN venue O
of NN stopwords O
Babesia CAPITAL NNP D
bigemina NN D

Research CAPITAL NNP research O
into NN stopwords O
long NN hanker O
term NN term O
use JJ use O
is NN stopwords be O
needed JJ necessitate O

Rapallo CAPITAL VB O
, , O
Italy CAPITAL PRP Italy O
, , O
14-15 CD O
March CAPITAL NNP March O
1997 DIGITS CD O

Risk CAPITAL NN hazard O
factors VB factor O
for NN stopwords O
HIV-1 CAPITAL NNP D
infection NN infection D
among DT O
pregnant NN pregnant O
women NN woman O
in NN stopwords inch O
French CAPITAL NNP French O
Guiana CAPITAL NNP Guiana O

Guanethidine CAPITAL NNP O

METHOD CAPITAL NNP method O
: : O
PIBF CAPITAL NNP O
expression NN expression O
on NN stopwords on O
T CAPITAL NN thymine O
lymphocytes NN lymphocyte O
was VB stopwords Washington O
measured NN measure O
using JJ exploitation O
an DT stopwords Associate_in_Nursing O
immunohistochemical JJ O
method NN method O
with NN stopwords O
a DT stopwords angstrom O
PIBF-specific CAPITAL NNP O
polyclonal NN O
antibody DT antibody O

Comparative CAPITAL NNP comparative O
studies NN survey O

For CAPITAL NNP O
additional DT extra O
evaluation NN evaluation O
, , O
females JJ female O
were NN stopwords be O
divided NN divide O
into NN stopwords O
two NN two O
subgroups NN subgroup O
, , O
osteoporotic JJ O
or NN stopwords Oregon O
nonosteoporotic JJ O
, , O
based VB establish O
on NN stopwords on O
x-rays LS X_ray O
and DT stopwords O
lumbar NN lumbar O
bone NN bone O
mineral NN mineral O
density NN density O
( ( O
BMD CAPITAL NNP O
) ) O
as DT stopwords arsenic O
measured NN measure O
by NN stopwords by O
qCT JJ O

Improved CAPITAL PRP better O
control NNS control O
will NN stopwords volition O
provide NN supply O
better NN better O
quality NN quality O

Body CAPITAL NNP body O
weight NN weight O
and DT stopwords O
mortality NN mortality O
among DT O
women NN woman O

Online CAPITAL NNP on-line O

Lumbar CAPITAL NNP lumbar D
puncture NN puncture D
need JJ need O
n't NN O
be NN stopwords beryllium O
a DT stopwords angstrom O
headache NN concern O

Interferon CAPITAL PRP interferon T
plays NN play O
a DT stopwords angstrom O
critical JJ critical O
role NN function O
in NN stopwords inch O
the NN stopwords O
host NN host O
's POS O
natural RB natural O
defense NN defense O
against DT stopwords O
viral NN viral D
infections NN infection D
and DT stopwords O
in NN stopwords inch O
their NN stopwords O
treatment NN treatment O

Rhinitis CAPITAL NNP rhinitis D
in NN stopwords inch O
herds NN herd O
with NN stopwords O
piglet NN piglet D
influenza NN influenza D

Potassium CAPITAL NNP potassium O
in NN stopwords inch O
heart NN heart D
failure VB failure D

Pneumosinus CAPITAL NNP O
dilatans NN O
: : O
a DT stopwords angstrom O
little-known NN little-known O
diagnostic NN diagnostic O
tool NN tool O

Fine CAPITAL NNP fine O
structure NN structure O
of NN stopwords O
desmosomes NN O

A CAPITAL DT angstrom O
patient VB patient O
with NN stopwords O
a DT stopwords angstrom O
vesico-enteric NN D
fistula NN fistulous_withers D
was VB stopwords Washington O
successfully NN successfully O
treated NN treat O
with NN stopwords O
resection NN resection T
of NN stopwords T
the NN stopwords T
small JJ small T
intestine NN intestine T
and DT stopwords T
dome NN dome T
of NN stopwords T
the NN stopwords T
bladder NN bladder T
and DT stopwords T
drainage NN drain T
of NN stopwords T
the NN stopwords T
intervening NN intervene T
abscess DT abscess T

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Analysis CAPITAL DT analysis O
of NN stopwords O
Cr CAPITAL NNP chromium O
, , O
Zn CAPITAL NNP zinc O
, , O
Fe CAPITAL NNP iron O
and DT stopwords O
Pb CAPITAL NNP lead O
contaminants NNS contaminant O
in NN stopwords inch O
food JJ food O
coal-tar NNS O
dyes NN dye O
and DT stopwords O
their NN stopwords O
aluminium DT aluminum O
lakes NN lake O
by NN stopwords by O
atomic DT atomic O
absorption DT absorption O
spectrophotometry NN O

343 DIGITS CD O
eligible NN eligible O
patients VB patient O
were NN stopwords be O
randomised VB randomize O
: : O
172 DIGITS CD O
to NN stopwords O
surgery NN surgery T
and DT stopwords O
171 DIGITS CD O
to NN stopwords O
radical VB group O
radiotherapy VB radiotherapy T

After CAPITAL DT after O
six NN six O
baiting IN baiting O
campaigns VB political_campaign O
( ( O
15-20 CD O
baits/km2 IN O
) ) O
over JJ stopwords over O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
14 DIGITS CD fourteen O
months NN calendar_month O
, , O
the NN stopwords O
prevalence NN prevalence O
of NN stopwords O
the NN stopwords O
cestode NNS tapeworm O
in NN stopwords inch O
foxes JJ fox O
, , O
initially JJ initially O
32 DIGITS CD thirty-two O
% NN O
, , O
had VB stopwords have O
fallen VB fall O
to NN stopwords O
4 DIGITS CD four O
% NN O

Investigation CAPITAL PRP probe O
of NN stopwords O
uncertainties JJ uncertainty O
in NN stopwords inch O
relaxation NN relaxation O
analysis DT analysis O
of NN stopwords O
2D CD second O
NOE CAPITAL NNP O
which NN stopwords O
arise DT originate O
from JJ stopwords O
spectral NN spectral O
noise JJ noise O

Fibromyalgia CAPITAL NNP D
: : O
La CAPITAL VB lanthanum O
Maladie CAPITAL NNP O
est NN Eastern_Time O
Morte CAPITAL NNP O

The CAPITAL NNP O
SAPHO CAPITAL VB D
syndrome NN syndrome D
: : O
an DT stopwords Associate_in_Nursing O
evolving NN evolve O
concept NNS concept O
for NN stopwords O
unifying JJ unify O
several NN several O
idiopathic JJ idiopathic O
disorders NN disorder O
of NN stopwords O
bone NN bone O
and DT stopwords O
skin JJ skin O

METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
present NN present O
rehabilitation NN rehabilitation O
data VB data O
on NN stopwords on O
21 DIGITS CD twenty-one O
adult DT adult O
patients VB patient O
provided NN supply O
with NN stopwords O
the NN stopwords O
Nucleus CAPITAL NNP nucleus O
CI22 CAPITAL NNP O
M CAPITAL NN meter O
cochlear NNS cochlear O
implant JJ implant O
using JJ exploitation O
the NN stopwords O
SPEAK CAPITAL NNP talk O
strategy NN scheme O

METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
used JJ use O
a DT stopwords angstrom O
randomised VB randomize O
double-blind NN O
study NN survey O
design NN design O

Two CAPITAL NNP two O
actions DT action O
are DT stopwords are O
possible NN possible O
for NN stopwords O
doctors NN doctor O
wanting VB desire O
to NN stopwords O
promote NN promote O
human NN homo O
welfare NN social_welfare O
in NN stopwords inch O
Africa CAPITAL DT Africa O

Immediate CAPITAL PRP immediate O
outcome JJ result O
and DT stopwords O
long-term NN long-run O
results NN consequence O
of NN stopwords O
108 DIGITS CD O
sphincterotomies NN O
of NN stopwords O
Oddi CAPITAL NNP O
's POS O
sphincter NN sphincter O
of NN stopwords O
biliary NN bilious O
indication NN indication O

novel JJ novel O
treatment NN treatment O
strategies NN scheme O
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance D
nsclc JJ D
may VB May O
involve NN involve O
chemotherapy NNS chemotherapy T
combined NNS unite O
with NN stopwords O
inhibition NN inhibition O
of NN stopwords O
nf-kappab-dependent RB O
cell-survival NNS O
pathways VB nerve_pathway O

New CAPITAL NNP new O
York CAPITAL NNP York O
, , O
New CAPITAL NNP new O
York CAPITAL NNP York O
, , O
USA CAPITAL NNP United_States O

Cerebral CAPITAL NNP cerebral D
infarct NN infarct D
following JJ following O
central NNS central T
venous NN venous T
cannulation VB cannulation T

Medication CAPITAL NNP medicine T
received NN receive O
by NN stopwords by O
patients VB patient O
with NN stopwords O
depression NN depression D
following JJ following O
the NN stopwords O
acute DT acute_accent O
episode NN episode O
: : O
adequacy DT adequacy O
and DT stopwords O
relation NN relation O
to NN stopwords O
outcome JJ result O

Gingyo-san CAPITAL NNP T
and DT stopwords O
its NN stopwords information_technology O
components NNS component O
were NN stopwords be O
administered DT administer O
orally NN orally O
to NN stopwords O
mice NN mouse O
1 DIGITS CD one O
day VB day O
before NN stopwords earlier O
, , O
then NN stopwords then O
1 DIGITS CD one O
and DT stopwords O
4 DIGITS CD four O
days VB days O
after DT stopwords after O
the NN stopwords O
inhalation NN inhalation O
of NN stopwords O
a DT stopwords angstrom O
mouse-adopted NN D
strain NN strain D
of NN stopwords D
influenza NN influenza D
A2 CAPITAL DT D
( ( D
H2N2 CAPITAL $ D
) ) D
virus NN virus D

Protection CAPITAL NNP protection O
of NN stopwords O
swine JJ swine O
from JJ stopwords O
foot-and-mouth JJ D
disease NN disease D
with NN stopwords O
one JJ one O
dose NN dose O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
all-D DT T
retro NN retro T
peptide NN peptide T

Acute CAPITAL DT acute_accent D
obstructive NN clogging D
hydrocephalus NN hydrocephalus D
complicating NNS complicate O
bacterial VB bacterial D
meningitis NN meningitis D
in NN stopwords inch O
childhood JJ childhood O

This CAPITAL NNP O
increased NN increase O
growth NN growth O
was VB stopwords Washington O
independent NN mugwump O
of NN stopwords O
potentially NN potentially O
confounding NNS confuse O
obstetric NN obstetric O
, , O
social NN sociable O
and DT stopwords O
demographic NN demographic O
factors VB factor O

Effects CAPITAL NNP effects O
of NN stopwords O
ultrasound JJ ultrasound T
energy NN energy T
on NN stopwords on O
total NN sum D
peripheral NN peripheral D
artery DT artery D
occlusions JJ occlusion D
: : O
initial JJ initial O
angiographic DT O
and DT stopwords O
angioscopic DT O
results NN consequence O
. . O

Do CAPITAL NNP bash O
no NNS stopwords no O
harm NN injury O

BACKGROUND CAPITAL IN background O
: : O
There CAPITAL NNP there O
is NN stopwords be O
serological NN serologic O
evidence NN evidence O
for NN stopwords O
an DT stopwords Associate_in_Nursing O
association DT association O
between NN stopwords between O
Chlamydia CAPITAL NNP chlamydia D
pneumoniae NN D
and DT stopwords O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D

CONCLUSION CAPITAL NNP decision O
: : O
Omega3 CAPITAL NNP T
fatty VB fatso T
acids DT acid T
were NN stopwords be O
well NN well O
tolerated NN digest O
and DT stopwords O
improved JJ better O
the NN stopwords O
short-term NN short-run O
course NNS course O
of NN stopwords O
illness NN illness O
in NN stopwords inch O
this NN stopwords O
preliminary NN preliminary O
study NN survey O
of NN stopwords O
patients VB patient O
with NN stopwords O
bipolar NN bipolar D
disorder NN disorder D

we NN stopwords O
evaluated NN measure O
the NN stopwords O
role NN function O
of NN stopwords O
chemotherapy NNS chemotherapy T
for NN stopwords O
patients VB patient O
with NN stopwords O
brain NN brain D
metastases NN metastasis D
from JJ stopwords D
nsclc JJ D

Therefore CAPITAL NNP therefore O
, , O
accelerated DT accelerate T
infusion NN infusion T
of NN stopwords T
alteplase DT T
over JJ stopwords over O
a DT stopwords angstrom O
period NN time_period O
of NN stopwords O
90 DIGITS CD ninety O
minutes NN minutes O
remains NN remains O
the NN stopwords O
preferred NN prefer O
regimen NN regimen O

They CAPITAL NNP O
knew NN know O
little NN little O
of NN stopwords O
how NN stopwords O
to NN stopwords O
reduce NN reduce O
this NN stopwords O
risk NN hazard O
but NN stopwords merely O
nearly RB about O
all DT stopwords all O
would NN O
accept DT accept O
a DT stopwords angstrom O
drug NN drug O
to NN stopwords O
prevent NN prevent O
transmission NN transmission O

Initially CAPITAL PRP initially O
the NN stopwords O
diagnosis NN diagnosis O
of NN stopwords O
the NN stopwords O
syndrome NN syndrome O
of NN stopwords O
hemorrhagic NN hemorrhagic D
shock NN daze D
and DT stopwords O
encephalopathy NN brain_disorder D
was VB stopwords Washington O
made VB make O

Subchorial CAPITAL NNP D
hematoma NN hematoma D
: : O
a DT stopwords angstrom O
probable NN probable O
cause VB cause O
of NN stopwords O
reversible NN reversible O
nonimmune JJ liable O
hydrops NN edema O
fetalis JJ D

BACKGROUND CAPITAL IN background O
: : O
Omega3 CAPITAL NNP O
fatty VB fatso O
acids DT acid O
may VB May O
inhibit NN suppress O
neuronal JJ neural O
signal NN signal O
transduction NN transduction O
pathways VB nerve_pathway O
in NN stopwords inch O
a DT stopwords angstrom O
manner VB manner O
similar NN similar O
to NN stopwords O
that NN stopwords O
of NN stopwords O
lithium NN lithium T
carbonate VB carbonate T
and DT stopwords O
valproate NN T
, , O
2 DIGITS CD two O
effective NN effective O
treatments NN treatment O
for NN stopwords O
bipolar NN bipolar D
disorder NN disorder D

Combination CAPITAL NNP combination T
therapy NN therapy T
with NN stopwords T
interferon-alpha NN T
( ( T
IFN CAPITAL PRP T
alpha DT alpha T
) ) T
plus NN asset T
Ribavirin CAPITAL NN ribavirin T
has VB stopwords hour_angle O
been NN stopwords be O
shown NN show O
to NN stopwords O
improve JJ better O
the NN stopwords O
response NN response O
rate VB rate O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D
as DT stopwords arsenic O
compared NNS compare O
to NN stopwords O
IFN CAPITAL PRP O
alpha DT alpha O
alone DT alone O

Field CAPITAL NNP field O
evaluation NN evaluation O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
effectiveness NN effectiveness O
of NN stopwords O
vaccines NN vaccine T
against DT stopwords O
pertussis NN whooping_cough D
, , D
measles NN measles D
, , D
rubella NN German_measles D
and DT stopwords D
mumps NN mumps D
: : O
comments NNS remark O

Brain CAPITAL NNP brain D
tumours NN tumor D
and DT stopwords O
mobile NN Mobile O
phones NN telephone O
? . O

Beverage CAPITAL NNP beverage O
use JJ use O
and DT stopwords O
risk NN hazard O
for NN stopwords O
kidney NN kidney D
stones NN rock D
in NN stopwords inch O
women NN woman O

Laugier-Hunziker CAPITAL VB D
syndrome NN syndrome D
: : O
case VB case O
report NN report O
and DT stopwords O
treatment NN treatment O
with NN stopwords O
the NN stopwords O
Q-switched CAPITAL NNP T
Nd-Yag CAPITAL NNP T
laser NN laser T

A CAPITAL DT angstrom O
methodical NN methodical O
strategy NN scheme O
for NN stopwords O
the NN stopwords O
isolation NN isolation O
of NN stopwords O
microsatellite NN O
markers NN marker O
specific NN particular O
for NN stopwords O
targeted VB target O
regions NN region O
of NN stopwords O
bovine NN bovine O
chromosomes NN chromosome O
is NN stopwords be O
presented NN show O

Discriminant CAPITAL NNP O
analysis DT analysis O
revealed NN uncover O
the NN stopwords O
following JJ following O
function JJ function O
to NN stopwords O
separate NN offprint O
the NN stopwords O
groups NN group O
: : O
0.7764 LS O
( ( O
UA CAPITAL IN O
) ) O
+ NN O
0.8086 LS O
( ( O
PGK CAPITAL NNP O
) ) O
-0.7032 : O
( ( O
G3PD CAPITAL NNP O
) ) O
+ NN O
0.1399 LS O
( ( O
LDL CAPITAL NNP low-density_lipoprotein O
) ) O
-0.2386 : O
( ( O
MPV CAPITAL NNP O
) ) O

Truncated-gene CAPITAL NNP O
reporter NN reporter O
system NN system O
for NN stopwords O
studying NN perusal O
the NN stopwords O
regulation NN regulation O
of NN stopwords O
manganese VB manganese O
peroxidase NN peroxidase O
expression NN expression O

Follow-up CAPITAL NNP follow-up O
analyses DT analysis O
revealed NN uncover O
4 DIGITS CD four O
regions NN region O
of NN stopwords O
continued NNS continue O
interest NN interest O
on NN stopwords on O
chromosomes NN chromosome O
4 DIGITS CD four O
, , O
6 DIGITS CD six O
, , O
12 DIGITS CD twelve O
, , O
and DT stopwords O
20 DIGITS CD twenty O
, , O
with NN stopwords O
the NN stopwords O
strongest NN strong O
results NN consequence O
observed NN detect O
forchromosome NN O
12 DIGITS CD twelve O

Lead CAPITAL NNP lead O
based VB establish O
paint IN paint O
hazards NN hazard O
in NN stopwords inch O
early VB early O
childhood JJ childhood O
centres NNS Centre O
in NN stopwords inch O
the NN stopwords O
Wellington CAPITAL NNP Wellington O
region NN region O

Hallux CAPITAL NNP big_toe O
length NN length O
was VB stopwords Washington O
well NN well O
maintained VB keep O
after DT stopwords after O
surgery NN surgery T
with NN stopwords O
bone NN bone T
grafting NN graft T
, , O
but NN stopwords merely O
it NN stopwords information_technology O
was VB stopwords Washington O
more NN stopwords More O
difficult NN difficult O
to NN stopwords O
obtain NN obtain O
the NN stopwords O
alignment DT alliance O
goals NN goal O

Dioxins CAPITAL NNP dioxin O
are DT stopwords are O
a DT stopwords angstrom O
family VB family O
of NN stopwords O
chlorinated NNS chlorinate O
aromatic DT aromatic O
hydrocarbons NN hydrocarbon O
that NN stopwords O
are DT stopwords are O
produced NN produce O
during NN stopwords O
combustion NNS combustion O
processes NN procedure O
in NN stopwords inch O
the NN stopwords O
presence NN presence O
of NN stopwords O
a DT stopwords angstrom O
chlorine NNS chlorine O
donor NN donor O
and DT stopwords O
as DT stopwords arsenic O
by-products NN by-product O
of NN stopwords O
the NN stopwords O
chlorine-processing NNS O
chemical NNS chemical O
industries NN industry O

Independent CAPITAL PRP mugwump O
occurrence JJ happening O
of NN stopwords O
the NN stopwords O
novel JJ novel O
Arg2163 CAPITAL DT O
to NN stopwords O
His CAPITAL NNP O
mutation NN mutant O
in NN stopwords inch O
the NN stopwords O
factor VB factor O
VIII CAPITAL NNP eight O
gene NN gene O
in NN stopwords inch O
three NN three O
unrelated JJ unrelated O
families VB family O
with NN stopwords O
haemophila VB D
A CAPITAL DT angstrom D
with NN stopwords O
different NN different O
phenotypes NN phenotype O

EU CAPITAL NN europium O
Working CAPITAL NNP working O
Group CAPITAL NNP group O
on NN stopwords on O
Tobacco CAPITAL NNP tobacco O
and DT stopwords O
Oral CAPITAL NNP oral O
Health CAPITAL NNP health O
Consensus CAPITAL NNP consensus O
Meeting CAPITAL NNP meeting O

Survanta CAPITAL NNP O
in NN stopwords inch O
Term CAPITAL NNP term O
Infants CAPITAL PRP baby O
Study CAPITAL NNP survey O
Group CAPITAL NNP group O

( ( O
2 DIGITS CD two O
) ) O
Incorporating CAPITAL PRP integrate O
a DT stopwords angstrom O
healthy NN healthy O
lifestyle NN life_style O
was VB stopwords Washington O
easy VB easy O
for NN stopwords O
some NN stopwords some O
and DT stopwords O
a DT stopwords angstrom O
struggle NN struggle O
for NN stopwords O
others JJ O

CONCLUSION CAPITAL NNP decision O
: : O
The CAPITAL NNP O
prevalence NN prevalence O
of NN stopwords O
drug NN drug O
misuse NN misuse O
antenatally DT O
was VB stopwords Washington O
nearly RB about O
3 DIGITS CD three O
% NN O
and DT stopwords O
postnatally NN O
almost DT about O
6 DIGITS CD six O
% NN O

B CAPITAL NN bacillus O

Review CAPITAL NNP reappraisal O
of NN stopwords O
the NN stopwords O
literature NN literature O
disclosed NN unwrap O
no NNS stopwords no O
previously NN previously O
documented NN document O
similar NN similar O
occurrence JJ happening O

A CAPITAL DT angstrom O
plan NN plan O
for NN stopwords O
improving JJ better O
outcomes JJ result O
for NN stopwords O
patients VB patient O
with NN stopwords O
chronic NN chronic D
renal NN nephritic D
failure VB failure D

United CAPITAL NNP unite O
Kingdom CAPITAL NNP kingdom O
collaborators NNS confederate O
in NN stopwords inch O
the NN stopwords O
International CAPITAL PRP International O
Stroke CAPITAL NNP stroke O
Trial CAPITAL NNP test O

Epoetin CAPITAL NNP T
: : O
a DT stopwords angstrom O
pharmacoeconomic NN O
review NN reappraisal O
of NN stopwords O
its NN stopwords information_technology O
use JJ use O
in NN stopwords inch O
chronic NN chronic D
renal NN nephritic D
failure VB failure D
and DT stopwords O
its NN stopwords information_technology O
effects NN effects O
on NN stopwords on O
quality NN quality O
of NN stopwords O
life NN life O

Chromosome CAPITAL NNP chromosome O
12 DIGITS CD twelve O
gave VB give O
the NN stopwords O
strongest NN strong O
and DT stopwords O
most NN stopwords most O
consistent NNS consistent O
results NN consequence O
with NN stopwords O
a DT stopwords angstrom O
peak NN extremum O
multipoint NN O
MLS CAPITAL NNP Master_of_Library_Science O
of NN stopwords O
3.5 LS O
, , O
suggesting NN propose O
that NN stopwords O
this NN stopwords O
region NN region O
contains NNS incorporate O
a DT stopwords angstrom O
new JJ new O
susceptibility NN susceptibility O
gene NN gene O
for NN stopwords O
AD CAPITAL DT ad O

Minimally CAPITAL NNP minimally O
invasive NN invasive O
treatment NN treatment O
of NN stopwords O
abscesses DT abscess D
by NN stopwords by O
CT-controlled CAPITAL NNP T
drainage NN drain T
with NN stopwords T
a DT stopwords angstrom T
basket VB basket T
catheter VB catheter T
system NN system T

Xenopus CAPITAL NN Xenopus O
Pax-2 CAPITAL VB O
displays NN display O
multiple NN multiple O
splice NN splice O
forms NN form O
during NN stopwords O
embryogenesis NN O
and DT stopwords O
pronephric NN O
kidney NN kidney O
development NN development O

1981 DIGITS CD O

However CAPITAL NNP however O
, , O
some NN stopwords some O
recovery NN recovery O
was VB stopwords Washington O
seen NN see O
for NN stopwords O
a DT stopwords angstrom O
change NNS change O
in NN stopwords inch O
the NN stopwords O
medium NN medium O
( ( O
growth NN growth O
medium NN medium O
to NN stopwords O
conditioned NNS condition O
medium NN medium O
) ) O
up JJ stopwords up O
to NN stopwords O
5-6 CD O
h NN hydrogen O
postirradiation NN O

How CAPITAL NNP O
long NN hanker O
should NN stopwords O
suction NN suction O
drains NN drain O
stay NN stay O
in NN stopwords inch O
after DT stopwords after O
breast NN breast T
surgery NN surgery T
with NN stopwords O
axillary DT axillary T
dissection NN dissection T
? . O

Reporting CAPITAL NNP coverage O
of NN stopwords O
adverse DT adverse O
drug NN drug O
reactions NN chemical_reaction O
by NN stopwords by O
hospital NN hospital O
doctors NN doctor O
and DT stopwords O
the NN stopwords O
response NN response O
to NN stopwords O
intervention NN intervention O

in NN stopwords inch O
contrast NNS contrast O
, , O
the NN stopwords O
introduction NN introduction O
and DT stopwords O
improvement JJ improvement O
of NN stopwords O
chemotherapy NNS chemotherapy T
since NN O
the NN stopwords O
1970s CD seventies O
gave VB give O
rise NN rise O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
improvement JJ improvement O
in NN stopwords inch O
- : O
only JJ stopwords lone O
short-term NN short-run O
( ( O
< NN O
2 DIGITS CD two O
years NN old_age O
) ) O
- : O
survival NN survival O
for NN stopwords O
patients VB patient O
with NN stopwords O
small-cell JJ D
lung NN lung D
cancer VB cancer D

Radical CAPITAL VB group O
reactions NN chemical_reaction O
can VB stopwords can O
cause VB cause O
mutations NN mutant O
, , O
inactivation NN inactivation O
or NN stopwords Oregon O
a DT stopwords angstrom O
decrease NN decrease O
in NN stopwords inch O
the NN stopwords O
turnover NN employee_turnover O
of NN stopwords O
mitochondrial NN O
DNA CAPITAL NNP deoxyribonucleic_acid O
which NN stopwords O
is NN stopwords be O
more NN stopwords More O
vulnerable NN vulnerable O
than NN stopwords O
the NN stopwords O
nuclear JJ nuclear O
genoma NN O
to NN stopwords O
the NN stopwords O
attack DT attack O
of NN stopwords O
mutagenic NN mutagenic O
agents DT agent O
, , O
acting DT acting O
also DT besides O
as DT stopwords arsenic O
a DT stopwords angstrom O
continuous NNS continuous O
source NN beginning O
of NN stopwords O
initial JJ initial O
and/or DT O
promoting NN promote O
factors VB factor O
of NN stopwords O
the NN stopwords O
carcinogenetic VB O
process NN procedure O

Tokyo CAPITAL NNP Tokyo O
, , O
Japan CAPITAL NNP Japan O
, , O
November CAPITAL NNP November O
11-13 CD O
, , O
1996 DIGITS CD O

Thermal CAPITAL NNP thermal O
equipment NN equipment O
usage JJ use O
patterns VB form O
in NN stopwords inch O
neonatal JJ neonatal O
intensive NN intensifier O
care VB care O
units JJ unit_of_measurement O
: : O
interunit NN O
variability NN variability O
and DT stopwords O
intraunit NN O
consistency NNS consistency O

Prevention CAPITAL NNP prevention O
of NN stopwords O
bacterial VB bacterial D
endocarditis NN endocarditis D
: : O
American CAPITAL DT American O
Heart CAPITAL NNP heart O
Association CAPITAL DT association O
recommendations NN recommendation O

A CAPITAL DT angstrom O
randomized VB randomize O
trial NN test O
of NN stopwords O
Lactobacillus CAPITAL VB lactobacillus T
acidophilus DT acidophilus T
BG2FO4 CAPITAL NNP T
to NN stopwords O
treat NN dainty O
lactose NN lactose D
intolerance NN intolerance D

Splenectomy CAPITAL NNP splenectomy T
during NN stopwords O
pregnancy NN pregnancy O
: : O
an DT stopwords Associate_in_Nursing O
option JJ option O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
autoimmune DT autoimmune D
thrombocytopenic NN D
purpura NN purpura D

Randomized CAPITAL VB randomize O
trial NN test O
of NN stopwords O
interferon-alpha NN T
plus NN asset T
ursodeoxycholic JJ T
acid DT acid T
versus NN O
interferon NN interferon T
plus NN asset T
placebo NN placebo T
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D
resistant NN immune D
to NN stopwords D
interferon NN interferon D

Thoracoscopic CAPITAL NNP T
operation JJ operation T
for NN stopwords O
secondary NN secondary D
pneumothorax NN pneumothorax D
under JJ stopwords nether O
local NN local O
and DT stopwords O
epidural NN epidural_anesthesia O
anesthesia DT anesthesia O
in NN stopwords inch O
high-risk NN bad O
patients VB patient O

The CAPITAL NNP O
gene NN gene O
contains NNS incorporate O
two NN two O
alternative DT option O
first NN first O
exons NN exon O
, , O
1a CD O
and DT stopwords O
1b CD O
, , O
both NN stopwords both O
including NN include O
a DT stopwords angstrom O
translation NN translation O
initiation JJ initiation O
codon NNS codon O

Percutaneous CAPITAL NNP transdermal T
transluminal NN T
angioplasty DT angioplasty T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
renovascular NN D
hypertension NN high_blood_pressure D
: : O
sequential NN consecutive O
prospective NN prospective O
study NN survey O

Differential CAPITAL NNP derived_function O
diagnosis NN diagnosis O
of NN stopwords O
infectious NN infectious D
hepatitis NN hepatitis D
in NN stopwords inch O
pregnancy NN pregnancy O

The CAPITAL NNP O
Integrative CAPITAL PRP integrative O
Neurobiology CAPITAL NNP neurobiology O
of NN stopwords O
Affiliation CAPITAL DT affiliation O

Normoxic CAPITAL NNP T
cardiopulmonary VB cardiopulmonary T
bypass NN beltway T
reduces NN reduce O
oxidative IN oxidative D
myocardial NN myocardial D
damage VB damage D
and DT stopwords D
nitric NN azotic D
oxide IN oxide D
during NN stopwords O
cardiac VB cardiac O
operations JJ operations O
in NN stopwords inch O
the NN stopwords O
adult DT adult O

Diabetes CAPITAL NNP diabetes D
mellitus NN D
is NN stopwords be O
a DT stopwords angstrom O
still JJ still O
growing NN growth O
disease NN disease O

Technical CAPITAL NNP technical O
Working CAPITAL NNP working O
Group CAPITAL NNP group O
, , O
World CAPITAL NNP universe O
Health CAPITAL NNP health O
Organization CAPITAL NNP organization O

we NN stopwords O
conducted NNS conduct O
a DT stopwords angstrom O
phase NN phase O
ii NN two O
study NN survey O
of NN stopwords O
etoposide NN T
( ( T
vp-16 NN T
) ) T
-ifosfamide-cisplatin : T
( ( T
vip NN very_important_person T
) ) T
combination NNS combination T
chemotherapy NNS chemotherapy T
plus NN asset T
early VB early T
concurrent NNS coincident T
thoracic NN pectoral T
irradiation NN irradiation T
for NN stopwords O
the NN stopwords O
patients VB patient O
with NN stopwords O
previously NN previously O
untreated JJ untreated D
limited NN express D
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
in NN stopwords inch O
order JJ order O
to NN stopwords O
assess DT buttocks O
if NN stopwords O
the NN stopwords O
treatment NN treatment O
modality NN modality O
could NNS O
improve JJ better O
the NN stopwords O
response NN response O
rate VB rate O
and DT stopwords O
the NN stopwords O
toxicity NN toxicity O

Experimental CAPITAL NNP experimental O
evaluation NN evaluation O
of NN stopwords O
the NN stopwords O
use JJ use O
of NN stopwords O
recombinant NN recombinant T
prourokinase NN T
and DT stopwords O
its NN stopwords information_technology O
immobilized JJ immobilize O
forms NN form O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
postoperative NN postoperative D
fibrinoid NN D
syndrome NN syndrome D
in NN stopwords inch O
ophthalmology JJ ophthalmology O

Cerebral CAPITAL NNP cerebral D
hemosiderosis NN hemosiderosis D
related NN associate O
to NN stopwords O
hereditary NN familial O
ceruloplasmin NNS D
deficiency NN lack D

Autoimmune CAPITAL DT autoimmune D
enteropathy NN enteropathy D
in NN stopwords inch O
adults DT adult O

This CAPITAL NNP O
article DT article O
discusses NN discus O
many VB many O
of NN stopwords O
the NN stopwords O
nutritional JJ nutritional O
topics NN subject O
important JJ important O
to NN stopwords O
the NN stopwords O
intensivist NN O

Maternal CAPITAL NNP maternal O
characteristics NNS feature O
were NN stopwords be O
similar NN similar O
in NN stopwords inch O
the NN stopwords O
two NN two O
groups NN group O

Case CAPITAL VB case O
of NN stopwords O
superficial NN superficial D
hemosiderosis NN hemosiderosis D
of NN stopwords D
the NN stopwords D
central NNS central D
nervous RB nervous D
system NN system D
treated NN treat O
with NN stopwords O
trientine NN T

Osteopathic CAPITAL NNP O
manifesto VB manifesto O

Quality CAPITAL NNP quality O
and DT stopwords O
clinical JJ clinical O
audit DT audited_account O

Methotrexate CAPITAL NNP methotrexate T
and DT stopwords O
trimethoprim NN T
: : O
a DT stopwords angstrom O
fatal VB fatal O
interaction NN interaction O

Poliomyelitis CAPITAL NNP poliomyelitis D
prevention NN prevention O
: : O
revised NN revise O
recommendations NN recommendation O
for NN stopwords O
use JJ use O
of NN stopwords O
inactivated NN demobilize O
and DT stopwords O
live NN populate O
oral NN oral O
poliovirus NN poliovirus D
vaccines NN vaccine T

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
10th CD tenth O
International CAPITAL PRP International O
Symposium CAPITAL NNP symposium O
on NN stopwords on O
the NN stopwords O
Pharmacology CAPITAL NNP pharmacology O
of NN stopwords O
Thermoregulation CAPITAL NNP O

Battling CAPITAL IN battle O
HI CAPITAL NNP hello D
on NN stopwords on O
many VB many O
fronts JJ front O

The CAPITAL NNP O
involved NN involve O
upper JJ upper_berth O
trapezius NN trapezius O
muscles NN muscle O
were NN stopwords be O
treated NN treat O
with NN stopwords O
three NN three O
different NN different O
methods NN method O
according DT harmonize O
to NN stopwords O
a DT stopwords angstrom O
random VB random O
assignment DT assignment O
: : O
group NN group O
A CAPITAL DT angstrom O
muscles NN muscle O
( ( O
n NN nitrogen O
= NN O
18 DIGITS CD eighteen O
) ) O
were NN stopwords be O
given NN given O
placebo NN placebo O
treatment NN treatment O
( ( O
control NNS control O
group NN group O
) ) O
; : O
group NN group O
B CAPITAL NN bacillus O
muscles NN muscle O
( ( O
n NN nitrogen O
= NN O
20 DIGITS CD twenty O
) ) O
were NN stopwords be O
treated NN treat O
with NN stopwords O
electrical NN electrical T
nerve RB nerve T
stimulation JJ stimulation T
( ( T
ENS CAPITAL NNP en T
) ) T
therapy NN therapy T
; : O
and DT stopwords O
group NN group O
C CAPITAL SYM degree_centigrade O
muscles NN muscle O
( ( O
n NN nitrogen O
= NN O
22 DIGITS CD twenty-two O
) ) O
were NN stopwords be O
given NN given O
electrical NN electrical T
muscle NN muscle T
stimulation JJ stimulation T
( ( T
EMS CAPITAL NNP em T
) ) T
therapy NN therapy T

Elective CAPITAL NNP elective_course T
surgery NN surgery T
for NN stopwords O
colorectal NNS colorectal D
cancer VB cancer D
in NN stopwords inch O
the NN stopwords O
aged DT aged O
: : O
a DT stopwords angstrom O
clinical-economical JJ O
evaluation NN evaluation O

Optimal CAPITAL NNP optimum O
rates VB rates O
of NN stopwords O
virus NN virus O
replication NN reproduction O
require NN necessitate O
protease NN protease O
cleavage NNS cleavage O
of NN stopwords O
precursor NN precursor O
polyproteins NN O

Diagnosed CAPITAL NNP diagnose O
if NN stopwords O
suspected NN suspect O

Mediastinal CAPITAL NNP O
growing NN growth O
teratoma NN teratoma D
syndrome NN syndrome D

sample VB sample O
: : O
45 DIGITS CD forty-five O
adults DT adult O
with NN stopwords O
primary NN primary O
cancer VB cancer D
of NN stopwords D
the NN stopwords D
lung NN lung D
receiving NN receive O
< NN O
outpatient JJ outpatient O
primary NN primary O
or NN stopwords Oregon O
adjuvant DT adjuvant O
radiation VB radiation T
therapy NN therapy T

Non-steroidal CAPITAL NNP T
anti-inflammatory DT anti-inflammatory T
therapy NN therapy T
for NN stopwords O
bronchial NN bronchial D
asthma DT asthma D

All CAPITAL DT all O
patients VB patient O
were NN stopwords be O
managed VB pull_off O
by NN stopwords by O
an DT stopwords Associate_in_Nursing O
intensified NN escalate O
protocol NN protocol O
, , O
including NN include O
stringent NN rigorous O
glycemic NN T
control NNS control T

These CAPITAL NNP O
black/white NN O
( ( O
B/W CAPITAL NNP O
) ) O
differences NN difference O
remained NN stay O
statistically NN statistically O
significant NN significant O
after DT stopwords after O
adjusting DT adjust O
for NN stopwords O
age DT age O
, , O
sex NN sexual_activity O
, , O
metropolitan NN metropolitan O
area DT area O
, , O
summary NN summary O
stage NN phase O
, , O
socioeconomic NN socioeconomic O
status NN status O
, , O
body NN body O
mass VB mass O
index NN index O
, , O
and DT stopwords O
health NN health O
care VB care O
access DT entree O
and DT stopwords O
utilization JJ use O

Continuous CAPITAL NNP continuous T
arterio-venous DT T
hemofiltration NN T
in NN stopwords inch O
a DT stopwords angstrom O
wearable NN clothing O
device NN device O
to NN stopwords O
treat NN dainty O
end-stage NN D
renal NN nephritic D
disease NN disease D

Sucrose CAPITAL NNP sucrose O
stabilization NN stabilization O
was VB stopwords Washington O
necessary JJ necessity O
for NN stopwords O
antibody DT antibody O
to NN stopwords O
undergo JJ undergo O
photoresist NN O
processing NN processing O
without NN O
loss NN loss O
of NN stopwords O
binding NN binding O
activity DT activity O

BACKGROUND CAPITAL IN background O
: : O
The CAPITAL NNP O
growing NN growth O
use JJ use O
of NN stopwords O
heparin NN heparin T
in NN stopwords inch O
acute DT acute_accent D
thrombotic NN D
disorders NN disorder D
, , O
coupled NNS match O
with NN stopwords O
the NN stopwords O
availability DT handiness O
of NN stopwords O
many VB many O
new JJ new O
antithrombotic DT T
agents DT agent T
, , O
emphasizes NN stress O
the NN stopwords O
need JJ need O
for NN stopwords O
adequate DT adequate O
characterization NNS word_picture O
of NN stopwords O
the NN stopwords O
platelet NN platelet O
effects NN effects O
of NN stopwords O
the NN stopwords O
various NN assorted O
anticoagulants DT anticoagulant T

Ondansetron CAPITAL NNP T
is NN stopwords be O
not JJ stopwords not O
a DT stopwords angstrom O
panacea VB Panacea O

A CAPITAL DT angstrom O

Application CAPITAL DT application O
to NN stopwords O
a DT stopwords angstrom O
novel JJ novel O
tin NN tin O
derivative NN derived_function O
of NN stopwords O
erythromycin NN erythromycin O
A CAPITAL DT angstrom O

Antimicrobial CAPITAL DT disinfectant T
therapy NN therapy T
for NN stopwords O
respiratory NN respiratory D
disease NN disease D

Reconstructive CAPITAL NNP reconstructive O
tubal NN tubal T
surgery NN surgery T

OBJECTIVES CAPITAL NNP aim O
: : O
The CAPITAL NNP O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
descriptive NN descriptive O
exploratory NN exploratory O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
examine NN analyze O
critical JJ critical O
care VB care O
nurses RB nurse O
' '' O
responses NN response O
to NN stopwords O
three NN three O
questions NN question O
about DT stopwords about O
health NN health O
practices NN practice O
in NN stopwords inch O
their NN stopwords O
daily IN daily O
lives NN life O
: : O
( ( O
1 DIGITS CD one O
) ) O
What CAPITAL NNP O
are DT stopwords are O
critical JJ critical O
care VB care O
nurses RB nurse O
doing NN stopwords make O
currently NNS presently O
to NN stopwords O
stay NN stay O
healthy NN healthy O
? . O
( ( O
2 DIGITS CD two O
) ) O
Do CAPITAL NNP bash O
they NN stopwords O
anticipate DT expect O
making NN devising O
any DT stopwords any O
changes NNS change O
in NN stopwords inch O
their NN stopwords O
lifestyle NN life_style O
in NN stopwords inch O
the NN stopwords O
future JJ future O
? . O
( ( O
3 DIGITS CD three O
) ) O
Would CAPITAL NNP O
they NN stopwords O
recommend NN recommend O
their NN stopwords O
lifestyle NN life_style O
to NN stopwords O
their NN stopwords O
patients VB patient O
? . O
METHODS CAPITAL NNP method O
: : O
One CAPITAL NNP one O
hundred NN hundred O
twenty-seven NN twenty-seven O
critical JJ critical O
care VB care O
nurses RB nurse O
attending DT attention O
a DT stopwords angstrom O
midwestern NN midwestern O
critical JJ critical O
care VB care O
conference NNS conference O
completed NNS complete O
a DT stopwords angstrom O
two-part NN bipartite O
questionnaire NN questionnaire O
designed NN plan O
to NN stopwords O
produce NN produce O
a DT stopwords angstrom O
health NN health O
profile NN profile O

Cloacal CAPITAL NNP D
anomalies DT anomaly D
are DT stopwords are O
extremely NN highly O
rare NN rare O
and DT stopwords O
have VB stopwords rich_person O
variable NN variable O
presentations NN presentation O

Recently CAPITAL NNP recently O
the NN stopwords O
demonstration NN presentation O
that NN stopwords O
telomerase NN telomerase O
is NN stopwords be O
not JJ stopwords not O
always DT always O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
restoration NN Restoration O
of NN stopwords O
telomere NN telomere O
length NN length O
shows NN show O
the NN stopwords O
complexity NNS complexity O
of NN stopwords O
the NN stopwords O
problems NN problem O
connected NNS connect O
to NN stopwords O
the NN stopwords O
cause VB cause O
of NN stopwords O
senescence NN aging O

We CAPITAL NNP O
have VB stopwords rich_person O
been NN stopwords be O
investigating NN investigation O
the NN stopwords O
potential NN potential O
of NN stopwords O
exploiting NN exploit O
the NN stopwords O
immunosensing JJ O
detection NN detection O
abilities DT ability O
of NN stopwords O
excitable NN excitable O
immune JJ immune O
cells NNS cell O
( ( O
i.e NN O
. . O
the NN stopwords O
mast VB mast O
cell NNS cell O
) ) O
for NN stopwords O
the NN stopwords O
development NN development O
of NN stopwords O
whole NN whole O
cell NNS cell O
immunobiosensors JJ O

No CAPITAL NNP no O
significant NN significant O
difference NN difference O
in NN stopwords inch O
frequency JJ frequency O
of NN stopwords O
absent DT absent O
response NN response O
and DT stopwords O
asymmetric DT asymmetrical O
response NN response O
was VB stopwords Washington O
also DT besides O
noted JJ note O

104 DIGITS CD O
, , O
S77-S95 CAPITAL NNP O
, , O
1985 DIGITS CD O
) ) O
, , O
lethal-potentially NN O
lethal NN deadly O
( ( O
LPL CAPITAL NNP O
) ) O
( ( O
S. CAPITAL NNP O
B CAPITAL NN bacillus O

Fluctuations CAPITAL NNP fluctuation O
in NN stopwords inch O
ambient DT ambient O
temperature NN temperature O
are DT stopwords are O
inversely NN inversely O
correlated NNS correlate O
to NN stopwords O
changes NNS change O
in NN stopwords inch O
AFI CAPITAL DT O

A CAPITAL DT angstrom O
total NN sum O
of NN stopwords O
397 DIGITS CD O
ears VB ear O
from JJ stopwords O
highly NN highly O
cooperative NNS cooperative O
adult DT adult O
subjects NN subject O
were NN stopwords be O
examined NN analyze O
under JJ stopwords nether O
laboratory NN lab O
conditions NNS conditions O

DESIGN CAPITAL NNP design O
: : O
A CAPITAL DT angstrom O
complete NNS complete O
genomic NN O
screen NN screen O
was VB stopwords Washington O
performed NN perform O
( ( O
N=280 CAPITAL NNP O
markers NN marker O
) ) O

Thermoelectric CAPITAL NNP thermoelectric O
cooling NNS cooling O
for NN stopwords O
NMR CAPITAL NNP nuclear_magnetic_resonance O
sample VB sample O
temperature NN temperature O
control NNS control O

CONCLUSIONS CAPITAL NNP decision O
: : O
Double-bolus CAPITAL NNP O
alteplase DT T
was VB stopwords Washington O
not JJ stopwords not O
shown NN show O
to NN stopwords O
be NN stopwords beryllium O
equivalent NN equivalent O
, , O
according DT harmonize O
to NN stopwords O
the NN stopwords O
prespecified NN O
criteria JJ standard O
, , O
to NN stopwords O
accelerated DT accelerate O
infusion NN infusion O
with NN stopwords O
regard NN respect O
to NN stopwords O
30-day CD O
mortality NN mortality O

Nerve-sparing CAPITAL NNP T
surgery NN surgery T
for NN stopwords O
advanced DT advance D
rectal NN rectal D
cancer VB cancer D
patients VB patient O
: : O
special NN special O
reference NN mention O
to NN stopwords O
Dukes CAPITAL NNP duke O
C CAPITAL SYM degree_centigrade O
patients VB patient O

106 DIGITS CD O
, , O
252-270 CD O
, , O
1986 DIGITS CD O
) ) O
and DT stopwords O
double-strand NN O
break NN interruption O
( ( O
DSB CAPITAL NNP O
) ) O
( ( O
J CAPITAL NN joule O

To CAPITAL NNP O
date VB date O
, , O
cardiac VB cardiac T
surgical NN surgical T
intervention NN intervention T
has VB stopwords hour_angle O
been NN stopwords be O
required NN necessitate O
in NN stopwords inch O
five NN five O
patients VB patient O

The CAPITAL NNP O
Nb2 CAPITAL NNP O
form NN form O
, , O
lacking NN miss O
198 DIGITS CD O
aa DT aa O
in NN stopwords inch O
the NN stopwords O
cytoplasmic NNS cytoplasmic O
domain NN sphere O
, , O
is NN stopwords be O
able DT able O
to NN stopwords O
transmit NN convey O
a DT stopwords angstrom O
lactogenic NN lactogenic O
signal NN signal O
similar NN similar O
to NN stopwords O
the NN stopwords O
long NN hanker O
form NN form O
, , O
whereas NN O
the NN stopwords O
short NN short O
form NN form O
of NN stopwords O
291 DIGITS CD O
aa DT aa O
is NN stopwords be O
inactive NN inactive O

Our CAPITAL NNP O
data VB data O
seem NN look O
to NN stopwords O
indicate NN bespeak O
similar NN similar O
results NN consequence O
in NN stopwords inch O
comparison NNS comparison O
to NN stopwords O
other JJ stopwords other O
groups NN group O
using JJ exploitation O
the NN stopwords O
CIS CAPITAL NNP Commonwealth_of_Independent_States O
strategy NN scheme O

objectives NN aim O
: : O
to NN stopwords O
review NN reappraisal O
the NN stopwords O
spectrum NN spectrum O
of NN stopwords O
presentation NN presentation O
and DT stopwords O
the NN stopwords O
surgical NN surgical T
management VB management T
of NN stopwords O
non JJ not D
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
nsclc JJ D
) ) D
and DT stopwords O
the NN stopwords O
role NN function O
of NN stopwords O
various NN assorted O
diagnostic NN diagnostic O
modalities NN modality O
in NN stopwords inch O
predicting NN predict O
the NN stopwords O
post-operative NN O
stage NN phase O
and DT stopwords O
the NN stopwords O
correlation NNS correlation O
of NN stopwords O
the NN stopwords O
post-operative NN O
stage NN phase O
with NN stopwords O
the NN stopwords O
chances NNS opportunity O
of NN stopwords O
recurrence NN recurrence O

The CAPITAL NNP O
catalytic VB catalytic O
role NN function O
of NN stopwords O
carbon VB carbon O
dioxide NN dioxide O
in NN stopwords inch O
the NN stopwords O
decomposition NN decomposition O
of NN stopwords O
peroxynitrite NN O

Pathogenesis CAPITAL VB pathogenesis O
and DT stopwords O
host NN host O
response NN response O

Bone CAPITAL NNP bone O
mineral NN mineral O
density NN density O
was VB stopwords Washington O
measured NN measure O
by NN stopwords by O
dual-energy NN O
x-ray LS X_ray O
absorptiometry DT O
, , O
blood NN blood O
and DT stopwords O
urine JJ urine O
were NN stopwords be O
analyzed DT analyze O
every NN every O
six NN six O
months NN calendar_month O
, , O
and DT stopwords O
cases VB case O
of NN stopwords O
nonvertebral JJ O
fracture NN fracture O
were NN stopwords be O
ascertained DT determine O
by NN stopwords by O
means NN means O
of NN stopwords O
interviews NN interview O
and DT stopwords O
verified NN verify O
with NN stopwords O
use JJ use O
of NN stopwords O
hospital NN hospital O
records NN record O

The CAPITAL NNP O
case VB case O
was VB stopwords Washington O
regarded NN see O
as DT stopwords arsenic O
successful NN successful O
if NN stopwords O
at DT stopwords astatine O
least NN least O
one JJ one O
testicular NN testicular O
spermatozoon NN sperm O
was VB stopwords Washington O
found JJ found O
allowing DT let O
intracytoplasmic NN O
sperm NN sperm O
injection NN injection O
( ( O
ICSI CAPITAL PRP O
) ) O
of NN stopwords O
at DT stopwords astatine O
least NN least O
one JJ one O
oocyte JJ oocyte O

RESULTS CAPITAL NNP consequence O
: : O
Tubularized CAPITAL NNP T
incised NN incise T
plate NN home_plate T
surgery NN surgery T
created NNS make O
a DT stopwords angstrom O
functional JJ functional O
neourethra JJ O
even NN evening O
in NN stopwords inch O
penoscrotal NN D
hypospadias NN hypospadias D

Bony CAPITAL NNP bony O
proliferation NN proliferation O
of NN stopwords O
neural JJ nervous O
arches DT arch O
with NN stopwords O
cord NNS cord O
compression NNS compaction O

3rd CD third O
Neurotrauma/Polytrauma CAPITAL NNP O
Symposium CAPITAL NNP symposium O

The CAPITAL NNP O
TSG101 CAPITAL NNP O
tumor NN tumor O
susceptibility NN susceptibility O
gene NN gene O
is NN stopwords be O
located NN locate O
in NN stopwords inch O
chromosome NN chromosome O
11 DIGITS CD eleven O
band VB set O
p15 NN O
and DT stopwords O
is NN stopwords be O
mutated NN mutate O
in NN stopwords inch O
human NN homo O
breast NN breast D
cancer VB cancer D

Therefore CAPITAL NNP therefore O
administration DT administration O
of NN stopwords O
TJ-135 CAPITAL NNP T
may VB May O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
severe NN severe O
acute DT acute_accent O
hepatitis NN hepatitis D
accompanying DT attach_to D
cholestasis NNS acholia D
or NN stopwords Oregon O
in NN stopwords inch O
those NN stopwords O
with NN stopwords O
autoimmune DT autoimmune D
hepatitis NN hepatitis D

Resolution CAPITAL NNP resolution O
due NN due O
in NN stopwords inch O
medical NN checkup O
software NN software O
regulation NN regulation O

Critical CAPITAL NNP critical O
care VB care O
nurses RB nurse O
routinely NN routinely O
teach NN Teach O
patients VB patient O
about DT stopwords about O
using JJ exploitation O
healthy NN healthy O
practices NN practice O
such NN stopwords such O
as DT stopwords arsenic O
low-fat NN O
diets NN diet O
, , O
exercise NN exercise O
, , O
and DT stopwords O
routine NN routine O
screening NN screening O
examinations NN examination O

for NN stopwords O
patients VB patient O
with NN stopwords O
lung NN lung D
carcinoma VB carcinoma D
who NN stopwords World_Health_Organization O
are DT stopwords are O
in NN stopwords inch O
relatively NN relatively O
poor NN poor_people O
health NN health O
, , O
the NN stopwords O
authors DT writer O
chose NNS choose O
videothoracoscopic NN T
lobectomy NN lobectomy T
or NN stopwords Oregon T
partial NN partial_derivative T
resection NN resection T
of NN stopwords T
the NN stopwords T
lung NN lung T
instead NN alternatively O
of NN stopwords O
an DT stopwords Associate_in_Nursing O
open JJ open O
thoracotomy NN thoracotomy O

Karen CAPITAL NNP Karen O
: : O
the NN stopwords O
other JJ stopwords other O
side NN side O
of NN stopwords O
the NN stopwords O
picture NN picture O

The CAPITAL NNP O
human NN homo O
DNA CAPITAL NNP deoxyribonucleic_acid O
mismatch NN mismatch O
repair NN repair O
( ( O
MMR CAPITAL NNP O
) ) O
genes NN gene O
are DT stopwords are O
highly NN highly O
conserved NNS conserve O
homologues NN O
of NN stopwords O
the NN stopwords O
Escherichia CAPITAL NNP escherichia O
coli NNS O
MutHLS CAPITAL NNP O
system NN system O
, , O
which NN stopwords O
contribute NNS lend O
to NN stopwords O
genomic NN O
stability NN stability O
by NN stopwords by O
surveillance NN surveillance O
and DT stopwords O
repair NN repair O
of NN stopwords O
replication NN reproduction O
misincorporation NN O
errors NN mistake O
and DT stopwords O
exogenous NN exogenous O
DNA CAPITAL NNP deoxyribonucleic_acid O
damage VB damage O

In CAPITAL PRP inch O
one JJ one O
patient VB patient O
, , O
a DT stopwords angstrom O
second NN second O
mutation NN mutant O
occurred JJ happen O
at DT stopwords astatine O
the NN stopwords O
gag VB joke O
p1/p6 NN O
cleavage NNS cleavage O
site NN site O
, , O
but NN stopwords merely O
it NN stopwords information_technology O
appeared DT look O
18 DIGITS CD eighteen O
weeks NN week O
after DT stopwords after O
the NN stopwords O
time NN time O
of NN stopwords O
appearance DT appearance O
of NN stopwords O
the NN stopwords O
p7/p1 NN O
mutation NN mutant O

The CAPITAL NNP O
present NN present O
study NN survey O
also DT besides O
investigates NN investigate O
the NN stopwords O
possible NN possible O
participation NN engagement O
of NN stopwords O
cytoplasmic NNS cytoplasmic O
receptors NN receptor O
in NN stopwords inch O
the NN stopwords O
signal NN signal O
transduction NN transduction O
pathway VB nerve_pathway O
, , O
using JJ exploitation O
cotransfection NNS O
experiments NN experiment O
and DT stopwords O
a DT stopwords angstrom O
new JJ new O
approach DT approach O
that NN stopwords O
selectively NN selectively O
determines NN determine O
the NN stopwords O
contribution NNS contribution O
of NN stopwords O
cytoplasmic NNS cytoplasmic O
receptors NN receptor O
in NN stopwords inch O
the NN stopwords O
process NN procedure O
of NN stopwords O
signal NN signal O
transduction NN transduction O

< NN O
TO_SEE CAPITAL NNP O
> NN O
BACKGROUND CAPITAL IN background O
: : O
The CAPITAL NNP O
cause VB cause O
of NN stopwords O
severe NN severe O
acquired DT get O
hyperammonemia NN O
, , O
an DT stopwords Associate_in_Nursing O
uncommon JJ uncommon O
but NN stopwords merely O
often JJ frequently O
fatal VB fatal O
complication NNS complication O
of NN stopwords O
organ JJ organ O
transplantation NN transplant O
and DT stopwords O
chemotherapy NNS chemotherapy O
for NN stopwords O
cancer VB cancer O
, , O
is NN stopwords be O
obscure NN obscure O

Angiogenesis CAPITAL DT angiogenesis O
in NN stopwords inch O
inflammatory NN inflammatory D
disease NN disease D

Exposed CAPITAL NNP expose O
regions NN region O
of NN stopwords O
immobilized JJ immobilize O
antibody DT antibody O
were NN stopwords be O
then NN stopwords then O
removed NN remove O
by NN stopwords by O
exposure NN exposure O
to NN stopwords O
a DT stopwords angstrom O
low NN low O
power NN power O
, , O
radio VB radio O
frequency JJ frequency O
oxygen JJ oxygen O
discharge NN discharge O

A CAPITAL DT angstrom O
novel JJ novel O
intracellular NN intracellular O
calcium-binding VB O
protein NN protein O
from JJ stopwords O
Echinococcus CAPITAL NNP echinococcus O
granulosus NN O
is NN stopwords be O
described NN describe O
in NN stopwords inch O
this NN stopwords O
work NN work O

Here CAPITAL NNP here O
we NN stopwords O
report NN report O
the NN stopwords O
identification NN designation O
of NN stopwords O
a DT stopwords angstrom O
novel JJ novel O
subfamily NN subfamily O
of NN stopwords O
bHLH NN O
proteins NN protein O
, , O
defined NN specify O
by NN stopwords by O
two NN two O
mammalian VB mammal O
enhancer-of-split- NN O
and DT stopwords O
hairy-related NN O
proteins NN protein O
, , O
termed NN term O
SHARP-1 CAPITAL NNP O
and DT stopwords O
SHARP-2 CAPITAL NNP O

MTX CAPITAL NNP T
in NN stopwords inch O
a DT stopwords angstrom O
low-dose NN O
regimen NN regimen O
is NN stopwords be O
useful JJ useful O
in NN stopwords inch O
refractory NN furnace_lining D
RA CAPITAL VB radium D
and DT stopwords O
superior NN superior O
to NN stopwords O
low-dose NN O
purine NN purine O
analogues DT analogue O

Low-molecular-weight CAPITAL NNP T
heparin NN heparin T
vs NN volt O
heparin NN heparin T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
pulmonary NN pneumonic D
embolism NN embolism D

The CAPITAL NNP O
light NN light O
of NN stopwords O
the NN stopwords O
profession NN profession O

This CAPITAL NNP O
relationship NN relationship O
should NN stopwords O
be NN stopwords beryllium O
taken VB take O
into NN stopwords O
account DT history O
when NN stopwords O
interpreting NN interpretation O
the NN stopwords O
AFI CAPITAL DT O
as DT stopwords arsenic O
a DT stopwords angstrom O
measure NN measure O
of NN stopwords O
fetal JJ fetal O
well-being NN wellbeing O

Coronary CAPITAL NNP coronary_thrombosis D
dissection NN dissection D
and DT stopwords D
total NN sum D
coronary NNS coronary_thrombosis D
occlusion JJ occlusion D
leading NN lead O
to NN stopwords O
emergency NN emergency T
coronary NNS coronary_thrombosis T
surgery NN surgery T
are DT stopwords are O
the NN stopwords O
most NN stopwords most O
frequent JJ patronize O
complications NNS complication O
of NN stopwords O
percutaneous NN transdermal O
transluminal NN O
coronary NNS coronary_thrombosis O
angioplasty DT angioplasty O
( ( O
PTCA CAPITAL NNP O
) ) O
and DT stopwords O
their NN stopwords O
occurrence JJ happening O
usually JJ normally O
is NN stopwords be O
unpredictable JJ unpredictable O

Malignant CAPITAL NNP malignant D
mesodermal NN mesoblastic D
mixed NN blend D
tumor NN tumor D
of NN stopwords O
the NN stopwords O
uterus JJ uterus O
following JJ following O
irradiation NN irradiation T

Genetic CAPITAL NNP familial O
sampling VB sampling O
: : O
big NN large O
brother NN brother O
or NN stopwords Oregon O
big NN large O
science JJ science O
? . O

Res CAPITAL NNP reticuloendothelial_system O

Fetal CAPITAL NNP fetal O
breathing NN breathing O
movements NN motion O
within NN inside O
24 DIGITS CD twenty-four O
hours NN hours O
of NN stopwords O
delivery NN delivery O
in NN stopwords inch O
prematurity NN prematureness O
are DT stopwords are O
related NN associate O
to NN stopwords O
histologic NN histological O
and DT stopwords O
clinical JJ clinical O
evidence NN evidence O
of NN stopwords O
amnionitis DT D

A CAPITAL DT angstrom O
unilateral JJ unilateral O
, , O
or NN stopwords Oregon O
localized NN place O
, , O
variant NN discrepancy O
has VB stopwords hour_angle O
been NN stopwords be O
identified NN identify O

Ropinirole CAPITAL NNP T
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
early VB early D
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D

Therapeutic CAPITAL NNP remedy O
effects NN effects O
of NN stopwords O
LDL CAPITAL NNP low-density_lipoprotein T
apheresis DT aphaeresis T
in NN stopwords inch O
the NN stopwords O
prevention NN prevention O
of NN stopwords O
atherosclerosis DT atherosclerosis D

We CAPITAL NNP O
summarize NN sum_up O
the NN stopwords O
pharmacologic NN pharmacological O
characteristics NNS feature O
of NN stopwords O
Sumatriptan CAPITAL NNP T
and DT stopwords O
give NN give O
recommendations NN recommendation O
about DT stopwords about O
its NN stopwords information_technology O
use JJ use O
in NN stopwords inch O
clinical JJ clinical O
practice NN practice O

Perinatal CAPITAL NNP perinatal O
features NN feature O
of NN stopwords O
omphalocele-exstrophy-imperforate JJ D
anus-spinal DT D
defects NN defect D
( ( D
OEIS CAPITAL NNP D
complex NNS complex D
) ) D
associated DT associate O
with NN stopwords O
large NN large O
meningomyeloceles NN D
and DT stopwords O
severe NN severe D
limb NN limb D
defects NN defect D

Clinically CAPITAL NNP clinically O
, , O
the NN stopwords O
hallmark VB hallmark O
of NN stopwords O
the NN stopwords O
human NN homo D
amnesic DT amnesic D
syndrome NN syndrome D
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
impaired JJ impair O
ability DT ability O
to NN stopwords O
consciously NNS consciously O
recollect NN remember O
or NN stopwords Oregon O
remember NN remember O
daily IN daily O
events NN event O

Similar CAPITAL NNP similar O
B/W CAPITAL NNP O
differences NN difference O
were NN stopwords be O
observed NN detect O
for NN stopwords O
patients VB patient O
with NN stopwords O
advanced DT advance O
disease NN disease O
but NN stopwords merely O
not JJ stopwords not O
with NN stopwords O
early VB early O
stage NN phase O

Social CAPITAL NNP sociable O
ties NN necktie O
and DT stopwords O
susceptibility NN susceptibility O
to NN stopwords O
the NN stopwords O
common NNS park D
cold NNS cold D

Increasing CAPITAL PRP increase O
resistance NN resistance O
among DT O
the NN stopwords O
common NNS park D
respiratory NN respiratory D
pathogens VB pathogen D
has VB stopwords hour_angle O
encouraged NN promote O
assessment DT appraisal O
of NN stopwords O
alternative DT option O
agents DT agent O
, , O
for NN stopwords O
example NN example O
, , O
levofloxacin NN T

Echocardiography-guided CAPITAL NNP T
ethanol NN ethyl_alcohol T
septal NN septal T
reduction NN decrease T
for NN stopwords O
hypertrophic NN D
obstructive NN clogging D
cardiomyopathy VB cardiomyopathy D

December CAPITAL NNP December O
5 DIGITS CD five O
, , O
1997 DIGITS CD O

Early CAPITAL NN early O
identification NN designation O
of NN stopwords O
variant NN discrepancy O
Creutzfeldt-Jakob CAPITAL NNP D
disease NN disease D

First CAPITAL NNP first O
the NN stopwords O
bad VB bad O
news JJ news O
... . O

Humoral CAPITAL NNP humoral O
immune JJ immune O
response NN response O
after DT stopwords after O
vaccination NN inoculation T
against DT stopwords O
influenza NN influenza D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
breast NN breast O
cancer VB cancer O

The CAPITAL NNP O
heart NN heart O
valves NN valve O
had VB stopwords have O
a DT stopwords angstrom O
glistening NN glitter O
white NN White O
appearance DT appearance O

New CAPITAL NNP new T
therapies NN therapy T
for NN stopwords O
severe NN severe D
meningococcal NN D
disease NN disease D

Muscle CAPITAL NNP muscle O
pathology VB pathology O
; : O
contribution NNS contribution O
of NN stopwords O
experimentation NN experiment O

CONCLUSION CAPITAL NNP decision O
: : O
Ligase CAPITAL NNP O
chain NNS chain O
reaction NN chemical_reaction O
on NN stopwords on O
urine JJ urine O
samples VB sample O
performs NN perform O
at DT stopwords astatine O
least NN least O
as DT stopwords arsenic O
well NN well O
as DT stopwords arsenic O
enzyme NN enzyme O
immunoassay JJ immunoassay O
on NN stopwords on O
cervical NNS cervical O
specimens NN specimen O
in NN stopwords inch O
this NN stopwords O
low NN low O
prevalence NN prevalence O
population NN population O

The CAPITAL NNP O
main VB main O
experimental NN experimental O
task VB undertaking O
was VB stopwords Washington O
picture NN picture O
naming RB naming O

New CAPITAL NNP new O
developments NN development O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
diabetes NN diabetes D
and DT stopwords O
hyperlipidemias NN lipemia D

background VB background O
: : O
at DT stopwords astatine O
present NN present O
the NN stopwords O
addition DT addition T
of NN stopwords T
thoracic NN pectoral T
irradiation NN irradiation T
to NN stopwords T
combination NNS combination T
chemotherapy NNS chemotherapy T
is NN stopwords be O
a DT stopwords angstrom O
standard NN standard O
treatment NN treatment O
for NN stopwords O
limited NN express D
staged NN stage D
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D

Phage CAPITAL NNP bacteriophage O
inserts NN insert O
were NN stopwords be O
assembled DT assemble O
into NN stopwords O
four JJ four O
contigs NNS O
with NN stopwords O
21 DIGITS CD twenty-one O
exons NN exon O
, , O
and DT stopwords O
an DT stopwords Associate_in_Nursing O
intron NN intron O
phase NN phase O
map VB map O
was VB stopwords Washington O
produced NN produce O
enabling NN enable O
the NN stopwords O
interpretation NN interpretation O
of NN stopwords O
translocation-generated NN O
fusion JJ fusion O
proteins NN protein O

The CAPITAL NNP O
ruptured NN tear D
horn NN horn D
was VB stopwords Washington O
excised NN strike O
by NN stopwords by O
laparotomy NN laparotomy T

PURPOSE CAPITAL NNP purpose O
: : O
Macrolide CAPITAL NNP T
antibiotics DT antibiotic T
are DT stopwords are O
frequently JJ frequently O
prescribed NN order O
to NN stopwords O
patients VB patient O
with NN stopwords O
symptoms NN symptom D
of NN stopwords D
a DT stopwords angstrom D
common NNS park D
cold NNS cold D

The CAPITAL NNP O
members NN member O
of NN stopwords O
this NN stopwords O
family VB family O
encode NN encode O
serine-proline-rich NN O
proteins NN protein O
with NN stopwords O
properties NN property O
of NN stopwords O
nuclear JJ nuclear O
transcription NN transcription O
factors VB factor O

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
mean NN mean O
( ( O
+/-SD NN O
) ) O
changes NNS change O
in NN stopwords inch O
bone NN bone O
mineral NN mineral O
density NN density O
in NN stopwords inch O
the NN stopwords O
calcium-vitamin VB O
D CAPITAL NN vitamin_D O
and DT stopwords O
placebo NN placebo O
groups NN group O
were NN stopwords be O
as DT stopwords arsenic O
follows JJ follow O
: : O
femoral JJ femoral O
neck JJ neck O
, , O
+0.50+/-4.80 RB O
and DT stopwords O
-0.70+/-5.03 : O
percent NN percentage O
, , O
respectively NN respectively O
( ( O
P=0.02 CAPITAL NNP O
) ) O
; : O
spine JJ spinal_column O
, , O
+2.12+/-4.06 RB O
and DT stopwords O
+1.22+/-4.25 RB O
percent NN percentage O
( ( O
P=0.04 CAPITAL NNP O
) ) O
; : O
and DT stopwords O
total NN sum O
body NN body O
, , O
+0.06+/-1.83 RB O
and DT stopwords O
-1.09+/-1.71 : O
percent NN percentage O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Pompholyx CAPITAL NNP D
( ( D
vesicular NN vesicular D
eczema NN eczema D
) ) D
after DT stopwords after O
i.v NN T
. . T
immunoglobulin JJ immunoglobulin T
therapy NN therapy T
for NN stopwords O
neurologic JJ neurological D
disease NN disease D

Small CAPITAL NNP small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
can VB stopwords can O
express NN express O
CD34 CAPITAL NNP O
antigen DT antigen O

Goldilocks CAPITAL NNP goldilocks O
and DT stopwords O
Mrs CAPITAL NNP Mrs O

over JJ stopwords over O
the NN stopwords O
past VB past O
17 DIGITS CD seventeen O
years NN old_age O
( ( O
1981 DIGITS CD O
to NN stopwords O
1997 DIGITS CD O
) ) O
, , O
29 DIGITS CD twenty-nine O
patients VB patient O
underwent JJ undergo O
complete NNS complete T
pulmonary NN pneumonic T
resection NN resection T
for NN stopwords O
primary NN primary D
lung NN lung D
cancer VB cancer D
accompanied DT attach_to O
by NN stopwords by O
satellite VB satellite O
nodules JJ nodule O
in NN stopwords inch O
the NN stopwords O
same VB stopwords Lapp O
lobe NN lobe O
as DT stopwords arsenic O
the NN stopwords O
primary NN primary O

An CAPITAL DT Associate_in_Nursing O
analysis DT analysis O
of NN stopwords O
34 DIGITS CD thirty-four O
cases VB case O

Neuraminic CAPITAL NNP O
acid-containing DT O
oligosaccharides IN oligosaccharide O
of NN stopwords O
human NN homo O
urine JJ urine O
: : O
isolation NN isolation O
and DT stopwords O
identification NN designation O
of NN stopwords O
di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine NN O
, , O
6-2-Nacetylneuraminyl-lactose CD O
, , O
6-2-N-acetylneuraminyl-N-acetyllactosamine CD O
and DT stopwords O
3-2-N-acetylneuraminyl-lactose LS O

RESULTS CAPITAL NNP consequence O
: : O
In CAPITAL PRP inch O
102 DIGITS CD O
women NN woman O
( ( O
12.8 CD O
% NN O
) ) O
, , O
clearly NNS clearly O
deleterious NN deleterious O
mutations NN mutant O
were NN stopwords be O
detected NN detect O

In CAPITAL PRP inch O
the NN stopwords O
third NN one-third O
trimester NN trimester O
, , O
the NN stopwords O
amniotic DT amniotic O
fluid JJ fluid O
index NN index O
( ( O
AFI CAPITAL DT O
) ) O
may VB May O
be NN stopwords beryllium O
affected DT affect O
by NN stopwords by O
maternal VB maternal O
fluid JJ fluid O
status NN status O

Prescribing CAPITAL NNP order O
protease NN protease T
inhibitors NN inhibitor T
for NN stopwords O
the NN stopwords O
homeless NN homeless O

Microelectrode-guided CAPITAL NNP T
posteroventral NN T
pallidotomy VB T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
Parkinson CAPITAL VB Parkinson D
's POS D
disease NN disease D
: : O
postoperative NN postoperative O
magnetic VB magnetic O
resonance NN resonance O
imaging NN imagination O
analysis DT analysis O

However CAPITAL NNP however O
, , O
the NN stopwords O
association DT association O
between NN stopwords between O
these NN stopwords O
favorable VB favorable O
effects NN effects O
and DT stopwords O
the NN stopwords O
clinical JJ clinical O
outcome JJ result O
of NN stopwords O
patients VB patient O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
no NNS stopwords no O
severe NN severe O
hemodynamic NN hemodynamic D
compromise NNS compromise D
at DT stopwords astatine O
presentation NN presentation O
remains NN remains O
unknown JJ unknown O

Rates CAPITAL VB rates O
of NN stopwords O
superoxide NN superoxide O
( ( O
SA CAPITAL VB SA O
) ) O
generation NN coevals O
by NN stopwords by O
blood NN blood O
monocytes NN monocyte O
stimulated JJ stimulate O
ex NN ex-husband O
vivo NN O
were NN stopwords be O
studied NN analyze O
before NN stopwords earlier O
and DT stopwords O
during NN stopwords O
corticosteroid NNS corticosteroid T
treatment NN treatment O
of NN stopwords O
rheumatoid NN arthritic D
arthritis DT arthritis D
( ( D
RA CAPITAL VB radium D
) ) D
patients VB patient O
, , O
in NN stopwords inch O
control NNS control O
patients VB patient O
and DT stopwords O
in NN stopwords inch O
healthy NN healthy O
controls NNS control O

Interferon CAPITAL PRP interferon T
alfa-2a DT T
appears DT look O
to NN stopwords O
have VB stopwords rich_person O
antineoplastic DT antineoplastic O
efficacy NN efficacy O
, , O
( ( O
and DT stopwords O
may VB May O
have VB stopwords rich_person O
antiretroviral DT O
efficacy NN efficacy O
as DT stopwords arsenic O
well NN well O
) ) O
in NN stopwords inch O
this NN stopwords O
epidemic NN epidemic O
neoplasm JJ tumor D

Persisting CAPITAL NNP prevail O
odours JJ smell O
as DT stopwords arsenic O
a DT stopwords angstrom O
biasing NN bias O
factor VB factor O
in NN stopwords inch O
open-field JJ O
research NN research O
with NN stopwords O
mice NN mouse O

Evolution CAPITAL NNP development O
of NN stopwords O
a DT stopwords angstrom O
placenta NN placenta O
circumvallata NN O

We CAPITAL NNP O
present NN present O
five NN five O
cases VB case O
of NN stopwords O
isolated NN isolate O
pleural NN pleural O
or NN stopwords Oregon O
pericardial NN pericardial D
effusion NN effusion D
with NN stopwords O
documented NN document O
maternal VB maternal O
parvovirus NN parvovirus D
infection NN infection D
in NN stopwords inch O
four JJ four O
of NN stopwords O
these NN stopwords O
pregnancies NN pregnancy O

Gene CAPITAL NNP gene T
therapy NN therapy T
for NN stopwords O
myocardial NN myocardial D
angiogenesis DT angiogenesis D

Acupuncture CAPITAL DT acupuncture T
treatment NN treatment O
of NN stopwords O
common NNS park D
cold NNS cold D

Academic CAPITAL DT academician O
medicine NN medicine O
and DT stopwords O
complementary NNS complementary_color O
medicine NN medicine O
-- : O
campaign VB political_campaign O
for NN stopwords O
the NN stopwords O
truth NN truth O
in NN stopwords inch O
medical NN checkup O
theories NN theory O

Spinal CAPITAL NNP spinal_anesthesia T
manipulation VB manipulation T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
episodic NN episodic D
tension-type NN D
headache NN concern D
: : O
a DT stopwords angstrom O
randomized VB randomize O
controlled NNS control O
trial NN test O

Five CAPITAL NNP five O
dental NN alveolar_consonant O
clinics JJ clinic O
had VB stopwords have O
separate NN offprint O
storage NN storage O
areas DT area O
for NN stopwords O
contaminated NNS pollute O
waste VB waste O
which NN stopwords O
compiled NNS roll_up O
with NN stopwords O
contaminated NNS pollute O
waste VB waste O
separation NN separation O
and DT stopwords O
disposal NN disposal O
guidelines NN guideline O

Comparison CAPITAL NNP comparison O
of NN stopwords O
the NN stopwords O
international NN International O
and DT stopwords O
American CAPITAL DT American O
systems NN system O
for NN stopwords O
the NN stopwords O
staging NN theatrical_production O
of NN stopwords O
breast NN breast D
cancer VB cancer D

we NN stopwords O
evaluated NN measure O
the NN stopwords O
role NN function O
of NN stopwords O
systemic NN systemic T
chemotherapy NNS chemotherapy T
for NN stopwords O
patients VB patient O
with NN stopwords O
malignant VB malignant D
pleural NN pleural D
effusions NN effusion D
from JJ stopwords D
nsclc JJ D

Concerns CAPITAL NNP concern O
about DT stopwords about O
the NN stopwords O
institutionalization NN O
of NN stopwords O
childbirth JJ childbirth O
education NN education O

Application CAPITAL DT application O
to NN stopwords O
biomedical NN biomedical O
magnetic VB magnetic O
resonance NN resonance O
spectroscopy NN spectroscopy O

Student CAPITAL NNP student O
's POS O
t-test SYM O
, , O
Fisher CAPITAL NNP fisherman O
exact NN demand O
test NN trial O
, , O
and DT stopwords O
Chi-square CAPITAL NNP O
were NN stopwords be O
used JJ use O
for NN stopwords O
statistical NN statistical O
analysis DT analysis O

The CAPITAL NNP O
pruning NN pruning O
of NN stopwords O
Doctor CAPITAL NNP doctor O
McDonough CAPITAL NNP O
and DT stopwords O
the NN stopwords O
`` `` O
humanizing NN humanize O
'' POS O
of NN stopwords O
statistics NN statistics O

The CAPITAL NNP O
first NN first O
step NN measure O
of NN stopwords O
purification NN purification O
of NN stopwords O
the NN stopwords O
effective NN effective O
signaling NN signal O
SCW CAPITAL NNP O
components NNS component O
from JJ stopwords O
both NN stopwords both O
snail NN snail O
species NN species O
was VB stopwords Washington O
achieved DT achieve O
by NN stopwords by O
ion-exchange NN O
chromatography NN chromatography O

OBJECTIVE CAPITAL NNP aim O
: : O
Reports CAPITAL NNP report O
suggest NN propose O
that NN stopwords O
there NN stopwords there O
is NN stopwords be O
an DT stopwords Associate_in_Nursing O
increased NN increase O
incidence NN incidence O
of NN stopwords O
preeclampsia NN preeclampsia D
after DT stopwords after O
a DT stopwords angstrom O
previously NN previously O
normal RB convention O
pregnancy NN pregnancy O
if NN stopwords O
there NN stopwords there O
is NN stopwords be O
a DT stopwords angstrom O
change NNS change O
in NN stopwords inch O
paternity VB paternity O

Furthermore CAPITAL NNP furthermore O
, , O
directing NN direct O
attention DT attention O
to NN stopwords O
psychophysiological NN O
cues NNS cue O
serves NN serve O
the NN stopwords O
same VB stopwords Lapp O
purpose NN purpose O
as DT stopwords arsenic O
in NN stopwords inch O
RPE CAPITAL NNP O
, , O
i.e NN O
. . O
increasing NN increase O
self-awareness NN self-awareness O

Of CAPITAL NNP O
note JJ note O
, , O
all DT stopwords all O
of NN stopwords O
the NN stopwords O
known NN know O
break NN interruption O
points NN point O
leave NN leave O
the NN stopwords O
cyclin NNS O
D1 CAPITAL NNP O
coding NNS cryptography O
region NN region O
structurally NN structurally O
intact NN integral O
and DT stopwords O
result NN consequence O
in NN stopwords inch O
increased NN increase O
protein NN protein O
expression NN expression O
, , O
implying JJ imply O
that NN stopwords O
this NN stopwords O
may VB May O
provide NN supply O
a DT stopwords angstrom O
highly NN highly O
sensitive NN medium O
and DT stopwords O
specific NN particular O
marker NN marker O
for NN stopwords O
MCL CAPITAL NNP D

The CAPITAL NNP O
1995 DIGITS CD O
list NN list O

DESIGN CAPITAL NNP design O
: : O
Case-control CAPITAL VB O
association DT association O
testing NN testing O

Clinical CAPITAL NNP clinical O
physiopathology NN O
of NN stopwords O
congenital NNS congenital D
cyanogenic NNS cyanogenetic D
cardiopathies VB heart_disease D

Distinction CAPITAL NNP differentiation O
awards DT award O
and DT stopwords O
racial VB racial O
discrimination NN discrimination O

Fish CAPITAL NNP fish T
protein NN protein T
concentrates NNS dressed_ore T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
kwashiorkor NN kwashiorkor D

Coupling CAPITAL NNP yoke O
of NN stopwords O
hemodynamic NN hemodynamic O
measurements NN measurement O
with NN stopwords O
oxygen JJ oxygen O
during NN stopwords O
exercise NN exercise O
does NN stopwords Department_of_Energy O
not JJ stopwords not O
improve JJ better O
risk NN hazard O
stratification NN stratification O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
heart NN heart D
failure VB failure D

Antagonism CAPITAL DT hostility O
of NN stopwords O
atracurium-induced DT O
neuromuscular JJ neuromuscular D
blockade NN blockade D
by NN stopwords by O
neostigmine JJ neostigmine T
or NN stopwords Oregon T
edrophonium NN T
has VB stopwords hour_angle O
been NN stopwords be O
studied NN analyze O
using JJ exploitation O
the NN stopwords O
tetanic NN tetanic O
( ( O
50 DIGITS CD fifty O
Hz CAPITAL NNP hertz O
) ) O
and DT stopwords O
train-of-four NN O
( ( O
2 DIGITS CD two O
Hz CAPITAL NNP hertz O
) ) O
or NN stopwords Oregon O
single NN single O
twitch NN twitch O
responses NN response O
of NN stopwords O
the NN stopwords O
adductor DT adductor O
pollicis NN O
muscle NN muscle O
in NN stopwords inch O
22 DIGITS CD twenty-two O
anaesthetized DT anesthetize O
patients VB patient O

Lipid CAPITAL NNP lipid O
metabolism NN metamorphosis O
during NN stopwords O
exercise NN exercise O

Gonorrhea CAPITAL NNP gonorrhea D
among DT O
men NN work_force O
who NN stopwords World_Health_Organization O
have VB stopwords rich_person O
sex NN sexual_activity O
with NN stopwords O
men NN work_force O
-- : O
selected NN choose O
sexually NN sexually O
transmitted NN convey O
diseases NN disease O
clinics JJ clinic O
, , O
1993-1996 CD O

Re CAPITAL NNP rhenium O
: : O
Intermediate CAPITAL PRP intermediate O
term NN term O
assessment DT appraisal O
of NN stopwords O
the NN stopwords O
reliability NN dependability O
, , O
function JJ function O
and DT stopwords O
patient VB patient O
satisfaction VB satisfaction O
with NN stopwords O
the NN stopwords O
AMS700 CAPITAL DT O
ultrex JJ O
penile NN penile O
prosthesis NN prosthesis O

Randomised CAPITAL VB randomize O
double-blind NN O
trial NN test O
of NN stopwords O
fixed NN repair O
low-dose NN O
warfarin NN warfarin T
with NN stopwords T
aspirin DT aspirin T
after DT stopwords after O
myocardial NN myocardial D
infarction NN infarct D

Many CAPITAL NNP many O
homosexual NN homosexual O
people NN people O
have VB stopwords rich_person O
been NN stopwords be O
forced NN coerce O
to NN stopwords O
undergo JJ undergo O
`` `` O
treatments NN treatment O
'' POS O
to NN stopwords O
change NNS change O
their NN stopwords O
sexual NN sexual O
orientation IN orientation O

Often CAPITAL NNP frequently O
, , O
the NN stopwords O
binding NN binding O
kinetics NN dynamics O
may VB May O
be NN stopwords beryllium O
described NN describe O
by NN stopwords by O
a DT stopwords angstrom O
single-fractal NN O
analysis DT analysis O

Rhesus CAPITAL NNP rhesus D
haemolytic VB hemolytic D
disease NN disease D
; : O
an DT stopwords Associate_in_Nursing O
approach DT approach O
to NN stopwords O
prevention NN prevention O

Research CAPITAL NNP research O
in NN stopwords inch O
Copenhagen CAPITAL NNP Copenhagen O
hospitals NN hospital O
-- : O
a DT stopwords angstrom O
bibliometric NN O
evaluation NN evaluation O

Intravenous CAPITAL PRP intravenous T
immune JJ immune T
globulin NN globulin T
for NN stopwords O
recurrent NN perennial D
spontaneous NN spontaneous D
abortion DT abortion D

Double CAPITAL NNP double O
aortic DT aortal O
arch DT arch O
associated DT associate O
with NN stopwords O
tetralogy NN tetralogy O
of NN stopwords O
Fallot CAPITAL NNP Fallot O
in NN stopwords inch O
infants NN baby O
; : O
report NN report O
of NN stopwords O
two NN two O
cases VB case O

Second CAPITAL NNP second O
Strang CAPITAL NNP O
International CAPITAL PRP International O
Cancer CAPITAL VB cancer O
Conference CAPITAL NNP conference O
: : O
genetics NN genetics O
and DT stopwords O
the NN stopwords O
environment NN environment O
New CAPITAL NNP new O
York CAPITAL NNP York O
, , O
USA CAPITAL NNP United_States O
, , O
15-16 CD O
November CAPITAL NNP November O
1996 DIGITS CD O

At CAPITAL DT astatine O
293 DIGITS CD O
sites NN site O
, , O
we NN stopwords O
randomly VB randomly O
assigned DT delegate O
8803 DIGITS CD O
patients VB patient O
who NN stopwords World_Health_Organization O
had VB stopwords have O
had VB stopwords have O
myocardial NN myocardial D
infarction NN infarct D
, , O
treatment NN treatment O
with NN stopwords O
160 DIGITS CD one_hundred_sixty T
mg NN milligram T
aspirin DT aspirin T
, , O
3 DIGITS CD three T
mg NN milligram T
warfarin NN warfarin T
with NN stopwords T
80 DIGITS CD eighty T
mg NN milligram T
aspirin DT aspirin T
, , O
or NN stopwords Oregon O
1 DIGITS CD one T
mg NN milligram T
warfarin NN warfarin T
with NN stopwords T
80 DIGITS CD eighty T
mg NN milligram T
aspirin DT aspirin T

neoadjuvant JJ T
therapy NN therapy T
with NN stopwords T
oxaliplatin/fluorouracil/folinic NN T
acid DT acid T
has VB stopwords hour_angle O
proven NN prove O
beneficial NN beneficial O
in NN stopwords inch O
enabling NN enable O
surgical NN surgical O
removal NN removal O
of NN stopwords O
previously NN previously O
unresectable JJ D
liver NN liver D
metastases NN metastasis D

A CAPITAL DT angstrom O
proactive NN proactive O
preventive NN preventive O
approach DT approach O
is NN stopwords be O
presented NN show O
that NN stopwords O
suggests NN propose O
strategies NN scheme O
to NN stopwords O
use JJ use O
during NN stopwords O
the NN stopwords O
previsit NN O
phase NN phase O
, , O
the NN stopwords O
visit NN visit O
experience NN experience O
, , O
and DT stopwords O
on NN stopwords on O
an DT stopwords Associate_in_Nursing O
ongoing JJ ongoing O
basis VB footing O

Applying CAPITAL DT use O
the NN stopwords O
AIDS CAPITAL DT AIDS D
paradigm NN paradigm O
to NN stopwords O
hepatitis NN hepatitis D

Paradigms CAPITAL VB paradigm O
and DT stopwords O
the NN stopwords O
rise NN rise O
( ( O
or NN stopwords Oregon O
fall VB fall O
? . O
) ) O
of NN stopwords O
molecular NN molecular O
biology NN biology O

Rorschach CAPITAL NNP Rorschach O
correlates NNS correlate O
of NN stopwords O
time NN time O
estimation NN appraisal O

athyrism DT D
in NN stopwords inch O
the NN stopwords O
fetal JJ fetal O
rat VB rat O

After CAPITAL DT after O
a DT stopwords angstrom O
2- CD O
to NN stopwords O
9-day CD O
placebo NN placebo O
lead-in NN lead O
, , O
79 DIGITS CD seventy-nine O
inpatients NN inpatient O
with NN stopwords O
schizophrenia JJ schizophrenia D
according DT harmonize O
to NN stopwords O
DSM-III-R CAPITAL NNP O
criteria JJ standard O
were NN stopwords be O
placed NN put O
on NN stopwords on O
an DT stopwords Associate_in_Nursing O
olanzapine NN T
dosage NN dose O
of NN stopwords O
10 DIGITS CD ten O
mg/day NN O
or NN stopwords Oregon O
1 DIGITS CD one O
mg/day NN O
for NN stopwords O
up JJ stopwords up O
to NN stopwords O
6 DIGITS CD six O
weeks NN week O

conclusions NNS decision O
: : O
heparin NN heparin T
and/or DT T
enoxaparin NN T
may VB May O
be NN stopwords beryllium O
considered NNS see O
as DT stopwords arsenic O
potential NN potential O
treatments NN treatment O
for NN stopwords O
patients VB patient O
with NN stopwords O
radiation-induced VB D
myelopathy NN D

In CAPITAL PRP inch O
both NN stopwords both O
cases VB case O
, , O
cardiopulmonary VB cardiopulmonary T
bypass NN beltway T
could NNS O
not JJ stopwords not O
be NN stopwords beryllium O
discontinued NN discontinue O
despite NN contempt O
the NN stopwords O
use JJ use O
of NN stopwords O
large NN large O
doses NN dose O
of NN stopwords O
inotropic NN T
drugs NN drug T

Physiological CAPITAL NNP physiological O
, , O
psychological NN psychological O
, , O
biochemical NN biochemical O
and DT stopwords O
immunological JJ immunological O
symptoms NN symptom O
must NN must O
be NN stopwords beryllium O
considered NNS see O
, , O
both NN stopwords both O
independently NN independently O
and DT stopwords O
together NN together O
, , O
to NN stopwords O
fully JJ fully O
understand JJ understand O
the NN stopwords O
'staleness POS O
' '' O
syndrome NN syndrome O

Verona CAPITAL NNP Verona O
, , O
Italy CAPITAL PRP Italy O
, , O
September CAPITAL NNP September O
21-22 CD O
, , O
1995 DIGITS CD O

Esophageal CAPITAL NNP esophageal T
intubation NN cannulation T
for NN stopwords O
palliative VB palliative O
treatment NN treatment O
in NN stopwords inch O
advanced DT advance D
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
esophagus NN esophagus D
and DT stopwords D
cardia VB cardia D

A CAPITAL DT angstrom O
modified NN modify O
technique NN technique O
of NN stopwords O
tubeless NN tubeless O
anaesthesia DT anesthesia O
for NN stopwords O
microlaryngoscopy NN T
and DT stopwords T
bronchoscopy NN T
in NN stopwords inch O
young NN young O
children JJ child O
with NN stopwords O
stridor NN stridor D

background VB background O
: : O
curative NNS remedy T
therapy NN therapy T
is NN stopwords be O
available DT available O
for NN stopwords O
patients VB patient O
with NN stopwords O
stage NN phase D
0 DIGITS CD zero D
lung NN lung D
carcinoma VB carcinoma D
, , O
with NN stopwords O
a DT stopwords angstrom O
> NN O
90 DIGITS CD ninety O
% NN O
5-year CD O
survival NN survival O
rate VB rate O

Heart CAPITAL NNP heart D
disease NN disease D
: : O
women NN woman O
's POS O
unique JJ alone O
risks NN hazard O
demand NN demand O
attention DT attention O

The CAPITAL NNP O
effectiveness NN effectiveness O
of NN stopwords O
acupuncture DT acupuncture T
in NN stopwords inch O
treating NN treat O
acute DT acute_accent D
dental NN alveolar_consonant D
pain IN pain D
: : O
a DT stopwords angstrom O
systematic NN systematic O
review NN reappraisal O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
MEASURES CAPITAL NNP measure O
: : O
Mean CAPITAL NNP mean O
blood NN blood O
pressure NN pressure O
and DT stopwords O
rate VB rate O
of NN stopwords O
high NN high D
blood NN blood D
pressure NN pressure D
of NN stopwords O
children JJ child O

methods NN method O
: : O
we NN stopwords O
placed NN put O
stents NN stent T
for NN stopwords O
both NN stopwords both O
esophageal NN esophageal D
and DT stopwords D
tracheobronchial NN D
stenoses NN stenosis D
in NN stopwords inch O
8 DIGITS CD eight O
patients VB patient O
( ( O
7 DIGITS CD seven O
with NN stopwords O
esophageal NN esophageal O
cancer VB cancer O
and DT stopwords O
1 DIGITS CD one O
with NN stopwords O
lung NN lung O
cancer VB cancer O
) ) O

Idiopathic CAPITAL PRP idiopathic D
atrial DT atrial D
flutter JJ waver D

Sequence CAPITAL NNP sequence O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
protease NN protease O
gene NN gene O
during NN stopwords O
the NN stopwords O
course NNS course O
of NN stopwords O
therapy NN therapy O
revealed NN uncover O
that NN stopwords O
in NN stopwords inch O
this NN stopwords O
second NN second O
group NN group O
there NN stopwords there O
was VB stopwords Washington O
a DT stopwords angstrom O
sequential NN consecutive O
acquisition DT acquisition O
of NN stopwords O
protease NN protease O
mutations NN mutant O
at DT stopwords astatine O
amino DT amino O
acids DT acid O
46 DIGITS CD forty-six O
, , O
82 DIGITS CD eighty-two O
, , O
54 DIGITS CD fifty-four O
, , O
71 DIGITS CD seventy-one O
, , O
89 DIGITS CD eighty-nine O
, , O
and DT stopwords O
90 DIGITS CD ninety O

Use CAPITAL NNP use O
of NN stopwords O
washed VB wash T
red NN red T
blood NN blood T
cells NNS cell T
was VB stopwords Washington O
effective NN effective O
in NN stopwords inch O
averting DT averting O
hemolytic NN hemolytic D
crisis JJ crisis D
throughout NN throughout O
perioperative NN O
period NN time_period O

This CAPITAL NNP O
indicates NN bespeak O
a DT stopwords angstrom O
change NNS change O
in NN stopwords inch O
the NN stopwords O
reaction NN chemical_reaction O
mechanism NN mechanism O
on NN stopwords on O
the NN stopwords O
surface NN surface O

< NN O
TO_SEE CAPITAL NNP O
> NN O
in NN stopwords inch O
another DT another O
randomised VB randomize O
phase NN phase O
iii NN three O
trial NN test O
in NN stopwords inch O
303 DIGITS CD O
patients VB patient O
with NN stopwords O
head NN head D
and DT stopwords D
neck JJ neck D
cancer VB cancer D
undergoing JJ undergo O
irradiation NN irradiation T
therapy NN therapy T
( ( O
total NN sum O
dose NN dose O
50 DIGITS CD fifty O
to NN stopwords O
70gy CD O
) ) O
, , O
pretreatment NN O
with NN stopwords O
intravenous NN intravenous O
amifostine DT T
200 DIGITS CD two_hundred O
mg/m2 NN O
significantly NN significantly O
reduced NN reduce O
the NN stopwords O
incidence NN incidence O
of NN stopwords O
acute DT acute_accent O
and DT stopwords O
late NN late O
grade NN class O
> NN O
or NN stopwords Oregon O
=2 $ O
xerostomia NN xerostomia D

Evaluation CAPITAL NNP evaluation O
of NN stopwords O
acquired DT get O
data VB data O
and DT stopwords O
current NNS current O
outlook JJ mentality O

Women CAPITAL NNP woman O
with NN stopwords O
recent NN Holocene O
cocaine NNS cocaine O
use JJ use O
present NN present O
with NN stopwords O
ruptured NN tear O
membranes NN membrane O
at DT stopwords astatine O
an DT stopwords Associate_in_Nursing O
earlier VB earlier O
gestational NN gestational O
age DT age O
and DT stopwords O
may VB May O
actually DT actually O
have VB stopwords rich_person O
a DT stopwords angstrom O
longer NN longer O
latency NN rotational_latency O
period NN time_period O
than NN stopwords O
women NN woman O
who NN stopwords World_Health_Organization O
do NN stopwords bash O
not JJ stopwords not O
use JJ use O
cocaine NNS cocaine O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Intensive CAPITAL PRP intensifier T
insulin NN insulin T
treatment NN treatment T
after DT stopwords after O
acute DT acute_accent D
myocardial NN myocardial D
infarction NN infarct D
in NN stopwords inch O
diabetes NN diabetes D
mellitus NN D

Subjectively CAPITAL NNP subjectively O
, , O
patients VB patient O
improved JJ better O
from JJ stopwords O
an DT stopwords Associate_in_Nursing O
average DT average O
of NN stopwords O
0.69 LS O
before NN stopwords earlier O
arthrodesis DT arthrodesis T
to NN stopwords O
4.89 CD O
after DT stopwords after O
arthrodesis DT arthrodesis T

The CAPITAL NNP O
mitochondrial NN D
diseases NN disease D
are DT stopwords are O
uncommon JJ uncommon O
multisystem NN O
disorders NN disorder O
characterized NNS qualify O
by NN stopwords by O
the NN stopwords O
presence NN presence O
of NN stopwords O
functionally JJ functionally O
and/or DT O
structurally NN structurally O
abnormal DT abnormal O
mitochondria NN mitochondrion O

Global CAPITAL NNP global O
risk NN hazard O
assessment DT appraisal O
for NN stopwords O
lipid NN lipid T
therapy NN therapy T
to NN stopwords O
prevent NN prevent O
coronary NNS coronary_thrombosis D
heart NN heart D
disease NN disease D

BACKGROUND CAPITAL IN background O
: : O
Diagnostic CAPITAL NNP diagnostic O
peritoneal NN peritoneal O
lavage NN lavage O
( ( O
DPL CAPITAL NNP O
) ) O
is NN stopwords be O
used JJ use O
to NN stopwords O
diagnose NN diagnose O
intra-abdominal NN D
injury NN injury D
in NN stopwords inch O
patients VB patient O
with NN stopwords O
stab NN pang D
wounds NN wound D
and DT stopwords O
blunt NN blunt D
trauma NN injury D

CONCLUSIONS CAPITAL NNP decision O
: : O
we NN stopwords O
found JJ found O
no NNS stopwords no O
evidence NN evidence O
of NN stopwords O
disturbances NN perturbation O
in NN stopwords inch O
gastric VB gastric O
remnant NN leftover O
emptying NN emptying O
after DT stopwords after O
Roux-en-Y CAPITAL NNP T
gastrojejunostomy VB T
to NN stopwords O
treat NN dainty O
postoperative NN postoperative D
alkaline DT alkaline D
gastric VB gastric D
reflux NN reflux D

The CAPITAL NNP O
objective NN aim O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
determine NN determine O
the NN stopwords O
rate VB rate O
of NN stopwords O
recent NN Holocene O
cocaine NNS cocaine O
use JJ use O
among DT O
a DT stopwords angstrom O
metropolitan NN metropolitan O
population NN population O
of NN stopwords O
predominantly NN predominantly O
Hispanic CAPITAL NNP Spanish_American O
and DT stopwords O
African-American CAPITAL DT African-American O
women NN woman O
with NN stopwords O
preterm NN O
premature NN premature D
rupture NN rupture D
of NN stopwords D
the NN stopwords D
membranes NN membrane D
( ( D
PROM CAPITAL NNP promenade D
) ) D
and DT stopwords O
to NN stopwords O
ascertain DT determine O
the NN stopwords O
impact JJ impact O
of NN stopwords O
cocaine NNS cocaine O
on NN stopwords on O
the NN stopwords O
latency NN rotational_latency O
period NN time_period O
between NN stopwords between O
rupture NN rupture O
of NN stopwords O
membranes NN membrane O
and DT stopwords O
delivery NN delivery O

Dry CAPITAL NNP dry T
powdered NN powderize T
formoterol NN T
, , O
twice NN twice O
a DT stopwords angstrom O
day VB day O
versus NN O
aerosolized DT aerosolize T
salbutamol VB T
, , O
four JJ four O
times NN times O
a DT stopwords angstrom O
day VB day O
, , O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
stable NN stable D
asthma DT asthma D

Infection CAPITAL PRP infection O
control NNS control O
and DT stopwords O
contaminated NNS pollute O
waste VB waste O
disposal NN disposal O
practices NN practice O
in NN stopwords inch O
Southern CAPITAL NNP southern O
Sydney CAPITAL NNP Sydney O
Area CAPITAL DT area O
Health CAPITAL NNP health O
Service CAPITAL NNP service O
Dental CAPITAL NNP alveolar_consonant O
Clinics CAPITAL NNP clinic O

Changing CAPITAL NNP change O
the NN stopwords O
law NN law O
on NN stopwords on O
decision NN decision O
making NN devising O
for NN stopwords O
mentally NN mentally O
incapacitated NN disable O
adults DT adult O

137 DIGITS CD O

Furthermore CAPITAL NNP furthermore O
, , O
as DT stopwords arsenic O
the NN stopwords O
IGF-1 CAPITAL PRP O
concentration NNS concentration O
in NN stopwords inch O
solution NN solution O
increases NN addition O
from JJ stopwords O
10 DIGITS CD ten O
to NN stopwords O
80 DIGITS CD eighty O
nM NNS nanometer O
in NN stopwords inch O
solution NN solution O
, , O
k2 NN K2 O
and DT stopwords O
Df2 CAPITAL NNP O
exhibit NN exhibit O
a DT stopwords angstrom O
linear NN linear O
increase NN addition O

The CAPITAL NNP O
ethics NN ethical_motive O
of NN stopwords O
genetic NN familial O
research NN research O
on NN stopwords on O
sexual NN sexual O
orientation IN orientation O

Saliva CAPITAL VB saliva O
composition NNS composition O
and DT stopwords O
exercise NN exercise O

Unethical CAPITAL NNP unethical O
trials NN test O
of NN stopwords O
interventions NN intervention O
to NN stopwords O
reduce NN reduce O
perinatal NN perinatal O
transmission NN transmission O
of NN stopwords O
the NN stopwords O
human NN homo O
immunodeficiency JJ immunodeficiency O
virus NN virus O
in NN stopwords inch O
developing NN development O
countries NNS state O

The CAPITAL NNP O
ability DT ability O
to NN stopwords O
detect NN detect O
UTI CAPITAL NNP D
by NN stopwords by O
dipstick NN dipstick O
only JJ stopwords lone O
and DT stopwords O
by NN stopwords by O
complete NNS complete O
urinalysis JJ urinalysis O
was VB stopwords Washington O
the NN stopwords O
same VB stopwords Lapp O
, , O
however NN however O
microscopic NN microscopic O
evaluation NN evaluation O
added DT add O
many VB many O
false-positive VB O
results NN consequence O
without NN O
detecting NN detection O
additional DT extra O
UTIs CAPITAL NNP D

CONCLUSIONS CAPITAL NNP decision O
: : O
These CAPITAL NNP O
data VB data O
, , O
the NN stopwords O
first NN first O
evidence NN evidence O
that NN stopwords O
chronic NN chronic O
stress NN stress O
can VB stopwords can O
inhibit NN suppress O
the NN stopwords O
stability NN stability O
of NN stopwords O
the NN stopwords O
IgG CAPITAL PRP immunoglobulin_G O
antibody DT antibody O
response NN response O
to NN stopwords O
a DT stopwords angstrom O
bacterial VB bacterial T
vaccine NN vaccine T
for NN stopwords O
pneumonia NN pneumonia D
, , O
provide NN supply O
additional DT extra O
evidence NN evidence O
of NN stopwords O
health NN health O
risks NN hazard O
associated DT associate O
with NN stopwords O
dementia NN dementia O
caregiving VB O

Patient CAPITAL VB patient O
consent NNS consent O
for NN stopwords O
publication NN publication O

141 DIGITS CD O
, , O
252-258 CD O
, , O
1995 DIGITS CD O
) ) O
on NN stopwords on O
the NN stopwords O
kinetics NN dynamics O
of NN stopwords O
the NN stopwords O
repair NN repair O
of NN stopwords O
potentially NN potentially O
lethal NN deadly O
damage VB damage O
in NN stopwords inch O
log-phase NN O
Chinese CAPITAL NNP Chinese O
hamster VB hamster O
V79 CAPITAL NNP O
cells NNS cell O
are DT stopwords are O
used JJ use O
to NN stopwords O
test NN trial O
some NN stopwords some O
predictions NN prediction O
which NN stopwords O
arise DT originate O
from JJ stopwords O
the NN stopwords O
different NN different O
assumptions DT premise O
of NN stopwords O
the NN stopwords O
repair-misrepair NN O
( ( O
RMR CAPITAL NNP O
) ) O
( ( O
C CAPITAL SYM degree_centigrade O

Many CAPITAL NNP many O
situations NN situation O
may VB May O
hamper VB shackle O
the NN stopwords O
signalling NN sign O
( ( O
i.e NN O
. . O
the NN stopwords O
detection NN detection O
of NN stopwords O
early VB early O
warning NN warning O
signs NN sign O
) ) O
of NN stopwords O
adverse DT adverse O
effects NN effects O
and DT stopwords O
new JJ new O
signals NN signal O
often JJ frequently O
differ NN differ O
from JJ stopwords O
previous NN previous O
experiences NN experience O

Internists CAPITAL PRP internist O
' '' O
and DT stopwords O
surgeons NN surgeon O
' '' O
attitudes DT attitude O
toward NN O
guns NN gun O
and DT stopwords O
firearm NN firearm O
injury NN injury O
prevention NN prevention O

Melatonin CAPITAL NNP melatonin T
treatment NN treatment T
of NN stopwords O
sleep-wake NN D
cycle NNS cycle D
disorders NN disorder D
in NN stopwords inch O
children JJ child O
and DT stopwords O
adolescents DT adolescent O

Based CAPITAL IN establish O
on NN stopwords on O
a DT stopwords angstrom O
roundtable NN round_table O
workshop NN workshop O
held NN keep O
in NN stopwords inch O
London CAPITAL NNP London O
, , O
United CAPITAL NNP unite O
Kingdom CAPITAL NNP kingdom O
, , O
9 DIGITS CD nine O
February CAPITAL NNP February O
1996 DIGITS CD O

`` `` O
Pull CAPITAL NNP pull O
'' POS O
or NN stopwords Oregon O
`` `` O
push NN push O
'' POS O
PEG CAPITAL NNP peg O
: : O
the NN stopwords O
reinsertion NN O
of NN stopwords O
the NN stopwords O
gastroscope VB gastroscope O
is NN stopwords be O
often JJ frequently O
unnecessary JJ unnecessary O

Clinical CAPITAL NNP clinical O
comparison NNS comparison O
with NN stopwords O
iomeprol NN D
and DT stopwords O
ioxaglate NN D

DESIGN CAPITAL NNP design O
: : O
A CAPITAL DT angstrom O
prospective NN prospective O
study NN survey O
consisting NNS dwell O
of NN stopwords O
anonymous DT anonymous O
, , O
unlinked JJ O
urine JJ urine O
testing NN testing O
of NN stopwords O
504 DIGITS CD O
'first POS O
visit NN visit O
' '' O
antenatal DT prenatal O
patients VB patient O
and DT stopwords O
a DT stopwords angstrom O
separate NN offprint O
group NN group O
of NN stopwords O
515 DIGITS CD O
patients VB patient O
six NN six O
weeks NN week O
after DT stopwords after O
delivery NN delivery O

Are CAPITAL DT are O
normal RB convention O
hearing NN hearing O
thresholds NN threshold O
a DT stopwords angstrom O
sufficient NN sufficient O
condition NNS condition O
for NN stopwords O
click-evoked JJ O
otoacoustic JJ O
emissions NN emission O
? . O

OBJECTIVE CAPITAL NNP aim O
: : O
To CAPITAL NNP O
study NN survey O
the NN stopwords O
safety VB safety O
and DT stopwords O
efficacy NN efficacy O
of NN stopwords O
methylphenidate NN methylphenidate T
in NN stopwords inch O
children JJ child O
with NN stopwords O
the NN stopwords O
dual NN double O
diagnosis NN diagnosis O
of NN stopwords O
epilepsy NN epilepsy D
and DT stopwords O
attention DT attention D
deficit NN deficit D
hyperactivity NN hyperactivity D
disorder NN disorder D
( ( D
ADHD CAPITAL DT attention_deficit_disorder D
) ) D

Congenital CAPITAL NNP congenital D
diaphragmatic NN D
hernia NN hernia D
: : O
what NN stopwords O
happens VB happen O
after DT stopwords after O
discharge NN discharge O
? . O

The CAPITAL NNP O
implications JJ deduction O
of NN stopwords O
this NN stopwords O
scientific JJ scientific O
incertitude NN doubt O
for NN stopwords O
the NN stopwords O
implementation JJ execution O
of NN stopwords O
preventive NN preventive O
measures NN measure O
are DT stopwords are O
briefly NN briefly O
discussed NN discourse O

US-guided CAPITAL NNP O
puncture NN puncture O
of NN stopwords O
the NN stopwords O
internal NN internal O
jugular NN jugular_vein O
vein NN vein O
: : O
complications NNS complication O
and DT stopwords O
anatomic DT anatomic O
considerations NNS consideration O

Proceedings CAPITAL NNP proceeding O
of NN stopwords O
the NN stopwords O
3rd CD third O
International CAPITAL PRP International O
Conference CAPITAL NNP conference O
on NN stopwords on O
Neuroprotective CAPITAL NNP O
Agents CAPITAL DT agent O
: : O
Clinical CAPITAL NNP clinical O
and DT stopwords O
Experimental CAPITAL NNP experimental O
Aspects CAPITAL DT aspect O

Amiodarone CAPITAL DT amiodarone T
and DT stopwords O
thyroid NN thyroid_gland O
function JJ function O

The CAPITAL NNP O
SSR CAPITAL NNP O
recombinase NN O
assay DT assay O
can VB stopwords can O
be NN stopwords beryllium O
performed NN perform O
in NN stopwords inch O
a DT stopwords angstrom O
transient NN transient O
fashion VB manner O
wherein NN O
extensive NN extensive O
, , O
B CAPITAL NN bacillus O
cell-specific NNS O
recombination NN recombination O
can VB stopwords can O
be NN stopwords beryllium O
visualized NN visualize O
within NN inside O
only JJ stopwords lone O
a DT stopwords angstrom O
few JJ stopwords few O
cell NNS cell O
divisions NN division O
post NN post O
proviral NN O
integration NN integration O

123 DIGITS CD O

Vividness CAPITAL NNP color O
of NN stopwords O
words NN words O
and DT stopwords O
learning NN learning O
to NN stopwords O
learn NN learn O
in NN stopwords inch O
free-recall JJ O
learning NN learning O

Because CAPITAL NNP O
activity DT activity O
and DT stopwords O
regular NN regular O
exercise NN exercise O
are DT stopwords are O
important JJ important O
factors VB factor O
to NN stopwords O
maintain VB keep O
general NN general O
good NN good O
health NN health O
in NN stopwords inch O
senior NN senior O
citizens NN citizen O
, , O
we NN stopwords O
investigated NN investigate O
whether NN O
senior NN senior O
dancing VB dancing O
has VB stopwords hour_angle O
any DT stopwords any O
effect NN consequence O
on NN stopwords on O
peripheral NN peripheral O
or NN stopwords Oregon O
lumbar NN lumbar O
bone NN bone O
density NN density O

Results CAPITAL NNP consequence O
of NN stopwords O
clinical JJ clinical O
trials NN test O
and DT stopwords O
meta-analysis NN O
suggest NN propose O
that NN stopwords O
dexamethasone NN dexamethasone T
therapy NN therapy T
improves JJ better O
the NN stopwords O
outcome JJ result O
for NN stopwords O
patients VB patient O
with NN stopwords O
bacterial VB bacterial D
meningitis NN meningitis D

Of CAPITAL NNP O
these NN stopwords O
children JJ child O
, , O
12 DIGITS CD twelve O
( ( O
63 DIGITS CD sixty-three O
% NN O
) ) O
had VB stopwords have O
abnormal DT abnormal O
neonatal JJ neonatal O
BAEP CAPITAL IN O
recordings NN recording O
and DT stopwords O
7 DIGITS CD seven O
( ( O
37 DIGITS CD thirty-seven O
% NN O
) ) O
had VB stopwords have O
a DT stopwords angstrom O
normal RB convention O
BAEP CAPITAL IN O
threshold NN threshold O
, , O
normal RB convention O
central NNS central O
auditory DT auditory O
conduction NNS conduction O
test NN trial O
results NN consequence O
, , O
or NN stopwords Oregon O
both NN stopwords both O
( ( O
p NN phosphorus O
= NN O
0.04 LS O
) ) O

The CAPITAL NNP O
improvement JJ improvement O
of NN stopwords O
ROM CAPITAL NNP read-only_memory O
was VB stopwords Washington O
significantly NN significantly O
more NN stopwords More O
in NN stopwords inch O
group NN group O
C CAPITAL SYM degree_centigrade O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.01 LS O
) ) O
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
that NN stopwords O
in NN stopwords inch O
group NN group O
A CAPITAL DT angstrom O
or NN stopwords Oregon O
group NN group O
B CAPITAL NN bacillus O

On CAPITAL NNP on O
the NN stopwords O
official JJ official O
inspection NN inspection O
of NN stopwords O
coal-tar NNS O
dyes NN dye O
in NN stopwords inch O
1969 DIGITS CD O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
botulinum NN botulinus T
toxin NN toxin T
and DT stopwords O
nitroglycerin NN nitroglycerin T
ointment NN ointment T
for NN stopwords O
chronic NN chronic D
anal DT anal D
fissure NN crevice D

The CAPITAL NNP O
previously NN previously O
defined NN specify O
DNL1L CAPITAL NNP O
or NN stopwords Oregon O
DNAS1L1 CAPITAL NNP O
is NN stopwords be O
expressed NN express O
highest NN high O
in NN stopwords inch O
heart NN heart O
and DT stopwords O
skeletal NN skeletal O
muscle NN muscle O
, , O
while NN stopwords while O
DNase CAPITAL NNP O
I CAPITAL PRP iodine O
is NN stopwords be O
expressed NN express O
in NN stopwords inch O
the NN stopwords O
pancreas VB pancreas O
, , O
parotid NN parotid O
gland NN gland O
, , O
and DT stopwords O
kidney NN kidney O

< NN O
TO_SEE CAPITAL NNP O
> NN O
FINDINGS CAPITAL NNP findings O
: : O
G-CSF CAPITAL NNP O
therapy NN therapy O
was VB stopwords Washington O
associated DT associate O
with NN stopwords O
earlier VB earlier O
eradication NN eradication O
of NN stopwords O
pathogens VB pathogen O
from JJ stopwords O
the NN stopwords O
infected NN infect O
ulcer JJ ulcer O
( ( O
median NN median O
4 DIGITS CD four O
( ( O
range VB scope O
2-10 CD O
) ) O
vs NN volt O
8 DIGITS CD eight O
( ( O
2-79 CD O
) ) O
days VB days O
in NN stopwords inch O
the NN stopwords O
placebo NN placebo O
group NN group O
; : O
p NN phosphorus O
= NN O
0.02 LS O
) ) O
, , O
quicker NN quick O
resolution NN resolution O
of NN stopwords O
cellulitis NNS cellulitis O
< NN O
( ( O
7 DIGITS CD seven O
( ( O
5-20 CD O
) ) O
vs NN volt O
12 DIGITS CD twelve O
( ( O
5-93 CD O
) ) O
days VB days O
; : O
p NN phosphorus O
= NN O
0.03 LS O
) ) O
, , O
shorter NN short O
hospital NN hospital O
stay NN stay O
( ( O
10 DIGITS CD ten O
( ( O
7-31 CD O
) ) O
vs NN volt O
17.5 CD O
( ( O
9-100 CD O
) ) O
days VB days O
; : O
p NN phosphorus O
= NN O
0.02 LS O
) ) O
, , O
and DT stopwords O
a DT stopwords angstrom O
shorter NN short O
duration NN duration O
of NN stopwords O
intravenous NN intravenous O
antibiotic DT antibiotic O
treatment NN treatment O
( ( O
8.5 CD O
( ( O
5-30 CD O
) ) O
vs NN volt O
14.5 CD O
( ( O
8-63 CD O
) ) O
days VB days O
; : O
p NN phosphorus O
= NN O
0.02 LS O
) ) O

However CAPITAL NNP however O
, , O
63 DIGITS CD sixty-three O
% NN O
of NN stopwords O
the NN stopwords O
trisomic NN O
fetuses JJ fetus O
belonged NN belong O
to NN stopwords O
mothers NN mother O
aged DT aged O
35 DIGITS CD thirty-five O
years NN old_age O
and DT stopwords O
above DT stopwords above O

MAIN CAPITAL NNP main O
OUTCOME CAPITAL NNP result O
STUDY CAPITAL NNP survey O
FACTORS CAPITAL NNP factor O
: : O
Cerebrovascular CAPITAL NNP cerebrovascular D
accident DT accident D
first-week NN O
fatality VB fatality O
rate VB rate O
; : O
age- DT O
and DT stopwords O
sex-related NN O
incidence NN incidence O

Masking CAPITAL NNP cover O
, , O
blinding NN blind O
, , O
and DT stopwords O
peer NN peer O
review NN reappraisal O
: : O
the NN stopwords O
blind NN blind O
leading NN lead O
the NN stopwords O
blinded NN blind O

The CAPITAL NNP O
named RB name O
nurse RB nurse O
: : O
patient VB patient O
and DT stopwords O
nurse RB nurse O
expectations NN expectation O

Online CAPITAL NNP on-line O

Because CAPITAL NNP O
the NN stopwords O
ability DT ability O
to NN stopwords O
detect NN detect O
UTI CAPITAL NNP D
( ( O
sensitivity NN sensitivity O
) ) O
is NN stopwords be O
maintained VB keep O
, , O
we NN stopwords O
now JJ stopwords now O
offer JJ offer O
a DT stopwords angstrom O
dipstick NN dipstick O
only JJ stopwords lone O
urinalysis JJ urinalysis O
to NN stopwords O
our NN stopwords O
emergency NN emergency O
room NN room O
for NN stopwords O
children JJ child O
2 DIGITS CD two O
years NN old_age O
of NN stopwords O
age DT age O
or NN stopwords Oregon O
older JJ aged O
, , O
with NN stopwords O
a DT stopwords angstrom O
microscopic NN microscopic O
analysis DT analysis O
performed NN perform O
automatically DT automatically O
if NN stopwords O
dipstick NN dipstick O
results NN consequence O
are DT stopwords are O
positive NN positive O

Results CAPITAL NNP consequence O
from JJ stopwords O
two NN two O
trials NN test O
( ( O
04 DIGITS CD O
- : O
Mossad CAPITAL NNP Mossad O
; : O
08 DIGITS CD O
- : O
Smith CAPITAL NNP Smith O
) ) O
suggested NN propose O
zinc NN zinc T
lozenges NN lozenge T
reduced NN reduce O
the NN stopwords O
severity NN badness O
and DT stopwords O
duration NN duration O
of NN stopwords O
cold NNS cold D
symptoms NN symptom D

5-year CD O
outcome JJ result O
of NN stopwords O
surgical NN surgical T
resection NN resection T
and DT stopwords O
watchful VB alert O
waiting IN wait O
for NN stopwords O
men NN work_force O
with NN stopwords O
moderately NN reasonably O
symptomatic NN diagnostic O
benign NN benign D
prostatic NN prostate D
hyperplasia NN hyperplasia D
: : O
a DT stopwords angstrom O
Department CAPITAL NNP department O
of NN stopwords O
Veterans CAPITAL NNP veteran O
Affairs CAPITAL DT personal_business O
cooperative NNS cooperative O
study NN survey O

corticosteroids NNS corticosteroid T
can VB stopwords can O
be NN stopwords beryllium O
considered NNS see O
for NN stopwords O
cases VB case O
of NN stopwords O
drug-induced NN D
hepatitis NN hepatitis D
, , O
especially NN particularly O
those NN stopwords O
with NN stopwords O
evidence NN evidence O
of NN stopwords O
immune JJ immune O
hypersensitivity NN hypersensitivity O
, , O
if NN stopwords O
no NNS stopwords no O
improvement JJ improvement O
is NN stopwords be O
seen NN see O
in NN stopwords inch O
8 DIGITS CD eight O
to NN stopwords O
12 DIGITS CD twelve O
weeks NN week O

Naloxone CAPITAL NNP naloxone T
-precipitated : O
acute DT acute_accent D
opioid IN D
withdrawal NN withdrawal D
syndrome NN syndrome D
after DT stopwords after O
epidural NN epidural_anesthesia T
morphine NN morphine T

Prevention CAPITAL NNP prevention O
of NN stopwords O
ankle DT ankle D
injuries NN injury D

we NN stopwords O
conclude NNS reason O
that NN stopwords O
for NN stopwords O
patients VB patient O
with NN stopwords O
osteosarcoma JJ osteosarcoma D
of NN stopwords D
the NN stopwords D
extremities NN extremity D
treated NN treat O
with NN stopwords O
neoadjuvant JJ T
chemotherapy NNS chemotherapy T
: : O
( ( O
a DT stopwords angstrom O
) ) O
the NN stopwords O
pattern VB form O
of NN stopwords O
systemic NN systemic O
relapse NN backsliding O
changes NNS change O
according DT harmonize O
to NN stopwords O
the NN stopwords O
efficacy NN efficacy O
of NN stopwords O
the NN stopwords O
protocol NN protocol O
of NN stopwords O
chemotherapy NNS chemotherapy O
used JJ use O

Effect CAPITAL NNP consequence O
of NN stopwords O
continuous NNS continuous O
spinal JJ spinal_anesthesia O
remifentanil NN O
infusion NN infusion O
on NN stopwords on O
behaviour NN behavior O
and DT stopwords O
spinal JJ spinal_anesthesia O
glutamate NN glutamate O
release NN release O
evoked NN arouse O
by NN stopwords by O
subcutaneous NN hypodermic O
formalin NN formalin O
in NN stopwords inch O
the NN stopwords O
rat VB rat O

The CAPITAL NNP O
study NN survey O
was VB stopwords Washington O
terminated NN end O
at DT stopwords astatine O
30 DIGITS CD thirty O
min NN minute O
if NN stopwords O
satisfactory VB satisfactory O
analgesia DT analgesia O
was VB stopwords Washington O
not JJ stopwords not O
achieved DT achieve O

Treatment CAPITAL NNP treatment O
uncertainties JJ uncertainty O
surround NN environment O
early VB early O
diagnosis NN diagnosis O
of NN stopwords O
breast NN breast D
cancer VB cancer D

Twinrix CAPITAL NNP T
( ( O
SmithKline CAPITAL NNP O
Beecham CAPITAL NNP O
Biologicals CAPITAL NNP O
) ) O
is NN stopwords be O
a DT stopwords angstrom O
combined NNS unite O
hepatitis NN hepatitis D
A CAPITAL DT angstrom D
and DT stopwords D
B CAPITAL NN bacillus D
vaccine NN vaccine T
licensed NN license O
with NN stopwords O
a DT stopwords angstrom O
three-dose NN O
schedule JJ agenda O

Tsa CAPITAL NNP Transportation_Security_Administration O
is NN stopwords be O
the NN stopwords O
point NN point O
during NN stopwords O
exercise NN exercise O
at DT stopwords astatine O
which NN stopwords O
the NN stopwords O
levels NN degree O
of NN stopwords O
salivary VB salivary O
alpha-amylase DT O
and DT stopwords O
electrolytes NN electrolyte O
( ( O
especially NN particularly O
Na+ CAPITAL NNP O
) ) O
also DT besides O
begin NN Begin O
to NN stopwords O
rise NN rise O
above DT stopwords above O
baseline VB baseline O
levels NN degree O

Linkage CAPITAL NNP linkage O
analysis DT analysis O
assigned DT delegate O
six NN six O
of NN stopwords O
them NN stopwords O
to NN stopwords O
their NN stopwords O
predefined NN O
subchromosomal NN O
origin IN beginning O
on NN stopwords on O
BTA CAPITAL NNP O
6 DIGITS CD six O
corresponding NNS match O
to NN stopwords O
the NN stopwords O
specific NN particular O
rehybridization NN O
signal NN signal O
of NN stopwords O
the NN stopwords O
DOP-PCR CAPITAL NNP O
product NN merchandise O
generated NN generate O
from JJ stopwords O
the NN stopwords O
microdissected NN O
chromosome NN chromosome O
area DT area O
6q21-31 CD O

OBJECTIVE CAPITAL NNP aim O
: : O
We CAPITAL NNP O
report NN report O
the NN stopwords O
results NN consequence O
of NN stopwords O
a DT stopwords angstrom O
double-blind NN O
, , O
double-dummy NN O
, , O
active-control DT O
study NN survey O
designed NN plan O
to NN stopwords O
evaluate NN measure O
the NN stopwords O
efficacy NN efficacy O
and DT stopwords O
safety VB safety O
of NN stopwords O
lamotrigine NN T
( ( T
LTG CAPITAL NNP T
) ) T
administered DT administer O
as DT stopwords arsenic O
monotherapy NN O
to NN stopwords O
adult DT adult O
outpatients JJ outpatient O
with NN stopwords O
partial NN partial_derivative D
seizures JJ seizure D

In CAPITAL PRP inch O
the NN stopwords O
mammalian VB mammal O
central NNS central O
nervous RB nervous O
system NN system O
, , O
a DT stopwords angstrom O
diverse NN divers O
group NN group O
of NN stopwords O
basic VB BASIC O
helix-loop-helix NN O
( ( O
bHLH NN O
) ) O
proteins NN protein O
is NN stopwords be O
involved NN involve O
in NN stopwords inch O
the NN stopwords O
determination NN determination O
of NN stopwords O
progenitor NN progenitor O
cells NNS cell O
and DT stopwords O
, , O
subsequently NN subsequently O
, , O
in NN stopwords inch O
regulating NN regulation O
neuronal JJ neural O
differentiation NN differentiation O

However CAPITAL NNP however O
, , O
no NNS stopwords no O
human NN homo O
studies NN survey O
have VB stopwords rich_person O
been NN stopwords be O
conducted NNS conduct O
, , O
and DT stopwords O
the NN stopwords O
pathological VB pathological O
and DT stopwords O
clinical JJ clinical O
potential NN potential O
for NN stopwords O
neurotoxicity JJ O
in NN stopwords inch O
humans NN world O
is NN stopwords be O
unknown JJ unknown O

A CAPITAL DT angstrom O
comparison NNS comparison O
of NN stopwords O
aspirin DT aspirin T
plus NN asset T
tirofiban NN T
with NN stopwords O
aspirin DT aspirin T
plus NN asset T
heparin NN heparin T
for NN stopwords O
unstable JJ unstable D
angina DT angina D

Equine CAPITAL NNP equine O
dinucleotide NN O
repeat NN repeat O
loci NN venue O
LEX049-LEX063 CAPITAL NNP O

Concomitant CAPITAL NNP accompaniment D
alveolitis DT alveolitis D
and DT stopwords O
asthma DT asthma D
following JJ following O
exposure NN exposure O
to NN stopwords O
triphenylmethane NN O
triisocyanate NN O

AIM CAPITAL DT purpose O
: : O
To CAPITAL NNP O
assess DT buttocks O
the NN stopwords O
impact JJ impact O
on NN stopwords on O
community-based NNS O
pediatricians NN baby_doctor O
of NN stopwords O
the NN stopwords O
conclusions NNS decision O
of NN stopwords O
the NN stopwords O
10th CD tenth O
Conference CAPITAL NNP conference O
de NN Delaware O
Consensus CAPITAL NNP consensus O
en NN en O
Therapeutique CAPITAL NNP O
Anti-Infectieuse CAPITAL DT O
( ( O
CCTAI CAPITAL NNP O
) ) O
on NN stopwords on O
the NN stopwords O
antibiotic DT antibiotic T
treatment NN treatment T
in NN stopwords inch O
acute DT acute_accent D
nasopharyngitis RB D
( ( D
ANP CAPITAL DT D
) ) D

The CAPITAL NNP O
purpose NN purpose O
of NN stopwords O
this NN stopwords O
study NN survey O
was VB stopwords Washington O
to NN stopwords O
determine NN determine O
if NN stopwords O
topical NN topical T
DL-alpha-tocopherol CAPITAL NNP T
( ( T
vitamin NN vitamin T
E CAPITAL NN vitamin_E T
) ) T
could NNS O
reduce NN reduce O
ultraviolet-induced JJ D
damage VB damage D
to NN stopwords D
the NN stopwords D
epidermis NN epidermis D

The CAPITAL NNP O
rate VB rate O
of NN stopwords O
severe NN severe O
preeclampsia NN preeclampsia D
was VB stopwords Washington O
increased NN increase O
significantly NN significantly O
in NN stopwords inch O
the NN stopwords O
triplet NN three O
group NN group O
12 DIGITS CD twelve O
of NN stopwords O
53 DIGITS CD fifty-three O
( ( O
22.6 CD O
% NN O
) ) O
as DT stopwords arsenic O
compared NNS compare O
with NN stopwords O
the NN stopwords O
twin NN twin O
group NN group O
3 DIGITS CD three O
of NN stopwords O
53 DIGITS CD fifty-three O
( ( O
5.7 CD O
% NN O
) ) O
( ( O
OR CAPITAL NNP Oregon O
= NN O
4.9 CD O
, , O
95 DIGITS CD ninety-five O
% NN O
CI CAPITAL NNP curie O
1.2-23.5 CD O
, , O
p NN phosphorus O
= NN O
0.02 LS O
) ) O

Have CAPITAL NNP rich_person O
we NN stopwords O
treated NN treat O
AIDS CAPITAL DT AIDS D
too NN stopwords excessively O
well NN well O
? . O
Rationing CAPITAL VB rationing O
and DT stopwords O
the NN stopwords O
future JJ future O
of NN stopwords O
AIDS CAPITAL DT AIDS O
exceptionalism NN O

The CAPITAL NNP O
Hemophilia CAPITAL NNP hemophilia O
Growth CAPITAL NNP growth O
and DT stopwords O
Development CAPITAL NNP development O
Study CAPITAL NNP survey O

to NN stopwords O
explore NN research O
the NN stopwords O
induction NN initiation O
of NN stopwords O
chemotherapy NNS chemotherapy T
( ( T
ct NNS Connecticut T
) ) T
dna NN deoxyribonucleic_acid O
damage VB damage O
and DT stopwords O
its NN stopwords information_technology O
correlation NNS correlation O
with NN stopwords O
tumor NN tumor O
response NN response O
and DT stopwords O
patient VB patient O
survival NN survival O
, , O
we NN stopwords O
undertook JJ undertake O
the NN stopwords O
present NN present O
study NN survey O
in NN stopwords inch O
20 DIGITS CD twenty O
small JJ small D
cell NNS cell D
lung NN lung D
cancer VB cancer D
( ( D
sclc JJ D
) ) D
patients VB patient O

All CAPITAL DT all O
children JJ child O
with NN stopwords O
croup NNS croup D
symptoms NN symptom O
who NN stopwords World_Health_Organization O
demonstrate NN show O
increased NN increase O
work NN work O
of NN stopwords O
breathing NN breathing O
in NN stopwords inch O
the NN stopwords O
clinics JJ clinic O
or NN stopwords Oregon O
emergency NN emergency O
departments NN department O
should NN stopwords O
be NN stopwords beryllium O
treated NN treat O
with NN stopwords O
glucocorticoids NN glucocorticoid T

Case CAPITAL VB case O
30-1997 CD O

The CAPITAL NNP O
retro-substrates NN O
' '' O
strong NN strong O
, , O
constitutive NNS constituent O
promoters NN promoter O
ensure NN guarantee O
that NN stopwords O
variations NN variation O
in NN stopwords inch O
cellular NNS cellular O
switch JJ switch O
recombinase NN O
activities DT activity O
are DT stopwords are O
independent NN mugwump O
of NN stopwords O
S CAPITAL NN second O
region NN region O
accessibility DT handiness O
control NNS control O

However CAPITAL NNP however O
, , O
only JJ stopwords lone O
primary NN primary D
thrombolysis NN thrombolysis D
was VB stopwords Washington O
found JJ found O
by NN stopwords by O
multivariate NN multivariate O
analysis DT analysis O
to NN stopwords O
be NN stopwords beryllium O
an DT stopwords Associate_in_Nursing O
independent NN mugwump O
predictor NN forecaster O
of NN stopwords O
survival NN survival O
( ( O
odds JJ odds O
ratio VB ratio O
for NN stopwords O
in-hospital NN O
death NN death O
, , O
0.46 LS O
; : O
95 DIGITS CD ninety-five O
% NN O
confidence NNS assurance O
interval NN time_interval O
, , O
0.21 LS O
to NN stopwords O
1.00 CD O
) ) O

Methotrexate CAPITAL NNP methotrexate T
( ( T
MTX CAPITAL NNP T
) ) T
appears DT look O
to NN stopwords O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
rheumatoid NN arthritic D
arthritis DT arthritis D
( ( D
RA CAPITAL VB radium D
) ) D
refractory NN furnace_lining O
to NN stopwords O
other JJ stopwords other O
drugs NN drug O
but NN stopwords merely O
its NN stopwords information_technology O
long-term NN long-run O
toxicity NN toxicity O
and DT stopwords O
efficacy NN efficacy O
are DT stopwords are O
uncertain JJ uncertain O

However CAPITAL NNP however O
, , O
it NN stopwords information_technology O
may VB May O
be NN stopwords beryllium O
even NN evening O
more NN stopwords More O
important JJ important O
that NN stopwords O
the NN stopwords O
nurses RB nurse O
themselves NN stopwords O
have VB stopwords rich_person O
a DT stopwords angstrom O
healthy NN healthy O
lifestyle NN life_style O
, , O
thus NN frankincense O
serving NN helping O
as DT stopwords arsenic O
role NN function O
models NN model O
for NN stopwords O
patients VB patient O

CONCLUSION CAPITAL NNP decision O
: : O
Gastric CAPITAL VB gastric O
acid DT acid O
secretion NN secretion O
increased NN increase O
into NN stopwords O
the NN stopwords O
normal RB convention O
range VB scope O
after DT stopwords after O
successful NN successful O
treatment NN treatment O
of NN stopwords O
H. CAPITAL NNP D
pylori NN pylorus D
infection NN infection D
, , O
suggesting NN propose O
that NN stopwords O
gastric VB gastric O
function JJ function O
can VB stopwords can O
recover NN recover O
to NN stopwords O
normal RB convention O
or NN stopwords Oregon O
almost DT about O
normal RB convention O
after DT stopwords after O
cure NNS remedy O
of NN stopwords O
H. CAPITAL NNP D
pylori NN pylorus D
infection NN infection D

BACKGROUND CAPITAL IN background O
: : O
To CAPITAL NNP O
evaluate NN measure O
the NN stopwords O
frequency JJ frequency O
of NN stopwords O
Blastocystis CAPITAL NNP D
hominis NN D
parasitation NN D
and DT stopwords O
to NN stopwords O
ascertain DT determine O
its NN stopwords information_technology O
role NN function O
as DT stopwords arsenic O
an DT stopwords Associate_in_Nursing O
intestinal NN intestinal O
a DT stopwords angstrom O
prospective NN prospective O
study NN survey O
during NN stopwords O
18 DIGITS CD eighteen O
months NN calendar_month O
pathogen VB pathogen O
has VB stopwords hour_angle O
been NN stopwords be O
carried VB transport O
out JJ stopwords out O

patients VB patient O
with NN stopwords O
limited-stage NN D
small-cell JJ D
carcinoma VB carcinoma D
of NN stopwords D
the NN stopwords D
lung NN lung D
are DT stopwords are O
treated NN treat O
with NN stopwords O
combined-modality NNS T
therapy NN therapy T
with NN stopwords O
the NN stopwords O
intent NN purpose O
to NN stopwords O
cure NNS remedy O

Will CAPITAL NNP volition O
the NN stopwords O
real NN real_number O
plastic NN plastic O
surgeon NN surgeon O
please NN please O
stand NN base O
up JJ stopwords up O
? . O

This CAPITAL NNP O
information NN information O
may VB May O
be NN stopwords beryllium O
useful JJ useful O
in NN stopwords inch O
counseling NNS guidance O
patients VB patient O
with NN stopwords O
high NN high O
order JJ order O
multifetal NN O
gestations NN gestation O

Many CAPITAL NNP many O
amino DT amino O
acids DT acid O
contain NNS incorporate O
an DT stopwords Associate_in_Nursing O
asymmetric DT asymmetrical O
centre NNS Centre O
, , O
occurring JJ happen O
as DT stopwords arsenic O
laevorotatory NN O
, , O
L CAPITAL NN liter O
, , O
or NN stopwords Oregon O
dextrorotatory NN dextrorotary O
, , O
D CAPITAL NN vitamin_D O
, , O
compounds NNS compound O

It CAPITAL PRP information_technology O
also DT besides O
describes NN describe O
a DT stopwords angstrom O
process NN procedure O
that NN stopwords O
program NN plan O
directors NN director O
and DT stopwords O
local NN local O
program NN plan O
committees NNS committee O
can VB stopwords can O
use JJ use O
to NN stopwords O
develop NN develop O
competency-based NNS O
curricula NNS course_of_study O

Second CAPITAL NNP second O
of NN stopwords O
two NN two O
parts NN parts O

Randomised CAPITAL VB randomize O
placebo-controlled NN O
trial NN test O
of NN stopwords O
granulocyte-colony NN T
stimulating JJ stimulate T
factor VB factor T
in NN stopwords inch O
diabetic NN diabetic D
foot JJ foot D
infection NN infection D

The CAPITAL NNP O
regulation NN regulation O
seems NN look O
to NN stopwords O
be NN stopwords beryllium O
multifactorial NN multifactorial O
and DT stopwords O
includes NN include O
: : O
( ( O
i NN stopwords iodine O
) ) O
dietary NN dietary O
and DT stopwords O
nutritional JJ nutritional O
status NN status O
; : O
( ( O
ii NN two O
) ) O
hormonal NN hormonal O
milieu NN milieu O
; : O
( ( O
iii NN three O
) ) O
exercise NN exercise O
mode NN manner O
, , O
intensity NN intensity O
and DT stopwords O
duration NN duration O
; : O
and DT stopwords O
( ( O
iv NN four O
) ) O
training NN training O
status NN status O

Localized CAPITAL NNP place O
Darier CAPITAL NNP D
disease NN disease D

The CAPITAL NNP O
measuring NN measurement O
function JJ function O
of NN stopwords O
the NN stopwords O
first NN first O
legs NN legs O
of NN stopwords O
Araneus CAPITAL DT Aranea O
diadematus NN O
Cl CAPITAL NNP chlorine O

The CAPITAL NNP O
lack NN lack O
of NN stopwords O
structure NN structure O
was VB stopwords Washington O
also DT besides O
shown NN show O
by NN stopwords by O
control NNS control O
region NN region O
sequences NN sequence O
although DT O
four JJ four O
of NN stopwords O
the NN stopwords O
maternal VB maternal O
lineages NN lineage O
shared NN share O
a DT stopwords angstrom O
near-perfect RB O
81 DIGITS CD eighty-one O
bp NN O
repeat NN repeat O

A CAPITAL DT angstrom O
significant NN significant O
proportion NN proportion O
of NN stopwords O
the NN stopwords O
women NN woman O
were NN stopwords be O
in NN stopwords inch O
the NN stopwords O
high NN high O
risk NN hazard O
categories VB class O
with NN stopwords O
regard NN respect O
to NN stopwords O
age DT age O
and DT stopwords O
socio-economic NN O
status NN status O

Taking CAPITAL VB pickings O
issue NN issue O
with NN stopwords O
UK CAPITAL NNP United_Kingdom O
funding JJ support O
priorities NN precedence O

This CAPITAL NNP O
supports NN support O
, , O
indirectly NN indirectly O
, , O
an DT stopwords Associate_in_Nursing O
immunologic JJ immunological O
basis VB footing O
for NN stopwords O
preeclampsia NN preeclampsia D

in NN stopwords inch O
this NN stopwords O
study NN survey O
we NN stopwords O
analyzed DT analyze O
33 DIGITS CD thirty-three O
cases VB case O
which NN stopwords O
underwent JJ undergo O
complete NNS complete T
surgical NN surgical T
resection NN resection T
to NN stopwords O
assess DT buttocks O
the NN stopwords O
role NN function O
of NN stopwords O
surgery NN surgery O
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
patients VB patient O
with NN stopwords O
n NN nitrogen D
2 DIGITS CD two D
nsclc JJ D

The CAPITAL NNP O
effect NN consequence O
of NN stopwords O
discharge NN discharge O
pack VB battalion O
formula NN formula O
and DT stopwords O
breast NN breast O
pumps NN pump O
on NN stopwords on O
breastfeeding NN breastfeed O
duration NN duration O
and DT stopwords O
choice NNS choice O
of NN stopwords O
infant NN baby O
feeding JJ eating O
method NN method O

Intra-articular CAPITAL PRP T
hyaluronan NN T
injections NN injection T
for NN stopwords O
treatment NN treatment O
of NN stopwords O
osteoarthritis JJ osteoarthritis D
of NN stopwords O
the NN stopwords O
knee NN knee O

These CAPITAL NNP O
results NN consequence O
indicate NN bespeak O
that NN stopwords O
the NN stopwords O
present NN present O
parthenogenesis NN parthenogenesis O
mechanism NN mechanism O
shares NN share O
the NN stopwords O
same VB stopwords Lapp O
characteristics NNS feature O
as DT stopwords arsenic O
that NN stopwords O
achieved DT achieve O
by NN stopwords by O
post-GVBD NN O
activation DT activation O
in NN stopwords inch O
the NN stopwords O
suppression NN suppression O
of NN stopwords O
polar NN polar O
body NN body O
formation NN formation O
as DT stopwords arsenic O
a DT stopwords angstrom O
key NN key O
means NN means O
for NN stopwords O
successful NN successful O
starfish NN starfish O
parthenogenesis NN parthenogenesis O

145 DIGITS CD one_hundred_forty-five O

Placebo CAPITAL NNP placebo O
in NN stopwords inch O
drug NN drug O
clinical JJ clinical O
trials NN test O

conclusions NNS decision O
: : O
gamma VB gamma T
knife NN knife T
radiosurgery VB T
without NN O
prophylactic NN preventive O
wbrt NN O
could NNS O
be NN stopwords beryllium O
a DT stopwords angstrom O
primary NN primary O
choice NNS choice O
of NN stopwords O
treatment NN treatment O
for NN stopwords O
patients VB patient O
with NN stopwords O
as DT stopwords arsenic O
many VB many O
as DT stopwords arsenic O
10 DIGITS CD ten O
cerebral NNS cerebral D
metastases NN metastasis D
from JJ stopwords D
nonsmall JJ D
cell NNS cell D
cancer VB cancer D

Troglitazone-induced CAPITAL NNP D
hepatic NN liverwort D
failure VB failure D
leading NN lead O
to NN stopwords O
liver NN liver T
transplantation NN transplant T

Research CAPITAL NNP research O
on NN stopwords on O
breeding NN breeding O
hygiene NN hygiene O
in NN stopwords inch O
pigs NN hog O
and DT stopwords O
piglets NN piglet O
free JJ free O
from JJ stopwords O
epidemic NN epidemic D
diseases NN disease D

New CAPITAL NNP new T
vaccines NN vaccine T
are DT stopwords are O
under JJ stopwords nether O
study NN survey O
to NN stopwords O
further NN stopwords foster O
control NNS control O
bacterial VB bacterial D
meningitis NN meningitis D

UV CAPITAL NNP ultraviolet O
radiation VB radiation O
induces NN induce O
two NN two O
major VB major O
DNA CAPITAL NNP deoxyribonucleic_acid O
damage VB damage O
products NN merchandise O
, , O
the NN stopwords O
cyclobutane NNS O
pyrimidine NN pyrimidine O
dimer NN dimer O
( ( O
CPD CAPITAL NNP O
) ) O
and DT stopwords O
, , O
at DT stopwords astatine O
a DT stopwords angstrom O
lower NN lower_berth O
frequency JJ frequency O
, , O
the NN stopwords O
pyrimidine NN pyrimidine O
( ( O
6-4 CD O
) ) O
pyrimidinone NN O
dimer NN dimer O
( ( O
6-4 CD O
product NN merchandise O
) ) O

SYT-SSX CAPITAL NNP O
gene NN gene O
fusion JJ fusion O
as DT stopwords arsenic O
a DT stopwords angstrom O
determinant NN determinant O
of NN stopwords O
morphology NN morphology O
and DT stopwords O
prognosis NN prognosis O
in NN stopwords inch O
synovial NN synovial O
sarcoma VB sarcoma O

An CAPITAL DT Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
the NN stopwords O
SDS CAPITAL NNP South_Dakota O
concentration NNS concentration O
reduces NN reduce O
the NN stopwords O
number JJ number O
of NN stopwords O
different NN different O
species NN species O
present NN present O
in NN stopwords inch O
micelles NN micelle O

The CAPITAL NNP O
predicted NN predict O
protein NN protein O
sequences NN sequence O
exhibit NN exhibit O
approximately DT approximately O
85 DIGITS CD eighty-five O
% NN O
identity NN identity O
with NN stopwords O
the NN stopwords O
Pbx-related CAPITAL NNP O
Meis1 CAPITAL NNP O
homeobox NN homeobox O
gene NN gene O
products NN merchandise O
, , O
which NN stopwords O
are DT stopwords are O
involved NN involve O
in NN stopwords inch O
myeloid NN myeloid D
leukemia NN leukemia D
in NN stopwords inch O
BXH-2 CAPITAL NNP O
mice NN mouse O
, , O
and DT stopwords O
one JJ one O
of NN stopwords O
the NN stopwords O
Stra10 CAPITAL NNP O
isoforms NN O
corresponds NNS match O
to NN stopwords O
the NN stopwords O
recently NN recently O
published NN print O
Meis2 CAPITAL NNP O
sequence NN sequence O
( ( O
Nakamura CAPITAL NNP O
et NN O
al DT aluminum O
. . O
( ( O
1996 DIGITS CD O
) ) O
Oncogene CAPITAL NNP oncogene O
13 DIGITS CD thirteen O
: : O
2235-2242 CD O
) ) O

Biobehavioral CAPITAL NNP O
pain IN pain D
research NN research O
: : O
a DT stopwords angstrom O
multi-institute NN O
assessment DT appraisal O
of NN stopwords O
cross-cutting NNS O
issues NN issue O
and DT stopwords O
research NN research O
needs JJ need O

Breastfeeding CAPITAL NNP breastfeed O
and DT stopwords O
catch-up VB O
growth NN growth O
in NN stopwords inch O
infants NN baby O
born NN Born O
small JJ small O
for NN stopwords O
gestational NN gestational O
age DT age O

Little CAPITAL NNP little O
attention DT attention O
has VB stopwords hour_angle O
been NN stopwords be O
directed NN direct O
toward NN O
identifying NN identify O
the NN stopwords O
changes NNS change O
which NN stopwords O
occur JJ happen O
in NN stopwords inch O
salivary VB salivary O
composition NNS composition O
in NN stopwords inch O
response NN response O
to NN stopwords O
exercise NN exercise O

Photorepair CAPITAL NNP O
mutants NN mutant O
of NN stopwords O
Arabidopsis CAPITAL DT Arabidopsis O

Abstracts CAPITAL DT abstraction O

Secondary CAPITAL NNP secondary O
prevention NN prevention O
for NN stopwords O
stroke NN stroke D
after DT stopwords after O
CAPRIE CAPITAL VB T
and DT stopwords T
ESPS-2 CAPITAL NNP T

< NN O
TO_SEE CAPITAL NNP O
> NN O
in NN stopwords inch O
conclusion NNS decision O
, , O
3d CD three-D O
computer-assisted NNS O
analysis DT analysis O
of NN stopwords O
the NN stopwords O
internal NN internal O
structure NN structure O
of NN stopwords O
small JJ small O
pulmonary NN pneumonic O
nodules JJ nodule O
using JJ exploitation O
contrast-enhanced NNS O
dh-ct NN O
was VB stopwords Washington O
found JJ found O
to NN stopwords O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
differentiating NN distinguish O
between NN stopwords between O
benign NN benign O
and DT stopwords O
malignant VB malignant O
nodules JJ nodule O

Mutations CAPITAL NNP mutant O
in NN stopwords inch O
brief NN brief O
no NNS stopwords no O

Partial CAPITAL VB partial_derivative O
or NN stopwords Oregon O
near RB approach O
total NN sum O
pancreatectomy VB pancreatectomy T
for NN stopwords O
persistent NN persistent D
neonatal JJ neonatal D
hyperinsulinaemic NN D
hypoglycaemia NN hypoglycemia D
: : O
the NN stopwords O
pathologist VB diagnostician O
's POS O
role NN function O

Contempo CAPITAL NNP O
1997 DIGITS CD O
: : O
obstetrics NN obstetrics O
and DT stopwords O
gynecology NN gynecology O

Effects CAPITAL NNP effects O
of NN stopwords O
clomiphene NNS clomiphene T
citrate NN citrate T
on NN stopwords on O
endometrial NN endometrial D
hyperplasia NN hyperplasia D
in NN stopwords inch O
the NN stopwords O
premenopausal NN premenopausal O
female JJ female O

The CAPITAL NNP O
tobacco NN tobacco O
settlement NN colony O

`` `` O
Return CAPITAL NNP tax_return O
the NN stopwords O
joy NN joy O
of NN stopwords O
home NN home O
delivery NN delivery O
'' POS O
with NN stopwords O
fathers VB father O
in NN stopwords inch O
the NN stopwords O
delivery NN delivery O
room NN room O

Classification CAPITAL NNP categorization O
of NN stopwords O
primary NN primary O
gastric VB gastric D
lymphomas NN lymphoma D
according DT harmonize O
to NN stopwords O
histologic NN histological O
features NN feature O

Breckenridge CAPITAL NNP O
, , O
Colorado CAPITAL NNP Colorado O
, , O
USA CAPITAL NNP United_States O

Familial CAPITAL NNP familial D
vitamin NN vitamin D
D CAPITAL NN vitamin_D D
resistant NN immune D
rickets NN rickets D
in NN stopwords inch O
untreated JJ untreated O
adult DT adult O

Chromosomal CAPITAL NNP chromosomal O
abnormalities DT abnormality O
of NN stopwords O
a DT stopwords angstrom O
new JJ new O
nasopharyngeal RB nasopharyngeal D
carcinoma VB carcinoma D
cell NNS cell O
line NN line O
( ( O
NPC-BM1 CAPITAL NNP O
) ) O
derived NN deduce O
from JJ stopwords O
a DT stopwords angstrom O
bone NN bone D
marrow NN marrow D
metastatic NN metastatic D
lesion NN lesion D

Fluoride CAPITAL NNP fluoride T
treatment NN treatment T
increased NN increase O
serum NN serum O
and DT stopwords O
bone NN bone O
fluoride JJ fluoride O
levels NN degree O
by NN stopwords by O
over JJ stopwords over O
an DT stopwords Associate_in_Nursing O
order JJ order O
of NN stopwords O
magnitude VB magnitude O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.001 LS O
) ) O
, , O
but NN stopwords merely O
did NN stopwords make O
not JJ stopwords not O
affect DT affect O
body NN body O
weight NN weight O
or NN stopwords Oregon O
the NN stopwords O
following JJ following O
serum NN serum O
biochemical NN biochemical O
variables NN variable O
: : O
urea JJ urea O
, , O
creatinine NNS O
, , O
phosphorus NN phosphorus O
, , O
total NN sum O
protein NN protein O
, , O
albumin DT albumin O
, , O
bilirubin NN bilirubin O
, , O
SGOT CAPITAL NNP O
, , O
or NN stopwords Oregon O
total NN sum O
alkaline DT alkaline O
phosphatase NN phosphatase O

Our CAPITAL NNP O
distinct NN distinct O
image NN image O

CONCLUSIONS CAPITAL NNP decision O
: : O
Many CAPITAL NNP many O
of NN stopwords O
the NN stopwords O
clinical JJ clinical O
features NN feature O
of NN stopwords O
localized NN place O
Darier CAPITAL NNP D
disease NN disease D
suggest NN propose O
that NN stopwords O
it NN stopwords information_technology O
is NN stopwords be O
a DT stopwords angstrom O
genetic NN familial O
mosaic NN mosaic O
of NN stopwords O
generalized NN generalize O
Darier CAPITAL NNP D
disease NN disease D

For CAPITAL NNP O
example NN example O
, , O
for NN stopwords O
the NN stopwords O
binding NN binding O
of NN stopwords O
10 DIGITS CD ten O
nM NNS nanometer O
insulin NN insulin O
growth NN growth O
factor-1 VB O
in NN stopwords inch O
solution NN solution O
to NN stopwords O
insulin NN insulin O
growth NN growth O
factor VB factor O
binding NN binding O
protein-1 NN O
immobilized JJ immobilize O
on NN stopwords on O
a DT stopwords angstrom O
biosensor NN O
surface NN surface O
, , O
a DT stopwords angstrom O
64 DIGITS CD sixty-four O
% NN O
increase NN addition O
in NN stopwords inch O
the NN stopwords O
fractal NN fractal O
dimension NN dimension O
from JJ stopwords O
1.73 CD O
( ( O
Df1 CAPITAL NNP O
) ) O
to NN stopwords O
2.85 CD O
( ( O
Df2 CAPITAL NNP O
) ) O
leads NN lead O
to NN stopwords O
an DT stopwords Associate_in_Nursing O
increase NN addition O
in NN stopwords inch O
the NN stopwords O
binding NN binding O
rate VB rate O
coefficient NNS coefficient O
by NN stopwords by O
a DT stopwords angstrom O
factor VB factor O
of NN stopwords O
31.8 CD O
from JJ stopwords O
3.92 LS O
( ( O
k1 NN O
) ) O
to NN stopwords O
125 DIGITS CD one_hundred_twenty-five O
( ( O
k2 NN K2 O
) ) O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Every CAPITAL NNP every O
effort NN attempt O
must NN must O
be NN stopwords beryllium O
made VB make O
to NN stopwords O
exclude NN exclude O
abdominal DT abdominal D
tuberculosis NN tuberculosis D
before NN stopwords earlier O
the NN stopwords O
patient VB patient O
is NN stopwords be O
diagnosed NN diagnose O
as DT stopwords arsenic O
having VB stopwords have O
Crohn CAPITAL NNP Crohn D
's POS D
disease NN disease D
and DT stopwords O
is NN stopwords be O
treated NN treat O
with NN stopwords O
steroids NN steroid T

The CAPITAL NNP O
60 DIGITS CD sixty O
women NN woman O
( ( O
71 DIGITS CD seventy-one O
% NN O
) ) O
, , O
who NN stopwords World_Health_Organization O
initiated JJ originate O
treatment NN treatment O
before NN stopwords earlier O
34 DIGITS CD thirty-four O
completed NNS complete O
weeks NN week O
, , O
composed NNS compose O
the NN stopwords O
`` `` O
early VB early O
'' POS O
group NN group O

Advanced CAPITAL DT advance O
practice NN practice O
nursing RB nursing O
: : O
is NN stopwords be O
the NN stopwords O
physician NN doctor O
's POS O
assistant DT assistant O
an DT stopwords Associate_in_Nursing O
accident DT accident O
of NN stopwords O
history NN history O
or NN stopwords Oregon O
a DT stopwords angstrom O
failure VB failure O
to NN stopwords O
act DT act O
? . O

METHODS CAPITAL NNP method O
: : O
We CAPITAL NNP O
reviewed NN review O
the NN stopwords O
charts NNS chart O
of NN stopwords O
20 DIGITS CD twenty O
eyes NN eyes O
of NN stopwords O
15 DIGITS CD fifteen O
children JJ child O
( ( O
aged DT aged O
1.5 CD O
to NN stopwords O
2 DIGITS CD two O
years NN old_age O
) ) O
who NN stopwords World_Health_Organization O
had VB stopwords have O
primary NN primary O
cataract VB cataract D
surgery NN surgery T
with NN stopwords T
PC CAPITAL NNP personal_computer T
IOL CAPITAL PRP lens_implant T
implantation JJ implantation T
during NN stopwords O
the NN stopwords O
past VB past O
5 DIGITS CD five O
years NN old_age O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Respiratory CAPITAL NNP respiratory O
arrest DT apprehension O
following JJ following O
peribulbar NN O
anesthesia DT anesthesia O
for NN stopwords O
cataract VB cataract O
surgery NN surgery O
: : O
case VB case O
report NN report O
and DT stopwords O
review NN reappraisal O
of NN stopwords O
the NN stopwords O
literature NN literature O

we NN stopwords O
treated NN treat O
27 DIGITS CD twenty-seven O
nsclcm JJ D
patients VB patient O
with NN stopwords O
concomitant NNS accompaniment O
daily IN daily O
low-dose NN O
cisplatin NN T
and DT stopwords T
radiotherapy VB radiotherapy T
between NN stopwords between O
1993 DIGITS CD O
and DT stopwords O
1995 DIGITS CD O

Abstracts CAPITAL DT abstraction O

hominis NN O
is NN stopwords be O
the NN stopwords O
most NN stopwords most O
frequent JJ patronize O
parasite NN parasite O
found JJ found O
in NN stopwords inch O
faecal VB faecal O
parasitological NN O
investigation NN probe O

Acute CAPITAL DT acute_accent O
effect NN consequence O
of NN stopwords O
lorazepam NN lorazepam T
on NN stopwords on O
respiratory NN respiratory O
muscles NN muscle O
in NN stopwords inch O
patients VB patient O
with NN stopwords O
chronic NN chronic D
obstructive NN clogging D
pulmonary NN pneumonic D
disease NN disease D

Therefore CAPITAL NNP therefore O
, , O
the NN stopwords O
present NN present O
paradigm NN paradigm O
enables NN enable O
the NN stopwords O
study NN survey O
of NN stopwords O
individual NN person O
changes NNS change O
in NN stopwords inch O
learning NN learning O
and DT stopwords O
memory NN memory O
capacities VB capacity O
over JJ stopwords over O
time NN time O

Therefore CAPITAL NNP therefore O
, , O
interest NN interest O
is NN stopwords be O
growing NN growth O
in NN stopwords inch O
mAbs NN T
as DT stopwords arsenic O
therapeutic NN remedy O
alternatives DT option O
for NN stopwords O
patients VB patient O
with NN stopwords O
low-grade NN low-grade D
NHL CAPITAL NNP D
and DT stopwords O
those NN stopwords O
with NN stopwords O
transformed NN transform O
histology NN histology O

Miracidia CAPITAL NNP O
clearly NNS clearly O
preferred NN prefer O
SCW CAPITAL NNP O
from JJ stopwords O
their NN stopwords O
specific NN particular O
host NN host O
snail NN snail O
versus NN O
other JJ stopwords other O
sympatric NN sympatric O
snail NN snail O
species NN species O
and DT stopwords O
did NN stopwords make O
not JJ stopwords not O
respond NN react O
to NN stopwords O
water VB water O
conditioned NNS condition O
with NN stopwords O
fish NN fish O
, , O
tadpoles VB tadpole O
, , O
or NN stopwords Oregon O
leeches NN leech O

Prospective CAPITAL NNP prospective O
, , O
randomized VB randomize O
, , O
largescale NN O
trials NN test O
supporting NN support O
any DT stopwords any O
of NN stopwords O
the NN stopwords O
different NN different O
treatment NN treatment O
strategies NN scheme O
are DT stopwords are O
not JJ stopwords not O
available DT available O
, , O
but NN stopwords merely O
antibiotics DT antibiotic T
and DT stopwords T
surgery NN surgery T
probably NN probably O
have VB stopwords rich_person O
improved JJ better O
the NN stopwords O
long-term NN long-run O
outcome JJ result O
of NN stopwords O
many VB many O
patients VB patient O
with NN stopwords O
bronchiectasis NN D

Linear CAPITAL NNP linear O
correlation NNS correlation O
between NN stopwords between O
the NN stopwords O
receptor NN receptor O
surface NN surface O
concentration NNS concentration O
and DT stopwords O
the NN stopwords O
response NN response O
to NN stopwords O
biotin NN biotin O
binding NN binding O
was VB stopwords Washington O
observed NN detect O

The CAPITAL NNP O
scope JJ scope O
of NN stopwords O
sphincterotomy NN T
in NN stopwords inch O
biliary NN bilious T
and DT stopwords T
pancreatic VB pancreatic T
surgery NN surgery T

Calcium CAPITAL VB calcium O
quantities NN measure O
calculated VB calculate O
for NN stopwords O
both NN stopwords both O
protocols NN protocol O
, , O
performed NN perform O
on NN stopwords on O
the NN stopwords O
same VB stopwords Lapp O
subjects NN subject O
, , O
were NN stopwords be O
sorted NN screen O
in NN stopwords inch O
ascending DT rise O
order JJ order O
and DT stopwords O
divided NN divide O
into NN stopwords O
equal NN peer O
quartiles NN quartile O

DATA CAPITAL NNP data O
SYNTHESIS CAPITAL NNP synthesis O
: : O
Recently CAPITAL NNP recently O
, , O
an DT stopwords Associate_in_Nursing O
expert NN expert O
panel VB panel O
of NN stopwords O
the NN stopwords O
Centers CAPITAL NNP center O
for NN stopwords O
Disease CAPITAL NNP disease O
Control CAPITAL NNP control O
and DT stopwords O
Prevention CAPITAL NNP prevention O
recommended NN recommend O
use JJ use O
of NN stopwords O
only JJ stopwords lone O
three NN three O
of NN stopwords O
16 DIGITS CD sixteen O
systemic NN systemic T
antibiotics DT antibiotic T
approved DT approve O
by NN stopwords by O
the NN stopwords O
Food CAPITAL NNP food O
and DT stopwords O
Drug CAPITAL NNP drug O
Administration CAPITAL DT administration O
for NN stopwords O
treatment NN treatment O
of NN stopwords O
AOM CAPITAL DT D
: : O
amoxicillin DT amoxicillin T
, , T
cefuroxime NNS cefuroxime T
axetil DT T
, , T
and DT stopwords T
ceftriaxone NNS ceftriaxone T

our NN stopwords O
conclusion NNS decision O
was VB stopwords Washington O
that NN stopwords O
the NN stopwords O
covered-ems NNS T
can VB stopwords can O
be NN stopwords beryllium O
effective NN effective O
for NN stopwords O
the NN stopwords O
palliation VB palliation O
of NN stopwords O
esophagorespiratory NN D
fistulas NN fistulous_withers D

A CAPITAL DT angstrom O
method NN method O
to NN stopwords O
aid DT aid O
correct NNS correct O
diagnosis NN diagnosis O

< NN O
TO_SEE CAPITAL NNP O
> NN O
In CAPITAL PRP inch O
this NN stopwords O
article DT article O
, , O
evidence NN evidence O
of NN stopwords O
effectiveness NN effectiveness O
and DT stopwords O
cost-effectiveness NNS O
of NN stopwords O
the NN stopwords O
following JJ following O
procedures NN procedure O
is NN stopwords be O
reviewed NN review O
: : O
( ( O
1 DIGITS CD one O
) ) O
laser NN laser T
treatment NN treatment T
of NN stopwords O
bladder NN bladder D
tumors NN tumor D
; : O
( ( O
2 DIGITS CD two O
) ) O
extracorporeal NN O
shock-wave NN O
lithotripsy NN O
and DT stopwords O
percutaneous NN transdermal O
nephrolithotomy JJ O
; : O
( ( O
3 DIGITS CD three O
) ) O
laparoscopic NN T
treatment NN treatment T
of NN stopwords O
endometriosis NN endometriosis D
; : O
( ( O
4 DIGITS CD four O
) ) O
laparoscopic NN T
removal NN removal T
of NN stopwords O
ovarian NN ovarian D
cysts NNS cyst D
; : O
( ( O
5 DIGITS CD five O
) ) O
laparoscopic NN O
cholecystectomy NNS cholecystectomy O
; : O
( ( O
6 DIGITS CD six O
) ) O
laparoscopic NN O
appendectomy DT appendectomy O
; : O
( ( O
7 DIGITS CD seven O
) ) O
catheter VB catheter T
treatment NN treatment T
of NN stopwords O
coronary NNS coronary_thrombosis D
artery DT artery D
disease NN disease D
; : O
( ( O
8 DIGITS CD eight O
) ) O
palliation VB palliation O
of NN stopwords O
colon NNS colon O
cancer VB cancer O
by NN stopwords by O
endoscopic NN endoscopic O
intervention NN intervention O
; : O
( ( O
9 DIGITS CD nine O
) ) O
treatment NN treatment O
of NN stopwords O
upper JJ upper_berth D
gastrointestinal VB gastrointestinal D
( ( D
UGI CAPITAL NNP D
) ) D
bleeding NN bleeding D
by NN stopwords by O
endoscopic NN endoscopic T
intervention NN intervention T
; : O
and DT stopwords O
( ( O
10 DIGITS CD ten O
) ) O
arthroscopic DT O
knee NN knee O
surgery NN surgery O

In CAPITAL PRP inch O
the NN stopwords O
present NN present O
study NN survey O
the NN stopwords O
potent NN potent O
5-HT1A CD O
receptor NN receptor O
agonist DT protagonist O
, , O
8-hydroxy-2- CD O
( ( O
di-n-propylamino NN O
) ) O
-tetralin : O
( ( O
8-OH-DPAT CD O
) ) O
was VB stopwords Washington O
tested NN test O
for NN stopwords O
its NN stopwords information_technology O
effect NN consequence O
on NN stopwords on O
plasma NN plasma O
cortisol NNS hydrocortisone O
concentrations NNS concentration O
in NN stopwords inch O
rainbow VB rainbow O
trout NN trout O
( ( O
Oncorhynchus CAPITAL NNP Oncorhynchus O
mykiss NN O
) ) O

The CAPITAL NNP O
implications JJ deduction O
of NN stopwords O
these NN stopwords O
cases VB case O
on NN stopwords on O
future JJ future O
genetic NN familial O
studies NN survey O
are DT stopwords are O
also DT besides O
discussed NN discourse O

Haemoptysis CAPITAL NNP hemoptysis D
: : O
a DT stopwords angstrom O
rare NN rare O
cause VB cause O

Systemic CAPITAL NNP systemic O
absorption DT absorption O
of NN stopwords O
sunscreen NN sunscreen O
after DT stopwords after O
topical NN topical O
application DT application O

Electrolyte CAPITAL NNP electrolyte O
and DT stopwords O
acid-base DT O
balance VB balance O
in NN stopwords inch O
fetal JJ fetal O
and DT stopwords O
maternal VB maternal O
blood NN blood O

Thirty CAPITAL NNP thirty O
per NN O
cent NNS cent O
of NN stopwords O
departments NN department O
considered NNS see O
calf VB calf O
vein NN vein O
visualization NN visual_image O
to NN stopwords O
be NN stopwords beryllium O
generally NN by_and_large O
adequate DT adequate O
and DT stopwords O
34 DIGITS CD thirty-four O
% NN O
thought NN idea O
that NN stopwords O
clinicians JJ clinician O
in NN stopwords inch O
their NN stopwords O
hospitals NN hospital O
invariably NN constantly O
anticoagulated DT O
patients VB patient O
with NN stopwords O
isolated NN isolate T
calf VB calf T
thrombus NN thrombus T

F CAPITAL NN degree_Fahrenheit O
100 DIGITS CD hundred O
and DT stopwords O
200 DIGITS CD two_hundred O
microg NN O
and DT stopwords O
S CAPITAL NN second O
20 DIGITS CD twenty O
and DT stopwords O
30 DIGITS CD thirty O
microg NN O
all DT stopwords all O
achieved DT achieve O
VAS CAPITAL VB vessel O
scores JJ tons O
& CC O
# # O
60 DIGITS CD sixty O
; : O
10 DIGITS CD ten O
mm NNS millimeter O
in NN stopwords inch O
all DT stopwords all O
women NN woman O
with NN stopwords O
no NNS stopwords no O
differences NN difference O
in NN stopwords inch O
time NN time O
to NN stopwords O
50 DIGITS CD fifty O
% NN O
reduction NN decrease O
in NN stopwords inch O
VAS CAPITAL VB vessel O
( ( O
mean NN mean O
11-16 CD O
min NN minute O
) ) O
and DT stopwords O
no NNS stopwords no O
differences NN difference O
in NN stopwords inch O
duration NN duration O
of NN stopwords O
analgesia DT analgesia O
( ( O
mean NN mean O
117-138 CD O
min NN minute O
) ) O

Cancer CAPITAL VB cancer D
of NN stopwords O
the NN stopwords O
vulva NN vulva O

An CAPITAL DT Associate_in_Nursing O
experimental NN experimental O
study NN survey O
of NN stopwords O
conflict NNS conflict O
and DT stopwords O
fear NN fear O
: : O
an DT stopwords Associate_in_Nursing O
analysis DT analysis O
of NN stopwords O
behavior NN behavior O
of NN stopwords O
young NN young O
chicks JJ chick O
toward NN O
a DT stopwords angstrom O
mealworm NN mealworm O

Guiding CAPITAL NNP steer O
surgical NN surgical T
therapy NN therapy T
of NN stopwords O
ventricular NN ventricular D
tachycardia VB tachycardia D
by NN stopwords by O
preoperative NN preoperative O
endocardial NN O
catheter VB catheter O
mapping VB function O
necessitates JJ necessitate O
improvement JJ improvement O
of NN stopwords O
the NN stopwords O
accuracy DT accuracy O
of NN stopwords O
localization NN localization O
of NN stopwords O
the NN stopwords O
arrhythmogenic DT O
site NN site O

five NN five O
new JJ new O
agents DT agent O
, , O
paclitaxel VB T
, , O
docetaxel NN T
, , O
vinorelbine NN T
, , O
gemcitabine NN T
and DT stopwords O
irinotecan JJ T
, , O
have VB stopwords rich_person O
been NN stopwords be O
introduced NN introduce O
for NN stopwords O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
nsclc JJ D
and DT stopwords O
investigated NN investigate O
extensively NN extensively O
both NN stopwords both O
preclinically NN O
and DT stopwords O
clinically JJ clinically O

Presumed CAPITAL NNP assume O
cavernomas VB O
have VB stopwords rich_person O
been NN stopwords be O
documented NN document O
following JJ following O
radiation VB radiation T
for NN stopwords O
malignancy VB malignancy D
( ( O
5-6 CD O
) ) O
, , O
and DT stopwords O
sterotactic NN O
cerebral NNS cerebral O
biopsy NN biopsy O
( ( O
7 DIGITS CD seven O
) ) O

Chemical CAPITAL NNP chemical O
disinfection NN disinfection O
solutions NN solution O
were NN stopwords be O
used JJ use O
in NN stopwords inch O
12 DIGITS CD twelve O
of NN stopwords O
the NN stopwords O
14 DIGITS CD fourteen O
dental NN alveolar_consonant O
clinics JJ clinic O
, , O
mainly VB chiefly O
for NN stopwords O
surface NN surface O
decontamination NN decontamination O

Tumours CAPITAL NNP tumor D
of NN stopwords O
the NN stopwords O
uterus JJ uterus O

This CAPITAL NNP O
research NN research O
is NN stopwords be O
worrisome NN unreassuring O
for NN stopwords O
many VB many O
reasons NN reason O
, , O
including NN include O
the NN stopwords O
fact VB fact O
that NN stopwords O
it NN stopwords information_technology O
has VB stopwords hour_angle O
been NN stopwords be O
used JJ use O
to NN stopwords O
harm NN injury O
lesbians NN lesbian O
and DT stopwords O
gay VB homosexual O
men NN work_force O

Urologic CAPITAL NNP O
complications NNS complication O
in NN stopwords inch O
non-recurrent JJ D
cancer VB cancer D
of NN stopwords O
the NN stopwords O
cervix NNS neck O

Eggs CAPITAL NNP egg O
derived NN deduce O
from JJ stopwords O
immature JJ immature O
oocytes JJ oocyte O
activated DT trip O
by NN stopwords by O
A23187 CAPITAL DT O
, , O
treated NN treat O
with NN stopwords O
1-MeAde CD T
and DT stopwords O
post-treated NN O
with NN stopwords O
cytochalasin NNS T
B CAPITAL NN bacillus T
failed VB fail O
to NN stopwords O
extrude NN extrude O
polar NN polar O
bodies NN body O
, , O
and DT stopwords O
eventually NN finally O
developed NN develop O
into NN stopwords O
parthenogenetic NN agamic O
embryos NN embryo O

Application CAPITAL DT application O
of NN stopwords O
infra-red NN O
absorption DT absorption O
spectroscopy NN spectroscopy O
to NN stopwords O
examination NN examination O
of NN stopwords O
drugs NN drug O
and DT stopwords O
their NN stopwords O
preparation NN preparation O

Successful CAPITAL NNP successful O
arthrodesis DT arthrodesis T
produces NN produce O
a DT stopwords angstrom O
foot JJ foot O
that NN stopwords O
is NN stopwords be O
more NN stopwords More O
functional JJ functional O
and DT stopwords O
durable NN durable O
than NN stopwords O
excisional NN T
arthroplasty DT arthroplasty T

Metastatic CAPITAL NNP metastatic D
malignant VB malignant D
mesothelioma NN mesothelioma D
presenting NN show O
as DT stopwords arsenic O
colonic NNS colonic_irrigation O
polyps NN polyp O

Trouble CAPITAL NNP trouble O
in NN stopwords inch O
paradise NN Eden O

There CAPITAL NNP there O
was VB stopwords Washington O
one JJ one O
retinal NN retinene O
dialysis NN dialysis O
, , O
and DT stopwords O
one JJ one O
lens NN lens D
dislocation NN dislocation D
requiring NN necessitate O
extraction NN extraction T

objective NN aim O
: : O
to NN stopwords O
examine NN analyze O
the NN stopwords O
effectiveness NN effectiveness O
of NN stopwords O
ninjin NN T
yoei NN T
to NN stopwords T
( ( T
nyt JJ T
; : T
ren-shen-yang-rong-tang NN T
in NN stopwords inch T
chinese JJ Chinese T
medicine NN medicine T
; : T
kotaro NN T
pharmaceutical NN pharmaceutical T
co. JJ T
, , T
ltd. NN limited_company T
, , T
osaka NN Osaka T
, , T
japan NN Japan T
) ) T
, , T
one JJ one T
of NN stopwords T
the NN stopwords T
traditional NN traditional T
herbal NN herb_tea T
medicines NN medicine T
, , O
against DT stopwords O
lung NN lung D
carcinoma VB carcinoma D

Ampicillin CAPITAL DT ampicillin T
should NN stopwords O
be NN stopwords beryllium O
included NN include O
if NN stopwords O
the NN stopwords O
patient VB patient O
has VB stopwords hour_angle O
predisposing NN predispose O
factors VB factor O
that NN stopwords O
are DT stopwords are O
associated DT associate O
with NN stopwords O
a DT stopwords angstrom O
risk NN hazard O
for NN stopwords O
infection NN infection D
with NN stopwords D
Listeria CAPITAL NNP listeria D
monocytogenes NN D

Amino CAPITAL DT amino O
acid DT acid O
metabolism NN metamorphosis O
and DT stopwords O
its NN stopwords information_technology O
relation NN relation O
to NN stopwords O
the NN stopwords O
biosynthesis NN biosynthesis O
of NN stopwords O
penicillin NN penicillin T

Injuries CAPITAL PRP injury O
found JJ found O
during NN stopwords O
the NN stopwords O
celiotomy NNS O
were NN stopwords be O
recorded NN record O

Autopsy CAPITAL DT autopsy O
Committee CAPITAL NNP committee O
of NN stopwords O
the NN stopwords O
College CAPITAL NNP college O
of NN stopwords O
American CAPITAL DT American O
Pathologists CAPITAL VB diagnostician O

Study CAPITAL NNP survey O
of NN stopwords O
three NN three O
different NN different O
doses NN dose O
of NN stopwords O
epidural NN epidural_anesthesia T
neostigmine JJ neostigmine T
coadministered NNS T
with NN stopwords T
lidocaine NN Lidocaine T
for NN stopwords O
postoperative NN postoperative D
analgesia DT analgesia D

If CAPITAL PRP O
no NNS stopwords no O
microscopic NN microscopic O
urinalysis JJ urinalysis O
is NN stopwords be O
required NN necessitate O
, , O
testing NN testing O
turn-around NN O
time NN time O
is NN stopwords be O
reduced NN reduce O
by NN stopwords by O
12.3 CD O
min/test NN O
and DT stopwords O
the NN stopwords O
hospital NN hospital O
charge NNS charge O
is NN stopwords be O
reduced NN reduce O
from JJ stopwords O
U.S CAPITAL NNP O

Dermatobia CAPITAL NNP Dermatobia O
-- : O
tropical NN tropical D
myiasis NN myiasis D

New CAPITAL NNP new O
operations JJ operations O
in NN stopwords inch O
children JJ child O
's POS O
cardiac VB cardiac O
disease NN disease O

When CAPITAL NNP O
recombinant NN recombinant O
HIV-1-containing CAPITAL NNP O
protease NN protease O
mutations NN mutant O
at DT stopwords astatine O
46 DIGITS CD forty-six O
and DT stopwords O
82 DIGITS CD eighty-two O
was VB stopwords Washington O
grown NN turn O
in NN stopwords inch O
MT2 CAPITAL NNP O
cells NNS cell O
, , O
there NN stopwords there O
was VB stopwords Washington O
a DT stopwords angstrom O
68 DIGITS CD sixty-eight O
% NN O
reduction NN decrease O
in NN stopwords inch O
its NN stopwords information_technology O
rate VB rate O
of NN stopwords O
replication NN reproduction O
compared NNS compare O
to NN stopwords O
the NN stopwords O
WT CAPITAL NNP O
virus NN virus O

Online CAPITAL NNP on-line O

Complementary CAPITAL NNP complementary_color O
and DT stopwords O
alternative DT option O
medicine NN medicine O
: : O
friend JJ friend O
, , O
foe JJ enemy O
, , O
or NN stopwords Oregon O
OWA CAPITAL NNP O
? . O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Sodium CAPITAL NNP sodium T
channel NNS channel T
block NN block T
with NN stopwords T
mexiletine NN mexiletine T
is NN stopwords be O
effective NN effective O
in NN stopwords inch O
reducing NN reduction O
dispersion NN dispersion O
of NN stopwords O
repolarization NN O
and DT stopwords O
preventing NN prevent O
torsade NN D
des NN diethylstilbestrol D
pointes NN indicate D
in NN stopwords inch O
LQT2 CAPITAL NNP O
and DT stopwords O
LQT3 CAPITAL NNP O
models NN model O
of NN stopwords O
the NN stopwords O
long-QT NN O
syndrome NN syndrome O

Granulocyte-colony CAPITAL NNP O
stimulating JJ stimulate O
factor VB factor O
( ( O
G-CSF CAPITAL NNP O
) ) O
increases NN addition O
the NN stopwords O
release NN release O
of NN stopwords O
neutrophils JJ neutrophil O
from JJ stopwords O
the NN stopwords O
bone NN bone O
marrow NN marrow O
and DT stopwords O
improves JJ better O
neutrophil JJ neutrophil O
function JJ function O

ROXIS CAPITAL NNP O
Study CAPITAL NNP survey O
Group CAPITAL NNP group O

The CAPITAL NNP O
particular NN particular O
sensibility NN sensibility O
of NN stopwords O
the NN stopwords O
fetus JJ fetus O
and DT stopwords O
newborn JJ neonate O
is NN stopwords be O
of NN stopwords O
concern NNS concern O
because NN stopwords O
the NN stopwords O
exposition NN exposition O
to NN stopwords O
dioxins NN dioxin O
is NN stopwords be O
particularly NN particularly O
important JJ important O
during NN stopwords O
those NN stopwords O
periods NN time_period O
of NN stopwords O
life NN life O

RESULTS CAPITAL NNP consequence O
: : O
The CAPITAL NNP O
HLA CAPITAL NNP O
effect NN consequence O
is NN stopwords be O
due NN due O
to NN stopwords O
the NN stopwords O
class NNS class O
II CAPITAL PRP two O
DR2 CAPITAL NNP O
haplotype VB haplotype O
, , O
DRB1*1501-DQA1*0102-DRB1*0602 CAPITAL NNP O
; : O
contributions NNS contribution O
to NN stopwords O
MS CAPITAL NNP multiple_sclerosis O
susceptibility NN susceptibility O
from JJ stopwords O
additional DT extra O
DRB1-DQB1 CAPITAL NNP O
alleles DT allele O
or NN stopwords Oregon O
other JJ stopwords other O
HLA CAPITAL NNP O
region NN region O
loci NN venue O
were NN stopwords be O
not JJ stopwords not O
observed NN detect O

In CAPITAL PRP inch O
a DT stopwords angstrom O
logistic NN logistic O
regression NN arrested_development O
analysis DT analysis O
controlled NNS control O
for NN stopwords O
age DT age O
, , O
sex NN sexual_activity O
, , O
BMI CAPITAL NNP body_mass_index O
, , O
and DT stopwords O
duration NN duration O
of NN stopwords O
diabetes NN diabetes D
, , O
any DT stopwords any O
retinopathy NN retinopathy D
was VB stopwords Washington O
significantly NN significantly O
associated DT associate O
with NN stopwords O
fasting VB fast O
plasma NN plasma O
glucose NN glucose O
concentrations NNS concentration O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
0.05 LS O
) ) O
, , O
2-h CD O
postload NN O
glucose NN glucose O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.02 LS O
) ) O
, , O
and DT stopwords O
HbA1c CAPITAL NNP O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.008 LS O
) ) O
, , O
but NN stopwords merely O
not JJ stopwords not O
with NN stopwords O
PAI-1 CAPITAL VB O
activity DT activity O
( ( O
P CAPITAL NN phosphorus O
= NN O
0.48 LS O
) ) O

< NN O
TO_SEE CAPITAL NNP O
> NN O
Progressive CAPITAL NNP progressive D
multifocal NN D
leukoencephalopathy NN D
following JJ following O
oral NN oral T
fludarabine JJ T
treatment NN treatment O
of NN stopwords O
chronic NN chronic D
lymphocytic NN lymphocytic D
leukemia NN leukemia D

A CAPITAL DT angstrom O
piece NN piece O
of NN stopwords O
my NN stopwords O
mind NN mind O

The CAPITAL NNP O
pallidal VB O
radiofrequency VB O
lesions NN lesion O
were NN stopwords be O
prolate NN prolate O
spheroid NN spheroid O
shaped NN determine O
and DT stopwords O
were NN stopwords be O
composed NNS compose O
of NN stopwords O
three NN three O
concentric NNS concentric O
zones NN zone O
in NN stopwords inch O
the NN stopwords O
early VB early O
postoperative NN postoperative O
studies NN survey O

> NN O
From CAPITAL NNP O
the NN stopwords O
Centers CAPITAL NNP center O
for NN stopwords O
Disease CAPITAL NNP disease O
Control CAPITAL NNP control O
and DT stopwords O
Prevention CAPITAL NNP prevention O

For CAPITAL NNP O
soft NN soft O
tissue NN tissue O
sarcomas VB sarcoma D
, , O
the NN stopwords O
RRs CAPITAL NNP O
showed NN show O
a DT stopwords angstrom O
stepwise NN bit-by-bit O
increase NN addition O
at DT stopwords astatine O
all DT stopwords all O
dose NN dose O
categories VB class O
, , O
and DT stopwords O
were NN stopwords be O
statistically NN statistically O
significant NN significant O
at DT stopwords astatine O
10 DIGITS CD ten O
to NN stopwords O
29.9 CD O
Gy CAPITAL NNP gray O
and DT stopwords O
30 DIGITS CD thirty O
to NN stopwords O
59.9 CD O
Gy CAPITAL NNP gray O

When CAPITAL NNP O
revascularizations NN D
were NN stopwords be O
included NN include O
, , O
there NN stopwords there O
was VB stopwords Washington O
a DT stopwords angstrom O
significant NN significant O
trend NN tendency O
toward NN O
higher NN higher O
frequencies JJ frequency O
of NN stopwords O
events NN event O
with NN stopwords O
increasing NN increase O
calcium VB calcium O
quantity NN measure O
( ( O
P CAPITAL NN phosphorus O
& CC O
# # O
60 DIGITS CD sixty O
; : O
.01 . O
) ) O

Bi-exponential CAPITAL NNP O
increase NN addition O
and DT stopwords O
decrease NN decrease O
of NN stopwords O
intercalator NN O
loading NN load O
was VB stopwords Washington O
observed NN detect O
, , O
indicating NN bespeak O
complex NNS complex O
interaction NN interaction O
kinetics NN dynamics O

The CAPITAL NNP O
absolute DT absolute O
difference NN difference O
was VB stopwords Washington O
0.44 LS O
percent NN percentage O
, , O
with NN stopwords O
a DT stopwords angstrom O
one-sided JJ nonreversible O
95 DIGITS CD ninety-five O
percent NN percentage O
upper JJ upper_berth O
boundary NN boundary O
of NN stopwords O
1.49 CD O
percent NN percentage O
, , O
which NN stopwords O
exceeded NN exceed O
the NN stopwords O
prespecified NN O
upper JJ upper_berth O
limit NN limit O
of NN stopwords O
0.40 LS O
percent NN percentage O
to NN stopwords O
indicate NN bespeak O
equivalence NN equality O
in NN stopwords inch O
30-day CD O
mortality NN mortality O
between NN stopwords between O
the NN stopwords O
two NN two O
regimens NN regimen O

Cases CAPITAL VB case O
8 DIGITS CD eight O
and DT stopwords O
9 DIGITS CD nine O

Recombinant CAPITAL NNP recombinant T
leukocyte NN leukocyte T
A CAPITAL DT angstrom T
interferon NN interferon T
( ( T
rIFN-alpha NN T
A CAPITAL DT angstrom T
) ) T
in NN stopwords inch O
the NN stopwords O
treatment NN treatment O
of NN stopwords O
disseminated NN circulate D
malignant VB malignant D
melanoma NN melanoma D

To CAPITAL NNP O
prove NN prove O
, , O
whether NN O
Ribavirin CAPITAL NN ribavirin T
has VB stopwords hour_angle O
any DT stopwords any O
additional DT extra O
effect NN consequence O
on NN stopwords on O
the NN stopwords O
decline NN decline O
of NN stopwords O
hepatitis NN hepatitis D
C CAPITAL SYM degree_centigrade D
viremia NN viremia D
during NN stopwords O
the NN stopwords O
first NN first O
weeks NN week O
of NN stopwords O
treatment NN treatment O
patients VB patient O
with NN stopwords O
and DT stopwords O
without NN O
combination NNS combination O
therapy NN therapy O
were NN stopwords be O
compared NNS compare O

Elective CAPITAL NNP elective_course T
surgery NN surgery T
for NN stopwords O
gastrointestinal VB gastrointestinal D
tumours NN tumor D
in NN stopwords inch O
the NN stopwords O
elderly NN aged O

Principles CAPITAL NNP principle O
of NN stopwords O
signal NN signal O
detection NN detection O
in NN stopwords inch O
pharmacovigilance NN O

depending NN depend O
on NN stopwords on O
the NN stopwords O
outcome JJ result O
of NN stopwords O
numerous JJ numerous O
ongoing JJ ongoing O
clinical JJ clinical O
trials NN test O
, , O
amifostine DT T
may VB May O
eventually NN finally O
find NN discovery O
broader NN wide O
clinical JJ clinical O
applications DT application O
, , O
both NN stopwords both O
as DT stopwords arsenic O
a DT stopwords angstrom O
cytoprotectant NNS O
and DT stopwords O
as DT stopwords arsenic O
a DT stopwords angstrom O
potential NN potential O
therapy NN therapy O
in NN stopwords inch O
myelodysplastic NN D
syndrome NN syndrome D

Online CAPITAL NNP on-line O
medical NN checkup O
surveys NN survey O
: : O
using JJ exploitation O
the NN stopwords O
Internet CAPITAL PRP internet O
as DT stopwords arsenic O
a DT stopwords angstrom O
research NN research O
tool NN tool O

objective NN aim O
: : O
to NN stopwords O
report NN report O
the NN stopwords O
use JJ use O
of NN stopwords O
heparin NN heparin T
and DT stopwords O
enoxaparin NN T
for NN stopwords O
radiation-induced VB D
myelopathy NN D

